<SEC-DOCUMENT>0001437749-25-009350.txt : 20250326
<SEC-HEADER>0001437749-25-009350.hdr.sgml : 20250326
<ACCEPTANCE-DATETIME>20250326160540
ACCESSION NUMBER:		0001437749-25-009350
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250326
DATE AS OF CHANGE:		20250326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		25773171

	BUSINESS ADDRESS:	
		STREET 1:		1044 NORTH U.S. HIGHWAY ONE
		STREET 2:		SUITE 201
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		1044 NORTH U.S. HIGHWAY ONE
		STREET 2:		SUITE 201
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dyai20241231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dyai="http://www.dyadic.com/20241231" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>dyai20241231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/26/2025 6:03:21 PM -->
  <meta http-equiv="Content-Type" content="text/html"/></head>
 <body class="vsc-initialized" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001213809</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">DYADIC INTERNATIONAL INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:AmendmentFlag" format="ixt:fixed-false" id="ixv-11436">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-11437">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-11438">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-11439">2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="c125843295" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="c125843826" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="c125843297" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="c125843299" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="c125843831" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="c125843834" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:Rule10b51ArrTrmntdFlag" id="c125843306" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:Rule10b51ArrAdoptedFlag" id="c125843837" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:NonRule10b51ArrTrmntdFlag" id="c125843856" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:NonRule10b51ArrAdoptedFlag" id="c125843857" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonFraction id="c125856487" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c125856489" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c125843807" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c125843808" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c125843809" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000,000</ix:nonFraction>
<ix:nonFraction id="c125843810" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000,000</ix:nonFraction>
<ix:nonFraction id="c125843811" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843813" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843812" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843814" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843815" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125843816" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125843817" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,000,000</ix:nonFraction>
<ix:nonFraction id="c125843818" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,000,000</ix:nonFraction>
<ix:nonFraction id="c125843819" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,089,301</ix:nonFraction>
<ix:nonFraction id="c125843820" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,064,563</ix:nonFraction>
<ix:nonFraction id="c125843821" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">29,835,799</ix:nonFraction>
<ix:nonFraction id="c125843822" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">28,811,061</ix:nonFraction>
<ix:nonFraction id="c125843823" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,253,502</ix:nonFraction>
<ix:nonFraction id="c125843824" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,253,502</ix:nonFraction>
<ix:nonFraction id="c125843372" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c125843379" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">19</ix:nonFraction>
<ix:nonFraction id="c125843380" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">16</ix:nonFraction>
<ix:nonFraction id="c125843382" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">9</ix:nonFraction>
<ix:nonFraction id="c125843383" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">13</ix:nonFraction>
<ix:nonFraction id="c125843386" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember" unitRef="Pure" name="dyai:ConcentrationRiskSignificantCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c125843897" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c125843393" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">11</ix:nonFraction>
<ix:nonFraction id="c125843394" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">6</ix:nonFraction>
<ix:nonFraction id="c125843400" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c125843401" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfCustomers" scale="0" format="ixt:num-dot-decimal" decimals="INF">6</ix:nonFraction>
<ix:nonFraction id="c125843407" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfSuppliers" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c125843408" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfSuppliers" scale="0" format="ixt:num-dot-decimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c125843413" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfSuppliers" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c125843416" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember" unitRef="Pure" name="dyai:ConcentrationRiskNumberOfSuppliers" scale="0" format="ixt:num-dot-decimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c125843898" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:RestrictedCash" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843899" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843554" contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-GatesFoundationMember_ProductOrServiceAxis-ResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843609" contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">2.0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-03-08_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember" name="us-gaap:DebtInstrumentTerm" id="c125843622" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember" name="us-gaap:DebtInstrumentIssuanceDate1" id="c125843007" format="ixt:date-monthname-day-year-en">March 8, 2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember" name="us-gaap:DebtInstrumentMaturityDate" id="c125843008" format="ixt:date-monthname-day-year-en">March 8, 2027</ix:nonNumeric>
<ix:nonFraction id="c125843009" contextRef="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember" name="us-gaap:DebtInstrumentIssuanceDate1" id="c125843014" format="ixt:date-monthname-day-year-en">March 8, 2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember" name="us-gaap:DebtInstrumentMaturityDate" id="c125843015" format="ixt:date-monthname-day-year-en">March 8, 2027</ix:nonNumeric>
<ix:nonFraction id="c125843016" contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" name="us-gaap:DebtInstrumentIssuanceDate1" id="c125843021" format="ixt:date-monthname-day-year-en">March 8, 2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" name="us-gaap:DebtInstrumentMaturityDate" id="c125843022" format="ixt:date-monthname-day-year-en">March 8, 2027</ix:nonNumeric>
<ix:nonFraction id="c125843023" contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-DescendantTrustMember" name="us-gaap:DebtInstrumentIssuanceDate1" id="c125843028" format="ixt:date-monthname-day-year-en">March 8, 2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-DescendantTrustMember" name="us-gaap:DebtInstrumentMaturityDate" id="c125843029" format="ixt:date-monthname-day-year-en">March 8, 2027</ix:nonNumeric>
<ix:nonFraction id="c125843030" contextRef="i_2024-12-31_DebtInstrumentAxis-DescendantTrustMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>
<ix:nonFraction id="c125843038" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,000,000</ix:nonFraction>
<ix:nonFraction id="c125843040" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">910,000</ix:nonFraction>
<ix:nonFraction id="c125843041" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,090,000</ix:nonFraction>
<ix:nonFraction id="c125843048" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsCurrentGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,124</ix:nonFraction>
<ix:nonFraction id="c125843055" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:LongTermDebt" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,065,876</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember" name="us-gaap:DebtInstrumentIssuanceDate1" id="c125843056" format="ixt:date-monthname-day-year-en">March 8, 2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember" name="us-gaap:DebtInstrumentMaturityDate" id="c125843057" format="ixt:date-monthname-day-year-en">March 8, 2027</ix:nonNumeric>
<ix:nonFraction id="c125843058" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>
<ix:nonFraction id="c125843059" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,000,000</ix:nonFraction>
<ix:nonFraction id="c125843062" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,000,000</ix:nonFraction>
<ix:nonFraction id="c125843069" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsCurrentGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">88,529</ix:nonFraction>
<ix:nonFraction id="c125843076" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember" unitRef="USD" name="us-gaap:LongTermDebt" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,911,471</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2021PlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c125843677" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_PlanNameAxis-The2021PlanMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c125843678" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_PlanNameAxis-The2021PlanMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c125843679" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c125843097" contextRef="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="4">62.22</ix:nonFraction>
<ix:nonFraction id="c125843098" contextRef="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="4">64.27</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-01-03_2023-01-03_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="c125843687" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-03_2023-01-03_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember_VestingAxis-SharebasedCompensationAwardTrancheTwoThroughFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843688" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-03_2023-01-03_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843690" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-02_2024-01-02_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-EmployeesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843692" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843694" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveOfficerMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843697" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-BoardOfDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843699" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-09-23_2024-09-23_TitleOfIndividualAxis-ConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843703" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-02_2024-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843738" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonFraction id="c125843986" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,253,502</ix:nonFraction>
<ix:nonFraction id="c125843987" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">18.9</ix:nonFraction>
<ix:nonFraction id="c125843992" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843993" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125843994" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843795" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843797" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843799" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125843801" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:footnote xml:lang="en-us" id="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e">Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Francisco Trust. Mr. Thomas Emalfarb  may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he  may have therein, directly or indirectly. The amount of accrued interest as of  December 31, 2024, is $20,000.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f9eb6a786-1eb8-4731-a986-e6549f25e955">Represents the following options exercised:


(a) 25,000 stock options exercised at $0.97, and (b) 30,000 stock options exercised at $1.36.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f804fad0d-2a65-4335-8b95-e20af567b94f">Represents the vesting of 212,709 RSUs granted to executives and key personnel, 174,837 RSUs granted to the Board of Directors, and 50,000 RSUs granted to a consultant.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fbaed1767-1ff0-47d3-a4fd-478ede0efb78">Represents the cancellation of RSUs granted to a former member of the Board of Directors.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fe6a258d7-2b50-4b5b-b18d-0f21596c8347">Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore,  may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he  may have therein, directly or indirectly. For the year ended  December 31, 2024, $500,000 of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into 294,891 shares of the Company&#8217;s common stock. For the year ended  December 31, 2024, $410,000 of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into 261,732 shares of the Company&#8217;s common stock. As of December 31, 2024, the amount of accrued interest for Bradley Emalfarb and Bradley Scott Emalfarb Irrevocable Trust was $1,733 and $3,640, respectively.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f7f686efb-cac5-4e80-ab47-429a51e099ad">(4) Represents the following options canceled:


(a) 50,000 stock options granted to a former member of the Board of Directors, (b) 13,125 stock options granted to the Company's former Chairman of the Board of Directors, and (c) 10,187 stock options granted to the Company's former employee.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fd4668ce7-78e0-474e-8a35-8a9ea1b23e6a">Represents the following options granted:

Annual share-based compensation awards on  January 2, 2024, with an exercise price of $1.59, including: (a) 387,500 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 352,500 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 17,600 stock options granted to employees, vesting annually in equal installments over four years, and (d)15,000 stock options granted to a consultant, vesting upon one year anniversary.

One-time awards on  April 11, 2024, with an exercise price of $1.84, including 20,000 stock options granted to an executive, vesting annually in equal installments over four years, and 13,125 stock options granted to a member of the Board of Directors, vesting upon one year anniversary.

A one-time award on  September 23, 2024, of 25,000 stock options granted to a consultant with an exercise price of $1.79, vesting in three months.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0">For the years ended December 31, 2024 and 2023, the Company received discounts of $78,770 and $39,012 to purchase held-to-maturity investment securities, respectively.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fab67f974-f11c-4ed5-814a-a224cb2f3c41">Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, are co-trustees of the Descendant Trust and  may therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Descendant Trust. The amount of accrued interest as of December 31, 2024, is $1,800.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fb14433de-4b52-4cc5-afe7-792fca231589">(3) Represents the following options expired:


(a) 300,000 stock options with an exercise price of $1.87 per share granted to an executive, (b) 25,000 stock options with an exercise price of $1.76 per share granted to a member of the Board of Directors, (c) 7,500 stock options with an exercise price of $5.56 per share granted to a consultant, (d) 25,000 stock options with an exercise price of $4.14 per share granted to a consultant, and (e) 25,563 stock options with a weighted average exercise price of $2.93 per share granted to employees.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f7c86250f-e2ac-4546-9dd0-9565d8e6fc5d">On  January 2, 2024, the Company granted 141,510 RSUs, vesting upon one year anniversary of the grant, to members of the Board of Directors. On  March 13, 2024, the Company granted 212,709 RSUs with immediate vesting, to executives and key personnel in lieu of cash bonuses earned for the year of 2023. The fair value of the restricted stock unit is the Company&#8217;s closing stock price on the grant date as reported on the Nasdaq Stock Exchange.</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dyai-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2024-01-01_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2025-03-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-ResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ProductOrServiceAxis-ResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-03-08_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-08</xbrli:startDate><xbrli:endDate>2024-03-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-03_DebtInstrumentAxis-SeniorSecured2024NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-04_DebtInstrumentAxis-SeniorSecured2024NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConversionOfConvertibleNotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-11-16_2024-11-16_CounterpartyNameAxis-GatesFoundationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-16</xbrli:startDate><xbrli:endDate>2024-11-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoSignificantCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoSignificantCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ElevenSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:ElevenSignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:SixSignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-FourSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:FourSignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-FourSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:FourSignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:SixSignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:SixSignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:ThreeCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:ThreeCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-01_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dyai:The1044NLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dyai:The1044NLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByAssetClassAxis-CashMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByAssetClassAxis-CashMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-30_CounterpartyNameAxis-GatesFoundationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-12-01_2024-12-31_CounterpartyNameAxis-GatesFoundationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_CounterpartyNameAxis-GatesFoundationMember_StatementScenarioAxis-ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2026-01-01_2026-12-31_CounterpartyNameAxis-GatesFoundationMember_StatementScenarioAxis-ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-GatesFoundationMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ProliantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-ProliantAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ProliantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-05_2023-10-05_CounterpartyNameAxis-InzymesAgreementApsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:InzymesAgreementApsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-05</xbrli:startDate><xbrli:endDate>2023-10-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-InzymesAgreementApsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:InzymesAgreementApsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-InzymesAgreementApsMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:InzymesAgreementApsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-AGlobalFoodIngredientCompanyMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:AGlobalFoodIngredientCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_CounterpartyNameAxis-AGlobalFoodIngredientCompanyMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:AGlobalFoodIngredientCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-01_OwnershipAxis-AlphazymeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:AlphazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-NetherlandsOfficeLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dyai:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:TheFranciscoTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:TheFranciscoTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConversionOfConvertibleNotesIntoCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-DescendantTrustMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:DescendantTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-DescendantTrustMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:DescendantTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dyai:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember_TitleOfIndividualAxis-MrThomasEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:TheFranciscoTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:MrThomasEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConversionOfConvertibleNotesIntoCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConversionOfConvertibleNotesIntoCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-16_2021-04-16_PlanNameAxis-The2021PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PlanNameAxis-The2021PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PlanNameAxis-The2021PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2021PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_PlanNameAxis-The2021PlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_PlanNameAxis-The2021PlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-03_2023-01-03_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-03_2023-01-03_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember_VestingAxis-SharebasedCompensationAwardTrancheTwoThroughFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyai:SharebasedCompensationAwardTrancheTwoThroughFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-03_2023-01-03_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-02_2024-01-02_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveAndBoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutiveAndBoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-11</xbrli:startDate><xbrli:endDate>2024-04-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-11</xbrli:startDate><xbrli:endDate>2024-04-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-BoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-11</xbrli:startDate><xbrli:endDate>2024-04-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-09-23_2024-09-23_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-23</xbrli:startDate><xbrli:endDate>2024-09-23</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dyai:StockOptions1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dyai:StockOptions2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerBoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:FormerBoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerChairmanOfTheBoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:FormerChairmanOfTheBoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:FormerEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-02_2024-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-03-13_2024-03-13_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-13</xbrli:startDate><xbrli:endDate>2024-03-13</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ContractorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConvertibleNotesConvertedIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConvertibleNotesConvertedIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConvertibleNotesConvertedIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConvertibleNotesConvertedIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:NonexecutiveEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:NonexecutiveEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e" fromRefs="c125843007 c125843008 c125843009 c125843010 c125843013"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f9eb6a786-1eb8-4731-a986-e6549f25e955" fromRefs="c125843149 c125843150"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f804fad0d-2a65-4335-8b95-e20af567b94f" fromRefs="c125843179 c125843180"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fbaed1767-1ff0-47d3-a4fd-478ede0efb78" fromRefs="c125843181 c125843182"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fe6a258d7-2b50-4b5b-b18d-0f21596c8347" fromRefs="c125843014 c125843015 c125843016 c125843017 c125843019 c125843020 c125843021 c125843022 c125843023 c125843024 c125843026 c125843027"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f7f686efb-cac5-4e80-ab47-429a51e099ad" fromRefs="c125843157 c125843158"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fd4668ce7-78e0-474e-8a35-8a9ea1b23e6a" fromRefs="c125843145 c125843146"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0" fromRefs="c125842941 c125842942 c125842943 c125842944 c125842988 c125842989 c125842990 c125842991"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0" fromRefs="c125842941 c125842942 c125842943 c125842944 c125842988 c125842989 c125842990 c125842991"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fab67f974-f11c-4ed5-814a-a224cb2f3c41" fromRefs="c125843028 c125843029 c125843030 c125843031 c125843034"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fb14433de-4b52-4cc5-afe7-792fca231589" fromRefs="c125843153 c125843154"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f7c86250f-e2ac-4546-9dd0-9565d8e6fc5d" fromRefs="c125843177 c125843178"/></ix:resources>
</ix:header></div>
  <div>
   &#160;
  </div>
  <div><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; margin: 0pt; text-align: center;"><b>UNITED STATES</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: center;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 18pt; margin: 0pt; text-align: center;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2024-01-01_2024-12-31" id="ixv-13143">10-K</ix:nonNumeric></b></p>
<table border="0" cellpadding="0" cellspacing="0" style="width:99.9%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="vertical-align:middle;width:2.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-13144">&#9746;</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:97.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:2.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td><td style="vertical-align:bottom;width:97.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" contextRef="d_2024-01-01_2024-12-31" id="ixv-13145">December 31, 2024</ix:nonNumeric></b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:2.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: left;">&#160;</p> </td><td style="vertical-align:bottom;width:97.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: left;">&#160;</p> </td></tr>
<tr><td style="vertical-align:top;width:2.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-13146">&#9744;</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:97.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:2.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td><td style="vertical-align:bottom;width:97.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>For the transition period from _____ to ______</b></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Commission file number: <b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-13147">000-55264</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><img alt="a01.jpg" src="a01.jpg"/><b>&#160;&#160;&#160;&#160;</b><span style="font-family:Times New Roman;font-size:18pt;"><b>DYADIC INTERNATIONAL, INC.</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 48%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2024-01-01_2024-12-31" id="ixv-13148">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#160;</b></p> </td><td style="vertical-align: bottom; width: 48%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-13149">45-0486747</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 48%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of incorporation or organization)</p> </td><td style="vertical-align: bottom; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td><td style="vertical-align: bottom; width: 48%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer Identification No.)</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2024-01-01_2024-12-31" id="ixv-13150">1044 North U.S. Highway One, Suite 201&#160;</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2024-01-01_2024-12-31" id="ixv-13151">Jupiter</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2024-01-01_2024-12-31" id="ixv-13152">Florida</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2024-01-01_2024-12-31" id="ixv-13153">33477</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices) (Zip Code)</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: center;"><b>&#160;</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2024-01-01_2024-12-31" id="ixv-13154">561</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-13155">743-8333</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Registrant&#8217;s telephone number, including area code)<b>&#160;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p>
<table cellpadding="2" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-color: black; border-style: solid; border-width: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Title of each class</p> </td><td style="vertical-align: bottom; width: 26%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Trading Symbol(s)</p> </td><td style="vertical-align: bottom; width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-color: black; border-style: solid; border-width: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Name of each exchange on which registered</p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black; border-left: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2024-01-01_2024-12-31" id="ixv-13156">Common Stock, par value $0.001 per share</ix:nonNumeric></p> </td><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 26%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2024-01-01_2024-12-31" id="ixv-13157">DYAI</ix:nonNumeric></p> </td><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black; border-left: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2024-01-01_2024-12-31" id="ixv-13158">NASDAQ</ix:nonNumeric> Stock Market LLC</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Securities registered pursuant to Section 12(g) of the Act: None.</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Yes &#9744; <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2024-01-01_2024-12-31" id="ixv-13159">No</ix:nonNumeric> &#9746;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Yes &#9744; <ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2024-01-01_2024-12-31" id="ixv-13160">No</ix:nonNumeric> &#9746;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and&#160;(2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2024-01-01_2024-12-31" id="ixv-13161">Yes</ix:nonNumeric> &#9746; No &#9744;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2024-01-01_2024-12-31" id="ixv-13162">Yes</ix:nonNumeric> &#9746; No &#9744;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="vertical-align: bottom; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Large accelerated filer &#9744;</p> </td><td colspan="1" style="vertical-align: bottom; width: 40%;">&#160;</td><td style="vertical-align: bottom; width: 35%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accelerated filer &#9744;</p> </td></tr>
<tr><td style="vertical-align: bottom; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2024-01-01_2024-12-31" id="ixv-13163">Non-accelerated filer</ix:nonNumeric> &#9746;</p> </td><td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td><td style="vertical-align: bottom; width: 35%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-13164">&#9746;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align: bottom; width: 25%;">&#160;</td><td style="vertical-align: bottom; width: 40%;">&#160;</td><td style="vertical-align: bottom; width: 35%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-13165">&#9744;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;Yes <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-13166">&#9744;</ix:nonNumeric> No &#9746;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-13167">&#9744;</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9744;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-13168">&#9744;</ix:nonNumeric> No &#9746;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#160;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The aggregate market value of the voting and non-voting common equity held by non-affil<span style="background-color:#ffffff;">iates of the registrant (20,592,720</span><span style="background-color:#ffffff;">&#160;shares) computed by reference to the closing price of&#160;$1.48&#160;</span><span style="background-color:#ffffff;">as reported on the NASDAQ Stock Market&#160;on June 28,&#160;2024&#160;</span><span style="background-color:#ffffff;">(the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $<ix:nonFraction name="dei:EntityPublicFloat" scale="0" unitRef="USD" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2024-06-30" id="ixv-13169">30,477,226</ix:nonFraction>.&#160;Shares of the registrant&#8217;s common stock held by executive officers, directors, and other affiliates have been excluded from this calculation. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: left;">&#160;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of&#160;March 26, 2025, the registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2025-03-26" id="ixv-13170">30,090,661</ix:nonFraction>&#160;sh<span style="background-color:#ffffff;">ares of common stock outstanding.</span></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 7pt; margin: 0pt; text-align: left;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: center;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: left;"><b>&#160;</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The information required by Part III of this Report, to the extent not set forth herein, is incorporated in this Report by reference to the Registrant&#8217;s definitive proxy statement relating to the 2025&#160;annual meeting of shareholders. The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2024 fiscal year.</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#160;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    &#160;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></div>
  <div>
   &#160;
  </div>
  <div>
   <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
    <tbody>
     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td colspan="3" style="vertical-align: bottom; width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><b><a id="toc" title="toc" href="#"></a>TABLE OF CONTENTS</b></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Page</b></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td colspan="2" style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Part_1" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">PART I</span></a></p> </td>
      <td style="vertical-align: top; border-bottom: 1px none rgb(0, 0, 0); width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Part_1">7</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 1.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item1_Business" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Business</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item1_Business">7</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 1A.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item1A_Risk" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Risk Factors</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item1A_Risk">16</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 1B.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item1B_Unresolved" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Unresolved Staff Comments</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item1B_Unresolved">34</a></span></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt 0pt 0pt 6.75pt; text-align: left;">Item 1C.</td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item1c" style="-sec-extract:exhibit;">Cybersecurity</a></td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><a class="tocPGNUM" href="#item1c">34</a></td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 2.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item2_Properties" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Properties</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item2_Properties">35</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 3.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item3_Legal" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Legal Proceedings</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item3_Legal">36</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 4.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item4_Mine" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Mine Safety Disclosures</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item4_Mine">36</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td colspan="2" style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Part_2" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">PART II</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Part_2">36</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 5.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item5_Market" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Market for Registrant&#8217;s Common Equity, and Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item5_Market">36</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 6.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item6_Selected" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Selected Financial Data</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item6_Selected">37</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 7.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item7_MDA" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item7_MDA">37</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 7A.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item7A_QQ" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Quantitative and Qualitative Disclosures about Market Risk</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item7A_QQ">43</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 8.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item8_Fin" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Financial Statements and Supplementary Data</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item8_Fin">43</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 9.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item9_Changes" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item9_Changes">43</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6.75pt; text-align: left;">Item 9A.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item9A_Controls" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Controls and Procedures</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item9A_Controls">44</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 9B.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item9B_Other" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Other Information</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item9B_Other">44</a></span></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt 0pt 0pt 6.75pt; text-align: left;">Item 9C.</td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item9c" style="-sec-extract:exhibit;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><a class="tocPGNUM" href="#item9c">45</a></td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td colspan="2" style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Part_3" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">PART III</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Part_3">45</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 10.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item10_Directors" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Directors, Executive Officers and Corporate Governance</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item10_Directors">45</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 11.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item11_Executive" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Executive Compensation</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item11_Executive">45</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 12.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item12_Security" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item12_Security">45</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 13.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item13_certain_" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certain Relationship and Related Transactions, and Director Independence</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item13_certain_">45</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 14.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item14_Principal" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Principal Accountant Fees and Services</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item14_Principal">45</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td colspan="2" style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Part_4" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">PART IV</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Part_4">46</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 15.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item15_FinancialStatements" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Exhibits and Financial Statement Schedules</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item15_FinancialStatements">46</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.75pt;margin-right:0pt;margin-top:0pt;text-align:left;">Item 16.</p> </td>
      <td style="vertical-align: top; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item16_Form10K" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form 10-K Summary</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Item16_Form10K">48</a></span></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="vertical-align: bottom; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td colspan="2" style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Signatures" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">SIGNATURES</span></a></p> </td>
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><a class="tocPGNUM" href="#Signatures">49</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="vertical-align: bottom; width: 82%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="vertical-align: bottom; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td colspan="2" style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Index" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">INDEX TO FINANCIAL STATEMENTS</span></a></p> </td>
      <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><a class="tocPGNUM" href="#Index">F-1</a></span></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM">
       &#160;
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       &#160;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </div>
  <div>
   &#160;
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="caution" title="caution" href="#"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Information (other than historical facts) set forth in this Annual Report on Form 10-K (the &#8220;Annual Report&#8221; or the &#8220;Form 10-K&#8221;) contains forward-looking statements within the meaning of the Federal securities laws, which involve many risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements generally can be identified by use of the words &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; and other similar terms or variations of them or similar terminology. Such forward-looking statements are included under Item 7 &#8220;Management&#8217;s Discussion and Analysis&#8221;. Dyadic International, Inc., and its subsidiaries cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic&#8217;s control. These factors include, but are not limited to, the items in the following list, which also summarizes some of our more principal risks:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Business and Financial Condition</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may not succeed in implementing our business strategy.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have a history of net losses, and we may not achieve or maintain profitability.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We could fail to manage our growth.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our revenue growth depends in part on market and regulatory acceptance of our microbial protein production platforms and other technologies to develop and manufacture animal and/or human biopharmaceutical products and non-pharmaceutical products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may fail to commercialize our microbial protein production platforms or our other technologies for the expression of therapeutic proteins, antibodies, vaccines, and metabolites or other non-pharmaceutical biologic products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If our competitors develop technologies and products more quickly and market more effectively than our product candidates, our commercial opportunity will be reduced or eliminated.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Alternative technologies may not require microbial or other cell produced proteins, such as our proprietary C1 cells and Dapibus&#8482;.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The results of nonclinical studies and early-stage clinical trials may not be predictive of future results.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may need substantial additional capital in the future to fund our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Changes in global economic and financial markets may have a negative effect on our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We face risks related to widespread outbreaks of contagious disease or other biological threats, any of which could significantly disrupt our operations and have a material adverse effect on our business, employees, directors, consultants, collaborators and other third parties, including business development activities and research and development projects conducted by third party contract research organizations parties.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our sales and operations are subject to the risks of doing business internationally.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we lose key personnel, including key management or board members, or are unable to attract and retain additional personnel, it could delay our technology and product development programs and harm our R&amp;D efforts, and we may be unable to pursue research funding, licenses and other forms of collaborations or develop our own products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be sued for product liability.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Foreign currency fluctuations could adversely affect our results.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may make acquisitions, investments and strategic alliances that may use significant resources, result in disruptions to our business or distractions of our management, may not proceed as planned, and could expose us to unforeseen liabilities.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We rely significantly on information technology, including artificial intelligence and machine learning, and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Information technology system failures, network disruptions or cyber security breaches could adversely affect our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The use of new and evolving technologies, such as artificial intelligence (&#8220;AI&#8221;), in our business may result in reputational harm, competitive harm or legal liability.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Changes to our outsourced software or infrastructure vendors as well as any sudden loss, breach of security, disruption or unexpected data or vendor loss associated with our information technology systems could have a material adverse effect on our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Dependence on Third Parties</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We are dependent on collaborations with third parties, and if we fail to maintain or successfully manage existing, or enter into new, strategic collaborations, we may not be able to develop and commercialize many of our technologies and products and achieve profitability.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have limited or no control over the resources that any collaborator or licensee may devote to our programs, and reductions in collaborators&#8217;&#160;R&amp;D budgets may affect our businesses.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We heavily rely on contracts with third-party contract research organizations (&#8220;CROs&#8221;) and other third-party service providers to conduct our research and development, pre-clinical, CMC (Chemistry, Manufacturing, and Controls)&#160;and cGMP (current Good Manufacturing Practices) manufacturing, fill and finish, and potential clinical trials, which may not be available to the Company on commercially reasonable terms or at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Conflicts with the CROs, other service providers, collaborators and/or licensees could harm our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We rely on our collaborators and other third parties to deliver timely and accurate information in order to accurately report our financial results as required by law.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Changes to our outsourced software or infrastructure vendors as well as any sudden loss, breach of security, disruption or unexpected data or vendor loss associated with our information technology systems could have a material adverse effect on our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Government Regulations and Environmental, Social, and Governance Issues</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Potential future regulations limiting our ability to sell genetically engineered products could harm our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Public views on ethical and social issues may limit use of our technologies.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our results of operations may be adversely affected by environmental, health and safety laws, regulations and liabilities.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Increasing scrutiny and changing expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have no experience submitting applications to the FDA or similar regulatory authorities in the past and may not be able to obtain regulatory approval or may be subject to lengthy and/or unfavorable regulatory proceedings.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Relating to Intellectual Property</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Failure to protect our intellectual property and the intellectual property of certain third parties could harm our competitive position.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and resources and could prevent us and our collaborators from commercializing our or their technologies and products or negatively impact our stock price.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Common Stock</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The price of our shares of common stock is likely to be volatile, and you could lose all or part of your investment.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our quarterly and annual operating results may be volatile.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We do not expect to pay cash dividends in the future.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our anti-takeover defense provisions may deter potential acquirers and depress our stock price.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Concentration of ownership among our existing officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Future resales of shares of our common stock may negatively affect our stock price.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company is exposed to credit risk and fluctuations in the values of its investment portfolio.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We are a smaller reporting company, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research or reports regarding us, our business or our market, our stock price and trading volume could decline.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We caution you that the foregoing list of important factors is not exclusive. Any forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Before investing in our common stock, investors should carefully read the information set forth under the caption &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this Annual Report which could have a material adverse effect on our business, results of operations and financial condition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Annual Report to conform these statements to actual results or to changes in our expectations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We qualify all our forward-looking statements by these cautionary statements. In addition, with respect to all our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Part_1" title="Part_1" href="#"></a>PART I</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;margin:0pt;text-align:left;"><b><a id="Item1_Business" title="Item1_Business" href="#"></a>Item 1.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;margin:0pt;text-align:left;"><b>Business</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Overview</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands, and it utilizes several third-party consultants and contract research organizations to carry out the Company&#8217;s activities. Over the past two plus decades, the Company developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and previously licensed this technology to third parties, such as Abengoa Bioenergy SA, BASF SE, Codexis, Inc. and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the <i>Thermothelomyces heterothallica </i>(formerly known as <i>Myceliophthora thermophila</i>) fungus, which the Company named C1.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the past nine years since&#160;the Company sold its industrial technology business to Danisco USA (&#8220;Danisco&#8221;), the industrial biosciences business of DuPont (NYSE: DD) (the &#8220;DuPont Transaction&#8221;), the Company has been focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health and for other biologic products for use in non-pharmaceutical applications.&#160;As part of the DuPont Transaction, Dyadic retained co-exclusive rights to its proprietary and patented C1 protein production platform (the &#8220;C1 platform&#8221;) for use in all human and animal pharmaceutical applications, and currently, the Company has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions) for use in all human and animal pharmaceutical applications. Danisco retained certain rights to utilize the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or in licensed by Danisco.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">After the DuPont Transaction, the Company has directed its efforts toward&#160;advancing the C1 platform to address the increasing global demand for the development and manufacturing of prophylactic and therapeutic biopharmaceuticals for human and animal health. The Company&#8217;s biopharmaceutical development efforts have been centered on enhancing the capability of the C1 platform to produce stable, properly folded, and functional proteins for pharmaceutical applications, including vaccines and monoclonal antibodies. In addition to improving the quality and productivity of the C1 platform, the Company has sought to validate its platform for human use through a series of fully funded biopharmaceutical projects, extensive animal studies utilizing C1-produced proteins, and in 2024, the successful completion of a Phase 1 first-in-human study for a vaccine antigen produced using C1, which demonstrated&#160;its safety for human applications.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Recognizing the longer development timelines, clinical testing, and regulatory requirements associated with human and animal pharmaceutical products, the Company has refined its core business strategy to expand into recombinant (non-animal derived) alternative proteins for non-pharmaceutical applications in research, nutrition, and industrial markets. To address these opportunities, the Company has developed and launched the Dapibus&#8482; Protein Production Platform (&#8220;Dapibus&#8482;&#8221;), which supports various applications within the alternative proteins field, namely&#160;in Life Sciences, Food &amp; Nutrition, and Bioindustrial applications. Given the reduced developmental costs, shorter timelines, and fewer regulatory requirements associated with alternative proteins, Dapibus&#8482; has enabled the Company to generate near-term recurring revenue while continuing to build long-term value through C1 for pharmaceutical applications. The Company anticipates achieving commercialization of certain alternative protein products in 2025 through a combination of existing collaborations and internal manufacturing efforts.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Dyadic Protein Production Technology</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company is focused on utilizing its proprietary, highly productive, and scalable microbial fungal protein production platforms C1 and Dapibus&#8482; to address the increasing global demand for non-animal-derived proteins in both pharmaceutical and non-pharmaceutical applications. By applying its industrially validated, efficient, and cost-effective bioproduction technology to high-value markets such as human therapeutics and alternative food and nutrition, the Company aims to facilitate the rapid development and large-scale manufacturing of proteins, enzymes, and other biologic products. Through targeting key products within its core business segments, the Company seeks to address global health and nutrition challenges by providing innovative, accessible, and economically viable solutions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">C1 is a versatile thermophilic filamentous fungal expression system customized for the development and production of biologic products including enzymes and other proteins for human and animal health that may offer potential competitive advantages compared to certain other legacy biopharmaceutical expression systems in the discovery, development, and cost-effective manufacturing of biologic medicines and vaccines. Potential applications to be produced from C1 include protein antigens, ferritin nanoparticles, virus-like particles (&#8220;VLPs&#8221;), monoclonal antibodies (&#8220;mAbs&#8221;), Bi/Tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, as well as other therapeutic enzymes and proteins. The Company participates in multiple funded research collaborations with certain leading animal and human pharmaceutical companies. These partnerships are strategically engaged to leverage the potential of C1 in the development of innovative vaccines and drugs, as well as biosimilars and/or biobetters, which we believe will contribute to advancements in medical science and healthcare.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company believes C1 possesses unique characteristics that distinguish it from conventional filamentous fungal cells. C1 offers potential competitive advantages in the discovery, development, and manufacturing of biologic medicines and vaccines compared to certain legacy biopharmaceutical expression systems. It allows for streamlined purification processes, retaining target secreted proteins efficiently through downstream processing without the need for viral (e.g., CHO (Chinese Hamster Ovary) and&#160;Baculovirus) or endotoxin (e.g., E. coli) removal. The platform also demonstrates high productivity, thriving under robust and versatile growth conditions while yielding large amounts of secreted protein with low viscosity due to C1&#8217;s unique morphology. Its robustness has been proven across scales, from laboratory microtiter plates and shaker flasks to single-use and stainless-steel microbial fermenters, producing stable, correctly folded mAbs&#160;with properties comparable to CHO-produced mAbs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dapibus&#8482; holds similar promise for cost-effective production of traditionally costly recombinant and animal derived proteins and enzymes such as serum albumin and dairy proteins. Dapibus&#8482; is designed to enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for non-pharmaceutical applications, including food, nutrition, and wellness. This platform enables streamlined purification processes, ensuring strong retention of the target secreted protein through downstream processing, with no requirement for endotoxin (e.g., E. coli) removal. It also boasts high productivity, supporting robust and versatile growth conditions that yield large amounts of secreted protein, while its unique morphology maintains low viscosity at large scales. Additionally, Dapibus&#8482; demonstrates exceptional robustness, with proven scalability from laboratory microtiter plates and shaker flasks to single-use and industrial-scale stainless-steel microbial bioreactors. Furthermore, it enables the production of glycosylated proteins, expanding its versatility for various biologic applications.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company believes that C1 and Dapibus&#8482;, have significant potential to become an alternative to several traditional production technologies currently used in pharmaceutical and non-pharmaceutical applications to produce antigens for use in vaccines, monoclonal antibodies, therapeutic proteins, reagents, food, and nutritional proteins The Company&#8217;s platforms have some inherent benefits and potential competitive advantages compared to CHO cells, <i>E. coli</i>, <i>Pichia pastoris</i>, and Insect Cells (i.e., Baculovirus) as discussed below:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Mammalian cells: Currently the preferred production host for most complex protein therapeutics due mainly to their ability to produce proteins with human-like glycosylation and regulatory acceptance. This market is dominated by CHO cells. Disadvantages include the longer duration required for cell line development, fermentation, and increased costs associated with production media&#160;and longer and more costly downstream processing steps.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Bacterial: Bacteria such as <i>E. coli </i>are currently an easy, inexpensive, and rapid method for recombinant protein expression often used in laboratory settings as well as commercial production of certain non-glycosylated proteins. However, bacterial platforms produce toxic and pyrogenic cell wall components that may make them less suitable for the production of biopharmaceuticals or other alternative proteins. Moreover, insoluble expression, a frequent outcome in bacterial expression, is challenging with regard to cost of goods due to the need for refolding and its direct impact on reduced overall yields and resultant waste streams.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Yeast: In contrast to bacteria, yeast, such as <i>Pichia pastoris</i>, do not produce potentially toxic and pyrogenic cell wall components. Moreover, the genetic tools for yeast production are advanced and enable continued engineering of new strains that may become more suitable than CHO cell lines. Disadvantages include lower protein production of select targets and traditional yeast cells have a greater number of higher N and O glycosylation structures.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Insect cells: Insect cells (i.e., Baculovirus) offer protein expression with post-translational modifications like mammalian cells, ease of scale-up, and simplified cell growth readily adapted to high-density suspension culture for large-scale expression. Baculovirus expression systems are used for producing recombinant protein, especially for vaccine antigens. Disadvantages include lower protein titers when compared to other platforms and the need for an additional viral inactivation step.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Trichoderma: One of the leading filamentous fungal platforms for bioindustrial and food protein production. Disadvantages may include a high level of extracellular proteases, which can degrade recombinant proteins and lower expression levels for heterologous proteins compared to other systems.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Competition</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The biotechnology industry is intensely competitive. The continuous demand for innovation, efficiency, and speed creates opportunities for the advantages of Dyadic&#8217;s C1 and Dapibus&#8482; platforms, however, as the Company&#8217;s target markets evolve, there is always the risk that a competitor may be able to develop other technologies that are able to achieve similar or better results. Currently, we are not aware of other companies pursuing a business model similar to what we are developing with our protein production platforms. However, our competitors using other protein production platforms who are significantly larger and better capitalized, could potentially adopt similar strategies and implement them at a faster pace. These potential competitors include multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities, governmental agencies, and other research institutions that are in the operating pharmaceutical sector. Moreover, smaller or early-stage companies may emerge as significant competitors, particularly through collaborative arrangements with large, established companies. In non-pharmaceutical applications, several other companies have and are actively engaged in utilizing filamentous fungal microorganisms for the development and manufacture of low-cost proteins, metabolites, and other biological products for use in food, nutrition, and wellness.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Our Industry and Potential Markets</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>Non-Pharmaceutical Applications</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The demand for non-animal-derived enzymes and proteins is rapidly increasing across various industries, driven by advancements in biotechnology, sustainability initiatives, and evolving consumer preferences. In the reagents sector, non-animal derived proteins are being utilized in diagnostic applications, research tools, and industrial processes, offering a sustainable and ethically responsible alternative to traditional animal-derived proteins. Within the food industry, the shift toward plant-based and fermentation-derived proteins is accelerating as consumers seek sustainable, allergen-free, and ethically sourced protein alternatives. Additionally, the alternative protein market&#8212;including cell-cultured, microbial, and precision fermentation-derived proteins&#8212;is experiencing significant growth as companies strive to meet the rising demand for environmentally friendly scalable, and sustainable protein solutions. The Company believes that Dapibus&#8482; is well-positioned to address these expanding markets by providing cost-effective, scalable, and high-quality non-animal proteins for use in reagents, food, and other alternative protein applications. Dapibus&#8482; has begun to generate revenue within non-pharmaceutical applications and the Company has selectively focused on these rapidly growing markets and prioritized our commercial focus accordingly.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Cell culture media products: A nutrient-rich solution designed to support the growth, maintenance, and proliferation of cells tailored to specific cell types within alternative protein, research or biopharmaceutical applications.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">DNA/RNA manipulation products: Reagents used in the modification, amplification, sequencing, and analysis of DNA and RNA for gene editing, MRNA, and other synthetic biology applications, serving research, diagnostics, biopharmaceutical, and agricultural biotechnology sectors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Non-Animal dairy protein and enzyme products: Proteins and enzymes produced through fermentation, precision fermentation, or plant-based processes to replicate the functional and nutritional properties of traditional dairy components catering to the sustainable and animal-free dairy alternatives market</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Bioindustrial protein and enzyme products: Proteins and enzymes used to enhance process efficiency, sustainability, product performance and reduce reliance on harsh chemicals for applications like food/feed additives, biomass conversion, fiber modification, and eco-friendly textile processing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As demand for more sustainable products in the alternative proteins segment grows, we believe recombinant protein and enzyme products offer clear advantages in overcoming cost, purity, and consistency challenges. By enabling scalable and controlled production, recombinant technologies reduce reliance on animal-derived or chemically synthesized alternatives while improving efficiency and performance. These benefits position recombinant enzyme and protein solutions as key enablers in the expansion of sustainable reagent, food, nutrition, and industrial applications.:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Reagents &amp; Biotech &#8211;&#160;Affordable recombinant enzymes and proteins enhance molecular biology workflows, diagnostics, and biopharmaceutical research.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Nutritional &amp; Food Ingredients &#8211;&#160;Lower production costs enable widespread adoption of recombinant dairy proteins, alternative meats, and functional food enzymes, meeting the rising demand for non-animal and precision-fermented ingredients.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Industrial Applications &#8211;&#160;Economically viable recombinant enzymes facilitate greener, more efficient bioprocessing in biofuels, biogas, textiles, pulp and paper, and waste management, displacing conventional chemical-intensive methods.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consistency &amp; Purity &#8211;&#160;Recombinant production enables high batch-to-batch consistency with minimal variability, reducing impurities and contamination risks compared to animal-derived or chemically synthesized alternatives.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company believes Dapibus&#8482; unlocks&#160;significant market opportunities within the alternative proteins segment by addressing key challenges related to cost, scalability, and quality. By leveraging the platform to produce cost-effective, high-quality non-animal derived proteins for non-pharmaceutical applications, the Company can capitalize on near-term revenue opportunities. These applications benefit from shorter commercialization timelines, lower development costs, and a more streamlined regulatory pathway compared to pharmaceutical products, accelerating market entry and adoption.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>Pharmaceutical Applications</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Based on feedback received from our collaborators and our ongoing discussions with leading pharmaceutical and biotechnology companies, contract manufacturing organizations, leading academic institutions, as well as U.S. and foreign governmental agencies, we believe that the biopharmaceutical market remains an attractive opportunity to apply C1. The Company continues to evaluate potential opportunities to expand the application of C1, and is currently focused on the following markets:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Recombinant vaccines and drugs for animal and human health</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">New innovative biotherapeutics</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Biosimilars / Biobetters non-Glycosylated/Glycosylated protein markets</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Drug formulation, research diagnostic and reagents</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The demand for biologic medicines, including infectious disease vaccines and therapeutics, has grown significantly in the post-COVID-19 healthcare landscape. However, access to these medicines remains limited due to high costs for both patients and healthcare systems. The Company believes that these challenges are, in part, the result of key bottlenecks in the development and manufacturing of biologic medicines, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Extended timelines for stable cell line development and manufacturing</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Insufficient titers and overall yields</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">High production costs, due to expensive media and other consumables</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Long production cycles for stable mammalian and insect (i.e., baculovirus) cell lines</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Historically underfunded development of more efficient next-generation protein production systems</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company believes that the biopharmaceutical industry would benefit from an innovative protein production platform that is safe, efficient, reliable, and cost-effective. Such a platform could enable the rapid and high-titer production of difficult-to-express proteins, improving patient access and reducing costs. The Company&#8217;s C1 platform has the potential to serve as an alternative to CHO, insect cells (i.e. Baculovirus), yeast and other traditional expression systems for the production of proteins used in vaccines, therapeutics, diagnostics, and other biologic products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Our Research Partners and CROs</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Currently, the Company is conducting its C1 research and other internal and external third-party programs with several contract research organizations as follows:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>(1)</i></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Research and Development Agreement with VTT Technical Research Centre of Finland, Ltd&#160;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Since September 2016, the Company has been working with VTT Technical Research Centre of Finland, Ltd. (&#8220;VTT&#8221;), a third-party contract research organization, to further modify and improve C1 to ensure a safe and efficient expression system for use in accelerating development and lowering the cost of manufacturing pharmaceutical and non-pharmaceutical products and processes. VTT is one of the leading research and technology organizations in Europe, and it has conducted research and development on fungi and other microorganisms for more than three decades. VTT is continuing their development work to further develop C1.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has extended its research contract with VTT multiple times to continue developing C1 for therapeutic protein production, including C1 host system improvement, glycoengineering, protease deletion, and management of third-party target protein projects. A significant portion of the research and development activities at VTT are being funded by the Company&#8217;s third-party collaborators.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>(2)</i></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Other CROs and cGMP Manufacturers</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company works with several other research providers, cGMP manufacturers, and contract research organizations from time to time, which are important to achieve the Company&#8217;s scientific and business objectives. These entities include but are not limited to 53Biologics (Valladolid, Spain), Fermbox Bio (Bangalore, KA, India), and Eleszto Genetika (Budapest, Hungary).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">These arrangements are typically work for hire on an as-needed basis;&#160;however, certain of these programs, if negatively impacted due to resource availability, disagreements, or other reasons could lead to delays or inability to realize our research and commercial objectives.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Our Research and Development (</b>&#8220;<b>R&amp;D</b>&#8221;<b>) Programs</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>(1)</i></b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Internal Research Programs</i></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>Production Host Improvements:</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company continued to invest in and advance Dapibus&#8482;. In conjunction with Eleszto Genetika (&#8220;EG&#8221;), our internal and third party research and development initiatives are focused on both enhancing the robustness, versatility, and efficiency of Dapibus&#8482; and developing new Dapibus&#8482; production strains for a range of non-pharmaceutical applications&#8212;including dairy, biofuels, biogas, biorefining enzymes, and alternative proteins. Key ongoing research and development projects include, but are not limited to, the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Continued development and refinement of Dapibus&#8482; to enhance overall robustness, versatility, and efficiency.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Generation of Dapibus&#8482; production strains specifically engineered for applications in dairy processing, biofuels, biogas, biorefining enzymes, and alternative protein production.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Ongoing improvement of genetic engineering tools to accelerate strain development and optimize expression profiles.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Identification and targeted deletion of background protease genes to further reduce proteolytic activity, thereby improving yield and product quality.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Modification and refinement of both fermentation protocols and downstream purification processes to increase production efficiency and reduce cost of goods.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Development of high expression Dapibus&#8482; cell lines through precision engineering techniques to meet the growing demand for cost&#8208;effective protein production.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Execution of a range of analytical methods and quality assessments to ensure that the developed strains and processes meet stringent performance and regulatory standards</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company collaborates with VTT, Eleszto Genetika, and other CROs and technical service providers to enhance C1 for greater robustness, versatility, and efficiency in protein production. Key initiatives include improving C1 genetic tools, reducing background protease levels, precision engineering high-expression C1 cell lines, developing C1-expressed vaccine and drug candidates, and glycoengineering C1 cells for mammalian-like glycosylation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Recent advancements demonstrate the platform&#8217;s capability to produce properly folded, biologically active proteins:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Expansion of the platform for human and bovine serum albumin and other recombinant proteins for therapeutic, drug formulation, research, and diagnostic applications.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Further development of DYAI-100 (SARS-CoV-2 RBD) vaccine candidate, including multivalent antigen expression to align with FDA recommendations for annual SARS-CoV-2 vaccines.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">High-yield production of SARS-CoV-2 Full Spike Protein, hemagglutinin (HA), and neuraminidase (NA), with demonstrated safety and efficacy in animal trials, including an Oslo University challenge study for influenza.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Expression of complex proteins, including conjugated antigens, scFv (MHCII), and trimerization domains to enhance efficacy.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Successful monoclonal antibody (mAb) production, with C1produced mAbs showing binding kinetics virtually identical to CHO-produced mAbs.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Glycoengineering of C1 cells to produce mAbs with human-like glycan structures and third-party validation of C1-produced mAbs' neutralizing and binding activity.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Production of bi-specifics, tri-specifics, and Fc-fusion proteins at high yields and quality, with C1produced bi-specific antibodies demonstrating similar dose-response activity to CHO produced proteins.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>Glycosylated Therapeutic Programs:</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company aims to leverage its C1&#160;platform for the large therapeutic glycoprotein market, requiring further investment in time and capital. Advances in genomics and synthetic biology support the engineering of C1&#8217;s glycosylation pathways to: (i) produce therapeutic proteins with human-like glycoforms (G0, G2, G0F, G2F), (ii) reduce or eliminate O-glycosylation, and (iii) enhance immunogenicity in vaccine applications.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Glycoengineering efforts at VTT are progressing, with early results demonstrating the potential of C1 as a viable platform for glycoprotein production. The Company is refining approaches to optimize gene expression, aiming to develop stable C1 cell lines capable of producing human-like glycosylated therapeutic proteins at high yields.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Early results confirm that C1-produced Nivolumab exhibits similar glycosylation structures, reinforcing the platform&#8217;s potential for manufacturing high-value monoclonal antibodies and glycoproteins for therapeutic and preventative applications.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>(2)</i></b></p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Non-pharmaceutical Programs</i></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dapibus&#8482; was developed to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness. We believe the Company&#8217;s industrial heritage provides our partners with the ability to move from demonstration to commercial production quickly and efficiently. The Company is actively utilizing Dapibus&#8482; and other technologies to address the unmet need to reduce the production cost in the global market for non-pharmaceutical recombinant proteins.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#160; &#160; &#160; &#160; &#160; &#160; Cell Culture Media Products&#160;</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Recombinant Serum Albumin&#160;is a vital cell culture media component that supports cell growth, survival and function for use in cell culture media, diagnostics, and as a stabilizing agent for vaccine production. The Company&#8217;s animal-free recombinant serum albumin projects were initiated in late 2022 using Dyadic pharmaceutical cell lines for use in potential therapeutic, product development, research, and/or diagnostic human and animal pharmaceutical applications. In June 2024, the Company announced a development and commercialization partnership for recombinant serum albumin with Proliant Health and Biologicals (&#8220;Proliant&#8221;), a leading supplier of purified proteins for diagnostic, nutrition, and cell culture markets. Prior to the agreement with Proliant, the Company completed initial testing of its recombinant albumin products with Certificates of Analysis issued demonstrating analytical comparability to reference standards. In addition, Dyadic&#8217;s recombinant bovine albumin demonstrated comparable efficacy in cell proliferation of animal muscle cells to albumin products currently used in the cultured meat industry.&#160;&#160;Under the terms of the Proliant Agreement, Dyadic has received an initial upfront payment of $500,000, a&#160;second&#160;payment of $500,000 for&#160;completing&#160;the transfer of a Production Strain (as defined in the Proliant Agreement) and will receive a final payment of $500,000&#160;upon the meeting of a certain productivity threshold. Upon commencing commercial sales of&#160;animal-free recombinant serum albumin products produced pursuant to the Proliant Agreement, the Company will receive royalties based on a certain percentage of the gross margin received by Proliant, as defined in the Proliant Agreement. Proliant is progressing toward an expected commercial launch in 2025 as a key component of cell culture media.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In March 2024, the Company entered into a co-promotion agreement with Biftek Co. for the promotion of growth media supplement for cell culture.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In&#160;2024, the Company began a development program to produce recombinant transferrin for use in cell culture media and other applications. Dyadic's recombinant transferrin is an animal-free alternative to serum-derived transferrin for use in cell culture media, diagnostic, research, and biopharmaceutical applications. The Company has completed the initial analysis of its recombinant transferrin product and has Certificates of Analysis for recombinant bovine transferrin that demonstrate comparability to reference standards used in the testing. In addition, the Company&#8217;s recombinant transferrin demonstrated comparable performance to a recombinant reference standard, highlighting its potential as a high-quality, cost-effective non-animal alternative for research and commercial bioprocessing applications.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In 2024, the Company conducted a development program to produce recombinant bovine fibroblast growth factor (&#8220;FGF&#8221;) for use in cell culture media and biopharmaceutical applications. As a critical driver of cell growth and proliferation, recombinant FGF plays an essential role in biomanufacturing, regenerative medicine, and cell-based therapies, particularly in serum-free and chemically defined cell culture media. Initial testing of the Company&#8217;s recombinant FGF demonstrated comparability to reference standard for use in cell culture media to proliferate animal muscle cells for the cultured meat industry. In addition to further characterization and validation efforts, sampling initiatives are expected to begin in Q2 2025.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company is currently providing samples of its recombinant cell culture media products such as transferrin and FGF for application testing as growth media for the biopharmaceutical and cultured meat industries in conjunction with ongoing protein characterization testing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>Non-animal Dairy Products</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In September 2024, the Company received a milestone payment of $425,000 for achieving the specified target yield of a recombinant diary enzyme, which is expected to be commercialized in late 2025 or early 2026. This milestone is in addition to the upfront payment of $600,000 received in 2023 when the Company entered a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus&#8482;.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In late 2024, the Company developed an improved highly productive strain of recombinant bovine alpha-lactalbumin, a whey protein for the non-animal dairy industry. Further development has demonstrated Dyadic&#8217;s alpha-lactalbumin product is comparable to other recombinant and animal derived products and a Certificate of Analysis has been issued. In addition to active sampling efforts to interested collaborators, the Company is conducting further characterization of its alpha-lactalbumin product through functional and analytical assays.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In 2024, the Company initiated development of recombinant human alpha-lactalbumin for use in the pharmaceutical, nutraceutical, medical nutrition, and infant formula markets.&#160;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;">o</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In 2024, the Company commenced a recombinant lactoferrin development program and initiated sampling efforts in late 2024. The Company has developed a cell line to produce stable human recombinant lactoferrin protein for use in research and pharmaceutical applications as potential antimicrobial, anti-inflammatory, and immune-supportive products.&#160;Ongoing optimization and characterization efforts are underway, and the Company expects to begin sampling efforts in 2H 2025.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;">o</td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company has produced four casein proteins and is in active discussions with potential collaborators.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>Reagent Proteins &amp; DNA/RNA Enzymes</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The&#160;Company&#8217;s DNase-1 product is designed for use in molecular diagnostics, biopharma, and other industries is progressing toward commercial availability.&#160;The Company has completed its development of DNASe-1, and a Certificate of Analysis has been issued for the product. In addition to exploring licensing opportunities, Dyadic has partnered with an EU-based Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;) to validate the production process for DNase-1 (RNase-Free) and to produce a research grade DNase-1 product by mid-2025. Additionally, development efforts have begun to produce research grade DNA/RNA Polymerases, DNA Ligase, and RNase Inhibitor products. Cell lines have been developed with optimization and analysis ongoing.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The&#160;Company has developed prototypes for four additional enzymes, including RNase Inhibitors and T7 RNA Polymerase, to support the growing demand for DNA/RNA manipulation tools.&#160;Development and optimization are ongoing with results expected by the end of 2025.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>Bio Industrial Products and Other Products&#160;</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company has developed several enzymes that have the potential for use in multiple industries, such as nutrition, pulp and paper, biogas, biofuels and biorefining.&#160;The Company is actively sampling bio industrial companies.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In 2023, the Company entered into a development and commercialization agreement with Fermbox Bio (&#8220;Fermbox&#8221;), a synthetic biology research and manufacturing company. In May 2024, Fermbox announced the launch of EN3ZYME, a cutting-edge enzyme cocktail designed to enhance both the efficiency and cost-effectiveness of transforming pre-treated agri-based residues into fermentable, cellulosic sugars produced using Dyadic&#8217;s expression platforms.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 9pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In 2024, the Company began development of hyaluronidase, an enzyme that breaks down hyaluronic acid (HA), a key component of the extracellular matrix in connective tissues. The Company is currently engaging and sampling hyaluronidase to interested parties for a variety of applications such as medical, aesthetic, reproductive, and infectious.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>(3)</i></b></p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Pharmaceutical Programs</i></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On February 13, 2024, the Company announced a strategic partnership with Cygnus Technologies&#174;, part of Maravai LifeSciences&#174; (Nasdaq: MRVI), which has developed the C1 Host Cell Protein ELISA Kit for the quality release of products produced using Dyadic&#8217;s C1 and Dapibus&#8482; platforms.&#160;The C1 host cell kit is commercially available through Cygnus Technologies (C1 HCP ELISA Kit).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On February 21, 2024, the Company announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic&#8217;s expertise in microbial platforms for flexible scale protein bioproduction and the IIBR&#8217;s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On February 28, 2024, the Company&#8217;s Dutch subsidiary, Dyadic Nederland BV, entered into a strategic partnership agreement and collaboration with Rabian BV (&#8220;Rabian&#8221;), a Dutch innovative SME founded by experienced entrepreneurs and vaccine scientists. Awarded by Eurostars for the AVATAR project, a part of the European Partnership on Innovative SMEs, and co-funded by the European Union through Horizon Europe, Rabian will use the total funding leveraging its expertise in virology to develop a rabies vaccine using C1 to tackle the challenges posed by rabies, particularly in lower- and middle-income countries. Dyadic is expected to receive an equity stake in Rabian, fully funded research and development costs, and specified product milestones and royalties upon commercialization.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In March 2024, a peer-reviewed study on a C1-produced monoclonal antibody was published in Nature Communications. The study included preclinical trials in non-human primates and hamsters, demonstrating broad neutralization and protection against Omicron (BA.1, BA.2) and earlier COVID-19 variants. A non-human primate challenge study with the SARS-CoV-2 Delta variant showed promising protection, marking the first validation of a C1-produced monoclonal antibody's safety and efficacy in primates for infectious diseases..</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In April 2024, the Clinical Study Report was issued from the Phase 1 study of DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1 produced protein tested in humans conducted in collaboration with the Company&#8217;s commercialization partner, Rubic One Health. The study met its primary endpoint demonstrating both the low and high dose levels of the vaccine are safe and well tolerated among participants. Additionally, the vaccine induced immune responses at both dose levels, suggesting its potential efficacy in generating protective immunity against the target virus. As the coronavirus has rapidly mutated away from the original strain, Dyadic and its DYAI-100 partner Rubic One Health determined exploring future COVID variants to be more feasible than continuing development of DYAI-100.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Rubic One Health, South Africa</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In April 2023, the Company expanded the license agreement with South Africa&#8217;s Rubic One Health (&#8220;Rubic&#8221;) to include vaccines and therapeutic proteins beyond COVID-19 for both human and animal health markets. This is a collaboration to develop end-to-end solutions to develop, manufacture, commercialize, and distribute affordable vaccines and biologics for human and animal health in underserved African countries. Tech transfer of the C1&#160;platform has been completed. Under the license agreement, Dyadic is expected to receive certain marketing rights and other considerations, including milestones and royalty payments, from Rubic. In 2024, Rubic began development of several livestock animal vaccines for the African market.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Phibro/Abic Sublicense Agreement</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On February 8, 2022, the Company entered into an exclusive sublicense agreement with Abic Biological Laboratories Ltd&#160;(&#8220;Abic&#8221;), an affiliate of Phibro Animal Health Corporation (&#8220;Phibro&#8221;), based on an existing July 1, 2020, non-exclusive sublicense and development agreement (the &#8220;Phibro/Abic Agreement&#8221;), to provide services for a targeted disease. On March 15, 2024, the Company expanded its collaboration with Phibro/Abic to develop vaccines and treatments for livestock animal diseases.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Fondazione Biotecnopolo di Siena (FBS)</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In 2024, the Company entered a strategic collaboration with Fondazione Biotecnopolo di Siena (FBS), a non-profit foundation backed by the Italian government, including the Ministry of Health, Ministry of Economy and Finance, Ministry of Universities and Research, and Ministry of Enterprise and Made in Italy. On March 20, 2025, the Company announced that it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vaccines through the partnership with FBS.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Gates Foundation</i>&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On November 21, 2024, the Company announced that it has been awarded an approximately $3.0&#160;million grant from the Gates Foundation for the cell line development of mAbs targeting respiratory syncytial virus and malaria utilizing the C1 platform to provide globally accessible treatment options for underserved populations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>C1 produced Ferritin Nanoparticle Vaccines</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H5 Avian Influenza (&#8220;Bird Flu&#8221;) Vaccine Candidate (in collaboration with ViroVax, LLC):</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:7.8%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9632;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A C1-produced, self-assembling ferritin nanoparticle antigen is under evaluation for diagnostics and vaccines across poultry, cattle, humans, and companion animals to help address the ongoing Bird Flu outbreak.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:7.8%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9632;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pre-commercial research and validation efforts are actively underway to support potential strategic partnerships and licensing opportunities.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mpox Vaccine Candidate (in collaboration with ViroVax): A C1-produced ferritin nanoparticle Mpox vaccine candidate is in the early stage of preclinical development.&#160;This project not only would expand our portfolio but also would reinforce the C1 platform&#8217;s proven ability to rapidly develop and produce cost-effective recombinant protein vaccine antigens.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Diagnostics &amp; Vaccine Advancements</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H5 Avian Influenza Cross-Protection: The C1-produced adjuvanted ferritin nanoparticle H5-2.3.4.4b A/Astrakhan vaccine candidate has demonstrated cross-protection against multiple H5 virus strains in early-stage research, indicating a broad protective potential.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Poultry &amp; Cattle Applications:</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:7.8%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9632;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Poultry: Early trials show that the C1-produced H5-2.3.4.4b A/Astrakhan antigen generates neutralizing antibodies, supporting its potential commercial viability for vaccines and diagnostic tools.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:7.8%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9632;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cattle: Preliminary diagnostic and vaccine development data suggest promising cross-protection, highlighting a significant opportunity in a broader market segment.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Government Regulation and Product Approval</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a small biotech&#160;company that operates in the United States, we are subject to extensive regulation. Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug products such as those we are developing. Product candidates that we develop must be approved by the FDA, before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. For additional discussion on the effect of existing or probable governmental regulations on our business, see &#8220;Item 1A. Risk Factors&#8212;Risks Related to Government Regulations and Environmental, Social, and Governance Issues.&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Employees</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of December 31, 2024, the Company had 6 full-time employees, all of whom are located in the United States.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Intellectual Property</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Patents are important to developing and protecting our competitive position. Our general policy is to seek patent protection in the United States, major European countries, and other jurisdictions as appropriate for our compounds and methods. U.S. patents, as well as most foreign patents, are generally effective for 20 years from the date the earliest patent application was filed. In some cases, the patent term may be extended to recapture a portion of the term lost during the U.S. FDA regulatory review or because of U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) delays in prosecuting the application. The duration of foreign patents varies similarly, in accordance with local law.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Currently, Dyadic owns or has exclusive rights to seven (7) patent families, all of which have entered the national phase. There are currently two (2) patents and six (6) pending patent applications in the United States, one patent in South Africa, and twenty-nine (29) additional patent applications in a variety of jurisdictions including Europe and China.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our success is significantly dependent on our ability to obtain and maintain patent protection for C1 and Dapibus&#8482;, both in the United States and abroad. Our patent position and proprietary rights are subject to various risks and uncertainties. Please read the &#8220;Item 1A. Risk Factors&#8221; of this Annual Report for information about certain risks and uncertainties that may affect our patent position and proprietary rights.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We also rely upon unpatented confidential information to remain competitive. We protect such information principally through confidentiality agreements with our employees, consultants, outside scientific collaborators, and other advisers. In the case of our employees, these agreements also provide, in compliance with relevant law, that inventions and other intellectual property conceived by such employees during their employment shall be our exclusive property.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Available Information</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Information that we furnish to or file with the SEC, including the Company&#8217;s annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to, or exhibits included in, these reports are made available for download, free of charge, through the Company&#8217;s website at www.dyadic.com as soon as reasonably practicable. The Company&#8217;s SEC filings, including exhibits filed therewith, are also available directly on the SEC&#8217;s website at www.sec.gov.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company may use its website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Company&#8217;s website. Accordingly, investors should monitor this channel, in addition to following the Company&#8217;s press releases, SEC filings and public conference calls and webcasts. Information contained on the Company&#8217;s website is not part of this report.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:28pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b><a id="Item1A_Risk" title="Item1A_Risk" href="#"></a>Item 1A. </b></p> </td>
     <td style="width: auto; vertical-align: bottom;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Risk Factors</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Investing in our common stock involves a high degree of risk. You should carefully consider the following material risks, together with the other matters described in this Annual Report and in our financial statements and the related notes thereto in evaluating our current business and future performance. We cannot assure you that any of the events discussed in the risk factors below will or will not occur. If we are not able to successfully address any of the following risks, we could experience significant changes in our business, operations and financial performance. In such circumstances, the trading price of our common stock could decline, and in some cases, such declines could be significant, and you could lose part or all of your investment. In addition to the risks described below, other unforeseeable risks that we currently believe are immaterial may arise that adversely affect our operating results. Certain statements contained in this Annual Report (including certain statements used in the discussion of our risk factors) constitute forward-looking statements. Please refer to the section entitled </i>&#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>&#8221;<i> for important information regarding reliance on forward-looking statements.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Business and Financial Condition</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We may not succeed in implementing our business strategy.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As we attempt to adapt our microbial protein production platforms, including C1 and Dapibus&#8482; and our other technologies for use in the biopharmaceutical and other markets, our business is subject to the execution, integration, and research and development risks that early-stage companies customarily face with new technologies, products and markets. These risks relate to, among other things, our ability to successfully further develop our protein production platforms and our other technologies, products and processes, assemble and maintain adequate production and research and development (&#8220;R&amp;D&#8221;) capabilities, comply with regulatory requirements, construct effective channels of distribution and manage growth. We have encountered and will continue to encounter risks and difficulties frequently experienced by early-stage companies in expanding and upgrading our intellectual property, regulatory, marketing, sales and R&amp;D capabilities, improving our accounting and financial reporting and internal controls infrastructure, and adapting to the rapidly evolving industries in which we operate. Additionally, we are subject to competition from much larger companies with more resources than we have. Also, the market for developing and manufacturing pharmaceutical proteins produced from a filamentous fungus, such as the C1 fungus, is a market that is not yet established and is subject to a high level of regulatory hurdles from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and other governmental bodies, and there is a risk that such technologies will not be adopted by the pharmaceutical industry or governmental agencies and therefore not succeed and/or not grow at the rates projected or at all.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have not yet commercialized any products based on our platforms and technologies, and we may never be able to do so. We do not know when or if we and/or our current and/or future collaborators and licensees will complete any of our or their product development efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved products. Even if we and/or our licensees and collaborators are successful in developing products that are approved for marketing, we and they will still require that these products gain regulatory approval and market acceptance. The biopharmaceutical industries in which we operate are high-risk industries in that even if we are successful at expressing certain proteins, these proteins may fail to be advanced or approved for use or sale for many reasons including their characteristics, biological activity, biological comparability, biological similarity, stability, glycosylation structures, containments, purity, performance, safety and regulatory reasons.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Because of the numerous risks and uncertainties associated with pharmaceutical and other product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve certain technology, product and/or commercial milestones, access fees and royalties, launch products and/or processes, or achieve profitability. For instance, we cannot predict whether Danisco intends to or will pursue the use of the C1 platform to develop or manufacture pharmaceutical products or whether or when we might receive royalties from Danisco. In addition, our expenses could increase if we are required by the FDA or other domestic and foreign regulatory authorities to perform studies or trials in addition to those currently expected, or if there are delays in completing additional safety studies such as toxicology and pathogenicity studies, clinical trials, preclinical studies, animal or human studies or the development of any of our or our collaborators&#8217; product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>A significant portion of our revenue is derived from a small number of customers.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the years ended December 31, 2024 and 2023, the Company&#8217;s revenue was generated from 19 and 16 customers, respectively. As of December 31, 2024 and 2023, the Company&#8217;s accounts receivable was from nine and thirteen customers, respectively. Significant customers are those that account for greater than 10% of the Company&#8217;s revenues. For the years ended December 31, 2024 and 2023, two significant customers accounted for approximately $1,915,000 or 54.8% and $1,503,000 or 51.9% of revenue, respectively. We cannot assure you that these customers will continue to contract with us on terms currently in effect or other terms which are favorable but not currently in effect, or whether they will elect to contract with our competitors or attempt to perform the services themselves. The loss of business from one or a combination of the Company&#8217;s customers, if not offset by revenue from new or other existing customers, or any inability of any customer to pay amounts as and when due, could adversely affect its operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We have a history of net losses, and we may not achieve or maintain profitability.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2024, we had an accumulated deficit of approximately $86.1 million. Our profitability has strongly relied on, and will be even more reliant going forward on, third-party industry and government research funding, licensing partnerships and other forms of collaborations. We believe that it is likely that if we do not sign license agreements or other forms of collaborations, we will incur losses because of our planned levels of R&amp;D and additional general and administrative expenditures that we believe are necessary to operate our business and further develop our microbial protein production platforms and other technologies for use in the pharmaceutical and non-pharmaceutical industries. The amount of our future net losses will depend, in part, on the rate of increase in our expenses along with other potential costs of unforeseen circumstances, our ability to generate research funding, government grants, receipt of access fees, milestones, royalty and other payments, and whether we are able to generate revenues by entering into license agreements or other forms of collaborations, launch new products and/or processes from future licensees or collaborators, and our ability to raise additional capital. The net losses we anticipate incurring over the next several years will have an adverse effect on our working capital, financial condition, results of operations and prospects.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The R&amp;D efforts needed to enhance and leverage our microbial protein production platforms, including C1 and Dapibus&#8482;, for use in developing and manufacturing human and animal biopharmaceuticals and other non-pharmaceutical products will require significant funding and increased staffing. Therefore, we expect near-term operating and research expenses to continue, and maybe even accelerate, as we further develop our research and business plans, and our goals and objectives. Consequently, we will require significant additional revenue to achieve profitability. We cannot provide assurance that we will be able to generate any revenues from our focus and efforts as we intend to apply our C1-cell and Dapibus&#8482; into the biopharmaceutical and non-pharmaceutical industries. If we fail to enter into new license agreements or other forms of collaborations or generate revenues and profit from additional research projects and government grants, the market price of our common stock will likely decrease. Further regulatory complications, competition from other technologies, or delays in our research programs and the adoption and use of the C1-cell and Dapibus&#8482; protein production platforms and our other technologies by the biopharmaceutical and non-pharmaceutical industries may force us to reduce our staffing and research and development efforts, which may further affect our ability to generate cash flow.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result of our limited financial and managerial resources, we must make strategic decisions as to which targets and product candidates to pursue and may forego or delay pursuit of opportunities with other targets or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business, financial condition, results of operations and prospects. Our spending on current and future R&amp;D programs and product candidates may not yield any commercially viable products. Our understanding and evaluation of biological targets for the discovery and development products expressed from C1 may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do not accurately evaluate the likelihood of clinical trial success, commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We could fail to manage our growth.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We will need to take the following steps, among others, to manage our growth. If we fail to achieve one or more of these, it could have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Balance our cash burn with technology and product development;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Maintain and add additional CROs, other third-party service providers or other technology collaborators;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Maintain and add additional collaborators, strategic partners technology licensees or other forms of structures</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Recruit, hire, and maintain the required employees necessary to maintain and grow our business and to advance our technologies and products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Achieve technical and commercial success in our research and product development programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Access required manufacturing capacity;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Access additional capital;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Recruit and maintain consultants, board members, and scientific advisory board members; and</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Manage scientific risks and uncertainties that may arise during our R&amp;D and regulatory programs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our revenue growth depends in part on market and regulatory acceptance of our microbial protein production platforms and other technologies to develop and manufacture animal and/or human biopharmaceutical and non-pharmaceutical products.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The success of our business will depend on our ability to develop, register, and introduce similar, new and improved technologies and products in a timely manner, at significantly lower manufacturing costs that address the evolving requirements of the relevant industries and potential customers. There is no assurance that the C1 platform or any product expressed from C1, or our other technologies, will perform the same or better or save our customers money relative to existing gene expression technologies or those of our competitors, obtain governmental safety and regulatory approvals, be registered or gain market acceptance. If we fail to develop similar, new and better performing technologies, products and processes at significantly lower manufacturing costs, make fermentation yield improvements on our existing production processes, generate the necessary safety and regulatory data or gain registration and market acceptance of the C1-cell and Dapibus&#8482; protein production platforms, or our other technologies, products or processes, we could fail to recoup our R&amp;D investments and fail to capitalize on potential opportunities or gain market share from our competitors. Any failure, for technological, quality, safety, regulatory, or other reasons, to develop and launch improved technologies and new products, could negatively impact our business, financial condition and results of operation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The dynamic and conservative nature of the industries in which we operate, the unpredictable nature of the product development process and the time and cost of new technology adoption in the industries in which we operate may affect our ability to meet the requirements of the marketplace or achieve market and/or regulatory acceptance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The expenses or losses associated with unsuccessful technology and product development activities or lack of market acceptance of our new technologies and products could harm our business, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We may fail to commercialize our microbial protein production platforms or other technologies for the expression of therapeutic proteins, antibodies, vaccines, and metabolites or other non-pharmaceutical biologic products.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have not yet completed the necessary safety, efficacy, cost and regulatory studies, or the commercialization of any therapeutic proteins, antibodies and vaccines, and metabolites or other non-pharmaceutical biologic products based on C1 or Dapibus&#8482;.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To date, drug companies have developed and commercialized only a small number of gene-based products in comparison to the total number of drug molecules available in the marketplace. Our biopharmaceutical business should be evaluated as having the same risks as those inherent to early-stage biotechnology companies because the application of the C1 platform for the expression of pre-clinical and clinical quantities of therapeutic proteins, antibodies and vaccines is still in early development.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Successful development of our microbial protein production platforms, including C1 and Dapibus&#8482;, for biopharmaceutical and non-pharmaceutical purposes will require significant research, development and capital investment, including testing, to prove its safety, efficacy and cost-effectiveness. In general, our experience has been that each step in the process has been longer and costlier than originally projected, and we anticipate that this is likely to remain the case with respect to the continuing development efforts of our biopharmaceutical and non-pharmaceutical business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>If our competitors develop technologies and products more quickly and market more effectively than our product candidates, our commercial opportunity will be reduced or eliminated.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The industries in which we operate are characterized by rapid technological change, and the area of gene and protein research and platform development is a rapidly evolving field. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the issues and conditions for which we are developing product candidates. As such, any products we or our current collaborators or licensees develop through the C1 platform, or through our other technologies, will compete in highly competitive and regulated markets. For more information on our competition, see &#8220;Item 1. Business&#8212;Competition.&#8221; Many of these competitors for such products have more capital resources, larger R&amp;D and marketing staff, facilities and capabilities, and greater experience in research and development, regulatory approval, manufacturing and commercialization of technology and products. Accordingly, our competitors may be able to develop technologies and products more rapidly. Our future success will depend on our ability to maintain a competitive position with respect to technological advances in terms of product and process quality, stability, safety, productivity and cost. If a competitor develops superior technology or products, or more cost-effective alternatives to our and our collaborators&#8217; or licensees&#8217; technologies, products or processes, it could have a material adverse effect on our business, financial condition and results of operations. Well-known and highly competitive biotechnology companies offer comparable or alternative technologies for the same products and services as our biopharmaceutical and non-pharmaceutical business. We anticipate that we and our current or future collaborators and licensees will continue to encounter increased competition as new companies enter these markets and as the development of biological processes and products evolves, and there is no guarantee that our product candidates will be able to compete with potential future products being developed by competitors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Alternative technologies may not require microbial or other cell produced proteins, such as our proprietary C1 cells.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Research is being conducted with cell or gene-based therapies and other technologies that offer a possible alternative to producing proteins as they are being produced today based on microbial, organic matter containing carbon, hydrogen, and oxygen or other organisms, such as our proprietary C1 cells or Dapibus&#8482;. Alternative methods may allow genes to be directly inserted into cells that can be implanted into animals and humans directly, displacing the need for the existing methods used for the development of biologic vaccines and drugs. If they are successful, these new methods may supplant or greatly reduce the need for microorganisms, carbon, hydrogen, and oxygen or other organisms, including our C1 cells and Dapibus&#8482;, to produce these proteins externally as the injected cells in animals and humans may be able to do so internally.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>The results of nonclinical studies and early-stage clinical trials may not be predictive of future results.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The results of nonclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence may not be predictive of the results of the later-stage clinical trials. Vaccine and drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and initial clinical trials. There is a high failure rate for drugs proceeding through clinical trials, and a number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our vaccine and drug candidates. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval of any products. Any such setbacks in our clinical development could have a material adverse effect on our business and operating results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We may need substantial additional capital in the future to fund our business.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our future capital requirements may be substantial, particularly as we continue to further develop, engineer and optimize our microbial protein production platforms and other proprietary technologies, products and processes for licensing for research and development, and commercialization of potential animal and human pharmaceutical and other products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We currently have very little leverage, and if our capital resources are insufficient to meet our capital requirements, we will have to raise additional funds to continue the development of our technologies and complete the development and commercialization of products, if any, resulting from our technologies. If the acquisition of additional funds is not possible or if we engage in future equity financings, dilution to our existing stockholders may result. If we raise capital through debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business. Also, to the extent we raise additional capital through the issuance of equity or convertible debt securities in the future, there will be further dilution to investors and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. We may not be able to raise funds on terms that are favorable to us, if at all. Our ability to raise additional funds when needed and on acceptable terms will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. See, for example,<i> </i>&#8220;&#8212;<i>Changes in global economic and financial markets may have a negative effect on our business.</i>&#8221; If we fail to raise sufficient funds and incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research or development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, sell certain assets of the company which will limit future opportunities, or grant licenses on terms that are not favorable to us. Without sufficient funding or revenue, we may have to curtail, cease, or dispose of one or more of our operations, which would have a material adverse effect on our business, financial condition, and future prospects.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Changes in global economic and financial markets may have a negative effect on our business.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our business is subject to a variety of market forces including, but not limited to, domestic and international economic, political and social conditions. Many of these forces are beyond our control, including generally weak or uncertain economic conditions, negative or uncertain political climates, changes in government and election results in the United States and other jurisdictions in which we operate. Any change in market conditions that negatively impacts our operations or the demand of our current or prospective customers could adversely affect our business operations. For example, economic uncertainty and volatility, including as a result of high-interest rates and inflation, have had and may continue to have a material adverse effect on our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Changes in the global financial, pharmaceutical and biotech markets may make it difficult to accurately forecast operating results. These changes have had, and may continue to have, a negative effect on our business, results of operations, financial condition and liquidity. In the event of a downturn in global economic activity, current or potential business partners may go out of business, may be unable to fund purchases or determine to reduce purchases, all of which could lead to reduced demand for our products and increased payment delays or defaults. We are also limited in our ability to reduce costs to offset the results of a prolonged or severe economic downturn given certain fixed costs associated with our operations and difficulties if we over strained our resources. The timing and nature of a sustained recovery in the credit and financial markets remain uncertain, and there can be no assurance that market conditions will significantly improve in the near future or that our results will not continue to be materially and adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, geopolitical risks, including those arising from political turmoil, trade tension or the imposition of trade tariffs and/or sanctions, terrorist activity and acts of civil or international hostility, are increasing. For instance, the ongoing military conflict between Russia and Ukraine, as well as conflicts in the Middle East have had negative impacts on the global economy and is expected to have further global economic consequences. Any such events and responses, including regulatory developments, may cause significant volatility and declines in the global markets, disproportionate impacts to certain industries or sectors, disruptions to commerce (including to economic activity, travel and supply chains), loss of life and property damage, and may materially and adversely affect the global economy or capital markets, as well as our business and results of operations. Should an economic slowdown occur in the U.S. or globally, our business and results of operations may be materially adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We face risks related to widespread outbreaks of contagious disease or other biological threats, any of which could significantly disrupt our operations and have a material adverse effect on our business, employees, directors, consultants, collaborators and other third parties, including business development activities and research and development projects conducted by third party contract research organizations parties.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Significant outbreaks of contagious diseases, and other adverse public health developments, have had and could have a material impact on our business operations, financial condition, and operating results. Pandemics and other outbreaks of contagious disease have in the past and could in the future significantly impact the operation of our business. For example, pandemics have in the past adversely affected our ability to carry on certain business development activities, including as a result of restrictions in business-related travel, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines. In addition, pandemics and other outbreaks of contagious disease have in the past and may in the future exacerbate other risks disclosed in this Annual Report. See, for example, &#8220;-<i>Changes in global economic and financial markets may have a negative effect on our business.</i>&#8221; Whether and to what extent future pandemics and other outbreaks of contagious diseases may impact our financial and operational performance will depend on developments that include the duration, spread and severity of the outbreak, the timetable for administering and efficacy of vaccines, the duration and geographic scope of related travel advisories and restrictions and the extent of the impact of the pandemic or outbreak on overall demand for our products, technologies and services, and other factors beyond our control, all of which are highly uncertain and cannot be predicted.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our sales and operations are subject to the risks of doing business internationally.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our sales and operations are subject to the risks of doing business internationally, as we have customers and partners located outside of the United States. Conducting business internationally exposes us to a variety of risks, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Changes in or interpretations of foreign regulations that may adversely affect our ability to sell our products, repatriate profits to the United States or operate our foreign-located facilities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The imposition of tariffs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The imposition of limitations on, or increase of, withholding and other taxes on remittances and other payments by our foreign subsidiary or joint ventures;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Uncertainties relating to foreign laws, regulations and legal proceedings including tax, import/export, anti-corruption and exchange control laws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The availability of government subsidies or other incentives that benefit competitors in their local markets that are not available to us;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Increased demands on our limited resources created by our operations may constrain the capabilities of our administrative and operational resources and restrict our ability to attract, train, manage and retain qualified management, technicians, scientists and other personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Economic or political instability in foreign countries;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Difficulties associated with staffing and managing foreign operations; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The need to comply with a variety of United States and foreign laws applicable to the conduct of international business, including import and export control laws and anti-corruption laws.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any violations of international laws and regulations may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>If we lose key personnel, including key management or board members, or are unable to attract and retain additional personnel, it could delay our technology and product development programs and harm our R&amp;D efforts, and we may be unable to pursue research funding, licenses and other forms of collaborations or develop our own products.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our planned activities will require retention, and ongoing recruiting of additional expertise in specific areas applicable to our industries, technologies and products being developed. These activities will not only require the development of additional expertise by existing management personnel, but also the addition of new research and scientific, regulatory, licensing, sales, marketing, management, accounting and finance and other personnel. The inability to acquire or develop this expertise or the loss of principal members of our management, board of directors, consultants, accounting and finance, sales, and scientific staff could impair the growth, if any, of our business. However, competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited number of individuals who possess the skills and experience required by our industry. As such, competition for experienced personnel from numerous companies, academic institutions and other research facilities may limit our ability to attract and retain qualified management, directors, consultants, and scientific personnel on acceptable terms. Failure to attract and retain qualified personnel would inhibit our ability to maintain and pursue collaborations and develop our products and core technologies.&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Personnel changes may disrupt our operations. Hiring and training new personnel will entail costs and may divert our resources and attention from revenue-generating efforts. In addition, we periodically engage consultants to assist us in our business and operations. These consultants operate as independent contractors, and we therefore do not have as much control over their activities as we do over the activities of our employees. Our directors and consultants may be affiliated with or employed by other parties, and some may have consulting or other advisory arrangements with other entities that may conflict or compete with their obligations to us.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt product development and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. Many compounds developed in the biopharmaceutical industry that initially showed promise in early stages have later been found to cause side effects that prevented their further development. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We may be sued for product liability.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We or our current and future collaborators and licenses may be held liable if any product we or they develop, or any product which is made with the use or incorporation of, any of our technologies, causes injury or is found otherwise unsuitable or unsafe during product testing, manufacturing, marketing or sale. These claims could be brought by various parties, including other companies who purchase products from our current and future collaborators and licenses or by end users of the products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Decreased demand for our current or future product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Injury to our reputation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Costs to defend the related litigation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Diversion of management&#8217;s time and our resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Loss of revenue; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The inability to commercialize our current or any future product candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">While we maintain product liability insurance, it may not fully cover all of our potential liabilities and our liability could in some cases exceed our total assets, which would have a material adverse effect on our business, results of operations, financial condition and cash flows, or cause us to go out of business. Further, insurance coverage is expensive and may be difficult to obtain and may not be available to us or to our collaborators and licensees in the future on acceptable terms, or at all. Inability to obtain sufficient insurance coverage at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products developed by us, or our collaborators and licensees.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Foreign currency fluctuations could adversely affect our results.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the conduct of our business, in certain instances, we are required to receive payments or pay our obligations in currencies other than U.S. dollars. Especially since a large portion of our research and development is done in Europe, our CROs and certain consultants request payments in Euros. As a result, we are exposed to changes in currency exchange rates with respect to our business transactions denominated in non-US dollars. Fluctuations in currency exchange rates have in the past and may in the future negatively affect our revenue, expenses and our financial position and results of operations as expressed in U.S. dollars.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our ability to use our net operating loss carryforwards (</i></b>&#8220;<b><i>NOLs</i></b>&#8221;<b><i>) to offset future taxable income may be subject to certain limitations.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In general, under Section 382 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its NOLs, to offset future taxable income. If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations arising from previous ownership changes, our ability to utilize NOLs could be limited by Section 382 of the Internal Revenue Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Internal Revenue Code. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We may make acquisitions, investments and strategic alliances that may use significant resources, result in disruptions to our business or distractions of our management, may not proceed as planned, and could expose us to unforeseen liabilities.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We may seek to expand our business through the acquisition of, investment in and strategic alliances with companies, technologies, products, and services. If we are able to identify suitable acquisition, investment or strategic alliance targets, we may be unable to successfully negotiate their acquisition at a price or on terms and conditions acceptable to us.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We cannot assure you that, following an acquisition, investment or strategic alliance, we will achieve expected research and development results, anticipated synergies, revenues, specific net income or loss levels that justify such transaction or that the transaction will result in increased earnings, or reduced losses, for the combined company in any future period. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or to provide funding for such business, which would result in dilution for stockholders or the incurrence of indebtedness and may not be available on terms which would otherwise be acceptable to us. We may not be able to oversee such investments nor operate acquired businesses profitably or otherwise implement our growth strategy successfully.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the ordinary course of our business, we collect, store and transmit&#160;confidential information, including intellectual property, proprietary business information and personal information. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cybersecurity attacks, ransomware attacks, breaches, intentional or accidental mistakes or errors, or other technological failures, which can include, among other things, computer viruses, malware, exploit of unpatched product or service vulnerabilities, unauthorized access attempts (including third parties gaining access to systems using stolen or inferred credentials), denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and telecommunication and electrical failures. As the cyber-threat landscape evolves, these attacks are growing in frequency, levels of persistence, sophistication and intensity, are becoming increasingly difficult to detect, and are being conducted by sophisticated groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Resulting system failures, accidents, or security breaches could cause interruptions in our operations and could result in a material disruption of our research activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. While we have experienced and continue to experience system failures, accidents and security breaches from time to time, none has been material to date. To the extent that any disruption or security breach was to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and delays in our research efforts and financial reporting compliance, as well as a significant increase in costs to recover or reproduce the data.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Of special note is our risk when implementing new capabilities. The implementation of new systems and information technology could adversely impact our operations by requiring substantial capital expenditures, diverting management&#8217;s attention, or causing delays or difficulties in transitioning to new systems. As we implement new systems, many times both new and old systems run in parallel until all processes have successfully transferred to the new system and thorough testing has been performed. These events could impact our customers, suppliers, subcontractors, employees, our financial reporting and our reputation and lead to financial losses from remediation actions, loss of business or potential liability, or an increase in expense, all of which may have a material adverse effect on our business. Our systems implementations may also not result in productivity improvements at the levels anticipated. In addition, the rapid evolution and increased adoption of artificial intelligence technologies may intensify our cybersecurity risks. <span style="background-color:#ffffff;">See &#8220;&#8212;</span><i><span style="background-color:#ffffff;">The use of new and evolving technologies, such as artificial intelligence (</span></i><span style="background-color:#ffffff;">&#8220;</span><i><span style="background-color:#ffffff;">AI</span></i><span style="background-color:#ffffff;">&#8221;</span><i><span style="background-color:#ffffff;">), in our business may result in reputational harm, competitive harm or legal liability.</span></i><span style="background-color:#ffffff;">&#8221;&#160;Likewise, cyber incidents, including malicious cyber-attacks perpetrated on our employees and cyber incidents caused by third parties surreptitiously accessing our systems by other means, are an on-going risk to the security of the systems, networks, inf</span>ormation and data of ours, our customers, subcontractors and suppliers. While we have security, internal control and technology measures in place to protect our systems and networks, confidential business information, personal data of ours, our customers, employees, suppliers and subcontractors, our information technology systems and those of our third-party service providers have been and may in the future be subject to system breaches. System breaches can lead to disclosure, modification and destruction of proprietary business data, personally identifiable information, other sensitive information, production downtime or loss of business, and damage to our reputation, competitiveness and operations. In addition, flexible working arrangements and remote working for overseas consultants may adversely impact our ability to maintain the security, proper function and availability of our information technology and systems since remote working by our employees and consultants could strain our technology resources and introduce operational risk, including heightened cybersecurity risk. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts that have sought, and may seek, to exploit remote working environments. In addition, current and future laws and regulations governing data privacy and the unauthorized disclosure of confidential information, including, but not limited to rules implemented by the SEC in 2023, may pose complex compliance challenges and result in additional costs. A failure to comply with such laws and regulations could result in penalties or fines, legal liabilities or reputational harm. The continuing and evolving threat of cyber-attacks has also resulted in increased regulatory focus on risk management and prevention. New cyber-related regulations or other requirements could require significant additional resources and cause us to incur significant costs, which could have an adverse effect on our results of operations and cash flows.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>The use of new and evolving technologies, such as artificial intelligence (</i></b>&#8220;<b><i>AI</i></b>&#8221;<b><i>), in our business may result in reputational harm, competitive harm or legal liability.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have in the past and will in the future integrate new and evolving technologies, such as AI, into our business. As with many innovations, AI presents risks and challenges that could affect its adoption and, as a result, our business. Our implementation of AI in our business may have unintended consequences due to its inherent limitations or our failure to use it effectively. For example, AI algorithms may be flawed due to a lack of back-testing or datasets of poor quality or inappropriate bias, and analyses generated by AI may be deficient or inaccurate, subjecting us to competitive or reputational harm. Additionally, AI entails significant legal risks. The intellectual property ownership and license rights of new technologies such as AI have not been fully addressed by U.S. courts, and the use or adoption of such technologies in our business may expose us to potential intellectual property claims, breach of a data or software license, website terms of service claims, claimed violations of privacy rights or other tort claims. Governmental regulation and laws related to AI may also increase the burden and cost of research and development or require increased transparency that makes it more difficult to protect our intellectual property. Other jurisdictions may decide to adopt similar or more restrictive legislation rendering the use of such technologies challenging. Social and ethical issues relating to the use of new and evolving technologies such as AI in our business could also harm our comp<span style="background-color:#ffffff;">etitive position and brand, or create legal liability, and may cause us to incur additional research and development costs to resolve such issues. Lastly, the rapid evolution and increased adoption of AI technologies may intensify our cybersecurity risks. For more information, see &#8220;&#8212;</span><i><span style="background-color:#ffffff;">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</span></i><span style="background-color:#ffffff;">&#8221;</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Changes to our outsourced software or infrastructure vendors as well as any sudden loss, breach of security, disruption or unexpected data or vendor loss associated with our information technology systems could have a material adverse effect on our business.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We rely on third-party software and infrastructure to run critical accounting, project management and financial information systems. If software or infrastructure vendors decide to discontinue further development, integration or long-term maintenance support for our information systems, or there is any system interruption, delay, breach of security, loss of data or loss of a vendor, we may need to migrate some or all of our accounting, project management and financial information to other systems. These disruptions could increase our operational expense as well as impact the management of our business operations, which could have a material adverse effect on our financial position, results of operations, cash flows and liquidity.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Dependence on Third Parties</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We are dependent on collaborations with third parties, and if we fail to maintain or successfully manage existing, or enter into new, strategic collaborations, we may not be able to develop and commercialize many of our technologies and products and achieve profitability. </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our R&amp;D revenue is generated from a small number of research collaborations. These collaborations could be delayed or be discontinued, as they have in the past, at any time with little advance notice. If these research collaborations are lost or do not perform as expected, it could have a material adverse effect on our business, financial condition and operating results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ability to enter into, maintain and manage collaborations in our target markets is fundamental to the success of our business. We currently rely on, and expect to continue to rely on, our current and future partners, in part, for research and development, manufacturing and distribution, sales and marketing services, and application and regulatory know how. In addition, we intend to enter into additional collaborations to conduct research, develop, produce, market, license and sell our technologies and products and processes we anticipate developing. However, we may not be successful in entering into collaborative arrangements with third parties. Any failure to enter into such arrangements on favorable terms could delay or hinder our ability to develop and commercialize our technologies, products and processes and could increase our costs of research and development and commercialization.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We have limited or no control over the resources that any collaborator or licensee may devote to our programs, and reductions in collaborators</i></b>&#8217;<b><i> R&amp;D budgets may affect our businesses.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any of our current or future collaborators or licensees may breach or terminate their agreements with us or otherwise fail to perform and conduct their required activities successfully and in a timely manner. Our collaborators or licensees may elect not to develop products arising out of our collaborative or license arrangements or may choose not to devote sufficient resources to the development, manufacture, market or sale of these products. If any of these events occur, we or our collaborators or licensees may not develop our technologies or commercialize our or their products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fluctuations in the R&amp;D budgets of government agencies, our customers, licensees, collaborators and research partners could have a significant impact on the interest in and demand for our technology. Our businesses could be seriously damaged by significant decreases in life sciences and/or pharmaceutical R&amp;D expenditures by government agencies and existing and potential partners.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We heavily rely on contracts with third-party CROs and other third-party service providers to conduct our research and development, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical trials, which may not be available to the Company on commercially reasonable terms or at all.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are dependent upon the performance and research capacity of a number of third-party CROs and other service providers to conduct our research and development projects, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical trials, which include services and programs in connection with the modification and enhancement of the Company&#8217;s C1 platform and to support our business development efforts for C1&#8217;s use in biopharmaceutical and other applications. For the year ended December 31, 2024, two CROs accounted for approximately 93.0% total research services we purchased and 58.9% of accounts payable. For more information, see &#8220;Item 1. Business&#8212;Our Research Partners and CROs.&#8221; The licensing and service arrangements with these third parties are not guaranteed to be obtained, renewed or continued on reasonable terms, if at all. The Company may be unable to obtain, maintain or expand its access to third party CROs and other service providers to conduct these services. Failure to obtain, maintain and expand access to certain third party CROs and other service providers could have a material adverse impact on the Company&#8217;s research projects, financial condition and operating results. In addition, from time to time there are disagreements with such third parties that if not resolved can have a material adverse effect on our business, financial condition and operating results. In sum, the loss of business from one of these CROs or a combination of them could in certain cases make it difficult to find a replacement and in turn adversely affect our operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are also heavily dependent upon the availability and performance of third-party research organizations. If we require research capacity and/or capabilities and are unable to obtain it in sufficient quantity, and quality or at terms and conditions that are acceptable to the Company or our third party collaborators, we may not be able to offer our technologies or products for license, or sale, or we may be required to make substantial capital investments to build out that capacity or to contract with other research organizations on terms that may be less favorable than our current arrangements. In addition, if we contract with other research organizations, we may experience delays of several months in qualifying them or in starting up research programs at these facilities, which could harm our relationships with our licensees, collaborators or customers, and we may be required to make a capital investment in connection with these arrangements. This could have a material adverse effect on our business, revenues or operating results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Additionally, if we were to be unsuccessful in retaining a CRO with the requisite experience and skills we require and were required to build our own research facility, it could take a year or longer before such owned research facility were able to be brought online to carry out the necessary technology and product development efforts of the Company.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Conflicts with the CROs, other service providers, collaborators and/or licensees could harm our business.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">An important part of our strategy includes involvement in proprietary research programs. We may pursue opportunities in the pharmaceutical and other fields that could conflict with those of our collaborators and licensees. Moreover, disagreements with Danisco, our current and/or future CROs, other service providers, collaborators or licensees could develop over rights to our intellectual property, over further licensing of our technologies to other parties in certain pharmaceutical and other fields, or for other reasons. Any conflict with Danisco, our current and/or future CROs, other service providers, collaborators or licensees could reduce our ability to obtain future collaboration agreements and negatively impact our relationship with existing collaborators or licensees, which could reduce our revenues and profits. For more information, see &#8220;Risk Factors&#8212;<i>We heavily rely on contracts with third-party CROs and other third-party service providers to conduct our research and development, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical trials, which may not be available to the Company on commercially reasonable terms or at all.</i>&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Some of our current and/or future CROs, other service providers, collaborators and/or licensees could also become competitors in the future. Our current and/or future CROs, other service providers, collaborators and/or licensees could develop competing technologies or products, preclude us from entering into collaborations or license agreements with their customers, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of their technology and products and processes. Any of these developments could harm our technology development and value, product development efforts, revenue, profits and overall business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We rely on our collaborators and other third parties to deliver timely and accurate information in order to accurately report our financial results as required by law.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We need to receive timely, accurate and complete information from a number of third parties in order to accurately and timely report our financial results. We rely on third parties to provide us with complete and accurate information regarding research developments and data, revenues, expenses and payments owed to or by us on a timely basis. We rely on the proper controls and procedures related to obtaining and reporting information from our CROs, licensees and collaborators related to research results and other data, when milestones are earned, if any, when royalties are earned, if any, as well as other types of potential revenues and expenses. If the information that we receive is not accurate, our consolidated financial statements may be materially incorrect and may require restatement. As a result, we may have difficulty in completing accurate and timely financial disclosures, which could have a material adverse effect on our business, financial condition and results of operations and the market price of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Government Regulations and Environmental, Social, and Governance Issues</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Potential future regulations limiting our ability to sell genetically engineered products could harm our business.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We, our current and future collaborators and licensees expect to develop biologic products using genetically engineered microorganisms (&#8220;GMOs&#8221;). Products derived from GMOs may in some instances be subject to bans or additional or changing regulation by federal, state, local and foreign government agencies. These agencies may not allow us or our collaborators and licensees to produce and market products derived from GMOs in a timely manner or under technically or commercially feasible conditions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Compliance with FDA, Environmental Protection Agency (&#8220;EPA&#8221;) and EU regulations could result in expenses, delays or other impediments to our product development programs or the commercialization of resulting products. The FDA currently applies the same regulatory standards to products made through genetic engineering as those applied to products developed through traditional methodologies. Regardless of GMO status, a product may be subject to lengthy FDA reviews and unfavorable FDA determinations due to safety concerns or changes in the FDA&#8217;s regulatory policy. The EPA regulates biologically derived enzyme-related chemical substances not within the FDA&#8217;s jurisdiction. An unfavorable EPA ruling could delay commercialization or require modification of the production process or product in question, resulting in higher manufacturing costs, thereby making the product uneconomical. The EU and other countries also have regulations regarding the development, production and marketing of products from GMOs, which may be as or more restrictive than U.S. regulations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Further, we, Danisco, and our current and future collaborators and licensees are subject to regulations in the other countries in which we operate outside of the U.S. and EU, which may have different rules and regulations depending on the jurisdiction. Different countries have different rules regarding which products qualify as GMOs. If any of these countries expand the definition of GMO and increase the regulatory burden on GMO products, our business could be harmed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other changes in regulatory requirements, laws and policies, or evolving interpretations of existing regulatory requirements, laws and policies, may result in increased compliance costs, delays, capital expenditures and other financial obligations that could adversely affect our business or financial results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may violate (intentionally or unintentionally) our internal processes and procedures, or engage in misconduct or other illegal activity. Such actions could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (1) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, including cGMP requirements, (3) data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (4) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify, prevent and deter these activities and/or misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be&#160;effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such actions, including fraud or other misconduct, even if none occurred. If any such actions are instituted against us, we may incur significant costs to respond, and if we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Public views on ethical and social issues may limit use of our technologies.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our success will depend in part upon our ability, and our current and future collaborators&#8217; or licensees&#8217; ability, to develop pharmaceutical and non-pharmaceutical products discovered, developed and manufactured through the C1 platform, and our other technologies. Governmental authorities could, for social, ethical or other purposes, limit the use of genetic processes or prohibit the practice of using a modified C1 organism to produce biologic vaccines, drugs and other biologic products. Concerns about the C1 platform and our other technologies, and particularly about the expression of genes from C1 for pharmaceutical and non-pharmaceutical purposes, could adversely affect their market acceptance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The commercial success of our current and future collaborations and our licensees&#8217; potential products will depend in part on public acceptance of the use of genetically engineered products including enzymes, vaccines, drugs and other protein products produced in this manner. Claims that genetically engineered products are unsafe for consumption or pose a danger to the environment, animals or humans may influence public attitudes. Our and our licensees&#8217; genetically engineered products may not gain public acceptance. Negative public reaction to GMOs and products could result in increased government regulation of genetic research and resulting products, including stricter labeling laws or other regulations, and could cause a decrease in the demand for our products. If we and/or our collaborators are not able to overcome the ethical, legal, and social concerns relating to genetic engineering, some or all of our products and processes may not gain public acceptance, which could have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our results of operations may be adversely affected by environmental, health and safety laws, regulations and liabilities.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We and the CROs, collaborators and licensees are subject to various federal, state and local environmental laws and regulations relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees. These laws, regulations and permits can often require expensive pollution control equipment or operational changes to limit actual or potential impacts to the environment. Even then, we cannot eliminate the risk of contamination or injury from these materials. A violation of these laws and regulations or permit conditions could result in substantial fines, criminal sanctions, permit revocations and/or facility shutdowns.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In recent years, environmental, health and safety laws and regulations have become increasingly more stringent, although this may change under the new U.S. presidential administration. In addition, new laws, new interpretations of existing laws, increased government enforcement of environmental laws, or other developments could require us or our CROs or other service providers to make additional significant expenditures. Present and future environmental laws and regulations and interpretations thereof, more vigorous enforcement of policies and discovery of currently unknown conditions may impair our research, development or production efforts or require substantial expenditures that could have a material adverse effect on our results of operations and financial position. Additionally, any such developments may have a negative impact on our contract manufacturers, which could harm our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Increasing scrutiny and changing expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Companies are facing increasing scrutiny from customers, regulators, investors, and other stakeholders related to their environmental, social and governance practices. Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, health and safety, supply chain management, diversity and human rights. Failure to adapt to or comply with regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation and the price of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, our customers may adopt policies that include social and environmental requirements or may seek to include such provisions in their contract terms and conditions. These social and environmental responsibility provisions and initiatives are subject to change and vary from jurisdiction to jurisdiction, and certain elements may be difficult and/or cost prohibitive for us to comply with given the inherent complexity and the global scope of our operations. In certain circumstances, in order to meet the requirements or standards of our customers, we may be obligated to modify our sourcing practices or make other operational choices which may require additional investments and increase our costs or result in inefficiencies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any of the factors mentioned above, or the perception that we or those with whom we conduct business have not responded appropriately to the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material adverse effect on our business, financial condition, results of operations cash flows and/or the price of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We have no experience submitting applications to the FDA or similar regulatory authorities in the past and may not be able to obtain regulatory approval or may be subject to lengthy and/or unfavorable regulatory proceedings.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">While we understand that many of our current and future collaborators or licensees may have a proven track record of experience submitting application to the FDA or other applicable regulatory authorities, we have no such experience in the past. Neither we nor any collaborator or licensee has yet submitted any application with the FDA or any other regulatory authority for any product candidate generated through the use of the C1 platform as it relates to the development and manufacture of pharmaceutical and other products. The FDA may not have substantial experience with technology similar to ours, which could result in delays or regulatory action against us. In addition, the new U.S. presidential administration has indicated it may institute significant changes to certain regulatory agencies, including the FDA, and it is difficult to predict the impact of these changes, if any. We and our current and future collaborators and licensees may not be able to able to obtain regulatory approval for C1 expressed products, which would harm our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The C1 platform has been tested for use in the manufacturing of an enzyme in the production of wine, beer and fruit juices, and has generated promising safety and toxicity data for that enzyme. The C1 platform could produce vaccines, antibodies, or therapeutic products and enzymes that have safety, toxicity, pathogenicity, immunogenicity and other issues associated with them. The C1 platform and our other technologies may be subject to lengthy regulatory reviews and unfavorable regulatory determinations if they raise safety questions which cannot be satisfactorily answered or if results from studies do not meet regulatory requirements. An unfavorable regulatory ruling could be difficult to resolve and could delay or possibly prevent a product from being commercialized, or even delay or prevent the use of the C1 platform or our other technologies to produce future products, which would have a material adverse effect on our growth and prospects. Additionally, future products produced by us or our current and future collaborators or licensees using the C1 platform, or our other technologies may not be approved by the FDA or other regulatory agencies in the U.S. or worldwide. There is no assurance that safety, toxicity, pathogenicity, immunogenicity and other issues will not arise in current or future product development and manufacturing programs due to media, fermentation, inherent properties or genetic changes in the C1 and other strains and fermentation processes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If these therapeutic protein products, antibodies or vaccines or other non-pharmaceutical products are not approved by regulators, we or our current and future customers or collaborators and licensees will not be able to commercialize them, and we may not receive research funding, upfront license fees, milestone and royalty payments, which are based upon the successful advancement of these products through the drug development and approval process. Even after investing significant time and expense, any regulatory approval may also impose limitations on the uses for which we can market a product, and any marketed product and its manufacturer are subject to continual review. Discovery of previously unknown problems with a product or manufacturer may result in new restrictions on the product, manufacturer and manufacturing facility, including withdrawal of the product from the market. In certain countries, regulatory agencies also set or approve prices, which may result in low or unprofitable margins and would have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Relating to Intellectual Property</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Failure to protect our intellectual property and the intellectual property of certain third parties could harm our competitive position.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our success will depend in part on our ability to obtain patents and on our and Danisco&#8217;s (as part of the DuPont Transaction, patents were assigned to Danisco) and our current and future collaborators&#8217; and licensees&#8217; ability to maintain adequate protection of our and their intellectual property. If we, Danisco, or our current and future collaborators and licensees do not adequately protect our intellectual property, competitors may be able to practice our technologies and erode our competitive advantage. The laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting their proprietary rights in these foreign countries.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">However, the patent positions of biotechnology companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our, and in certain instances the C1 patents assigned to Danisco, and our current and future collaborators&#8217; and licensees&#8217; proprietary technologies, are covered by valid and enforceable patents or are effectively maintained as trade secrets. We intend, from time to time, to apply for patents covering both our technologies and our products, while at other times, we only maintain such knowledge as trade secrets without applying for patents, as we deem appropriate. However, existing and future patent applications may be challenged and are not guaranteed to result in the issuing of patents. Even if a patent is obtained, it may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Others, including Danisco and our current and future collaborators and licensees, may independently develop similar or alternative technologies or design around our, Danisco&#8217;s or our current and future collaborators&#8217; and licensees&#8217; patented technologies. In addition, Danisco, our current and future collaborators, licensees, or other third parties may challenge or invalidate our patents, or our patents may fail to provide us with any competitive advantages. If any third party is able to gain intellectual property protections for technology similar to our own, they may be successful in blocking us and our licensees from using the C1 platform or our other technologies and/or commercializing products derived from them.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth of the claims upheld in our and other companies&#8217; patents. Given that the degree of future protection for our proprietary rights is uncertain, we cannot ensure that we were the first to invent the inventions covered by our pending patent applications, or that we were the first to file patent applications for these inventions or the patents we have obtained.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, Dyadic will continue to review its existing and potential patent positions and rights. Based on our analysis if and when the commercial opportunities and patent enforceability are questionable, we may abandon certain patents in some countries. There is a risk that we will abandon potentially valuable patents.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and resources and could prevent us and our collaborators from commercializing our or their technologies and products or negatively impact our stock price.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our commercial success depends in part on neither infringing patents and proprietary rights of third parties, nor breaching any licenses that we have entered into with regard to our technologies and products. Others have filed, and in the future are likely to file, patent applications covering genes or gene fragments, genetic elements, screening, gene expression and fermentation processes and other intellectual property that we may wish to utilize with the C1 platform or our other technologies or products and systems that are similar to those developed with its use. If these patent applications result in issued patents and we wish to use the claimed technology, we may need to obtain a license from the appropriate third party.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Third parties do and may continue to assert that we and/or our current and future collaborators and licensees are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes these patents. We could incur substantial costs and diversion of management and technical personnel in defending ourselves against any of these claims or enforcing our patents and other intellectual property rights. Parties making claims against us may be able to obtain injunctive or other equitable relief, which could effectively block our ability to further develop, commercialize and sell products, and could result in the award of substantial damages against us. If a claim of infringement against us is successful, we may be required to pay damages and obtain one or more licenses from third parties. In the event that we are unable to obtain these licenses at a reasonable cost, we and/or current and future collaborators and licensees could encounter delays in product commercialization while we attempt to develop alternative methods or products. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing available products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, unauthorized parties may attempt to steal, copy or otherwise obtain and use our C1 microbial strains, genetic elements, development and manufacturing processes, other technology or products. Monitoring unauthorized use of our intellectual property is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our technologies, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the United States. Moreover, third parties could practice our inventions in territories where we do not have patent protection. Such third parties may then try to import into the United States or other territories products, or information leading to potentially competing products, made using our inventions in countries where we do not have patent protection for those inventions. If competitors are able to use our technologies, our ability and our current and future collaborators&#8217; and licensees&#8217; ability to compete effectively could be harmed. Moreover, others may independently develop and obtain patents for technologies that are similar to or superior to our technologies. If that happens, we may need to license these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could harm our business, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We rely in part on trade secret protection to protect our confidential and proprietary information and processes. However, trade secrets are difficult to protect. We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective. We require employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, our proprietary information may be disclosed, third parties could reverse engineer our biocatalysts and others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Common Stock</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>The price of our shares of common stock is likely to be volatile, and you could lose all or part of your investment.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The trading price of our common stock has been, and is likely to continue to be, volatile. Biotechnology company stocks generally tend to experience extreme price fluctuations. The valuations of many biotechnology companies without consistent product sales and earnings are extraordinarily high based on conventional valuation standards such as price-to-earnings and price-to-sales ratios. These trading prices and valuations may not be sustained. Factors that may result in fluctuations in our stock price include, but are not limited to, the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Changes in the public&#8217;s perception of the prospects of biotechnology companies&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Sales of our common stock in the public market by such stockholders or other significant stockholders, executive officers, or directors&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Announcements of new technological innovations, patents or new products or processes by us, Danisco or our current or future collaborators, licensees and competitors&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Announcements by us, Danisco or our collaborators and licensees relating to our relationships with third parties&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Coverage of, or changes in financial estimates by us or securities and industry analysts&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Conditions or trends in the biotechnology industry&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Changes in investor interest in the areas in which we and/or our collaborators and licensees are applying our technologies, such as COVID-19&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Changes in the market valuations of other biotechnology companies&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Limitations or expanded uses in the areas within the biopharmaceutical or other industries into which we can apply our technologies and products&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Actual or anticipated changes in our growth rate relative to our competitors&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Developments in domestic and international governmental policy or regulations&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Announcements by us, Danisco, our current and future collaborators and licensees, or our competitors of significant acquisitions, divestures, strategic partnerships, license agreements, joint ventures or capital commitments&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The position of our cash, cash equivalents and marketable securities&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any changes in our debt position&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Developments in patent or other proprietary rights held by us, Danisco or by others&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Negative effects related to the stock or business performance of Danisco, our current and future collaborators and licensees, or the abandonment of projects using our technology by our collaborators and/or licensees&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Scientific risks inherent to emerging technologies such as the C1 platform or our other technologies&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Set-backs, and/or failures, and or delays in our or our current and future collaborators&#8217;&#160;and licensees&#8217;&#160;R&amp;D and commercialization programs&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Delays or failure to receive regulatory approvals by us, Danisco and/or our current and future collaborators and licensees&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Loss or expiration of our or Danisco&#8217;s intellectual property rights&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological material owned by us and/or Danisco US, Inc., and VTT Technical Research Centre of Finland Ltd&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Lawsuits initiated by or against us, Danisco, or our current and future collaborators and licensees&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Period-to-period fluctuations in our operating results&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Future royalties from product sales, if any, by Danisco, our current or future strategic partners, collaborators or licensees&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Future royalties may be owed to Danisco by us, our collaborators, licenses, or sub-licensees under certain circumstances related to our Danisco Pharma License&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Short positions taken in our common stock&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Sales of our common stock or other securities in the open market&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Stock buy-back programs&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Stock splits&#894;&#160;and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Decisions made by the board related to potential registration of Dyadic&#8217;s stock under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and/or up listing to another stock exchange.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we were to become party to a securities class action suit, we could incur substantial legal fees and our management&#8217;s attention and resources could be diverted from operating our business to responding to litigation.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our quarterly and annual operating results may be volatile.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our quarterly and annual operating results have fluctuated in the past and are likely to do so in the future. These fluctuations could cause our stock price to vary significantly or decline. Some of the factors that could impact our operating results include:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Expiration of or cancellations of our research contracts with current and future collaborators and/or licensees, which may not be renewed or replaced&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Setbacks or failures in our and our current and future collaborators&#8217;&#160;and licensees&#8217;&#160;research, development and commercialization efforts&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Setbacks, or delays in our research and development efforts to develop and produce biologics&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Setbacks, or delays in our research and development efforts to re-engineer the C1 platform or our other technologies for their applications and use in developing and producing biologics&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The speed, and success rate of our discovery and research and development efforts leading to potential licenses, or other forms of collaborations, access fees, milestones and royalties&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The timing and willingness of current and future collaborators and licensees to utilize C1 to develop and commercialize their products which would result in potential upfront fees, milestones and royalties&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">General and industry specific economic conditions, which may affect our current and future collaborators&#8217;&#160;and licensees&#8217;&#160;R&amp;D expenditures&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The adoption and acceptance of the C1 platform and our other technologies by biopharmaceutical and non-pharmaceutical companies and regulatory agencies&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The addition or loss of one or more of the collaborative partners, grants, research funding, or licensees we are working with to further develop and commercialize our technologies and products in the pharmaceutical industry&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our ability to file, maintain and defend our intellectual property and to protect our proprietary information and trade secrets&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our ability to develop technology, products and processes that do not infringe on the intellectual property of third parties&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The improvement and advances made by our competitors to CHO, <i>E.coli</i>, yeast, inset cells, plant and other expression systems&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The introduction by our competitors of new discovery and expression technologies competitive with the C1 platform&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our ability to enter into new research projects, grants, licenses or other forms of collaborations and generate revenue from such parties&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Scientific risk associated with emerging technologies such as the C1 platform&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Failure to bring on the necessary research and manufacturing capacity, e.g., CRO, CMO (contract manufacturing organization), and CDMO (contract development and manufacturing organization), if required&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Uncertainty regarding the timing of research funding, grants or upfront license fees for new C1 platform, our other technologies, collaborations, license agreements or expanded license agreements&#894;&#160;and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Delays or failure to receive upfront fees, milestones and royalties and other payments.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Due to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results are not necessarily a good indication of our future performance. Our operating results in some quarters, or even in some years, may not meet the expectations of stock market analysts and investors, potentially causing our stock price to decline.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We do not expect to pay cash dividends in the future.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have never paid cash dividends on our stock and do not anticipate paying any dividends for the foreseeable future. The payment of dividends on our stock, if ever, will depend on our earnings, financial condition and other business and economic factors deemed relevant for consideration by our board of directors. If we do not pay dividends, our stock may be less valuable because a return on investment will only occur if and to the extent that our stock price appreciates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our anti-takeover defense provisions may deter potential acquirers and depress our stock price.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Certain provisions of our certificate of incorporation, bylaws and Delaware law, as well as certain agreements we have with our executives, could make it substantially more difficult for a third party to acquire control of us. These provisions include the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may issue preferred stock with rights senior to those of our common stock&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have a classified board of directors&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Action by written consent by stockholders is not permitted&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our board of directors has the exclusive right to fill vacancies and set the number of directors&#894;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Cumulative voting by our stockholders is not allowed&#894;&#160;and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We require advance notice for nomination of directors by our stockholders and for stockholder proposals.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">These provisions may discourage certain types of transactions involving an actual or potential change in control. These provisions may also limit our stockholders&#8217; ability to approve transactions that they may deem to be in their best interests and discourage transactions in which our stockholders might otherwise receive a premium for their stock over the current market price.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Concentration of ownership among our existing officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our executive officers, directors and principal stockholders (5% stockholders) together control approximately 34.7% of our 29,835,799 shares of outstanding common stock as of December 31, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Founder and Chief Executive Officer Mark Emalfarb, through the Mark A. Emalfarb Trust U/A/D October 1, 1987, as amended (the &#8220;MAE Trust&#8221;) of which he is the trustee and beneficiary, owned approximately 15.6% of our outstanding common stock as of December 31, 2024. Further, the Francisco Trust U/A/D February 28, 1996 (the &#8220;Francisco Trust&#8221;), whose beneficiaries are the descendants and spouse of Mr. Emalfarb, owned approximately 11.4% of our outstanding common stock as of December 31, 2024. We have historically been partially controlled, managed and partially funded by Mr. Emalfarb, and affiliates of Mr. Emalfarb. Collectively, Mr. Emalfarb and stockholders affiliated with Mr. Emalfarb controlled approximately 27.0% of our outstanding common stock as of December 31, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr. Emalfarb may be able to control or significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of Mr. Emalfarb may not always coincide with the interests of other stockholders, and he may take actions that advance his personal interests and are contrary to the desires of our other stockholders.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If our existing officers, directors and principal stockholders act together, they will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. In addition, this concentration of ownership may delay or prevent a change in control and might affect the market price of our stock, even when a change may be in the best interests of all stockholders. Certain of our principal stockholders may elect to increase their holdings of our common stock, which may have the impact of delaying or preventing a change of control. Moreover, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders, and, accordingly, they could cause us to enter into transactions or agreements, which we would not otherwise consider.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Future resales of shares of our common stock may negatively affect our stock price.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The resale of shares of our common stock, or the perception that such resales could occur, could harm the prevailing market price of shares of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2024, there were 29,835,799 shares of our common stock outstanding. Approximately 34.7% of these outstanding common shares are beneficially owned or controlled by our executive officers, directors and principal stockholders.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our common stock has a relatively small public float. As a result, sales of substantial amounts of shares of our common stock, or even the potential for such sales, may materially and adversely affect prevailing market prices for our common stock. In addition, any adverse effect on the market price of our common stock could make it difficult for us to raise additional capital through sales of equity securities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>The Company is exposed to credit risk and fluctuations in the values of its investment portfolio.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s investments can be negatively affected by liquidity, credit deterioration, financial results, market and economic conditions, political risk, sovereign risk, interest rate fluctuations or other factors. As a result, the value and liquidity of the Company&#8217;s cash, cash equivalents, and marketable and non-marketable securities may fluctuate substantially, which could result in significant losses and could have a material adverse impact on the Company&#8217;s financial condition and operating results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We are a smaller reporting company, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are a smaller reporting company and are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. We are also exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley Act. These exemptions and reduced disclosures in our filings with the Securities and Exchange Commission due to our status as a smaller reporting company mean our auditors do not review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock prices may be more volatile.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research or reports regarding us, our business or our market, our stock price and trading volume could decline.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us, our business or our market<span style="background-color:#ffffff;">. We currently have two&#160;securities analysts publishing research about our stock.&#160;I</span>f no or few securities or industry analysts commence or maintain coverage of us, the trading price for our stock would be&#160;negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item1B_Unresolved" title="Item1B_Unresolved" href="#"></a>Item 1B.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Unresolved Staff Comments</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: left;">Not applicable.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><a id="item1c" title="item1c" href="#"></a>Item 1C.</b>&#160;<b> Cybersecurity</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="c2877256" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Cybersecurity Risk Management and Strategy</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item <em style="font: inherit;">106</em>(a) of Regulation S-K. These risks include, among other things, operational risks, the risk of intellectual property theft, fraud, harm to employees or <span style="-sec-ix-hidden:c125843295">third</span> parties with which we conduct business and violation of data privacy or security laws.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="c125843825">Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. We have established policies and controls for assessing, identifying and managing material cybersecurity risks and responding to material cybersecurity incidents.</ix:nonNumeric></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">34</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We routinely assess material cybersecurity risks, including potential unauthorized occurrences on, or conducted through, our information systems that <em style="font: inherit;"> may </em>compromise the confidentiality, integrity or availability of those systems or information maintained in them. We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments when there is a material change in our business practices that we believe could affect information systems that are vulnerable to cybersecurity threats. These risk assessments include identifying reasonably foreseeable internal and external risks and the potential harm if the risks were to materialize. We conduct these risk assessments directly and also periodically engage <span style="-sec-ix-hidden:c125843297">third</span>-party providers to support these processes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Following these risk assessments, we evaluate how to appropriately implement and maintain reasonable safeguards to mitigate identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We have implemented cybersecurity tools, conducted employee training, and monitored emerging laws and regulations related to data protection and information security. We <em style="font: inherit;"> may </em>a<span style="background-color:#ffffff;">lso obligate&#160;certa</span>in <em style="font: inherit;">third</em>-party business partners to certify that they can implement and maintain appropriate security measures, consistent with all applicable laws, in connection with their work for us, and to promptly report any suspected breach of their security measures that <em style="font: inherit;"> may </em>affect the&#160;Company.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cybersecurity events and data incidents are evaluated, assessed based on severity and prioritized for response and remediation. Under our incident response policies, incidents are evaluated to determine materiality as well as operational and business impact and reviewed for privacy impact.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="c125843827">We have not, to date, experienced a cybersecurity incident that was determined to be material, although, as a technology provider, we have experienced incidents in the past. Despite our cybersecurity efforts, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on our business. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to &#8220;Item 1A, Risk Factors&#8221; in this Annual Report on Form 10-K.</ix:nonNumeric>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="c2877257" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Cybersecurity Governance</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c125843828">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management team. Our board of directors has delegated responsibility to the Audit Committee for the oversight of risks from cybersecurity threats. Members of the Audit Committee receive regular updates from senior management, including leaders from our information technology, legal and compliance teams regarding matters of cybersecurity. This includes existing and new cybersecurity risks, information on how management is addressing and/or mitigating those risks, cybersecurity incidents (if any) and the status on key information security initiatives.</ix:nonNumeric></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="c125843832">Our Chief Executive Officer and Chief Financial Officer are principally responsible for overseeing the cybersecurity risk management program, in partnership with outside consultants, as well as managing and responding to material cyber incidents if any occur. Our CFO also serves as a board member at a cybersecurity and mobile IT solutions company. Although our CEO and CFO do not otherwise have cybersecurity expertise, their many years in Company management and risk oversight more generally position them well to oversee the cybersecurity risk management program, which they do in partnership with outside consultants. They provide periodic briefings to the Audit Committee and to the Board of Directors about our cybersecurity risks and activities, including cybersecurity incidents and responses, cybersecurity systems testing, third-party activities and related topics. In addition, our policies for managing and responding to cybersecurity incidents include procedures for appropriate escalations to our Audit Committee Chair.</ix:nonNumeric>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item2_Properties" title="Item2_Properties" href="#"></a>Item 2.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Properties</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company maintains its corporate headquarters at 1044 N US 1, Jupiter, Florida&#160;under a lease expiring&#160;on August 31, 2026,&#160;with an option to extend for two (2) successive one (1) year terms. The Company occupies this space with an annual rental rate of approximately $59,000, excluding common maintenance expenses. Rent is subject to three percent (3%) annual increases, and the Company is responsible for certain common area maintenance charges and taxes throughout the life of the lease.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">The Company maintains a small satellite office in Wageningen, The Netherlands under a lease with an annual rental rate of approximately $4,600. The lease expires on January 31, 2026,&#160;and thereafter, the Company&#160;</span>intends to reevaluate the need for <span style="background-color:#ffffff;">the leased space to align with the future operations of the Company.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We believe that our current office spaces are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space is available to accommodate any expansion of our operations, but such space may not be available in the same building if and when such space is needed.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item3_Legal" title="Item3_Legal" href="#"></a>Item 3.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Legal Proceedings</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently involved in any litigation that we believe could have a materially adverse effect on our financial condition or results of operations. For more information, see Note 4 to the Consolidated Financial Statements. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company&#8217;s or our subsidiaries&#8217; officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item4_Mine" title="Item4_Mine" href="#"></a>Item 4.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Mine Safety Disclosures</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Not applicable for our operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Part_2" title="Part_2" href="#"></a>PART II</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#160;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item5_Market" title="Item5_Market" href="#"></a>Item 5.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Market Information</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2024<span style="background-color:#ffffff;">, Dyadic had two classes of capital stock authorized, common stock and preferred stock. Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC&#8217;s NASDAQ Capital Market, under the symbol &#8220;DYAI&#8221;. There were no shares of preferred stock outstanding for the reported period.&#160;The number of record holders of our common stock as of </span>December 31, 2024<span style="background-color:#ffffff;"> was 47</span>, including The Depository Trust Company, which holds shares of our common stock on behalf of an indeterminate number of beneficial owners.<span style="background-color:#ffffff;">&#160;We have never declared or paid any&#160;dividends in the past. Any future determination to pay dividends will be at the discretion of our Board of Directors (the &#8220;Board&#8221;).</span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b><span style="background-color:#ffffff;">Securities Authorized for Issuance Under Equity Compensation Plans </span></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">See Part III, Item 12.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Equity Performance Graph</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Recent Sales of Unregistered Securities</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">None.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Issuer Purchases of Equity Securities </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">None.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt; text-indent: 45pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item6_Selected" title="Item6_Selected" href="#"></a>Item 6.</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>[Reserved]</b></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item7_MDA" title="Item7_MDA" href="#"></a>Item 7.</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i>The following discussion and analysis of financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, assumptions and uncertainties. Important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis include, but not limited to those set forth in &#8220;Item 1A. Risk Factors&#8221; in this Annual Report. All forward-looking statements included in this Annual Report are based on information available to us as of the time we file this Annual Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Overview </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Description of Business</i></b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands, and it utilizes several third-party consultants and contract research organizations to carry out the Company&#8217;s activities. Over the past two plus decades, the Company developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and previously licensed this technology to third parties, such as Abengoa Bioenergy SA, BASF SE, Codexis, Inc. and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the <i>Thermothelomyces heterothallica </i>(formerly known as <i>Myceliophthora thermophila</i>) fungus, which the Company named C1.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the past nine years since&#160;the Company sold its industrial technology business to Danisco USA (&#8220;Danisco&#8221;), the industrial biosciences business of DuPont (NYSE: DD) (the &#8220;DuPont Transaction&#8221;), the Company has been focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health and for other biologic products for use in non-pharmaceutical applications.&#160;As part of the DuPont Transaction, Dyadic retained co-exclusive rights to its proprietary and patented C1 protein production platform (the &#8220;C1 platform&#8221;) for use in all human and animal pharmaceutical applications, and currently, the Company has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions) for use in all human and animal pharmaceutical applications. Danisco retained certain rights to utilize the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or in licensed by Danisco.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">After the DuPont Transaction, the Company has directed its efforts toward&#160;advancing the C1 platform to address the increasing global demand for the development and manufacturing of prophylactic and therapeutic biopharmaceuticals for human and animal health. The Company&#8217;s biopharmaceutical development efforts have been centered on enhancing the capability of the C1 platform to produce stable, properly folded, and functional proteins for pharmaceutical applications, including vaccines and monoclonal antibodies. In addition to improving the quality and productivity of the C1 platform, the Company has sought to validate its platform for human use through a series of fully funded biopharmaceutical projects, extensive animal studies utilizing C1-produced proteins, and&#160;in 2024, the successful completion of a Phase 1 first-in-human study for a vaccine antigen produced using C1, which demonstrated&#160;its safety for human applications.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Recognizing the longer development timelines, clinical testing, and regulatory requirements associated with human and animal pharmaceutical products, the Company has refined its core business strategy to expand into recombinant (non-animal derived) alternative proteins for non-pharmaceutical applications in research, nutrition, and industrial markets. To address these opportunities, the Company has developed and launched the Dapibus&#8482; Protein Production Platform (&#8220;Dapibus&#8482;&#8221;), which supports various applications within the alternative proteins field, namely&#160;in Life Sciences, Food &amp; Nutrition, and Bioindustrial applications. Given the reduced developmental costs, shorter timelines, and fewer regulatory requirements associated with alternative proteins, Dapibus&#8482; has enabled the Company to generate near-term recurring revenue while continuing to build long-term value through C1 for pharmaceutical applications. The Company anticipates achieving commercialization of certain alternative protein products in 2025 through a combination of existing collaborations and internal manufacturing efforts.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b style="font-size: 10pt; text-align: left;">Critical Accounting Estimates</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The preparation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We define critical accounting estimates as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting estimates, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting estimates include the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"><b><i>Revenue Recognition</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has no products approved for sale. All our revenue to date has been research revenue from third-party collaborations and government grants, as well as revenue from sublicensing&#160;agreements and collaborative arrangements, which may include upfront payments,&#160;options to obtain a license, payment for research and development services,&#160;milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest).</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to research collaborations and agreements:</i>&#160;The Company typically&#160;performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (&#8220;Topic 606&#8221;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 36pt; text-align: justify;">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under the input method, revenue will be recognized based on the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to grants: </i>The Company may receive&#160;grants&#160;from governments, agencies, and other private and not-for-profit organizations.&#160;These grants are intended to be used to fund the Company&#8217;s research collaborations partially or fully, including opportunities and projects that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for vaccines and/or antibodies candidates.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i style="font-size: 10pt; text-indent: 36pt;">Revenue related to sublicensing agreements: </i>If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
       &#160;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Customer options: </i>If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate&#160;if such&#160;options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i><span style="background-color:#ffffff;">Milestone payments: </span></i><span style="background-color:#ffffff;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i><span style="background-color:#ffffff;">Royalties: </span></i><span style="background-color:#ffffff;">With respect to licenses deemed to be the predominant item to which the<i></i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><span style="background-color:#ffffff;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><span style="background-color:#ffffff;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</p>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-align: justify; text-indent: 36pt;"><b><i>Accrued Research and Development Expenses</i></b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b><i>&#160;</i></b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and adjust if necessary. Examples of accrued research and development expenses include amounts ow<span style="background-color:#ffffff;">ed to contract research organizations, to service providers in connection with research and development activities.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 36pt;"><b><i><span style="background-color:#ffffff;">Stock-Based Compensation</span></i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">We have granted stock options to employees, directors and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options.&#160;We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option.&#160;The expected stock price volatility was calculated based on the Company&#8217;s own volatility since the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company&#8217;s historical volatilities since 2016, as the DuPont Transaction resulted in significant changes in the Company&#8217;s business and capital structure.&#160;</span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the performance-based options issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain.&#160;</span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 36pt;"><b><i><span style="background-color:#ffffff;">Accounting for Income Taxes</span></i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized because of applying the provision of ASC 740.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company currently is not subject to U.S. federal, state and local tax examinations by tax authorities for the years before 2017.&#160;See Note 8&#160;to the Consolidated Financial Statements.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Off-Balance Sheet Arrangements</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We do not have any off-balance sheet arrangements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Recent Accounting Pronouncements </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">See Note 1 to the Consolidated Financial Statements for information about recent accounting pronouncements<i>.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Results of Operations</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Year Ended December 31, 2024 Compared to the Year Ended&#160;December 31, 2023</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Revenue and Cost of Revenue</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The following table summarizes the Company&#8217;s revenue and&#160;cost of research and development revenue&#160;for the years ended December 31, 2024 and 2023:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Year Ended December 31,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Research and development revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,605,220</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,545,865</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">License revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,890,169</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">352,941</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cost of research and development revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,194,624</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,975,849</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For the years ended December 31, 2024 and 2023, the Company&#8217;s revenue was generated from&#160;19 and 16 collaborations, respectively. The decrease in research and development revenue and cost of research and development revenue was due to higher individual contract amounts on certain research funding and related work performed during 2023. The license revenue for&#160;the year ended&#160;December 31, 2024&#160;was in connection with the Inzymes and Proliant license agreements, and for the year ended December 31, 2023&#160;was in connection with the Janssen license agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i><span style="background-color:#ffffff;">Research and Development Expenses</span></i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Research and development costs are expensed as incurred and primarily include salary and benefits of research personnel, third-party contract research organization services and supply costs.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Research and development expenses for the year ended December 31, 2024&#160;decreased to $2,044,000 compared to $3,297,000 for the year ended December 31, 2023.&#160;The decrease was due to the completion&#160;of activities related to the Company&#8217;s Phase 1 clinical trial of DYAI-100 COVID-19 vaccine candidate.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>General and Administrative Expenses</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">General and administrative expenses for the year ended December 31, 2024&#160;increase<span style="background-color:#ffffff;">d to&#160;$6,135,000</span><span style="background-color:#ffffff;">&#160;compared to $5,817,000</span><span style="background-color:#ffffff;">&#160;for the year ended </span>December 31, 2023<span style="background-color:#ffffff;">.&#160;The increase reflected increases&#160;in&#160;business development and investor relations expenses of $294,000, share-based compensation expenses of $109,000, professional service expenses of $82,000, and other increases&#160;of $84,000, partially offset by decreases in&#160;management incentive expenses of&#160;$124,000, legal expenses of $65,000 and insurance expenses of $64,000.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><b><i>Foreign Currency Exchange</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Foreign currency exchange loss for the year ended December 31, 2024&#160;was $23,000 compared to $38,000&#160;for the year ended December 31, 2023. The decrease reflected the currency fluctuation of the Euro in comparison to the U.S. dollar.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b><i>&#160; &#160;Loss from Operations</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Loss from operations&#160;for the year ended December 31, 2024, decreased <span style="background-color:#ffffff;">to $5,901,000&#160;compared to $8,230,000 f</span>or the year ended December 31, 2023. The decrease in loss from operations was largely due to an increase in licensing revenue of $1,000,000 from Proliant and $890,000 from Inzymes,&#160;including success fees&#160;in 2024 and the above-discussed&#160;decrease in research and development expenses associated with the completion of activities related to the Company&#8217;s Phase 1 clinical trial of DYAI-100 COVID-19 vaccine candidate.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>&#160; &#160; &#160; &#160;Other Income, Net</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended December 31, 2024, the total other income, net, of $92,000&#160;compared to $1,434,000&#160;for the year ended December 31, 2023.&#160;The decrease was largely due to an increase in interest expenses of $428,000 related to the Convertible Notes in 2024 and a gain on the&#160;sale of the Company&#8217;s equity interest in Alphazyme, LLC&#160;of $1,018,000 in 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b style="font-size: 10pt; text-align: left; text-indent: 9pt;"><i>Income <span style="background-color:#ffffff;">Taxes</span></i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">
   </p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">
   </p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">
   </p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">
   </p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">The Company had net operating loss (&#8220;NOL&#8221;) carryforwards available as of </span>December 31, 2024 and 2023<span style="background-color:#ffffff;">, in the amount of approximately $49,903,000&#160;and $45,850,000, respectively. Approximately $46,965,000</span><span style="background-color:#ffffff;">&#160;of the NOL carryforwards will be carried forward indefinitely and will be available to offset 80% of taxable income. The remaining amount of the net operating loss carryforwards will expire at varying dates through 2038.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: left;"><b><i>Net Loss</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: left;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net loss for the year ended December 31, 2024 was $<span style="background-color:#ffffff;">5,809,000 compared to a net loss of $6,795,000&#160;for the year ended </span>December 31, 2023<span style="background-color:#ffffff;">.&#160;The decrease in net loss of $986,000&#160;was principally due to an increase in license revenue of $1,537,000&#160;and a decrease in research and development expenses of $1,253,000, partially offset by an increase in general and administrative expenses of $318,000&#160;and a decrease in other income of $1,343,000.</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><span style="background-color:#ffffff;">Liquidity and Capital Resources</span></b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Presentation of Financial Statements &#8211; Going Concern (&#8220;Topic 205-40&#8221;), management is required to evaluate whether there are conditions and events, considered in the aggregate that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least 12 months from the issuance date of the Company&#8217;s condensed interim financial statements. This evaluation does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company expects to incur losses and have negative net cash flows from operating activities as it continues developing its microbial protein production platforms and related products, and as it expands its pipelines and engages in further research and development activities for internal products as well as for its third-party collaborators and licensees. The success of the Company depends on its ability to develop its technologies and products to the point of regulatory approval and subsequent revenue generation or through the sublicensing of the Company&#8217;s technologies and products, and its ability to raise capital to finance these developmental efforts.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On March 8, 2024, the Company&#160;issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 (the <span style="background-color:#ffffff">&#8220;</span>Convertible Notes&#8221;) in a private placement.&#160;The purchasers of the Convertible Notes included immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company&#8217;s outstanding common stock, (collectively, the <span style="background-color:#ffffff">&#8220;</span>Purchasers&#8221;).&#160;The net proceeds from the sale of the Convertible Notes, after deducting offering expenses, were&#160;$5,824,000. The Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes are&#160;senior, secured obligations of Dyadic and its affiliates, and interest is&#160;payable quarterly in cash on the principal amount equal to 8% per annum. The Convertible Notes will mature on March 8, 2027 (the <span style="background-color:#ffffff">&#8220;</span>Maturity Date&#8221;), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes. The Convertible Notes can be&#160;converted&#160;into shares of Dyadic&#8217;s Class A common stock (the <span style="background-color:#ffffff;">&#8220;</span>Common Stock&#8221;), at the option of the holders of the Convertible Notes (the "Noteholders&#8221;) at any time prior to the Maturity Date.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">This private placement funding is expected to support our near-term revenue growth and accelerate our strategic objective of commercialization opportunities for pharmaceutical and non-pharmaceutical applications.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On October 4, 2024, the Company entered into an amendment (the "Amendment&#8221;) to the Convertible Notes. Pursuant to the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company&#8217;s common stock is $1.40 per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fall on any <span style="background-color:#ffffff;">of the 26, 29 and 32-month anniversaries of the origi</span>nal issue date of the Convertible Notes, which are May 8, 2026, August 8, 2026 and November 8, 2026.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restrictions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of December 31, 2024.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><span style="background-color:#ffffff;">As of December 31, 2024, $910,000 of the Convertible Notes were converted into 556,623 shares of Common Stock.&#160;For more information regarding the Convertible Notes, including the covenants related thereto, see Note 5&#160;to the Consolidated Financial Statements.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, on November 16, 2024, Dyadic entered into an agreement with the Bill &amp; Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;) relating to a grant in the amount of $3,092,136&#160;awarded from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company&#8217;s C1 platform to provide globally accessible treatment options for underserved populations (the &#8220;Gates Foundation Grant&#8221;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company expects its existing cash and cash equivalents and cash raised from the Convertible Notes, the Gates Foundation Grant, investments in debt securities, and operating cash flows&#160;from its existing and future license agreement(s)&#160;will be sufficient to meet its operational, business, and other liquidity requirements for at least the next twelve (12) months from the date of issuance of the financial statements contained in this Annual Report. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. In the event our financing needs are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise additional capital through strategic financial opportunities that could include, but are not limited to, future public or private equity offerings, collaboration agreements,&#160;convertible notes or other debt instruments, and/or other means. Any amounts raised may be used for the further development and commercialization of product candidates, and for other working capital purposes. There is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing shareholders</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"><span style="background-color:#ffffff;">At </span>December 31, 2024<span style="background-color:#ffffff;">, cash and cash equivalents were $6,507,000&#160;</span><span style="background-color:#ffffff;">compared to $6,515,000&#160;</span><span style="background-color:#ffffff;">at </span>December 31, 2023<span style="background-color:#ffffff;">. The carrying value of investment grade securities, including accrued interest at </span>December 31, 2024<span style="background-color:#ffffff;"> was $2,781,000</span><span style="background-color:#ffffff;">&#160;compared to $758,000&#160;</span><span style="background-color:#ffffff;">at </span>December 31, 2023<span style="background-color:#ffffff;">.</span></p>
  <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">Net cash used in operating activities for the year ended </span>December 31, 2024<span style="background-color:#ffffff;"> of $3,975,000</span><span style="background-color:#ffffff;">&#160;resulted from a net loss of $5,809,000</span><span style="background-color:#ffffff;">&#160;adjusted for share-based compensation expenses of $1,126,000</span><span style="background-color:#ffffff;">, partially offset by&#160;changes in&#160;operating assets and liabilities of $755,000.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Net cash used in operating activities for the year ended&#160;D<span style="background-color:#ffffff;">ecember 31, 2023&#160;of $6,727,000&#160;resulted from a net loss of $6,795,000&#160;adjusted for share-based compensation expenses of $1,244,000, partially offset by sale of our investment in Alphazyme of $1,018,000,&#160;and changes in&#160;operating assets and liabilities of $143,000.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">Net cash used in&#160;investing activities for the year ended </span>December 31, 2024<span style="background-color:#ffffff;"> was $1,876,000</span><span style="background-color:#ffffff;">&#160;compared to net cash provided by investing activities of&#160;$7,450,000</span><span style="background-color:#ffffff;">&#160;for the year ended </span>December 31, 2023<span style="background-color:#ffffff;">. Cash flows from investing activities in </span>2024<span style="background-color:#ffffff;">&#160;and 2023 were&#160;primarily related to proceeds from maturities, net of purchases of investment grade debt securities, and proceeds from the sale of investment in Alphazyme.&#160;</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Net cash provided by&#160;financing activities&#160;for the&#160;<span style="background-color:#ffffff">year ended </span>December 31, 2024&#160;was $5,849,000, which was related to net proceeds from issuance of convertible notes, and proceed from exercise of options.&#160;There were no cash flows from financing activities in 2023.&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item7A_QQ" title="Item7A_QQ" href="#"></a>Item 7A.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Quantitative and Qualitative Disclosures about Market Risk</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item8_Fin" title="Item8_Fin" href="#"></a>Item 8.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Financial Statements and Supplementary Data</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Consolidated Financial Statements and supplementary data required by this item are presented elsewhere in this report beginning on page F-1, in the order shown below:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Report of Independent Registered Public Accounting Firm (PCAOB ID 173)</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Consolidated Balance Sheets as of December 31, 2024&#160;and 2023&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Consolidated Statements of Operations for the years ended December 31, 2024, 2023</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Consolidated Statements of Stockholders' Equity for the years ended December 31, 2024&#160;and 2023</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2024&#160;and 2023</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Notes to Consolidated Financial Statements</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item9_Changes" title="Item9_Changes" href="#"></a>Item 9.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">None.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item9A_Controls" title="Item9A_Controls" href="#"></a>Item 9A.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Controls and Procedures</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Evaluation of Disclosure Controls and Procedures</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;) , means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based on the evaluation of our disclosure controls and procedures as of December 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Management&#8217;s Report on Internal Control Over Financial Reporting</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Our management is responsible for establishing and maintaining adequate &#8220;internal control over financial reporting,&#8221; as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024 based on the criteria set forth in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the assessment, our management has concluded that our internal control over financial reporting was effective as of December 31, 2024. This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management&#8217;s report in this Annual Report because we are a &#8220;smaller reporting company&#8221; and &#8220;non-accelerated filer.&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Changes in Internal Controls Over Financial Reporting</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the year ended December 31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Inherent Limitation on Effectiveness of Controls</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty&#160;and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or because the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c2877258" escape="true">
   <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 79px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item9B_Other" title="Item9B_Other" href="#"></a>Item <em style="font: inherit;">9B.</em></b></p> </td><td style="vertical-align: top; width: 941px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Other Information</b></p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 23pt;"><b><i>Insider Trading Arrangements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">During the quarter ended <em style="font: inherit;"> December 31, 2024, </em><span style="-sec-ix-hidden:c125843306"><span style="-sec-ix-hidden:c125843837"><span style="-sec-ix-hidden:c125843856"><span style="-sec-ix-hidden:c125843857">none</span></span></span></span> of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) under the Exchange Act) adopted or terminated a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or a &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; (each as defined in Item <em style="font: inherit;">408</em>(a) and (c), respectively, of Regulation S-K).</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&#160;<a id="item9c" title="item9c" href="#"></a>Item&#160;9C.</b>&#160; <b>Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Not applicable.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Part_3" title="Part_3" href="#"></a>PART III</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"><a id="Item10_Directors" title="Item10_Directors" href="#"></a><b style="font-size: 10pt;">Item 10.</b></td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Directors, Executive Officers and Corporate Governance</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The information required by this item is incorporated by reference to the Company&#8217;s definitive proxy statement relating to the 2025&#160;annual meeting of shareholders. The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2024 fiscal year.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-size: 10pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><b><a id="Item11_Executive" title="Item11_Executive" href="#"></a>Item 11.</b></p> </td>
     <td> <p style="font-size: 10pt; margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif"><b>Executive Compensation</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The information required by this item is incorporated by reference to the Company&#8217;s definitive proxy statement relating to the 2025&#160;annual meeting of shareholders. The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2024 fiscal year.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item12_Security" title="Item12_Security" href="#"></a>Item 12.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The information required by this item is incorporated by reference to the Company&#8217;s definitive proxy statement relating to the 2025&#160;annual meeting of shareholders. The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2024 fiscal year.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"><a id="Item13_certain_" title="Item13_certain " href="#"></a><b style="font-size: 10pt;">Item 13.</b></td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Certain Relationships and Related Transactions, and Director Independence</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The information required by this item is incorporated by reference to the Company&#8217;s definitive proxy statement relating to the 2025&#160;annual meeting of shareholders. The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2024 fiscal year.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"><a id="Item14_Principal" title="Item14_Principal" href="#"></a><b style="font-size: 10pt;">Item 14.</b></td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Principal Accounting Fees and Services</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The information required by this item is incorporated by reference to the Company&#8217;s definitive proxy statement relating to the 2025&#160;annual meeting of shareholders. The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2024 fiscal year.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Part_4" title="Part_4" href="#"></a>PART IV</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"><a id="Item15_FinancialStatements" title="Item15_FinancialStatements" href="#"></a><b style="font-size: 10pt;">Item 15.</b></td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Financial Statement and Exhibits</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>(a)&#160;&#160;&#160;&#160;&#160;Financial Statement</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Our financial statements and related notes thereto are listed and included in this Annual Report on Form 10-K beginning on page F-1.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>(b)&#160;&#160;&#160;&#160;&#160;Exhibits</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 51%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="7" style="vertical-align: bottom; width: 31%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by Reference</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 51%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Description of Exhibit</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Form</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Original No.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Date Filed</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Filed Herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.1#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit31form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Restated Certificate of Incorporation dated November 1, 2004</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.2#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774923008314/ex_493964.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; "><span style="background-color:#ffffff;">Third Amended and Restated Bylaws dated March 28, 2023</span></span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="background-color:#ffffff;">8-K</span></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="background-color:#ffffff;">3.1</span></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"><span style="background-color:#ffffff;">March 29, 2023</span></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.1#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit41form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Specimen Stock Certificate Evidencing Shares of Common Stock</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.2#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000121380920000018/exhibit42descriptionof.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Description of Registered Securities</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">10-K</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">4.2</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">March 30, 2020</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">4.3#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924007270/ex_637328.htm" style="-sec-extract:exhibit;">Senior Secured Convertible Promissory Note due March 8, 2027, dated March 8, 2024</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;"><span style="background-color:#ffffff">8-K</span></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">4.1</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">March 11, 2024</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">4.3.1#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001213809/000143774924030893/dyai20241006_8k.htm" style="-sec-extract:exhibit;">Amendment, dated as of October 4, 2024, to Form of Senior Secured Convertible Promissory&#160;Note due March 8, 2027</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;"><span style="background-color:#ffffff">8-K</span></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">4.1</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">October 8, 2024</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.1**#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit102form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Dyadic International, Inc. 2011 Equity Incentive Plan</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.2</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">10.2**#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774921019717/dyai20210616_s8.htm" style="-sec-extract:exhibit;">Dyadic International, Inc. 2021 Equity Incentive Plan</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">S-8</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">4.3</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;">August 12, 2021</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">10.2.1**#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="ex_727226.htm" style="-sec-extract:exhibit;">Form of Stock Option Agreement Pursuant to the Dyadic International, Inc. 2021 Equity Incentive Plan</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">10-K</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">10.2.1</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;">March 28, 2024</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">10.2.2**#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="ex_727227.htm" style="-sec-extract:exhibit;">Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc. 2021 Equity Incentive Plan</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">10-K</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">10.2.2</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;">March 28, 2024</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.3**#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit103form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc. 2011 Equity Incentive Plan</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.3</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.4**#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit104form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Stock Option Agreement Pursuant to the Dyadic International, Inc. 2011 Equity Incentive Plan</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.4</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.5**#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit105form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, dated June 16, 2016, and First Amendment dated January 23, 2017, by and between Dyadic International, Inc. and Mark A. Emalfarb</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.5</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.5.1**#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000072/emalfarbeaamendmentno2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Second Amendment to Employment Agreement between Dyadic International, Inc. and Mark A. Emalfarb, dated as of November 12, 2019</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">November 13, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.6**#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit107form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consulting Agreement, dated January 1, 2016, by and between Dyadic Netherlands B.V. and Sky Blue Biotech kft on behalf of Ronen Tchelet</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.7</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.7**#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924034347/ex_744301.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement dated November 8, 2024, between Dyadic International, Inc. and Ping Rawson</span></a><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924034347/ex_744301.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">&#160;</span></a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">8-K</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">November 2024</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">10.8**#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774921025790/ex_303847.htm" style="-sec-extract:exhibit;">Employment Agreement between Dyadic International Inc. and Joseph Hazelton dated November 9, 2021</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">8-K</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">November&#160;9, 2021</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.9**#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1010form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; "><span style="background-color:#ffffff;">Form of Director and Officer Indemnification Agreement</span></span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.10</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;">10.10#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774923030937/ex_588629.htm" style="-sec-extract:exhibit;">Lease Agreement with Jupiter Harbour Office, LLC dated August 19, 2023</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;">November 8, 2023</td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.11&#8224;#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1012form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Pharma License Agreement with Danisco US, Inc. dated December 31, 2015</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.12</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.12&#8224;#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1013form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Commission Contract with VTT Technical Research Centre of Finland Ltd dated September 2, 2016</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.13</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.12.1&#8224;#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000054/a101vttagreement.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Commission Contract with VTT Technical Research Centre of Finland Ltd dated June 28, 2019</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="background-color:#ffffff;">8-K</span></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="background-color:#ffffff;">10.1</span></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="background-color:#ffffff;">July 5, 2019</span></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.13&#8224;#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1015form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Service Framework Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. dated June 30, 2017</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="background-color:#ffffff;">10-Q</span></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="background-color:#ffffff;">10.2</span></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="background-color:#ffffff;">November 8, 2023</span></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">10.13.1&#8224;#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="http://www.sec.gov/Archives/edgar/data/0001213809/000143774921017633/ex_267349.htm" style="-sec-extract:exhibit"><span style="text-decoration: underline; "><span style="background-color:#ffffff;">Amendment No. 1 dated July 26, 2021, to the Service Framework Agreement</span></span><span style="background-color:#ffffff;">&#160;</span><span style="text-decoration: underline; "><span style="background-color:#ffffff;">dated June 30, 2017</span></span></a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">8-K</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">10.3</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;">July 27, 2021</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.14&#8224;#</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1017form10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">License Agreement with VTT Technical Research Centre of Finland Ltd dated July 17, 2017</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">10-12G</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.17</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">January 14, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">10.15&#8224;#</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 51%;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774922011845/ex_336879.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Joint Development Agreement with Leprino Foods Company, dated May 12, 2022</span></a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">10.1</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 12%;">May 11, 2022</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.16&#8224;#</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000024/a101sublicenseagreementalp.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; "><span style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated May 5, 2019</span></span></a></p> </td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.1</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">May 8, 2019</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.17&#8224;#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000121380920000026/ex-101amendedandrestat.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; "><span style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amended and Restated Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated June 24, 2020</span></span></a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">June 29, 2020</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.18&#8224;#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/ex_466461.htm" style="-sec-extract:exhibit;">Alphazyme Sale Agreement dated January 18, 2023</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">January 23, 2023</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.19&#8224;#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/ex_498815.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">RUBIC License Agreement dated April 6, 2023</span></a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">April 6, 2023</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.20&#8224;#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/ex_571018.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Inzyme Development and Exclusive License Agreement,&#160;effective&#160;September 18, 2023</span></a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">September 19, 2023</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.21#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924007270/ex_637064.htm" style="-sec-extract:exhibit;">Securities Purchase Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 11, 2024</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.22#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924007270/ex_637099.htm" style="-sec-extract:exhibit;">Registration Rights Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.2</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 11, 2024</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.23#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924007270/ex_637100.htm" style="-sec-extract:exhibit;">Security Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.3</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 11, 2024</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.24#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924007270/ex_637101.htm" style="-sec-extract:exhibit;">Subsidiary Guarantee Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.4</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 11, 2024</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.25</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213809/000143774924021877/dyai20240627_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">License and Development Agreement between Dyadic International (USA), Inc. and Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals, dated June 27, 2024</span></a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">July 2, 2024</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.28&#8224;#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924036247/ex_751025.htm" style="-sec-extract:exhibit;">Grant Agreement between Dyadic International, Inc. and the Bill &amp; Melinda Gates Foundation, dated as of November 16, 2024</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">November 26, 2024</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_794841.htm" style="-sec-extract:exhibit;">Insider Trading Policy</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">21.1</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001213809/000143774924009857/dyai20231231_10k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Subsidiaries of the Registrant </span></a></p> </td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">23.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <div style="font-size:13px">
       <div style="font-family:&quot;Times New Roman&quot;,Times,serif">
        <a href="ex_727229.htm" style="-sec-extract:exhibit;"><span style="background-color:#ffffff">Consent of Independent Registered Public Accounting Firm - Crowe LLP</span></a>
       </div>
      </div> </td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24.1</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#poa" style="-sec-extract:exhibit;">Power of Attorney (included on signature page)</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">31.1</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_727231.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Chief Executive Officer of Dyadic International, Inc, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p> </td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">x</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">31.2</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_727232.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Chief Financial Officer of Dyadic International, Inc. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p> </td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">x</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">32.1&#x5E;</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_727233.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Chief Executive Officer of Dyadic International, Inc.&#160;Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p> </td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">32.2&#x5E;</p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_727234.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Chief Financial Officer of Dyadic International, Inc. Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p> </td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">97#</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213809/000143774924009857/ex_638431.htm" style="-sec-extract:exhibit;">Policy Related to Recovery of Erroneously Awarded Compensation</a></td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10-K</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">97</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2024</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.INS</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inline XBRL Instance Document</td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.SCH</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inline XBRL Taxonomy Extension Schema Document</td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.CAL</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.DEF</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.LAB</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.PRE</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">x</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">104</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 530px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td>
     <td style="vertical-align: bottom; width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 82px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Legend:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">**&#160;&#160;&#160;Identifies a&#160;management contract or compensatory plan or arrangement.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#8224;&#160;&#160;&#160;&#160;&#160;Certain provisions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">#&#160;&#160;&#160;&#160;&#160;Previously filed with the SEC.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#x5E;&#160; &#160; &#160;Furnished herewith.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="Item16_Form10K" title="Item16_Form10K" href="#"></a>Item 16.</b></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Form 10-K Summary</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Not applicable.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Signatures" title="Signatures" href="#"></a>SIGNATURES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:99.9%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:32.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td colspan="2" style="vertical-align:top;width:67.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DYADIC INTERNATIONAL, INC.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align:bottom;width:7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align:bottom;width:60.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 26, 2025</p> </td>
     <td style="vertical-align:bottom;width:7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p> </td>
     <td style="vertical-align: bottom; width: 60.2%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Mark A. Emalfarb</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align:bottom;width:7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:60.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Mark A. Emalfarb</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align:bottom;width:7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align:bottom;width:60.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">President and Chief Executive Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;">&#160;</td>
     <td style="vertical-align:bottom;width:7%;">&#160;</td>
     <td style="vertical-align:bottom;width:60.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Executive Officer)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;">&#160;</td>
     <td style="vertical-align:bottom;width:7%;">&#160;</td>
     <td style="vertical-align:bottom;width:60.2%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 26, 2025</p> </td>
     <td style="vertical-align:bottom;width:7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p> </td>
     <td style="vertical-align: bottom; width: 60.2%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Ping W. Rawson</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;">&#160;</td>
     <td style="vertical-align:bottom;width:7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:60.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ping W. Rawson</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;">&#160;</td>
     <td style="vertical-align:bottom;width:7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align:bottom;width:60.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:32.8%;">&#160;</td>
     <td style="vertical-align:bottom;width:7%;">&#160;</td>
     <td style="vertical-align:bottom;width:60.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Financial Officer and Principal Accounting Officer)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: center;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: center;"><b><a id="poa" title="poa" href="#"></a>POWER OF ATTORNEY</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark&#160;A. Emalfarb and Ping W. Rawson, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Pursuant to the requirements of Securities Exchange Act of 1934,&#160;this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; ">Signature</span></p> </td>
     <td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; ">Title</span></p> </td>
     <td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; ">Date</span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Mark A. Emalfarb</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Executive Officer, Director</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">March 26, 2025</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; border-bottom: 1px none rgb(0, 0, 0); width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Mark A. Emalfarb</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Executive Officer)</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Ping W. Rawson</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">March 26, 2025</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; border-bottom: 1px none rgb(0, 0, 0); width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ping W. Rawson</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Financial Officer and Principal Accounting Officer)</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Patrick Lucy</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chairman, Director</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">March 26, 2025</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Patrick Lucy</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Jack L. Kaye</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Director</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">March 26, 2025</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Jack L. Kaye</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Seth J. Herbst</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Director</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">March 26, 2025</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Seth J. Herbst, MD</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/Arindam Bose</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Director</p> </td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">March 26, 2025</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Arindam Bose, Ph.D.</p> </td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Michael P. Tarnok</td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">March 26, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Michael P. Tarnok</td>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <div><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<div>
 &#160;
</div>
<div>
 &#160;
</div>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Index" title="Index" href="#"></a>Index to Consolidated Financial Statements</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width:99.9%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="vertical-align:bottom;width:92.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td><td style="vertical-align:top;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Page</b></p> </td></tr>
<tr><td style="vertical-align:top;width:92.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Financial Statements:</b></p> </td><td style="vertical-align:bottom;border-bottom: 1px #000000;;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> </td></tr>
<tr><td style="vertical-align:bottom;width:92.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a style="-sec-extract:exhibit;" href="#Report"><span style="text-decoration: underline; ">Report of Independent Registered Public Accounting Firm (PCAOB ID <ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2024-01-01_2024-12-31" id="ixv-13176">173</ix:nonNumeric>) </span></a></p> </td><td style="vertical-align:top;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><a style="-sec-extract:exhibit;" href="#Report"><span style="text-decoration: underline; ">F-2</span></a></p> </td></tr>
<tr><td style="vertical-align:top;width:92.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a style="-sec-extract:exhibit;" href="#BalSheet"><span style="text-decoration: underline; ">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p> </td><td style="vertical-align: top; width: 7.5%; text-align: center;"><a class="tocPGNUM" href="#BalSheet">F-3</a></td></tr>
<tr><td style="vertical-align:top;width:92.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a style="-sec-extract:exhibit;" href="#Operations"><span style="text-decoration: underline; ">Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023</span></a></p> </td><td style="vertical-align: middle; width: 7.5%; text-align: center;"><a class="tocPGNUM" href="#Operations">F-4</a></td></tr>
<tr><td style="vertical-align:top;width:92.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a style="-sec-extract:exhibit;" href="#Equity"><span style="text-decoration: underline; ">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2024 and 2023</span></a></p> </td><td style="vertical-align: middle; width: 7.5%; text-align: center;"><a class="tocPGNUM" href="#Equity">F-5</a></td></tr>
<tr><td style="vertical-align:top;width:92.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a style="-sec-extract:exhibit;" href="#CashFlows"><span style="text-decoration: underline; ">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</span></a></p> </td><td style="vertical-align: top; width: 7.5%; text-align: center;"><a class="tocPGNUM" href="#CashFlows">F-6</a></td></tr>
<tr><td style="vertical-align:bottom;width:92.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a style="-sec-extract:exhibit;" href="#Notes"><span style="text-decoration: underline; ">Notes to Consolidated Financial Statements</span></a></p> </td><td style="vertical-align: top; width: 7.5%; text-align: center;"><a class="tocPGNUM" href="#Notes">F-7</a></td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-1
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    &#160;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>&#160;</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b></b><b><span style="text-decoration: underline; ">Report of Independent Registered Public Accounting Firm</span></b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="background-color:#ffffff;">Shareholders and the Board of Directors of Dyadic International, Inc.</span></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="background-color:#ffffff;">Jupiter, Florida</span></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="background-color:#ffffff;">Opinion on the Financial Statements</span></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have audited the accompanying consolidated balance sheets of Dyadic International, Inc. (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the years ended December 31, 2024 and 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years ended December 31, 2024 and 2023, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="background-color:#ffffff;">Basis for Opinion</span></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><span style="background-color:#ffffff;">Critical Audit Matters</span></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="background-color:#ffffff;">/s/<ix:nonNumeric name="dei:AuditorName" contextRef="d_2024-01-01_2024-12-31" id="ixv-13177">Crowe LLP</ix:nonNumeric></span></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="background-color:#ffffff;">We have served as the Company's auditor since 2023.</span></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="background-color:#ffffff;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2024-01-01_2024-12-31" id="ixv-13178">Livingston, New Jersey</ix:nonNumeric></span></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">March 26, 2025</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-2
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#160;
   </div>
  </div>
 </div>
</div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p></div>
  <div>
   &#160;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;"><b><a id="BalSheet" title="BalSheet" href="#"></a>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">&#160;</p>
  <p style="text-indent: 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
  <p style="text-indent: 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842573" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,506,750</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842574" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,515,028</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Short-term investment securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842575" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,756,577</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842576" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">748,290</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Interest receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842577" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,248</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842578" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,083</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842579" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">237,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842580" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">466,159</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842581" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">303,066</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842582" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">327,775</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842583" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,827,668</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842584" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,067,335</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Non-current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Operating lease right-of-use asset, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842585" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:num-dot-decimal" decimals="INF">92,211</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842586" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:num-dot-decimal" decimals="INF">141,439</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842587" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,396</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842588" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,462</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Total assets</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842589" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,930,275</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842590" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,219,236</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Liabilities and stockholders&#8217; equity</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -9pt; text-indent: 9pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842591" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">482,320</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842592" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">656,445</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842593" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">970,462</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842594" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,057,164</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Deferred research and development obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842595" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">833,813</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842596" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">490,113</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Operating lease liability, current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c125842597" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">54,249</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c125842598" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">48,059</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Accrued interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842599" contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" format="ixt:num-dot-decimal" decimals="INF">80,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842600" contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Accrued interest- related party</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842601" contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" format="ixt:num-dot-decimal" decimals="INF">27,173</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842602" contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842603" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,448,017</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842604" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,251,781</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Non-current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Convertible notes, net of issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842605" contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="us-gaap:ConvertibleDebtNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,911,471</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842606" contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="us-gaap:ConvertibleDebtNoncurrent" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Convertible notes, net of issuance costs - related party</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842607" contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:ConvertibleDebtNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,065,876</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842608" contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:ConvertibleDebtNoncurrent" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Operating lease liability, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842609" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">34,621</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842610" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">88,870</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842611" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,459,985</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842612" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,340,651</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Commitments and contingencies (Note 4)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c125856487">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c125856489">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Stockholders&#8217; equity:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Preferred stock, $<span style="-sec-ix-hidden:c125843807"><span style="-sec-ix-hidden:c125843808">.0001</span></span> par value:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Authorized shares - <span style="-sec-ix-hidden:c125843809"><span style="-sec-ix-hidden:c125843810">5,000,000</span></span>; <span style="-sec-ix-hidden:c125843811"><span style="-sec-ix-hidden:c125843813"><span style="-sec-ix-hidden:c125843812"><span style="-sec-ix-hidden:c125843814">none</span></span></span></span> issued and outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842613" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842614" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Common stock, $<span style="-sec-ix-hidden:c125843815"><span style="-sec-ix-hidden:c125843816">.001</span></span> par value:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0pt;">Authorized shares - <span style="-sec-ix-hidden:c125843817"><span style="-sec-ix-hidden:c125843818">100,000,000</span></span>; issued shares - <span style="-sec-ix-hidden:c125843819">42,089,301</span> and <span style="-sec-ix-hidden:c125843820">41,064,563</span>, outstanding shares - <span style="-sec-ix-hidden:c125843821">29,835,799</span> and <span style="-sec-ix-hidden:c125843822">28,811,061</span> as of December 31, 2024 and 2023, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842615" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,090</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842616" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,065</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842617" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:num-dot-decimal" decimals="INF">107,444,595</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842618" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:num-dot-decimal" decimals="INF">105,044,756</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Treasury stock, shares held at cost - <span style="-sec-ix-hidden:c125843823"><span style="-sec-ix-hidden:c125843824">12,253,502</span></span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842619" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">18,929,915</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842620" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">18,929,915</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842621" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">86,086,480</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842622" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">80,277,321</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total stockholders&#8217; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842623" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,470,290</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842624" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,878,585</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Total liabilities and stockholders&#8217; equity</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842625" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,930,275</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842626" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,219,236</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">The accompanying notes are an integral part of these audited consolidated financial statements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;"><b><a id="Operations" title="Operations" href="#"></a>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS </b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Revenues:</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Research and development revenue</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842641" contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-ResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,605,220</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842642" contextRef="d_2023-01-01_2023-12-31_ProductOrServiceAxis-ResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,545,865</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">License revenue</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842643" contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,890,169</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842644" contextRef="d_2023-01-01_2023-12-31_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">352,941</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Total revenue</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842645" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,495,389</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842646" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,898,806</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Costs and expenses:</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Costs of research and development revenue</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842647" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,194,624</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842648" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,975,849</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Research and development</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842649" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,044,253</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842650" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,297,266</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842651" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,134,773</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842652" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,817,013</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Foreign currency exchange loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842653" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">22,561</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842654" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">38,417</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Total costs and expenses</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842655" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,396,211</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842656" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,128,545</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Loss from operations</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842657" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,900,822</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842658" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">8,229,739</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Other income (expense):</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Interest income</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842659" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dyai:InterestIncomeNonoperating" scale="0" format="ixt:num-dot-decimal" decimals="INF">456,992</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842660" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="dyai:InterestIncomeNonoperating" scale="0" format="ixt:num-dot-decimal" decimals="INF">416,686</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Gain on sale of Alphazyme</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842661" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GainLossOnSaleOfInvestments" scale="0" format="ixt:num-dot-decimal" decimals="INF">62,642</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842662" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:GainLossOnSaleOfInvestments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,017,592</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Interest expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">(<ix:nonFraction id="c125842663" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="0" format="ixt:num-dot-decimal" decimals="INF">288,142</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c125842664" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Interest expense - related party</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">(<ix:nonFraction id="c125842665" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="0" format="ixt:num-dot-decimal" decimals="INF">139,829</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842666" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Total other income (expense), net</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842667" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,663</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842668" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,434,278</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Net loss</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125842669" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,809,159</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125842670" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6,795,461</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Basic and diluted net loss per common share</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842671" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.20</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842672" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.24</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Basic and diluted weighted-average common shares outstanding</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842673" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">29,318,123</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842674" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">28,798,833</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">The accompanying notes are an integral part of these audited consolidated financial statements.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;"><b><a id="Equity" title="Equity" href="#"></a>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Common Stock</em></em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Treasury Stock</em></em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Additional</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Accumulated</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Amount</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Amount</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">paid-in capital</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">deficit</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Balance at December 31, 2022</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842692" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,816,602</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842693" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,817</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842694" contextRef="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">12,253,502</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842695" contextRef="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842696" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">103,458,697</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842697" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">73,481,860</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842698" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,087,739</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Stock-based compensation expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842700" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842702" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842703" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,244,121</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842704" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842705" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,244,121</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Issuance of common stock upon vesting of restricted stock units</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842706" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">247,961</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842707" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">248</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842708" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842709" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842710" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">341,938</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842711" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842712" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">342,186</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842714" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842716" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842717" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842718" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6,795,461</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842719" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6,795,461</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Balance at December 31, 2023</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><ix:nonFraction id="c125842720" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,064,563</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><ix:nonFraction id="c125842721" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,065</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842722" contextRef="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">12,253,502</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842723" contextRef="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><ix:nonFraction id="c125842724" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">105,044,756</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842725" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">80,277,321</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><ix:nonFraction id="c125842726" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,878,585</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Stock-based compensation expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842728" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842730" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842731" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,126,279</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842732" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842733" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,126,279</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Issuance of common stock upon vesting of restricted stock units</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842734" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">437,546</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842735" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">437</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842736" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842737" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842738" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">339,897</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842739" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842740" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">340,334</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Issuance of common stock upon exercise of stock options</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842741" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">30,569</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842742" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">31</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842743" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842744" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842745" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,220</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842746" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842747" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,251</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td style="padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Issuance of common stock upon settlement of convertible debt</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842748" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">556,623</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842749" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">557</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842750" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842751" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842752" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">909,443</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842753" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842754" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">910,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842756" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842758" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842759" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842760" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,809,159</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842761" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,809,159</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Balance at December 31, 2024</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842762" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,089,301</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842763" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,090</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125842764" contextRef="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">12,253,502</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125842765" contextRef="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">18,929,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842766" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">107,444,595</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125842767" contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">86,086,480</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842768" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,470,290</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">The accompanying notes are an integral part of these audited consolidated financial statements.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;"><b><a id="CashFlows" title="CashFlows" href="#"></a>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Cash flows from operating activities</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842773" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,809,159</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125842774" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6,795,461</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Stock-based compensation expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-indent: 9pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842775" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,126,279</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842776" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,244,121</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Amortization of held-to-maturity securities, net</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842777" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dyai:InvestmentIncomeAmortizationAccretionOfPremium" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">71,057</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842778" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="dyai:InvestmentIncomeAmortizationAccretionOfPremium" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">53,032</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Amortization of debt issuance costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842779" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">63,021</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842780" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Gain on investment in Alphazyme</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842781" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GainLossOnInvestments" scale="0" format="ixt:num-dot-decimal" decimals="INF">60,977</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842782" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:GainLossOnInvestments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,017,592</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Foreign currency exchange loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842783" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">22,561</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842784" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">38,418</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Interest receivable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842785" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">14,165</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842786" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">48,202</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Accounts receivable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842787" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">219,425</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842788" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:num-dot-decimal" decimals="INF">141,332</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Prepaid expenses and other current assets</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842789" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">24,742</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842790" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">64,902</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Operating lease assets and liabilities, net</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842791" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,169</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842792" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">4,510</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Accounts payable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842793" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">180,182</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842794" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">651,168</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Accrued expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842795" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="INF">252,664</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842796" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="INF">444,269</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Accrued interest</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842797" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="dyai:IncreaseDecreaseInAccruedInterest" scale="0" format="ixt:num-dot-decimal" decimals="INF">80,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842798" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="dyai:IncreaseDecreaseInAccruedInterest" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Accrued interest - related party</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842799" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="dyai:IncreaseDecreaseInAccruedInterest" scale="0" format="ixt:num-dot-decimal" decimals="INF">27,173</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842800" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="dyai:IncreaseDecreaseInAccruedInterest" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Deferred license revenue</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842801" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842802" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">352,942</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 18pt;">Deferred research and development obligations</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842803" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF">343,700</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842804" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF">449,370</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Net cash used in operating activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c125842805" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">3,974,806</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c125842806" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6,726,755</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Cash flows from investing activities</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Purchases of held-to-maturity investment securities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842807" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,343,230</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125842808" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,995,988</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Proceeds from maturities of investment securities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842809" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,406,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842810" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,148,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Proceeds from the sale of investment in Alphazyme</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842811" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleOfInvestmentProjects" scale="0" format="ixt:num-dot-decimal" decimals="INF">60,977</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842812" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleOfInvestmentProjects" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,297,884</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Net cash (used in) provided by investing activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c125842813" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1,876,253</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c125842814" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,449,896</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Cash flows from financing activities</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Proceeds from issuance of convertible notes, net of issuance costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842815" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,882,884</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842816" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Proceeds from issuance of convertible notes, net of issuance costs - related party</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842817" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,941,442</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842818" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Proceeds from exercise of options</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842819" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,251</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842820" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Net cash provided by financing activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c125842821" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,848,577</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c125842822" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Effect of exchange rate changes on cash</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842823" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,796</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842824" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2,385</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Net (decrease) increase in cash and cash equivalents</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c125842825" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">8,278</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c125842826" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:num-dot-decimal" decimals="INF">720,756</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash and cash equivalents at beginning of period</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842827" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,515,028</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842828" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,794,272</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Cash and cash equivalents at end of period</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c125842829" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,506,750</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c125842830" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,515,028</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
      <td style="padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Supplemental cash flow information</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Vesting of restricted stock units</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842831" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dyai:VestingOfRestrictedStock" scale="0" format="ixt:num-dot-decimal" decimals="INF">340,334</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842832" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="dyai:VestingOfRestrictedStock" scale="0" format="ixt:num-dot-decimal" decimals="INF">342,186</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Conversion of convertible notes</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842833" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" format="ixt:num-dot-decimal" decimals="INF">910,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842834" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Cash paid for interest</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842835" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InterestPaidNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">257,778</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842836" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:InterestPaidNet" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Right-of-use asset obtained in exchange for lease obligations</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842837" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842838" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,983</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">The accompanying notes are an integral part of these audited consolidated financial statements.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Notes" title="Notes" href="#"></a>Notes to Consolidated Financial Statements</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="c2877259" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">1:</em>&#160;&#160;&#160;&#160;&#160;Organization and Summary of Significant Accounting Policies</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Description of Business</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands, and it utilizes several <em style="font: inherit;">third</em>-party consultants and contract research organizations to carry out the Company&#8217;s activities. Over the past <em style="font: inherit;">two</em> plus decades, the Company developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and previously licensed this technology to <em style="font: inherit;">third</em> parties, such as Abengoa Bioenergy SA, BASF SE, Codexis, Inc. and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the <i>Thermothelomyces heterothallica </i>(formerly known as <i>Myceliophthora thermophila</i>) fungus, which the Company named <em style="font: inherit;">C1.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the past <em style="font: inherit;">nine</em> years since&#160;the Company sold its industrial technology business to Danisco USA (&#8220;Danisco&#8221;), the industrial biosciences business of DuPont (NYSE: DD) (the &#8220;DuPont Transaction&#8221;), the Company has been focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health and for other biologic products for use in non-pharmaceutical applications.&#160;As part of the DuPont Transaction, Dyadic retained co-exclusive rights to its proprietary and patented <em style="font: inherit;">C1</em> protein production platform (the <em style="font: inherit;">&#8220;C1</em> platform&#8221;) for use in all human and animal pharmaceutical applications, and currently, the Company has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions) for use in all human and animal pharmaceutical applications. Danisco retained certain rights to utilize the <em style="font: inherit;">C1</em> platform in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic <em style="font: inherit;"> may </em>owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or in licensed by Danisco.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">After the DuPont Transaction, the Company has directed its efforts toward&#160;advancing the <em style="font: inherit;">C1</em> platform to address the increasing global demand for the development and manufacturing of prophylactic and therapeutic biopharmaceuticals for human and animal health. The Company&#8217;s biopharmaceutical development efforts have been centered on enhancing the capability of the <em style="font: inherit;">C1</em> platform to produce stable, properly folded, and functional proteins for pharmaceutical applications, including vaccines and monoclonal antibodies. In addition to improving the quality and productivity of the <em style="font: inherit;">C1</em> platform, the Company has sought to validate its platform for human use through a series of fully funded biopharmaceutical projects, extensive animal studies utilizing <em style="font: inherit;">C1</em>-produced proteins, and&#160;in <em style="font: inherit;">2024,</em> the successful completion of a Phase <em style="font: inherit;">1</em> <em style="font: inherit;">first</em>-in-human study for a vaccine antigen produced using <em style="font: inherit;">C1,</em> which demonstrated&#160;its safety for human applications.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Recognizing the longer development timelines, clinical testing, and regulatory requirements associated with human and animal pharmaceutical products, the Company has refined its core business strategy to expand into recombinant (non-animal derived) alternative proteins for non-pharmaceutical applications in research, nutrition, and industrial markets. To address these opportunities, the Company has developed and launched the Dapibus&#8482; Protein Production Platform (&#8220;Dapibus&#8482;&#8221;), which supports various applications within the alternative proteins field, namely&#160;in Life Sciences, Food &amp; Nutrition, and Bioindustrial applications. Given the reduced developmental costs, shorter timelines, and fewer regulatory requirements associated with alternative proteins, Dapibus&#8482; has enabled the Company to generate near-term recurring revenue while continuing to build long-term value through <em style="font: inherit;">C1</em> for pharmaceutical applications. The Company anticipates achieving commercialization of certain alternative protein products in <em style="font: inherit;">2025</em> through a combination of existing collaborations and internal manufacturing efforts.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><span style="background-color:#ffffff;">Liquidity,&#160;Capital Resources, and Going Concern</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) <em style="font: inherit;">205</em>-<em style="font: inherit;">40,</em> Presentation of Financial Statements &#8211; Going Concern (&#8220;Topic <em style="font: inherit;">205</em>-<em style="font: inherit;">40&#8221;</em>), management is required to evaluate whether there are conditions and events, considered in the aggregate that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least <em style="font: inherit;">12</em> months from the issuance date of the Company&#8217;s condensed interim financial statements. This evaluation does <em style="font: inherit;">not</em> take into consideration the potential mitigating effect of management&#8217;s plans that have <em style="font: inherit;">not</em> been fully implemented or are <em style="font: inherit;">not</em> within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (<em style="font: inherit;">1</em>) it is probable that the plans will be effectively implemented within <em style="font: inherit;">one</em> year after the date that the financial statements are issued, and (<em style="font: inherit;">2</em>) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company expects to incur losses and have negative net cash flows from operating activities as it continues developing its microbial protein production platforms and related products, and as it expands its pipelines and engages in further research and development activities for internal products as well as for its&#160;<em style="font: inherit;">third</em>-party collaborators and licensees. The success of the Company depends on its ability to develop its technologies and products to the point of regulatory approval and subsequent revenue generation or through the sublicensing of the Company&#8217;s technologies and products, and its ability to raise capital to finance these developmental efforts.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On&#160;<em style="font: inherit;"> March 8, 2024,&#160;</em>the Company&#160;issued an aggregate principal amount of $<ix:nonFraction id="c125843347" contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">6.0</ix:nonFraction>&#160;million of its&#160;<ix:nonFraction id="c125843348" contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8.0</ix:nonFraction>% Senior Secured Convertible Promissory Notes due&#160;<em style="font: inherit;"> March 8, 2027 (</em>the &#8220;Convertible Notes&#8221;) in a private placement. The purchasers of the Convertible Notes included immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than&#160;<em style="font: inherit;">5%</em>&#160;of the Company&#8217;s outstanding common stock, (collectively, the &#8220;Purchasers&#8221;).&#160;The net proceeds from the sale of the Convertible Notes, after deducting offering expenses, we<span style="background-color:#ffffff;">re&#160;$<ix:nonFraction id="c125843350" contextRef="d_2024-03-08_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,824,326</ix:nonFraction>. The</span> Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes are&#160;senior, secured obligations of Dyadic and its affiliates, and interest is&#160;payable quarterly in cash on the principal amount equal to&#160;<ix:nonFraction id="c125843351" contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>% per annum. The Convertible Notes will mature on&#160;<em style="font: inherit;"> March 8, 2027 (</em>the &#8220;Maturity Date&#8221;), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes can be&#160;converted&#160;into shares of Dyadic&#8217;s Class A common stock (the &#8220;Common Stock&#8221;), at the option of the holders of the Convertible Notes (the &#8220;Noteholders&#8221;) at any time prior to the Maturity Date.&#160;This private placement funding is expected to support our near-term revenue growth and accelerate our strategic objective of commercialization opportunities for pharmaceutical and non-pharmaceutical applications.&#160;On&#160;<em style="font: inherit;"> October 4, 2024,&#160;</em>the Company entered into an amendment (the &#8220;Amendment&#8221;) to the Convertible Notes. Pursuant to the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company&#8217;s common stock is changed from $<ix:nonFraction id="c125843352" contextRef="i_2024-10-03_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.79</ix:nonFraction> to $<ix:nonFraction id="c125843353" contextRef="i_2024-10-04_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.40</ix:nonFraction>&#160;per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fall on any of the&#160;<em style="font: inherit;">26,</em>&#160;<em style="font: inherit;">29</em>&#160;and&#160;<em style="font: inherit;">32</em>-month anniversaries of the original issue date of the Convertible Notes, which are <em style="font: inherit;"> May 8, 2026, </em><em style="font: inherit;"> August 8, 2026 </em>and <em style="font: inherit;"> November 8, 2026.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restrictions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of&#160;<em style="font: inherit;"> December 31, 2024, </em>$<ix:nonFraction id="c125843357" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" format="ixt:num-dot-decimal" decimals="INF">910,000</ix:nonFraction>&#160;of the Convertible Notes have been converted into <ix:nonFraction id="c125843358" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">556,623</ix:nonFraction>&#160;shares of Common Stock.&#160;For more information regarding the Convertible Notes, including the covenants related thereto<span style="background-color:#ffffff;">, see Note <em style="font: inherit;">5</em>&#160;to the Co</span>nsolidated Financial Statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, on <em style="font: inherit;"> November 16, 2024, </em>Dyadic entered into an agreement with the Bill &amp; Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;) relating to a grant in the amount of $<ix:nonFraction id="c125843360" contextRef="d_2024-11-16_2024-11-16_CounterpartyNameAxis-GatesFoundationMember" unitRef="USD" name="us-gaap:ProceedsFromGrantors" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,092,136</ix:nonFraction>&#160;awarded from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company&#8217;s <em style="font: inherit;">C1</em> platform to provide globally accessible treatment options for underserved populations (the &#8220;Gates Foundation Grant&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2024, </em>the Company had $<ix:nonFraction id="c125843362" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,506,750</ix:nonFraction> cash and $<ix:nonFraction id="c125843363" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,780,825</ix:nonFraction> short-term investment securities (including accrued interest) on its balance sheet, totaling $<ix:nonFraction id="c125843364" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,287,575</ix:nonFraction>.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company expects its existing cash and cash equivalents, and cash raised from the Convertible Notes, or other debt instruments, and or other means, the Gates Foundation Grant, investments in debt securities, and operating cash flows will be sufficient to meet its operational, business, and other liquidity requirements for at least the next&#160;<em style="font: inherit;">twelve</em>&#160;(<em style="font: inherit;">12</em>) months from the date of issuance of the financial statements contained in this Annual Report. However, the Company has based this estimate on assumptions that&#160;<em style="font: inherit;"> may&#160;</em>prove to be wrong, and its operating plan&#160;<em style="font: inherit;"> may&#160;</em>change as a result of many factors currently unknown to it. In the event our financing needs are&#160;<em style="font: inherit;">not</em>&#160;able to be met by our existing cash, cash equivalents and investments, we would seek to raise additional capital through strategic financial opportunities that could include, but are&#160;<em style="font: inherit;">not</em>&#160;limited to, future public or private equity offerings, collaboration agreements,&#160;convertible notes and other debt instruments, and/or other means. Any amounts raised&#160;<em style="font: inherit;"> may&#160;</em>be used for the further development and commercialization of product candidates, and for other working capital purposes. There is&#160;<em style="font: inherit;">no</em>&#160;guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing shareholders.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -36pt; text-align: justify; text-indent: 36pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c125860054" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -36pt; text-align: justify; text-indent: 36pt;"><b><i>Basis of Presentation </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Dyadic consolidates entities in which we have a controlling financial interest. We consolidate our subsidiaries in which we hold and/or control, directly or indirectly, more than <em style="font: inherit;">50%</em> of the voting rights.&#160;All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c125860055" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Segment Information</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The CODM is the Company's senior management team that includes the Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer. The Company views its operations as and manages its business in <span style="-sec-ix-hidden:c125843372">one</span>&#160;operating segment, which is the business of developing and commercializing synthetic protein products using the Company&#8217;s proprietary microbial platforms, including <em style="font: inherit;">C1</em> and Dapibus&#8482;. Segment information is further described in Note <em style="font: inherit;">9</em> to the consolidated financial statements included in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:UseOfEstimates" id="c125860056" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Estimates inherent in the preparation of these consolidated financial statements include, but are <em style="font: inherit;">not</em> limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense,&#160;and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c125860109" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="background-color:#ffffff;">For the years&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s revenue was generated from&#160;</span><span style="-sec-ix-hidden:c125843379">19</span>&#160;<span style="background-color:#ffffff;">and&#160;<span style="-sec-ix-hidden:c125843380">16</span> customers, respectively. As of&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s accounts receivable was from <span style="-sec-ix-hidden:c125843382">nine</span>&#160;and <span style="-sec-ix-hidden:c125843383">thirteen</span> customers, respectively. Significant customers are those that account for greater than <em style="font: inherit;">10%</em> of the Company&#8217;s revenues. For the years&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843386"><span style="-sec-ix-hidden:c125843897">two</span></span> significant customers accounted for approximately $<ix:nonFraction id="c125843387" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,915,000</ix:nonFraction> or <ix:nonFraction id="c125843388" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="3">54.8</ix:nonFraction>% and $<ix:nonFraction id="c125843389" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,503,000</ix:nonFraction> or <ix:nonFraction id="c125843390" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="3">51.9</ix:nonFraction>%&#160;of revenue, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company&#8217;s customers could adversely affect its operations.</span></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company had <span style="-sec-ix-hidden:c125843393">eleven</span>&#160;</span><span style="font-size: 10pt;"><span style="background-color:#ffffff;">and <span style="-sec-ix-hidden:c125843394">six</span> customers outside of the United States (i.e., European and Asian customers) that accounted for&#160;approximately&#160;$<ix:nonFraction id="c125843395" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ElevenSignificantCustomersMember_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,526,000</ix:nonFraction>&#160;or <ix:nonFraction id="c125843396" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ElevenSignificantCustomersMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="3">43.7</ix:nonFraction>% and&#160;</span></span>$<ix:nonFraction id="c125843397" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">537,000</ix:nonFraction><span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;or&#160;</span></span><ix:nonFraction id="c125843398" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="3">18.5</ix:nonFraction>%<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;of total revenue, respectively.&#160;As of&#160;</span></span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="font-size: 10pt;"><span style="background-color:#ffffff;">, the Company&#160;had <span style="-sec-ix-hidden:c125843400">four</span> and&#160;</span></span><span style="-sec-ix-hidden:c125843401">six</span><span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;customers outside of the United States (i.e., European and Asian customers) that accounted for approximately $<ix:nonFraction id="c125843402" contextRef="i_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-FourSignificantCustomersMember_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">146,000</ix:nonFraction> or <ix:nonFraction id="c125843403" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-FourSignificantCustomersMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="3">61.5</ix:nonFraction>% and&#160;</span></span>$<ix:nonFraction id="c125843404" contextRef="i_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">213,000</ix:nonFraction><span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;or </span></span><ix:nonFraction id="c125843405" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="3">45.6</ix:nonFraction>%<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;of&#160;accounts receivable, respectively.</span></span></p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company uses CROs&#160;to conduct its research projects and manage its clinical trial. For&#160;the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843407">two</span> and <span style="-sec-ix-hidden:c125843408">three</span> CROs&#160;accounted for approximately $<ix:nonFraction id="c125843409" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember" unitRef="USD" name="dyai:ResearchServicesPurchased" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,389,000</ix:nonFraction>&#160;or <ix:nonFraction id="c125843410" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">93.0</ix:nonFraction>% and $<ix:nonFraction id="c125843411" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember" unitRef="USD" name="dyai:ResearchServicesPurchased" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,644,000</ix:nonFraction>&#160;or <ix:nonFraction id="c125843412" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">96.0</ix:nonFraction>%&#160;of total research serv</span>ices we purchased, respectively. As of&#160;<em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843413">two</span>&#160;CROs accounted for approximately&#160;$<ix:nonFraction id="c125843414" contextRef="i_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember" unitRef="USD" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">284,000</ix:nonFraction> or <ix:nonFraction id="c125843415" contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="3">58.9</ix:nonFraction>%&#160;of ac</span>counts payable. As of&#160;<em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843416">three</span>&#160;CROs accounted for approximately&#160;$<ix:nonFraction id="c125843417" contextRef="i_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember" unitRef="USD" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">620,000</ix:nonFraction> or <ix:nonFraction id="c125843418" contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="3">94.4</ix:nonFraction>%&#160;of accounts payable. The loss of business from <em style="font: inherit;">one</em> of these CROs or a combination of them could adversely affect the Company's operations.</span></p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c125860110" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We treat highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.&#160;The Company has <ix:nonFraction id="c125843422" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RestrictedCash" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> restricted cash balances as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em></p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><em style="font: inherit;"></em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:InvestmentPolicyTextBlock" id="c125860111" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Investment Securities</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months or less, and long-term investment securities mature over <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months from the applicable reporting date. Management determines the appropriate classification of each investment&#160;at the time of purchase and reevaluates the classifications at each balance sheet date.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company classifies its&#160;investments in debt securities as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than <em style="font: inherit;">not</em> the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. The Company measures expected credit losses on held to maturity debt securities on an individual security basis. The estimate of expected credit losses considers historical credit information from external sources. The impairment of the investment that is related to the credit loss, if any,&#160;is expensed in the period in which the event or change occurred.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>, all of our money market funds were invested in U.S. Government money market funds. The Company did <em style="font: inherit;">not</em> have any investment securities classified as trading as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="c125860112" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accounts Receivable</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company&#8217;s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances&#160;and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company&#8217;s evaluation of current and expected future economic conditions and changes in our customer collection trends. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. Management determined that&#160;<ix:nonFraction id="c125843434" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> allowance for credit losses was required as of&#160;<em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">10</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#160;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="c2877260" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842849" contextRef="i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">173,993</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842850" contextRef="i_2023-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">410,617</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842851" contextRef="i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">63,034</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842852" contextRef="i_2023-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">55,542</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842853" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">237,027</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842854" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">466,159</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" id="c125860113" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Prepaid Expenses and Other Current Assets</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="c2877261" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842859" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="0" format="ixt:num-dot-decimal" decimals="INF">182,270</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842860" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="0" format="ixt:num-dot-decimal" decimals="INF">209,888</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842861" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">117,560</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842862" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">117,887</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842863" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidTaxes" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,236</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842864" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidTaxes" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    </ix:nonNumeric></ix:nonNumeric>
   <div>
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"/><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842865" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">303,066</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842866" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">327,775</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </div>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dyai:AccountsPayablePolicyPolicyTextBlock" id="c125860114" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accounts Payable</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts payable consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="c2877262" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonFraction id="c125842871" contextRef="i_2024-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">340,698</ix:nonFraction></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842872" contextRef="i_2023-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">575,436</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842873" contextRef="i_2024-12-31" unitRef="USD" name="dyai:LegalExpensesPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">68,420</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842874" contextRef="i_2023-12-31" unitRef="USD" name="dyai:LegalExpensesPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,957</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842875" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableOtherCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">73,202</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842876" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsPayableOtherCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">79,052</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    </ix:nonNumeric></ix:nonNumeric>
   <div>
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"/><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842877" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">482,320</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842878" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">656,445</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </div>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dyai:AccruedExpensesPolicyPolicyTextBlock" id="c125860115" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accrued expenses consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c2877263" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842883" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">496,905</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842884" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">561,720</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842885" contextRef="i_2024-12-31" unitRef="USD" name="dyai:AccruedResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">437,196</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842886" contextRef="i_2023-12-31" unitRef="USD" name="dyai:AccruedResearchAndDevelopmentInProcessCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">274,080</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842887" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842888" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">210,004</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842889" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,360</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842890" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,360</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842891" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">970,462</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842892" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,057,164</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="c125860116" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Revenue Recognition </i></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has <em style="font: inherit;">no</em> products approved for sale. All our revenue to date has been research revenue from <em style="font: inherit;">third</em>-party collaborations and government grants, as well as revenue from sublicensing&#160;agreements and collaborative arrangements, which <em style="font: inherit;"> may </em>include upfront payments,&#160;options to obtain a license, payment for research and development services,&#160;milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest).</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">11</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
         &#160;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to research collaborations and agreements:</i>&#160;The Company typically&#160;performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the <em style="font: inherit;">5</em>-step process outlined in ASC Topic <em style="font: inherit;">606</em> (&#8220;Topic <em style="font: inherit;">606&#8221;</em>): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic <em style="font: inherit;">606</em> to measure the progress toward complete satisfaction of a performance obligation.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under the input method, revenue will be recognized based on the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and <em style="font: inherit;">third</em>-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i><span style="background-color:#ffffff;">Revenue related to grants: </span></i><span style="background-color:#ffffff;">T</span>he Company <em style="font: inherit;"> may </em>receive&#160;grants&#160;from governments, agencies, and other private and <em style="font: inherit;">not</em>-for-profit organizations. These grants are intended to be used to partially or fully fund the Company&#8217;s research collaborations<span style="background-color:#ffffff;">.</span> However, most, if <em style="font: inherit;">not</em> all, of such potential grant revenues, when&#160;received, is expected to be earmarked for <em style="font: inherit;">third</em> parties to advance the research required, including preclinical and clinical trials.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Customer options: </i>If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate&#160;if such&#160;options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i><span style="background-color:#ffffff;">Milestone payments: </span></i><span style="background-color:#ffffff;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which the<i> </i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all&#160;the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <em style="font: inherit;">not</em> recognized any royalty revenue resulting from any of its sublicensing arrangements.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We invoice customers based on our contractual arrangements with each customer, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">12</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#160;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are <em style="font: inherit;">not</em> required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of <em style="font: inherit;">one</em> year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c125860117" escape="true"><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. The Company does&#160;<em style="font: inherit;">not</em>&#160;recognize leases with terms of&#160;<em style="font: inherit;">twelve</em>&#160;months or less on the balance sheet. Options to extend or terminate a lease are&#160;<em style="font: inherit;">not</em>&#160;included in the Company&#8217;s initial lease term assessment, unless there is&#160;reasonable&#160;certainty that the Company will exercise any such option. Leases are classified as either finance leases or operating leases based on criteria in Accounting Standards Codification (&#8220;ASC&#8221;)&#160;<em style="font: inherit;">842.</em>&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For operating leases, right-of-use assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses an estimated rate of interest that they would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating lease right-of-use asset also includes any lease payments made and excludes any lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s&#160;prior lease for its corporate headquarters located at&#160;<em style="font: inherit;">140</em>&#160;Intracoastal Pointe Dr. expired on&#160;<em style="font: inherit;"> August 31, 2023,&#160;</em>and there was&#160;<em style="font: inherit;">no</em>&#160;right-of-use asset or lease liability recognized for this lease due to its short-term nature. In&#160;<em style="font: inherit;"> August&#160;</em><em style="font: inherit;">2023,</em>&#160;the Company entered into a new lease (<em style="font: inherit;">&#8220;1044</em>&#160;N Lease&#8221;) for&#160;office space for its new corporate headquarters located at&#160;<em style="font: inherit;">1044</em>&#160;N US&#160;<em style="font: inherit;">1,</em>&#160;Jupiter, Florida, commencing&#160;<em style="font: inherit;"> September 1, 2023 (</em>&#8220;Commencement Date&#8221;) and expiring&#160;on <em style="font: inherit;"> August 31, 2026. </em>Rent is subject to <em style="font: inherit;">three</em>&#160;percent (<ix:nonFraction id="c125843465" contextRef="d_2023-08-01_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember" unitRef="Pure" name="dyai:LesseeOperatingLeaseYearlyPercentageIncrease" scale="-2" format="ixt:num-dot-decimal" decimals="2">3</ix:nonFraction>%) annual increases, and the Company is responsible for certain common area maintenance charges and taxes throughout the life of the&#160;<em style="font: inherit;">1044</em>&#160;N Lease. The&#160;<em style="font: inherit;">1044</em>&#160;N Lease has an initial term of&#160;<em style="font: inherit;">three</em>&#160;(<ix:nonNumeric contextRef="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c125843469" format="ixt-sec:duryear">3</ix:nonNumeric>) years, following the Commencement Date with an option to extend for&#160;<em style="font: inherit;">two</em>&#160;(<ix:nonFraction id="c125843471" contextRef="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember" unitRef="Pure" name="dyai:LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>) successive&#160;<em style="font: inherit;">one</em>&#160;(<ix:nonNumeric contextRef="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c125843473" format="ixt-sec:duryear">1</ix:nonNumeric>) year terms. The options were&#160;<em style="font: inherit;">not</em>&#160;included in the lease term used in determining the right-of-use asset or lease liability as the Company did&#160;<em style="font: inherit;">not</em>&#160;consider it reasonably certain they would exercise the options.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For<span style="background-color:#ffffff;"> the years ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s total operating lease expense was&#160;</span>$<ix:nonFraction id="c125843477" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">106,785</ix:nonFraction>&#160;and $<ix:nonFraction id="c125843478" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">71,656</ix:nonFraction>, <span style="background-color:#ffffff;">respectively. As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the Company&#8217;s total operating lease liabilities was $</span><ix:nonFraction id="c125843479" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF">88,870</ix:nonFraction>, <span style="background-color:#ffffff;">which is presented net of imputed interest o</span>f $<ix:nonFraction id="c125843480" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,669</ix:nonFraction>, and the&#160;oper<span style="background-color:#ffffff;">ating lease right-of-use&#160;asset was&#160;</span>$<ix:nonFraction id="c125843481" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:num-dot-decimal" decimals="INF">92,211</ix:nonFraction>.&#160;As of <em style="font: inherit;"> December 31, 2023, </em>the Company&#8217;s total operating lease liabilities was $<ix:nonFraction id="c125843482" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF">136,929</ix:nonFraction>, which is presented net of imputed interest of $<ix:nonFraction id="c125843483" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,770</ix:nonFraction>, and the operating lease right-of-use asset was $<ix:nonFraction id="c125843484" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:num-dot-decimal" decimals="INF">141,439</ix:nonFraction>.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff">, the </span>weighted average remaining lease term was&#160;<ix:nonNumeric contextRef="i_2024-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c125843485" format="ixt-sec:duryear">1.7</ix:nonNumeric>&#160;years, and the weighted average discount rate was <ix:nonFraction id="c125860141" contextRef="i_2024-12-31" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">8.8</ix:nonFraction>%.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><em style="font: inherit;"></em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 27pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c125860118" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Research and Development Costs</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are related to the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock" id="c2877264" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842897" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseOutsideContractedServices" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,503,397</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842898" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseOutsideContractedServices" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,677,941</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842899" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">473,444</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842900" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">553,741</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842901" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">67,412</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842902" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,584</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    </ix:nonNumeric></ix:nonNumeric>
   <div>
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"/><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842903" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,044,253</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842904" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,297,266</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </div>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="c125860119" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Foreign Currency Transaction Gain or Loss</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure&#160;the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c125860120" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Fair Value Measurements </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into <em style="font: inherit;">three</em> levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">1</em> &#8211; Quoted prices in active markets for identical assets or liabilities.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;">Level <em style="font: inherit;">2</em> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;">Level <em style="font: inherit;">3</em> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#8217;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the <em style="font: inherit;">third</em>-party broker service for disclosure purposes.</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c125860121" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Income Taxes</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than <em style="font: inherit;">not</em> some portion or all the deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company is required to evaluate the provisions of ASC <em style="font: inherit;">740</em> related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements. ASC <em style="font: inherit;">740</em> prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-<em style="font: inherit;">not</em> to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was <em style="font: inherit;">not</em> recognized as a result of applying the provision of ASC <em style="font: inherit;">740.</em></p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><em style="font: inherit;"></em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="c125860122" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i><span style="background-color:#ffffff;">Comprehensive Income (Loss)</span></i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under U.S. GAAP. The Company does <em style="font: inherit;">not</em> have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does <em style="font: inherit;">not</em> separately present a statement of comprehensive income (loss) in its consolidated financial statements.</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c125860123" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We recognize all share-based payments to employees, consultants, and our Board of Directors (the &#8220;Board&#8221;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c125860124" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock, restricted stock units and convertible debt, were exercised and&#160;converted into common stock, calculated by applying the treasury stock method.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">For the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the effect of the potential exercise of options to purchase&#160;</span><ix:nonFraction id="c125843506" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,788,597</ix:nonFraction><span style="background-color:#ffffff;">&#160;and </span><ix:nonFraction id="c125843507" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,469,247</ix:nonFraction><span style="background-color:#ffffff;">&#160;shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</span></p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c125860125" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>New and Recently Adopted Accounting Pronouncements</i></b>&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> November 2023, </em>the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (the &#8220;ASU&#8221;) <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> &#8211; Segment Reporting (Topic ASC <em style="font: inherit;">280</em>), or ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosure about significant segment expenses. The enhancements under this update require disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss, require disclosure of <i>other segment items </i>by reportable segment and a description of the composition of <i>other segment items</i>, require annual disclosures under ASC <em style="font: inherit;">280</em> to be provided in interim periods, clarify use of more than <em style="font: inherit;">one</em> measure of segment profit or loss by the CODM, require that the title of the CODM be disclosed with an explanation of how the CODM uses the reported measures of segment profit or loss to make decisions, and require that entities with a single reportable segment provide all disclosures required by this update and required under ASC <em style="font: inherit;">280.</em> ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for public business entities for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company adopted ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> and applied the guidance retrospectively to all periods presented in the consolidated financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> &#8211; Income Taxes (Topic ASC <em style="font: inherit;">740</em>) Income Taxes. The ASU improves the transparency of income tax disclosures by requiring (<em style="font: inherit;">1</em>) consistent categories and greater disaggregation of information in the rate reconciliation and (<em style="font: inherit;">2</em>) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> will become effective beginning with our <em style="font: inherit;">2025</em> fiscal year. We do <em style="font: inherit;">not</em> expect that this guidance will have a material impact on our financial position and our results of operations.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="c2877265" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">2:</em>&#160;&#160;&#160;&#160;&#160;Cash, Cash Equivalent, and Investments </b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost,&#160;net of allowance for credit losses, and its investments in money market funds are classified as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. The following table shows the Company&#8217;s cash, available-for-sale securities, and investment securities by major security type as&#160;of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="BC338F45-26BE-4997-AEB0-8547E4EAA83C" escape="true" continuedAt="c739115BD-3ECC-407E-AFCE-B2ED26FB5399">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2024</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842926" contextRef="i_2024-12-31_FairValueByAssetClassAxis-CashMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="INF">926,287</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842929" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Cash" scale="0" format="ixt:num-dot-decimal" decimals="INF">926,287</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842931" contextRef="i_2024-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,580,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842934" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,580,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842936" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,506,750</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842939" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,506,750</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842941" contextRef="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,756,428</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842942" contextRef="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842943" contextRef="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF">149</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842944" contextRef="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,756,577</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842946" contextRef="i_2024-12-31" unitRef="USD" name="dyai:CashCashEquivalentsAndInvestmentsFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,263,178</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842947" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125842948" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF">149</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842949" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:InvestmentsAndCash" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,263,327</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:continuation id="c739115BD-3ECC-407E-AFCE-B2ED26FB5399">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2023</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" rowspan="1" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842973" contextRef="i_2023-12-31_FairValueByAssetClassAxis-CashMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,775</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125842976" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Cash" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,775</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842978" contextRef="i_2023-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,489,253</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842981" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,489,253</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842983" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,515,028</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842986" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,515,028</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842988" contextRef="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">748,105</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842989" contextRef="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125842990" contextRef="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF">185</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125842991" contextRef="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:HeldToMaturitySecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">748,290</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842993" contextRef="i_2023-12-31" unitRef="USD" name="dyai:CashCashEquivalentsAndInvestmentsFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,263,133</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842994" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125842995" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF">185</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125842996" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:InvestmentsAndCash" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,263,318</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notes:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(<em style="font: inherit;">1</em>) Definition of the <em style="font: inherit;">three</em>-level fair value hierarchy:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:14pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">1</em> - Quoted prices (unadjusted) in active markets for identical assets or liabilities</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:14pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">2</em> - Other inputs that are directly or indirectly observable in the markets</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:14pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">3</em> - Inputs that are generally unobservable</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">(<em style="font: inherit;">2</em>) Short-term investment securities will mature within <em style="font: inherit;">12</em> months or less, from the applicable reporting date.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">(<em style="font: inherit;">3</em>) For the&#160;years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>,&#160;the Company received discounts of<span style="background-color:#ffffff;">$<ix:nonFraction id="c125843541" contextRef="d_2024-01-01_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="dyai:DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" scale="0" format="ixt:num-dot-decimal" decimals="INF">78,770</ix:nonFraction>&#160;and $<ix:nonFraction id="c125843542" contextRef="d_2023-01-01_2023-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="dyai:DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" scale="0" format="ixt:num-dot-decimal" decimals="INF">39,012</ix:nonFraction> to purchase held-to-maturity investment securities,&#160;</span>respectively.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company considers declines in market value of its investment portfolio to be temporary in nature. The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than <em style="font: inherit;">not</em> the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. As of <em style="font: inherit;"> December 31, 2024</em>, the Company does <em style="font: inherit;">not</em> consider any of its investments to be other-than-temporarily impaired.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c2877268" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">3:</em>&#160;&#160;&#160;&#160;&#160;Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 17pt;"><b><i>Gates Foundation Grant</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> November 2024, </em>Bill &amp; Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;) awarded the Company a grant in the amount of $<ix:nonFraction id="c125843547" contextRef="i_2024-11-30_CounterpartyNameAxis-GatesFoundationMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,092,136</ix:nonFraction> for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company&#8217;s <em style="font: inherit;">C1</em> platform to provide globally accessible treatment options for underserved populations (the &#8220;Gates Foundation Grant&#8221;).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> December 2024,&#160;</em>the Company received approximately $<ix:nonFraction id="c125843549" contextRef="d_2024-12-01_2024-12-31_CounterpartyNameAxis-GatesFoundationMember" unitRef="USD" name="dyai:ProceedsFromGrant" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction> million of the Gates Foundation Grant, and the remaining award will be received in <em style="font: inherit;">2025</em> and <em style="font: inherit;">2026</em> in the amount of approximately $<ix:nonFraction id="c125843552" contextRef="d_2025-01-01_2025-12-31_CounterpartyNameAxis-GatesFoundationMember_StatementScenarioAxis-ScenarioForecastMember" unitRef="USD" name="dyai:ProceedsFromGrant" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million and $<ix:nonFraction id="c125843553" contextRef="d_2026-01-01_2026-12-31_CounterpartyNameAxis-GatesFoundationMember_StatementScenarioAxis-ScenarioForecastMember" unitRef="USD" name="dyai:ProceedsFromGrant" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction> million, respectively. For the year ended <em style="font: inherit;"> December 31, 2024, </em>the Company has <span style="-sec-ix-hidden:c125843554">not</span> recognized any research and development revenue, in connection with the Gates Foundation Grant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Proliant</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On&#160;<em style="font: inherit;"> June 27, 2024</em><i>,</i>&#160;the Company entered into a License and Development Agreement (the &#8220;Proliant Agreement&#8221;) with Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals (&#8220;Proliant&#8221;), pursuant to which, Proliant will license Dyadic&#8217;s proprietary fungal microbial expression and production platforms and microbial strains for the production of recombinant serum albumin, for an initial period of <ix:nonNumeric contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember" name="dyai:LicenseAndDevelopmentInitialTerm" id="c125843555" format="ixt-sec:duryear">10</ix:nonNumeric> years with an option to extend for an additional <ix:nonNumeric contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember" name="dyai:LicenseAndDevelopmentExtensionTerm" id="c125843556" format="ixt-sec:duryear">3</ix:nonNumeric> years under certain circumstances. &#160;Under the terms of the Proliant Agreement, Dyadic has received an initial upfront payment of $<ix:nonFraction id="c125843557" contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember" unitRef="USD" name="dyai:InitialUpFrontPayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction>, a&#160;<em style="font: inherit;">second</em>&#160;payment of $<ix:nonFraction id="c125843559" contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember" unitRef="USD" name="dyai:SecondPaymentUponCompletionTransfer" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction> for&#160;completing&#160;the transfer of a Production Strain (as defined in the Proliant Agreement) and will receive a final payment of $<ix:nonFraction id="c125843560" contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember" unitRef="USD" name="dyai:FinalPaymentUponMeetingCertainProductivityThreshold" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction>&#160;upon the meeting of a certain productivity threshold. Upon commencing commercial sales of&#160;animal-free recombinant serum albumin products produced pursuant to the Proliant Agreement, the Company will receive royalties based on a certain percentage of the gross margin received by Proliant, as defined in the Proliant Agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended&#160;<em style="font: inherit;"> December 31, 2024</em>, the Company recognized a total of $<ix:nonFraction id="c125843561" contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-ProliantAgreementMember" unitRef="USD" name="dyai:DeferredLicenseRevenue" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction>&#160;million in license revenue&#160;related to the Proliant Agreement, as the performance obligations&#160;for the <em style="font: inherit;">first</em> and <em style="font: inherit;">second</em> payments have been satisfied.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Inzymes ApS</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> September 18, 2023, </em>Dyadic International (USA) Inc., a subsidiary of the Company, signed a Development and Exclusive License Agreement (the &#8220;Inzymes Agreement&#8221;) with Inzymes ApS (&#8220;Inzymes&#8221;), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic&#8217;s proprietary Dapibus&#8482; platform. In <em style="font: inherit;"> October 2023, </em>the Company received an upfront payment of $<ix:nonFraction id="c125843564" contextRef="d_2023-10-05_2023-10-05_CounterpartyNameAxis-InzymesAgreementApsMember" unitRef="USD" name="dyai:NonrefundableUpfrontPaymentReceived" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million in accordance with the terms of the Inzymes Agreement.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> October 11, 2024, </em>the Inzymes Agreement was amended (&#8220;the Amended Inzymes Agreement&#8221;) to&#160;change the scope of research and development services required under the agreement as well as adjust the success fees&#160;upon the achievement of certain target yields, milestone payments upon <em style="font: inherit;">first</em> commercial sale of each product and royalties.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended&#160;<em style="font: inherit;"> December 31, 2024</em>, the Company has completed all product research and development services and satisfied all related performance obligations under the Amended Inzymes Agreement, and recognized $<ix:nonFraction id="c125843566" contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-InzymesAgreementApsMember" unitRef="USD" name="dyai:DeferredLicenseRevenue" scale="0" format="ixt:num-dot-decimal" decimals="INF">890,169</ix:nonFraction> in license revenues, including success fees upon the achievement of target yield of <em style="font: inherit;">one</em> related product. For the year ended <em style="font: inherit;"> December 31, 2024, </em>the Company also recognized research and development revenues of $<ix:nonFraction id="c125843568" contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-InzymesAgreementApsMember_ProductOrServiceAxis-ResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction> related to the Amended Inzymes Agreement.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company will continue evaluating the achievement of milestones related to target yields and product commercialization of each product when they are considered probable and estimable under the Inzymes Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;"><b><i>A Global Food Ingredient</i></b>&#160;<b><i>Company</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> May 10, 2022, </em>the Company entered into a Joint Development Agreement (the &#8220;JDA&#8221;) with a Global Food Ingredient Company (&#8220;GFIC&#8221;) to develop and manufacture several&#160;animal free ingredient products using the Company&#8217;s biotechnologies.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under&#160;the initial terms of the JDA, Dyadic was to develop its proprietary production cell lines for the manufacture of animal free ingredient product candid<span style="background-color:#ffffff;">ates. As of <em style="font: inherit;"> December 31, 2023, </em>th</span>e GFIC has completed its <em style="font: inherit;">one</em>-year funding commitment for the initial phase of research collaboration in an amount approximatin<span style="background-color:#ffffff;">g&#160;<em style="font: inherit;">$1.35</em> million, and, pu</span>rsuant to the GFIC&#8217;s rights under the JDA, the Company and&#160;the GFIC are conferring to decide whether or <em style="font: inherit;">not,</em> and if it is possible, to&#160;move forward to the next phase of the proj<span style="background-color:#ffffff;">ect. The Company is also considering other funding sources to continue the project.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the years ended<span style="background-color:#ffffff">&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>, the Company recorded research and development revenues, including milestone payments, of&#160;<span style="background-color:#ffffff;">$<ix:nonFraction id="c125843574" contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-AGlobalFoodIngredientCompanyMember_ProductOrServiceAxis-ResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> and </span>approximately <span style="background-color:#ffffff;">$<ix:nonFraction id="c125843575" contextRef="d_2023-01-01_2023-12-31_CounterpartyNameAxis-AGlobalFoodIngredientCompanyMember_ProductOrServiceAxis-ResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">631,000</ix:nonFraction>, respectively, in c</span>onnection with the&#160;JDA.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;"><i><b>Janssen</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; text-indent: 18pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; text-indent: 36pt; margin: 0pt;">On <em style="font: inherit;"> December 16, 2021, </em>the Company entered&#160;a Research, License, and Collaboration Agreement (the &#8220;Janssen Agreement&#8221;) for the manufacture of therapeutic protein candidates using its <em style="font: inherit;">C1</em> platform with Janssen Biotech, Inc., <em style="font: inherit;">one</em> of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (&#8220;Janssen&#8221;).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><span style="background-color:#ffffff;">On <em style="font: inherit;"> October 2, 2023, </em>Janssen provided written notice to Dyadic that it has decided to wind down the collaboration with an effective end date of <em style="font: inherit;"> December 31, 2023.</em></span></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the year ended&#160;<em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">,&#160;</span>there were <ix:nonFraction id="c125843578" contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> revenues related to the Janssen Agreement. For the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company recognized approximately $<ix:nonFraction id="c125843579" contextRef="d_2023-01-01_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember" unitRef="USD" name="dyai:DeferredLicenseRevenue" scale="0" format="ixt:num-dot-decimal" decimals="INF">353,000</ix:nonFraction> in license revenue and approximately $<ix:nonFraction id="c125843580" contextRef="d_2023-01-01_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember_ProductOrServiceAxis-ResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">520,000</ix:nonFraction> in research and development revenues in connection with the Janssen Agreement.<span style="background-color:#ffffff;">&#160;As of&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, $<ix:nonFraction id="c125843582" contextRef="i_2024-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction></span><span style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="background-color:#ffffff;">&#160;an</span></span><span style="background-color:#ffffff;">d approximately $<ix:nonFraction id="c125843583" contextRef="i_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">145,000</ix:nonFraction>&#160;of&#160;accounts receivable&#160;were related to Janssen, respectively.&#160;&#160;</span></p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Alphazyme</i></b></p>
   <p style="text-align: left; margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;">2019</em> the Company entered into a sub-licensing agreement with Alphazyme, LLC (&#8220;Alphazyme&#8221;) that was subsequently amended (the &#8220;Amended Alphazyme LLC Agreement&#8221;). Under the Amended Alphazyme LLC Agreement,&#160;Alphazyme obtained additional capital contribution&#160;and Dyadic&#8217;s ownership was diluted to <ix:nonFraction id="c125843585" contextRef="i_2020-12-01_OwnershipAxis-AlphazymeMember" unitRef="Pure" name="dyai:OwnershipPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.99</ix:nonFraction>%.&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of Alphazyme as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investment&#160;in Alphazyme. The Company reports&#160;its investment in Alphazyme under the cost method of accounting, given that it does <em style="font: inherit;">not</em> have the ability to exercise significant influence or control over Alphazyme.&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">On <em style="font: inherit;"> January 18, 2023, </em>the Company entered into a Securities Purchase Agreement, under which the Company agreed to sell its equity interest in Alphazyme, LLC (the &#8220;Alphazyme Sale Agreement&#8221;). The Company continues to have&#160;the potential to receive additional payments based on the future sales of Alphazyme&#8217;s existing products, pursuant to the Alphazyme Sale Agreement.</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">The Amended Sublicense Agreement between Dyadic and Alphazyme, which was previously entered on <em style="font: inherit;"> June 24, 2020, </em>remains in effect. Under the Amended Alphazyme Sub-License Agreement, Dyadic is entitled to potential milestone and royalty payments upon the commercialization of Alphazyme products using Dyadic&#8217;s proprietary <em style="font: inherit;">C1</em> platform.&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended <em style="font: inherit;"> December 31, 2024, </em>there were <ix:nonFraction id="c125843592" contextRef="d_2024-01-01_2024-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember" unitRef="USD" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> revenues related to Alphazyme. For the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company recognized a total revenue of approximately $<ix:nonFraction id="c125843593" contextRef="d_2023-01-01_2023-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember" unitRef="USD" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million from the sale of its equity interest in Alphazyme, LLC.</p>
  </ix:nonNumeric>
  <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2877269" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">4:</em>&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Leases</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b><i>Jupiter&#160;Florida Headquarters</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">In&#160;<em style="font: inherit;"> August&#160;</em><em style="font: inherit;">2023,</em>&#160;the Company entered into a new lease comprising approximately&#160;<ix:nonFraction id="c125843596" contextRef="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,719</ix:nonFraction>&#160;square feet of office space located at&#160;<em style="font: inherit;">1044</em>&#160;N US&#160;<em style="font: inherit;">1,</em>&#160;Jupiter, Florida, commencing&#160;<em style="font: inherit;"> September 1, 2023,&#160;</em>and will expire on <em style="font: inherit;"> August 31, 2026. </em>The Company occupies this space for an annual rental rate of approximately $<ix:nonFraction id="c125843599" contextRef="d_2023-08-01_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember" unitRef="USD" name="dyai:OperatingLeasesMonthlyRentalRate" scale="0" format="ixt:num-dot-decimal" decimals="INF">59,000</ix:nonFraction>, excluding common area maintenance expenses.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>The Netherlands Office</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies a flexible office space for an annual rental rate of approximatel<span style="background-color:#ffffff;">y $<ix:nonFraction id="c125843600" contextRef="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-NetherlandsOfficeLeaseMember" unitRef="USD" name="dyai:OperatingLeasesAnnualRentalRate" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,600</ix:nonFraction>. The lease expires on <em style="font: inherit;"> January 31, 2026, </em>and thereafter, the Company will reconsider the leased space to align with the future operations of the Company.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the future minimum annual lease payments under the operating leases are below. There are <em style="font: inherit;">no</em> future minimum annual lease payments after <em style="font: inherit;">2026.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c2877270" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125842999" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" format="ixt:num-dot-decimal" decimals="INF">59,901</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843000" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" format="ixt:num-dot-decimal" decimals="INF">35,638</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843001" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843002" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" format="ixt:num-dot-decimal" decimals="INF">95,539</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="text-align: left; text-indent: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <div style="font-size:10pt">
    <div style="font-family:'Times New Roman', Times, serif">
     <b><i>&#160; &#160; &#160; &#160;Purchase Obligations</i></b>
    </div>
   </div>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Purchase obligations are primarily related to our contracts with the Company&#8217;s contract research organizations to provide certain research services. The contracts set forth the Company&#8217;s minimum purchase requirements that are subject to adjustments based on certain performance conditions.&#160;</p>
   <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="background-color:#ffffff">As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the commitments related to agreements to purchase certain services in the ordinary course of business are below. All current contracts expire in or before <em style="font: inherit;">2026.</em></span></p>
   <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" id="c2877271" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843003" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,134,460</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843004" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PurchaseObligationDueInSecondYear" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,429,044</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843005" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PurchaseObligationDueInThirdYear" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843006" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PurchaseObligation" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,563,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate.&#160;The Company is <em style="font: inherit;">not</em> currently involved in any litigation that it believes could have a materially adverse effect in our financial condition or results of operations. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of <em style="font: inherit;">one</em> or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#8217;s consolidated financial position, cash flows or results of operations.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dyai:ConvertibleDebtTextBlock" id="c2877272" escape="true">
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note</b> <b><em style="font: inherit;">5:</em></b>&#160;&#160;&#160; <b>Convertible Notes&#160;</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On&#160;<em style="font: inherit;"> March 8, 2024,&#160;</em>the Company issued senior secured convertible promissory notes (the &#8220;Convertible Notes&#8221;) with an aggregate principal amount of $<ix:nonFraction id="c125843608" contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">6.0</ix:nonFraction>&#160;million, of which,&#160;<span style="-sec-ix-hidden:c125843609">$2.0</span>&#160;million were sold to related parties, including immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Convertible Notes are senior, secured obligations of the Company and its affiliates, and interest is payable quarterly in cash on the principal amount equal to&#160;<ix:nonFraction id="c125843610" contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>% per annum, and guaranteed by its subsidiary, Dyadic International (USA), Inc. under a subsidiary guarantee for the benefit of the holders of the Convertible Notes (each such holder, a &#8220;Holder&#8221;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Convertible Notes mature on&#160;<em style="font: inherit;"> March 8, 2027,&#160;</em>unless earlier converted or redeemed in accordance with the terms of the Convertible Notes. The Convertible Notes are secured by a&#160;<em style="font: inherit;">first</em>&#160;priority lien on substantially all assets of the Company and Dyadic International (USA), Inc.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Convertible Notes are accounted for in accordance with ASC&#160;<em style="font: inherit;">470</em>-<em style="font: inherit;">20,</em> <i>Debt with Conversion and Other Options</i>&#160;and ASC&#160;<em style="font: inherit;">815</em>-<em style="font: inherit;">15,</em> <i>Derivatives and Hedging</i>. Under ASC&#160;<em style="font: inherit;">815,</em>&#160;contracts that are both indexed to its own stock and classified in stockholders&#8217; equity in its statement of financial position are&#160;<em style="font: inherit;">not</em>&#160;considered to be derivative instruments. Based on the Company&#8217;s analysis, it is determined that the Convertible Notes contain embedded features that are indexed to the Company&#8217;s own stock and are classified in stockholders&#8217; equity in the Company&#8217;s statement of financial position, but do&#160;<em style="font: inherit;">not</em>&#160;meet the requirements for bifurcation and recognition as derivatives, and therefore, do&#160;<em style="font: inherit;">not</em>&#160;need to be accounted for separately. Accordingly, the proceeds received from the issuance of the Convertible Notes were recorded as a single liability in accordance with ASC&#160;<em style="font: inherit;">470</em>&#160;on the Company&#8217;s consolidated balance sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company incurred $<ix:nonFraction id="c125843621" contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">175,674</ix:nonFraction>&#160;of debt issuance costs associated with the Convertible Notes, which were recorded as a reduction of&#160;the Convertible Notes on the consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Convertible Notes using the effective interest method. We determined the expected life of the debt is equal to the&#160;<span style="-sec-ix-hidden:c125843622">three</span>-year term of the Convertible Notes.</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On&#160;<em style="font: inherit;"> October 4, 2024,&#160;</em>the Company entered into an amendment (the &#8220;Amendment&#8221;) to the Convertible Notes. Under the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company&#8217;s common stock is $<ix:nonFraction id="c125843623" contextRef="i_2024-10-04_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.40</ix:nonFraction>&#160;per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fal<span style="background-color:#ffffff;">l on any of the&#160;<em style="font: inherit;">26,</em>&#160;<em style="font: inherit;">29</em>&#160;and&#160;<em style="font: inherit;">32</em>-month anniversaries of the original issue date of the Convertible Notes&#160;which are <em style="font: inherit;"> May 8, 2026, </em><em style="font: inherit;"> August 8, 2026 </em>and <em style="font: inherit;"> November 8, 2026.</em></span></p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company assessed the Amendment for a debt extinguishment or modification in accordance with ASC <em style="font: inherit;">470</em>-<em style="font: inherit;">50.</em>&#160;As both the change in the present value of future cash flows of the modified Convertible Notes to that of the original Convertible Notes (including callable features) and the change in fair value of the embedded conversion option to that of the carrying value of the Convertible Notes immediately before modification resulted in a less than&#160;<em style="font: inherit;">10%</em> change, the Amendment was deemed <em style="font: inherit;">not</em> substantial and is regarded as a note modification. The Company did <em style="font: inherit;">not</em> incur any gain or loss relating to the modification and any incremental costs related to the Amendment were expensed.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the year&#160;ended&#160;<em style="font: inherit;"> December 31, 2024</em>,&#160;$<span style="background-color:#ffffff;"><ix:nonFraction id="c125843633" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USD" name="us-gaap:InterestPaidNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">257,778</ix:nonFraction>&#160;o</span>f interest was paid and debt issuance costs o<span style="background-color:#ffffff;">f $<ix:nonFraction id="c125843634" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">63,020</ix:nonFraction>&#160;wer</span>e amortized and recorded in interest expense in the consolidated statements of operations.&#160;As of <em style="font: inherit;"> December 31, 2024</em>, accrued interest&#160;on the Convertible Notes to related parties and other&#160;<em style="font: inherit;">third</em>&#160;parties was&#160;<span style="background-color:#ffffff;">$<ix:nonFraction id="c125843636" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">27,173</ix:nonFraction>&#160;and $<ix:nonFraction id="c125843637" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">80,000</ix:nonFraction>, respe</span>ctively. As of <em style="font: inherit;"> December 31, 2024</em>, accumulated amortized debt issuance costs were $<ix:nonFraction id="c125843638" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">36,376</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024,</em><span style="background-color:#ffffff;"> $<ix:nonFraction id="c125843641" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" format="ixt:num-dot-decimal" decimals="INF">910,000</ix:nonFraction>&#160;of the Convertible Notes were converted into&#160;<ix:nonFraction id="c125843642" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">556,623</ix:nonFraction>&#160;shares o</span>f the Company&#8217;s common stock. As of <em style="font: inherit;"> December 31, 2024</em>, convertible notes payable consisted of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ConvertibleDebtTableTextBlock" id="c2877273" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Holder</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Issuance Date</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Due Date</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Interest Rate</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Convertible Note </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Repayments</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Conversion to </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Francisco Trust dated 2/28/1996 (1)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843007">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843008">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843009">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125843010" contextRef="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,000,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125843013" contextRef="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,000,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Bradley Emalfarb (2)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843014">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843015">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843016">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125843017" contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c125843019" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125843020" contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Bradley Scott Emalfarb Irrevocable Trust (2)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843021">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843022">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843023">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125843024" contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">410,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c125843026" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">410,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125843027" contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Emalfarb Descendent Trust (3)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843028">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843029">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843030">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843031" contextRef="i_2024-12-31_DebtInstrumentAxis-DescendantTrustMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">90,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843034" contextRef="i_2024-12-31_DebtInstrumentAxis-DescendantTrustMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="0" format="ixt:num-dot-decimal" decimals="INF">90,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Convertible Notes - Related Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843038">2,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843040">(910,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843041">1,090,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Unamortized Debt Issuance Costs - Related Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843048">(24,124</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843055">1,065,876</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%; text-align: center;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Convertible Notes - Third Party</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843056">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843057">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843058">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><span style="-sec-ix-hidden:c125843059">4,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><b><em style="font: inherit;">&#8212;</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><b><em style="font: inherit;">&#8212;</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><span style="-sec-ix-hidden:c125843062">4,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Unamortized Debt Issuance Costs - Third Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843069">(88,529</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843076">3,911,471</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="background-color:#ffffff;">Notes:</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">(<em style="font: inherit;">1</em>) Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Francisco Trust. Mr. Thomas Emalfarb&#160;<em style="font: inherit;"> may&#160;</em>be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he&#160;<em style="font: inherit;"> may&#160;</em>have therein, directly or indirectly. The amount of accrued interest as of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, is $<ix:nonFraction id="c125843644" contextRef="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember_TitleOfIndividualAxis-MrThomasEmalfarbMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">20,000</ix:nonFraction>.</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">(<em style="font: inherit;">2</em>) Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore,&#160;<em style="font: inherit;"> may&#160;</em>be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he&#160;<em style="font: inherit;"> may&#160;</em>have therein, directly or indirectly.&#160;For the year&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, $<ix:nonFraction id="c125843646" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction>&#160;of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into&#160;<ix:nonFraction id="c125843647" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">294,891</ix:nonFraction>&#160;shares of the Company&#8217;s common stock. For the year&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, $<ix:nonFraction id="c125843648" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" format="ixt:num-dot-decimal" decimals="INF">410,000</ix:nonFraction>&#160;of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into <ix:nonFraction id="c125843649" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">261,732</ix:nonFraction>&#160;shares of the Company&#8217;s common stock. As of </span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the amount of accrued interest for Bradley Emalfarb and&#160;Bradley Scott Emalfarb Irrevocable Trust was $<ix:nonFraction id="c125843650" contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,733</ix:nonFraction>&#160;and $<ix:nonFraction id="c125843651" contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,640</ix:nonFraction>,&#160;respectively.</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">(<em style="font: inherit;">3</em>) Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, are co-trustees of the Descendant Trust and&#160;<em style="font: inherit;"> may&#160;</em>therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Descendant Trust. The amount of accrued interest as of </span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, is $<ix:nonFraction id="c125843653" contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,800</ix:nonFraction>.</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restri<span style="background-color:#ffffff;">ctions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of <em style="font: inherit;"> December 31, 2024.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">21</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2877274" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">6:</em>&#160;&#160;&#160;&#160;&#160;Share-Based Compensation</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Description of Equity Plans</i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The <em style="font: inherit;">2021</em> Equity Incentive Award Plan (the <em style="font: inherit;">&#8220;2021</em> Plan&#8221;) was adopted by the Company's Board of Directors on <em style="font: inherit;"> April 9, 2021,&#160;</em>and approved&#160;by the Company&#8217;s&#160;Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) on <em style="font: inherit;"> June 11, 2021. </em>The <em style="font: inherit;">2021</em> Plan serves as a successor to the Company&#8217;s <em style="font: inherit;">2011</em> Equity Incentive Plan (the <em style="font: inherit;">&#8220;2011</em> Plan&#8221;).&#160;Since the adoption of the <em style="font: inherit;">2021</em> Plan, all equity awards were made from the <em style="font: inherit;">2021</em> Plan and <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2011</em> Plan. The <em style="font: inherit;">2021</em> Plan provides&#160;for the issuance of a variety of share-based compensation awards, including&#160;stock options,&#160;restricted stock awards, restricted stock unit awards, performance awards, dividend equivalents awards, deferred stock awards, stock payment awards and stock appreciation rights. As of <em style="font: inherit;"> April 16, 2021, </em>the <em style="font: inherit;">2021</em> Plan increased the number of shares available for grant by&#160;<ix:nonFraction id="c125843667" contextRef="d_2021-04-16_2021-04-16_PlanNameAxis-The2021PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction>&#160;in addition to&#160;the number of shares remaining available for the grant of new awards under the <em style="font: inherit;">2011</em> Plan.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2024</em>, the Company had <ix:nonFraction id="c125843669" contextRef="i_2024-12-31_PlanNameAxis-The2021PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,788,597</ix:nonFraction>&#160;stock options outstanding and an additio<span style="background-color:#ffffff;">nal&#160;</span><ix:nonFraction id="c125843670" contextRef="i_2024-12-31_PlanNameAxis-The2021PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,056,629</ix:nonFraction><span style="background-color:#ffffff;"> share</span>s of common stock available for grant under the <em style="font: inherit;">2021</em> Plan. As of <em style="font: inherit;"> December 31, 2023</em>, there were <ix:nonFraction id="c125843672" contextRef="i_2023-12-31_PlanNameAxis-The2021PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,469,247</ix:nonFraction> stock options outstanding and an additional <ix:nonFraction id="c125843673" contextRef="i_2023-12-31_PlanNameAxis-The2021PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,672,561</ix:nonFraction> shares of common stock available for grant under the <em style="font: inherit;">2021</em> Plan.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Stock Options </i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company&#8217;s <em style="font: inherit;">2011</em> Plan and <em style="font: inherit;">2021</em> Plan is <span style="-sec-ix-hidden:c125843677">ten</span> years, except for certain options granted to the contractors which are between <span style="-sec-ix-hidden:c125843678">two</span> to&#160;<span style="-sec-ix-hidden:c125843679">three</span> years.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i>Risk-free interest rate</i>. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i>Expected dividend yield</i>. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does <em style="font: inherit;">not</em> currently anticipate paying any in the foreseeable future.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i>Expected stock price volatility.</i> The expected stock price volatility was calculated based on the Company&#8217;s own volatility. The Company reviews its volatility assumption on an annual basis and has used the Company&#8217;s historical volatilities.&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Expected life of option. </i>The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option<span style="background-color:#ffffff;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The assumptions used in the Black-Scholes option pricing model for stock options granted for the years ended&#160;<em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>&#160;are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2877275" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Years Ended December 31,</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2024</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2023</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; width: 70%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Risk-free interest rate</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843085" contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.56</ix:nonFraction>% - <ix:nonFraction id="c125843086" contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.61</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3.90% -5.12</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected dividend yield</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected stock price volatility</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843089" contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" format="ixt:num-dot-decimal" decimals="4">63.02</ix:nonFraction>-<ix:nonFraction id="c125843090" contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="4">63.64</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c125843097">62.22%</span> - <span style="-sec-ix-hidden:c125843098">64.27</span></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected life of options (in years)</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c125843091" format="ixt-sec:duryear">2.63</ix:nonNumeric>-<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c125843092" format="ixt-sec:duryear">6.25</ix:nonNumeric></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">1.13 -6.25</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">22</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The following table summarizes the combined stock option activity under the Company&#8217;s Equity Compensation Plans:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2877276" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Term (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843121" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,031,097</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843122" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.25</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c125843123" format="ixt-sec:duryear">5.75</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843124" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843125" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">805,350</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843126" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.45</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843129" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843130" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125843133" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">351,520</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843134" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.71</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125843137" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">15,680</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843138" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.50</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843141" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,469,247</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843142" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.08</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c125843143" format="ixt-sec:duryear">5.66</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843144" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">322,738</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted<sup style="vertical-align:top;line-height:120%;"> (1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843145" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">830,725</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843146" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.61</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Exercised<sup style="vertical-align:top;line-height:120%;"> (2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125843149" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">55,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843150" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expired <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125843153" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">383,063</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843154" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.16</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Canceled<sup style="vertical-align:top;line-height:120%;"> (4)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125843157" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">73,312</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843158" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.73</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843161" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,788,597</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843162" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.97</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c125843163" format="ixt-sec:duryear">5.34</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843164" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">655,578</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Exercisable at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"><ix:nonFraction id="c125843165" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,438,810</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"><ix:nonFraction id="c125843166" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c125843167" format="ixt-sec:duryear">4.44</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"><ix:nonFraction id="c125843168" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" format="ixt:num-dot-decimal" decimals="INF">436,263</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notes:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(<em style="font: inherit;">1</em>) Represents the following options granted:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Annual share-based compensation awards on&#160;<em style="font: inherit;"> January 2,&#160;</em><em style="font: inherit;">2024,</em> with an exercise price of $<ix:nonFraction id="c125843685" contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.59</ix:nonFraction>, including: (a)&#160;<ix:nonFraction id="c125843686" contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">387,500</ix:nonFraction>&#160;stock options granted to executives and key personnel, vesting upon&#160;<span style="-sec-ix-hidden:c125843687">one</span>&#160;year anniversary, or annually in equal installments over&#160;<span style="-sec-ix-hidden:c125843688">four</span>&#160;years, (b)&#160;<ix:nonFraction id="c125843689" contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">352,500</ix:nonFraction>&#160;stock options granted to members of the Board of Directors, vesting upon&#160;<span style="-sec-ix-hidden:c125843690">one</span>&#160;year anniversary, (c)&#160;<ix:nonFraction id="c125843691" contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-EmployeesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">17,600</ix:nonFraction>&#160;stock options&#160;granted to employees, vesting annually in equal installments over&#160;<span style="-sec-ix-hidden:c125843692">four</span>&#160;years, and (d)<ix:nonFraction id="c125843693" contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ConsultantMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">15,000</ix:nonFraction>&#160;stock options&#160;granted to a consultant, vesting upon&#160;<span style="-sec-ix-hidden:c125843694">one</span>&#160;year anniversary.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">One-time awards on&#160;<em style="font: inherit;"> April 11, 2024,&#160;</em>with an exercise price of $<ix:nonFraction id="c125843695" contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveAndBoardOfDirectorsMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.84</ix:nonFraction>, including&#160;<ix:nonFraction id="c125843696" contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">20,000</ix:nonFraction>&#160;stock options&#160;granted to an executive, vesting annually in equal installments over&#160;<span style="-sec-ix-hidden:c125843697">four</span>&#160;years, and <ix:nonFraction id="c125843698" contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-BoardOfDirectorsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,125</ix:nonFraction>&#160;stock options&#160;granted to a member of the Board of Directors, vesting upon&#160;<span style="-sec-ix-hidden:c125843699">one</span>&#160;year anniversary.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">A&#160;<em style="font: inherit;">one</em>-time award on&#160;<em style="font: inherit;"> September 23, 2024,&#160;</em>of&#160;<ix:nonFraction id="c125843701" contextRef="d_2024-09-23_2024-09-23_TitleOfIndividualAxis-ConsultantMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction>&#160;stock options granted to a consultant with an exercise price of $<ix:nonFraction id="c125843702" contextRef="d_2024-09-23_2024-09-23_TitleOfIndividualAxis-ConsultantMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.79</ix:nonFraction>, vesting in&#160;<span style="-sec-ix-hidden:c125843703">three</span>&#160;months.</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(<em style="font: inherit;">2</em>) Represents the following options exercised:&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;">&#160;</td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(a) <span style="background-color:#ffffff;"><ix:nonFraction id="c125843705" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions1Member" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction>&#160;stock options exercised at $<ix:nonFraction id="c125843706" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.97</ix:nonFraction>, and (b) <ix:nonFraction id="c125843707" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions2Member" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">30,000</ix:nonFraction>&#160;stock options exercised at $<ix:nonFraction id="c125843708" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.36</ix:nonFraction>.</span></p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(<em style="font: inherit;">3</em>) Represents the following options expired:&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;">&#160;</td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(a)&#160;<ix:nonFraction id="c125843710" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">300,000</ix:nonFraction>&#160;stock options with an exercise price of $<ix:nonFraction id="c125843711" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.87</ix:nonFraction>&#160;per share&#160;granted to an executive, (b)&#160;<ix:nonFraction id="c125843712" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction>&#160;stock options with an exercise price of $<ix:nonFraction id="c125843713" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-DirectorMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.76</ix:nonFraction>&#160;per share granted to a member&#160;of the Board of Directors, (c)&#160;<ix:nonFraction id="c125843714" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,500</ix:nonFraction>&#160;stock options with an exercise price of $<ix:nonFraction id="c125843715" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantOneMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.56</ix:nonFraction>&#160;per share granted to&#160;a consultant, (d)&#160;<ix:nonFraction id="c125843716" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantTwoMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction>&#160;stock options with an exercise price of $<ix:nonFraction id="c125843717" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantTwoMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.14</ix:nonFraction>&#160;per share granted to&#160;a consultant, and (e) <ix:nonFraction id="c125843718" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,563</ix:nonFraction>&#160;stock options with a weighted average&#160;exercise price of $<ix:nonFraction id="c125843719" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.93</ix:nonFraction> per share&#160;granted to employees.</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(<em style="font: inherit;">4</em>) Represents the following options canceled:&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;">&#160;</td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(a)&#160;<ix:nonFraction id="c125843721" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerBoardOfDirectorsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">50,000</ix:nonFraction>&#160;stock options granted to a former member of the Board of Directors, (b)&#160;<ix:nonFraction id="c125843722" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerChairmanOfTheBoardOfDirectorsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,125</ix:nonFraction>&#160;stock options&#160;granted to the Company's former Chairman of the Board of Directors, and (c)&#160;<ix:nonFraction id="c125843723" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerEmployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,187</ix:nonFraction>&#160;stock options granted to the Company's former employee.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">The weighted average grant-date fair market value of stock options granted for the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;"> was&#160;$<ix:nonFraction id="c125843725" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.95</ix:nonFraction> and </span>$<ix:nonFraction id="c125843726" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.81</ix:nonFraction><span style="background-color:#ffffff;">, respectively, based on the Black-Scholes option pricing model. The intrinsic value of options exercised for the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;"> was </span>$<ix:nonFraction id="c125843728" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,300</ix:nonFraction><span style="background-color:#ffffff;">&#160;and </span>$<ix:nonFraction id="c125843729" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction><span style="background-color:#ffffff;">, respectively.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, total unrecognized compensation cost related to non-vested stock options granted under the Company&#8217;s equity compensation plans was </span>$<ix:nonFraction id="c125843731" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">319,978</ix:nonFraction><span style="background-color:#ffffff;">&#160;and </span>$<ix:nonFraction id="c125843732" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">559,121</ix:nonFraction><span style="background-color:#ffffff;">, respectively, which is expected to be recognized over a weighted average period of </span><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c125843733" format="ixt-sec:duryear">2.40</ix:nonNumeric><span style="background-color:#ffffff;">&#160;years and </span><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c125843734" format="ixt-sec:duryear">2.68</ix:nonNumeric><span style="background-color:#ffffff;">&#160;years, respectively. The Company adjusts the unrecognized compensation cost for actual forfeitures as they occur.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">23</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt; text-align: left;"><b><i>Restricted Stock Units</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Restricted stock units (the &#8220;RSUs&#8221;) are granted subject to certain restrictions. Vesting conditions are determined at the discretion of the Board of Directors.&#160;The fair market value of RSUs is generally determined based on the closing market price of the stock on the grant date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The following table summarizes the&#160;restricted stock units activity during the&#160;year&#160;ended&#160;<em style="font: inherit;"> December 31, 2024</em>:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="c2877277" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grant Date</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843175" contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">213,044</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843176" contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.43</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843177" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">354,219</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843178" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.60</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125843179" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">437,546</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843180" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.52</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Unvested shares forfeited<sup style="vertical-align:top;line-height:120%;"> (3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125843181" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,792</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843182" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.59</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843183" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">117,925</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843184" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.59</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notes:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">On&#160;<em style="font: inherit;"> January 2, 2024,&#160;</em>the Company granted&#160;<ix:nonFraction id="c125843737" contextRef="d_2024-01-02_2024-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">141,510</ix:nonFraction>&#160;RSUs, vesting upon&#160;<span style="-sec-ix-hidden:c125843738">one</span>&#160;year anniversary of the grant, to members of the Board of Directors.&#160;On&#160;<em style="font: inherit;"> March 13, 2024,&#160;</em>the Company granted&#160;<ix:nonFraction id="c125843739" contextRef="d_2024-03-13_2024-03-13_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">212,709</ix:nonFraction>&#160;RSUs with immediate vesting, to&#160;executives and key personnel in lieu of cash bonuses earned for the year of <em style="font: inherit;">2023.</em>&#160;The fair value of the restricted stock unit is the Company&#8217;s closing stock price on the grant date as reported on the Nasdaq Stock Exchange.&#160;</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">2</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the vesting of&#160;<ix:nonFraction id="c125843742" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">212,709</ix:nonFraction>&#160;RSUs granted to executives and key personnel,&#160;<ix:nonFraction id="c125843743" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">174,837</ix:nonFraction>&#160;RSUs granted to the Board of Directors, and&#160;<ix:nonFraction id="c125843744" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ContractorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">50,000</ix:nonFraction>&#160;RSUs granted to a consultant.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">3</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the cancellation of RSUs granted to a former member of the Board of Directors.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Compensation Expenses</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We recognize all share-based payments to employees, consultants, and our Board, as non-cash compensation expenses, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had <em style="font: inherit;">no</em> impact on the Company&#8217;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. There was <em style="font: inherit;">no</em> performance-based award recognized during the years ended&#160;<em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Total non-cash stock option compensation expense was allocated among the following expense categories:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="EFBBBEFB-AC01-49C7-BA37-9C8A063D774B" escape="true" continuedAt="B63FD642-7E72-4B93-BDC8-491A52038D27">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843189" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1,067,750</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843190" contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1,201,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843191" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">58,529</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843192" contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,094</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843193" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,126,279</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843194" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,244,121</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The following table summarizes the Company&#8217;s non-cash share-based compensation expense&#160;allocation between options and restricted stock units:</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <ix:continuation id="B63FD642-7E72-4B93-BDC8-491A52038D27">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses- stock option</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843199" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">861,999</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843200" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,004,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses- restricted stock units</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843201" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">264,280</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843202" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">240,067</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843203" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,126,279</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843204" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,244,121</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">24</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2877280" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">7:</em>&#160;&#160;&#160;&#160;&#160;Shareholders&#8217; Equity</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Issuances of Common Stock</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For the year&#160;ended&#160;<em style="font: inherit;"> December 31, 2024</em>, there wer<span style="background-color:#ffffff;">e <ix:nonFraction id="c125843751" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConvertibleNotesConvertedIntoCommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">556,623</ix:nonFraction>&#160;shares of the Company&#8217;s common stock issued resulting from the conversion of convertible notes with a weighted average issue price of&#160;$<ix:nonFraction id="c125843752" contextRef="i_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConvertibleNotesConvertedIntoCommonStockMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.63</ix:nonFraction>&#160;pe</span>r share,&#160;<span style="background-color:#ffffff;"><ix:nonFraction id="c125843753" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">437,546</ix:nonFraction>&#160;shares of the Company&#8217;s common stock issued resulting from the vesting of restricted stock units with a weighted average issue price of&#160;$<ix:nonFraction id="c125843754" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.52</ix:nonFraction>&#160;pe</span>r share, and <ix:nonFraction id="c125843755" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">30,569</ix:nonFraction> shares of the Company's common stock issued resulting from the exercise of stock options, with a weighted average issue price of $<ix:nonFraction id="c125843756" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.04</ix:nonFraction> per share.&#160;For the year&#160;ended <em style="font: inherit;"> December 31, 2023,&#160;</em>there were&#160;<ix:nonFraction id="c125843757" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">247,961</ix:nonFraction>&#160;shares of the Company&#8217;s common stock issued resulting from the vesting of restricted stock units with a weighted average issue price of&#160;$<ix:nonFraction id="c125843758" contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.38</ix:nonFraction>&#160;per share.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Treasury Stock </i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2024</em>, and <em style="font: inherit;">2023</em>, there were <ix:nonFraction id="c125843760" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:TreasuryStockCommonShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,253,502</ix:nonFraction>&#160;shares of common stock held in treasury, at a cost of approximately $<ix:nonFraction id="c125843761" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">18.9</ix:nonFraction> million, representing the purchase price on the date the shares were surrendered to the Company.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2877281" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">8:</em>&#160;&#160;&#160;&#160;&#160;Income Taxes </b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;">For the year ended <em style="font: inherit;"> December 31, 2024</em>, there was&#160;<em style="font: inherit;">no</em> provision for income taxes or unrecognized tax benefits recorded.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;">The significant components of gain (loss) before income taxes are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="c2877282" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">U.S. operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843209" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,757,824</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843210" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6,766,409</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Foreign operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843211" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">51,335</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843212" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">29,052</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total loss before provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125843213" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeLossAttributableToParent" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,809,159</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125843214" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncomeLossAttributableToParent" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6,795,461</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Company has <ix:nonFraction id="c125843764" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> current or deferred income tax&#160;for the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to&#160;permanent differences, state income taxes and a change in the deferred tax valuation allowance.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The reconciliation between the statutory tax rate and the Company&#8217;s actual effective tax rate is as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2877283" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Tax at U.S. statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843219" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843220" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">State taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843221" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">4.29</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843222" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">4.19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Non-deductible items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843223" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="4">0.26</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843224" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="4">0.76</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843225" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="4">20.59</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843226" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="4">14.54</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">True-up adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843227" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="dyai:EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.44</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843228" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="dyai:EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" scale="-2" format="ixt:num-dot-decimal" decimals="1">10.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Foreign operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843229" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843230" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">0.11</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Change in tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843231" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" format="ixt:fixed-zero" decimals="0" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843232" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" format="ixt:fixed-zero" decimals="0" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843233" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843234" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843235" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843236" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">25</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The significant components of the Company&#8217;s net deferred income tax assets are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2877284" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Section 174 - R&amp;D expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843241" contextRef="i_2024-12-31" unitRef="USD" name="dyai:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,123,800</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843242" contextRef="i_2023-12-31" unitRef="USD" name="dyai:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,769,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843243" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,584,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843244" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,419,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">NOL carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843245" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,655,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843246" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,620,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General Business credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843247" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,278,400</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843248" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,503,600</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Operating lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843249" contextRef="i_2024-12-31" unitRef="USD" name="dyai:DeferredTaxAssetsOperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF">22,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843250" contextRef="i_2023-12-31" unitRef="USD" name="dyai:DeferredTaxAssetsOperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="INF">34,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Right-of-use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843251" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" format="ixt:num-dot-decimal" decimals="INF">23,400</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c125843252" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" format="ixt:num-dot-decimal" decimals="INF">35,800</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843253" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="0" format="ixt:num-dot-decimal" decimals="INF">800</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843254" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="0" format="ixt:num-dot-decimal" decimals="INF">134,800</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Deferred tax asset, net of deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843255" contextRef="i_2024-12-31" unitRef="USD" name="dyai:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="INF">17,642,100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843256" contextRef="i_2023-12-31" unitRef="USD" name="dyai:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,446,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125843257" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="INF">17,642,100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125843258" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,446,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843259" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125843260" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets, Management evaluates whether it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on Management&#8217;s evaluation, the net deferred tax asset, was offset by a full valuation allowance as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em>&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards available as of <em style="font: inherit;"> December 31, 2024, </em>and <em style="font: inherit;">2023,</em> in the amount of <span style="background-color:#ffffff;">approximately $<ix:nonFraction id="c125843771" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="INF">49,903,000</ix:nonFraction>&#160;and $<ix:nonFraction id="c125843772" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="INF">45,850,000</ix:nonFraction>, respectively. Approximately $<ix:nonFraction id="c125843773" contextRef="i_2024-12-31" unitRef="USD" name="dyai:OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" scale="0" format="ixt:num-dot-decimal" decimals="INF">46,965,000</ix:nonFraction></span>&#160;of the federal net operating loss carryforwards will be carried forward indefinitely and will be available to offset <ix:nonFraction id="c125843774" contextRef="i_2024-12-31" unitRef="Pure" name="dyai:OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="1">80</ix:nonFraction>% of taxable income. The remaining amount of the net operating loss carryforwards will expire at varying dates through <em style="font: inherit;">2038.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Tax Cuts and Jobs Act eliminated the current year deduction election for research and experimental expenditures. Instead, a taxpayer must charge such expenditures to a capital account and is allowed to amortize such expenditures ratably over a <em style="font: inherit;">five</em>-year period (or <em style="font: inherit;">fifteen</em>-year period for expenditures attributable to foreign research), beginning with the midpoint of the tax year in which such expenditures are paid or incurred.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SegmentReportingDisclosureTextBlock" id="c2877285" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Note <em style="font: inherit;">9:</em>&#160;&#160;&#160;&#160; Segment</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company operates and manages its business as <ix:nonFraction id="c125843779" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction>&#160;reportable segment and <ix:nonFraction id="c125843780" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction>&#160;operating segment, which is the business of developing and commercializing synthetic protein products using the Company&#8217;s proprietary microbial platforms, including <em style="font: inherit;">C1</em> and Dapibus&#8482;. The Company's chief operating decision maker, or CODM, is the Company's senior management team that includes the Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The Company operates in the U.S. and Europe.&#160;All material long-lived assets of the Company reside in the U.S. For geographic information about the Company&#8217;s product revenues, see Note <em style="font: inherit;">1,</em> <i>Concentration</i>. Long-lived assets primarily consist of operating lease right-of-use assets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The CODM uses consolidated net loss to evaluate the Company's spend and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing performance of the segment and in establishing resource allocation across the organization. Factors used in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note <em style="font: inherit;">1</em> of the notes to the consolidated financial statements included in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">26</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#160;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The C<span style="background-color:#ffffff;">ODM reviews cash, cash equivalents and investment securities as a measure of segment assets.&#160;As of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Company&#8217;s cash, cash equivalents and investment securities were $<ix:nonFraction id="c125843787" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.3</ix:nonFraction>&#160;million and $<ix:nonFraction id="c125843788" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:num-dot-decimal" decimals="-5">7.3</ix:nonFraction>&#160;million, respectively.</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><span style="background-color:#ffffff;">The following table presents information about segment revenue, significant segment expenses and segment operating loss for the years ended <em style="font: inherit;"> December 31, 2024 </em>and&#160;<em style="font: inherit;">2023:</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="c2877286" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843265" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,495,389</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c125843266" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,898,806</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843267" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,194,624</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843268" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,975,849</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843269" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseOutsideContractedServices" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,503,397</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843270" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseOutsideContractedServices" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,677,941</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125843271" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">414,916</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843272" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">510,647</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Facilities, overhead, and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843273" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" scale="0" format="ixt:num-dot-decimal" decimals="INF">67,411</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843274" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" scale="0" format="ixt:num-dot-decimal" decimals="INF">65,584</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General and administrative expenses:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Compensation and related expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843277" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:LaborAndRelatedExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,308,566</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843278" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:LaborAndRelatedExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,200,914</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Business consulting expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843279" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="dyai:BusinessConsultingExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">764,326</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843280" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="dyai:BusinessConsultingExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">305,348</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Legal and professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843281" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:ProfessionalFees" scale="0" format="ixt:num-dot-decimal" decimals="INF">998,630</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843282" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:ProfessionalFees" scale="0" format="ixt:num-dot-decimal" decimals="INF">931,038</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other G&amp;A expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843283" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">995,501</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843284" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,244,121</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843285" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,126,279</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843286" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,178,686</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign currency exchange loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843287" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">22,561</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125843288" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">38,417</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Income (expenses), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843289" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,663</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125843290" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,434,278</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net loss</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125843291" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5,809,159</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125843292" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6,795,461</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2877287" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">10:</em>&#160;&#160;&#160;&#160;&#160;Subsequent Events </b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through <em style="font: inherit;"> March 26, 2025</em>, the date the consolidated financial statements were available to be issued. Except for items mentioned in the notes, and as discussed below, management is <em style="font: inherit;">not</em> aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> January 2, 2025, </em>the Company granted an annual stock option award with an exercise price of $<ix:nonFraction id="c125843792" contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.74</ix:nonFraction>, including: (a) <ix:nonFraction id="c125843793" contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">356,500</ix:nonFraction> stock options granted to executives and key personnel, vesting upon <em style="font: inherit;">one</em> year anniversary, or annually in equal installments over <span style="-sec-ix-hidden:c125843795">four</span> years, (b) <ix:nonFraction id="c125843796" contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">277,500</ix:nonFraction> stock options granted to members of the Board of Directors, vesting upon <span style="-sec-ix-hidden:c125843797">one</span> year anniversary, (c) <ix:nonFraction id="c125843798" contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">19,500</ix:nonFraction> stock options granted to employees, vesting annually in equal installments over <span style="-sec-ix-hidden:c125843799">four</span> years, and (d) <ix:nonFraction id="c125843800" contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ConsultantMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">20,000</ix:nonFraction> stock options granted to a consultant, vesting upon <span style="-sec-ix-hidden:c125843801">one</span> year anniversary.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> January 2, 2025, </em>the Company granted <ix:nonFraction id="c125843802" contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">96,984</ix:nonFraction> restricted stock units, vesting upon <em style="font: inherit;">one</em> year anniversary, to the Board of Directors as a result of reduction in director cash compensation of <em style="font: inherit;">2025,</em> and &#160;an aggregate of <ix:nonFraction id="c125843805" contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">133,039</ix:nonFraction> restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> March 20, 2025, </em>the Company announced that it has received a funding award from CEPI to use <em style="font: inherit;">C1</em> to accelerate the development of protein-based vaccines through the partnership with Fondazione Biotecnopolo di Siena (FBS), a non-profit foundation backed by the Italian government.</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-27
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>2
<FILENAME>ex_727226.htm
<DESCRIPTION>EXHIBIT 10.2.1
<TEXT>
<html><head>
	<title>ex_727226.htm</title>

	<!-- Generated by ThunderDome Portal - 9/25/2024 5:02:07 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body class="vsc-initialized" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.2.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DYADIC INTERNATIONAL, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021 EQUITY INCENTIVE AWARD PLAN</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>STOCK OPTION GRANT NOTICE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Dyadic International, Inc., a Delaware corporation, (the &#8220;<u>Company</u>&#8221;), pursuant to its 2021 Equity Incentive Award Plan, as amended from time to time (the &#8220;<u>Plan</u>&#8221;), hereby grants to the Holder listed below (&#8220;<u>Participant</u>&#8221;), an option to purchase the number of shares of the Company&#8217;s common stock, par value $0.001 (&#8220;<u>Stock</u>&#8221;), set forth below (the &#8220;<u>Option</u>&#8221;). This Option is subject to all of the terms and conditions set forth herein and in the Stock Option Agreement attached hereto as <u>Exhibit A</u> (the &#8220;<u>Stock Option Agreement</u>&#8221;) and the Plan, each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Stock Option Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Participant Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Participant ID: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Plan Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Award Number:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Shares Granted: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Award Type:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Award Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Award Price: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Vesting Schedule: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Expiration Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">By signing the Stock Option Grant Notice below and the Stock Option Agreement attached hereto as <u>Exhibit A</u>, Participant agrees to be bound by the terms and conditions of the Plan, the Stock Option Agreement and this Grant Notice. Participant has reviewed the Stock Option Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and the Stock Option Agreement and fully understands all provisions of this Grant Notice, the Stock Option Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Stock Option Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>DYADIC INTERNATIONAL,</b>&nbsp;<b>INC.:</b></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 48%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PARTICIPANT:</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Signature:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 38%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Print Name:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Print Name:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 38%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Title:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 38%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><u>EXHIBIT A</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DYADIC INTERNATIONAL, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>STOCK OPTION AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Pursuant to the Stock Option Grant Notice (the &#8220;<u>Grant Notice</u>&#8221;) to which this Stock Option Agreement (this &#8220;<u>Agreement</u>&#8221;) is attached, Dyadic International, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), has granted to Participant an Option under the Company&#8217;s 2021 Equity Incentive Award Plan, as amended from time to time (the &#8220;<u>Plan</u>&#8221;), to purchase the number of shares of Stock indicated in the Grant Notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE 1. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GENERAL </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">1.1 <u>Defined Terms</u>. Wherever the following terms are used in this Agreement they shall have the meanings specified below, unless the context clearly indicates otherwise. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">1.2 <u>Incorporation of Terms of Plan</u>. The Option is subject to the terms and conditions of the Plan which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE 2. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GRANT OF OPTION </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">2.1 <u>Grant of Option</u>. In consideration of Participant&#8217;s past and/or continued employment with or service to the Company or a Subsidiary and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice (the &#8220;<u>Grant Date</u>&#8221;), the Company grants to Participant the Option to purchase any part or all of an aggregate of the number of shares of Stock set forth in the Grant Notice, upon the terms and conditions set forth in the Plan and this Agreement, subject to adjustments as provided in Section&nbsp;14.2 of the Plan. Unless designated as a Nonstatutory Stock Option in the Grant Notice, the Option shall be an Incentive Stock Option to the maximum extent permitted by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">2.2 <u>Exercise Price</u>. The exercise price of the shares of Stock subject to the Option shall be as set forth in the Grant Notice, without commission or other charge; <i>provided</i>, <i>however</i>, that the price per share of the shares of Stock subject to the Option shall not be less than 100% of the Fair Market Value of a share of Stock on the Grant Date. Notwithstanding the foregoing, if this Option is designated as an Incentive Stock Option and Participant owns (within the meaning of Section&nbsp;424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or any &#8220;subsidiary corporation&#8221; of the Company or any &#8220;parent corporation&#8221; of the Company (each within the meaning of Section&nbsp;424 of the Code), the price per share of the shares of Stock subject to the Option shall not be less than 110% of the Fair Market Value of a share of Stock on the Grant Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">2.3 <u>Consideration to the Company</u>. In consideration of the grant of the Option by the Company, Participant agrees to render faithful and efficient services to the Company or any Subsidiary. Nothing in the Plan or this Agreement shall confer upon Participant any right to continue in the employ or service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE 3. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PERIOD OF EXERCISABILITY </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">3.1 <u>Commencement of Exercisability</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(a) Subject to Sections 3.2, 3.3, 5.10 and 5.16 hereof, the Option shall become vested and exercisable in such amounts and at such times as are set forth in the Grant Notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(b) No portion of the Option which has not become vested and exercisable at the date of Participant&#8217;s Termination of Service shall thereafter become vested and exercisable, except as may be otherwise provided by the Administrator or as set forth in a written agreement between the Company and Participant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(c) Notwithstanding Sections 3.1(a) hereof and the Grant Notice, but subject to Section&nbsp;3.1(b) hereof, pursuant to Section&nbsp;14.2 of the Plan, the Option shall become fully vested and exercisable with respect to all shares of Stock covered thereby in the event of a Change in Control, in connection with which the successor corporation does not assume the Option or substitute an equivalent right for the Option. Should the successor corporation assume the Option or substitute an equivalent right, then no such acceleration shall apply.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">3.2 <u>Duration of Exercisability</u>. The installments provided for in the vesting schedule set forth in the Grant Notice are cumulative. Each such installment which becomes vested and exercisable pursuant to the vesting schedule set forth in the Grant Notice shall remain vested and exercisable until it becomes unexercisable under Section&nbsp;3.3 hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">3.3 <u>Expiration of Option</u>. The Option may not be exercised to any extent by anyone after the first to occur of the following events:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(a) The Expiration Date set forth in the Grant Notice, which shall in no event be more than ten (10)&nbsp;years from the Grant Date;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(b) If this Option is designated as an Incentive Stock Option and Participant owned (within the meaning of Section&nbsp;424(d) of the Code), at the time the Option was granted, more than 10% of the total combined voting power of all classes of stock of the Company or any &#8220;subsidiary corporation&#8221; of the Company or any &#8220;parent corporation&#8221; of the Company (each within the meaning of Section&nbsp;424 of the Code), the expiration of five (5)&nbsp;years from the Grant Date;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(c) The expiration of three (3)&nbsp;months from the date of Participant&#8217;s Termination of Service, unless such termination occurs by reason of Participant&#8217;s death or disability; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(d) The expiration of one (1)&nbsp;year from the date of Participant&#8217;s Termination of Service by reason of Participant&#8217;s death or disability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">3.4 <u>Special Tax Consequences</u>. Participant acknowledges that, to the extent that the aggregate Fair Market Value (determined as of the time the Option is granted) of all shares of Stock with respect to which Incentive Stock Options, including the Option (if applicable), are exercisable for the first time by Participant in any calendar year exceeds $100,000, the Option and such other options shall be Nonstatutory Stock Options to the extent necessary to comply with the limitations imposed by Section&nbsp;422(d) of the Code. Participant further acknowledges that the rule set forth in the preceding sentence shall be applied by taking the Option and other &#8220;incentive stock options&#8221; into account in the order in which they were granted, as determined under Section&nbsp;422(d) of the Code and the Treasury Regulations thereunder. Participant also acknowledges that an Incentive Stock Option exercised more than three (3)&nbsp;months after Participant&#8217;s Termination of Employment, other than by reason of death or disability, will be taxed as a Nonstatutory Stock Option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">3.5 <u>Tax Indemnity</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:50pt;">(a) The Participant agrees to indemnify and keep indemnified the Company, any Subsidiary and his/her employing company, if different, from and against any liability for or obligation to pay any Tax Liability (a &#8220;Tax Liability&#8221; being any liability for income tax, withholding tax and any other employment related taxes or social security contributions in any jurisdiction) that is attributable to (1)&nbsp;the grant or exercise of, or any benefit derived by the Participant from, the Option, (2)&nbsp;the acquisition by the Participant of the Stock on exercise of the Option, or (3)&nbsp;the disposal of any Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(b) The Option cannot be exercised until the Participant has made such arrangements as the Company may require for the satisfaction of any Tax Liability that may arise in connection with the exercise of the Option and/or the acquisition of the Stock by the Participant. The Company shall not be required to issue, allot or transfer Stock until the Employee has satisfied this obligation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE 4. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXERCISE OF OPTION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">4.1 <u>Person Eligible to Exercise</u>. During the lifetime of Participant, only Participant may exercise the Option or any portion thereof. After the death of Participant, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section&nbsp;3.3 hereof, be exercised by Participant&#8217;s personal representative or by any person empowered to do so under the deceased Participant&#8217;s will or under the then applicable laws of descent and distribution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">4.2 <u>Partial Exercise</u>. Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised in whole or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section&nbsp;3.3 hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">4.3 <u>Manner of Exercise</u>. The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the Company (or any third-party administrator or other person or entity designated by the Company), during regular business hours, of all of the following prior to the time when the Option or such portion thereof becomes unexercisable under Section&nbsp;3.3 hereof:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(a) An exercise notice in a form specified by the Administrator, stating that the Option or portion thereof is thereby exercised, such notice complying with all applicable rules established by the Administrator;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(b) The receipt by the Company of full payment for the shares of Stock with respect to which the Option or portion thereof is exercised, including payment of any applicable withholding tax, which shall be made by deduction from other compensation payable to Participant or in such other form of consideration permitted under Section&nbsp;4.4 hereof that is acceptable to the Company;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(c) Any other written representations as may be required in the Administrator&#8217;s reasonable discretion to evidence compliance with the Securities Act or any other applicable law, rule or regulation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(d) In the event the Option or portion thereof shall be exercised pursuant to Section&nbsp;4.1 hereof by any person or persons other than Participant, appropriate proof of the right of such person or persons to exercise the Option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Notwithstanding any of the foregoing, the Company shall have the right to specify all conditions of the manner of exercise, which conditions may vary by country, and which may be subject to change from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">4.4 <u>Method of Payment</u>. Payment of the exercise price shall be by any of the following, or a combination thereof, at the election of Participant:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(a) Cash or check;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(b) With the consent of the Administrator, surrender of shares of Stock (including, without limitation, shares of Stock otherwise issuable upon exercise of the Option) held for such period of time as may be required by the Administrator in order to avoid adverse accounting consequences and having a Fair Market Value on the date of delivery equal to the aggregate exercise price of the Option or exercised portion thereof; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(c) Other property acceptable to the Administrator (including, without limitation, through the delivery of a notice that Participant has placed a market sell order with a broker with respect to shares of Stock then issuable upon exercise of the Option, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the Option exercise price; <i>provided</i> that payment of such proceeds is then made to the Company at such time as may be required by the Company, but in any event not later than the settlement of such sale).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">4.5 <u>Conditions to Issuance of Stock</u>. The shares of Stock deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but unissued shares of Stock or issued shares of Stock which have then been reacquired by the Company. Such shares of Stock shall be fully paid and nonassessable. The Company shall not be required to issue or deliver any shares of Stock purchased upon the exercise of the Option or portion thereof prior to fulfillment of all of the following conditions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(a) The admission of such shares of Stock to listing on all stock exchanges on which such Stock is then listed;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(b) The completion of any registration or other qualification of such shares of Stock under any state or federal law or under rulings or regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Administrator shall, in its absolute discretion, determine to be necessary or advisable;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(d) The receipt by the Company of full payment for such shares of Stock, including payment of any applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section&nbsp;4.4 hereof; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:49pt;">(e) The lapse of such reasonable period of time following the exercise of the Option as the Administrator may from time to time establish for reasons of administrative convenience.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">4.6 <u>Rights as Stockholder</u>. The holder of the Option shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of any shares of Stock purchasable upon the exercise of any part of the Option unless and until such shares of Stock shall have been issued by the Company and held of record by such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Stock are issued, except as provided in Section&nbsp;14.2 of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE 5. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OTHER PROVISIONS </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.1 <u>Administration</u>. The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon Participant, the Company and all other interested persons. No member of the Committee or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the Option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.2 <u>Whole Shares</u>. The Option may only be exercised for whole shares of Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.3 <u>Option Not Transferable</u>. Subject to Section&nbsp;4.1 hereof, the Option may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution, unless and until the shares of Stock underlying the Option have been issued, and all restrictions applicable to such shares of Stock have lapsed. Neither the Option nor any interest or right therein shall be liable for the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.4 <u>Binding Agreement</u>. Subject to the limitation on the transferability of the Option contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.5 <u>Adjustments Upon Specified Events</u>. The Administrator may accelerate the vesting of the Option in such circumstances as it, in its sole discretion, may determine. In addition, upon the occurrence of certain events relating to the Stock contemplated by Section&nbsp;14.2 of the Plan (including, without limitation, an extraordinary cash dividend on such Stock), the Administrator shall make such adjustments the Administrator deems appropriate in the number of shares of Stock subject to the Option, the exercise price of the Option and the kind of securities that may be issued upon exercise of the Option. Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and Section&nbsp;14.2 of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.6 <u>Notices</u>. Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company&#8217;s principal office, and any notice to be given to Participant shall be addressed to Participant at Participant&#8217;s last address reflected on the Company&#8217;s records. By a notice given pursuant to this Section&nbsp;5.6, either party may hereafter designate a different address for notices to be given to that party. Any notice which is required to be given to Participant shall, if Participant is then deceased, be given to the person entitled to exercise his or her Option pursuant to Section&nbsp;4.1 hereof by written notice under this Section&nbsp;5.6. Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.7 <u>Titles</u>. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.8 <u>Governing Law</u>. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.9 <u>Conformity to Securities Laws</u>. Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Option is granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.10 <u>Amendments, Suspension and Termination</u>. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board;<i> provided</i> that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the Option in any material way without the prior written consent of Participant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.11 <u>Successors and Assigns</u>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in Section&nbsp;5.3 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.12 <u>Notification of Disposition</u>. If this Option is designated as an Incentive Stock Option, Participant shall give prompt notice to the Company of any disposition or other transfer of any shares of Stock acquired under this Agreement if such disposition or transfer is made (a)&nbsp;within two (2)&nbsp;years from the Grant Date with respect to such shares of Stock or (b)&nbsp;within one (1)&nbsp;year after the transfer of such shares of Stock to Participant. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.13 <u>Limitations Applicable to Section</u><u>&nbsp;</u><u>16 Persons</u>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Option and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section&nbsp;16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.14 <u>Not a Contract of Employment</u>. Nothing in this Agreement or in the Plan shall confer upon the Participant any right to continue to serve as an employee or other service provider of the Company or any of its Subsidiaries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.15 <u>Entire Agreement</u>. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.16 <u>Section</u><u>&nbsp;</u><u>409A</u>. This Option is not intended to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section&nbsp;409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;<u>Section 409A</u>&#8221;). However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Administrator determines that the Option (or any portion thereof) may be subject to Section&nbsp;409A, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate either for the Option to be exempt from the application of Section&nbsp;409A or to comply with the requirements of Section&nbsp;409A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.17 <u>Limitation on Participant</u><u>&#8217;</u><u>s Rights</u>. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Stock as a general unsecured creditor with respect to options, as and when exercised pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">5.18 Award Subject to Company Clawback or Recoupment. To the extent permitted by applicable law, the Restricted Stock Units or any Common Stock issued in settlement thereof will be subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of your service with the Company or its affiliates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>IN WITNESS WHEREOF</b>, the Company has caused a duly authorized officer to execute this Agreement, and Participant has executed this Agreement, effective as of the Grant Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">THE COMPANY:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DYADIC INTERNATIONAL, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="vertical-align: bottom; width: 42%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Print Name:</p>
			</td>
			<td style="vertical-align: bottom; width: 42%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Title:</p>
			</td>
			<td style="vertical-align: bottom; width: 42%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PARTICIPANT:</b></p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Print Name:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>3
<FILENAME>ex_727227.htm
<DESCRIPTION>EXHIBIT 10.2.2
<TEXT>
<html><head>
	<title>ex_727227.htm</title>

	<!-- Generated by ThunderDome Portal - 9/25/2024 5:02:19 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body class="vsc-initialized" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.2.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DYADIC INTERNATIONAL, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021 EQUITY INCENTIVE AWARD PLAN</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><font style="font-variant: small-caps; font-size: 12pt;"><b>Restricted</b>&nbsp;<b>Stock</b>&nbsp;<b>Unit</b>&nbsp;<b>Award</b>&nbsp;<b>Grant</b>&nbsp;<b>Notice</b></font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Dyadic International, Inc., a Delaware corporation, (the &#8220;<b>Company</b>&#8221;), pursuant to its 2021 Equity Incentive Plan (the &#8220;<b>Plan</b>&#8221;), hereby grants to the Holder named below a Restricted Stock Unit Award (the &#8220;<b>Award</b>&#8221;) for the number of restricted stock units (&#8220;<b>Restricted Stock Units</b>&#8221;) set forth below. The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Award Grant Notice (this &#8220;<b>Grant Notice</b>&#8221;) and in the Restricted Stock Unit Award Agreement (the &#8220;<b>RSU Award Agreement</b>&#8221;) and the Plan, both of which are attached hereto and hereby incorporated herein by reference. Capitalized terms used but not defined in this Grant Notice shall have the meanings set forth in the RSU Award Agreement or the Plan, as applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 90%;">
			<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Participant Name:</p>

			<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Participant ID: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

			<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Plan Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

			<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Award Number:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

			<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Shares Granted: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

			<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Award Type:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

			<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Award Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

			<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Vesting Schedule: Subject to the Participant not experiencing a Termination of Service prior to any&#8217;s Continuous Service through the applicable vesting date, the unvested Restricted Stock Units will vest in accordance with the following vesting schedule</p>
			</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Additional Terms/Acknowledgements</b>: The Participant acknowledges receipt of, and understands and agrees to, this Grant Notice, the RSU Award Agreement and the Plan. &nbsp;The Participant further acknowledges that, as of the Date of Grant, this Grant Notice, the RSU Award Agreement, the Plan and the Participant&#8217;s written employment agreement (if any) with the Company set forth the entire understanding between the Participant and the Company regarding the Restricted Stock Units and supersede all prior oral and written agreements regarding the Restricted Stock Units. In the event Participant does not execute this Grant Notice within [60] days of the Award Date, this Award shall be deemed [void <i>ab initio</i>][to have been automatically duly executed and accepted, unless the Participant affirmatively notifies the Company that the Participant does not wish to accept this Award. Participant&#8217;s acceptance of this Award constitutes his or her instruction and authorization to the Company or Employer and any brokerage firm determined acceptable to the Company or Employer for such purpose to sell on Participant&#8217;s behalf shares of Common Stock from those shares issuable to Participant as the Company or Employer determines to be appropriate to generate cash proceeds sufficient to satisfy Participant&#8217;s tax withholding obligation.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="2" style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DYADIC INTERNATIONAL,</b>&nbsp;<b>INC.:</b></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PARTICIPANT:</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Signature:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 39%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Print Name:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Print Name:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 9%;">&nbsp;</td>
			<td style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Attachments: &nbsp;Restricted Stock Unit Award Agreement and 2021 Equity Incentive Plan</p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><font style="font-variant:small-caps;"><b>ATTACHMENT</b>&nbsp;<b>I</b></font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><font style="font-variant:small-caps"><b>Restricted Stock Unit Award Agreement</b></font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><font style="font-variant:small-caps;"><b>DYADIC INTERNATIONAL, Inc.</b></font></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><font style="font-variant:small-caps;"><b>2021 Equity Incentive Plan</b></font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the attached Restricted Stock Unit Award Grant Notice (the &#8220;<b>Grant Notice</b>&#8221;) and this Restricted Stock Unit Award Agreement (this &#8220;<b>Agreement</b>&#8221;), Dyadic International, Inc. (the &#8220;<b>Company</b>&#8221;) has granted you a Restricted Stock Unit Award (the &#8220;<b>Award</b>&#8221;) under its 2021 Equity Incentive Plan (the &#8220;<b>Plan</b>&#8221;) for the number of restricted stock units (&#8220;<b>Restricted Stock Units</b>&#8221;) indicated in the Grant Notice.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Capitalized terms not expressly defined in this Agreement or the Grant Notice but defined in the Plan shall have the same definitions as are set forth in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The terms of your Award, in addition to those set forth in the Grant Notice, are as follows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>GRANT</b>&nbsp;<b>OF</b>&nbsp;<b>THE</b>&nbsp;<b>AWARD</b>. Your Award represents the right to be issued on a future date one share of Common Stock (subject to any adjustment under Section 3 below) for each Restricted Stock Unit that vests in accordance with the Grant Notice and this Agreement. As of the Date of Grant, the Company shall credit to a bookkeeping account maintained by the Company for your benefit (the &#8220;<b>Account</b>&#8221;) the number of Restricted Stock Units subject to your Award. This Award was granted in consideration of your services to the Company or an affiliate.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>VESTING; ACCELERATED</b>&nbsp;<b>VESTING</b>&nbsp;<b>UPON</b>&nbsp;<b>A</b>&nbsp;<b>CORPORATE</b>&nbsp;<b>TRANSACTION</b>. Subject to the limitations contained in this Agreement and unless otherwise provided in a written employment agreement between you and the Company, your Award shall vest, if at all, in accordance with the vesting schedule set forth in the Grant Notice. Unless otherwise provided in a written employment agreement between you and the Company, vesting shall cease upon your Termination of Service and the Restricted Stock Units credited to the Account that were not vested on the date of such termination shall be cancelled and you shall have no further right, title or interest in or to such Restricted Stock Units or the shares of Common Stock to be issued in respect of the Restricted Stock Units. &nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>CAPITALIZATION</b>&nbsp;<b>ADJUSTMENTS</b>. The number of Restricted Stock Units issuable is subject to the adjustment from time to time as provided in Section 14.2 of the Plan. Any additional Restricted Stock Units or shares of Common Stock that become subject to your Award pursuant to this Section 3 shall be subject, in a manner determined by the Board, to the same vesting restrictions, restrictions on transfer, and time and manner of delivery as applicable to the other Restricted Stock Units and shares of Common Stock covered by your Award. Notwithstanding the provisions of this Section 3, no fractional share or right for a fractional share of Common Stock shall be created pursuant to this Section 3. Any fraction of a share shall be rounded down to the nearest whole share.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>SECURITIES</b>&nbsp;<b>LAW</b>&nbsp;<b>COMPLIANCE</b>. You shall not be issued any shares of Common Stock under your Award unless the issuance of the shares of Common Stock issuable in respect of your Award is (a) then registered under the Securities Act or (b) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Your Award must also comply with other applicable laws and regulations governing your Award, and you shall not receive such shares of Common Stock if the Company determines that such receipt would not be in material compliance with such laws and regulations.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>TRANSFER</b>&nbsp;<b>RESTRICTIONS</b>. Prior to the time that shares of Common Stock have been delivered to you, you may not transfer, pledge, sell or otherwise dispose of your Award or the shares of Common Stock issuable in respect of your Award, except as expressly provided in this Section 5. For example, you may not pledge shares of Common Stock that may be issued in respect of your Restricted Stock Units as security for a loan. The restrictions on transfer set forth herein shall lapse upon delivery to you of shares of Common Stock in respect of your vested Restricted Stock Units.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Death</b>. Your Award and the shares of Common Stock issuable in respect of your Award are transferable by the laws of descent and distribution. At your death, vesting of your Award shall cease and your executor or administrator of your estate shall be entitled to receive, on behalf of your estate, any shares of Common Stock or other consideration issuable in respect of your Award that vested but were not issued before your death.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Domestic Relations Orders</b>. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your right to receive the distribution of shares of Common Stock or other consideration hereunder, pursuant to a domestic relations order that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of your Award with the Company prior to finalizing the domestic relations order to verify that you may make such transfer, and if so, to help ensure the required information is contained within the domestic relations order.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>DATE</b>&nbsp;<b>OF</b>&nbsp;<b>ISSUANCE</b>&nbsp;<b>OF</b>&nbsp;<b>COMMON</b>&nbsp;<b>STOCK</b>. Subject to the satisfaction of the tax withholding obligation set forth in Section 11 of this Agreement, promptly following the vesting date, and in any event no later than March 15 of the calendar year following the calendar year in which such vesting occurs, the Company shall issue and deliver to you one share of Common Stock (subject to any adjustment under Section 3 above) for each Restricted Stock Unit that vests on the applicable vesting date. The form of delivery (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company. &nbsp;The issuance of shares of Common Stock in respect of the Restricted Stock Units is intended to comply with Treasury Regulation Section 1.409A-1(b)(4) and shall be construed and administered in such a manner.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>DIVIDENDS</b>. You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from an Equity Restructuring or other adjustment pursuant to Section 14.2 of the Plan ; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your Award after such shares have been delivered to you.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>RESTRICTIVE</b>&nbsp;<b>LEGENDS</b>. The shares of Common Stock issued in respect of your Award shall be endorsed with any appropriate securities law legends as determined by the Company.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>EMPLOYMENT</b>&nbsp;<b>AGREEMENT</b>. &nbsp;If you have entered into a written employment agreement with the Company, then in the event of any inconsistency between a provision contained in your employment agreement and a provision contained in this Agreement, the Grant Notice or the Plan, the provision that is more favorable to you shall prevail.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>AWARD</b>&nbsp;<b>NOT</b>&nbsp;<b>A</b>&nbsp;<b>SERVICE</b>&nbsp;<b>CONTRACT</b>. &nbsp;Your Award is not an employment or service contract, and nothing in your Award shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an affiliate, or of the Company or an affiliate to continue your employment. &nbsp;In addition, nothing in your Award shall obligate the Company or an affiliate, their respective stockholders, Boards of Directors, officers or Employees to continue any relationship that you might have as a Director or Consultant for the Company or an affiliate.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>RESPONSIBILITY FOR TAXES.</b>&nbsp;&nbsp;You acknowledges that, to the extent permitted by applicable law, regardless of any action taken by the Company or, if different, any affiliate employing or retaining you (the &#8220;<b>Employer</b>&#8221;), the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;<b>Tax-Related Items</b>&#8221;) is and remains your responsibility and may exceed any amount actually withheld by the Company or the Employer. You further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Restricted Stock Units, including, but not limited to, the grant, vesting or settlement of the Restricted Stock Units and the subsequent sale of Common Stock acquired pursuant to such settlement and the receipt of any dividends, and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Restricted Stock Units to reduce or eliminate your liability for Tax- Related Items or achieve any particular tax result.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>WITHHOLDING</b>&nbsp;<b>OBLIGATION</b>.&nbsp;&nbsp;In the event your Restricted Stock Units are subject to the withholding obligation of the Company or the Employer, prior to any relevant taxable or tax withholding event, to the extent permitted by applicable law and as applicable, you agree to make arrangements satisfactory to the Company and/or the Employer to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy any withholding obligations for Tax-Related Items by one or a combination of the following:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">withholding from Participant&#8217;s wages or other cash compensation paid to Participant by the Company and/or the Employer; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">instructing a broker on Participant&#8217;s behalf to sell Shares otherwise issuable to Participant upon vesting of the RSUs sufficient to generate net proceeds sufficient to satisfy the Company&#8217;s minimum statutory withholding obligations with respect to the income recognized by Participant upon the vesting of the RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income) and the net proceeds of such sale shall be submitted to the Company;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">withholding Shares to be issued upon settlement of the RSUs, provided the Company only withholds the number of Shares necessary to satisfy no more than the maximum applicable statutory withholding amounts;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Participant&#8217;s payment of a cash amount (including by check representing readily available funds or a wire transfer); or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other arrangement approved by the Committee and permitted under applicable law;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">all under such rules as may be established by the Committee and in compliance with the Company&#8217;s Security Trading Policy and 10b5-1 Trading Plan Policy. Until determined otherwise by the Company, clause (ii) will be the method by which such withholding obligations are satisfied.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable statutory withholding rates or other applicable withholding rates, including up to the maximum permissible statutory rate for your tax jurisdiction(s) in which case you will have no entitlement to the equivalent amount in Common Shares and will receive a refund of any over-withheld amount in cash in accordance with applicable law. If the obligation for Tax-Related Items is satisfied by withholding in Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested Restricted Stock Units, notwithstanding that a number of the shares of Common Stock are held back solely for the purpose of satisfying the withholding obligation for Tax-Related Items.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">You agree to pay to the Company and/or the Employer any amount of Tax-Related Items that the Company and/or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company has no obligation to deliver shares of Common Stock or proceeds from the sale of such shares of Common Stock to you until you have satisfied the obligations in connection with the Tax-Related Items as described in this Section.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>UNSECURED</b>&nbsp;<b>OBLIGATION</b>. Your Award is unfunded, and as the holder of your Award you shall be considered an unsecured creditor of the Company with respect to the Company&#8217;s obligation, if any, to issue shares of Common Stock or other property pursuant to this Agreement. You shall not have voting or any other rights as a stockholder of the Company with respect to the shares of Common Stock issuable in respect of the Restricted Stock Units. &nbsp;Upon and following the settlement of the Restricted Stock Units, you shall be the record owner of the shares of Common Stock underlying the Restricted Stock Units unless and until such shares are sold or otherwise disposed of, and as record owner you shall be entitled to all rights of a stockholder of the Company (including voting rights). Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">14.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTICES</b>. Any notices provided for in your Award, this Agreement or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and your Award by electronic means or to request your consent to participate in the Plan by electronic means. &nbsp;You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">15.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>APPLICABILITY</b>&nbsp;<b>OF</b>&nbsp;<b>THE</b>&nbsp;<b>PLAN.</b>&nbsp;&nbsp;Your Award and this Agreement are subject to all of the provisions of the Plan, the provisions of which are hereby made a part of your Award and are further subject to all interpretations and amendments of the Plan which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of this Agreement and those of the Plan, the provisions of the Plan shall control. &nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">16.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>SEVERABILITY.</b>&nbsp;If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement or the Plan (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">17.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>EFFECT</b>&nbsp;<b>ON</b>&nbsp;<b>OTHER</b>&nbsp;<b>EMPLOYEE</b>&nbsp;<b>BENEFIT</b>&nbsp;<b>PLANS.</b>&nbsp;The value of your Award subject to this Agreement shall not be included as compensation, earnings, salaries or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its right to amend, modify or terminate any of the Company&#8217;s or any affiliate&#8217;s employee benefit plans.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">18.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>AMENDMENT.</b>&nbsp;This Agreement may not be modified or amended except by an instrument in writing, signed by a duly authorized representative of the Company, provided that no such amendment materially adversely affecting your rights hereunder may be made without your written consent. However, the Board reserves the right to change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the Award as a result of any change in applicable laws or regulations or any future law, regulation, ruling or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of your Award which is then subject to restrictions as provided herein.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">19.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>COMPLIANCE</b>&nbsp;<b>WITH</b>&nbsp;<b>SECTION</b>&nbsp;<b>409A</b>&nbsp;<b>OF</b>&nbsp;<b>THE</b>&nbsp;<b>CODE</b>. Your Award is intended to be exempt from the application of Section 409A of the Code, including but not limited to, by reason of complying with the &#8220;short-term deferral&#8221;&nbsp;rule set forth in Treasury Regulation Section 1.409A-1(b)(4) and any ambiguities herein shall be interpreted accordingly. Notwithstanding the foregoing, if it is determined that your Award fails to satisfy the requirements of the short-term deferral rule and is otherwise not exempt from&nbsp;and determined to be deferred compensation subject to Section 409A of the Code, your Award shall comply with Section 409A to the extent necessary to avoid adverse personal tax consequences and any ambiguities herein shall be interpreted accordingly. If it is determined that your Award is deferred compensation subject to Section 409A and you are a &#8220;specified employee&#8221;&nbsp;(within the meaning set forth in Section 409A(a)(2)(B)(i) of the Code) as of the date of your &#8220;separation from service&#8221;&nbsp;(as defined in Section 409A), then the issuance of any shares of Common Stock that would otherwise be made upon the date of your separation from service or within the first six months thereafter shall not be made on the originally scheduled date and shall instead be issued in a lump sum on the date that is six months and one day after the date of the separation from service, with the balance of such shares issued thereafter in accordance with the original vesting and issuance schedule set forth above, but if and only if such delay in the issuance of such shares is necessary to avoid the imposition of adverse taxation on you in respect of such shares under Section 409A of the Code. Each installment of shares of Common Stock that vests is intended to constitute a &#8220;separate payment&#8221;&nbsp;for purposes of Treasury Regulation Section 1.409A-2(b)(2).&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">20.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>AWARD SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT</u></b>. To the extent permitted by applicable law, the Restricted Stock Units or any Common Stock issued in settlement thereof will be subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of your service with the Company or its affiliates.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">21.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>MISCELLANEOUS.</b>&nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company may assign any of its rights under the Grant Notice, this Agreement and the Plan to one or more assignees, and all covenants contained in the Grant Notice, this Agreement and the Plan shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns. All obligations of the Company under the Grant Notice, this Agreement and the Plan shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation or otherwise, of all or substantially all of the business and/or assets of the Company. &nbsp;Your rights and obligations under your Award may only be assigned with the prior written consent of the Company. &nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.&nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">You acknowledge and agree that you have reviewed this Agreement, the Grant Notice and the Plan in their entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award, and fully understand all provisions of your Award.&nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Agreement shall be subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ATTACHMENT</b>&nbsp;<b>II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021 EQUITY</b>&nbsp;<b>INCENTIVE</b>&nbsp;<b>PLAN</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>ex_794841.htm
<DESCRIPTION>EXHIBIT 19.1
<TEXT>
<html><head>
	<title>ex_794841.htm</title>

	<!-- Generated by ThunderDome Portal - 3/26/2025 2:07:28 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 19.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div style="text-align: center;"><img alt="d01.jpg" src="d01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DYADIC INTERNATIONAL, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Procedures And Guidelines Governing Insider Trading And Tipping</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Purpose</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In order to comply with federal and state securities laws governing (a) trading in Company securities while in the possession of &#8220;material non-public information&#8221; concerning the Company, and (b) tipping or disclosing material non-public information to outsiders, and in order to, among other things, prevent even the appearance of improper insider trading or tipping, protect the Company from controlling person liability and protect the reputation of the Company, its directors, officers and employees, the Company has adopted this policy for all of its directors, officers and employees, their family members, and specially designated outsiders, such as consultants, who may<b><i> </i></b>have access to the Company&#8217;s material non-public information.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">II.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Scope</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This policy covers all directors, officers and employees of the Company, their family members and any corporations, partnerships, trusts or other entities owned or controlled by the foregoing persons and any trusts in which such persons are trustees or beneficiaries ("Applicable Trusts") or any corporation in which such persons hold more than 20% of the equity or voting rights ("Applicable Corporations&#8221;) (collectively referred to as &#8220;Insiders&#8221;), and any outsiders, including consultants, whom the Insider Trading Compliance Officer may designate as Insiders because they have or may gain access to material non-public information concerning the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">B.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The policy applies to any and all transactions in the Company&#8217;s securities, including (unless specifically excluded herein) its common stock and options to purchase common stock, and any other type of securities that the Company may issue, such as preferred stock, convertible debentures, warrants and exchange-traded options or other derivative securities. Transactions subject to this policy include, but are not necessarily limited to, purchases and sales (including short-selling), whether in the open market or with the Company; transfers to anyone or any entity, whether with or without consideration; gifts; pledging of shares of options; and the granting of an option to acquire an Insider&#8217;s interest in Company securities.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">C.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The policy will be delivered to all directors, officers, employees and designated outsiders upon its adoption by the Company, and to all new directors, officers, employees and designated outsiders at the start of their employment or relationship with the Company. Upon first receiving a copy of the policy or any revised versions, each Insider must sign an acknowledgement that he or she has received a copy and agrees to comply with the policy&#8217;s terms. Officers, employees, directors and certain designated Insiders and outsiders may be required to certify compliance with the policy on an annual basis.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">III.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Insider Trading Compliance Officer and Compliance Committee</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company has designated <b>Ping Rawson</b>, Chief Accounting Officer, as its Insider Trading Compliance Officer (the &#8220;Compliance Officer&#8221;). The Insider Trading Compliance Committee (the &#8220;Committee&#8221;) will consist of the Compliance Officer , and <b>Mark Emalfarb</b>, Chief Executive Officer. The Committee will review and either approve or prohibit all proposed trades by Insiders and designated outsiders in accordance with the procedures set forth in Section V.C., below.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition to the trading approval duties described in Section V.C., below, the duties of the Compliance Officer will include the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Administering this policy and monitoring and enforcing compliance with all policy provisions and procedures.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">B.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Responding to all inquiries relating to this policy and its procedures.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">C.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Designating and announcing Special Blackout Periods, as defined below.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">D.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Providing copies of this policy and other appropriate materials to all current and new directors, officers and employees, and such outsiders who the Compliance Officer determines have or may gain access to material non-public information concerning the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">E.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Administering, monitoring and enforcing compliance with all federal and state insider trading laws and regulations, including without limitation Sections 10(b), 15, 20A and 21A of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and the rules and regulations promulgated thereunder, and Rule 144 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and related regulations of the Financial Industry Regulatory Authority, Inc. (&#8221;FINRA&#8221;) or The Nasdaq Stock Market Inc. (&#8220;Nasdaq&#8221;); and assisting in the preparation and filing of all required reports with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) relating to insider trading in the Company&#8217;s securities, including without limitation Forms 3, 4, 5 and 144 and Schedules 13D and 13G.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">F.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Revising the policy as necessary to reflect changes in federal or state insider trading laws and regulations or the regulations of FINRA or Nasdaq.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">G.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Maintaining as Company records originals or copies of all documents required by the provisions of this policy or the procedures set forth herein, and copies of all required SEC reports relating to insider trading, including without limitation Forms 3, 4, 5 and 144 and Schedules 13D and 13G.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: justify;">The Compliance Officer may designate one or more individuals who may perform his duties or the duties of the other member of the Committee in the event that he or the other Committee member is unable to or unavailable to perform such duties.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">IV.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Definition of &#8220;Material Nonpublic Information&#8221;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;Material&#8221;&nbsp;Information</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">There is no bright-line rule as to what constitutes &#8220;material&#8221; information. Generally speaking, information about the Company is &#8220;material&#8221; if there is a substantial likelihood that a reasonable stockholder would consider the information important in making a decision to buy or sell the Company&#8217;s securities, or, stated another way, if the disclosure of the information would be expected to significantly alter the total mix of the information in the marketplace about the Company. In simple terms, material information is any type of information that could reasonably be expected to affect the price of Company securities, beyond normal daily fluctuations. While it is not possible to identify all information that would be deemed &#8220;material,&#8221; the following types of information ordinarily would be considered material:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Financial performance, especially quarterly and year-end earnings, and significant changes in financial performance or liquidity.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Company projections and strategic plans.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Clinical results of the Company&#8217;s drug candidates.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Potential mergers and acquisitions or the sale of Company assets or subsidiaries.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Partnership agreements for the Company&#8217;s clinical-stage drug candidates.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">New major contracts, order, suppliers, customer, or finance sources, or the loss thereof.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Major discoveries or significant changes or developments in products or product lines, clinical trial results, research or technologies.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Significant changes or developments in supplies or inventory, including significant product defects, recalls or product returns.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Significant pricing changes.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Stock splits, public or private securities/debt offerings, or changes in Company dividend policies or amounts.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Sales of the Company&#8217;s securities by the Named Executive Officers (identified as such in the Company&#8217;s Annual Meeting Proxy Statement filed each year with the SEC (the &#8220;NEO&#8217;s&#8221;)) or by members of the Company&#8217;s Board of Directors.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Significant changes in senior management.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Significant labor disputes or negotiations.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Actual or threatened major litigation, or the resolution of such litigation.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Content of material formal FDA responses to the Company</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Impending bankruptcy or the existence of severe liquidity problems;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The imposition of a ban on trading in Company Securities or the securities of another company.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">When doubt exists, the information should be presumed to be material. <b>If you are unsure whether information of which you are aware is material or non-public, you should consult with the Compliance Officer.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">B.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;Non-public&#8221;&nbsp;Information</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">Material information is &#8220;non-public&#8221; if it has not been widely disseminated to the public in a manner making it available to investors generally, including, without limitation, through major newswire services, national news services and financial news services or the filing of public documents as required with the SEC. For the purposes of this policy, information will be considered public, i.e., no longer &#8220;non-public,&#8221; after the close of trading on the second full trading day following the company&#8217;s widespread public release of the information.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">V.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Statement of Company Policy and Procedures</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Prohibited Activities</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No Insider may trade in Company securities while possessing material non-public information concerning the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No Insider may trade in Company securities during any Special Blackout Periods designated by the Compliance Officer.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No Insider may trade in Company securities unless the trade(s) have been approved by the Committee in accordance with the procedures set forth in Section V.C., below, and, if required for such trade, a Form 144 filing with the SEC was also approved by the Committee. Insiders who wish to sell Company securities in order to realize their profits are strongly encouraged to sell their securities pursuant to a predetermined written plan meeting the requirements of Rule 10b5-1 of the Exchange Act (&#8220;Rule 10b5-1&#8221;) which is approved by the Committee. To the extent possible, Insiders should retain all records and documents that support their reasons for making each trade.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No member of the Committee may trade in Company securities unless the trade(s) and, if required, a Form 144, have been approved by the other members of the Committee and the Company&#8217;s outside legal counsel in accordance with the procedures set forth in Section V.C., below.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No Insider may &#8220;tip&#8221;&nbsp;or disclose material non-public information concerning the Company to any outside person (including family members, analysts, individual investors and members of the investment community and news media), unless required as part of that Insider&#8217;s regular duties for the Company. In any instance in which such information is disclosed to outsiders, the Company shall take such steps as are necessary to preserve the confidentiality of the information, including requiring the outsider to agree in writing to comply with the terms of this policy and/or to sign a confidentiality agreement. All inquiries from outsiders regarding material non-public information about the Company must be forwarded to the Compliance Officer.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">6.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No Insider may give trading advice of any kind about the Company to anyone while possessing material non-public information about the Company, except that Insiders should advise others not to trade if doing so might violate the law or this policy. The Company strongly discourages all Insiders from giving trading advice concerning the Company to third parties even when the Insiders do not possess material non-public information about the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No Insider may trade in any interest or position relating to the future price of Company securities, such as a put, call or short sale.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">B.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Blackout Periods</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The period beginning fourteen days prior to the end of each quarter and ending two trading days following the date of public disclosure of the financial results for that quarter (the "Blackout Period") is a particularly sensitive period of time for transactions in the Company's stock from the perspective of compliance with applicable securities laws. This sensitivity is due to the fact that officers, directors and certain other employees and consultants will, during that period, often possess material non-public information about the expected financial results for the quarter. Except as set forth in Section V.D., no Insider may trade in Company Securities during a Blackout Period, although the Committee may waive the restriction if it determines such person does not possess material non-public information.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Compliance Officer, in consultation with Company management, may, from time to time, designate special blackout periods ("Special Blackout Periods") during which trading in Company securities by all Insiders shall be prohibited.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No Insiders may disclose to any outside third party that a Special Blackout Period has been designated.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">C.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Procedures Relating to Trades by Insiders and Regulatory Filings</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Regardless of the proposed timing or type of trade, no Insider may trade in Company securities until:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The person trading has notified the Compliance Officer in writing of the amount and nature of the proposed trade(s);</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The person trading has certified to the Compliance Officer in writing at the time of such proposed trade(s) that (i) he or she is not in possession of material non-public information concerning the Company and (ii) the proposed trade(s) do not violate the trading restrictions of Section 16 of the Exchange Act or Rule 144 of the Securities Act;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The person trading has notified and received approval from the Committee for the filing of a Form 144 with the SEC; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Committee has approved the trade(s), and the Compliance Officer has certified such approval in writing.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Trades made pursuant to Rule 10b5-1 Plans</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company must pre-approve any plan, arrangement or trading instructions, etc. prepared pursuant to Rule 10b5-1 involving potential sales (or purchases) of stock or option exercises and sales, etc. (any such plan prepared in accordance with Rule 10b5-1, a &#8220;10b5-1 Plan&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In reviewing any 10b5-1 Plan, the Company shall:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 108pt;">i.&nbsp; Verify that at the time a 10b5-1 Plan is entered into, there is no non-public material information about the Company (even if the Insider proposing the 10b5-1 Plan is not aware of such information).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 108pt;">ii.&nbsp; Ensure that the first trade authorized by any 10b5-1 Plan does not occur until a time following the release of the Company&#8217;s next quarterly filing with the SEC subsequent to the 10b5-1 Plan going into effect;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 108pt;">iii.&nbsp;Ensure that the 10b5-1 Plan provides, where appropriate, for compliance with the restrictions set forth in Section V.B. above;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 108pt;">iv.&nbsp; Consider whether a public announcement of the 10b5-1 Plan should be made; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 108pt;">v.&nbsp; &nbsp;Ensure that the 10b5-1 Plan includes a procedure with whomever is handling the transactions pursuant to the 10b5-1 Plan that will guarantee:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 126pt; text-align: justify;">1.&nbsp; Prompt filings of Forms 4 and 5 with the SEC after each transaction;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 126pt; text-align: justify;">2.&nbsp;&nbsp;Compliance with Rule 144 and/or Rule 145, if appropriate, at the time any sale; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 126pt; text-align: justify;">3.&nbsp;&nbsp;Cessation of any transactions during any Special Blackout Periods imposed on Insiders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The existence of the foregoing approval processes does not in any way obligate the Compliance Officer or the Committee to approve any particular trades or 10b5-1 Plans proposed by Insiders. The Compliance Officer or the Committee may reject any trading requests or 10b5-1 Plans at their sole reasonable discretion.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Regardless of whether an NEO or a member of the Company&#8217;s Board of Directors has plans to trade in the Company&#8217;s securities, any Form 144 filing by such an Insider with the SEC must be pre-approved by the Committee prior to any filing. In addition, such an Insider must also provide notice to the chair of the Compensation Committee of the Company&#8217;s Board of Directors of his or her intention to file a Form 144 with the SEC or to effect any trading in the securities of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">D.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Exceptions to Trading Prohibitions</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The prohibition on trading in Company securities during Blackout Periods, during Special Blackout Periods, or while otherwise in possession of material non-public information does not apply to:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">purchases made under an employee stock purchase plan operated by the Company; <u>provided</u>, <u>however</u>, that the securities so acquired may not be sold during a Blackout Period or any Special Blackout Period;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">exercises of stock options or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligation, in each case in a manner permitted by the applicable stock option; <u>provided</u>, <u>however</u>, that the securities so acquired may not be sold (either outright or in connection with a &#8220;cashless&#8221;&nbsp;exercise transaction through a broker) during a Blackout Period or Special Blackout Period or, if outside a Blackout Period or Special Blackout Period, without receiving the approval of the Committee</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">automatic sales of shares of the Company&#8217;s common stock through a Company-contracted service provider or broker to cover any taxes due as a result of the vesting of restricted stock or restricted stock units, where the amount of shares sold is based on the Insider&#8217;s taxable income, the market price of the common stock on the date that the restricted stock or restricted stock units vest (the &#8220;Vesting Date&#8221;) and the market price on the date of the sale, which date shall be as soon as possible after the Vesting Date;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">acquisitions or dispositions of Company common stock under the Company&#8217;s 401(k) plan, which are made pursuant to standing instructions not entered into or modified during a Blackout Period or Special Blackout Period or while otherwise in possession of material non-public information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">e.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">purchases or sales made pursuant to a 10b5-1 Plan.<b> </b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">E.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Priority of Statutory or Regulatory Trading Restrictions</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The trading prohibitions and restrictions set forth in this policy will be superseded by any greater prohibitions or restrictions prescribed by federal or state securities laws and regulations, e.g., short swing trading by officer and directors or restrictions on the sale of securities subject to Rule 144 under the Securities Act. Any Insider who is uncertain whether other prohibitions or restrictions apply should ask the Compliance Officer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">F.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Notification of Approved Trades After Execution</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">Any Insider who is permitted to trade Company securities pursuant to any provision of this Section V must notify the Compliance Officer, by email and/or facsimile transmission, promptly upon the execution of such trade, but in no event later than next business day after the execution of such trade. Such notice shall include all relevant details of such trade, including, but not limited to:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the name of the entity in whose name the trade was made;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the type and amount of securities subject to the trade;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the price at which the securities were traded; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the new number of securities owned, directly or indirectly, by the Insider subsequent to the execution of the trade.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">VI.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Potential Civil, Criminal and Disciplinary Sanctions</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Civil and Criminal Penalties</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The consequences of prohibited insider trading or tipping can be severe. Under US law, persons violating insider trading or tipping rules may be required to disgorge the profit made or the loss avoided by the trading, pay the loss suffered by the person who purchased securities from or sold securities to the insider, pay civil penalties up to three times the profit made or loss avoided, pay a criminal penalty of up to $1 million, and serve a jail term of up to ten years. The Company and/or the supervisors of the person violating the rules may also face major civil and/or criminal penalties.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">B.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Company Discipline</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">Violation of this policy or federal or state insider trading or tipping laws by any director, officer or employee, or their family members, or by any corporation, partnerships, trust or other entity owned or controlled by any of the foregoing persons or any Applicable Trust or Applicable Company, may subject the director to dismissal proceedings and the officer or employee to disciplinary action by the Company up to and including termination for cause.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">C.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Reporting of Violations</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">Any Insider who violates this policy or any federal or state laws governing insider trading or tipping, or knows of such violation by any other Insiders, must report the violation immediately to the Compliance Officer. Upon learning of any such violation, the Compliance Officer, in consultation with the other Committee member and the Company&#8217;s outside legal counsel, will determine whether the Company should release any material non-public information, or whether the Company should report the violation to the SEC, Nasdaq, or other appropriate governmental authority.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">VII.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inquiries</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Please direct all inquiries regarding this policy to the Compliance Officer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>ACKNOWLEDGEMENT OF RECEIPT</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I hereby acknowledge that I have received a copy of the "Procedures and Guidelines Governing Insider Trading and Tipping" and agree to comply with its terms. I understand that violation of insider trading or tipping laws or regulations may subject me to severe civil and/or criminal penalties and that violation of the terms of this policy may subject me to discipline by Dyadic International, Inc.. and its subsidiaries up to and including termination for cause.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Signed: _______________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Name (please print): _____________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Date: _________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="width: 100%; text-align: justify;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%; text-align: justify;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTIFICATION OF PROPOSED TRADE</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Insider Trading Compliance Committee (the "Compliance Committee") of Dyadic International, Inc. ("Dyadic ")</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">From:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;____________________________________________ (Name of Insider)</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;____________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(Please fill out that which is applicable)</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I hereby notify the Compliance Committee that I intend to exercise __________ (number) of options/warrants (cross out the inapplicable word) of Dyadic common stock on ____________ (date), on behalf of _______________________________________ (indicate in whose name the shares will be registered).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I hereby notify the Compliance Committee that I intend to buy/sell (cross out the inapplicable word) __________ (number) of shares of Dyadic common stock on ________________ (date), on behalf of ______________________________________ (indicate in whose name the shares will be registered).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In connection with this proposed trade, I hereby certify that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">I am not in possession of any "material non-public information" concerning Dyadic , as defined in Dyadic 's "Procedures and Guidelines Governing Insider Trading and Tipping" (the "Policy").</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To the best of my knowledge, the proposed trade does not violate the trading restrictions of Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities Act of 1933, as amended.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I understand that if I trade while possessing such information or in violation of such trading restrictions, I may be subject to severe civil and/or criminal penalties, and may be subject to sanctions by Dyadic as set forth in the Policy.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 216pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 50%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Submitted by</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">_____________________________________________</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(Signature)</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">_____________________________________________</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(Name)</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">_____________________________________________</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(Title if signing on behalf of a corporation, partnership or other such entity)</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 216pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Reviewed and approved/disapproved on behalf of the Compliance Committee:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 50%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">____________________________________________</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Mark Emalfarb</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Compliance Officer</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">_____________________________________________</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Ping Rawson</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Compliance Officer</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 180pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Date: _________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ex_727228.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html><head>
	<title>ex_727228.htm</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 21.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div style="text-align: center;"><img alt="orgchart.jpg" src="orgchart.jpg"></div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex_727229.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_727229.htm</title>
	<!-- Generated by ThunderDome Portal - 3/26/2025 1:04:38 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body class="vsc-initialized" style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We consent to the incorporation by reference in Registration Statements No. 333-258755 and 333-231712 on Form S-8, and 333-273829 and 333-278916 on Form S-3 of Dyadic International, Inc. of our report dated March 26, 2025, relating to the financial statements, appearing in this Annual Report on Form 10-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 33%;">/s/ Crowe LLP</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Livingston, New Jersey</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 26, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex_727231.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 12/23/2020 7:04:05 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_727231.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;text-align:right;margin:0pt;"><b>Exhibit</b>&nbsp;<b>31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>Certification of Principal Executive Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>and Securities and Exchange Commission Release 34-46427</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">I, Mark A. Emalfarb, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">I have reviewed this <a data-tblloc="4x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611679584762">annual</a>&nbsp;report on Form <a data-tblloc="5x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611679609768">10-K</a>&nbsp;of Dyadic International Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and we have:</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; text-align: justify;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;">

		<tr>
			<td style="width: 19%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">Date:</p>
			</td>
			<td style="width: 1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="1" style="width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;"><a data-tblloc="1x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611680873103">March 26, 2025</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 19%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">By: &nbsp;<br>
			&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
			Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
			Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="width: 1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">/s/&nbsp;&nbsp;&nbsp;Mark A. Emalfarb<br>
			<br>
			Mark A. Emalfarb<br>
			Chief Executive Officer</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex_727232.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 12/23/2020 7:06:25 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_727232.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;text-align:right;margin:0pt;"><b>Exhibit</b>&nbsp;<b>31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>Certification of Principal Executive Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>and Securities and Exchange Commission Release 34-46427</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">I, Ping W. Rawson, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">&nbsp;I have reviewed this <a data-tblloc="4x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681076579">annual</a>&nbsp;report on Form <a data-tblloc="5x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681096537">10-K</a>&nbsp;of Dyadic International Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and we have:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; text-align: justify;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;">

		<tr>
			<td style="width: 19%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">Date:</p>
			</td>
			<td style="width: 1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="3" style="width: 80%;"><a data-tblloc="1x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681034731">March 26, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 19%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">By: &nbsp;<br>
			&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
			Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
			Title: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="width: 1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="3" rowspan="1" style="width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">/s/&nbsp;&nbsp;&nbsp;Ping W. Rawson<br>
			<br>
			Ping W. Rawson<br>
			Chief Financial Officer</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex_727233.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_727233.htm</title>

	<!-- Generated by ThunderDome Portal - 11/21/2023 9:13:12 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In connection with the <a data-tblloc="3x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681157155">Annual</a>&nbsp;Report of Dyadic International Inc. (the "Company") on Form&nbsp;<a data-tblloc="5x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681172614">10-K</a> for the&nbsp;<a data-tblloc="7x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611682600813">year</a> ended <a data-tblloc="5x1" data-tblname="97348" data-tblv="28" id="led97348F20210261611681387943">December 31, 2024</a>&nbsp;as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Mark A. Emalfarb, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: bottom; width: 19%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date:</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a data-tblloc="1x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681227974">March 26, 2025</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 19%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By: &nbsp;<br>
			&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
			Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
			Title: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/&nbsp;&nbsp; Mark A. Emalfarb<br>
			<br>
			Mark A. Emalfarb<br>
			Chief Executive Officer</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>ex_727234.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>ex_727234.htm</title>

	<!-- Generated by ThunderDome Portal - 11/21/2023 9:13:25 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In connection with the <a data-tblloc="3x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681299302">Annual</a>&nbsp;Report of Dyadic International Inc. (the "Company") on Form&nbsp;<a data-tblloc="5x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681317151">10-K</a> for the <a data-tblloc="7x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611682641854">year</a>&nbsp;ended&nbsp;<a data-tblloc="5x1" data-tblname="97348" data-tblv="28" id="led97348F20210261611681339513">December 31, 2024</a> as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Ping W. Rawson, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: bottom; width: 19%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date:</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a data-tblloc="1x0" data-tblname="106956" data-tblv="28" id="led106956F20210261611681283199">March 26, 2025</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 19%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By: &nbsp;<br>
			&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
			Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
			Title: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/&nbsp;&nbsp; Ping W. Rawson<br>
			<br>
			Ping W. Rawson<br>
			Chief Financial Officer</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>dyai-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:28PM UTC 2025-03-26--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dyai="http://www.dyadic.com/20241231" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dyadic.com/20241231">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.dyadic.com/20241231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity" roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies" roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995553 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-cash-cash-equivalents-and-investments-" roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995554 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies" roleURI="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995555 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-commitments-and-contingencies-" roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995556 - Disclosure - Note 4 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-convertible-notes-payable" roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995557 - Disclosure - Note 5 - Convertible Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-sharebased-compensation-" roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995558 - Disclosure - Note 6 - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-shareholders-equity-" roleURI="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995559 - Disclosure - Note 7 - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-" roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995560 - Disclosure - Note 8 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-segment" roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995561 - Disclosure - Note 9 - Segment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-subsequent-events-" roleURI="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995562 - Disclosure - Note 10 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995563 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995564 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-cash-cash-equivalents-and-investments-tables" roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995565 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-commitments-and-contingencies-tables" roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995566 - Disclosure - Note 4 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-convertible-notes-payable-tables" roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995567 - Disclosure - Note 5 - Convertible Notes Payable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-sharebased-compensation-tables" roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995568 - Disclosure - Note 6 - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-tables" roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995569 - Disclosure - Note 8 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-segment-tables" roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995570 - Disclosure - Note 9 - Segment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995571 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995572 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995573 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995574 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995575 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995576 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-cash-cash-equivalents-and-investments-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995577 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995578 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments - Major Security Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995579 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-commitments-and-contingencies-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995580 - Disclosure - Note 4 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995581 - Disclosure - Note 4 - Commitments and Contingencies - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-commitments-and-contingencies-purchase-obligations-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995582 - Disclosure - Note 4 - Commitments and Contingencies - Purchase Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-convertible-notes-payable-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995583 - Disclosure - Note 5 - Convertible Notes Payable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-convertible-notes-payable-convertible-debt-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995584 - Disclosure - Note 5 - Convertible Notes Payable - Convertible Debt (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-sharebased-compensation-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995585 - Disclosure - Note 6 - Share-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995586 - Disclosure - Note 6 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-sharebased-compensation-stock-option-activity-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995587 - Disclosure - Note 6 - Share-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-sharebased-compensation-restricted-stock-units-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995588 - Disclosure - Note 6 - Share-based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995589 - Disclosure - Note 6 - Share-based Compensation - Noncash Stock Option Compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-shareholders-equity-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995590 - Disclosure - Note 7 - Shareholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995591 - Disclosure - Note 8 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995592 - Disclosure - Note 8 - Income Taxes - Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995593 - Disclosure - Note 8 - Income Taxes - Reconciliation Between Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-component-of-deferred-tax-assets-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995594 - Disclosure - Note 8 - Income Taxes - Component of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-segment-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995595 - Disclosure - Note 9 - Segment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-segment-schedule-of-segment-reporting-information-details" roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995596 - Disclosure - Note 9 - Segment - Schedule of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-subsequent-events-details-textual" roleURI="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995597 - Disclosure - Note 10 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="dyai_AGlobalFoodIngredientCompanyMember" name="AGlobalFoodIngredientCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_AccountsPayablePolicyPolicyTextBlock" name="AccountsPayablePolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_AccruedExpensesPolicyPolicyTextBlock" name="AccruedExpensesPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_AccruedResearchAndDevelopmentInProcessCurrent" name="AccruedResearchAndDevelopmentInProcessCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_AlphazymeMember" name="AlphazymeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_BradleyEmalfarbMember" name="BradleyEmalfarbMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_BradleyScottEmalfarbMember" name="BradleyScottEmalfarbMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_BusinessConsultingExpense" name="BusinessConsultingExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_CashCashEquivalentsAndInvestmentsFairValue" name="CashCashEquivalentsAndInvestmentsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_ConcentrationRiskNumberOfCustomers" name="ConcentrationRiskNumberOfCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ConcentrationRiskNumberOfSuppliers" name="ConcentrationRiskNumberOfSuppliers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ConcentrationRiskSignificantCustomers" name="ConcentrationRiskSignificantCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ConsultantMember" name="ConsultantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ConsultantOneMember" name="ConsultantOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ConsultantTwoMember" name="ConsultantTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ContractResearchOrganizationsMember" name="ContractResearchOrganizationsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ContractorMember" name="ContractorMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" name="ConversionOfConvertibleNotesIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ConvertibleDebtTextBlock" name="ConvertibleDebtTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ConvertibleNotesConvertedIntoCommonStockMember" name="ConvertibleNotesConvertedIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" name="DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_DeferredLicenseRevenue" name="DeferredLicenseRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" name="DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_DescendantTrustMember" name="DescendantTrustMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" name="EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ElevenSignificantCustomersMember" name="ElevenSignificantCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_EmployeesMember" name="EmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ExecutiveAndBoardOfDirectorsMember" name="ExecutiveAndBoardOfDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ExecutivesAndKeyPersonnelMember" name="ExecutivesAndKeyPersonnelMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_FinalPaymentUponMeetingCertainProductivityThreshold" name="FinalPaymentUponMeetingCertainProductivityThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_FormerBoardOfDirectorsMember" name="FormerBoardOfDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_FormerChairmanOfTheBoardOfDirectorsMember" name="FormerChairmanOfTheBoardOfDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_FormerEmployeeMember" name="FormerEmployeeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_FourSignificantCustomersMember" name="FourSignificantCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_GatesFoundationMember" name="GatesFoundationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_IncreaseDecreaseInAccruedInterest" name="IncreaseDecreaseInAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_InitialUpFrontPayment" name="InitialUpFrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_InterestIncomeNonoperating" name="InterestIncomeNonoperating" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_InvestmentIncomeAmortizationAccretionOfPremium" name="InvestmentIncomeAmortizationAccretionOfPremium" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_InzymesAgreementApsMember" name="InzymesAgreementApsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_IrrevocableTrustMember" name="IrrevocableTrustMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_JanssenPharmaceuticalCompaniesMember" name="JanssenPharmaceuticalCompaniesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_LegalExpensesPayableCurrent" name="LegalExpensesPayableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" name="LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="dyai_LesseeOperatingLeaseYearlyPercentageIncrease" name="LesseeOperatingLeaseYearlyPercentageIncrease" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_LicenseAndDevelopmentExtensionTerm" name="LicenseAndDevelopmentExtensionTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="instant"/>
  <xsd:element id="dyai_LicenseAndDevelopmentInitialTerm" name="LicenseAndDevelopmentInitialTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_MrThomasEmalfarbMember" name="MrThomasEmalfarbMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_NetherlandsOfficeLeaseMember" name="NetherlandsOfficeLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_NonexecutiveEmployeesMember" name="NonexecutiveEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_NonrefundableUpfrontPaymentReceived" name="NonrefundableUpfrontPaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_OperatingLeasesAnnualRentalRate" name="OperatingLeasesAnnualRentalRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_OperatingLeasesMonthlyRentalRate" name="OperatingLeasesMonthlyRentalRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" name="OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" name="OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dyai_OwnershipPercentage" name="OwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ProceedsFromGrant" name="ProceedsFromGrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ProliantAgreementMember" name="ProliantAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" name="ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" name="ResearchAndDevelopmentExpenseIncludingRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" name="ResearchAndDevelopmentExpenseOutsideContractedServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" name="ResearchAndDevelopmentExpensePersonnelRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchAndDevelopmentInProcessCurrent" name="ResearchAndDevelopmentInProcessCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ResearchServicesPurchased" name="ResearchServicesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" name="ScheduleOfResearchAndDevelopmentCostsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_SecondPaymentUponCompletionTransfer" name="SecondPaymentUponCompletionTransfer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dyai_SeniorSecured2024NotesMember" name="SeniorSecured2024NotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" name="SharebasedCompensationAwardTrancheTwoThroughFiveMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ShortTermCorporateBondsMember" name="ShortTermCorporateBondsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_SixSignificantCustomersMember" name="SixSignificantCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_StockOptions1Member" name="StockOptions1Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_StockOptions2Member" name="StockOptions2Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_The1044NLeaseMember" name="The1044NLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_The2021PlanMember" name="The2021PlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_TheFranciscoTrustMember" name="TheFranciscoTrustMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ThirdPartyMember" name="ThirdPartyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" name="ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_ThreeCROsMember" name="ThreeCROsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_TwoCROsMember" name="TwoCROsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_TwoSignificantCustomersMember" name="TwoSignificantCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dyai_VestingOfRestrictedStock" name="VestingOfRestrictedStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" name="statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables" name="statement-statement-note-2-cash-cash-equivalents-and-investments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" name="statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details" name="statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-4-commitments-and-contingencies-tables" name="statement-statement-note-4-commitments-and-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details" name="statement-statement-note-5-convertible-notes-payable-convertible-debt-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-5-convertible-notes-payable-tables" name="statement-statement-note-5-convertible-notes-payable-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" name="statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" name="statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details" name="statement-statement-note-6-sharebased-compensation-restricted-stock-units-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details" name="statement-statement-note-6-sharebased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-6-sharebased-compensation-tables" name="statement-statement-note-6-sharebased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details" name="statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" name="statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" name="statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-8-income-taxes-tables" name="statement-statement-note-8-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details" name="statement-statement-note-9-segment-schedule-of-segment-reporting-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-note-9-segment-tables" name="statement-statement-note-9-segment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dyai_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>dyai-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:28PM UTC 2025-03-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations" xlink:href="dyai-20241231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InterestIncomeNonoperating" xlink:label="dyai_InterestIncomeNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="dyai_InterestIncomeNonoperating" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dyai-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IncreaseDecreaseInAccruedInterest" xlink:label="dyai_IncreaseDecreaseInAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:label="dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dyai_IncreaseDecreaseInAccruedInterest" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidTaxes" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LegalExpensesPayableCurrent" xlink:label="dyai_LegalExpensesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="dyai_LegalExpensesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:label="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:href="dyai-20241231.xsd#statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BusinessConsultingExpense" xlink:label="dyai_BusinessConsultingExpense" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfessionalFees" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_LaborAndRelatedExpense" xlink:type="arc"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="dyai_BusinessConsultingExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="dyai-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="us-gaap_HeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_HeldToMaturitySecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>dyai-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:28PM UTC 2025-03-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-document-and-entity-information" xlink:href="dyai-20241231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dyai-20241231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ElevenSignificantCustomersMember" xlink:label="dyai_ElevenSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FourSignificantCustomersMember" xlink:label="dyai_FourSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SixSignificantCustomersMember" xlink:label="dyai_SixSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoCROsMember" xlink:label="dyai_TwoCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoSignificantCustomersMember" xlink:label="dyai_TwoSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_GatesFoundationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_TwoSignificantCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_ElevenSignificantCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_SixSignificantCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_FourSignificantCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="dyai_ContractResearchOrganizationsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_TwoCROsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dyai_The1044NLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies" xlink:href="dyai-20241231.xsd#statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AGlobalFoodIngredientCompanyMember" xlink:label="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InzymesAgreementApsMember" xlink:label="dyai_InzymesAgreementApsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_JanssenPharmaceuticalCompaniesMember" xlink:label="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ProliantAgreementMember" xlink:label="dyai_ProliantAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentMember" xlink:label="dyai_ResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_GatesFoundationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dyai_ResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_ProliantAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_InzymesAgreementApsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NetherlandsOfficeLeaseMember" xlink:label="dyai_NetherlandsOfficeLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dyai_The1044NLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dyai_NetherlandsOfficeLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable" xlink:href="dyai-20241231.xsd#statement-note-5-convertible-notes-payable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyScottEmalfarbMember" xlink:label="dyai_BradleyScottEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConvertibleDebtTextBlock" xlink:label="dyai_ConvertibleDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IrrevocableTrustMember" xlink:label="dyai_IrrevocableTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_MrThomasEmalfarbMember" xlink:label="dyai_MrThomasEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TheFranciscoTrustMember" xlink:label="dyai_TheFranciscoTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThirdPartyMember" xlink:label="dyai_ThirdPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:label="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dyai_ThirdPartyMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_TheFranciscoTrustMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_MrThomasEmalfarbMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_BradleyScottEmalfarbMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_IrrevocableTrustMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dyai_ConvertibleDebtTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BoardOfDirectorsMember" xlink:label="dyai_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantOneMember" xlink:label="dyai_ConsultantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantTwoMember" xlink:label="dyai_ConsultantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutiveAndBoardOfDirectorsMember" xlink:label="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerBoardOfDirectorsMember" xlink:label="dyai_FormerBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:label="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerEmployeeMember" xlink:label="dyai_FormerEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions1Member" xlink:label="dyai_StockOptions1Member" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions2Member" xlink:label="dyai_StockOptions2Member" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The2021PlanMember" xlink:label="dyai_The2021PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyai_The2021PlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_EmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dyai_StockOptions1Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dyai_StockOptions2Member" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantOneMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_FormerBoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_FormerEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ContractorMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-" xlink:href="dyai-20241231.xsd#statement-note-7-shareholders-equity-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:label="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment" xlink:href="dyai-20241231.xsd#statement-note-9-segment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-" xlink:href="dyai-20241231.xsd#statement-note-10-subsequent-events-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NonexecutiveEmployeesMember" xlink:label="dyai_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_NonexecutiveEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies" xlink:href="dyai-20241231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccountsPayablePolicyPolicyTextBlock" xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables" xlink:href="dyai-20241231.xsd#statement-note-5-convertible-notes-payable-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-tables" xlink:href="dyai-20241231.xsd#statement-note-9-segment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskNumberOfCustomers" xlink:label="dyai_ConcentrationRiskNumberOfCustomers" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskNumberOfSuppliers" xlink:label="dyai_ConcentrationRiskNumberOfSuppliers" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskSignificantCustomers" xlink:label="dyai_ConcentrationRiskSignificantCustomers" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ElevenSignificantCustomersMember" xlink:label="dyai_ElevenSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FourSignificantCustomersMember" xlink:label="dyai_FourSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" xlink:label="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LesseeOperatingLeaseYearlyPercentageIncrease" xlink:label="dyai_LesseeOperatingLeaseYearlyPercentageIncrease" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchServicesPurchased" xlink:label="dyai_ResearchServicesPurchased" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SixSignificantCustomersMember" xlink:label="dyai_SixSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoCROsMember" xlink:label="dyai_TwoCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoSignificantCustomersMember" xlink:label="dyai_TwoSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromGrantors" xlink:label="us-gaap_ProceedsFromGrantors" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_GatesFoundationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_TwoSignificantCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_ElevenSignificantCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_SixSignificantCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_FourSignificantCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="dyai_ContractResearchOrganizationsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_TwoCROsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dyai_The1044NLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromGrantors" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskNumberOfCustomers" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskSignificantCustomers" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskNumberOfSuppliers" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchServicesPurchased" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LesseeOperatingLeaseYearlyPercentageIncrease" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" xlink:label="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual" xlink:href="dyai-20241231.xsd#statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AGlobalFoodIngredientCompanyMember" xlink:label="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredLicenseRevenue" xlink:label="dyai_DeferredLicenseRevenue" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FinalPaymentUponMeetingCertainProductivityThreshold" xlink:label="dyai_FinalPaymentUponMeetingCertainProductivityThreshold" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InitialUpFrontPayment" xlink:label="dyai_InitialUpFrontPayment" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InzymesAgreementApsMember" xlink:label="dyai_InzymesAgreementApsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_JanssenPharmaceuticalCompaniesMember" xlink:label="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LicenseAndDevelopmentExtensionTerm" xlink:label="dyai_LicenseAndDevelopmentExtensionTerm" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LicenseAndDevelopmentInitialTerm" xlink:label="dyai_LicenseAndDevelopmentInitialTerm" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NonrefundableUpfrontPaymentReceived" xlink:label="dyai_NonrefundableUpfrontPaymentReceived" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OwnershipPercentage" xlink:label="dyai_OwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ProceedsFromGrant" xlink:label="dyai_ProceedsFromGrant" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ProliantAgreementMember" xlink:label="dyai_ProliantAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentMember" xlink:label="dyai_ResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SecondPaymentUponCompletionTransfer" xlink:label="dyai_SecondPaymentUponCompletionTransfer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_GatesFoundationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dyai_ResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_ProliantAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_InzymesAgreementApsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ProceedsFromGrant" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LicenseAndDevelopmentInitialTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LicenseAndDevelopmentExtensionTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_InitialUpFrontPayment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SecondPaymentUponCompletionTransfer" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_FinalPaymentUponMeetingCertainProductivityThreshold" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredLicenseRevenue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_NonrefundableUpfrontPaymentReceived" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NetherlandsOfficeLeaseMember" xlink:label="dyai_NetherlandsOfficeLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLeasesAnnualRentalRate" xlink:label="dyai_OperatingLeasesAnnualRentalRate" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLeasesMonthlyRentalRate" xlink:label="dyai_OperatingLeasesMonthlyRentalRate" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dyai_The1044NLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dyai_NetherlandsOfficeLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OperatingLeasesMonthlyRentalRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OperatingLeasesAnnualRentalRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual" xlink:href="dyai-20241231.xsd#statement-note-5-convertible-notes-payable-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyScottEmalfarbMember" xlink:label="dyai_BradleyScottEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IrrevocableTrustMember" xlink:label="dyai_IrrevocableTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_MrThomasEmalfarbMember" xlink:label="dyai_MrThomasEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TheFranciscoTrustMember" xlink:label="dyai_TheFranciscoTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThirdPartyMember" xlink:label="dyai_ThirdPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:label="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dyai_ThirdPartyMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_TheFranciscoTrustMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_MrThomasEmalfarbMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_BradleyScottEmalfarbMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_IrrevocableTrustMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BoardOfDirectorsMember" xlink:label="dyai_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantOneMember" xlink:label="dyai_ConsultantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantTwoMember" xlink:label="dyai_ConsultantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutiveAndBoardOfDirectorsMember" xlink:label="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerBoardOfDirectorsMember" xlink:label="dyai_FormerBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:label="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerEmployeeMember" xlink:label="dyai_FormerEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions1Member" xlink:label="dyai_StockOptions1Member" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions2Member" xlink:label="dyai_StockOptions2Member" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The2021PlanMember" xlink:label="dyai_The2021PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyai_The2021PlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_EmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dyai_StockOptions1Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dyai_StockOptions2Member" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantOneMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_FormerBoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_FormerEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ContractorMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual" xlink:href="dyai-20241231.xsd#statement-note-7-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:label="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual" xlink:href="dyai-20241231.xsd#statement-note-9-segment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual" xlink:href="dyai-20241231.xsd#statement-note-10-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NonexecutiveEmployeesMember" xlink:label="dyai_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_NonexecutiveEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:href="dyai-20241231.xsd#statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyEmalfarbMember" xlink:label="dyai_BradleyEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyScottEmalfarbMember" xlink:label="dyai_BradleyScottEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DescendantTrustMember" xlink:label="dyai_DescendantTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IrrevocableTrustMember" xlink:label="dyai_IrrevocableTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TheFranciscoTrustMember" xlink:label="dyai_TheFranciscoTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThirdPartyMember" xlink:label="dyai_ThirdPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_TheFranciscoTrustMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_IrrevocableTrustMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_BradleyEmalfarbMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dyai_BradleyScottEmalfarbMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_DescendantTrustMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dyai_ThirdPartyMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations" xlink:href="dyai-20241231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InterestIncomeNonoperating" xlink:label="dyai_InterestIncomeNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentMember" xlink:label="dyai_ResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dyai_ResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_NonrelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="dyai_InterestIncomeNonoperating" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dyai-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IncreaseDecreaseInAccruedInterest" xlink:label="dyai_IncreaseDecreaseInAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:label="dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_VestingOfRestrictedStock" xlink:label="dyai_VestingOfRestrictedStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_NonrelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="dyai_IncreaseDecreaseInAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dyai_VestingOfRestrictedStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidTaxes" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LegalExpensesPayableCurrent" xlink:label="dyai_LegalExpensesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LegalExpensesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossAttributableToParent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:label="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:href="dyai-20241231.xsd#statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BusinessConsultingExpense" xlink:label="dyai_BusinessConsultingExpense" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_BusinessConsultingExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="dyai-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_NonrelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="dyai-20241231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ShortTermCorporateBondsMember" xlink:label="dyai_ShortTermCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="us-gaap_HeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="dyai_ShortTermCorporateBondsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>dyai-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:28PM UTC 2025-03-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DocumentAndEntityInformation" xlink:label="dyai_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dyai_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DocumentAndEntityInformation" xlink:to="dyai_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dyai_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="dyai_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible notes, net of issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-significant-accounting-policies-policies" xlink:label="dyai_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-significant-accounting-policies-policies" xlink:to="dyai_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:label="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Cash, Cash Equivalents, and Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:to="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-4-commitments-and-contingencies-tables" xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-4-commitments-and-contingencies-tables" xlink:to="dyai_statement-statement-note-4-commitments-and-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free interest rate, maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-5-convertible-notes-payable-tables" xlink:label="dyai_statement-statement-note-5-convertible-notes-payable-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-5-convertible-notes-payable-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Convertible Notes Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-5-convertible-notes-payable-tables" xlink:to="dyai_statement-statement-note-5-convertible-notes-payable-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-tables" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-6-sharebased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-tables" xlink:to="dyai_statement-statement-note-6-sharebased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-8-income-taxes-tables" xlink:label="dyai_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-8-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-8-income-taxes-tables" xlink:to="dyai_statement-statement-note-8-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-9-segment-tables" xlink:label="dyai_statement-statement-note-9-segment-tables" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-9-segment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Segment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-9-segment-tables" xlink:to="dyai_statement-statement-note-9-segment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free interest rate, minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:to="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:label="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Cash, Cash Equivalents, and Investments - Major Security Type (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:to="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Commitments and Contingencies - Future Minimum Lease Payments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:to="dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Commitments and Contingencies - Purchase Obligations (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:to="dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:label="dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Convertible Notes Payable - Convertible Debt (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:to="dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:to="dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life of options (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Share-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:to="dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Share-based Compensation - Restricted Stock Units (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:to="dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Share-based Compensation - Noncash Stock Option Compensation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:to="dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:label="dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Components of Loss Before Income Taxes (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:to="dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:label="dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Reconciliation Between Statutory Tax Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:to="dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:label="dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Component of Deferred Tax Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:to="dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:label="dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:type="locator"/>
    <link:label xlink:label="dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Segment - Schedule of Segment Reporting Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:to="dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatements" xlink:label="dyai_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dyai_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NotesToFinancialStatements" xlink:to="dyai_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dyai_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="dyai_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investment securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, Weighted-average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, Weighted-average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested shares forfeited, Weighted-average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted-average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted-average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Balance, RSU (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Balance, RSU (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, RSU (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested, RSU (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of investment in Alphazyme</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted-average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted-average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of held-to-maturity investment securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IncreaseDecreaseInAccruedInterest" xlink:label="dyai_IncreaseDecreaseInAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="dyai_IncreaseDecreaseInAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_IncreaseDecreaseInAccruedInterest</link:label>
    <link:label xlink:label="dyai_IncreaseDecreaseInAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label xlink:label="dyai_IncreaseDecreaseInAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total increase (decrease) in accrued interest during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_IncreaseDecreaseInAccruedInterest" xlink:to="dyai_IncreaseDecreaseInAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canceled, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred research and development obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee wages and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DescendantTrustMember" xlink:label="dyai_DescendantTrustMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_DescendantTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Descendant Trust [Member]</link:label>
    <link:label xlink:label="dyai_DescendantTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the descendant trust.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DescendantTrustMember" xlink:to="dyai_DescendantTrustMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyScottEmalfarbMember" xlink:label="dyai_BradleyScottEmalfarbMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_BradleyScottEmalfarbMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bradley Scott Emalfarb [Member]</link:label>
    <link:label xlink:label="dyai_BradleyScottEmalfarbMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Bradley Scott Emalfarb.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_BradleyScottEmalfarbMember" xlink:to="dyai_BradleyScottEmalfarbMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConvertibleDebtTextBlock" xlink:label="dyai_ConvertibleDebtTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConvertibleDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Text Block]</link:label>
    <link:label xlink:label="dyai_ConvertibleDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure representing convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConvertibleDebtTextBlock" xlink:to="dyai_ConvertibleDebtTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unvested shares forfeited, RSU (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IrrevocableTrustMember" xlink:label="dyai_IrrevocableTrustMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_IrrevocableTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Irrevocable Trust [Member]</link:label>
    <link:label xlink:label="dyai_IrrevocableTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Irrevocable Trust</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_IrrevocableTrustMember" xlink:to="dyai_IrrevocableTrustMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyEmalfarbMember" xlink:label="dyai_BradleyEmalfarbMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_BradleyEmalfarbMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bradley Emalfarb [Member]</link:label>
    <link:label xlink:label="dyai_BradleyEmalfarbMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Bradley Emalfarb.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_BradleyEmalfarbMember" xlink:to="dyai_BradleyEmalfarbMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_MrThomasEmalfarbMember" xlink:label="dyai_MrThomasEmalfarbMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_MrThomasEmalfarbMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mr. Thomas Emalfarb [Member]</link:label>
    <link:label xlink:label="dyai_MrThomasEmalfarbMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Mr. Thomas Emalfarb</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_MrThomasEmalfarbMember" xlink:to="dyai_MrThomasEmalfarbMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TheFranciscoTrustMember" xlink:label="dyai_TheFranciscoTrustMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_TheFranciscoTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Francisco Trust [Member]</link:label>
    <link:label xlink:label="dyai_TheFranciscoTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Francisco Trust</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_TheFranciscoTrustMember" xlink:to="dyai_TheFranciscoTrustMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" xlink:type="locator"/>
    <link:label xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely</link:label>
    <link:label xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Will Be Carried Forward Indefinitely</link:label>
    <link:label xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of operating loss carryforward that will be carried forward Indefinitely, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" xlink:to="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NonrefundableUpfrontPaymentReceived" xlink:label="dyai_NonrefundableUpfrontPaymentReceived" xlink:type="locator"/>
    <link:label xlink:label="dyai_NonrefundableUpfrontPaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_NonrefundableUpfrontPaymentReceived</link:label>
    <link:label xlink:label="dyai_NonrefundableUpfrontPaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable Upfront Payment, Received</link:label>
    <link:label xlink:label="dyai_NonrefundableUpfrontPaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-refundable upfront payment, received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NonrefundableUpfrontPaymentReceived" xlink:to="dyai_NonrefundableUpfrontPaymentReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredLicenseRevenue" xlink:label="dyai_DeferredLicenseRevenue" xlink:type="locator"/>
    <link:label xlink:label="dyai_DeferredLicenseRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_DeferredLicenseRevenue</link:label>
    <link:label xlink:label="dyai_DeferredLicenseRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred License Revenue</link:label>
    <link:label xlink:label="dyai_DeferredLicenseRevenue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred license revenue.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DeferredLicenseRevenue" xlink:to="dyai_DeferredLicenseRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThirdPartyMember" xlink:label="dyai_ThirdPartyMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ThirdPartyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Party [Member]</link:label>
    <link:label xlink:label="dyai_ThirdPartyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the third party group.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ThirdPartyMember" xlink:to="dyai_ThirdPartyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" xlink:type="locator"/>
    <link:label xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage</link:label>
    <link:label xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Will Be Carried Forward Indefinitely, Available to Offset Taxable Income, Percentage</link:label>
    <link:label xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage available to Offset Taxable Income related to amount of operating loss carryforward that will be carried forward Indefinitely, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" xlink:to="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentMember" xlink:label="dyai_ResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentMember" xlink:to="dyai_ResearchAndDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Legal expenses</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:label="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb [Member]</link:label>
    <link:label xlink:label="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:to="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InterestIncomeNonoperating" xlink:label="dyai_InterestIncomeNonoperating" xlink:type="locator"/>
    <link:label xlink:label="dyai_InterestIncomeNonoperating-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:label="dyai_InterestIncomeNonoperating-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of interest income during the period, classified as nonoperating</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_InterestIncomeNonoperating" xlink:to="dyai_InterestIncomeNonoperating-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableOtherCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsPayableOtherCurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableOtherCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ProliantAgreementMember" xlink:label="dyai_ProliantAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ProliantAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proliant Agreement [Member]</link:label>
    <link:label xlink:label="dyai_ProliantAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Proliant Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ProliantAgreementMember" xlink:to="dyai_ProliantAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerBoardOfDirectorsMember" xlink:label="dyai_FormerBoardOfDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_FormerBoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Board of Directors [Member]</link:label>
    <link:label xlink:label="dyai_FormerBoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to former Board of Directors members.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_FormerBoardOfDirectorsMember" xlink:to="dyai_FormerBoardOfDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets and liabilities, net</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_JanssenPharmaceuticalCompaniesMember" xlink:label="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_JanssenPharmaceuticalCompaniesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceutical Companies [Member]</link:label>
    <link:label xlink:label="dyai_JanssenPharmaceuticalCompaniesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Janssen Pharmaceutical Companies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_JanssenPharmaceuticalCompaniesMember" xlink:to="dyai_JanssenPharmaceuticalCompaniesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:label="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_FormerChairmanOfTheBoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Chairman of the Board of Directors [Member]</link:label>
    <link:label xlink:label="dyai_FormerChairmanOfTheBoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information relating to the former Chairman of the Board of Directors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:to="dyai_FormerChairmanOfTheBoardOfDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SecondPaymentUponCompletionTransfer" xlink:label="dyai_SecondPaymentUponCompletionTransfer" xlink:type="locator"/>
    <link:label xlink:label="dyai_SecondPaymentUponCompletionTransfer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_SecondPaymentUponCompletionTransfer</link:label>
    <link:label xlink:label="dyai_SecondPaymentUponCompletionTransfer-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Payment Upon Completion Transfer</link:label>
    <link:label xlink:label="dyai_SecondPaymentUponCompletionTransfer-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the second payment upon the completion of a transfer in an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SecondPaymentUponCompletionTransfer" xlink:to="dyai_SecondPaymentUponCompletionTransfer-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InitialUpFrontPayment" xlink:label="dyai_InitialUpFrontPayment" xlink:type="locator"/>
    <link:label xlink:label="dyai_InitialUpFrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_InitialUpFrontPayment</link:label>
    <link:label xlink:label="dyai_InitialUpFrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Up Front Payment</link:label>
    <link:label xlink:label="dyai_InitialUpFrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the upfront payment for an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_InitialUpFrontPayment" xlink:to="dyai_InitialUpFrontPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FinalPaymentUponMeetingCertainProductivityThreshold" xlink:label="dyai_FinalPaymentUponMeetingCertainProductivityThreshold" xlink:type="locator"/>
    <link:label xlink:label="dyai_FinalPaymentUponMeetingCertainProductivityThreshold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_FinalPaymentUponMeetingCertainProductivityThreshold</link:label>
    <link:label xlink:label="dyai_FinalPaymentUponMeetingCertainProductivityThreshold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final Payment Upon Meeting Certain Productivity Threshold</link:label>
    <link:label xlink:label="dyai_FinalPaymentUponMeetingCertainProductivityThreshold-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the final payment upon meeting certain productivity thresholds in an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_FinalPaymentUponMeetingCertainProductivityThreshold" xlink:to="dyai_FinalPaymentUponMeetingCertainProductivityThreshold-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Convertible Notes Into Common Stock [Member]</link:label>
    <link:label xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the monetary value of convertible notes converted into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BoardOfDirectorsMember" xlink:label="dyai_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_BoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors [Member]</link:label>
    <link:label xlink:label="dyai_BoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a member of the board of directors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_BoardOfDirectorsMember" xlink:to="dyai_BoardOfDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutiveAndBoardOfDirectorsMember" xlink:label="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ExecutiveAndBoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive And Board Of Directors [Member]</link:label>
    <link:label xlink:label="dyai_ExecutiveAndBoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents executives and board of directors members.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:to="dyai_ExecutiveAndBoardOfDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoCROsMember" xlink:label="dyai_TwoCROsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_TwoCROsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two CROs [Member]</link:label>
    <link:label xlink:label="dyai_TwoCROsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding two contract research organizations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_TwoCROsMember" xlink:to="dyai_TwoCROsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="us-gaap_HeldToMaturitySecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bonds, adjusted cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LegalExpensesPayableCurrent" xlink:label="dyai_LegalExpensesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="dyai_LegalExpensesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal expenses</link:label>
    <link:label xlink:label="dyai_LegalExpensesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of legal expenses payable, current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_LegalExpensesPayableCurrent" xlink:to="dyai_LegalExpensesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnInvestments</link:label>
    <link:label xlink:label="us-gaap_GainLossOnInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on investment in Alphazyme</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other G&amp;A expenses</link:label>
    <link:label xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherGeneralAndAdministrativeExpense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestrictedCash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="dyai_DeferredTaxAssetsOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label xlink:label="dyai_DeferredTaxAssetsOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents portion of the deferred tax assets related to operating lease liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="dyai_DeferredTaxAssetsOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, adjusted cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal, adjusted cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseNonoperating-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseNonoperating</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseNonoperating-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</link:label>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Corporate Bonds, gross unrealized holding losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bonds, gross unrealized holding gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LaborAndRelatedExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related expenses</link:label>
    <link:label xlink:label="us-gaap_LaborAndRelatedExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LaborAndRelatedExpense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleConversionPrice1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerEmployeeMember" xlink:label="dyai_FormerEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_FormerEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Employee [Member]</link:label>
    <link:label xlink:label="dyai_FormerEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a former employee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_FormerEmployeeMember" xlink:to="dyai_FormerEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds, adjusted cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_SeniorSecured2024NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured 2024 Notes [Member]</link:label>
    <link:label xlink:label="dyai_SeniorSecured2024NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2024 Senior Secured Convertible Promissory Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SeniorSecured2024NotesMember" xlink:to="dyai_SeniorSecured2024NotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentIssuanceDate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuanceDate1" xlink:to="us-gaap_DebtInstrumentIssuanceDate1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FourSignificantCustomersMember" xlink:label="dyai_FourSignificantCustomersMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_FourSignificantCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Significant Customers [Member]</link:label>
    <link:label xlink:label="dyai_FourSignificantCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to four significant customers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_FourSignificantCustomersMember" xlink:to="dyai_FourSignificantCustomersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred research and development obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use asset obtained in exchange for lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible note principal</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" xlink:label="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" xlink:type="locator"/>
    <link:label xlink:label="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount</link:label>
    <link:label xlink:label="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Securities Purchased, Discount</link:label>
    <link:label xlink:label="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents securities that were purchased at a discount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" xlink:to="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ContractResearchOrganizationsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Research Organizations [Member]</link:label>
    <link:label xlink:label="dyai_ContractResearchOrganizationsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to contract research organizations, or to research services purchased from such organizations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ContractResearchOrganizationsMember" xlink:to="dyai_ContractResearchOrganizationsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskNumberOfCustomers" xlink:label="dyai_ConcentrationRiskNumberOfCustomers" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ConcentrationRiskNumberOfCustomers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConcentrationRiskNumberOfCustomers" xlink:to="dyai_ConcentrationRiskNumberOfCustomers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentsAndCash</link:label>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, adjusted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableNet</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_AlphazymeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alphazyme [Member]</link:label>
    <link:label xlink:label="dyai_AlphazymeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to Alphazyme.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AlphazymeMember" xlink:to="dyai_AlphazymeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:to="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccountsPayablePolicyPolicyTextBlock" xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for accounts payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:to="dyai_AccountsPayablePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for accrued expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:to="dyai_AccruedExpensesPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplierConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllowanceForDoubtfulAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TreasuryStockValue</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares held at cost - 12,253,502</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ResearchAndDevelopmentInProcessCurrent</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents current research and development in process.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentInProcessCurrent" xlink:to="dyai_ResearchAndDevelopmentInProcessCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:type="locator"/>
    <link:label xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_AccruedResearchAndDevelopmentInProcessCurrent</link:label>
    <link:label xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents current accrued research and development in process.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:to="dyai_AccruedResearchAndDevelopmentInProcessCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:label xlink:label="ecd_TradingArrByIndTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Facilities, overhead, and other</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facilities, overhead and other</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents facilities, overhead and other for research and development expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Personnel related costs</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personnel related costs</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents personnel related costs for research and development expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProfessionalFees-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Legal and professional services</link:label>
    <link:label xlink:label="us-gaap_ProfessionalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProfessionalFees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ElevenSignificantCustomersMember" xlink:label="dyai_ElevenSignificantCustomersMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ElevenSignificantCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eleven Significant Customers [Member]</link:label>
    <link:label xlink:label="dyai_ElevenSignificantCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents eleven significant customers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ElevenSignificantCustomersMember" xlink:to="dyai_ElevenSignificantCustomersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</link:label>
    <link:label xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outside contracted services</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside contracted services</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents outside contracted services for research and development expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_GatesFoundationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gates Foundation [Member]</link:label>
    <link:label xlink:label="dyai_GatesFoundationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Gates Foundation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_GatesFoundationMember" xlink:to="dyai_GatesFoundationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon settlement of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon settlement of convertible debt (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BusinessConsultingExpense" xlink:label="dyai_BusinessConsultingExpense" xlink:type="locator"/>
    <link:label xlink:label="dyai_BusinessConsultingExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business consulting expenses</link:label>
    <link:label xlink:label="dyai_BusinessConsultingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_BusinessConsultingExpense</link:label>
    <link:label xlink:label="dyai_BusinessConsultingExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of expense in the period for business consulting.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_BusinessConsultingExpense" xlink:to="dyai_BusinessConsultingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:label="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConvertibleNotesConvertedIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Converted into Common Stock [Member]</link:label>
    <link:label xlink:label="dyai_ConvertibleNotesConvertedIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents convertible notes converted into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:to="dyai_ConvertibleNotesConvertedIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ProceedsFromGrant" xlink:label="dyai_ProceedsFromGrant" xlink:type="locator"/>
    <link:label xlink:label="dyai_ProceedsFromGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ProceedsFromGrant</link:label>
    <link:label xlink:label="dyai_ProceedsFromGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Grant</link:label>
    <link:label xlink:label="dyai_ProceedsFromGrant-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of proceeds from grant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ProceedsFromGrant" xlink:to="dyai_ProceedsFromGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Costs [Table Text Block]</link:label>
    <link:label xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:to="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnSaleOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on sale of Alphazyme</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The2021PlanMember" xlink:label="dyai_The2021PlanMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_The2021PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 Plan [Member]</link:label>
    <link:label xlink:label="dyai_The2021PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2021 plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_The2021PlanMember" xlink:to="dyai_The2021PlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ShortTermCorporateBondsMember" xlink:label="dyai_ShortTermCorporateBondsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ShortTermCorporateBondsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Corporate Bonds [Member]</link:label>
    <link:label xlink:label="dyai_ShortTermCorporateBondsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents short-term corporate bonds.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ShortTermCorporateBondsMember" xlink:to="dyai_ShortTermCorporateBondsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:type="locator"/>
    <link:label xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_CashCashEquivalentsAndInvestmentsFairValue</link:label>
    <link:label xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, fair value</link:label>
    <link:label xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents fair value of cash, cash equivalents and investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:to="dyai_CashCashEquivalentsAndInvestmentsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions2Member" xlink:label="dyai_StockOptions2Member" xlink:type="locator"/>
    <link:label xlink:label="dyai_StockOptions2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options 2 [Member]</link:label>
    <link:label xlink:label="dyai_StockOptions2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_StockOptions2Member" xlink:to="dyai_StockOptions2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions1Member" xlink:label="dyai_StockOptions1Member" xlink:type="locator"/>
    <link:label xlink:label="dyai_StockOptions1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options 1 [Member]</link:label>
    <link:label xlink:label="dyai_StockOptions1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_StockOptions1Member" xlink:to="dyai_StockOptions1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bonds, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LesseeOperatingLeaseYearlyPercentageIncrease" xlink:label="dyai_LesseeOperatingLeaseYearlyPercentageIncrease" xlink:type="locator"/>
    <link:label xlink:label="dyai_LesseeOperatingLeaseYearlyPercentageIncrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_LesseeOperatingLeaseYearlyPercentageIncrease</link:label>
    <link:label xlink:label="dyai_LesseeOperatingLeaseYearlyPercentageIncrease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Yearly Percentage Increase</link:label>
    <link:label xlink:label="dyai_LesseeOperatingLeaseYearlyPercentageIncrease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage increase in operating lease payment based on lease agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_LesseeOperatingLeaseYearlyPercentageIncrease" xlink:to="dyai_LesseeOperatingLeaseYearlyPercentageIncrease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionGainLossRealized</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange loss</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" xlink:label="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" xlink:type="locator"/>
    <link:label xlink:label="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms</link:label>
    <link:label xlink:label="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Additional Number of Renewal Terms</link:label>
    <link:label xlink:label="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional number of renewal terms available for the lessee operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" xlink:to="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liability, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset, net</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Conversion to common stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of convertible notes</link:label>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRenewalTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalent, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:label="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:type="locator"/>
    <link:label xlink:label="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">True-up adjustment</link:label>
    <link:label xlink:label="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying true-up adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:to="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskSignificantCustomers" xlink:label="dyai_ConcentrationRiskSignificantCustomers" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConcentrationRiskSignificantCustomers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ConcentrationRiskSignificantCustomers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskSignificantCustomers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Significant Customers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskSignificantCustomers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of significant customer, which represent over 10%.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConcentrationRiskSignificantCustomers" xlink:to="dyai_ConcentrationRiskSignificantCustomers-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SixSignificantCustomersMember" xlink:label="dyai_SixSignificantCustomersMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_SixSignificantCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Six Significant Customers [Member]</link:label>
    <link:label xlink:label="dyai_SixSignificantCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to six significant customers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SixSignificantCustomersMember" xlink:to="dyai_SixSignificantCustomersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_VestingOfRestrictedStock" xlink:label="dyai_VestingOfRestrictedStock" xlink:type="locator"/>
    <link:label xlink:label="dyai_VestingOfRestrictedStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label xlink:label="dyai_VestingOfRestrictedStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cash flow effect of the vesting of restricted stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_VestingOfRestrictedStock" xlink:to="dyai_VestingOfRestrictedStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockCommonShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockCommonShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockCommonShares-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockCommonShares-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLeasesMonthlyRentalRate" xlink:label="dyai_OperatingLeasesMonthlyRentalRate" xlink:type="locator"/>
    <link:label xlink:label="dyai_OperatingLeasesMonthlyRentalRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_OperatingLeasesMonthlyRentalRate</link:label>
    <link:label xlink:label="dyai_OperatingLeasesMonthlyRentalRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Monthly Rental Rate</link:label>
    <link:label xlink:label="dyai_OperatingLeasesMonthlyRentalRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents monthly rental rate for operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_OperatingLeasesMonthlyRentalRate" xlink:to="dyai_OperatingLeasesMonthlyRentalRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 42,089,301 and 41,064,563, outstanding shares - 29,835,799 and 28,811,061 as of December 31, 2024 and 2023, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositLiabilitiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLeasesAnnualRentalRate" xlink:label="dyai_OperatingLeasesAnnualRentalRate" xlink:type="locator"/>
    <link:label xlink:label="dyai_OperatingLeasesAnnualRentalRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_OperatingLeasesAnnualRentalRate</link:label>
    <link:label xlink:label="dyai_OperatingLeasesAnnualRentalRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Annual Rental Rate</link:label>
    <link:label xlink:label="dyai_OperatingLeasesAnnualRentalRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual rental rate for operating leases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_OperatingLeasesAnnualRentalRate" xlink:to="dyai_OperatingLeasesAnnualRentalRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NetherlandsOfficeLeaseMember" xlink:label="dyai_NetherlandsOfficeLeaseMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_NetherlandsOfficeLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Netherlands Office Lease [Member]</link:label>
    <link:label xlink:label="dyai_NetherlandsOfficeLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to Netherlands Office lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NetherlandsOfficeLeaseMember" xlink:to="dyai_NetherlandsOfficeLeaseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ContractorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractor [Member]</link:label>
    <link:label xlink:label="dyai_ContractorMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to contractor.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ContractorMember" xlink:to="dyai_ContractorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_EquityMethodInvesteeNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award Tranche Two through Five [Member]</link:label>
    <link:label xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shares-based compensation award tranche two through five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_EmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees [Member]</link:label>
    <link:label xlink:label="dyai_EmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_EmployeesMember" xlink:to="dyai_EmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherPrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses - various</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ExecutivesAndKeyPersonnelMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executives and Key Personnel [Member]</link:label>
    <link:label xlink:label="dyai_ExecutivesAndKeyPersonnelMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents executives and key personnel.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ExecutivesAndKeyPersonnelMember" xlink:to="dyai_ExecutivesAndKeyPersonnelMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LicenseAndDevelopmentInitialTerm" xlink:label="dyai_LicenseAndDevelopmentInitialTerm" xlink:type="locator"/>
    <link:label xlink:label="dyai_LicenseAndDevelopmentInitialTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_LicenseAndDevelopmentInitialTerm</link:label>
    <link:label xlink:label="dyai_LicenseAndDevelopmentInitialTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Development, Initial Term (Year)</link:label>
    <link:label xlink:label="dyai_LicenseAndDevelopmentInitialTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The initial term length for the research and development agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_LicenseAndDevelopmentInitialTerm" xlink:to="dyai_LicenseAndDevelopmentInitialTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant [Member]</link:label>
    <link:label xlink:label="dyai_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to consultant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConsultantMember" xlink:to="dyai_ConsultantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LicenseAndDevelopmentExtensionTerm" xlink:label="dyai_LicenseAndDevelopmentExtensionTerm" xlink:type="locator"/>
    <link:label xlink:label="dyai_LicenseAndDevelopmentExtensionTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_LicenseAndDevelopmentExtensionTerm</link:label>
    <link:label xlink:label="dyai_LicenseAndDevelopmentExtensionTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Development, Extension Term (Year)</link:label>
    <link:label xlink:label="dyai_LicenseAndDevelopmentExtensionTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The duration of the term extension for the research and development agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_LicenseAndDevelopmentExtensionTerm" xlink:to="dyai_LicenseAndDevelopmentExtensionTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromGrantors" xlink:label="us-gaap_ProceedsFromGrantors" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromGrantors-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromGrantors</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromGrantors-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Grantors</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromGrantors" xlink:to="us-gaap_ProceedsFromGrantors-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_MajorCustomersAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_NameOfMajorCustomerDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Including Related Party</link:label>
    <link:label xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents research and development expense including related party.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NonexecutiveEmployeesMember" xlink:label="dyai_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_NonexecutiveEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonexecutive Employees [Member]</link:label>
    <link:label xlink:label="dyai_NonexecutiveEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to nonexecutive employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_NonexecutiveEmployeesMember" xlink:to="dyai_NonexecutiveEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred license revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportableSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsAndShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OwnershipPercentage" xlink:label="dyai_OwnershipPercentage" xlink:type="locator"/>
    <link:label xlink:label="dyai_OwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_OwnershipPercentage</link:label>
    <link:label xlink:label="dyai_OwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership Percentage</link:label>
    <link:label xlink:label="dyai_OwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of ownership.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_OwnershipPercentage" xlink:to="dyai_OwnershipPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term investment securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Business credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (expenses), net</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NOL carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:label="dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:type="locator"/>
    <link:label xlink:label="dyai_InvestmentIncomeAmortizationAccretionOfPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of held-to-maturity securities, net</link:label>
    <link:label xlink:label="dyai_InvestmentIncomeAmortizationAccretionOfPremium-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents amortization (accretion) of premium on investment income.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:to="dyai_InvestmentIncomeAmortizationAccretionOfPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:label xlink:label="srt_DirectorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance</link:label>
    <link:label xlink:label="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset, net of deferred tax liabilities</link:label>
    <link:label xlink:label="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents net of liabilities before valuation allowance for deferred tax assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenues</link:label>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs of research and development revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidationItemsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherIncomeDisclosureNonoperatingAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidationItemsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AGlobalFoodIngredientCompanyMember" xlink:label="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_AGlobalFoodIngredientCompanyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A Global Food Ingredient Company [Member]</link:label>
    <link:label xlink:label="dyai_AGlobalFoodIngredientCompanyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a global food ingredient company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_AGlobalFoodIngredientCompanyMember" xlink:to="dyai_AGlobalFoodIngredientCompanyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonrelatedPartyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development revenue</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockCommonMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CurrentIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsCurrentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsCurrentGross</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsCurrentGross-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Costs - Related Party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 174 - R&amp;D expenses</link:label>
    <link:label xlink:label="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Senior Long-Term Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchServicesPurchased" xlink:label="dyai_ResearchServicesPurchased" xlink:type="locator"/>
    <link:label xlink:label="dyai_ResearchServicesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ResearchServicesPurchased</link:label>
    <link:label xlink:label="dyai_ResearchServicesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Services Purchased</link:label>
    <link:label xlink:label="dyai_ResearchServicesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research services purchased during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ResearchServicesPurchased" xlink:to="dyai_ResearchServicesPurchased-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossAttributableToParent</link:label>
    <link:label xlink:label="us-gaap_IncomeLossAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total loss before provision for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantOneMember" xlink:label="dyai_ConsultantOneMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConsultantOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant One [Member]</link:label>
    <link:label xlink:label="dyai_ConsultantOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding a first consultant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConsultantOneMember" xlink:to="dyai_ConsultantOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantTwoMember" xlink:label="dyai_ConsultantTwoMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConsultantTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant Two [Member]</link:label>
    <link:label xlink:label="dyai_ConsultantTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding a second consultant, or a second transaction with a consultant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConsultantTwoMember" xlink:to="dyai_ConsultantTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PurchaseObligation</link:label>
    <link:label xlink:label="us-gaap_PurchaseObligation-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonUsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_ThreeCROsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three CROs [Member]</link:label>
    <link:label xlink:label="dyai_ThreeCROsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding three contract research organizations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ThreeCROsMember" xlink:to="dyai_ThreeCROsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByAssetClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseObligationDueInSecondYear-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label xlink:label="us-gaap_PurchaseObligationDueInSecondYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PurchaseObligationDueInSecondYear</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseObligationDueInThirdYear-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label xlink:label="us-gaap_PurchaseObligationDueInThirdYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PurchaseObligationDueInThirdYear</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInThirdYear" xlink:to="us-gaap_PurchaseObligationDueInThirdYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PurchaseObligationDueInNextTwelveMonths</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskNumberOfSuppliers" xlink:label="dyai_ConcentrationRiskNumberOfSuppliers" xlink:type="locator"/>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dyai_ConcentrationRiskNumberOfSuppliers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Suppliers</link:label>
    <link:label xlink:label="dyai_ConcentrationRiskNumberOfSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of suppliers accounting for 10% or more of the specified concentration risk benchmark.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_ConcentrationRiskNumberOfSuppliers" xlink:to="dyai_ConcentrationRiskNumberOfSuppliers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible notes, net of issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-deductible items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign operations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax at U.S. statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoSignificantCustomersMember" xlink:label="dyai_TwoSignificantCustomersMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_TwoSignificantCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Significant Customers [Member]</link:label>
    <link:label xlink:label="dyai_TwoSignificantCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents two significant customers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_TwoSignificantCustomersMember" xlink:to="dyai_TwoSignificantCustomersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InzymesAgreementApsMember" xlink:label="dyai_InzymesAgreementApsMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_InzymesAgreementApsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inzymes Agreement APS [Member]</link:label>
    <link:label xlink:label="dyai_InzymesAgreementApsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Inzymes Agreement ApS.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_InzymesAgreementApsMember" xlink:to="dyai_InzymesAgreementApsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:label xlink:label="dyai_The1044NLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 1044 N Lease [Member]</link:label>
    <link:label xlink:label="dyai_The1044NLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent the 1044 N Lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyai_The1044NLeaseMember" xlink:to="dyai_The1044NLeaseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingSegmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>dyai-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:28PM UTC 2025-03-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-document-and-entity-information" xlink:href="dyai-20241231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dyai-20241231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_TradingArrByIndTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ElevenSignificantCustomersMember" xlink:label="dyai_ElevenSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FourSignificantCustomersMember" xlink:label="dyai_FourSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SixSignificantCustomersMember" xlink:label="dyai_SixSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoCROsMember" xlink:label="dyai_TwoCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoSignificantCustomersMember" xlink:label="dyai_TwoSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_GatesFoundationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_TwoSignificantCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_ElevenSignificantCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_SixSignificantCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_FourSignificantCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="dyai_ContractResearchOrganizationsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_TwoCROsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="dyai_The1044NLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies" xlink:href="dyai-20241231.xsd#statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AGlobalFoodIngredientCompanyMember" xlink:label="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InzymesAgreementApsMember" xlink:label="dyai_InzymesAgreementApsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_JanssenPharmaceuticalCompaniesMember" xlink:label="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ProliantAgreementMember" xlink:label="dyai_ProliantAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentMember" xlink:label="dyai_ResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_GatesFoundationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="dyai_ResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_ProliantAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_InzymesAgreementApsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NetherlandsOfficeLeaseMember" xlink:label="dyai_NetherlandsOfficeLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="dyai_The1044NLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="dyai_NetherlandsOfficeLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable" xlink:href="dyai-20241231.xsd#statement-note-5-convertible-notes-payable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyScottEmalfarbMember" xlink:label="dyai_BradleyScottEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConvertibleDebtTextBlock" xlink:label="dyai_ConvertibleDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IrrevocableTrustMember" xlink:label="dyai_IrrevocableTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_MrThomasEmalfarbMember" xlink:label="dyai_MrThomasEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TheFranciscoTrustMember" xlink:label="dyai_TheFranciscoTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThirdPartyMember" xlink:label="dyai_ThirdPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:label="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="dyai_ThirdPartyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_TheFranciscoTrustMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_MrThomasEmalfarbMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_BradleyScottEmalfarbMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_IrrevocableTrustMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dyai_ConvertibleDebtTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BoardOfDirectorsMember" xlink:label="dyai_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantOneMember" xlink:label="dyai_ConsultantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantTwoMember" xlink:label="dyai_ConsultantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutiveAndBoardOfDirectorsMember" xlink:label="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerBoardOfDirectorsMember" xlink:label="dyai_FormerBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:label="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerEmployeeMember" xlink:label="dyai_FormerEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions1Member" xlink:label="dyai_StockOptions1Member" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions2Member" xlink:label="dyai_StockOptions2Member" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The2021PlanMember" xlink:label="dyai_The2021PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dyai_The2021PlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_EmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dyai_StockOptions1Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dyai_StockOptions2Member" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantOneMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantTwoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_FormerBoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_FormerEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ContractorMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-" xlink:href="dyai-20241231.xsd#statement-note-7-shareholders-equity-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:label="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment" xlink:href="dyai-20241231.xsd#statement-note-9-segment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-" xlink:href="dyai-20241231.xsd#statement-note-10-subsequent-events-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NonexecutiveEmployeesMember" xlink:label="dyai_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NotesToFinancialStatementsAbstract" xlink:label="dyai_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_NonexecutiveEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies" xlink:href="dyai-20241231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccountsPayablePolicyPolicyTextBlock" xlink:label="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:label="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:label="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-significant-accounting-policies-policies" xlink:label="dyai_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_AccountsPayablePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyai_AccruedExpensesPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:label="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:label="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-4-commitments-and-contingencies-tables" xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-4-commitments-and-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables" xlink:href="dyai-20241231.xsd#statement-note-5-convertible-notes-payable-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-5-convertible-notes-payable-tables" xlink:label="dyai_statement-statement-note-5-convertible-notes-payable-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-5-convertible-notes-payable-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-tables" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-8-income-taxes-tables" xlink:label="dyai_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-8-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-tables" xlink:href="dyai-20241231.xsd#statement-note-9-segment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-9-segment-tables" xlink:label="dyai_statement-statement-note-9-segment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-9-segment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskNumberOfCustomers" xlink:label="dyai_ConcentrationRiskNumberOfCustomers-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskNumberOfSuppliers" xlink:label="dyai_ConcentrationRiskNumberOfSuppliers-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConcentrationRiskSignificantCustomers" xlink:label="dyai_ConcentrationRiskSignificantCustomers-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractResearchOrganizationsMember" xlink:label="dyai_ContractResearchOrganizationsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ElevenSignificantCustomersMember" xlink:label="dyai_ElevenSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FourSignificantCustomersMember" xlink:label="dyai_FourSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms" xlink:label="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LesseeOperatingLeaseYearlyPercentageIncrease" xlink:label="dyai_LesseeOperatingLeaseYearlyPercentageIncrease-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchServicesPurchased" xlink:label="dyai_ResearchServicesPurchased-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SixSignificantCustomersMember" xlink:label="dyai_SixSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThreeCROsMember" xlink:label="dyai_ThreeCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoCROsMember" xlink:label="dyai_TwoCROsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TwoSignificantCustomersMember" xlink:label="dyai_TwoSignificantCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromGrantors" xlink:label="us-gaap_ProceedsFromGrantors-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_GatesFoundationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_TwoSignificantCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_ElevenSignificantCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_SixSignificantCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_FourSignificantCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="dyai_ContractResearchOrganizationsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_TwoCROsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="dyai_ThreeCROsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="dyai_The1044NLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromGrantors-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskNumberOfCustomers-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskSignificantCustomers-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ConcentrationRiskNumberOfSuppliers-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchServicesPurchased-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LesseeOperatingLeaseYearlyPercentageIncrease-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount" xlink:label="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual" xlink:href="dyai-20241231.xsd#statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AGlobalFoodIngredientCompanyMember" xlink:label="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AlphazymeMember" xlink:label="dyai_AlphazymeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredLicenseRevenue" xlink:label="dyai_DeferredLicenseRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FinalPaymentUponMeetingCertainProductivityThreshold" xlink:label="dyai_FinalPaymentUponMeetingCertainProductivityThreshold-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_GatesFoundationMember" xlink:label="dyai_GatesFoundationMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InitialUpFrontPayment" xlink:label="dyai_InitialUpFrontPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InzymesAgreementApsMember" xlink:label="dyai_InzymesAgreementApsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_JanssenPharmaceuticalCompaniesMember" xlink:label="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LicenseAndDevelopmentExtensionTerm" xlink:label="dyai_LicenseAndDevelopmentExtensionTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LicenseAndDevelopmentInitialTerm" xlink:label="dyai_LicenseAndDevelopmentInitialTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NonrefundableUpfrontPaymentReceived" xlink:label="dyai_NonrefundableUpfrontPaymentReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OwnershipPercentage" xlink:label="dyai_OwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ProceedsFromGrant" xlink:label="dyai_ProceedsFromGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ProliantAgreementMember" xlink:label="dyai_ProliantAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentMember" xlink:label="dyai_ResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SecondPaymentUponCompletionTransfer" xlink:label="dyai_SecondPaymentUponCompletionTransfer-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_GatesFoundationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="dyai_ResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_ProliantAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_InzymesAgreementApsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_AGlobalFoodIngredientCompanyMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dyai_JanssenPharmaceuticalCompaniesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="dyai_AlphazymeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ProceedsFromGrant-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LicenseAndDevelopmentInitialTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LicenseAndDevelopmentExtensionTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_InitialUpFrontPayment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_SecondPaymentUponCompletionTransfer-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_FinalPaymentUponMeetingCertainProductivityThreshold-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredLicenseRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_NonrefundableUpfrontPaymentReceived-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NetherlandsOfficeLeaseMember" xlink:label="dyai_NetherlandsOfficeLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLeasesAnnualRentalRate" xlink:label="dyai_OperatingLeasesAnnualRentalRate-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLeasesMonthlyRentalRate" xlink:label="dyai_OperatingLeasesMonthlyRentalRate-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The1044NLeaseMember" xlink:label="dyai_The1044NLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="dyai_The1044NLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="dyai_NetherlandsOfficeLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OperatingLeasesMonthlyRentalRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OperatingLeasesAnnualRentalRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual" xlink:href="dyai-20241231.xsd#statement-note-5-convertible-notes-payable-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyScottEmalfarbMember" xlink:label="dyai_BradleyScottEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IrrevocableTrustMember" xlink:label="dyai_IrrevocableTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_MrThomasEmalfarbMember" xlink:label="dyai_MrThomasEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TheFranciscoTrustMember" xlink:label="dyai_TheFranciscoTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThirdPartyMember" xlink:label="dyai_ThirdPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:label="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="dyai_ThirdPartyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_TheFranciscoTrustMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_MrThomasEmalfarbMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_BradleyScottEmalfarbMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_IrrevocableTrustMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaidNet-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BoardOfDirectorsMember" xlink:label="dyai_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantOneMember" xlink:label="dyai_ConsultantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantTwoMember" xlink:label="dyai_ConsultantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ContractorMember" xlink:label="dyai_ContractorMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EmployeesMember" xlink:label="dyai_EmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutiveAndBoardOfDirectorsMember" xlink:label="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerBoardOfDirectorsMember" xlink:label="dyai_FormerBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:label="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_FormerEmployeeMember" xlink:label="dyai_FormerEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:label="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions1Member" xlink:label="dyai_StockOptions1Member" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_StockOptions2Member" xlink:label="dyai_StockOptions2Member" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_The2021PlanMember" xlink:label="dyai_The2021PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dyai_The2021PlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_EmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ExecutiveAndBoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dyai_StockOptions1Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dyai_StockOptions2Member" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantOneMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantTwoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_FormerBoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_FormerChairmanOfTheBoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_FormerEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ContractorMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual" xlink:href="dyai-20241231.xsd#statement-note-7-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:label="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="dyai_ConvertibleNotesConvertedIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely" xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage" xlink:label="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual" xlink:href="dyai-20241231.xsd#statement-note-9-segment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual" xlink:href="dyai-20241231.xsd#statement-note-10-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConsultantMember" xlink:label="dyai_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ExecutivesAndKeyPersonnelMember" xlink:label="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NonexecutiveEmployeesMember" xlink:label="dyai_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_NoteToFinancialStatementDetailsTextual" xlink:label="dyai_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ExecutivesAndKeyPersonnelMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_NonexecutiveEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:href="dyai-20241231.xsd#statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:label="dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligationDueInSecondYear-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligationDueInThirdYear-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligation-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:href="dyai-20241231.xsd#statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyEmalfarbMember" xlink:label="dyai_BradleyEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BradleyScottEmalfarbMember" xlink:label="dyai_BradleyScottEmalfarbMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:label="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DescendantTrustMember" xlink:label="dyai_DescendantTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IrrevocableTrustMember" xlink:label="dyai_IrrevocableTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_SeniorSecured2024NotesMember" xlink:label="dyai_SeniorSecured2024NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_TheFranciscoTrustMember" xlink:label="dyai_TheFranciscoTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ThirdPartyMember" xlink:label="dyai_ThirdPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:label="dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_TheFranciscoTrustMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_IrrevocableTrustMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_BradleyEmalfarbMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="dyai_ConversionOfConvertibleNotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="dyai_BradleyScottEmalfarbMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_DescendantTrustMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dyai_SeniorSecured2024NotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="dyai_ThirdPartyMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations" xlink:href="dyai-20241231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InterestIncomeNonoperating" xlink:label="dyai_InterestIncomeNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentMember" xlink:label="dyai_ResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="dyai_ResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_NonrelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="dyai_InterestIncomeNonoperating" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_InterestExpenseNonoperating-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dyai-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_IncreaseDecreaseInAccruedInterest" xlink:label="dyai_IncreaseDecreaseInAccruedInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:label="dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_VestingOfRestrictedStock" xlink:label="dyai_VestingOfRestrictedStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_NonrelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dyai_InvestmentIncomeAmortizationAccretionOfPremium" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="dyai_IncreaseDecreaseInAccruedInterest-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dyai_VestingOfRestrictedStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidTaxes" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_LegalExpensesPayableCurrent" xlink:label="dyai_LegalExpensesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_ResearchAndDevelopmentInProcessCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentInProcessCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_LegalExpensesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_AccruedResearchAndDevelopmentInProcessCurrent" xlink:label="dyai_AccruedResearchAndDevelopmentInProcessCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_AccruedResearchAndDevelopmentInProcessCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:href="dyai-20241231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:label="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-3" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:label="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-n1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-n1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:label="dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossAttributableToParent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:label="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:label="dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:href="dyai-20241231.xsd#statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance-3" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:label="dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:href="dyai-20241231.xsd#statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_BusinessConsultingExpense" xlink:label="dyai_BusinessConsultingExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther" xlink:label="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-1" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:label="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-1" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:label="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-1" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:label="dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LaborAndRelatedExpense-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_BusinessConsultingExpense-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees-1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized-n9" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense-1" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="dyai-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_NonrelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="dyai-20241231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:href="dyai-20241231.xsd#statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:label="dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:href="dyai-20241231.xsd#statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_CashCashEquivalentsAndInvestmentsFairValue" xlink:label="dyai_CashCashEquivalentsAndInvestmentsFairValue-3" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_ShortTermCorporateBondsMember" xlink:label="dyai_ShortTermCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="dyai-20241231.xsd#dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:label="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="us-gaap_HeldToMaturitySecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CashMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="dyai_ShortTermCorporateBondsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyai_CashCashEquivalentsAndInvestmentsFairValue-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>a01.jpg
<TEXT>
begin 644 a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  M #D# 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>d01.jpg
<TEXT>
begin 644 d01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !H 'P# 2(  A$! Q$!_\0
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&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>orgchart.jpg
<TEXT>
begin 644 orgchart.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
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MZ)]^T-_X2?PV_P#GLT?\0TX\_P"B7S/_ ,%T_P#Y:'^O?"'_ $/\!_X'/_Y
M_9*BOQM_X?@_LH?]$^_:&_\ "3^&W_SV:/\ A^#^RA_T3[]H;_PD_AM_\]FC
M_B&G'G_1+YG_ ."Z?_RT/]>^$/\ H?X#_P #G_\ ('[)45^-O_#\']E#_HGW
M[0W_ (2?PV_^>S1_P_!_90_Z)]^T-_X2?PV_^>S1_P 0TX\_Z)?,_P#P73_^
M6A_KWPA_T/\  ?\ @<__ ) _9*BOQM_X?@_LH?\ 1/OVAO\ PD_AM_\ /9H_
MX?@_LH?]$^_:&_\ "3^&W_SV:/\ B&G'G_1+YG_X+I__ "T/]>^$/^A_@/\
MP.?_ ,@?LE17XV_\/P?V4/\ HGW[0W_A)_#;_P">S1_P_!_90_Z)]^T-_P"$
MG\-O_GLT?\0TX\_Z)?,__!=/_P"6A_KWPA_T/\!_X'/_ .0/V2HK\;?^'X/[
M*'_1/OVAO_"3^&W_ ,]FC_A^#^RA_P!$^_:&_P#"3^&W_P ]FC_B&G'G_1+Y
MG_X+I_\ RT/]>^$/^A_@/_ Y_P#R!^R5%?C;_P /P?V4/^B??M#?^$G\-O\
MY[-'_#\']E#_ *)]^T-_X2?PV_\ GLT?\0TX\_Z)?,__  73_P#EH?Z]\(?]
M#_ ?^!S_ /D#]DJ*_&W_ (?@_LH?]$^_:&_\)/X;?_/9H_X?@_LH?]$^_:&_
M\)/X;?\ SV:/^(:<>?\ 1+YG_P""Z?\ \M#_ %[X0_Z'^ _\#G_\@?LE17XV
M_P##\']E#_HGW[0W_A)_#;_Y[-'_  _!_90_Z)]^T-_X2?PV_P#GLT?\0TX\
M_P"B7S/_ ,%T_P#Y:'^O?"'_ $/\!_X'/_Y _9*BOQM_X?@_LH?]$^_:&_\
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M::^P@Y58NU*HW&<(R48N3233?D5%=QX,\$7OBCXD^%/AMJ+W7AO4/$7CC0O
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M *L,K/T,HHHK^03^E@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!/[*?A?X6Z/\-]1T/QG\.OB@-/\ V;?'%]X5NK'Q(OC"Q\2^!]7\<ZQXJO\
MQ;J=KJ*V5BNM:;I=C_/E17S[\/DX5:;S7FIU</7PKIO"XJE35+%8#!Y?6:6$
MS7"S=2-' T(X:\W2I4ZF*IU*-=5J<J'M+C-J=.:R_EE3K4<0IK$8><W4H8S$
M8RE=XG+L1'DE5Q5:5>T%4J3CAYPJT72FJWZY7EY)):?\$=[.)[A--@\32WEE
M9SS+/]FDO?VF-/BF=I$AMXY+B6WL;&*XG2"!9OLL;"&, (MO4+NZ\5Q_\%:4
M\3^)YH()_C-\(H;O7==,NMV>DVNG?M8/X9T[4+VQNVF6\L?#/AZZGL[*QP([
M?1HWTFU6*R=K=OR"HKTEP<ER-9@HRABOK$9K!Q<E?C"'%DH+GQ$E>4H+!.4E
M)2DEBY0E;ZL<'^LTM4\&W%X?V$H/%2496X9?#D9M1HQ?NQ<L4E%IQ4GAHSC?
MVY_19J7P\\1:?XW_ &[KJY^#GC_4[O6_V8OCCHD'[3'Q)\0P7NH?'.2X\#>$
M'\!>'O@[X1\">&_AU\+6\()H7@V]\1G3_#7A/Q]KVB?8M(MKSQ;X<BMK?1;_
M ,JATC6'&C>+AH^JKX5U+_@BCXL\.Z;XE;3[H:!J&O>&OAI?1>(-&L=9\HZ=
M=ZKHK75H=5TZ"YDO-.6\M3>P0&XB#?A117F4> *U.'++.:<OW%'#>[EV(Y8T
MZ6"I85JG&MF]=44Y4:=2G1H\F%PU)/#4,/3IJ#AWU.,J<Y7CE<X_OJM;7&T;
MN=3%2Q"YY4LMHNJU&<X5*M7GQ%>HU7K5YSYU/]W])TOQ7J7[:GP4_:(\+SS6
M_P"QKH/P/\ PV_Q$MU"?"?P3\'- ^%LGASQW\*?%.K.B>']%UM_'T/B[3;[X
M=ZI=R>(TUK7[.Z_LT3W=J\?F:>)-1L[S_@CS:^'M4UC2=#_X32^N=.T^"_NK
M;[/;ZW^TE%H]XDHAN7WRWV@,-'U$M--]JL'GLYI)K>:59/QLHKJCP,N;"NIF
M-.I'!8*&748_V>HNIA:.5\09;1J8J3Q<OK&.DL_J5L3BE&E"O*@XQP]%XBI4
M7.^+7:OR8*<98G%3QM5_76U'$5<PR7'588=+#1]CA%_8T*5##MU)4554I5ZJ
MH0@_W,NOA]>KI>EW?A[X<>+?V@])A_:__:<E7POX<\0+\/?@W^S?XLT_XA>'
M=$T7QQ\<9?AEX;TWQWK>KCP[;)XITWQAXU^+'@3PYX.\%6]GIMDD&A0:K-?:
MG[=&BWNH>"?VR]&T+2;J^U+7/VY_@@FD:3I-A-<WVL7_ (A^!AGL$TVQLXGG
MU"[URXOXIK1;6*:;4IKV.2$3/<*7_!^M#2;Z/3-4TW4IM.T_6(M/U"SOI=)U
M9;I]+U2.TN(YWT[4DL;NPO7T^^6,VUXMG?6=TUO+(+>[MY2DR8TN!JU''83'
MO-U5E@IU*D*2P-6"K2EF^!S:*E%YH\)2DOJ2PLJF'PN'GB/:?6L9.OB%.I4T
MJ<64JN$Q&#_LUTUBHTZ<ZOUNG)TXQRW%9=)Q:R]8BI%_6G7C"MB*T*/)[##0
MI4'&$#5=*U30=4U+0]<TW4-&UK1M0O-*UC1]5L[G3M4TK5-.N)+/4--U+3[R
M.&[L=0L;N&:UO+.ZABN+6XBD@GC25&4?N7^T=K.JZ%KG_!7"]T;4+K3+N?P)
M^R#HTUS9S/!-)I7B*]^&WA_7=/=T(+6NK:)J>H:5?0GY+BQO+BWD!25@?Q(\
M9>*]7\=^+_%7CC7W@DU[QEXDUSQ7K<EK +:V?5_$.IW6KZD]M;*66W@:\O)F
MA@5BL496,$A<US=>_FF0SSFME>*Q%>GAZF"I4HU\/&@\12K36=\-YU5A&<JM
M)JFY9!+"+FISO'%^V:_<>QK>/E^<1RRECZ%&C.M#%5*CI5G5]C4IQ>59YE=.
M3C&G4O-+.%B'RSC:6&]DG^]]K2_=[PFBWGP\^#-MI&ISP_&;XB_\$R?B+\-?
MA.TFHV=GJFN^(;'XINVG^$_#FH731:@?%5[X4&NZ'X5T^TNPTEFUUI.GI!+-
M"LGY8>-O@Y^U#HV@^ _!/COP9\3$LM)T#Q[XS\%_#/5TO[[Q/X)\(6VIQ2^.
MO%=Q\,//N?%_PY\(:AJEC)J,NNZ_X<\/:!XAGL-6UC3+K419:M=Q?.%%895P
MWB,HKXBK1QV%KQQ.)JXJ2Q.62G6H5)SQ[I1PM>&84U1IT:6,5+E=*I*4?K7+
M*DL7RT=LQSRCF5&C3J83$494*%+#Q=#'1C2JPC#!JK+$4I8*;JU*M3"NKS*I
M!1;PZ<:CPW-5****^L/G HHHH *_LD_X)4?\F#_ ;_NJ/_JY_B)7\;=?V2?\
M$J/^3!_@-_W5'_U<_P 1*_#?'_\ Y(W+/^RFP?\ ZJLY/UKP;_Y*?'_]B'%?
M^K#*S]#****_D$_I8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *_FU^.G_!';]IGXG?&WXQ?$G0?'/P*M-"^(7Q4^(7CC1;35_$WQ M]6M=
M)\6>+=7U[3K?5(++X8W]G#J,-G?PQWL5I?WMM'<K*D%W<Q*DS_TE45]5PMQC
MG7!V(Q6)R6>'A5QE&%"N\1AXXB+ITY^TCRJ37*^;=K=:'SW$/#&5<3T</0S6
M%>=/"U9U:2H5I46ISAR2YFD^9<NR/Y8?^''W[5__ $4']GG_ ,*SXD__ #IJ
M/^''W[5__10?V>?_  K/B3_\Z:OZGJ*^U_XCCQY_T$99_P"&VG_\F?*_\0FX
M0_Y\X_\ \+I__(G\L/\ PX^_:O\ ^B@_L\_^%9\2?_G34?\ #C[]J_\ Z*#^
MSS_X5GQ)_P#G35_4]11_Q''CS_H(RS_PVT__ ),/^(3<(?\ /G'_ /A=/_Y$
M_EA_X<??M7_]%!_9Y_\ "L^)/_SIJ/\ AQ]^U?\ ]%!_9Y_\*SXD_P#SIJ_J
M>HH_XCCQY_T$99_X;:?_ ,F'_$)N$/\ GSC_ /PNG_\ (G\L/_#C[]J__HH/
M[//_ (5GQ)_^=-1_PX^_:O\ ^B@_L\_^%9\2?_G35_4]11_Q''CS_H(RS_PV
MT_\ Y,/^(3<(?\^<?_X73_\ D3^6'_AQ]^U?_P!%!_9Y_P#"L^)/_P Z:C_A
MQ]^U?_T4']GG_P *SXD__.FK^IZBC_B./'G_ $$99_X;:?\ \F'_ !";A#_G
MSC__  NG_P#(G\L/_#C[]J__ **#^SS_ .%9\2?_ )TU'_#C[]J__HH/[//_
M (5GQ)_^=-7]3U%'_$<>//\ H(RS_P -M/\ ^3#_ (A-PA_SYQ__ (73_P#D
M3^6'_AQ]^U?_ -%!_9Y_\*SXD_\ SIJXWXC?\$=OVF?AC\/?'?Q)U[QS\"KO
M0OA[X-\3^.-:M-(\3?$"XU:ZTGPGHE]KVHV^EP7OPQL+.;49K.PFCLHKN_LK
M:2Y:))[NVB9YD_K0KYY_:Z_Y-0_:>_[-Y^-/_JMO$M=N6^-7'&*S' 8:K7RU
MTL1C<+0J*.74XMTZM>G3FDU/1\LG9]'J<N.\+.$\/@L97IT<=[2AA<16A?&S
M:YZ=&<XW7+JN:*NNJ/YY_P#AQ]^U?_T4']GG_P *SXD__.FH_P"''W[5_P#T
M4']GG_PK/B3_ /.FK^IZBN+_ (CCQY_T$99_X;:?_P F=7_$)N$/^?./_P#"
MZ?\ \B?RP_\ #C[]J_\ Z*#^SS_X5GQ)_P#G34?\./OVK_\ HH/[//\ X5GQ
M)_\ G35_4]11_P 1QX\_Z",L_P##;3_^3#_B$W"'_/G'_P#A=/\ ^1/Y8?\
MAQ]^U?\ ]%!_9Y_\*SXD_P#SIJ/^''W[5_\ T4']GG_PK/B3_P#.FK^IZBC_
M (CCQY_T$99_X;:?_P F'_$)N$/^?./_ /"Z?_R)_+#_ ,./OVK_ /HH/[//
M_A6?$G_YTU'_  X^_:O_ .B@_L\_^%9\2?\ YTU?U/44?\1QX\_Z",L_\-M/
M_P"3#_B$W"'_ #YQ_P#X73_^1/Y8?^''W[5__10?V>?_  K/B3_\Z:C_ (<?
M?M7_ /10?V>?_"L^)/\ \Z:OZGJ*/^(X\>?]!&6?^&VG_P#)A_Q";A#_ )\X
M_P#\+I__ ")_+#_PX^_:O_Z*#^SS_P"%9\2?_G34?\./OVK_ /HH/[//_A6?
M$G_YTU?U/44?\1QX\_Z",L_\-M/_ .3#_B$W"'_/G'_^%T__ )$_EA_X<??M
M7_\ 10?V>?\ PK/B3_\ .FH_X<??M7_]%!_9Y_\ "L^)/_SIJ_J>HH_XCCQY
M_P!!&6?^&VG_ /)A_P 0FX0_Y\X__P +I_\ R)_+#_PX^_:O_P"B@_L\_P#A
M6?$G_P"=-1_PX^_:O_Z*#^SS_P"%9\2?_G35_4]11_Q''CS_ *",L_\ #;3_
M /DP_P"(3<(?\^<?_P"%T_\ Y$_EA_X<??M7_P#10?V>?_"L^)/_ ,Z:OWW_
M &*/@?XL_9O_ &9/AI\%_'&H>'M5\4>#/^$R_M2_\*7>I7V@3_\ "1?$#Q7X
MKLOL%UJ^DZ%J,OE:=KMI#=?:-*M=E['<QQ>? D5S-]3T5\WQ1XC<3<7Y?1RW
M.:N#GA:&,IXZFL/A(4)^WI4<1AXMSC)MQ]GB:J<=FW%]#W,@X(R+AK&5<=E=
M/$QQ%7#3PDW6Q,JT?8U*M&M)*+BDI<]"G:71774****^$/KPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KYY_:Z_Y-0_:>_[-Y^-/_JMO$M?0
MU?//[77_ ":A^T]_V;S\:?\ U6WB6O3R7_D<Y3_V,\!_ZE4C@S7_ )%>9?\
M8!C/_4>H?0U%%%>8=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\\_M=?\FH
M?M/?]F\_&G_U6WB6OH:OGG]KK_DU#]I[_LWGXT_^JV\2UZ>2_P#(YRG_ +&>
M _\ 4JD<&:_\BO,O^P#&?^H]0^AJ***\P[PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH?\ 1/OVAO\ PD_AM_\ /9K^6&BOW;_B!W ?_0/F?_ARJ?\ R!^1?\19XO\
M^?V _P#"&'_R1_4]_P /P?V4/^B??M#?^$G\-O\ Y[-'_#\']E#_ *)]^T-_
MX2?PV_\ GLU_+#11_P 0.X#_ .@?,_\ PY5/_D _XBSQ?_S^P'_A##_Y(_J>
M_P"'X/[*'_1/OVAO_"3^&W_SV:/^'X/[*'_1/OVAO_"3^&W_ ,]FOY8:*/\
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M?AN\\2:@_A[Q7H/@SQ"]QHT]N+FSN=-U"R;RWQ1^RW\4&\<^)O#6@?#6_P#
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MSHQ495,1^\QV&ER8>%6HZ=15%!QU/VL_X?@_LH?]$^_:&_\ "3^&W_SV:/\
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M $3[]H;_ ,)/X;?_ #V:/^'X/[*'_1/OVAO_  D_AM_\]FOY8:*/^('<!_\
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M]#****_GP_9PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_A5_:Z_P"3K_VGO^SAOC3_
M .K)\2U_=57\*O[77_)U_P"T]_V<-\:?_5D^):_H7Z/?_(YXA_[%F%_]2F?B
MWC3_ ,BO)?\ L/Q'_J.CYYHHHK^JS^> HHHH **** "BBB@ HHHH ^A?!GQ:
MT&+X!_$[X$>.X=?FTK5/$>A?%;X5ZEH=KIUX/#'Q6T6SG\-ZK#K5G=:AHDTW
MAGQUX,OWTK5]0CU#4KGP_J'A_P /:CIOAO5&DU!#9\._M9_'?POI_A6RTSQ3
MX?GN_ FB1^&O _BK7_AC\*_%GQ#\&:!;-?/INC^$OB=XJ\%:S\1/#>GZ&=2O
M1X:MM&\464?AA)_+\/#3(XXE3YQHKS)Y-EE5XCZQ@L/BH8G$O%SHXJA2Q-&&
M(GAZ>%JU*-.M"<:3K4J4?;*%E4G*K4DN>M5E/OCFF/IJA['%5\/.A06&A5P]
M6I0JRHQK3Q%.%2=.<745*I4?LG*[A%4X)\E*FH^O>!OCQ\5OAY_PF$7A_P 4
MK>:=\03#)X[\/>-- \,_$GPCXQO+;5(=;L]5\3>#?B-HWBKPIK>NV&K0+?Z;
MX@U'1KC6]-N);I[&_M_MMX)^J'[5OQXAO7O--\9V/AY/^$$\7?#:RTGPCX'^
M'W@[PSH/A'Q]+'-XTMO"GA+PKX5T?POX/UCQ/+##)K/BSPMI&C^+;UX8FEUP
MF--OSO15U,HRJM4G5JY9E]6K4M[2K4P6&G4G:DJ"YYRI.4K48QHKF;M2BJ?P
M)(F&99C3A&G3Q^-ITX?!3ABJ\(0_>.K[L8S48_O6ZFB7[QN?Q.YZ#\,?BGX]
M^#?BZT\=?#?7W\.>)[.QU?2TO3IVDZS:7&F:]IEUH^KZ=J.BZ_8:KH>K6-]I
M]Y/%)::IIMY;K+Y-W%''>6UM/#]'0?M!?#K3[S]E'P=;Z#K&L?!SX"S3>)_'
M.E>*O!W@O7]3^(?C7QIK4&M_%%9O"VL:GJO@^ZT&ZT^PTGP-X/DUF2?4-+T?
M3O\ A([F+^UKG^S8/C"BHQF48#'58UZ]%>VC3G3]K3485)*6&Q>$@ZE11]I4
M>'H9ACX8:,Y2IT7C,1.,.>?,JPN9XS"4W2HU7[)SC/V<W*5--5\-B9J--RY(
M>WJX+!RKRC%3JK#48N?+&SW]*\3:MH/BG3?&.@R6^CZYHNOV?B;1I;2SMI+7
M2]5T[48]4TZ2VL+R.ZLWM[*\AA:&TNH;FV:.)89XYHBRMW_B3X\_%?Q=H7C[
MPSXA\5?VAHGQ/^)T_P 9/'-E_8?ANT_MSXD7/]J>?XC^TV.CVUWIF_\ MG4O
M^)/H]QI^@K]I^32U\F#RO(:*ZJF#PE:I3JUL+AZM6ER>RJU:%.I4I^RJ1K4^
M2I.,IQ]G5A&K#E:Y:D8S5I),YX8K$TX3IT\17ITZG/[2G3JSA3G[2#ISYX1D
MHRYZ<I4Y73YH-P?NMH^A(/VJ?CQ!XBC\3GQQ'=WX^'>B_":\L-4\)^"=7\*Z
MY\._#NG_ -EZ)X5\4^!]5\-WG@OQ=8:;:[6MI/%&@:O>+>QPZFURVI0PW:<Y
MXO\ CS\3?'MQJ%QXOU3P_KBWOA;2_!5C8W/P^^'D6C^$/"VC>0=/T?X9Z%:^
M%8-%^%%O');^=-)\,[#PG<WMS<ZC=7TUQ<:KJ<MWX]16$,HRJE4A5IY9E].K
M3A&G"I#!8:%2%.#BX4X3C24HP@X0<8IJ,7&+23BK;3S+,:D)4YX_&SISE*<J
M<\57E"4Y)J4Y1<W%RDI24I--M2:;LV%%%%>@<04444 %%%% !1110 4444 %
M?V2?\$J/^3!_@-_W5'_U<_Q$K^-NO[)/^"5'_)@_P&_[JC_ZN?XB5^&^/_\
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MGE4<OG!I+GI2IU'=S;91117OGCA1110 4444 %%%% !1110 5_9)_P $J/\
MDP?X#?\ =4?_ %<_Q$K^-NO[)/\ @E1_R8/\!O\ NJ/_ *N?XB5^&^/_ /R1
MN6?]E-@__55G)^M>#?\ R4^/_P"Q#BO_ %896?H91117\@G]+!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OX5?VNO^3K_P!I[_LX
M;XT_^K)\2U_=57Y/_$;_ (([?LS?$[XA>._B3KWCGXZVFN_$+QEXG\<:U::1
MXF^']OI-KJWBS6[[7M1M]+@O?AC?WD.G0WE_-'917=_>W,=LL23W=S*KS/\
MK?A)QCDO!V8YOB<ZGB(4L9@J%"@\/AY8ANI3KNI)246N5<NSZO0_-_$CAC->
M)\%EM#*H49U,+BJM:K[>M&BE"=%0CRN2?,^;IT1_)?17]3W_  X^_90_Z*#^
MT-_X5GPV_P#G34?\./OV4/\ HH/[0W_A6?#;_P"=-7[M_P 1QX#_ .@C,_\
MPVU/_DS\B_XA-Q?_ ,^<!_X70_\ D3^6&BOZGO\ AQ]^RA_T4']H;_PK/AM_
M\Z:C_AQ]^RA_T4']H;_PK/AM_P#.FH_XCCP'_P!!&9_^&VI_\F'_ !";B_\
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MX@_$B.PN;A)KSP9I8\1Z=8:/XLTY+O1[O6Y+2YTV[O[-))H\WQ!\./%W[/\
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MT4XQBFH\E"I>71V74]DHHHK^?#]G"BBB@ HHHH **** "BBB@ HHHH ****
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M'_\ AUS3_P";#YY_X1K]J_\ Z+3^SS_XC#\2?_HNJ/\ A&OVK_\ HM/[//\
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M .BT_L\_^(P_$G_Z+JC_ (1K]J__ *+3^SS_ .(P_$G_ .BZKZ&HH_M;%?\
M/K+/_#+DW_S ']FX?_GYC_\ PZYI_P#-A\\_\(U^U?\ ]%I_9Y_\1A^)/_T7
M5'_"-?M7_P#1:?V>?_$8?B3_ /1=5]#44?VMBO\ GUEG_AER;_Y@#^S</_S\
MQ_\ X=<T_P#FP^>?^$:_:O\ ^BT_L\_^(P_$G_Z+JC_A&OVK_P#HM/[//_B,
M/Q)_^BZKZ&HH_M;%?\^LL_\ #+DW_P P!_9N'_Y^8_\ \.N:?_-A\\_\(U^U
M?_T6G]GG_P 1A^)/_P!%U1_PC7[5_P#T6G]GG_Q&'XD__1=5]#44?VMBO^?6
M6?\ AER;_P"8 _LW#_\ /S'_ /AUS3_YL/GG_A&OVK_^BT_L\_\ B,/Q)_\
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MK/\ M;%?\^LL_P##+DW_ ,P%_P!FX?\ Y^8__P .N:?_ #8?//\ PC7[5_\
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MU?\ ]%I_9Y_\1A^)/_T75'_"-?M7_P#1:?V>?_$8?B3_ /1=5]#44?VMBO\
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M3^SS_P"(P_$G_P"BZKZ&HH_M;%?\^LL_\,N3?_, ?V;A_P#GYC__  ZYI_\
M-AY7\"_'&K?$[X)?!WXDZ];Z=::[\0OA7\/?'&M6FD0W-OI-KJWBSPEI&O:C
M;Z7!>W=_>0Z=#>7\T=E%=W][<QVRQ)/=W,JO,_JE?//[(O\ R:A^S#_V;S\%
MO_5;>&J^AJSS6E3H9IF5&E!0I4<?C*5.$=H4Z>(J0A%>48I)>2+RZI.KE^!J
MU).=2I@\+4G-[RG.A"4I/SE)MOS84445P'8%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!\\_LB_\FH?LP_]F\_!;_U6WAJOH:OGG]D7_DU#]F'_ +-Y^"W_ *K;
MPU7T-7IYU_R.<V_[&>/_ /4JJ<&5?\BO+?\ L P?_J/3"BBBO,.\**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA_\ ('[)?\/P?VK_ /HGW[//_A)_$G_Y[-'_  _!_:O_ .B??L\_^$G\2?\
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M//\ X2?Q)_\ GLU^-M%'_$-. _\ HE\L_P#!=3_Y:'^O?%__ $/\?_X'#_Y
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MVK_^B??L\_\ A)_$G_Y[-?C;11_Q#3@/_HE\L_\ !=3_ .6A_KWQ?_T/\?\
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M_P#1/OV>?_"3^)/_ ,]FOQMHH_XAIP'_ -$OEG_@NI_\M#_7OB__ *'^/_\
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MJ/#YI0CF"KUXO"*4ZM3.I6X3I4JU"A&EBE1G4HPKUXXS#U,;"."PBPN)C[/
MU:M-+,_KU;$05? 5G@W2I-8EJ%.'U;XJ_9F^%WP?^-7PPT;7_@=^TOH&F?\
M#1?A#PE#??$;7O ?C/X/_%[P#K5U:S:!J/ASXD^'OA7IGAI->O?.L=6UKP$-
M,\:Z5J'A9?$.D7'B[0]?T\V\FW\=/@_^SOJVL?MQ?'[Q-H_Q@CD^&/[6.L>
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M5AX4_9!7XJ)\<)_'O[4'BWQEX(U6#P?XI\":%H?P[U'PS\8]9^%<&K?8=;\
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MB_\ )J'[,/\ V;S\%O\ U6WAJOYZ^D)_R)N'O^QGBO\ U%1^T^"W_(TSK_L
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MUG>>9F@B?/X"Z1\=OC?X?UCQ5XAT'XR?%71-?\=/%+XVUS2/B'XNTW6/&,D
MN5@D\5:G9ZO#>^(7A6\NQ$^K3W;1BZN0A GEW8NM?%+XF^)(?$EOXB^(OCO7
MK?QE=Z+?^+X-:\7>(-4A\5W_ (;M19>';WQ)%?:A.FNW>@60%IHMSJBW4VE6
MH%O8O!$-E14X#Q]9T.?'82G6I4ZL:N:4Z=669XJ=?/<BSF+KU9*+FLMAE57
MY>YU9_N98=\M!1J0=0XOPE+VO+A,3.E4G3<,OG.G' 4(T<JS7+7[*G%OE>/G
MCZ>+QRC"/[U5E>LY0DOK7]I/XH_M1>)O$7[2_P /?%A\:^(/A9X,^),2:YX;
MU?PO-K/@WX*0:+XNU+0?ARWA-KG3;NP^#5I>65T?"FE/X8N?#=IXMTC4#H]T
M=:BGMU7U']D'XL^+?@9^R5^T7\5?!-Q'!XA\'_&[]F^_AAN%WV.JV$TWCBRU
MG0=4BZS:3K^CW-]HVIQ*4E:QOI_(EAG$4T?P/XK^,OQ@\>>'M+\)>.?BM\2?
M&?A30YK2XT3PSXK\<^*/$7A[1[C3[&?3+"?2]%U?5+S3=/FLM-N;G3[26TMH
M7MK&XGM(62"62-N4M/%7BBP\/ZOX2L?$FO67A7Q!=Z;?Z_X9M-8U&V\/ZW?Z
M.9FTB]U?1H;A-.U*[TIKFX;3;F]MIIK$SS&U>(RON^AGPS'$Y'#)J^%RJA2>
M/RG$8JAA*$EA<70R_$9?4Q*KQ<*;J5L;2P<Z;YH6ITYTJ,YUE2=:IXL,^E0S
M6>9TL1F%6I]3S&CAZV(JKZQAJV,I8R-!TI*<U"GA:F)C-6E><XU*L8T_:*E#
M]UO$'PI^!\WP6^ 6N>%KVQ'[.7[2'_!1+X0?$6R\/Z@MF1X)T3Q/X'\0:'XX
M^$FO16#K;6D?A3Q!I>M^%4G4R6MGH+Z?++>ZBUK=WL_%?$SQ!HOC:;]L_P #
M_%GQ-^T)X[\%^!K[2I;C0/%GPH^'/P\\"?LNZKI7Q"L]%\!:E\--6U?]H+Q-
M)HNDW_ANXU7P9IWACP%\.'\1_$GP_J%MJ<6B:H=-EMI_Q@_X2WQ5_P (J/ O
M_"3>(/\ A"!X@/BT>#?[9U+_ (14>*FTY=';Q,/#WVG^R!X@;2%72CK(L_[1
M.G*MB;G[,!%74>+/C)\7O'F@:5X4\<_%3XD>,_"VA2VL^A^&O%GCCQ/XBT#1
MIK&RETVRFTK1M8U2\T[3I;/3IY["UDM+:%[>RFEM8BD$CQGQ*/ V/I5Z52><
M+$QIXN52%:M2C]:H48X_!8JC6IU72J5)8^>&P<,+BJ]&O@U6K4Z.*JNK2C4P
M-7UJO%N#J4IQCEGL'/#1IRI4JDEAZU26#Q.'JTITXU(0C@XU\1.OAZ52EB72
MISJX>FJ<Y0Q5/]L;SQ/\9+'XZ_\ !17X023ZO#\!/!'[(WQNF\#^!;*.YD^&
M'@7PQ:_"R'3OA3J?@G3F,FB>&+K7?"5]=^==>'Q:-XJDU#Q#?7PU&9;FYM[U
MGJ/ACP?\7OV9?@GX6\0?&WQ9\)O$O[/G@XZ;^SUX+^%GP[E^#GQW\,^(_A]J
MFM?$'QGXE\4>+/V@_ /AS4?%-_J9\2:_K_C#Q#X#L9_"6J:%$L3^7I,5[<?B
MBOQ\^.B^%8/ J_&GXLKX(MM'NO#MMX-7XC>,!X5M_#]]IUQH][H4'AX:S_9$
M6CWFD7EWI5UID=FME<:==7%C+ ]M/)$U#3?C-\8-&\%77PVTCXK?$K2OAU?0
MW]M>^ =-\=>*+'P5>6^J2/+J=O=>%K75(M"N(=1EDDDOXIK!X[R21WN%D9F)
MY7P!C7#E6*RZE_L=+!2ITL._95JM/+8Y?_;%;VE&I4681E!UHJA.CB%3Q%>A
M3S6C5Y<9+=<8X53YGA\=/_::F*C.I6_>4J<\<\9_9E)PJP@\$XR5*3JQJ4'.
MC2K3R^K3OA5^I?A_QUXK\*^!/^"5'@GP9XP\5:)X)\4_%GQ[;>(M(TW6YM+M
MO&FEZ?\ MAE=%M_&EKH&H/I'B6'34,UQI]I=S:KI>FW>H:I/I+A=1N9KCLO$
M^K:W\'KGQ)XCL_$7Q6\.W'QJ_;*_:;A\)Z#^RMIJ>&_BA\5/&G@WQVWACP5X
M0^,/QL\1>)-8LM"T%-?U^^;P=\-M"^#OC?3=0T^77-<U"QN-9UHRVGXQQ^._
M'$47@ZWB\9>*XX/AW<SWOP_AC\0ZND7@6\NM7_X2"YN_!T:W@3PQ<W&O@:W/
M/HBV,LNK_P#$RD=KW]]76:)\>?CEX9M_$EKX;^,WQ7\/VOC+5-2USQA;:)\1
M/%^E6_BO6M93R]7UCQ)#8:Q;QZ[JFJQ_N]2U#5%NKN^3Y;J:5>*[J_!%>=3V
ME.M@9QJXS-L1C:%6BX+'PS'.,TS*E&M55*LXU,.L;A;UE3E5Y\&H8>IAG*EB
M*')2XKHJ*C.EBXNGA<NH86K3J\SPD\%EN78&I*E3]I24H5G@\1:DYQI\N*<J
MU.O&-2A6_:G]J/7]6^"OA7_@H;?_  DO9_AQJ<7[4?P(;3M8\%R2>&]9T*X\
M1_#E=8\0WWAS5](:TU'P_J&NW-YJD&KWVCW-G<ZAIFMZ[I5U))IVLZC;7''_
M !(N-9TSP9\8_P!H+P7</:?M):U^Q5^Q+\3+KQQX<MDLO'=E;_$2WET?X\_$
M/0#I44<VB:G?V%EX>@\5>+]"M]-NM&TC5M0D^UV$6H7MS-^-FN_%7XH>*;;7
M++Q-\2/'OB.S\3WNBZEXEM-=\8>(=7MO$.H^&]-BT;P[?ZY!J&HW$6K7N@:/
M!#I.BW5^EQ/I6FPQ6-C)!:QI$)=.^+GQ6T?Q!H/BS2/B;\0M+\4^%?#]IX2\
M+^)=.\:>)+'Q!X;\*V%C)I=CX9T'6;;4HM1T?P_9:9--IUIHVGW-OIMM8RR6
MD-LEN[1GGPG 6)PV%PT)8O!UL52>#>+K2HU/^%&C@\+PW3G@,74:E4E@\;6R
M&K'$1FJT51Q?,Z%:49TY[XCC"A7Q%>2PV*IX>I'$K#TXU8_[#5Q.(SN<<9AH
M)QA'$X6GFT)47!TY.KA^55:<7&<?N[]O#7?''B?X(_L#^(?B-)>W/B_6O@5X
MCU+4-1U,R2:IKEG=>*XI="\1ZK=S237.IZIXE\/MI>OZEK-Y--?ZW?:E/J]_
M+)>7L[M%\0O''AGPA^Q?^PI'X@^#OPX^*;WVG_M)O:S^/-3^+NGRZ*MO\:+A
M98M-'PQ^*?PYAECOC+&]T=8AU:5&M8!926:-<K<?!/C+XD_$7XC2V-Q\0O'W
MC7QW/IG]H?V;-XR\4Z[XHET_^UKU]2U7[#)K=_?/:?VGJ,LE_J'D-']LO9'N
MKGS)W:0]=X3_ &BOV@O 6@V7A7P-\=?C'X+\+Z8;IM.\-^$_B=XV\.Z#I[7M
MW/J%Z;+1]'UNST^U-W?W5S>W1@MXS<7=Q/<R[YII';V:7#.)H99DF#A+#.IE
M6=YGFLJ.'Q.,RVA*EF$,^A##8;$X6G/$T%AUG%.UJ?+4AAY4FHQJ:>94S[#U
ML?FN)FL1R9CE. RZ-6M0PN.K*I@IY-*5>O0Q$XT*SK_V9.]YWA.M&HKRAK^J
MFN^.?"UE^W4/#/B_^U?#7A']M?\ 9Y^&G@+XT?#^]OYKJX^$/BSXM?#?0K'P
MIX8^R-;V,FGW7PXUBV\&_P!D?VWIEK?^&O#VIW:BTL+8BW7Y*_:ITB^_9Z^"
M?P6_9"O4BM?&<.H:M^T'\=K6"1+J*#Q_XNAF\,_#W0))Y)7N;6^\*?#6P6:]
MLHH;?3Y'\5I?P^?<7-PZ_!NJZMJFO:IJ6N:YJ6H:SK6LZA>:KK&L:K>7.HZI
MJNJ:C<27FH:EJ6H7DDUW?:A?7<TUU>7EU-+<75Q+)//(\KLQO^*/%?BGQQKV
MH>*?&GB37_%_B?5F@?5?$?BC6-1\0:]J3VUK!96SZAJ^K7-WJ%XUO96UM:0-
M<W$ABM;>"WC*Q11HKR_A*6!Q>45?KD:F%P&!P4,5A?9SMB,QRO"XC Y=BHRE
M4F_9TL)C:U.<:WM*SG@,IJ^U=3#SFYQO$:Q>&S*G]6<,1B\7BIT,1SQO0P68
M5Z.+QV'DHPBO:5,3A:=2+I<E)1QF8T_9J%:,5@4445]H?+!1110 4444 %?U
M/?\ !#[_ )-0^(/_ &<-XL_]5M\)J_EAK^I[_@A]_P FH?$'_LX;Q9_ZK;X3
M5^0>.'_)!XC_ +&>6_\ IR9^E^$W_)7T?^P#'?\ I$3]DJ***_BX_J4*_A5_
M:Z_Y.O\ VGO^SAOC3_ZLGQ+7]U5?PJ_M=?\ )U_[3W_9PWQI_P#5D^):_H7Z
M/?\ R.>(?^Q9A?\ U*9^+>-/_(KR7_L/Q'_J.CYYHHHK^JS^> HHHH ****
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MM9U9H=%73M$TA5O]6U"SAF@,O70_LC?$JT\8_&#PKXTUGP/\-].^!-GI5_\
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M//\ W2[_ -4Q\.Z_LDK^-O\ X*K_ /)_'QY_[I=_ZICX=U^Y> '_ "669_\
M9,XS_P!6N3'Y+XR?\DQ@/^Q]A?\ U7YH?GG1117]?'\TA1110 4444 %%%%
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M<XU'6C)U)N4:LG%RJQE>ZJ2<(-S3YFXQ;?NJWJ/A3XX?&KP'X>N_"/@?XO\
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MG\.FSO5@M^ L_CQX*\)>'?B+8?"_X7ZWX(UGXH>$[7PAXA^U_%'4/$W@G2K
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M#/W4RSF<XTJF%SF=1U8X;#U*J]BN_P!DKPO+X:^(DMAIGQ,T9O!?PM\2>/\
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M]DSC/_5KDQ^2^,G_ "3& _['V%_]5^:'YYT445_7Q_-(4444 %%%% !1110
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MO_Z*#^SS_P"%9\2?_G34?\1+X#_Z*C+/_!E3_P"5!_J)Q?\ ]"#'_P#@$/\
MY,_&VBOV2_X<??M7_P#10?V>?_"L^)/_ ,Z:C_AQ]^U?_P!%!_9Y_P#"L^)/
M_P Z:C_B)? ?_1499_X,J?\ RH/]1.+_ /H08_\ \ A_\F?C;17[)?\ #C[]
MJ_\ Z*#^SS_X5GQ)_P#G34?\./OVK_\ HH/[//\ X5GQ)_\ G34?\1+X#_Z*
MC+/_  94_P#E0?ZB<7_]"#'_ /@$/_DS\;:*_9+_ (<??M7_ /10?V>?_"L^
M)/\ \Z:C_AQ]^U?_ -%!_9Y_\*SXD_\ SIJ/^(E\!_\ 1499_P"#*G_RH/\
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M94_^5!_J)Q?_ -"#'_\ @$/_ ),_&VBOV2_X<??M7_\ 10?V>?\ PK/B3_\
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MH/[//_A6?$G_ .=-1_PX^_:O_P"B@_L\_P#A6?$G_P"=-1_Q$O@/_HJ,L_\
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M\&5/_E1^"_ZB<7_]"#'_ /@$/_DS\;:*_9+_ (<??M7_ /10?V>?_"L^)/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 26, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DYADIC INTERNATIONAL INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-55264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0486747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1044 North U.S. Highway One, Suite 201&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">743-8333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DYAI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,477,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,090,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Crowe LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Livingston, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,506,750<span></span>
</td>
<td class="nump">$ 6,515,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">2,756,577<span></span>
</td>
<td class="nump">748,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">24,248<span></span>
</td>
<td class="nump">10,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">237,027<span></span>
</td>
<td class="nump">466,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">303,066<span></span>
</td>
<td class="nump">327,775<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,827,668<span></span>
</td>
<td class="nump">8,067,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">92,211<span></span>
</td>
<td class="nump">141,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">10,396<span></span>
</td>
<td class="nump">10,462<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,930,275<span></span>
</td>
<td class="nump">8,219,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">482,320<span></span>
</td>
<td class="nump">656,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">970,462<span></span>
</td>
<td class="nump">1,057,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred research and development obligations</a></td>
<td class="nump">833,813<span></span>
</td>
<td class="nump">490,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">54,249<span></span>
</td>
<td class="nump">48,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,448,017<span></span>
</td>
<td class="nump">2,251,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">34,621<span></span>
</td>
<td class="nump">88,870<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,459,985<span></span>
</td>
<td class="nump">2,340,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 42,089,301 and 41,064,563, outstanding shares - 29,835,799 and 28,811,061 as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">42,090<span></span>
</td>
<td class="nump">41,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">107,444,595<span></span>
</td>
<td class="nump">105,044,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, shares held at cost - 12,253,502</a></td>
<td class="num">(18,929,915)<span></span>
</td>
<td class="num">(18,929,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(86,086,480)<span></span>
</td>
<td class="num">(80,277,321)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,470,290<span></span>
</td>
<td class="nump">5,878,585<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">9,930,275<span></span>
</td>
<td class="nump">8,219,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes, net of issuance costs</a></td>
<td class="nump">3,911,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">27,173<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes, net of issuance costs</a></td>
<td class="nump">$ 1,065,876<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued but unpaid interest on deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">42,089,301<span></span>
</td>
<td class="nump">41,064,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">29,835,799<span></span>
</td>
<td class="nump">28,811,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">12,253,502<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Research and development revenue</a></td>
<td class="nump">$ 3,495,389<span></span>
</td>
<td class="nump">$ 2,898,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of research and development revenue</a></td>
<td class="nump">1,194,624<span></span>
</td>
<td class="nump">1,975,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,044,253<span></span>
</td>
<td class="nump">3,297,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,134,773<span></span>
</td>
<td class="nump">5,817,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency exchange loss</a></td>
<td class="nump">22,561<span></span>
</td>
<td class="nump">38,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">9,396,211<span></span>
</td>
<td class="nump">11,128,545<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,900,822)<span></span>
</td>
<td class="num">(8,229,739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_InterestIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">456,992<span></span>
</td>
<td class="nump">416,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of Alphazyme</a></td>
<td class="nump">62,642<span></span>
</td>
<td class="nump">1,017,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">91,663<span></span>
</td>
<td class="nump">1,434,278<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,809,159)<span></span>
</td>
<td class="num">$ (6,795,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Basic and diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">29,318,123<span></span>
</td>
<td class="nump">28,798,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">$ (288,142)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(139,829)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Research and development revenue</a></td>
<td class="nump">1,605,220<span></span>
</td>
<td class="nump">2,545,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Research and development revenue</a></td>
<td class="nump">$ 1,890,169<span></span>
</td>
<td class="nump">$ 352,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_InterestIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income during the period, classified as nonoperating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_InterestIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">40,816,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 40,817<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">$ 103,458,697<span></span>
</td>
<td class="num">$ (73,481,860)<span></span>
</td>
<td class="nump">$ 11,087,739<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,253,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,244,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,244,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">247,961<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">341,938<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 342,186<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,795,461)<span></span>
</td>
<td class="num">$ (6,795,461)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">41,064,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 41,065<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">105,044,756<span></span>
</td>
<td class="num">(80,277,321)<span></span>
</td>
<td class="nump">$ 5,878,585<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,253,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,126,279<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,126,279<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">437,546<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,546<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">$ 437<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">339,897<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 340,334<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,809,159)<span></span>
</td>
<td class="num">$ (5,809,159)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">30,569<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 24,251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible debt (in shares)</a></td>
<td class="nump">556,623<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible debt</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">909,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">42,089,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 42,090<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">$ 107,444,595<span></span>
</td>
<td class="num">$ (86,086,480)<span></span>
</td>
<td class="nump">$ 2,470,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,253,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the following options exercised:


(a) 25,000 stock options exercised at $0.97, and (b) 30,000 stock options exercised at $1.36.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,809,159)<span></span>
</td>
<td class="num">$ (6,795,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,126,279<span></span>
</td>
<td class="nump">1,244,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_InvestmentIncomeAmortizationAccretionOfPremium', window );">Amortization of held-to-maturity securities, net</a></td>
<td class="num">(71,057)<span></span>
</td>
<td class="num">(53,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">63,021<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on investment in Alphazyme</a></td>
<td class="num">(60,977)<span></span>
</td>
<td class="num">(1,017,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange loss</a></td>
<td class="nump">22,561<span></span>
</td>
<td class="nump">38,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(14,165)<span></span>
</td>
<td class="nump">48,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">219,425<span></span>
</td>
<td class="num">(141,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">24,742<span></span>
</td>
<td class="nump">64,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease assets and liabilities, net</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="num">(4,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(180,182)<span></span>
</td>
<td class="num">(651,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">252,664<span></span>
</td>
<td class="nump">444,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred license revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,942)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred research and development obligations</a></td>
<td class="nump">343,700<span></span>
</td>
<td class="nump">449,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,974,806)<span></span>
</td>
<td class="num">(6,726,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of held-to-maturity investment securities</a></td>
<td class="num">(7,343,230)<span></span>
</td>
<td class="num">(2,995,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Proceeds from maturities of investment securities</a></td>
<td class="nump">5,406,000<span></span>
</td>
<td class="nump">9,148,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInvestmentProjects', window );">Proceeds from the sale of investment in Alphazyme</a></td>
<td class="nump">60,977<span></span>
</td>
<td class="nump">1,297,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(1,876,253)<span></span>
</td>
<td class="nump">7,449,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">24,251<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,848,577<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(5,796)<span></span>
</td>
<td class="num">(2,385)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(8,278)<span></span>
</td>
<td class="nump">720,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">6,515,028<span></span>
</td>
<td class="nump">5,794,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">6,506,750<span></span>
</td>
<td class="nump">6,515,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_VestingOfRestrictedStock', window );">Vesting of restricted stock units</a></td>
<td class="nump">340,334<span></span>
</td>
<td class="nump">342,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of convertible notes</a></td>
<td class="nump">910,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">257,778<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">156,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_IncreaseDecreaseInAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="nump">3,882,884<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_IncreaseDecreaseInAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">27,173<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="nump">$ 1,941,442<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_IncreaseDecreaseInAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total increase (decrease) in accrued interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_IncreaseDecreaseInAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_InvestmentIncomeAmortizationAccretionOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amortization (accretion) of premium on investment income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_InvestmentIncomeAmortizationAccretionOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_VestingOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cash flow effect of the vesting of restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_VestingOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInvestmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInvestmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">
   <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 79px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a href="#" id="Item9B_Other" title="Item9B_Other"></a>Item <em style="font: inherit;">9B.</em></b></p> </td><td style="vertical-align: top; width: 941px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Other Information</b></p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 23pt;"><b><i>Insider Trading Arrangements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">During the quarter ended <em style="font: inherit;"> December 31, 2024, </em><span style="-sec-ix-hidden:c125843306"><span style="-sec-ix-hidden:c125843837"><span style="-sec-ix-hidden:c125843856"><span style="-sec-ix-hidden:c125843857">none</span></span></span></span> of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) under the Exchange Act) adopted or terminated a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or a &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; (each as defined in Item <em style="font: inherit;">408</em>(a) and (c), respectively, of Regulation S-K).</p>
  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Cybersecurity Risk Management and Strategy</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item <em style="font: inherit;">106</em>(a) of Regulation S-K. These risks include, among other things, operational risks, the risk of intellectual property theft, fraud, harm to employees or <span style="-sec-ix-hidden:c125843295">third</span> parties with which we conduct business and violation of data privacy or security laws.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. We have established policies and controls for assessing, identifying and managing material cybersecurity risks and responding to material cybersecurity incidents.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We routinely assess material cybersecurity risks, including potential unauthorized occurrences on, or conducted through, our information systems that <em style="font: inherit;"> may </em>compromise the confidentiality, integrity or availability of those systems or information maintained in them. We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments when there is a material change in our business practices that we believe could affect information systems that are vulnerable to cybersecurity threats. These risk assessments include identifying reasonably foreseeable internal and external risks and the potential harm if the risks were to materialize. We conduct these risk assessments directly and also periodically engage <span style="-sec-ix-hidden:c125843297">third</span>-party providers to support these processes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Following these risk assessments, we evaluate how to appropriately implement and maintain reasonable safeguards to mitigate identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We have implemented cybersecurity tools, conducted employee training, and monitored emerging laws and regulations related to data protection and information security. We <em style="font: inherit;"> may </em>a<span style="background-color:#ffffff;">lso obligate&#160;certa</span>in <em style="font: inherit;">third</em>-party business partners to certify that they can implement and maintain appropriate security measures, consistent with all applicable laws, in connection with their work for us, and to promptly report any suspected breach of their security measures that <em style="font: inherit;"> may </em>affect the&#160;Company.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cybersecurity events and data incidents are evaluated, assessed based on severity and prioritized for response and remediation. Under our incident response policies, incidents are evaluated to determine materiality as well as operational and business impact and reviewed for privacy impact.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   We have not, to date, experienced a cybersecurity incident that was determined to be material, although, as a technology provider, we have experienced incidents in the past. Despite our cybersecurity efforts, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on our business. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to &#8220;Item 1A, Risk Factors&#8221; in this Annual Report on Form 10-K.
  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. We have established policies and controls for assessing, identifying and managing material cybersecurity risks and responding to material cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">We have not, to date, experienced a cybersecurity incident that was determined to be material, although, as a technology provider, we have experienced incidents in the past. Despite our cybersecurity efforts, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on our business. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to &#8220;Item 1A, Risk Factors&#8221; in this Annual Report on Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Cybersecurity Governance</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management team. Our board of directors has delegated responsibility to the Audit Committee for the oversight of risks from cybersecurity threats. Members of the Audit Committee receive regular updates from senior management, including leaders from our information technology, legal and compliance teams regarding matters of cybersecurity. This includes existing and new cybersecurity risks, information on how management is addressing and/or mitigating those risks, cybersecurity incidents (if any) and the status on key information security initiatives.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   Our Chief Executive Officer and Chief Financial Officer are principally responsible for overseeing the cybersecurity risk management program, in partnership with outside consultants, as well as managing and responding to material cyber incidents if any occur. Our CFO also serves as a board member at a cybersecurity and mobile IT solutions company. Although our CEO and CFO do not otherwise have cybersecurity expertise, their many years in Company management and risk oversight more generally position them well to oversee the cybersecurity risk management program, which they do in partnership with outside consultants. They provide periodic briefings to the Audit Committee and to the Board of Directors about our cybersecurity risks and activities, including cybersecurity incidents and responses, cybersecurity systems testing, third-party activities and related topics. In addition, our policies for managing and responding to cybersecurity incidents include procedures for appropriate escalations to our Audit Committee Chair.
  <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management team. Our board of directors has delegated responsibility to the Audit Committee for the oversight of risks from cybersecurity threats. Members of the Audit Committee receive regular updates from senior management, including leaders from our information technology, legal and compliance teams regarding matters of cybersecurity. This includes existing and new cybersecurity risks, information on how management is addressing and/or mitigating those risks, cybersecurity incidents (if any) and the status on key information security initiatives.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our Chief Executive Officer and Chief Financial Officer are principally responsible for overseeing the cybersecurity risk management program, in partnership with outside consultants, as well as managing and responding to material cyber incidents if any occur. Our CFO also serves as a board member at a cybersecurity and mobile IT solutions company. Although our CEO and CFO do not otherwise have cybersecurity expertise, their many years in Company management and risk oversight more generally position them well to oversee the cybersecurity risk management program, which they do in partnership with outside consultants. They provide periodic briefings to the Audit Committee and to the Board of Directors about our cybersecurity risks and activities, including cybersecurity incidents and responses, cybersecurity systems testing, third-party activities and related topics. In addition, our policies for managing and responding to cybersecurity incidents include procedures for appropriate escalations to our Audit Committee Chair.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">1:</em>&#160;&#160;&#160;&#160;&#160;Organization and Summary of Significant Accounting Policies</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Description of Business</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands, and it utilizes several <em style="font: inherit;">third</em>-party consultants and contract research organizations to carry out the Company&#8217;s activities. Over the past <em style="font: inherit;">two</em> plus decades, the Company developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and previously licensed this technology to <em style="font: inherit;">third</em> parties, such as Abengoa Bioenergy SA, BASF SE, Codexis, Inc. and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the <i>Thermothelomyces heterothallica </i>(formerly known as <i>Myceliophthora thermophila</i>) fungus, which the Company named <em style="font: inherit;">C1.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the past <em style="font: inherit;">nine</em> years since&#160;the Company sold its industrial technology business to Danisco USA (&#8220;Danisco&#8221;), the industrial biosciences business of DuPont (NYSE: DD) (the &#8220;DuPont Transaction&#8221;), the Company has been focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health and for other biologic products for use in non-pharmaceutical applications.&#160;As part of the DuPont Transaction, Dyadic retained co-exclusive rights to its proprietary and patented <em style="font: inherit;">C1</em> protein production platform (the <em style="font: inherit;">&#8220;C1</em> platform&#8221;) for use in all human and animal pharmaceutical applications, and currently, the Company has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions) for use in all human and animal pharmaceutical applications. Danisco retained certain rights to utilize the <em style="font: inherit;">C1</em> platform in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic <em style="font: inherit;"> may </em>owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or in licensed by Danisco.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">After the DuPont Transaction, the Company has directed its efforts toward&#160;advancing the <em style="font: inherit;">C1</em> platform to address the increasing global demand for the development and manufacturing of prophylactic and therapeutic biopharmaceuticals for human and animal health. The Company&#8217;s biopharmaceutical development efforts have been centered on enhancing the capability of the <em style="font: inherit;">C1</em> platform to produce stable, properly folded, and functional proteins for pharmaceutical applications, including vaccines and monoclonal antibodies. In addition to improving the quality and productivity of the <em style="font: inherit;">C1</em> platform, the Company has sought to validate its platform for human use through a series of fully funded biopharmaceutical projects, extensive animal studies utilizing <em style="font: inherit;">C1</em>-produced proteins, and&#160;in <em style="font: inherit;">2024,</em> the successful completion of a Phase <em style="font: inherit;">1</em> <em style="font: inherit;">first</em>-in-human study for a vaccine antigen produced using <em style="font: inherit;">C1,</em> which demonstrated&#160;its safety for human applications.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Recognizing the longer development timelines, clinical testing, and regulatory requirements associated with human and animal pharmaceutical products, the Company has refined its core business strategy to expand into recombinant (non-animal derived) alternative proteins for non-pharmaceutical applications in research, nutrition, and industrial markets. To address these opportunities, the Company has developed and launched the Dapibus&#8482; Protein Production Platform (&#8220;Dapibus&#8482;&#8221;), which supports various applications within the alternative proteins field, namely&#160;in Life Sciences, Food &amp; Nutrition, and Bioindustrial applications. Given the reduced developmental costs, shorter timelines, and fewer regulatory requirements associated with alternative proteins, Dapibus&#8482; has enabled the Company to generate near-term recurring revenue while continuing to build long-term value through <em style="font: inherit;">C1</em> for pharmaceutical applications. The Company anticipates achieving commercialization of certain alternative protein products in <em style="font: inherit;">2025</em> through a combination of existing collaborations and internal manufacturing efforts.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><span style="background-color:#ffffff;">Liquidity,&#160;Capital Resources, and Going Concern</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) <em style="font: inherit;">205</em>-<em style="font: inherit;">40,</em> Presentation of Financial Statements &#8211; Going Concern (&#8220;Topic <em style="font: inherit;">205</em>-<em style="font: inherit;">40&#8221;</em>), management is required to evaluate whether there are conditions and events, considered in the aggregate that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least <em style="font: inherit;">12</em> months from the issuance date of the Company&#8217;s condensed interim financial statements. This evaluation does <em style="font: inherit;">not</em> take into consideration the potential mitigating effect of management&#8217;s plans that have <em style="font: inherit;">not</em> been fully implemented or are <em style="font: inherit;">not</em> within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (<em style="font: inherit;">1</em>) it is probable that the plans will be effectively implemented within <em style="font: inherit;">one</em> year after the date that the financial statements are issued, and (<em style="font: inherit;">2</em>) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company expects to incur losses and have negative net cash flows from operating activities as it continues developing its microbial protein production platforms and related products, and as it expands its pipelines and engages in further research and development activities for internal products as well as for its&#160;<em style="font: inherit;">third</em>-party collaborators and licensees. The success of the Company depends on its ability to develop its technologies and products to the point of regulatory approval and subsequent revenue generation or through the sublicensing of the Company&#8217;s technologies and products, and its ability to raise capital to finance these developmental efforts.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On&#160;<em style="font: inherit;"> March 8, 2024,&#160;</em>the Company&#160;issued an aggregate principal amount of $6.0&#160;million of its&#160;8.0% Senior Secured Convertible Promissory Notes due&#160;<em style="font: inherit;"> March 8, 2027 (</em>the &#8220;Convertible Notes&#8221;) in a private placement. The purchasers of the Convertible Notes included immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than&#160;<em style="font: inherit;">5%</em>&#160;of the Company&#8217;s outstanding common stock, (collectively, the &#8220;Purchasers&#8221;).&#160;The net proceeds from the sale of the Convertible Notes, after deducting offering expenses, we<span style="background-color:#ffffff;">re&#160;$5,824,326. The</span> Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes are&#160;senior, secured obligations of Dyadic and its affiliates, and interest is&#160;payable quarterly in cash on the principal amount equal to&#160;8% per annum. The Convertible Notes will mature on&#160;<em style="font: inherit;"> March 8, 2027 (</em>the &#8220;Maturity Date&#8221;), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes can be&#160;converted&#160;into shares of Dyadic&#8217;s Class A common stock (the &#8220;Common Stock&#8221;), at the option of the holders of the Convertible Notes (the &#8220;Noteholders&#8221;) at any time prior to the Maturity Date.&#160;This private placement funding is expected to support our near-term revenue growth and accelerate our strategic objective of commercialization opportunities for pharmaceutical and non-pharmaceutical applications.&#160;On&#160;<em style="font: inherit;"> October 4, 2024,&#160;</em>the Company entered into an amendment (the &#8220;Amendment&#8221;) to the Convertible Notes. Pursuant to the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company&#8217;s common stock is changed from $1.79 to $1.40&#160;per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fall on any of the&#160;<em style="font: inherit;">26,</em>&#160;<em style="font: inherit;">29</em>&#160;and&#160;<em style="font: inherit;">32</em>-month anniversaries of the original issue date of the Convertible Notes, which are <em style="font: inherit;"> May 8, 2026, </em><em style="font: inherit;"> August 8, 2026 </em>and <em style="font: inherit;"> November 8, 2026.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restrictions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of&#160;<em style="font: inherit;"> December 31, 2024, </em>$910,000&#160;of the Convertible Notes have been converted into 556,623&#160;shares of Common Stock.&#160;For more information regarding the Convertible Notes, including the covenants related thereto<span style="background-color:#ffffff;">, see Note <em style="font: inherit;">5</em>&#160;to the Co</span>nsolidated Financial Statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, on <em style="font: inherit;"> November 16, 2024, </em>Dyadic entered into an agreement with the Bill &amp; Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;) relating to a grant in the amount of $3,092,136&#160;awarded from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company&#8217;s <em style="font: inherit;">C1</em> platform to provide globally accessible treatment options for underserved populations (the &#8220;Gates Foundation Grant&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2024, </em>the Company had $6,506,750 cash and $2,780,825 short-term investment securities (including accrued interest) on its balance sheet, totaling $9,287,575.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company expects its existing cash and cash equivalents, and cash raised from the Convertible Notes, or other debt instruments, and or other means, the Gates Foundation Grant, investments in debt securities, and operating cash flows will be sufficient to meet its operational, business, and other liquidity requirements for at least the next&#160;<em style="font: inherit;">twelve</em>&#160;(<em style="font: inherit;">12</em>) months from the date of issuance of the financial statements contained in this Annual Report. However, the Company has based this estimate on assumptions that&#160;<em style="font: inherit;"> may&#160;</em>prove to be wrong, and its operating plan&#160;<em style="font: inherit;"> may&#160;</em>change as a result of many factors currently unknown to it. In the event our financing needs are&#160;<em style="font: inherit;">not</em>&#160;able to be met by our existing cash, cash equivalents and investments, we would seek to raise additional capital through strategic financial opportunities that could include, but are&#160;<em style="font: inherit;">not</em>&#160;limited to, future public or private equity offerings, collaboration agreements,&#160;convertible notes and other debt instruments, and/or other means. Any amounts raised&#160;<em style="font: inherit;"> may&#160;</em>be used for the further development and commercialization of product candidates, and for other working capital purposes. There is&#160;<em style="font: inherit;">no</em>&#160;guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing shareholders.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -36pt; text-align: justify; text-indent: 36pt;"><b><i></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -36pt; text-align: justify; text-indent: 36pt;"><b><i>Basis of Presentation </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Dyadic consolidates entities in which we have a controlling financial interest. We consolidate our subsidiaries in which we hold and/or control, directly or indirectly, more than <em style="font: inherit;">50%</em> of the voting rights.&#160;All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Segment Information</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The CODM is the Company's senior management team that includes the Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer. The Company views its operations as and manages its business in <span style="-sec-ix-hidden:c125843372">one</span>&#160;operating segment, which is the business of developing and commercializing synthetic protein products using the Company&#8217;s proprietary microbial platforms, including <em style="font: inherit;">C1</em> and Dapibus&#8482;. Segment information is further described in Note <em style="font: inherit;">9</em> to the consolidated financial statements included in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Estimates inherent in the preparation of these consolidated financial statements include, but are <em style="font: inherit;">not</em> limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense,&#160;and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="background-color:#ffffff;">For the years&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s revenue was generated from&#160;</span><span style="-sec-ix-hidden:c125843379">19</span>&#160;<span style="background-color:#ffffff;">and&#160;<span style="-sec-ix-hidden:c125843380">16</span> customers, respectively. As of&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s accounts receivable was from <span style="-sec-ix-hidden:c125843382">nine</span>&#160;and <span style="-sec-ix-hidden:c125843383">thirteen</span> customers, respectively. Significant customers are those that account for greater than <em style="font: inherit;">10%</em> of the Company&#8217;s revenues. For the years&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843386"><span style="-sec-ix-hidden:c125843897">two</span></span> significant customers accounted for approximately $1,915,000 or 54.8% and $1,503,000 or 51.9%&#160;of revenue, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company&#8217;s customers could adversely affect its operations.</span></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company had <span style="-sec-ix-hidden:c125843393">eleven</span>&#160;</span><span style="font-size: 10pt;"><span style="background-color:#ffffff;">and <span style="-sec-ix-hidden:c125843394">six</span> customers outside of the United States (i.e., European and Asian customers) that accounted for&#160;approximately&#160;$1,526,000&#160;or 43.7% and&#160;</span></span>$537,000<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;or&#160;</span></span>18.5%<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;of total revenue, respectively.&#160;As of&#160;</span></span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="font-size: 10pt;"><span style="background-color:#ffffff;">, the Company&#160;had <span style="-sec-ix-hidden:c125843400">four</span> and&#160;</span></span><span style="-sec-ix-hidden:c125843401">six</span><span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;customers outside of the United States (i.e., European and Asian customers) that accounted for approximately $146,000 or 61.5% and&#160;</span></span>$213,000<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;or </span></span>45.6%<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;of&#160;accounts receivable, respectively.</span></span></p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company uses CROs&#160;to conduct its research projects and manage its clinical trial. For&#160;the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843407">two</span> and <span style="-sec-ix-hidden:c125843408">three</span> CROs&#160;accounted for approximately $2,389,000&#160;or 93.0% and $4,644,000&#160;or 96.0%&#160;of total research serv</span>ices we purchased, respectively. As of&#160;<em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843413">two</span>&#160;CROs accounted for approximately&#160;$284,000 or 58.9%&#160;of ac</span>counts payable. As of&#160;<em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843416">three</span>&#160;CROs accounted for approximately&#160;$620,000 or 94.4%&#160;of accounts payable. The loss of business from <em style="font: inherit;">one</em> of these CROs or a combination of them could adversely affect the Company's operations.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We treat highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.&#160;The Company has no restricted cash balances as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><em style="font: inherit;"></em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Investment Securities</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months or less, and long-term investment securities mature over <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months from the applicable reporting date. Management determines the appropriate classification of each investment&#160;at the time of purchase and reevaluates the classifications at each balance sheet date.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company classifies its&#160;investments in debt securities as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than <em style="font: inherit;">not</em> the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. The Company measures expected credit losses on held to maturity debt securities on an individual security basis. The estimate of expected credit losses considers historical credit information from external sources. The impairment of the investment that is related to the credit loss, if any,&#160;is expensed in the period in which the event or change occurred.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>, all of our money market funds were invested in U.S. Government money market funds. The Company did <em style="font: inherit;">not</em> have any investment securities classified as trading as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accounts Receivable</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company&#8217;s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances&#160;and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company&#8217;s evaluation of current and expected future economic conditions and changes in our customer collection trends. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. Management determined that&#160;no allowance for credit losses was required as of&#160;<em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
      <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">173,993</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">410,617</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,034</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,542</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">237,027</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">466,159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Prepaid Expenses and Other Current Assets</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">182,270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">209,888</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117,560</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,236</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <div>
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">327,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </div>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accounts Payable</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts payable consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">340,698</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">575,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">68,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,957</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,202</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <div>
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">482,320</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">656,445</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </div>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accrued expenses consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">496,905</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">561,720</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">437,196</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">274,080</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">25,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">210,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,462</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,057,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Revenue Recognition </i></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has <em style="font: inherit;">no</em> products approved for sale. All our revenue to date has been research revenue from <em style="font: inherit;">third</em>-party collaborations and government grants, as well as revenue from sublicensing&#160;agreements and collaborative arrangements, which <em style="font: inherit;"> may </em>include upfront payments,&#160;options to obtain a license, payment for research and development services,&#160;milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest).</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to research collaborations and agreements:</i>&#160;The Company typically&#160;performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the <em style="font: inherit;">5</em>-step process outlined in ASC Topic <em style="font: inherit;">606</em> (&#8220;Topic <em style="font: inherit;">606&#8221;</em>): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic <em style="font: inherit;">606</em> to measure the progress toward complete satisfaction of a performance obligation.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under the input method, revenue will be recognized based on the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and <em style="font: inherit;">third</em>-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i><span style="background-color:#ffffff;">Revenue related to grants: </span></i><span style="background-color:#ffffff;">T</span>he Company <em style="font: inherit;"> may </em>receive&#160;grants&#160;from governments, agencies, and other private and <em style="font: inherit;">not</em>-for-profit organizations. These grants are intended to be used to partially or fully fund the Company&#8217;s research collaborations<span style="background-color:#ffffff;">.</span> However, most, if <em style="font: inherit;">not</em> all, of such potential grant revenues, when&#160;received, is expected to be earmarked for <em style="font: inherit;">third</em> parties to advance the research required, including preclinical and clinical trials.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Customer options: </i>If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate&#160;if such&#160;options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i><span style="background-color:#ffffff;">Milestone payments: </span></i><span style="background-color:#ffffff;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which the<i> </i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all&#160;the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <em style="font: inherit;">not</em> recognized any royalty revenue resulting from any of its sublicensing arrangements.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We invoice customers based on our contractual arrangements with each customer, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are <em style="font: inherit;">not</em> required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of <em style="font: inherit;">one</em> year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. The Company does&#160;<em style="font: inherit;">not</em>&#160;recognize leases with terms of&#160;<em style="font: inherit;">twelve</em>&#160;months or less on the balance sheet. Options to extend or terminate a lease are&#160;<em style="font: inherit;">not</em>&#160;included in the Company&#8217;s initial lease term assessment, unless there is&#160;reasonable&#160;certainty that the Company will exercise any such option. Leases are classified as either finance leases or operating leases based on criteria in Accounting Standards Codification (&#8220;ASC&#8221;)&#160;<em style="font: inherit;">842.</em>&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For operating leases, right-of-use assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses an estimated rate of interest that they would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating lease right-of-use asset also includes any lease payments made and excludes any lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s&#160;prior lease for its corporate headquarters located at&#160;<em style="font: inherit;">140</em>&#160;Intracoastal Pointe Dr. expired on&#160;<em style="font: inherit;"> August 31, 2023,&#160;</em>and there was&#160;<em style="font: inherit;">no</em>&#160;right-of-use asset or lease liability recognized for this lease due to its short-term nature. In&#160;<em style="font: inherit;"> August&#160;</em><em style="font: inherit;">2023,</em>&#160;the Company entered into a new lease (<em style="font: inherit;">&#8220;1044</em>&#160;N Lease&#8221;) for&#160;office space for its new corporate headquarters located at&#160;<em style="font: inherit;">1044</em>&#160;N US&#160;<em style="font: inherit;">1,</em>&#160;Jupiter, Florida, commencing&#160;<em style="font: inherit;"> September 1, 2023 (</em>&#8220;Commencement Date&#8221;) and expiring&#160;on <em style="font: inherit;"> August 31, 2026. </em>Rent is subject to <em style="font: inherit;">three</em>&#160;percent (3%) annual increases, and the Company is responsible for certain common area maintenance charges and taxes throughout the life of the&#160;<em style="font: inherit;">1044</em>&#160;N Lease. The&#160;<em style="font: inherit;">1044</em>&#160;N Lease has an initial term of&#160;<em style="font: inherit;">three</em>&#160;(3) years, following the Commencement Date with an option to extend for&#160;<em style="font: inherit;">two</em>&#160;(2) successive&#160;<em style="font: inherit;">one</em>&#160;(1) year terms. The options were&#160;<em style="font: inherit;">not</em>&#160;included in the lease term used in determining the right-of-use asset or lease liability as the Company did&#160;<em style="font: inherit;">not</em>&#160;consider it reasonably certain they would exercise the options.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For<span style="background-color:#ffffff;"> the years ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s total operating lease expense was&#160;</span>$106,785&#160;and $71,656, <span style="background-color:#ffffff;">respectively. As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the Company&#8217;s total operating lease liabilities was $</span>88,870, <span style="background-color:#ffffff;">which is presented net of imputed interest o</span>f $6,669, and the&#160;oper<span style="background-color:#ffffff;">ating lease right-of-use&#160;asset was&#160;</span>$92,211.&#160;As of <em style="font: inherit;"> December 31, 2023, </em>the Company&#8217;s total operating lease liabilities was $136,929, which is presented net of imputed interest of $16,770, and the operating lease right-of-use asset was $141,439.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff">, the </span>weighted average remaining lease term was&#160;1.7&#160;years, and the weighted average discount rate was 8.8%.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><em style="font: inherit;"></em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 27pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Research and Development Costs</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are related to the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,503,397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,677,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">473,444</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">553,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,412</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">65,584</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <div>
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,044,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,297,266</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </div>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Foreign Currency Transaction Gain or Loss</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure&#160;the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Fair Value Measurements </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into <em style="font: inherit;">three</em> levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">1</em> &#8211; Quoted prices in active markets for identical assets or liabilities.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;">Level <em style="font: inherit;">2</em> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;">Level <em style="font: inherit;">3</em> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#8217;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the <em style="font: inherit;">third</em>-party broker service for disclosure purposes.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Income Taxes</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than <em style="font: inherit;">not</em> some portion or all the deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company is required to evaluate the provisions of ASC <em style="font: inherit;">740</em> related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements. ASC <em style="font: inherit;">740</em> prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-<em style="font: inherit;">not</em> to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was <em style="font: inherit;">not</em> recognized as a result of applying the provision of ASC <em style="font: inherit;">740.</em></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><em style="font: inherit;"></em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i><span style="background-color:#ffffff;">Comprehensive Income (Loss)</span></i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under U.S. GAAP. The Company does <em style="font: inherit;">not</em> have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does <em style="font: inherit;">not</em> separately present a statement of comprehensive income (loss) in its consolidated financial statements.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We recognize all share-based payments to employees, consultants, and our Board of Directors (the &#8220;Board&#8221;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock, restricted stock units and convertible debt, were exercised and&#160;converted into common stock, calculated by applying the treasury stock method.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">For the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the effect of the potential exercise of options to purchase&#160;</span>5,788,597<span style="background-color:#ffffff;">&#160;and </span>5,469,247<span style="background-color:#ffffff;">&#160;shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>New and Recently Adopted Accounting Pronouncements</i></b>&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> November 2023, </em>the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (the &#8220;ASU&#8221;) <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> &#8211; Segment Reporting (Topic ASC <em style="font: inherit;">280</em>), or ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosure about significant segment expenses. The enhancements under this update require disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss, require disclosure of <i>other segment items </i>by reportable segment and a description of the composition of <i>other segment items</i>, require annual disclosures under ASC <em style="font: inherit;">280</em> to be provided in interim periods, clarify use of more than <em style="font: inherit;">one</em> measure of segment profit or loss by the CODM, require that the title of the CODM be disclosed with an explanation of how the CODM uses the reported measures of segment profit or loss to make decisions, and require that entities with a single reportable segment provide all disclosures required by this update and required under ASC <em style="font: inherit;">280.</em> ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for public business entities for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company adopted ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> and applied the guidance retrospectively to all periods presented in the consolidated financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> &#8211; Income Taxes (Topic ASC <em style="font: inherit;">740</em>) Income Taxes. The ASU improves the transparency of income tax disclosures by requiring (<em style="font: inherit;">1</em>) consistent categories and greater disaggregation of information in the rate reconciliation and (<em style="font: inherit;">2</em>) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> will become effective beginning with our <em style="font: inherit;">2025</em> fiscal year. We do <em style="font: inherit;">not</em> expect that this guidance will have a material impact on our financial position and our results of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Cash, Cash Equivalents, and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">2:</em>&#160;&#160;&#160;&#160;&#160;Cash, Cash Equivalent, and Investments </b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost,&#160;net of allowance for credit losses, and its investments in money market funds are classified as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. The following table shows the Company&#8217;s cash, available-for-sale securities, and investment securities by major security type as&#160;of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2024</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">926,287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">926,287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,580,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,580,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,506,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,506,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,756,428</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(149</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,756,577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,263,178</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(149</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,263,327</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2023</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" rowspan="1" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,489,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,489,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,515,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,515,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">748,105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(185</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">748,290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,263,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(185</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,263,318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notes:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(<em style="font: inherit;">1</em>) Definition of the <em style="font: inherit;">three</em>-level fair value hierarchy:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:14pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">1</em> - Quoted prices (unadjusted) in active markets for identical assets or liabilities</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:14pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">2</em> - Other inputs that are directly or indirectly observable in the markets</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:14pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">3</em> - Inputs that are generally unobservable</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">(<em style="font: inherit;">2</em>) Short-term investment securities will mature within <em style="font: inherit;">12</em> months or less, from the applicable reporting date.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">(<em style="font: inherit;">3</em>) For the&#160;years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>,&#160;the Company received discounts of<span style="background-color:#ffffff;">$78,770&#160;and $39,012 to purchase held-to-maturity investment securities,&#160;</span>respectively.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company considers declines in market value of its investment portfolio to be temporary in nature. The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than <em style="font: inherit;">not</em> the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. As of <em style="font: inherit;"> December 31, 2024</em>, the Company does <em style="font: inherit;">not</em> consider any of its investments to be other-than-temporarily impaired.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">3:</em>&#160;&#160;&#160;&#160;&#160;Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 17pt;"><b><i>Gates Foundation Grant</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> November 2024, </em>Bill &amp; Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;) awarded the Company a grant in the amount of $3,092,136 for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company&#8217;s <em style="font: inherit;">C1</em> platform to provide globally accessible treatment options for underserved populations (the &#8220;Gates Foundation Grant&#8221;).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> December 2024,&#160;</em>the Company received approximately $0.8 million of the Gates Foundation Grant, and the remaining award will be received in <em style="font: inherit;">2025</em> and <em style="font: inherit;">2026</em> in the amount of approximately $1.5 million and $0.7 million, respectively. For the year ended <em style="font: inherit;"> December 31, 2024, </em>the Company has <span style="-sec-ix-hidden:c125843554">not</span> recognized any research and development revenue, in connection with the Gates Foundation Grant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Proliant</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On&#160;<em style="font: inherit;"> June 27, 2024</em><i>,</i>&#160;the Company entered into a License and Development Agreement (the &#8220;Proliant Agreement&#8221;) with Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals (&#8220;Proliant&#8221;), pursuant to which, Proliant will license Dyadic&#8217;s proprietary fungal microbial expression and production platforms and microbial strains for the production of recombinant serum albumin, for an initial period of 10 years with an option to extend for an additional 3 years under certain circumstances. &#160;Under the terms of the Proliant Agreement, Dyadic has received an initial upfront payment of $500,000, a&#160;<em style="font: inherit;">second</em>&#160;payment of $500,000 for&#160;completing&#160;the transfer of a Production Strain (as defined in the Proliant Agreement) and will receive a final payment of $500,000&#160;upon the meeting of a certain productivity threshold. Upon commencing commercial sales of&#160;animal-free recombinant serum albumin products produced pursuant to the Proliant Agreement, the Company will receive royalties based on a certain percentage of the gross margin received by Proliant, as defined in the Proliant Agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended&#160;<em style="font: inherit;"> December 31, 2024</em>, the Company recognized a total of $1.0&#160;million in license revenue&#160;related to the Proliant Agreement, as the performance obligations&#160;for the <em style="font: inherit;">first</em> and <em style="font: inherit;">second</em> payments have been satisfied.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Inzymes ApS</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> September 18, 2023, </em>Dyadic International (USA) Inc., a subsidiary of the Company, signed a Development and Exclusive License Agreement (the &#8220;Inzymes Agreement&#8221;) with Inzymes ApS (&#8220;Inzymes&#8221;), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic&#8217;s proprietary Dapibus&#8482; platform. In <em style="font: inherit;"> October 2023, </em>the Company received an upfront payment of $0.6 million in accordance with the terms of the Inzymes Agreement.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> October 11, 2024, </em>the Inzymes Agreement was amended (&#8220;the Amended Inzymes Agreement&#8221;) to&#160;change the scope of research and development services required under the agreement as well as adjust the success fees&#160;upon the achievement of certain target yields, milestone payments upon <em style="font: inherit;">first</em> commercial sale of each product and royalties.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended&#160;<em style="font: inherit;"> December 31, 2024</em>, the Company has completed all product research and development services and satisfied all related performance obligations under the Amended Inzymes Agreement, and recognized $890,169 in license revenues, including success fees upon the achievement of target yield of <em style="font: inherit;">one</em> related product. For the year ended <em style="font: inherit;"> December 31, 2024, </em>the Company also recognized research and development revenues of $25,000 related to the Amended Inzymes Agreement.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company will continue evaluating the achievement of milestones related to target yields and product commercialization of each product when they are considered probable and estimable under the Inzymes Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;"><b><i>A Global Food Ingredient</i></b>&#160;<b><i>Company</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> May 10, 2022, </em>the Company entered into a Joint Development Agreement (the &#8220;JDA&#8221;) with a Global Food Ingredient Company (&#8220;GFIC&#8221;) to develop and manufacture several&#160;animal free ingredient products using the Company&#8217;s biotechnologies.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under&#160;the initial terms of the JDA, Dyadic was to develop its proprietary production cell lines for the manufacture of animal free ingredient product candid<span style="background-color:#ffffff;">ates. As of <em style="font: inherit;"> December 31, 2023, </em>th</span>e GFIC has completed its <em style="font: inherit;">one</em>-year funding commitment for the initial phase of research collaboration in an amount approximatin<span style="background-color:#ffffff;">g&#160;<em style="font: inherit;">$1.35</em> million, and, pu</span>rsuant to the GFIC&#8217;s rights under the JDA, the Company and&#160;the GFIC are conferring to decide whether or <em style="font: inherit;">not,</em> and if it is possible, to&#160;move forward to the next phase of the proj<span style="background-color:#ffffff;">ect. The Company is also considering other funding sources to continue the project.&#160;</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the years ended<span style="background-color:#ffffff">&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>, the Company recorded research and development revenues, including milestone payments, of&#160;<span style="background-color:#ffffff;">$0 and </span>approximately <span style="background-color:#ffffff;">$631,000, respectively, in c</span>onnection with the&#160;JDA.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;"><i><b>Janssen</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; text-indent: 18pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; text-indent: 36pt; margin: 0pt;">On <em style="font: inherit;"> December 16, 2021, </em>the Company entered&#160;a Research, License, and Collaboration Agreement (the &#8220;Janssen Agreement&#8221;) for the manufacture of therapeutic protein candidates using its <em style="font: inherit;">C1</em> platform with Janssen Biotech, Inc., <em style="font: inherit;">one</em> of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (&#8220;Janssen&#8221;).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><span style="background-color:#ffffff;">On <em style="font: inherit;"> October 2, 2023, </em>Janssen provided written notice to Dyadic that it has decided to wind down the collaboration with an effective end date of <em style="font: inherit;"> December 31, 2023.</em></span></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the year ended&#160;<em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">,&#160;</span>there were no revenues related to the Janssen Agreement. For the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company recognized approximately $353,000 in license revenue and approximately $520,000 in research and development revenues in connection with the Janssen Agreement.<span style="background-color:#ffffff;">&#160;As of&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, $0</span><span style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="background-color:#ffffff;">&#160;an</span></span><span style="background-color:#ffffff;">d approximately $145,000&#160;of&#160;accounts receivable&#160;were related to Janssen, respectively.&#160;&#160;</span></p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Alphazyme</i></b></p>
   <p style="text-align: left; margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;">2019</em> the Company entered into a sub-licensing agreement with Alphazyme, LLC (&#8220;Alphazyme&#8221;) that was subsequently amended (the &#8220;Amended Alphazyme LLC Agreement&#8221;). Under the Amended Alphazyme LLC Agreement,&#160;Alphazyme obtained additional capital contribution&#160;and Dyadic&#8217;s ownership was diluted to 1.99%.&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of Alphazyme as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investment&#160;in Alphazyme. The Company reports&#160;its investment in Alphazyme under the cost method of accounting, given that it does <em style="font: inherit;">not</em> have the ability to exercise significant influence or control over Alphazyme.&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">On <em style="font: inherit;"> January 18, 2023, </em>the Company entered into a Securities Purchase Agreement, under which the Company agreed to sell its equity interest in Alphazyme, LLC (the &#8220;Alphazyme Sale Agreement&#8221;). The Company continues to have&#160;the potential to receive additional payments based on the future sales of Alphazyme&#8217;s existing products, pursuant to the Alphazyme Sale Agreement.</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>


   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">The Amended Sublicense Agreement between Dyadic and Alphazyme, which was previously entered on <em style="font: inherit;"> June 24, 2020, </em>remains in effect. Under the Amended Alphazyme Sub-License Agreement, Dyadic is entitled to potential milestone and royalty payments upon the commercialization of Alphazyme products using Dyadic&#8217;s proprietary <em style="font: inherit;">C1</em> platform.&#160;</p>
   <p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended <em style="font: inherit;"> December 31, 2024, </em>there were no revenues related to Alphazyme. For the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company recognized a total revenue of approximately $1.3 million from the sale of its equity interest in Alphazyme, LLC.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">4:</em>&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Leases</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b><i>Jupiter&#160;Florida Headquarters</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">In&#160;<em style="font: inherit;"> August&#160;</em><em style="font: inherit;">2023,</em>&#160;the Company entered into a new lease comprising approximately&#160;1,719&#160;square feet of office space located at&#160;<em style="font: inherit;">1044</em>&#160;N US&#160;<em style="font: inherit;">1,</em>&#160;Jupiter, Florida, commencing&#160;<em style="font: inherit;"> September 1, 2023,&#160;</em>and will expire on <em style="font: inherit;"> August 31, 2026. </em>The Company occupies this space for an annual rental rate of approximately $59,000, excluding common area maintenance expenses.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>The Netherlands Office</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies a flexible office space for an annual rental rate of approximatel<span style="background-color:#ffffff;">y $4,600. The lease expires on <em style="font: inherit;"> January 31, 2026, </em>and thereafter, the Company will reconsider the leased space to align with the future operations of the Company.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the future minimum annual lease payments under the operating leases are below. There are <em style="font: inherit;">no</em> future minimum annual lease payments after <em style="font: inherit;">2026.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">59,901</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">35,638</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">95,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="text-align: left; text-indent: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <div style="font-size:10pt">
    <div style="font-family:'Times New Roman', Times, serif">
     <b><i>&#160; &#160; &#160; &#160;Purchase Obligations</i></b>
    </div>
   </div>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Purchase obligations are primarily related to our contracts with the Company&#8217;s contract research organizations to provide certain research services. The contracts set forth the Company&#8217;s minimum purchase requirements that are subject to adjustments based on certain performance conditions.&#160;</p>
   <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="background-color:#ffffff">As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the commitments related to agreements to purchase certain services in the ordinary course of business are below. All current contracts expire in or before <em style="font: inherit;">2026.</em></span></p>
   <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,134,460</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,429,044</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,563,504</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate.&#160;The Company is <em style="font: inherit;">not</em> currently involved in any litigation that it believes could have a materially adverse effect in our financial condition or results of operations. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of <em style="font: inherit;">one</em> or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#8217;s consolidated financial position, cash flows or results of operations.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConvertibleDebtTextBlock', window );">Convertible Debt [Text Block]</a></td>
<td class="text">
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note</b> <b><em style="font: inherit;">5:</em></b>&#160;&#160;&#160; <b>Convertible Notes&#160;</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On&#160;<em style="font: inherit;"> March 8, 2024,&#160;</em>the Company issued senior secured convertible promissory notes (the &#8220;Convertible Notes&#8221;) with an aggregate principal amount of $6.0&#160;million, of which,&#160;<span style="-sec-ix-hidden:c125843609">$2.0</span>&#160;million were sold to related parties, including immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Convertible Notes are senior, secured obligations of the Company and its affiliates, and interest is payable quarterly in cash on the principal amount equal to&#160;8% per annum, and guaranteed by its subsidiary, Dyadic International (USA), Inc. under a subsidiary guarantee for the benefit of the holders of the Convertible Notes (each such holder, a &#8220;Holder&#8221;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Convertible Notes mature on&#160;<em style="font: inherit;"> March 8, 2027,&#160;</em>unless earlier converted or redeemed in accordance with the terms of the Convertible Notes. The Convertible Notes are secured by a&#160;<em style="font: inherit;">first</em>&#160;priority lien on substantially all assets of the Company and Dyadic International (USA), Inc.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Convertible Notes are accounted for in accordance with ASC&#160;<em style="font: inherit;">470</em>-<em style="font: inherit;">20,</em> <i>Debt with Conversion and Other Options</i>&#160;and ASC&#160;<em style="font: inherit;">815</em>-<em style="font: inherit;">15,</em> <i>Derivatives and Hedging</i>. Under ASC&#160;<em style="font: inherit;">815,</em>&#160;contracts that are both indexed to its own stock and classified in stockholders&#8217; equity in its statement of financial position are&#160;<em style="font: inherit;">not</em>&#160;considered to be derivative instruments. Based on the Company&#8217;s analysis, it is determined that the Convertible Notes contain embedded features that are indexed to the Company&#8217;s own stock and are classified in stockholders&#8217; equity in the Company&#8217;s statement of financial position, but do&#160;<em style="font: inherit;">not</em>&#160;meet the requirements for bifurcation and recognition as derivatives, and therefore, do&#160;<em style="font: inherit;">not</em>&#160;need to be accounted for separately. Accordingly, the proceeds received from the issuance of the Convertible Notes were recorded as a single liability in accordance with ASC&#160;<em style="font: inherit;">470</em>&#160;on the Company&#8217;s consolidated balance sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company incurred $175,674&#160;of debt issuance costs associated with the Convertible Notes, which were recorded as a reduction of&#160;the Convertible Notes on the consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Convertible Notes using the effective interest method. We determined the expected life of the debt is equal to the&#160;<span style="-sec-ix-hidden:c125843622">three</span>-year term of the Convertible Notes.</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On&#160;<em style="font: inherit;"> October 4, 2024,&#160;</em>the Company entered into an amendment (the &#8220;Amendment&#8221;) to the Convertible Notes. Under the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company&#8217;s common stock is $1.40&#160;per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fal<span style="background-color:#ffffff;">l on any of the&#160;<em style="font: inherit;">26,</em>&#160;<em style="font: inherit;">29</em>&#160;and&#160;<em style="font: inherit;">32</em>-month anniversaries of the original issue date of the Convertible Notes&#160;which are <em style="font: inherit;"> May 8, 2026, </em><em style="font: inherit;"> August 8, 2026 </em>and <em style="font: inherit;"> November 8, 2026.</em></span></p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company assessed the Amendment for a debt extinguishment or modification in accordance with ASC <em style="font: inherit;">470</em>-<em style="font: inherit;">50.</em>&#160;As both the change in the present value of future cash flows of the modified Convertible Notes to that of the original Convertible Notes (including callable features) and the change in fair value of the embedded conversion option to that of the carrying value of the Convertible Notes immediately before modification resulted in a less than&#160;<em style="font: inherit;">10%</em> change, the Amendment was deemed <em style="font: inherit;">not</em> substantial and is regarded as a note modification. The Company did <em style="font: inherit;">not</em> incur any gain or loss relating to the modification and any incremental costs related to the Amendment were expensed.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the year&#160;ended&#160;<em style="font: inherit;"> December 31, 2024</em>,&#160;$<span style="background-color:#ffffff;">257,778&#160;o</span>f interest was paid and debt issuance costs o<span style="background-color:#ffffff;">f $63,020&#160;wer</span>e amortized and recorded in interest expense in the consolidated statements of operations.&#160;As of <em style="font: inherit;"> December 31, 2024</em>, accrued interest&#160;on the Convertible Notes to related parties and other&#160;<em style="font: inherit;">third</em>&#160;parties was&#160;<span style="background-color:#ffffff;">$27,173&#160;and $80,000, respe</span>ctively. As of <em style="font: inherit;"> December 31, 2024</em>, accumulated amortized debt issuance costs were $36,376.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024,</em><span style="background-color:#ffffff;"> $910,000&#160;of the Convertible Notes were converted into&#160;556,623&#160;shares o</span>f the Company&#8217;s common stock. As of <em style="font: inherit;"> December 31, 2024</em>, convertible notes payable consisted of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Holder</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Issuance Date</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Due Date</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Interest Rate</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Convertible Note </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Repayments</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Conversion to </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Francisco Trust dated 2/28/1996 (1)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843007">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843008">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843009">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Bradley Emalfarb (2)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843014">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843015">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843016">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Bradley Scott Emalfarb Irrevocable Trust (2)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843021">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843022">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843023">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">410,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(410,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Emalfarb Descendent Trust (3)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843028">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843029">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843030">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Convertible Notes - Related Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843038">2,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843040">(910,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843041">1,090,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Unamortized Debt Issuance Costs - Related Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843048">(24,124</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843055">1,065,876</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%; text-align: center;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Convertible Notes - Third Party</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843056">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843057">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843058">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><span style="-sec-ix-hidden:c125843059">4,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><b><em style="font: inherit;">&#8212;</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><b><em style="font: inherit;">&#8212;</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><span style="-sec-ix-hidden:c125843062">4,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Unamortized Debt Issuance Costs - Third Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843069">(88,529</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843076">3,911,471</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="background-color:#ffffff;">Notes:</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">(<em style="font: inherit;">1</em>) Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Francisco Trust. Mr. Thomas Emalfarb&#160;<em style="font: inherit;"> may&#160;</em>be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he&#160;<em style="font: inherit;"> may&#160;</em>have therein, directly or indirectly. The amount of accrued interest as of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, is $20,000.</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">(<em style="font: inherit;">2</em>) Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore,&#160;<em style="font: inherit;"> may&#160;</em>be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he&#160;<em style="font: inherit;"> may&#160;</em>have therein, directly or indirectly.&#160;For the year&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, $500,000&#160;of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into&#160;294,891&#160;shares of the Company&#8217;s common stock. For the year&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, $410,000&#160;of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into 261,732&#160;shares of the Company&#8217;s common stock. As of </span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the amount of accrued interest for Bradley Emalfarb and&#160;Bradley Scott Emalfarb Irrevocable Trust was $1,733&#160;and $3,640,&#160;respectively.</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">(<em style="font: inherit;">3</em>) Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, are co-trustees of the Descendant Trust and&#160;<em style="font: inherit;"> may&#160;</em>therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Descendant Trust. The amount of accrued interest as of </span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, is $1,800.</span></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restri<span style="background-color:#ffffff;">ctions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of <em style="font: inherit;"> December 31, 2024.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ConvertibleDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure representing convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ConvertibleDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">6:</em>&#160;&#160;&#160;&#160;&#160;Share-Based Compensation</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Description of Equity Plans</i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The <em style="font: inherit;">2021</em> Equity Incentive Award Plan (the <em style="font: inherit;">&#8220;2021</em> Plan&#8221;) was adopted by the Company's Board of Directors on <em style="font: inherit;"> April 9, 2021,&#160;</em>and approved&#160;by the Company&#8217;s&#160;Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) on <em style="font: inherit;"> June 11, 2021. </em>The <em style="font: inherit;">2021</em> Plan serves as a successor to the Company&#8217;s <em style="font: inherit;">2011</em> Equity Incentive Plan (the <em style="font: inherit;">&#8220;2011</em> Plan&#8221;).&#160;Since the adoption of the <em style="font: inherit;">2021</em> Plan, all equity awards were made from the <em style="font: inherit;">2021</em> Plan and <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2011</em> Plan. The <em style="font: inherit;">2021</em> Plan provides&#160;for the issuance of a variety of share-based compensation awards, including&#160;stock options,&#160;restricted stock awards, restricted stock unit awards, performance awards, dividend equivalents awards, deferred stock awards, stock payment awards and stock appreciation rights. As of <em style="font: inherit;"> April 16, 2021, </em>the <em style="font: inherit;">2021</em> Plan increased the number of shares available for grant by&#160;3,000,000&#160;in addition to&#160;the number of shares remaining available for the grant of new awards under the <em style="font: inherit;">2011</em> Plan.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2024</em>, the Company had 5,788,597&#160;stock options outstanding and an additio<span style="background-color:#ffffff;">nal&#160;</span>2,056,629<span style="background-color:#ffffff;"> share</span>s of common stock available for grant under the <em style="font: inherit;">2021</em> Plan. As of <em style="font: inherit;"> December 31, 2023</em>, there were 5,469,247 stock options outstanding and an additional 3,672,561 shares of common stock available for grant under the <em style="font: inherit;">2021</em> Plan.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Stock Options </i></b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company&#8217;s <em style="font: inherit;">2011</em> Plan and <em style="font: inherit;">2021</em> Plan is <span style="-sec-ix-hidden:c125843677">ten</span> years, except for certain options granted to the contractors which are between <span style="-sec-ix-hidden:c125843678">two</span> to&#160;<span style="-sec-ix-hidden:c125843679">three</span> years.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i>Risk-free interest rate</i>. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i>Expected dividend yield</i>. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does <em style="font: inherit;">not</em> currently anticipate paying any in the foreseeable future.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i>Expected stock price volatility.</i> The expected stock price volatility was calculated based on the Company&#8217;s own volatility. The Company reviews its volatility assumption on an annual basis and has used the Company&#8217;s historical volatilities.&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><i style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Expected life of option. </i>The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option<span style="background-color:#ffffff;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The assumptions used in the Black-Scholes option pricing model for stock options granted for the years ended&#160;<em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>&#160;are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Years Ended December 31,</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2024</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2023</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; width: 70%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Risk-free interest rate</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">3.56% - 4.61</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3.90% -5.12</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected dividend yield</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected stock price volatility</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">63.02-63.64</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c125843097">62.22%</span> - <span style="-sec-ix-hidden:c125843098">64.27</span></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected life of options (in years)</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">2.63-6.25</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">1.13 -6.25</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The following table summarizes the combined stock option activity under the Company&#8217;s Equity Compensation Plans:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Term (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,031,097</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">805,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(351,520</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,469,247</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">322,738</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted<sup style="vertical-align:top;line-height:120%;"> (1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">830,725</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Exercised<sup style="vertical-align:top;line-height:120%;"> (2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(55,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expired <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(383,063</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Canceled<sup style="vertical-align:top;line-height:120%;"> (4)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(73,312</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,788,597</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.97</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">655,578</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Exercisable at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">4,438,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">3.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">4.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">436,263</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notes:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(<em style="font: inherit;">1</em>) Represents the following options granted:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Annual share-based compensation awards on&#160;<em style="font: inherit;"> January 2,&#160;</em><em style="font: inherit;">2024,</em> with an exercise price of $1.59, including: (a)&#160;387,500&#160;stock options granted to executives and key personnel, vesting upon&#160;<span style="-sec-ix-hidden:c125843687">one</span>&#160;year anniversary, or annually in equal installments over&#160;<span style="-sec-ix-hidden:c125843688">four</span>&#160;years, (b)&#160;352,500&#160;stock options granted to members of the Board of Directors, vesting upon&#160;<span style="-sec-ix-hidden:c125843690">one</span>&#160;year anniversary, (c)&#160;17,600&#160;stock options&#160;granted to employees, vesting annually in equal installments over&#160;<span style="-sec-ix-hidden:c125843692">four</span>&#160;years, and (d)15,000&#160;stock options&#160;granted to a consultant, vesting upon&#160;<span style="-sec-ix-hidden:c125843694">one</span>&#160;year anniversary.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">One-time awards on&#160;<em style="font: inherit;"> April 11, 2024,&#160;</em>with an exercise price of $1.84, including&#160;20,000&#160;stock options&#160;granted to an executive, vesting annually in equal installments over&#160;<span style="-sec-ix-hidden:c125843697">four</span>&#160;years, and 13,125&#160;stock options&#160;granted to a member of the Board of Directors, vesting upon&#160;<span style="-sec-ix-hidden:c125843699">one</span>&#160;year anniversary.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">A&#160;<em style="font: inherit;">one</em>-time award on&#160;<em style="font: inherit;"> September 23, 2024,&#160;</em>of&#160;25,000&#160;stock options granted to a consultant with an exercise price of $1.79, vesting in&#160;<span style="-sec-ix-hidden:c125843703">three</span>&#160;months.</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(<em style="font: inherit;">2</em>) Represents the following options exercised:&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;">&#160;</td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(a) <span style="background-color:#ffffff;">25,000&#160;stock options exercised at $0.97, and (b) 30,000&#160;stock options exercised at $1.36.</span></p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(<em style="font: inherit;">3</em>) Represents the following options expired:&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;">&#160;</td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(a)&#160;300,000&#160;stock options with an exercise price of $1.87&#160;per share&#160;granted to an executive, (b)&#160;25,000&#160;stock options with an exercise price of $1.76&#160;per share granted to a member&#160;of the Board of Directors, (c)&#160;7,500&#160;stock options with an exercise price of $5.56&#160;per share granted to&#160;a consultant, (d)&#160;25,000&#160;stock options with an exercise price of $4.14&#160;per share granted to&#160;a consultant, and (e) 25,563&#160;stock options with a weighted average&#160;exercise price of $2.93 per share&#160;granted to employees.</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(<em style="font: inherit;">4</em>) Represents the following options canceled:&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 36pt;">&#160;</td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(a)&#160;50,000&#160;stock options granted to a former member of the Board of Directors, (b)&#160;13,125&#160;stock options&#160;granted to the Company's former Chairman of the Board of Directors, and (c)&#160;10,187&#160;stock options granted to the Company's former employee.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">The weighted average grant-date fair market value of stock options granted for the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;"> was&#160;$0.95 and </span>$0.81<span style="background-color:#ffffff;">, respectively, based on the Black-Scholes option pricing model. The intrinsic value of options exercised for the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;"> was </span>$33,300<span style="background-color:#ffffff;">&#160;and </span>$0<span style="background-color:#ffffff;">, respectively.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, total unrecognized compensation cost related to non-vested stock options granted under the Company&#8217;s equity compensation plans was </span>$319,978<span style="background-color:#ffffff;">&#160;and </span>$559,121<span style="background-color:#ffffff;">, respectively, which is expected to be recognized over a weighted average period of </span>2.40<span style="background-color:#ffffff;">&#160;years and </span>2.68<span style="background-color:#ffffff;">&#160;years, respectively. The Company adjusts the unrecognized compensation cost for actual forfeitures as they occur.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt; text-align: left;"><b><i>Restricted Stock Units</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Restricted stock units (the &#8220;RSUs&#8221;) are granted subject to certain restrictions. Vesting conditions are determined at the discretion of the Board of Directors.&#160;The fair market value of RSUs is generally determined based on the closing market price of the stock on the grant date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The following table summarizes the&#160;restricted stock units activity during the&#160;year&#160;ended&#160;<em style="font: inherit;"> December 31, 2024</em>:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grant Date</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">213,044</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">354,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(437,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Unvested shares forfeited<sup style="vertical-align:top;line-height:120%;"> (3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(11,792</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">117,925</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notes:</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">On&#160;<em style="font: inherit;"> January 2, 2024,&#160;</em>the Company granted&#160;141,510&#160;RSUs, vesting upon&#160;<span style="-sec-ix-hidden:c125843738">one</span>&#160;year anniversary of the grant, to members of the Board of Directors.&#160;On&#160;<em style="font: inherit;"> March 13, 2024,&#160;</em>the Company granted&#160;212,709&#160;RSUs with immediate vesting, to&#160;executives and key personnel in lieu of cash bonuses earned for the year of <em style="font: inherit;">2023.</em>&#160;The fair value of the restricted stock unit is the Company&#8217;s closing stock price on the grant date as reported on the Nasdaq Stock Exchange.&#160;</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">2</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the vesting of&#160;212,709&#160;RSUs granted to executives and key personnel,&#160;174,837&#160;RSUs granted to the Board of Directors, and&#160;50,000&#160;RSUs granted to a consultant.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">3</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the cancellation of RSUs granted to a former member of the Board of Directors.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Compensation Expenses</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We recognize all share-based payments to employees, consultants, and our Board, as non-cash compensation expenses, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had <em style="font: inherit;">no</em> impact on the Company&#8217;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. There was <em style="font: inherit;">no</em> performance-based award recognized during the years ended&#160;<em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Total non-cash stock option compensation expense was allocated among the following expense categories:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,067,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,201,027</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">58,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">43,094</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,126,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,244,121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The following table summarizes the Company&#8217;s non-cash share-based compensation expense&#160;allocation between options and restricted stock units:</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses- stock option</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">861,999</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,004,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses- restricted stock units</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">264,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">240,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,126,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,244,121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">7:</em>&#160;&#160;&#160;&#160;&#160;Shareholders&#8217; Equity</b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Issuances of Common Stock</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For the year&#160;ended&#160;<em style="font: inherit;"> December 31, 2024</em>, there wer<span style="background-color:#ffffff;">e 556,623&#160;shares of the Company&#8217;s common stock issued resulting from the conversion of convertible notes with a weighted average issue price of&#160;$1.63&#160;pe</span>r share,&#160;<span style="background-color:#ffffff;">437,546&#160;shares of the Company&#8217;s common stock issued resulting from the vesting of restricted stock units with a weighted average issue price of&#160;$1.52&#160;pe</span>r share, and 30,569 shares of the Company's common stock issued resulting from the exercise of stock options, with a weighted average issue price of $1.04 per share.&#160;For the year&#160;ended <em style="font: inherit;"> December 31, 2023,&#160;</em>there were&#160;247,961&#160;shares of the Company&#8217;s common stock issued resulting from the vesting of restricted stock units with a weighted average issue price of&#160;$1.38&#160;per share.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Treasury Stock </i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2024</em>, and <em style="font: inherit;">2023</em>, there were 12,253,502&#160;shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">8:</em>&#160;&#160;&#160;&#160;&#160;Income Taxes </b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;">For the year ended <em style="font: inherit;"> December 31, 2024</em>, there was&#160;<em style="font: inherit;">no</em> provision for income taxes or unrecognized tax benefits recorded.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;">The significant components of gain (loss) before income taxes are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">U.S. operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(5,757,824</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(6,766,409</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Foreign operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(51,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(29,052</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total loss before provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,809,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,795,461</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Company has no current or deferred income tax&#160;for the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to&#160;permanent differences, state income taxes and a change in the deferred tax valuation allowance.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The reconciliation between the statutory tax rate and the Company&#8217;s actual effective tax rate is as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Tax at U.S. statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">State taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(4.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(4.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Non-deductible items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">0.26</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">0.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">20.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">14.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">True-up adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">4.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">10.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Foreign operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(0.11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Change in tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The significant components of the Company&#8217;s net deferred income tax assets are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Section 174 - R&amp;D expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,123,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,769,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,584,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,419,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">NOL carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">12,655,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">11,620,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General Business credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,278,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,503,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Operating lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">22,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">34,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Right-of-use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(23,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(35,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">134,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Deferred tax asset, net of deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,642,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,446,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,642,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,446,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets, Management evaluates whether it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on Management&#8217;s evaluation, the net deferred tax asset, was offset by a full valuation allowance as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em>&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards available as of <em style="font: inherit;"> December 31, 2024, </em>and <em style="font: inherit;">2023,</em> in the amount of <span style="background-color:#ffffff;">approximately $49,903,000&#160;and $45,850,000, respectively. Approximately $46,965,000</span>&#160;of the federal net operating loss carryforwards will be carried forward indefinitely and will be available to offset 80% of taxable income. The remaining amount of the net operating loss carryforwards will expire at varying dates through <em style="font: inherit;">2038.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Tax Cuts and Jobs Act eliminated the current year deduction election for research and experimental expenditures. Instead, a taxpayer must charge such expenditures to a capital account and is allowed to amortize such expenditures ratably over a <em style="font: inherit;">five</em>-year period (or <em style="font: inherit;">fifteen</em>-year period for expenditures attributable to foreign research), beginning with the midpoint of the tax year in which such expenditures are paid or incurred.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Segment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Note <em style="font: inherit;">9:</em>&#160;&#160;&#160;&#160; Segment</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company operates and manages its business as one&#160;reportable segment and one&#160;operating segment, which is the business of developing and commercializing synthetic protein products using the Company&#8217;s proprietary microbial platforms, including <em style="font: inherit;">C1</em> and Dapibus&#8482;. The Company's chief operating decision maker, or CODM, is the Company's senior management team that includes the Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The Company operates in the U.S. and Europe.&#160;All material long-lived assets of the Company reside in the U.S. For geographic information about the Company&#8217;s product revenues, see Note <em style="font: inherit;">1,</em> <i>Concentration</i>. Long-lived assets primarily consist of operating lease right-of-use assets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The CODM uses consolidated net loss to evaluate the Company's spend and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing performance of the segment and in establishing resource allocation across the organization. Factors used in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note <em style="font: inherit;">1</em> of the notes to the consolidated financial statements included in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The C<span style="background-color:#ffffff;">ODM reviews cash, cash equivalents and investment securities as a measure of segment assets.&#160;As of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Company&#8217;s cash, cash equivalents and investment securities were $9.3&#160;million and $7.3&#160;million, respectively.</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><span style="background-color:#ffffff;">The following table presents information about segment revenue, significant segment expenses and segment operating loss for the years ended <em style="font: inherit;"> December 31, 2024 </em>and&#160;<em style="font: inherit;">2023:</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">3,495,389</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,898,806</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,194,624</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,975,849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,503,397</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,677,941</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">414,916</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">510,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Facilities, overhead, and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,584</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General and administrative expenses:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Compensation and related expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,308,566</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,200,914</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Business consulting expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">764,326</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">305,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Legal and professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">998,630</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">931,038</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other G&amp;A expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">995,501</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,244,121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,126,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,178,686</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign currency exchange loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,417</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Income (expenses), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,663</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,434,278</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net loss</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,809,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,795,461</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">10:</em>&#160;&#160;&#160;&#160;&#160;Subsequent Events </b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through <em style="font: inherit;"> March 26, 2025</em>, the date the consolidated financial statements were available to be issued. Except for items mentioned in the notes, and as discussed below, management is <em style="font: inherit;">not</em> aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> January 2, 2025, </em>the Company granted an annual stock option award with an exercise price of $1.74, including: (a) 356,500 stock options granted to executives and key personnel, vesting upon <em style="font: inherit;">one</em> year anniversary, or annually in equal installments over <span style="-sec-ix-hidden:c125843795">four</span> years, (b) 277,500 stock options granted to members of the Board of Directors, vesting upon <span style="-sec-ix-hidden:c125843797">one</span> year anniversary, (c) 19,500 stock options granted to employees, vesting annually in equal installments over <span style="-sec-ix-hidden:c125843799">four</span> years, and (d) 20,000 stock options granted to a consultant, vesting upon <span style="-sec-ix-hidden:c125843801">one</span> year anniversary.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> January 2, 2025, </em>the Company granted 96,984 restricted stock units, vesting upon <em style="font: inherit;">one</em> year anniversary, to the Board of Directors as a result of reduction in director cash compensation of <em style="font: inherit;">2025,</em> and &#160;an aggregate of 133,039 restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> March 20, 2025, </em>the Company announced that it has received a funding award from CEPI to use <em style="font: inherit;">C1</em> to accelerate the development of protein-based vaccines through the partnership with Fondazione Biotecnopolo di Siena (FBS), a non-profit foundation backed by the Italian government.</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -36pt; text-align: justify; text-indent: 36pt;"><b><i>Basis of Presentation </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Dyadic consolidates entities in which we have a controlling financial interest. We consolidate our subsidiaries in which we hold and/or control, directly or indirectly, more than <em style="font: inherit;">50%</em> of the voting rights.&#160;All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Segment Information</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The CODM is the Company's senior management team that includes the Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer. The Company views its operations as and manages its business in <span style="-sec-ix-hidden:c125843372">one</span>&#160;operating segment, which is the business of developing and commercializing synthetic protein products using the Company&#8217;s proprietary microbial platforms, including <em style="font: inherit;">C1</em> and Dapibus&#8482;. Segment information is further described in Note <em style="font: inherit;">9</em> to the consolidated financial statements included in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Estimates inherent in the preparation of these consolidated financial statements include, but are <em style="font: inherit;">not</em> limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense,&#160;and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="background-color:#ffffff;">For the years&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s revenue was generated from&#160;</span><span style="-sec-ix-hidden:c125843379">19</span>&#160;<span style="background-color:#ffffff;">and&#160;<span style="-sec-ix-hidden:c125843380">16</span> customers, respectively. As of&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s accounts receivable was from <span style="-sec-ix-hidden:c125843382">nine</span>&#160;and <span style="-sec-ix-hidden:c125843383">thirteen</span> customers, respectively. Significant customers are those that account for greater than <em style="font: inherit;">10%</em> of the Company&#8217;s revenues. For the years&#160;ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843386"><span style="-sec-ix-hidden:c125843897">two</span></span> significant customers accounted for approximately $1,915,000 or 54.8% and $1,503,000 or 51.9%&#160;of revenue, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company&#8217;s customers could adversely affect its operations.</span></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company had <span style="-sec-ix-hidden:c125843393">eleven</span>&#160;</span><span style="font-size: 10pt;"><span style="background-color:#ffffff;">and <span style="-sec-ix-hidden:c125843394">six</span> customers outside of the United States (i.e., European and Asian customers) that accounted for&#160;approximately&#160;$1,526,000&#160;or 43.7% and&#160;</span></span>$537,000<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;or&#160;</span></span>18.5%<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;of total revenue, respectively.&#160;As of&#160;</span></span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="font-size: 10pt;"><span style="background-color:#ffffff;">, the Company&#160;had <span style="-sec-ix-hidden:c125843400">four</span> and&#160;</span></span><span style="-sec-ix-hidden:c125843401">six</span><span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;customers outside of the United States (i.e., European and Asian customers) that accounted for approximately $146,000 or 61.5% and&#160;</span></span>$213,000<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;or </span></span>45.6%<span style="font-size: 10pt;"><span style="background-color:#ffffff;">&#160;of&#160;accounts receivable, respectively.</span></span></p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company uses CROs&#160;to conduct its research projects and manage its clinical trial. For&#160;the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843407">two</span> and <span style="-sec-ix-hidden:c125843408">three</span> CROs&#160;accounted for approximately $2,389,000&#160;or 93.0% and $4,644,000&#160;or 96.0%&#160;of total research serv</span>ices we purchased, respectively. As of&#160;<em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843413">two</span>&#160;CROs accounted for approximately&#160;$284,000 or 58.9%&#160;of ac</span>counts payable. As of&#160;<em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c125843416">three</span>&#160;CROs accounted for approximately&#160;$620,000 or 94.4%&#160;of accounts payable. The loss of business from <em style="font: inherit;">one</em> of these CROs or a combination of them could adversely affect the Company's operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We treat highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.&#160;The Company has no restricted cash balances as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Investment Securities</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months or less, and long-term investment securities mature over <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months from the applicable reporting date. Management determines the appropriate classification of each investment&#160;at the time of purchase and reevaluates the classifications at each balance sheet date.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company classifies its&#160;investments in debt securities as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than <em style="font: inherit;">not</em> the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. The Company measures expected credit losses on held to maturity debt securities on an individual security basis. The estimate of expected credit losses considers historical credit information from external sources. The impairment of the investment that is related to the credit loss, if any,&#160;is expensed in the period in which the event or change occurred.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>, all of our money market funds were invested in U.S. Government money market funds. The Company did <em style="font: inherit;">not</em> have any investment securities classified as trading as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accounts Receivable</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company&#8217;s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances&#160;and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company&#8217;s evaluation of current and expected future economic conditions and changes in our customer collection trends. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. Management determined that&#160;no allowance for credit losses was required as of&#160;<em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
      <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts receivable consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">173,993</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">410,617</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,034</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,542</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">237,027</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">466,159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Prepaid Expenses and Other Current Assets</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">182,270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">209,888</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117,560</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,236</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_AccountsPayablePolicyPolicyTextBlock', window );">Accounts Payable, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accounts Payable</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accounts payable consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">340,698</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">575,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">68,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,957</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,202</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_AccruedExpensesPolicyPolicyTextBlock', window );">Accrued Expenses, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Accrued expenses consist of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">496,905</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">561,720</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">437,196</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">274,080</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">25,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">210,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,462</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,057,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contract with Customer [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Revenue Recognition </i></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has <em style="font: inherit;">no</em> products approved for sale. All our revenue to date has been research revenue from <em style="font: inherit;">third</em>-party collaborations and government grants, as well as revenue from sublicensing&#160;agreements and collaborative arrangements, which <em style="font: inherit;"> may </em>include upfront payments,&#160;options to obtain a license, payment for research and development services,&#160;milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest).</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to research collaborations and agreements:</i>&#160;The Company typically&#160;performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the <em style="font: inherit;">5</em>-step process outlined in ASC Topic <em style="font: inherit;">606</em> (&#8220;Topic <em style="font: inherit;">606&#8221;</em>): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic <em style="font: inherit;">606</em> to measure the progress toward complete satisfaction of a performance obligation.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under the input method, revenue will be recognized based on the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and <em style="font: inherit;">third</em>-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i><span style="background-color:#ffffff;">Revenue related to grants: </span></i><span style="background-color:#ffffff;">T</span>he Company <em style="font: inherit;"> may </em>receive&#160;grants&#160;from governments, agencies, and other private and <em style="font: inherit;">not</em>-for-profit organizations. These grants are intended to be used to partially or fully fund the Company&#8217;s research collaborations<span style="background-color:#ffffff;">.</span> However, most, if <em style="font: inherit;">not</em> all, of such potential grant revenues, when&#160;received, is expected to be earmarked for <em style="font: inherit;">third</em> parties to advance the research required, including preclinical and clinical trials.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Customer options: </i>If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate&#160;if such&#160;options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i><span style="background-color:#ffffff;">Milestone payments: </span></i><span style="background-color:#ffffff;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which the<i> </i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all&#160;the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <em style="font: inherit;">not</em> recognized any royalty revenue resulting from any of its sublicensing arrangements.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We invoice customers based on our contractual arrangements with each customer, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are <em style="font: inherit;">not</em> required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of <em style="font: inherit;">one</em> year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. The Company does&#160;<em style="font: inherit;">not</em>&#160;recognize leases with terms of&#160;<em style="font: inherit;">twelve</em>&#160;months or less on the balance sheet. Options to extend or terminate a lease are&#160;<em style="font: inherit;">not</em>&#160;included in the Company&#8217;s initial lease term assessment, unless there is&#160;reasonable&#160;certainty that the Company will exercise any such option. Leases are classified as either finance leases or operating leases based on criteria in Accounting Standards Codification (&#8220;ASC&#8221;)&#160;<em style="font: inherit;">842.</em>&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For operating leases, right-of-use assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses an estimated rate of interest that they would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating lease right-of-use asset also includes any lease payments made and excludes any lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s&#160;prior lease for its corporate headquarters located at&#160;<em style="font: inherit;">140</em>&#160;Intracoastal Pointe Dr. expired on&#160;<em style="font: inherit;"> August 31, 2023,&#160;</em>and there was&#160;<em style="font: inherit;">no</em>&#160;right-of-use asset or lease liability recognized for this lease due to its short-term nature. In&#160;<em style="font: inherit;"> August&#160;</em><em style="font: inherit;">2023,</em>&#160;the Company entered into a new lease (<em style="font: inherit;">&#8220;1044</em>&#160;N Lease&#8221;) for&#160;office space for its new corporate headquarters located at&#160;<em style="font: inherit;">1044</em>&#160;N US&#160;<em style="font: inherit;">1,</em>&#160;Jupiter, Florida, commencing&#160;<em style="font: inherit;"> September 1, 2023 (</em>&#8220;Commencement Date&#8221;) and expiring&#160;on <em style="font: inherit;"> August 31, 2026. </em>Rent is subject to <em style="font: inherit;">three</em>&#160;percent (3%) annual increases, and the Company is responsible for certain common area maintenance charges and taxes throughout the life of the&#160;<em style="font: inherit;">1044</em>&#160;N Lease. The&#160;<em style="font: inherit;">1044</em>&#160;N Lease has an initial term of&#160;<em style="font: inherit;">three</em>&#160;(3) years, following the Commencement Date with an option to extend for&#160;<em style="font: inherit;">two</em>&#160;(2) successive&#160;<em style="font: inherit;">one</em>&#160;(1) year terms. The options were&#160;<em style="font: inherit;">not</em>&#160;included in the lease term used in determining the right-of-use asset or lease liability as the Company did&#160;<em style="font: inherit;">not</em>&#160;consider it reasonably certain they would exercise the options.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For<span style="background-color:#ffffff;"> the years ended&#160;</span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the Company&#8217;s total operating lease expense was&#160;</span>$106,785&#160;and $71,656, <span style="background-color:#ffffff;">respectively. As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff;">, the Company&#8217;s total operating lease liabilities was $</span>88,870, <span style="background-color:#ffffff;">which is presented net of imputed interest o</span>f $6,669, and the&#160;oper<span style="background-color:#ffffff;">ating lease right-of-use&#160;asset was&#160;</span>$92,211.&#160;As of <em style="font: inherit;"> December 31, 2023, </em>the Company&#8217;s total operating lease liabilities was $136,929, which is presented net of imputed interest of $16,770, and the operating lease right-of-use asset was $141,439.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">As of&#160;</span><em style="font: inherit;"> December 31, 2024</em><span style="background-color:#ffffff">, the </span>weighted average remaining lease term was&#160;1.7&#160;years, and the weighted average discount rate was 8.8%.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Research and Development Costs</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are related to the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,503,397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,677,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">473,444</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">553,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,412</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">65,584</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>Foreign Currency Transaction Gain or Loss</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure&#160;the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Fair Value Measurements </i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into <em style="font: inherit;">three</em> levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Level <em style="font: inherit;">1</em> &#8211; Quoted prices in active markets for identical assets or liabilities.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;">Level <em style="font: inherit;">2</em> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;">Level <em style="font: inherit;">3</em> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company&#8217;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#8217;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the <em style="font: inherit;">third</em>-party broker service for disclosure purposes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Income Taxes</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than <em style="font: inherit;">not</em> some portion or all the deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company is required to evaluate the provisions of ASC <em style="font: inherit;">740</em> related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements. ASC <em style="font: inherit;">740</em> prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-<em style="font: inherit;">not</em> to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was <em style="font: inherit;">not</em> recognized as a result of applying the provision of ASC <em style="font: inherit;">740.</em></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i><span style="background-color:#ffffff;">Comprehensive Income (Loss)</span></i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under U.S. GAAP. The Company does <em style="font: inherit;">not</em> have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does <em style="font: inherit;">not</em> separately present a statement of comprehensive income (loss) in its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We recognize all share-based payments to employees, consultants, and our Board of Directors (the &#8220;Board&#8221;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock, restricted stock units and convertible debt, were exercised and&#160;converted into common stock, calculated by applying the treasury stock method.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><span style="background-color:#ffffff;">For the years ended </span><em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff;">, the effect of the potential exercise of options to purchase&#160;</span>5,788,597<span style="background-color:#ffffff;">&#160;and </span>5,469,247<span style="background-color:#ffffff;">&#160;shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"><b><i>New and Recently Adopted Accounting Pronouncements</i></b>&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> November 2023, </em>the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (the &#8220;ASU&#8221;) <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> &#8211; Segment Reporting (Topic ASC <em style="font: inherit;">280</em>), or ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosure about significant segment expenses. The enhancements under this update require disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss, require disclosure of <i>other segment items </i>by reportable segment and a description of the composition of <i>other segment items</i>, require annual disclosures under ASC <em style="font: inherit;">280</em> to be provided in interim periods, clarify use of more than <em style="font: inherit;">one</em> measure of segment profit or loss by the CODM, require that the title of the CODM be disclosed with an explanation of how the CODM uses the reported measures of segment profit or loss to make decisions, and require that entities with a single reportable segment provide all disclosures required by this update and required under ASC <em style="font: inherit;">280.</em> ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for public business entities for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company adopted ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> and applied the guidance retrospectively to all periods presented in the consolidated financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> &#8211; Income Taxes (Topic ASC <em style="font: inherit;">740</em>) Income Taxes. The ASU improves the transparency of income tax disclosures by requiring (<em style="font: inherit;">1</em>) consistent categories and greater disaggregation of information in the rate reconciliation and (<em style="font: inherit;">2</em>) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> will become effective beginning with our <em style="font: inherit;">2025</em> fiscal year. We do <em style="font: inherit;">not</em> expect that this guidance will have a material impact on our financial position and our results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_AccountsPayablePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_AccountsPayablePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_AccruedExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_AccruedExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">173,993</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">410,617</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,034</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,542</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">237,027</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">466,159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">182,270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">209,888</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117,560</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,236</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">340,698</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">575,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">68,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,957</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,202</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">496,905</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">561,720</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">437,196</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">274,080</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">25,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">210,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,462</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,057,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock', window );">Schedule of Research and Development Costs [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,503,397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,677,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">473,444</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">553,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,412</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">65,584</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Cash, Cash Equivalents, and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash, Cash Equivalents and Investments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2024</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">926,287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">926,287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,580,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,580,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,506,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,506,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,756,428</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(149</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,756,577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,263,178</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(149</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,263,327</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2023</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="1" rowspan="1" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,489,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,489,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,515,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,515,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">748,105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(185</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">748,290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,263,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(185</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,263,318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">59,901</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">35,638</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">95,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock', window );">Purchase Commitment, Excluding Long-Term Commitment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,134,460</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,429,044</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,563,504</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of arrangements in which the entity has agreed to procure goods or services from one or more suppliers. May include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Convertible Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Holder</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Issuance Date</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Due Date</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Interest Rate</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Convertible Note </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Repayments</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Conversion to </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); vertical-align: middle;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Francisco Trust dated 2/28/1996 (1)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843007">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843008">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843009">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Bradley Emalfarb (2)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843014">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843015">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843016">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Bradley Scott Emalfarb Irrevocable Trust (2)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843021">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843022">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843023">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">410,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(410,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">Emalfarb Descendent Trust (3)</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843028">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843029">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843030">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Convertible Notes - Related Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843038">2,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843040">(910,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843041">1,090,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Unamortized Debt Issuance Costs - Related Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843048">(24,124</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843055">1,065,876</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%; text-align: center;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Convertible Notes - Third Party</b></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843056">03/08/24</span></p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c125843057">03/08/27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c125843058">8%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><span style="-sec-ix-hidden:c125843059">4,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><b><em style="font: inherit;">&#8212;</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"><b><em style="font: inherit;">&#8212;</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><span style="-sec-ix-hidden:c125843062">4,000,000</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Unamortized Debt Issuance Costs - Third Party</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843069">(88,529</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"><b>)</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 6%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 9%;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;"><b>&#160;</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><span style="-sec-ix-hidden:c125843076">3,911,471</span></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Years Ended December 31,</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2024</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2023</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; width: 70%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Risk-free interest rate</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">3.56% - 4.61</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3.90% -5.12</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected dividend yield</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected stock price volatility</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">63.02-63.64</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c125843097">62.22%</span> - <span style="-sec-ix-hidden:c125843098">64.27</span></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expected life of options (in years)</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">2.63-6.25</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">1.13 -6.25</em></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Term (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,031,097</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">805,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(351,520</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,469,247</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">322,738</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted<sup style="vertical-align:top;line-height:120%;"> (1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">830,725</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Exercised<sup style="vertical-align:top;line-height:120%;"> (2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(55,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expired <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(383,063</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Canceled<sup style="vertical-align:top;line-height:120%;"> (4)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(73,312</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,788,597</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.97</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">655,578</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Exercisable at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">4,438,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">3.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">4.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">436,263</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grant Date</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">213,044</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">354,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(437,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Unvested shares forfeited<sup style="vertical-align:top;line-height:120%;"> (3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(11,792</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">117,925</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,067,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,201,027</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">58,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">43,094</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,126,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,244,121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses- stock option</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">861,999</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,004,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses- restricted stock units</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">264,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">240,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,126,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,244,121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">U.S. operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(5,757,824</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(6,766,409</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Foreign operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(51,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(29,052</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total loss before provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,809,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,795,461</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Tax at U.S. statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">State taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(4.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(4.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Non-deductible items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">0.26</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">0.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">20.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">14.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">True-up adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">4.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">10.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Foreign operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(0.11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Change in tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Section 174 - R&amp;D expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,123,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,769,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,584,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,419,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">NOL carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">12,655,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">11,620,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General Business credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,278,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,503,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Operating lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">22,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">34,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Right-of-use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(23,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(35,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">134,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Deferred tax asset, net of deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,642,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,446,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,642,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,446,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Segment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">3,495,389</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,898,806</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,194,624</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,975,849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,503,397</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,677,941</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">414,916</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">510,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Facilities, overhead, and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,584</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General and administrative expenses:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Compensation and related expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,308,566</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,200,914</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Business consulting expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">764,326</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">305,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Legal and professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">998,630</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">931,038</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other G&amp;A expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">995,501</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,244,121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,126,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,178,686</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign currency exchange loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,417</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Income (expenses), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,663</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,434,278</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net loss</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,809,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,795,461</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 04, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 03, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 910,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,506,750<span></span>
</td>
<td class="nump">6,515,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,780,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,287,575<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,495,389<span></span>
</td>
<td class="nump">2,898,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,785<span></span>
</td>
<td class="nump">71,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,870<span></span>
</td>
<td class="nump">136,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,669<span></span>
</td>
<td class="nump">16,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,211<span></span>
</td>
<td class="nump">$ 141,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,788,597<span></span>
</td>
<td class="nump">5,469,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dyai_The1044NLeaseMember', window );">The 1044 N Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_LesseeOperatingLeaseYearlyPercentageIncrease', window );">Lessee Operating Lease Yearly Percentage Increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms', window );">Lessee Operating Lease Additional Number of Renewal Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Significant Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskSignificantCustomers', window );">Concentration Risk, Significant Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,915,000<span></span>
</td>
<td class="nump">$ 1,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.80%<span></span>
</td>
<td class="nump">51.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Eleven Significant Customers [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Six Significant Customers [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfCustomers', window );">Concentration Risk, Number of Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Six Significant Customers [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Significant Customers [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Two CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfSuppliers', window );">Concentration Risk, Number of Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchServicesPurchased', window );">Research Services Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Three CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfSuppliers', window );">Concentration Risk, Number of Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchServicesPurchased', window );">Research Services Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Accounts Payable [Member] | Three CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Accounts Payable [Member] | Two CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfSuppliers', window );">Concentration Risk, Number of Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Accounts Payable [Member] | Three CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberOfSuppliers', window );">Concentration Risk, Number of Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_GatesFoundationMember', window );">Gates Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromGrantors', window );">Proceeds from Grantors</a></td>
<td class="nump">$ 3,092,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,092,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember', window );">Conversion Of Convertible Notes Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from Issuance of Senior Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,824,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ConcentrationRiskNumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ConcentrationRiskNumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ConcentrationRiskNumberOfSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of suppliers accounting for 10% or more of the specified concentration risk benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ConcentrationRiskNumberOfSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ConcentrationRiskSignificantCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of significant customer, which represent over 10%.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ConcentrationRiskSignificantCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional number of renewal terms available for the lessee operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_LesseeOperatingLeaseYearlyPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in operating lease payment based on lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_LesseeOperatingLeaseYearlyPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchServicesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research services purchased during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchServicesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromGrantors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromGrantors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dyai_The1044NLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dyai_The1044NLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dyai_TwoSignificantCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dyai_TwoSignificantCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dyai_ElevenSignificantCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dyai_ElevenSignificantCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dyai_SixSignificantCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dyai_SixSignificantCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dyai_FourSignificantCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dyai_FourSignificantCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=dyai_ContractResearchOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=dyai_ContractResearchOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dyai_TwoCROsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dyai_TwoCROsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dyai_ThreeCROsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dyai_ThreeCROsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=dyai_ThreeCROsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=dyai_ThreeCROsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 237,027<span></span>
</td>
<td class="nump">$ 466,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">173,993<span></span>
</td>
<td class="nump">410,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 63,034<span></span>
</td>
<td class="nump">$ 55,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 182,270<span></span>
</td>
<td class="nump">$ 209,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses - various</a></td>
<td class="nump">117,560<span></span>
</td>
<td class="nump">117,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">3,236<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid Expense and Other Assets, Current</a></td>
<td class="nump">$ 303,066<span></span>
</td>
<td class="nump">$ 327,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentInProcessCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 340,698<span></span>
</td>
<td class="nump">$ 575,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_LegalExpensesPayableCurrent', window );">Legal expenses</a></td>
<td class="nump">68,420<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">73,202<span></span>
</td>
<td class="nump">79,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="nump">$ 482,320<span></span>
</td>
<td class="nump">$ 656,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_LegalExpensesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of legal expenses payable, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_LegalExpensesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentInProcessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents current research and development in process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentInProcessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee wages and benefits</a></td>
<td class="nump">$ 496,905<span></span>
</td>
<td class="nump">$ 561,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_AccruedResearchAndDevelopmentInProcessCurrent', window );">Research and development expenses</a></td>
<td class="nump">437,196<span></span>
</td>
<td class="nump">274,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal expenses</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">210,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">11,360<span></span>
</td>
<td class="nump">11,360<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="nump">$ 970,462<span></span>
</td>
<td class="nump">$ 1,057,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_AccruedResearchAndDevelopmentInProcessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents current accrued research and development in process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_AccruedResearchAndDevelopmentInProcessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices', window );">Outside contracted services</a></td>
<td class="nump">$ 1,503,397<span></span>
</td>
<td class="nump">$ 2,677,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts', window );">Personnel related costs</a></td>
<td class="nump">473,444<span></span>
</td>
<td class="nump">553,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther', window );">Facilities, overhead and other</a></td>
<td class="nump">67,412<span></span>
</td>
<td class="nump">65,584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty', window );">Research And Development Expense, Including Related Party</a></td>
<td class="nump">$ 2,044,253<span></span>
</td>
<td class="nump">$ 3,297,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents facilities, overhead and other for research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents research and development expense including related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents outside contracted services for research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseOutsideContractedServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents personnel related costs for research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Cash, Cash Equivalents, and Investments (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount', window );">Debt Securities, Held-to-maturity, Securities Purchased, Discount</a></td>
<td class="nump">$ 78,770<span></span>
</td>
<td class="nump">$ 39,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents securities that were purchased at a discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Cash, Cash Equivalents, and Investments - Major Security Type (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,506,750<span></span>
</td>
<td class="nump">$ 6,515,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, adjusted cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">926,287<span></span>
</td>
<td class="nump">25,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money Market Funds, adjusted cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,580,463<span></span>
</td>
<td class="nump">6,489,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Subtotal, adjusted cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,506,750<span></span>
</td>
<td class="nump">6,515,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Corporate Bonds, gross unrealized holding gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Corporate Bonds, gross unrealized holding losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_CashCashEquivalentsAndInvestmentsFairValue', window );">Total, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,263,178<span></span>
</td>
<td class="nump">7,263,133<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,263,327<span></span>
</td>
<td class="nump">7,263,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember', window );">Cash [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">926,287<span></span>
</td>
<td class="nump">25,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,580,463<span></span>
</td>
<td class="nump">6,489,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=dyai_ShortTermCorporateBondsMember', window );">Short-term Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Corporate Bonds, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">2,756,428<span></span>
</td>
<td class="nump">748,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Corporate Bonds, gross unrealized holding gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Corporate Bonds, gross unrealized holding losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Corporate Bonds, adjusted cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 2,756,577<span></span>
</td>
<td class="nump">$ 748,290<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">For the years ended December 31, 2024 and 2023, the Company received discounts of $78,770 and $39,012 to purchase held-to-maturity investment securities, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CashCashEquivalentsAndInvestmentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents fair value of cash, cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CashCashEquivalentsAndInvestmentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=dyai_ShortTermCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=dyai_ShortTermCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,495,389<span></span>
</td>
<td class="nump">$ 2,898,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember', window );">Alphazyme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from Sale, Maturity and Collection of Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dyai_AlphazymeMember', window );">Alphazyme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_OwnershipPercentage', window );">Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,605,220<span></span>
</td>
<td class="nump">2,545,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_GatesFoundationMember', window );">Gates Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,092,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ProceedsFromGrant', window );">Proceeds From Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_GatesFoundationMember', window );">Gates Foundation [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_GatesFoundationMember', window );">Gates Foundation [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ProceedsFromGrant', window );">Proceeds From Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_ProliantAgreementMember', window );">Proliant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_LicenseAndDevelopmentInitialTerm', window );">License and Development, Initial Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_LicenseAndDevelopmentExtensionTerm', window );">License and Development, Extension Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_InitialUpFrontPayment', window );">Initial Up Front Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_SecondPaymentUponCompletionTransfer', window );">Second Payment Upon Completion Transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_FinalPaymentUponMeetingCertainProductivityThreshold', window );">Final Payment Upon Meeting Certain Productivity Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_DeferredLicenseRevenue', window );">Deferred License Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_InzymesAgreementApsMember', window );">Inzymes Agreement APS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_DeferredLicenseRevenue', window );">Deferred License Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_NonrefundableUpfrontPaymentReceived', window );">Non-refundable Upfront Payment, Received</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_InzymesAgreementApsMember', window );">Inzymes Agreement APS [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_AGlobalFoodIngredientCompanyMember', window );">A Global Food Ingredient Company [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_JanssenPharmaceuticalCompaniesMember', window );">Janssen Pharmaceutical Companies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_DeferredLicenseRevenue', window );">Deferred License Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_JanssenPharmaceuticalCompaniesMember', window );">Janssen Pharmaceutical Companies [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DeferredLicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents deferred license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DeferredLicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_FinalPaymentUponMeetingCertainProductivityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the final payment upon meeting certain productivity thresholds in an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_FinalPaymentUponMeetingCertainProductivityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_InitialUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront payment for an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_InitialUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_LicenseAndDevelopmentExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of the term extension for the research and development agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_LicenseAndDevelopmentExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_LicenseAndDevelopmentInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The initial term length for the research and development agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_LicenseAndDevelopmentInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_NonrefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents non-refundable upfront payment, received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_NonrefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ProceedsFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds from grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ProceedsFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SecondPaymentUponCompletionTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the second payment upon the completion of a transfer in an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SecondPaymentUponCompletionTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_AlphazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_AlphazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_ProliantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_ProliantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_InzymesAgreementApsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_InzymesAgreementApsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_AGlobalFoodIngredientCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_AGlobalFoodIngredientCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_JanssenPharmaceuticalCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_JanssenPharmaceuticalCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Commitments and Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dyai_The1044NLeaseMember', window );">The 1044 N Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_OperatingLeasesMonthlyRentalRate', window );">Operating Leases, Monthly Rental Rate</a></td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dyai_NetherlandsOfficeLeaseMember', window );">Netherlands Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_OperatingLeasesAnnualRentalRate', window );">Operating Leases, Annual Rental Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_OperatingLeasesAnnualRentalRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents annual rental rate for operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_OperatingLeasesAnnualRentalRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_OperatingLeasesMonthlyRentalRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents monthly rental rate for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_OperatingLeasesMonthlyRentalRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dyai_The1044NLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dyai_The1044NLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dyai_NetherlandsOfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dyai_NetherlandsOfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Commitments and Contingencies - Future Minimum Lease Payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 59,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">35,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 95,539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Commitments and Contingencies - Purchase Obligations (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,134,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2026</a></td>
<td class="nump">1,429,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total</a></td>
<td class="nump">$ 3,563,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Convertible Notes Payable (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 04, 2024</div></th>
<th class="th"><div>Oct. 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Excluding Capitalized Interest, Operating Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,778<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,021<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember', window );">Conversion Of Convertible Notes Into Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 175,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Excluding Capitalized Interest, Operating Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member] | Bradley Scott Emalfarb [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member] | Conversion Of Convertible Notes Into Common Stock [Member] | Bradley Scott Emalfarb [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member] | Third Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_TheFranciscoTrustMember', window );">The Francisco Trust [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_TheFranciscoTrustMember', window );">The Francisco Trust [Member] | Mr. Thomas Emalfarb [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember', window );">Irrevocable Trust [Member] | Bradley Scott Emalfarb [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember', window );">Irrevocable Trust [Member] | Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember', window );">Irrevocable Trust [Member] | Conversion Of Convertible Notes Into Common Stock [Member] | Bradley Scott Emalfarb [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Francisco Trust. Mr. Thomas Emalfarb  may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he  may have therein, directly or indirectly. The amount of accrued interest as of  December 31, 2024, is $20,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore,  may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he  may have therein, directly or indirectly. For the year ended  December 31, 2024, $500,000 of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into 294,891 shares of the Company&#8217;s common stock. For the year ended  December 31, 2024, $410,000 of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into 261,732 shares of the Company&#8217;s common stock. As of December 31, 2024, the amount of accrued interest for Bradley Emalfarb and Bradley Scott Emalfarb Irrevocable Trust was $1,733 and $3,640, respectively.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_BradleyScottEmalfarbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_BradleyScottEmalfarbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dyai_ThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dyai_ThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyai_TheFranciscoTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyai_TheFranciscoTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_MrThomasEmalfarbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_MrThomasEmalfarbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Convertible Notes Payable - Convertible Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember', window );">Conversion Of Convertible Notes Into Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion to common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(556,623)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_TheFranciscoTrustMember', window );">The Francisco Trust [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Due date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar.  08,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Principal outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember', window );">Irrevocable Trust [Member] | Bradley Emalfarb [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">Mar.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Due date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">Mar.  08,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Principal outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember', window );">Irrevocable Trust [Member] | Bradley Emalfarb [Member] | Conversion Of Convertible Notes Into Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion to common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember', window );">Irrevocable Trust [Member] | Bradley Scott Emalfarb [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">Mar.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Due date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">Mar.  08,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Principal outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion to common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(410,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember', window );">Irrevocable Trust [Member] | Bradley Scott Emalfarb [Member] | Conversion Of Convertible Notes Into Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion to common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(261,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_DescendantTrustMember', window );">Descendant Trust [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">Mar.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Due date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">Mar.  08,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Principal outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Principal outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion to common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(910,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Unamortized Debt Issuance Costs - Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (24,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Carrying Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,065,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member] | Third Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Mar.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Due date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Mar.  08,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note principal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Principal outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Unamortized Debt Issuance Costs - Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(88,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Carrying Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,911,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember', window );">Senior Secured 2024 Notes [Member] | Bradley Scott Emalfarb [Member] | Conversion Of Convertible Notes Into Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion to common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(294,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Francisco Trust. Mr. Thomas Emalfarb  may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he  may have therein, directly or indirectly. The amount of accrued interest as of  December 31, 2024, is $20,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore,  may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he  may have therein, directly or indirectly. For the year ended  December 31, 2024, $500,000 of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into 294,891 shares of the Company&#8217;s common stock. For the year ended  December 31, 2024, $410,000 of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into 261,732 shares of the Company&#8217;s common stock. As of December 31, 2024, the amount of accrued interest for Bradley Emalfarb and Bradley Scott Emalfarb Irrevocable Trust was $1,733 and $3,640, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, are co-trustees of the Descendant Trust and  may therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Descendant Trust. The amount of accrued interest as of December 31, 2024, is $1,800.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConversionOfConvertibleNotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyai_TheFranciscoTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyai_TheFranciscoTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyai_IrrevocableTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_BradleyEmalfarbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_BradleyEmalfarbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_BradleyScottEmalfarbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_BradleyScottEmalfarbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyai_DescendantTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyai_DescendantTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyai_SeniorSecured2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dyai_ThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dyai_ThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Share-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2024</div></th>
<th class="th"><div>Apr. 11, 2024</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Jan. 03, 2023</div></th>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,788,597<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,469,247<span></span>
</td>
<td class="nump">5,031,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">830,725<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">805,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">(0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,063<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">351,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,063<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">351,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">15,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,978<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 559,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">2 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember', window );">Executives and Key Personnel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_EmployeesMember', window );">Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ExecutiveAndBoardOfDirectorsMember', window );">Executive And Board Of Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_BoardOfDirectorsMember', window );">Board of Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ConsultantOneMember', window );">Consultant One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ConsultantTwoMember', window );">Consultant Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_FormerBoardOfDirectorsMember', window );">Former Board of Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_FormerChairmanOfTheBoardOfDirectorsMember', window );">Former Chairman of the Board of Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_FormerEmployeeMember', window );">Former Employee [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Executives and Key Personnel [Member] | Share-based Compensation Award Tranche Two through Five [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dyai_StockOptions1Member', window );">Stock Options 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dyai_StockOptions2Member', window );">Stock Options 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Executives and Key Personnel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Contractor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2021PlanMember', window );">The 2021 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,788,597<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,469,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,056,629<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,672,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2021PlanMember', window );">The 2021 Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2021PlanMember', window );">The 2021 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Nonemployee [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_The2021PlanMember', window );">The 2021 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Nonemployee [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the following options granted:

Annual share-based compensation awards on  January 2, 2024, with an exercise price of $1.59, including: (a) 387,500 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 352,500 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 17,600 stock options granted to employees, vesting annually in equal installments over four years, and (d)15,000 stock options granted to a consultant, vesting upon one year anniversary.

One-time awards on  April 11, 2024, with an exercise price of $1.84, including 20,000 stock options granted to an executive, vesting annually in equal installments over four years, and 13,125 stock options granted to a member of the Board of Directors, vesting upon one year anniversary.

A one-time award on  September 23, 2024, of 25,000 stock options granted to a consultant with an exercise price of $1.79, vesting in three months.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the following options exercised:


(a) 25,000 stock options exercised at $0.97, and (b) 30,000 stock options exercised at $1.36.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">(3) Represents the following options expired:


(a) 300,000 stock options with an exercise price of $1.87 per share granted to an executive, (b) 25,000 stock options with an exercise price of $1.76 per share granted to a member of the Board of Directors, (c) 7,500 stock options with an exercise price of $5.56 per share granted to a consultant, (d) 25,000 stock options with an exercise price of $4.14 per share granted to a consultant, and (e) 25,563 stock options with a weighted average exercise price of $2.93 per share granted to employees.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">(4) Represents the following options canceled:


(a) 50,000 stock options granted to a former member of the Board of Directors, (b) 13,125 stock options granted to the Company's former Chairman of the Board of Directors, and (c) 10,187 stock options granted to the Company's former employee.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">On  January 2, 2024, the Company granted 141,510 RSUs, vesting upon one year anniversary of the grant, to members of the Board of Directors. On  March 13, 2024, the Company granted 212,709 RSUs with immediate vesting, to executives and key personnel in lieu of cash bonuses earned for the year of 2023. The fair value of the restricted stock unit is the Company&#8217;s closing stock price on the grant date as reported on the Nasdaq Stock Exchange.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ExecutiveAndBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ExecutiveAndBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ConsultantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ConsultantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ConsultantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ConsultantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_FormerBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_FormerBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_FormerChairmanOfTheBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_FormerChairmanOfTheBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_FormerEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_FormerEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dyai_StockOptions1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dyai_StockOptions1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dyai_StockOptions2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dyai_StockOptions2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dyai_The2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dyai_The2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-Free interest rate, minimum</a></td>
<td class="nump">3.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">63.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (Year)</a></td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-Free interest rate, maximum</a></td>
<td class="nump">4.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">63.64%<span></span>
</td>
<td class="nump">64.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (Year)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Share-based Compensation - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">5,469,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,031,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual term (Year)</a></td>
<td class="text">5 years 4 months 2 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 655,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 322,738<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares (in shares)</a></td>
<td class="nump">830,725<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">805,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares (in shares)</a></td>
<td class="num">(55,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, shares (in shares)</a></td>
<td class="num">(383,063)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(351,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled, shares (in shares)</a></td>
<td class="num">(73,312)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(15,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">5,788,597<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,469,247<span></span>
</td>
<td class="nump">5,031,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">4,438,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual term (Year)</a></td>
<td class="text">4 years 5 months 8 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 436,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the following options granted:

Annual share-based compensation awards on  January 2, 2024, with an exercise price of $1.59, including: (a) 387,500 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 352,500 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 17,600 stock options granted to employees, vesting annually in equal installments over four years, and (d)15,000 stock options granted to a consultant, vesting upon one year anniversary.

One-time awards on  April 11, 2024, with an exercise price of $1.84, including 20,000 stock options granted to an executive, vesting annually in equal installments over four years, and 13,125 stock options granted to a member of the Board of Directors, vesting upon one year anniversary.

A one-time award on  September 23, 2024, of 25,000 stock options granted to a consultant with an exercise price of $1.79, vesting in three months.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the following options exercised:


(a) 25,000 stock options exercised at $0.97, and (b) 30,000 stock options exercised at $1.36.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">(3) Represents the following options expired:


(a) 300,000 stock options with an exercise price of $1.87 per share granted to an executive, (b) 25,000 stock options with an exercise price of $1.76 per share granted to a member of the Board of Directors, (c) 7,500 stock options with an exercise price of $5.56 per share granted to a consultant, (d) 25,000 stock options with an exercise price of $4.14 per share granted to a consultant, and (e) 25,563 stock options with a weighted average exercise price of $2.93 per share granted to employees.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">(4) Represents the following options canceled:


(a) 50,000 stock options granted to a former member of the Board of Directors, (b) 13,125 stock options granted to the Company's former Chairman of the Board of Directors, and (c) 10,187 stock options granted to the Company's former employee.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Share-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Balance, RSU (in shares) | shares</a></td>
<td class="nump">213,044<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted-average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, RSU (in shares) | shares</a></td>
<td class="nump">354,219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted-average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, RSU (in shares) | shares</a></td>
<td class="num">(437,546)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted-average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Unvested shares forfeited, RSU (in shares) | shares</a></td>
<td class="num">(11,792)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Unvested shares forfeited, Weighted-average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Balance, RSU (in shares) | shares</a></td>
<td class="nump">117,925<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted-average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On  January 2, 2024, the Company granted 141,510 RSUs, vesting upon one year anniversary of the grant, to members of the Board of Directors. On  March 13, 2024, the Company granted 212,709 RSUs with immediate vesting, to executives and key personnel in lieu of cash bonuses earned for the year of 2023. The fair value of the restricted stock unit is the Company&#8217;s closing stock price on the grant date as reported on the Nasdaq Stock Exchange.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the vesting of 212,709 RSUs granted to executives and key personnel, 174,837 RSUs granted to the Board of Directors, and 50,000 RSUs granted to a consultant.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents the cancellation of RSUs granted to a former member of the Board of Directors.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Share-based Compensation - Noncash Stock Option Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,126,279<span></span>
</td>
<td class="nump">$ 1,244,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">1,126,279<span></span>
</td>
<td class="nump">1,244,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">861,999<span></span>
</td>
<td class="nump">1,004,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">861,999<span></span>
</td>
<td class="nump">1,004,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">264,280<span></span>
</td>
<td class="nump">240,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">264,280<span></span>
</td>
<td class="nump">240,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="num">(1,067,750)<span></span>
</td>
<td class="num">(1,201,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="num">(1,067,750)<span></span>
</td>
<td class="num">(1,201,027)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">58,529<span></span>
</td>
<td class="nump">43,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 58,529<span></span>
</td>
<td class="nump">$ 43,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Shareholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)</a></td>
<td class="nump">437,546<span></span>
</td>
<td class="nump">247,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">30,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares (in shares)</a></td>
<td class="nump">12,253,502<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="nump">$ 18,929,915<span></span>
</td>
<td class="nump">$ 18,929,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConvertibleNotesConvertedIntoCommonStockMember', window );">Convertible Notes Converted into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)</a></td>
<td class="nump">556,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConvertibleNotesConvertedIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=dyai_ConvertibleNotesConvertedIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">49,903,000<span></span>
</td>
<td class="nump">45,850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely', window );">Operating Loss Carryforwards, Will Be Carried Forward Indefinitely</a></td>
<td class="nump">$ 46,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage', window );">Operating Loss Carryforwards, Will Be Carried Forward Indefinitely, Available to Offset Taxable Income, Percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward that will be carried forward Indefinitely, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage available to Offset Taxable Income related to amount of operating loss carryforward that will be carried forward Indefinitely, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. operations</a></td>
<td class="num">$ (5,757,824)<span></span>
</td>
<td class="num">$ (6,766,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign operations</a></td>
<td class="num">(51,335)<span></span>
</td>
<td class="num">(29,052)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Total loss before provision for income taxes</a></td>
<td class="num">$ (5,809,159)<span></span>
</td>
<td class="num">$ (6,795,461)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Reconciliation Between Statutory Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at U.S. statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(4.29%)<span></span>
</td>
<td class="num">(4.19%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">20.59%<span></span>
</td>
<td class="nump">14.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent', window );">True-up adjustment</a></td>
<td class="nump">4.44%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign operations</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.11%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying true-up adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Component of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Section 174 - R&amp;D expenses</a></td>
<td class="nump">$ 2,123,800<span></span>
</td>
<td class="nump">$ 1,769,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock option expense</a></td>
<td class="nump">1,584,700<span></span>
</td>
<td class="nump">1,419,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforward</a></td>
<td class="nump">12,655,300<span></span>
</td>
<td class="nump">11,620,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General Business credits</a></td>
<td class="nump">1,278,400<span></span>
</td>
<td class="nump">1,503,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">34,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use asset</a></td>
<td class="num">(23,400)<span></span>
</td>
<td class="num">(35,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">134,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance', window );">Deferred tax asset, net of deferred tax liabilities</a></td>
<td class="nump">17,642,100<span></span>
</td>
<td class="nump">16,446,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(17,642,100)<span></span>
</td>
<td class="num">(16,446,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents net of liabilities before valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents portion of the deferred tax assets related to operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Segment (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-Term Investments</a></td>
<td class="nump">$ 9,287,575<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Segment - Schedule of Segment Reporting Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,495,389<span></span>
</td>
<td class="nump">$ 2,898,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">1,194,624<span></span>
</td>
<td class="nump">1,975,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices', window );">Outside contracted services</a></td>
<td class="nump">1,503,397,000<span></span>
</td>
<td class="nump">2,677,941,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts', window );">Personnel related costs</a></td>
<td class="nump">473,444,000<span></span>
</td>
<td class="nump">553,741,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther', window );">Facilities, overhead, and other</a></td>
<td class="nump">67,412,000<span></span>
</td>
<td class="nump">65,584,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,126,279<span></span>
</td>
<td class="nump">1,244,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency exchange loss</a></td>
<td class="nump">22,561<span></span>
</td>
<td class="nump">38,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other Income (expenses), net</a></td>
<td class="nump">91,663<span></span>
</td>
<td class="nump">1,434,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,809,159)<span></span>
</td>
<td class="num">(6,795,461)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,495,389<span></span>
</td>
<td class="nump">2,898,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">1,194,624<span></span>
</td>
<td class="nump">1,975,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices', window );">Outside contracted services</a></td>
<td class="nump">1,503,397<span></span>
</td>
<td class="nump">2,677,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts', window );">Personnel related costs</a></td>
<td class="nump">414,916<span></span>
</td>
<td class="nump">510,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther', window );">Facilities, overhead, and other</a></td>
<td class="nump">67,411<span></span>
</td>
<td class="nump">65,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation and related expenses</a></td>
<td class="nump">2,308,566<span></span>
</td>
<td class="nump">2,200,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dyai_BusinessConsultingExpense', window );">Business consulting expenses</a></td>
<td class="nump">764,326<span></span>
</td>
<td class="nump">305,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Legal and professional services</a></td>
<td class="nump">998,630<span></span>
</td>
<td class="nump">931,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other G&amp;A expenses</a></td>
<td class="nump">995,501<span></span>
</td>
<td class="nump">1,244,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,126,279<span></span>
</td>
<td class="nump">1,178,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency exchange loss</a></td>
<td class="nump">22,561<span></span>
</td>
<td class="nump">38,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other Income (expenses), net</a></td>
<td class="nump">91,663<span></span>
</td>
<td class="nump">1,434,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,809,159)<span></span>
</td>
<td class="num">$ (6,795,461)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_BusinessConsultingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense in the period for business consulting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_BusinessConsultingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents facilities, overhead and other for research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents outside contracted services for research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseOutsideContractedServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents personnel related costs for research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Subsequent Events (Details Textual) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2025</div></th>
<th class="th"><div>Sep. 23, 2024</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Jan. 03, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">830,725<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">805,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember', window );">Executives and Key Personnel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember', window );">Executives and Key Personnel [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=dyai_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Executives and Key Personnel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">356,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Executives and Key Personnel [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Executives and Key Personnel [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">133,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">277,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Director [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Director [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">96,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Nonexecutive Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Nonexecutive Employees [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Consultant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Consultant [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the following options granted:

Annual share-based compensation awards on  January 2, 2024, with an exercise price of $1.59, including: (a) 387,500 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 352,500 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 17,600 stock options granted to employees, vesting annually in equal installments over four years, and (d)15,000 stock options granted to a consultant, vesting upon one year anniversary.

One-time awards on  April 11, 2024, with an exercise price of $1.84, including 20,000 stock options granted to an executive, vesting annually in equal installments over four years, and 13,125 stock options granted to a member of the Board of Directors, vesting upon one year anniversary.

A one-time award on  September 23, 2024, of 25,000 stock options granted to a consultant with an exercise price of $1.79, vesting in three months.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On  January 2, 2024, the Company granted 141,510 RSUs, vesting upon one year anniversary of the grant, to members of the Board of Directors. On  March 13, 2024, the Company granted 212,709 RSUs with immediate vesting, to executives and key personnel in lieu of cash bonuses earned for the year of 2023. The fair value of the restricted stock unit is the Company&#8217;s closing stock price on the grant date as reported on the Nasdaq Stock Exchange.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ExecutivesAndKeyPersonnelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=dyai_NonexecutiveEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=dyai_NonexecutiveEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +" >EI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( +" >EI-Y%G$\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DE%+PS 0Q[^*Y+V]-&4#0]>7B4\*@@/%MY#<
MMF"3AN2DW;<WK5NGZ ?P,7?__.YW<(T.4O<1GV(?,)+%=#.ZSB>IPX8=B8($
M2/J(3J4R)WQN[OOH%.5G/$!0^ET=$ 3G:W!(RBA2, &+L!!9VQ@M=41%?3SC
MC5[PX2-V,\QHP X=>DI0E16P=IH83F/7P!4PP0BC2U\%- MQKOZ)G3O SLDQ
MV24U#$,YU',N[U#!Z^/#\[QN87TBY37F7\E*.@7<L,ODEWI[M[MGK>!B5?"Z
M$.N=X)*OI+A]FUQ_^%V%76_LWOXOXUI\,[X(M@W\NHOV$U!+ P04    " "P
M@'I:F5R<(Q &  "<)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4
M?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-
MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( +" >EI<7QVCN0<  #LR   8
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M(   &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;.U:6V\;-Q;^*X0*%+N
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MSNV*EL*8L(!+G[P2_T+^GRUN8"88!OKZ$U>H^@*S1Z $PSP@=[#%PQK75-5
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M(,,++!WVGYWTR#?7O>8ENBI=L>8NXL*6'E>X(;.7"?B^<#C[VA?9H+MS3W\
M4$L#!!0    ( +" >EJ!I]#,KP0  $ *   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;(56WV_;-A!^WU]Q<(L^:;%LRVZ2)@:2=D%;K&W0=.O#L =:
M.EM<*5$EJ3C97[_O*%EQAM0%XDBD[K[[[B=YMK7NFR^9 ]U5IO;GHS*$YG0\
M]GG)E?)'MN$:7];652I@Z39CWSA6152JS'B:IHMQI70]6I[%O6NW/+-M,+KF
M:T>^K2KE[B_9V.WY:#+:;7S6FS+(QGAYUJ@-WW#XH[EV6(T'E$)77'MM:W*\
M/A]=3$XO,Y&/ G]JWOJ]=Q)/5M9^D\6[XGR4"B$VG =!4'C<\FLV1H! XWN/
M.1I,BN+^^P[]*OH.7U;*\VMKONHBE.>CXQ$5O%:M"9_M]BWW_LP%+[?&Q_^T
M[63GV8CRU@=;]<I@4.FZ>ZJ[/@Y["L?I#Q2FO<(T\NX,199O5%#+,V>WY$0:
M:/(278W:(*=K2<I-</BJH1>6'VU@RNA7>FVK2@>$.WA2=8%U'72]X3K7[,_&
M ;9$8YSWN)<=[O0'N),I?0!"Z>FWNN#B,< 8) >FTQW3R^E!Q#><']%LDM T
MG68'\&:#Y[.(-SO@N:=@Z4K7"EXJ0S=!!8XA>,KA#BY[&DZ:Y]0W*N?S$;K#
ML[OET?+%L\DB?76 ;#:0S0ZA+P]FA]YHGQOK6\?TUQ>^"W1I;/[M[Z><.&RF
MJX93^IU1Z)[>MXT.[.C*6*<+16_1]=];Y;#GZ5U-%^T&%2H)F24T2;.,D)X;
M;A#$%=2Z7.%3+]<G;W%$7TJFCQQ*=@;>>/JT7NN<XS8\;51]3S)0 G[PEWRE
MC"&/Y!@#0F0[<5W35PR..@8B^3_HT2,XF^=PA@5M;?A.K\P $[-&F&^(+/[J
M%I7@$&EYJ&B-5-,X>Z<K84#W]#Q+%FG:&3 2*N*[1B/KA#GS7@'!W0_>PGTO
M&*C?+BR[&J:$0);6;9#$H;=UU58[ AULH^Z[G+=H(A?%,8[!"BYW(G (RBL9
MKI$/%K)1VS[2^#^GYS0_24[22=RCV3Q9S([E_26]>'8\G4Q?T1<K[CZGDWDR
MGYW\<MVZO!0"GU9&;Y3,3T_#IMW;%&.-0V2<-O<(FT&("NDJVSK*4:4.<]=C
MJ(4RTN_S$>V^?.4'$9*>43! .&!4K?_M\8&$T-_J@BEG)P7Q("E-A@3VF7XP
MYG&6(9T_L+@+=+-SQ_'W%LGK AU*%:)3OEW]@Y-#"*CB'Y1O]UU.@$+2O&.#
M=,2CL<XCA4)'WD<_27J^U\][05,;QSLB]H'ASM;.8:G\6 NNP.Q"K>6(MH^5
MNFH]>MH_*HL+-$_>.JGIO2AU)2M0J/P5PPE^7#/39#++DFR1=F4S2;+I22)-
M_F3ES)+Y K\TP_#88.?:V9P9_#:>KIRM*. L%Z_DF>QGAK3?C[:)ZLV#>D+*
MPW,)46Z4KKH)J.M;]F&HPY]')(%,;EJ!C.%G%V=^!YD05XVQL=LBO)4Y@B$4
M9-8EM"TU"@Y9QKRI^CAZ%"7FH*YD+#A@B85"HU;1P&B&CF6DI39(+*CRXZ$$
MQVL;4$W\U!$QWCO5P783[R[2,6T=N@-^V!VN1Q?=K>!!O+M;?5!N(Z/4\!JJ
MZ='+^8A<=U_I%L$V\8ZPL@$WCOA:8MBS$P%\7UN<#/U"# R7QN5_4$L#!!0
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MID>0 )W 6GM**PG&D*1:3QR7%0F\$);6N@ 7V'/Z)[3M*^:(.OQ-Z??Q_9A
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M6\PJ[/,7/QM/8BU>B6O:06M_-O= Y;EY/2)<1H3\"80L%^^-]GLGWNF&FH<
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M+"F]:_M'1?[Q-:HZ<%]_E#1 6U#.!0)!D%IUAWX/;J)KX 4'7H)^SE92>%L
M2YV38GCR!BMR?V'I]GQ#QQ$OU$B.$O&A,8#ZE"$[MRJMV@5^=1AB^B,7 =A@
M48R^(PL";/[39#9/QN,Q'F@^&9W\3.OPZ7KX9O^,,2LT:+HNKKY8IR&1+QSY
M+& <O%'8&#5H[#+1@ P4.1BY0M0&9.NYA *N!/:2LF<(O]U_SMC'&<#- S;N
M--BXTV&SXU4[??@0*][G6;<?W ;CJ-I(H/1&K3= U$+!RUCC.T6FC5J#!BL
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M5%: _J\D79K=QCKHA^+9/U!+ P04    " "P@'I:+^-0@D4#   \"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6S-5E%SFS@0_BL[]*9CS]  PAB2
MVIZ)TZ;M3'N3J=/VH=,'&=8VC4"N).ST?OVM !/2.'ZYEWL!2;O[[7[[&:TG
M>ZGN] ;1P'TA2CUU-L9L+SQ/IQLLN#Z36RS)LI*JX(:V:NWIK4*>U4&%\)CO
MC[V"YZ4SF]1G-VHVD941>8DW"G15%%S]GJ.0^ZD3.(>#S_EZ8^R!-YML^1H7
M:+YL;Q3MO XERPLL=2Y+4+B:.I?!Q7QD_6N'KSGN=6\-ELE2RCN[^9!-'=\6
MA )38Q$XO79XA4)8("KC5XOI="EM8']]0+^NN1.7)==X)<6W/#.;J9,XD.&*
M5\)\EOOWV/*)+%XJA:Z?L&]\(W).*VUDT093!45>-F]^W_:A%Y#XSP2P-H#5
M=3>)ZBK?<,-G$R7WH*PWH=E%3;6.IN+RTHJR,(JL.<69V=_2(#!X!5=<;]SZ
M"6]_5?F."RR-=H&7&7PH=ZA-80]@<,N7 O5PXAE*;T&\M$TU;U*Q9U(%##[)
MTFPTO"TSS!X#>%1W5SP[%#]G)Q'?8'H&8> "\]GH!%[8-2.L\<(3S=#0$#S&
MKXD>'8^VG\^%WO(4IPY]'QK5#IW9RQ?!V']]HK915]OH%/KLN#Y/Y/E>5P^W
M>&]@+F1Z]^,8D9.ICA.A7F.Q1-7U&]XIJ77[_(@[%/"EI'M!Y/]@UE\.@B%<
M\US!5RXJA/=29'FYAG=T8^AN]Y%0J/>7V4_ZS5/0E=2F86L9/J%='_P%YVSL
MLB2FU<L7"0O8ZT>K@Y5^=?@;/G%U1Y?<=55F&@*(W"CQW=$X[ (.[P?+HEH:
M:;B L1OY8S>._"?.#Y;%1BKSZA95T1,$%IA6*C<Y<1NP(=%26ZDX?7-S:>L8
MA$/Z^A@!C-T12SK803 ZAV%KB.(8;NLZB)/+QJ$;Q,DCIJW[P1RR&/[4*_P_
MZ,4B-XZC9^1JC4?5HNXDQ"UZJM:#I:]6$+E^KYT]M5K+?U K'B5NX$<]K9*(
MFF^/V;G?*14W2H7A'TK5S@=S&"1P['+P>C=Z@6I=SRT-J:Q*TUSNW6DW&B^;
MB?#@WLQ5ZN3:*B=P1:'^61PYH)I9U6R,W-;S82D-39MZN:'QCLHZD'TEZ5IL
M-S9!]X=A]B]02P,$%     @ L(!Z6LAU/Y:F @  +P8  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&ULC55=3]LP%/TK5V%"FQ3(=VFAC42!:9-@JX!M
M#],>W.2VL7#LS'9H^?>SG9)U4HGVT,8?]YY[SG%\,]T(^:0J1 W;FG$U\RJM
MF_,@4$6%-5&GHD%N=E9"UD2;J5P'JI%(2I=4LR .PU%0$\J]?.K6%C*?BE8S
MRG$A0;5U3>3+')G8S+S(>UVXI^M*VX4@GS9DC0^HOS4+:69!CU+2&KFB@H/$
MU<R[C,[GF8UW =\I;M3>&*R2I1!/=O*YG'FA)80,"VT1B'D\XQ4R9H$,C=\[
M3*\O:1/WQZ_H'YUVHV5)%%X)]H.6NIIY8P]*7)&6Z7NQ^80[/8Y@(9AR_[#I
M8L]&'A2MTJ+>)1L&->7=DVQW/NPE9.,W$N)=0NQX=X4<RVNB23Z58@/21ALT
M.W!27;8A1[D]E <MS2XU>3K_(C1""B=P)>J::F.W5D!X:>9<4[Y&7E!4\/Z1
M+!FJ#]- FZ(V-2AV!>9=@?B- E$,=P:J4G##2RS_!0@,VYYR_$IY'@\B7F-Q
M"DGD0QS&Z0!>TEN0.+QDP (%G<!#^KKL]'"VO33GJB$%SCQS*Q3*9_3RXZ-H
M%%X,<$M[;ND0>GZ+2B'Z\+5!2>QYP"V:=]"'6TJ6E%']XH,6L$18$%KZ<$=T
M*\TJ_'1ZX!&W&N9,%$^_#DD;+'Y8FC$]@W>03?Q)&-DC&$&2^:-D;,=G<'PT
MCJ/X AZ%)LS$33(_2R8P8$766Y$-6K%H95$9[7MOJ@\WVX*UI?-%\/7)(\IZ
M;_\_71BL.^A"[$=)ZJ>CL#,B\M-XXH=I>MB+Q,]&YA>F!^T(]BYQC7+M6I6"
M0K1<=_>Y7^V[X677!/Z&=ZWTCL@UY0H8KDQJ>'IF%,JN/743+1K7$I9"FP;C
MAI7IZ"AM@-E?"7,G=A-;H/]&Y'\ 4$L#!!0    ( +" >EJK_#[G3 ,  !,(
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;(56;7/:.!#^*SON78?,
MT/@%0TP*S 1HI_G0'I.D=Q]N[H.P%_!$EGR2"*&__E;R"Z0%[@-H=[7[[+/2
M2O)H)]6SWB :>"VXT&-O8TQYZ_LZW6#!]+4L4=#,2JJ"&5+5VM>E0I:YH(+[
M41 ,_(+EPIN,G&VA)B.Y-3P7N%"@MT7!U'Z*7.[&7N@UAH=\O3'6X$]&)5OC
M(YKOY4*1YK<H65Z@T+D4H' U]N["VVEL_9W#GSGN])$,MI*EE,]6N<_&7F )
M(<?46 1&PPO.D',+1#3^K3&]-J4-/)8;],^N=JIER33.)/\KS\QF["4>9+AB
M6VX>Y.X+UO7T+5XJN7;_L*M\X]B#=*N-+.I@8E#DHAK9:[T.1P%)<"8@J@,B
MQ[M*Y%C.F6&3D9([4-:;T*S@2G711"X7=E,>C:+9G.+,Y)LT"'WX #,I7E"9
M?,D1K%'#@NV9U3I/=M!7(]]00AOFIS7XM */SH"'$7R5PFPT?!(99F\!?&+:
MTHT:NM/H(N(<TVOHA5V(@BB^@-=KR^\YO-Z%\C54!9ZJKXJ.3T?; W.K2Y;B
MV*,3H5&]H#=Y_RX<!!\O<(M;;O$E],GQCLQQ:>!OQQ.>\-7 E,OT^9]3E"^"
MGJ;\1?(,%=QKO64BI6R,FF*^K85[89!<#3Q8[><^@87*19J7C!])#UBR/1U=
MHVM_=X:-)*TH2'HTQ/[(_X^MT8:)+!=K^*R(0ZY3"4^*^A\RRII!Y$>)'PZ'
M ^B$5Q#T_"#QH[@1;B#Y'7Z#L!L$@?V1_/Y=$H71QS?287ZJ6,9Q#Y\*QE=,
M+:$3G4'MUQ$-2J<Q7+6F!NPQE<8<(.^5PA>95GOF2CF;) Y_2M(8#DE:V#GJ
M%.DX"=.@]LZ@#M^"-F-M_O7 ?Z!]XVZU%TR9/2U8=')!.\.6':UH#?==L$(2
MW \*=]W:=M-,:O,K>">*NR$1OH)O]/3,F%)[N_MWA=Q296ZO!OUN<C,X2?1I
MDZL&Z4PSQ!>;X3#[_\2/DW62I-N/AF=I][K#,.S&-R&<N@'\HXNZ0+5VSY&&
MU 97=W9K;5^\N^JB/[A7S^57IM:YT,!Q1:'!]4W? U4]095B9.FN_24UI2R<
MN*%7&Y5UH/F5I+6L%9N@_0Z8_ =02P,$%     @ L(!Z6O/';Q,/!0  & T
M !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULI5?;;MLX$/V5@7=;.( L
M4]35;6+ 22_;AVZ#)&U1+/:!D<8V$5V\)&TG?[]#2E9<U.NDVQ=K>)GAS)PS
MY/ATVZ@[O40T<%^5M3X;+(U9O1J/=;[$2FB_66%-*_-&5<+04"W&>J50%$ZI
M*L><L61<"5D/IJ=N[E)-3YNU*66-EPKTNJJ$>CC'LMF>#8+!;N)*+I;&3HRG
MIRNQP&LTGU>7BD;CWDHA*ZRU;&I0.#\;S()7YZG=[S9\D;C5>S+82&Z;YLX.
M/A1G V8=PA)S8RT(^FSP LO2&B(W_NEL#OHCK>*^O+/^SL5.L=P*C1=-^546
M9GDVR 90X%RL2W/5;/_ +I[8VLN;4KM?V'9[V0#RM39-U2F3!Y6LVZ^X[_+P
M' 7>*7#G=WN0\_*-,&)ZJIHM*+N;K%G!A>JTR3E96U"NC:)527IF^F=C$!(8
MP?52*!S9  NX:"H"70N7M^&-N"U1GYR.#9UGM<9Y9_N\M<W_PW; X6-3FZ6&
MMW6!Q?<&QN1H[RW?>7O.CUI\@[D/8> !9SPZ8B_LHP^=O?!(]!K:  _%UVI'
MA[5MO;S2*Y'CV8 *0J/:X&#Z\K<@8:^/^!;UOD7'K$^OJ?Z*=8G0S#MPSATX
ME^*!BL+ ;"M4X<&U:?([^+2R6&D/OHARW>(VTU1H[33\Y4*$&[PW<%Z2PM^'
MHCWJS^%HOZ%0';Q X&!UBZH'R/Z$<"7UW6BN$$'6!DG3@!)$NM"/DQ=$O,A/
M GA!PPFC8>P3:U[ V_L5E2T9+>1&%E@7\""Q+.#E;QD/^&O:\2CU>[5+Q4K)
M'&'3E)2&4IH'2$*?\1'])A'M3KC/.7TBGZ?[RJ6<NU0W7<J&LH8'&]T)<#\)
M1XG/8PC\((16/()PW",<'T?X$*I*B7J!5O8Z5#V8V:O+AO(\'(^>>AC'K^[V
MPF($LPTJNHWA<>8*[>4NZP7,%@N%"PO>;M<%U;>BFW4M2OA HJ3;.F_I2K2X
M1Y5+C7#I(+E!5<'P6YM3RU.$3VNCC:@+:UR8'QC$(?88R6R2PN_$$$I[[*<Q
MR4'H,<;@/27+@I>QV MC1OA$<7_L(UMV7P);*IH?AG'@Q9S!"6FD 5R(.J=W
M@A:"V$LR.T_L9$^Y%Y)[43+Q>-2ZQS)R+TFLS+F7AEGOWS X@2QD7NHX1'Q_
M]''(3V 8QRX<ZTZ0[;E)2V%&H28A6!H&R9ZK$2VFH1=2O;@PPJ?<C<C=-,N\
MV&63^_2)_3 B.:'SXS3;>>4X=M! Y$5AYF4!<_$&$RK>R!J(PL3CY.21HDCZ
MHDA^K2BNZ 8A/MFTMG<?1?SCY.=:FI\NG*.>/5$XNXIPD,,;6R1=&;P34CV/
M[R%P2VQ**1$Y_(X]81QYG!).[&'PA:+=42<*4R^.$L>!F%/<FW91MX=3VS9'
M:79L"@(OG;2$B2=/$R8(4F_"7<'9_4?@37MXTU^#]R<A.WK:_WZSWF--:):.
M6J*@MDL2O83M'VTJJ!Y3+XV9DSFC,3TEQ$"RFR^=3H$;:G=7+KJ8*HY3I1"P
MDPAN&D-VK6+ J6;226LDBF@<P#-<V^_3\OT^#>^MC'K4O8/M0T;FLR3P)I/V
M(,8BC\71<ZRHQY)J#:ZII#3PA(A(5R2/F,W#$P$=8LQXKUNM4"U<3Z[)C75M
MVL:UG^W;_EG;[3YN;_\S?!1J04\.E#@G549OPP!4VX>W ].L7.][VQCJI)VX
MI+\NJ.P&6I\WU %V WM _V=H^B]02P,$%     @ L(!Z6F-EL4%@!   5PH
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M6+U,$?\-8N K/EM8MJI\_/\U7:<K_XM"[_<,J./8K5!/77>/F(@\H=Q2[]Y
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M:7G"U_Q2-?"89M_J;E_^#U!+ P04    " "P@'I:O^24I8D"  !Q!P  &0
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M,=#[!=>EW4U,I^A_#.E_4$L#!!0    ( +" >EJ/GO#4H0(  -8&   9
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MK37-$G\\H&P SN<2+Z.N8^^V_E<V^0=02P,$%     @ L(!Z6C.9TD;H @
M*0<  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULC95=3]LP%(;_BA7M
M B1&FL\":BN5%C0N&%4[MFN3G"86CMW93@O[]3MV0E;ZI=VTMG/>-\\YMD\&
M&ZE>=0E@R%O%A1YZI3&K&]_760D5U9=R!0*?+*6JJ,&I*GR]4D!S)ZJX'_9Z
MJ5]1)KS1P*W-U&@@:\.9@)DBNJXJJMYO@<O-T N\CX4Y*TIC%_S18$4+6(!Y
M7LT4SOS.)6<5",VD( J60V\<W$Q2&^\"?C+8Z*TQL9F\2/EJ)P_YT.M9(."0
M&>M \6\-$^#<&B'&[];3ZUYIA=OC#_=[ESOF\D(U3"3_Q7)3#KTKC^2PI#4W
M<[GY!FT^B?7+)-?NEVS:V)Y'LEH;6;5B)*B8:/[I6UN'+4&0'A&$K2#<%<1'
M!%$KB%RB#9E+:TH-'0V4W!!EH]'-#EQMG!JS8<+NXL(H?,I09T;?I0$2D*_D
M2154L#^T*:[(R:+95R*79,$*P98LH\*0<9;)6A@F"C*3G&4,-*KGH(&JK'3*
M*:SQ=*QPKPV92&TT.9N"H8SK<PQ]7DS)V9=S\H4P07Z4LM:HT0/?8#:6R<]:
M\MN&/#Q"'H3D40I3:G(G<L@_&_A8AJX6X4<M;L.3CE/(+DD47)"P%\8'@";_
M+X].X$3=UD3.+S[B]U0;S7(@&6:I\+A#3C2H-<O@8+4:L\29V;N['@5)+XJN
M^P-_O9W$?ER8]OO7<=#%?:*-.]KX).T,E)9" ,>[S:F%S>S6'R)MC-(M@K@?
MQ7&\ [H?EB11_QAGTG$F)SGO:<8X,WAL+XA<@RJQ];E3*TT)ZA!NLL>1(D6X
M0WL@*DFNXL.P:0>;GH3MKM5XYUK=O6$;UW!!'D3&Z]S>QGE;]AE5YOU0'NG^
MQO?B.$RBG4SVXZ+PNA^FZ4XN_E;7J4 5KAEKXMI#<^FZU:;?WV*_=WUQ9QV_
M V/7_OQ_-LU'Y)&J@@E-."S1LG?91RK5-.9F8N3*];87:;!3NJ'=4% V )\O
M)?:W=F)?T'T=1W\!4$L#!!0    ( +" >EI"W!,7@@(  .T%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;*U4WT_;,!#^5ZQLFD JY%>AC*61: N"
M!Z:*CNUAVH.;7!L+QP[VI87_?K83LM*UU1[VDOC.]WUWWR5WR5JJ)UT ('DI
MN=!#KT"L+GU?9P645)_*"H2Y64A54C2F6OJZ4D!S!RJY'P7!N5]2)KPT<;ZI
M2A-9(V<"IHKHNBRI>AT!E^NA%WIOC@>V+- Z_#2IZ!)F@(_55!G+[UAR5H+0
M3 JB8#'TKL++<=_&NX#O#-9ZXTRLDKF43]:XRX=>8 L"#AE:!FI>*Q@#YY;(
ME/'<<GI=2@O</+^QWSCM1LN<:AA+_H/E6 R]"X_DL* UQP>YOH56SYGERR37
M[DG63>Q@X)&LUBC+%FPJ*)EHWO2E[<,&(#S? XA:0+0-Z.\!Q"T@=D*;RIRL
M"46:)DJNB;+1ALT>7&\<VJAAPG[%&2ISRPP.TZ\2@43DA(RI+GKN2:Z?:[:B
M' 3J'J$B)W=B!1I+ZR!'$T#*N";?X 5KRH\-]G$V(4<?CQ,?3466U\_:[*,F
M>[0G>QB1>RFPT.1:Y)"_)_"-E$Y/]*9G%!UDG$!V2N*P1Z(@ZN\H:/SO\/A
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M]LFU+)MI.=%B4?2CF=#4W8IA3/\?*,T&>A[1-[V9& ?5'TWO-U!+ P04
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M#P$IX<A.PMZI[@L,>;S!0@GC?TG7]RZC@!0G8Y4<P.A \J9_LL?A'BX T35
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MH#072B-0&H72&)3&K>I*$;6#1F2E/HJF"DD:(ZP#QHCYS2RY"\-,_W@/ZH*
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M*,V%T@B41J$T!J5Q*,V#TGP43=62M!N,FFR'<:\94[F@\>'I4GTTK=4%]2-
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MNG?@>H%Z/F.JH:L&^@7U_X'P-U!+ P04    " "P@'I:-8\D*6P'   ((P
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MH)T3Q6<7Q8GDB_R[@B<N)4_RPSFC4R:4 -Q_YEQN3I2![<<O-_\#4$L#!!0
M   ( +" >EH[!USEH 0  &\/   9    >&PO=V]R:W-H965T<R]S:&5E=#0T
M+GAM;,U7;6_;-A#^*P=O&%K L41)CN/,,5 G;;<!:8-D23\$_<!(9TN(1+HD
M92? ?OR.E"P[MJ.D P+LBRV2]_(\=WRY&RVENM<IHH&'(A?ZI),:,S_V/!VG
M6'#=DW,4M#*5JN"&AFKFZ;E"GCBE(O<"WS_T"IZ)SGCDYB[4>"1+DV<"+Q3H
MLBBX>IQ@+I<G'=9935QFL]38"6\\FO,97J&YGE\H&GF-E20K4.A,"E X/>E\
M8,>G++(*3N(FPZ7>^ 9+Y4[*>SOX,SGI^!81YA@;:X+3WP)/,<^M)<+QHS;:
M:7Q:Q<WOE?5/CCR1N>,:3V7^+4M,>M(YZD""4U[FYE(N_\":4-_:BV6NW2\L
M:UF_ W&IC2QJ94)09*+ZYP]U(#84PN 9A:!6"+846/B,0E@KA(YHA<S1.N.&
MCT=*+D%9:;)F/UQLG#:QR81-XY51M)J1GAE_D0;A$ [@*N4*#VQ$$CB5!6T3
MS5V@#^ 2M5%9;&CERLCX'JY%9C2\.T/#LUR_;Q&YO+JF]=MS+.Y0?1]YAB!;
MQUY<PYM4\()GX+$ SJ4PJ8:/(L'DJ0&/N#:$@Q7A2=!J\0SC'H2L"X$?1/ K
M>* M<UW_M7@(FY"&SD/TC(>OI=&&BR03LRY,>,Y%C%V@2,"[3-1NWL,_>QU6
M#"K[A\Z^/8>+<<!"/XI&WF(/KJC!%;T>US>WOS$YX M4=%[AL^+" .TAA$\\
M4W##\Q(=XD3F.5<:YJ@JS!;\.G#["%1 F+_!@/6B<#_^?H._WXK?(<3DYT+9
MWPEEV(\"-FR@.+'3=L^W['O+OCAL\!^^#O_;QKX",7P2^L,MNNU V^D.&KJ#
M5BLW="7\;+8&.]DZB,)!/]K&W^[Y-FC#?]3@/WH5_K?-UM&^D](/MOBV(VWG
M.VSX#ENM7(N%8[RZ#ZE$F&+VTRD<[J:0L<%PFU$[EMNPC1'SUX^;_U\YO6U:
M:US;>=V^=EZ _T(8-MYX]L8O4NU@,ZTNJ_W]5SH+UM""_\NC5"-Y/B=/*=CG
M_NG,^J%E[2\M7:!?!<!?7)14&D-0%1M=,"FZVHJ+1YA5KP&PB'7[S+?9T%VP
MVY5" >6<*B\I$!Z1*^!"4*VKM#4FI\Z,4R>+$@I76^G5PD1RE=C!6::H5)9*
M]\"".><J3H&%;5@"%G0'_M!AH3K4I) 5!2:9C7^-S+G$!XQ+6WYK@I; /3[:
M/&@I!.9 R<DS+"V$F.L4[J0H-4D2$4$^Z @ZWXX8R1":L =_T\S49GCA,EQS
M4>NJ4KNJLJ2J$C*]"?ZW7XX"-OA=0YQ+;4-72<Y)C^R(=; @L32X)JMSJ:S-
M>O4+UPG_4=>M'Q_BE(L9]NA2O43JC#0*4SE<Y<:"W@S4*GHO!*8+;!!UC\+!
MCM;^M'6=B;[?]7U_1X5#+(6F5H5F>G1-;$&-[0FG ^(*>#*ZJVX;0#HZU>9I
MV3O[[A]OH]T@(S/7A5$"9"E,5<XULZM.+Z16SS4L6RN3X/@TV#-/)VS5'&YK
MV*YQK\;Q!V?)6T.J6E':^;-,:,AQ2O#\WH"*/55U=]7 R+EKD.ZDH7;+?:;4
M$:.R K0^E=0DU0/KH.FQQ_\"4$L#!!0    ( +" >EIVL^+=L@,  #</   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;*U746^C.!#^*Q9W6G6E;<$.
MD*2;1&J2W;M[Z%[5J'</JWUP81)0 7.VDW3__=F&$I(0DJYX:8R9^?AFYJO'
M,]HR_B(B (E>TR038RN2,K^U;1%$D%)QPW+(U)LEXRF5ZI&O;)%SH*%Q2A.;
M.(YOIS3.K,G([#WPR8BM91)G\,"16*<IY3^GD+#MV,+6V\9CO(JDWK GHYRN
M8 'R*7_@ZLFN4,(XA4S$+$,<EF/K#M_.L*\=C,4_,6Q%;8UT*,^,O>B'O\*Q
MY6A&D$ @-015/QN809)H),7COQ+4JKZI'>OK-_2O)G@5S#,5,&/)OW$HH[$U
ML% (2[I.Y"/;_@EE0)[&"U@BS%^T+6T="P5K(5E:.BL&:9P5O_2U3$3-007:
M[$!*!W+HX)YPZ)4./1-HP<R$-:>23D:<;1'7U@I-+TQNC+>*)LYT&1>2J[>Q
M\I.3;TP"\M$U6D24P[7.2(AF+%4R$=0D^AI]8UE 1806D@4OZ._<;._97,U!
MTC@1'Y7UTV*.KG[_.+*EHJ<_8@<EE6E!A9R@@@FZ9YF,!/J2A1#N ]@JKBHX
M\A;<E+0BSB&X03W\"1&'N V$9I>[]UKH]*I<]PR>>P+/Y*],<5!+7U.J"B3/
M(.E_Q<T$8^*3_G!D;^H1--@1U\4$5W9[5-V*JMM.M::&.E4$KWH-HHES >F?
MY=Q@U\;9JSA[%W">&LX/]*<Z:R2ZXYQF*]#K3V_*_7X/Z3/P'TTAM'Y!'ZFW
M(J<!C"UU9@K@&[ F'W[#OO.Y25T=@>TEPZ^2X7>F-?^H'@,?#X>'93LVPX[C
M.I[;7+9^Q;3?O=3ZEU$^-FNE/*@H#UHI/X*0/ ZD8ER<B4]9+ 6Z>EP\J2.P
M35^MN._55T=@>RD85BD8=J:OX5$5B.^2@7-0K 8S5UU&^LVUPLZNPSG="ZS$
M/$NZR:Z-=:TOXU;6?T &G":(9B&Z"U7GCY7FJ+[SH"\%[U:AM:._5VE=H>WG
M@NQR03H36PE5+\@U5O7H>T>E:[(D#G;(J>+M&CT^T^E_27*]BYDW6;8RW_5]
MW-[XU=$&E >1T=T<-NJ>GYM.>I'H6K'?+;J.T/8SL;M-X#/7B?>(SCLJB#?P
MR&$[:C!S>\[P1#?"NUZ/SS3[7Y*;?W1U;.1\;-;$V:Z-("GPE9G,A&*SSF1Q
M8:]VB^EOJJ<_/<(<[*NI\,[,0O8.IA@I[RE?Q9E "2P5I'/35YQX,:45#Y+E
M9M!Y9E*-3689J<D6N#90[Y=,#3OE@_Y -2M/_@=02P,$%     @ L(!Z6IXX
M[;[< P  * X  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULO5=;<]HX
M%/XK&F]G-YFA\=U %I@)T,[V(2D3FN[#SCX(^X UL24JR9#\^Y5DQS&7F*3-
M[ M8\KE\W[E81X,MX_<B!9#H(<^H&%JIE.M+VQ9Q"CD6%VP-5+U9,IYCJ99\
M98LU!YP8I3RS/<>)[!P3:HT&9F_&1P-6R(Q0F'$DBCS'_'$,&=L.+==ZVK@E
MJU3J#7LT6.,5S$'>K6=<K>S:2D)RH((PBC@LA]:5>SEQ?:U@)+X3V(K&,])4
M%HS=Z\679&@Y&A%D$$MM JN_#4P@R[0EA>-'9=2J?6K%YO.3]<^&O"*SP (F
M+/N;)#(=6CT+);#$129OV?8OJ B%VE[,,F%^T;:2=2P4%T*RO%)6"')"RW_\
M4 6BH>!&+RAXE8*WKQ"\H.!7"B9R=HG,T)IBB4<#SK:(:VEE33^8V!AMQ890
MG<:YY.HM47IR=,,DH"[ZB.8IYI"R+ $N_D"??A1$/J*S*4A,,H&^P8,L<':N
M!._F4W3VX7Q@2^5>&['CRM6X=.6]X,KUT#6C,A7H$TT@V35@*]PU>.\)_-AK
MM3B%^ +Y;@=YCA<< 31YO;K? L>O8^D;>\$+]N:2Q??HBQ %)&A:<$)7: :<
ML*13AE=TT"T(R4DLE40I?K7%7+V_41W+EDB5YA*(+)0L.B,4":-V--@EELA@
MT<VZ&05^-PRB@;UIAN!0S NZ_<BMQ7:H!C75X)>IWJ@>-A(GJ00'&'TGC/I[
M3%H1Z<_=I5CC&(:6^IX)X!NP1K__YD;.GRVI#6N^82O?;^H3*0K^6":M@R8L
MSQE]XGJ*7WC S_6\T \=;X_B*P1WX$<U_.A-\+_CK(!C2$LS81- K^_U^VZX
MA_05@CM(NS72;BO2@_ZXHT2J -_.[\0Y^N<:\@7P?X]!;[7[^O(HZ;V3L9T0
M].H0]-I[JZRILKDZ:*;" ;JYRF(SM9:P+,-<H+7:-75WM.Q*-Z[33-)%N%]S
M1Z7\WO$T]FL._=,</H[5^9J@&7Y4Y[Y$5YQCN@+]W$%?U^84;TMHJX>W)O2=
MC.T$PW6>#UGG_TEIY6<O6TZPE]-V.#]+MS%3N*UT)XQN@$NRR #I 4.@:D=5
M Z&259_/JL/;:J#=T5N+X+VL[8;%>PZ+]\N'9ADH,R2K<: 9R#G$2D62T\=-
M!:-YC(1A%.D99[=*6N'^;#B>IR7WQ+CT;DWA'VN*Z(!N*YRWTK4;,W<.?&6N
M(@+%K*"RG&#KW?*Z,];7'3VS[^VK:]"5&?[M9S/E'>H:\Q6A F6P5":=BZXZ
M;GEY+2D7DJW-9+]@4MT3S&.JKG+ M8!ZOV2J^:J%=E!?#D?_ 5!+ P04
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MP6GA7I<XST%9!]Q/)/;X8F$/*/\AC'X!4$L#!!0    ( +" >EH;''--@ (
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M(5T2:4VT!VD/5;MUKZE]25"Q\8 T[;<?8-=S!;;V)C;F_G>_.\+!\L3XO3@
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MQ1!%J45J6\7)9$GS@3.?Y32'PAG;G1T5)-9]PP686Z'/HMBNI<,L3HLIQ&)
M+.9+*0_ 752%%<[>U;9-&">32(L!:3&+-'1;J;JMJ=H[U(!IQ-5XZGG5B;LU
M+6RX/$NBT,K"89@E23:YZ\/@W]D2S&9RB^D1=Z<U5?<%W)3.[M1[>;&T$ZQ.
MTWG:T4D8SG<I5>/*JKT3.+3:N04Z9](!^J-36U^9OF&^)XU0>WJG-,%YKL2\
MNX5T \E:<Y#?,:FN!>;UH&YNP+6!FM\Q=9CW WTW&.Z"Z[]02P,$%     @
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MDN.?)JC5/E,Y'E\?HG^H)B\G\YAPF-/\SVPAUE,KLM "ELDV%_=T_SLT$ZH
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M^S95"L&:O?L%!\Y[G=2]5;27<^^D#_]W[6M<@Q^*G\;0J'ZXDS_\__4/_ZP
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M7TZH/Z8)7X!]?QO'V>(-;V#YH/>S_P%02P,$%     @ L(!Z6O_[(G!# P
M3!0   T   !X;"]S='EL97,N>&ULW5A=;]HP%/TKD;M.K30U0-9 5D#:D"I-
MVJ9*Y6%OE2$.6'+LS#$=]-?/-P[AH[Z(]6$M"VICW^-S[K%]0]SV2[,2['[.
MF F6N9#E@,R-*3Z%83F=LYR65ZI@TB*9TCDUMJMG85EH1M,22+D(.ZU6'.:4
M2S+LRT5^FYLRF*J%- /2;4*!NWU-!Z0=?R2!DQNIE W(P\7[7PME;MX%[G[V
MX>RL]7!YLQ^_J(!+$GI%KX\0O6K9"U6N4$P^/E+^H#HFWCU*_( T)MP[SO4A
MTYATLBN]'GYNM1KN.4+NMCSD#=/1PKJ8AOU,R4U-1<0%K"[-6?!(Q8",J. 3
MS8&5T9R+E0MW(#!50NG V&*VB=H0*9\<W'8]J/-:)^=2Z2JWR^!^3^KA>\"Z
M!P:Y$(W!#G&!8;^@QC M;VVG&EP%GT%!W1ZO"NMPINFJW;DF&T)ULTDF2J=,
M-VG:9!T:]@7+P([FLSG<C2I" (U1N6VDG,Z4I)6'-:-N6-DI$^(>O@1^9CO:
MRVQKQZK]DDW3&JJ;3L9U0'];S6EORT8OT@T*_JC,EX6=CJSZ4*#L3K.,+ZO^
M,FL,8.IM7)T6A5A]%GPF<^8F?W3"89^N><%<:?YDLT&I3&V :1(\,FWX=#OR
M6]-BS)9F74[+#/?<.4'/_W:=9TPR3<6V:5O[;WF57^RX?FN^AN?J:V7?L==D
MU'W['NN3PELW&9^"R9/8[MXIF$Q.P&3WU;XU#YH,ZU/&UE%FYR#31 ,X, [(
M#SAXBDW28++@PG!9]^8\39E\=IZQ\H9.[)]*._IV?,HRNA!FW( #LFE_9RE?
MY$DSZ@X6HAZU:7^#Z;7CYK1J<W&9LB5+1W57SR95,[ -F[6^@+"/W%:7'\$X
M#O,C@&%Y, <8Q[&P//_3?'KH?!R&>>MYD1[*Z:$<Q_(AH^J#Y?%S$GOY9YHD
M413'V(J.1EX'(VS=XAA^_&J8-V!@>2#3WZTUOMMXA1RN VQ/#U4(-E.\$K&9
MXFL-B'_=@)$D_MW&\@ #VP6L=B"_/P_4E)\31;"KF#?L"<:1),$0J$5_C<8Q
MLCHQ?/S[@STE490D?@0POX,HPA!X&G$$<P >,"2*JO?@WOLH7+^GPLW_#X=_
M %!+ P04    " "P@'I:EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y
M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI
M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W
MO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:
M>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B
MM/XU@LD/['X 4$L#!!0    ( +" >EHIE)LT9 0  .LC   /    >&PO=V]R
M:V)O;VLN>&ULQ9I;;^(X%(#_BL7+=J2=A=SH1<-(LVUW%VEVB@J:UY%)#%A-
M;,9VZ.77K^T([4E;'\U+S M@QSA?CO'Y')-/CU(]K*5\($]-+?1LM#-F?S4>
MZW+'&JK_D'LF[)&-5 TUMJBV8[U7C%9ZQYAIZG$ZF4S'#>5B]/G3L:^%&L."
M-*PT7 I;Z2J^<_:H_S_NBN3 -5_SFIOGV<A_KMF(-%SPAK^P:C::C(C>R<=_
MI.(O4AA:+TLEZWHV2KH#WYDRO'Q3O720*[K6OL;0]3VU(+/1=&([W'"EC6_A
M^Z>6\<!LXZ[4&OD7KPU3-]2POY5L]UQL73?V*L;@,GP<CN]=$*_4KX11;C:\
M9#>R;!LF3!='Q6H'*/2.[_6("-JPV>C8A'P1%;D5Q@:)S$77E6WKKM2>>EYU
M5VTL+HBANN+V@)I7'GPXR&M;EC6O[-DK\B>MJ2@9\<'5 #!% -.3 9*S!060
M&0*9181<.@CW!4WDAMSMF0*0.0*9GPQR:60)( L$LC@9Y#75.P Y12"GPT+.
MA>854V2E:&6S"_FB%!7;CA00GB.$YP.'\7G-E&9EJUS6N>?Z@?Q+!>T8"9PU
M%PCDQ;"0WZQ@2$(^DCNUI8*_^!:$VFRY;)L&0EXBD)<1(%,+Z7Y^O_M7<ONS
MY0=:OQKN9(*E\4D$S,QBWC/-J"IW/H[75JIT+16,98+:9F#=>,S<15,V#3?=
MW.Y(K2![3L2<DPPL'8]9>$QQ<$L4>WKB*C59T.=>-#'K) -KQV-.+>9R1Q7[
MN*::N4@VMDMM6T-,S#O)P.+QF.='S)VL;>[4O_E99)XA).:=9&#Q>,@+"SD7
MI6P86=$GUIO=F&^2@87CX2Y=!-G6-85<F&62@3739?") VO7FOULG5UN#Z\3
M(^:89&#)+/E6<-N6NH5X6<K6Y9DM6=A%1LG[(XQ9)HFAF9 +?Z1P+8YI)HVA
MF9 -^YB89M)3:J:/B=[:G%(S?4Q,,^DI-=/'Q#23QM#,ZPQ.SE;48N@/D!+S
M3!K#,R"5OPN(N2:-X9I@)LH@)J:>-(IZ0I@YQ,3TDY[R'N=' 3$Q_:0GU<\4
M[K)@^LEBZ">(>0XQ,?UD,?03Q+R F)A^LACZ"<H<SO0,W5N+H9\@)ISI&::?
M+(9^0G?@/4MFF'^R&/X)+HUZ@XY9*(MAH2!F;] Q"V4Q+!3$A.D]PRR4Q;!0
M<*'9&W3,0ED,"P4QX:#GF(7R&!8*KH=A-'/,0GD,"P4Q>]'$+)3'L% 0$TZA
M'+-0?M*;(+A"RM'_>&)8*(@)5T@Y9J$\AH5"6X+D#&)B%LIC6.CM+>4-,Y37
MFD!,S$)Y# N]P?12VDO!("9FH3R&A=[!O&>E%"7<KLXQ"^4Q+!2*9F\A5V 6
M*F)8J+>1</Q9KMB3:2$F9J$BAH4@IOUDNZU:JW:Y@5.HP"Q4Q+#0^SO9+K 0
M$[-0X2TT/CY<4K$-%ZSZ9D^A;7U)ZW*AB'OK_N+*"[?IO&GK^MK6W8FODE;'
M9U6.S]E\_@]02P,$%     @ L(!Z6GQ^Z1O4 0  QA\  !H   !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<\W9.T[#0!2%X:U$7@"3^YCP4$)%0XO8@!4F
M#Y'$EF<0R>Z)0A&.14&#YE36V/+U7UB?K/'\)>W:LNT.>;/M\^2XWQWRHMF4
MTC^$D)>;M&_S3=>GP_G*JAOV;3DOAW7HV^5[NTY!I]-9&'[.:![G/V=.7D]]
M^LO$;K7:+M-3M_S8IT/Y97#X[(;WO$FI-)/7=EBGLFC"<7<]G</E(#?GR<WD
M^6W1#,]OTH3:00I!6C_((,CJ!SD$>?V@"$&Q?M ,@F;U@VXAZ+9^T!T$W=4/
MNH>@^_I!,D49IP1)(ZP)M!;D6@B\%@1;",06)%L(S!9$6PC4%F1;"-P6A%L(
MY!:D6PCL%L1;"/16U%L)]%;46PGTUM''-H'>BGHK@=Z*>BN!WHIZ*X'>BGHK
M@=Z*>BN!WHIZ*X'>BGHK@=Z&>AN!WH9Z&X'>AGH;@=XVVBPAT-M0;R/0VU!O
M(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M1;R?0VU%O)]#;46\GT-M1;R?0VT>;
MW01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>D?4.Q+H'5'O2*!W1+TC@=X1
M]8[_J7<NIUW*UY[O-3[_/ZDNYWO3]?&7Y??)T:MRP3G ;_O'+U!+ P04
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MR4\^ 5!+ 0(4 Q0    ( +" >EI&QTU(E0   ,T    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ L(!Z6DWD6<3R
M*P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ L(!Z6IE<G",0!@  G"<  !,              ( !Y $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "P@'I:7%\=H[D'   [,@  &
M            @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ L(!Z6J<D&CX_!P  :B(  !@              ("!%!   'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +" >EJ/K^3UV0(  .L)
M   8              " @8D7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "P@'I:M$;QP:4%  !7&@  &               @(&8&@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ L(!Z6KOG]_2R
M!@  .B8  !@              ("!<R   'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( +" >EJRSD?W0P@   \H   8              "
M@5LG  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "P@'I:
MU;TD4*P"  #1!P  &               @('4+P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ L(!Z6E2,=.<D"0  /"   !@
M     ("!MC(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M +" >EJ^<R6]VAP  #-2   8              " @1 \  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "P@'I:9MUU67T%  !B#0  &0
M            @($@60  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( +" >EHP)<5,^@0  '\+   9              " @=1>  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ L(!Z6H&GT,RO!
M0 H  !D              ("!!60  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "P@'I:+=6N"RX'  !,$@  &0              @('K
M:   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +" >EJA
MZ^;\3PH  'D<   9              " @5!P  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ L(!Z6A>? \#/ @  =08  !D
M     ("!UGH  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +" >EK9,BH3-00  " +   9              "
M@8"F  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ L(!Z
M6B_C4()% P  / @  !D              ("![*H  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "P@'I:R'4_EJ8"   O!@  &0
M        @(%HK@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( +" >EJK_#[G3 ,  !,(   9              " @46Q  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ L(!Z6O/';Q,/!0  & T
M !D              ("!R+0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "P@'I:8V6Q06 $  !7"@  &0              @($.N@
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +" >EIH!P0R
MK@,  &@'   9              " @:6^  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ L(!Z6M'**-\@$0  0M,  !D
M ("!BL(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "P
M@'I:O^24I8D"  !Q!P  &0              @('ATP  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( +" >EJ#AO]?=@(  $\&   9
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M970S,RYX;6Q02P$"% ,4    " "P@'I:^NVZ5N\$  !^$P  &0
M    @(&FY   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M +" >EHV9;, _ D  *9R   9              " @<SI  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ L(!Z6M^ \>SH @  W0@  !D
M             ("!__,  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " "P@'I:7[L[7!$"  #&!   &0              @($>]P  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +" >EHC&\L##@(
M ,,$   9              " @6;Y  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ L(!Z6L#V>E?7"@  ?5X  !D              ("!
MJ_L  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "P@'I:
M@=T_RS0)  !4/0  &0              @(&Y!@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( +" >EH](<5V<1<  /Y' 0 9
M      " @200 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ L(!Z6C?%Q2,^ P  &PP  !D              ("!S"<! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "P@'I:-8\D*6P'   ((P
M&0              @(%!*P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( +" >EH[!USEH 0  &\/   9              " @>0R 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ L(!Z6G:SXMVR
M P  -P\  !D              ("!NS<! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " "P@'I:GCCMOMP#   H#@  &0
M@(&D.P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( +"
M>EHW?PYJY@(  "T(   9              " @;<_ 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ L(!Z6AL<<TV  @  + 8  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( +" >EJ_7_1"GPL  /1]   9
M  " @2M4 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
ML(!Z6O_[(G!# P  3!0   T              ( ! 6 ! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " "P@'I:EXJ[',     3 @  "P              @ %O
M8P$ 7W)E;',O+G)E;'-02P$"% ,4    " "P@'I:*92;-&0$  #K(P  #P
M            @ %89 $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ L(!Z
M6GQ^Z1O4 0  QA\  !H              ( !Z6@! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ L(!Z6BIDTJ;* 0  FQ\  !,
M         ( !]6H! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #T /0"B
)$   \&P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>191</ContextCount>
  <ElementCount>342</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995554 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-</Role>
      <ShortName>Note 2 - Cash, Cash Equivalents, and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies</Role>
      <ShortName>Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995556 - Disclosure - Note 4 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-</Role>
      <ShortName>Note 4 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Note 5 - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable</Role>
      <ShortName>Note 5 - Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995558 - Disclosure - Note 6 - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-</Role>
      <ShortName>Note 6 - Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995559 - Disclosure - Note 7 - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-</Role>
      <ShortName>Note 7 - Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995560 - Disclosure - Note 8 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-</Role>
      <ShortName>Note 8 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995561 - Disclosure - Note 9 - Segment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-9-segment</Role>
      <ShortName>Note 9 - Segment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995562 - Disclosure - Note 10 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-</Role>
      <ShortName>Note 10 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995564 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables</Role>
      <ShortName>Note 2 - Cash, Cash Equivalents, and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995566 - Disclosure - Note 4 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables</Role>
      <ShortName>Note 4 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Note 5 - Convertible Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables</Role>
      <ShortName>Note 5 - Convertible Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995568 - Disclosure - Note 6 - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables</Role>
      <ShortName>Note 6 - Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995569 - Disclosure - Note 8 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables</Role>
      <ShortName>Note 8 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995570 - Disclosure - Note 9 - Segment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-9-segment-tables</Role>
      <ShortName>Note 9 - Segment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-9-segment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995571 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995572 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995574 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995576 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual</Role>
      <ShortName>Note 2 - Cash, Cash Equivalents, and Investments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995578 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments - Major Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details</Role>
      <ShortName>Note 2 - Cash, Cash Equivalents, and Investments - Major Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995579 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual</Role>
      <ShortName>Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995580 - Disclosure - Note 4 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 4 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995581 - Disclosure - Note 4 - Commitments and Contingencies - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details</Role>
      <ShortName>Note 4 - Commitments and Contingencies - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995582 - Disclosure - Note 4 - Commitments and Contingencies - Purchase Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details</Role>
      <ShortName>Note 4 - Commitments and Contingencies - Purchase Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Note 5 - Convertible Notes Payable (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual</Role>
      <ShortName>Note 5 - Convertible Notes Payable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995584 - Disclosure - Note 5 - Convertible Notes Payable - Convertible Debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details</Role>
      <ShortName>Note 5 - Convertible Notes Payable - Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Note 6 - Share-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual</Role>
      <ShortName>Note 6 - Share-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995586 - Disclosure - Note 6 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details</Role>
      <ShortName>Note 6 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Note 6 - Share-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 6 - Share-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995588 - Disclosure - Note 6 - Share-based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details</Role>
      <ShortName>Note 6 - Share-based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995589 - Disclosure - Note 6 - Share-based Compensation - Noncash Stock Option Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details</Role>
      <ShortName>Note 6 - Share-based Compensation - Noncash Stock Option Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995590 - Disclosure - Note 7 - Shareholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual</Role>
      <ShortName>Note 7 - Shareholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995591 - Disclosure - Note 8 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual</Role>
      <ShortName>Note 8 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995592 - Disclosure - Note 8 - Income Taxes - Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details</Role>
      <ShortName>Note 8 - Income Taxes - Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995593 - Disclosure - Note 8 - Income Taxes - Reconciliation Between Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details</Role>
      <ShortName>Note 8 - Income Taxes - Reconciliation Between Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995594 - Disclosure - Note 8 - Income Taxes - Component of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details</Role>
      <ShortName>Note 8 - Income Taxes - Component of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Note 9 - Segment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual</Role>
      <ShortName>Note 9 - Segment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-9-segment-tables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995596 - Disclosure - Note 9 - Segment - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details</Role>
      <ShortName>Note 9 - Segment - Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dyai20241231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Note 10 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual</Role>
      <ShortName>Note 10 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dyai-20241231.xsd</File>
    <File>dyai-20241231_cal.xml</File>
    <File>dyai-20241231_def.xml</File>
    <File>dyai-20241231_lab.xml</File>
    <File>dyai-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="dyai20241231_10k.htm">dyai20241231_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>a01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="657">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dyai20241231_10k.htm": {
   "nsprefix": "dyai",
   "nsuri": "http://www.dyadic.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "dyai-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "dyai-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dyai-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dyai-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dyai-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "dyai20241231_10k.htm"
     ]
    }
   },
   "keyStandard": 300,
   "keyCustom": 42,
   "axisStandard": 29,
   "axisCustom": 0,
   "memberStandard": 33,
   "memberCustom": 44,
   "hidden": {
    "total": 103,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://xbrl.sec.gov/cyd/2024": 6,
    "http://fasb.org/us-gaap/2024": 73,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://www.dyadic.com/20241231": 14
   },
   "contextCount": 191,
   "entityCount": 1,
   "segmentCount": 80,
   "elementCount": 541,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 657,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/cyd/2024": 12,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.dyadic.com/20241231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:HeldToMaturitySecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
     "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
     "longName": "995553 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
     "longName": "995554 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments",
     "shortName": "Note 2 - Cash, Cash Equivalents, and Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
     "longName": "995555 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies",
     "shortName": "Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
     "longName": "995556 - Disclosure - Note 4 - Commitments and Contingencies",
     "shortName": "Note 4 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
     "longName": "995557 - Disclosure - Note 5 - Convertible Notes Payable",
     "shortName": "Note 5 - Convertible Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dyai:ConvertibleDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dyai:ConvertibleDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
     "longName": "995558 - Disclosure - Note 6 - Share-based Compensation",
     "shortName": "Note 6 - Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
     "longName": "995559 - Disclosure - Note 7 - Shareholders' Equity",
     "shortName": "Note 7 - Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-",
     "longName": "995560 - Disclosure - Note 8 - Income Taxes",
     "shortName": "Note 8 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-9-segment",
     "longName": "995561 - Disclosure - Note 9 - Segment",
     "shortName": "Note 9 - Segment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
     "longName": "995562 - Disclosure - Note 10 - Subsequent Events",
     "shortName": "Note 10 - Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies",
     "longName": "995563 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
     "longName": "995564 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables",
     "longName": "995565 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments (Tables)",
     "shortName": "Note 2 - Cash, Cash Equivalents, and Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables",
     "longName": "995566 - Disclosure - Note 4 - Commitments and Contingencies (Tables)",
     "shortName": "Note 4 - Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables",
     "longName": "995567 - Disclosure - Note 5 - Convertible Notes Payable (Tables)",
     "shortName": "Note 5 - Convertible Notes Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dyai:ConvertibleDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dyai:ConvertibleDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables",
     "longName": "995568 - Disclosure - Note 6 - Share-based Compensation (Tables)",
     "shortName": "Note 6 - Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables",
     "longName": "995569 - Disclosure - Note 8 - Income Taxes (Tables)",
     "shortName": "Note 8 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-9-segment-tables",
     "longName": "995570 - Disclosure - Note 9 - Segment (Tables)",
     "shortName": "Note 9 - Segment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
     "longName": "995571 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DebtConversionOriginalDebtAmount1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
     "longName": "995572 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
     "longName": "995573 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
     "longName": "995574 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "dyai:ResearchAndDevelopmentInProcessCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "dyai:AccountsPayablePolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "dyai:ResearchAndDevelopmentInProcessCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "dyai:AccountsPayablePolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
     "longName": "995575 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "dyai:AccruedExpensesPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "dyai:AccruedExpensesPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
     "longName": "995576 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual",
     "longName": "995577 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments (Details Textual)",
     "shortName": "Note 2 - Cash, Cash Equivalents, and Investments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember",
      "name": "dyai:DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember",
      "name": "dyai:DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details",
     "longName": "995578 - Disclosure - Note 2 - Cash, Cash Equivalents, and Investments - Major Security Type (Details)",
     "shortName": "Note 2 - Cash, Cash Equivalents, and Investments - Major Security Type (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual",
     "longName": "995579 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual)",
     "shortName": "Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual",
     "longName": "995580 - Disclosure - Note 4 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 4 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "SquareFoot",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "SquareFoot",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details",
     "longName": "995581 - Disclosure - Note 4 - Commitments and Contingencies - Future Minimum Lease Payments (Details)",
     "shortName": "Note 4 - Commitments and Contingencies - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details",
     "longName": "995582 - Disclosure - Note 4 - Commitments and Contingencies - Purchase Obligations (Details)",
     "shortName": "Note 4 - Commitments and Contingencies - Purchase Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
     "longName": "995583 - Disclosure - Note 5 - Convertible Notes Payable (Details Textual)",
     "shortName": "Note 5 - Convertible Notes Payable (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "dyai:ConvertibleDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
     "longName": "995584 - Disclosure - Note 5 - Convertible Notes Payable - Convertible Debt (Details)",
     "shortName": "Note 5 - Convertible Notes Payable - Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember",
      "name": "us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "dyai:ConvertibleDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
     "longName": "995585 - Disclosure - Note 6 - Share-based Compensation (Details Textual)",
     "shortName": "Note 6 - Share-based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
     "longName": "995586 - Disclosure - Note 6 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)",
     "shortName": "Note 6 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_RangeAxis-MinimumMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_RangeAxis-MinimumMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details",
     "longName": "995587 - Disclosure - Note 6 - Share-based Compensation - Stock Option Activity (Details)",
     "shortName": "Note 6 - Share-based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details",
     "longName": "995588 - Disclosure - Note 6 - Share-based Compensation - Restricted Stock Units (Details)",
     "shortName": "Note 6 - Share-based Compensation - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
     "longName": "995589 - Disclosure - Note 6 - Share-based Compensation - Noncash Stock Option Compensation (Details)",
     "shortName": "Note 6 - Share-based Compensation - Noncash Stock Option Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual",
     "longName": "995590 - Disclosure - Note 7 - Shareholders' Equity (Details Textual)",
     "shortName": "Note 7 - Shareholders' Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual",
     "longName": "995591 - Disclosure - Note 8 - Income Taxes (Details Textual)",
     "shortName": "Note 8 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details",
     "longName": "995592 - Disclosure - Note 8 - Income Taxes - Components of Loss Before Income Taxes (Details)",
     "shortName": "Note 8 - Income Taxes - Components of Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details",
     "longName": "995593 - Disclosure - Note 8 - Income Taxes - Reconciliation Between Statutory Tax Rate (Details)",
     "shortName": "Note 8 - Income Taxes - Reconciliation Between Statutory Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details",
     "longName": "995594 - Disclosure - Note 8 - Income Taxes - Component of Deferred Tax Assets (Details)",
     "shortName": "Note 8 - Income Taxes - Component of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "dyai:DeferredTaxAssetsCapitalizedResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "dyai:DeferredTaxAssetsCapitalizedResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual",
     "longName": "995595 - Disclosure - Note 9 - Segment (Details Textual)",
     "shortName": "Note 9 - Segment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details",
     "longName": "995596 - Disclosure - Note 9 - Segment - Schedule of Segment Reporting Information (Details)",
     "shortName": "Note 9 - Segment - Schedule of Segment Reporting Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
     "longName": "995597 - Disclosure - Note 10 - Subsequent Events (Details Textual)",
     "shortName": "Note 10 - Subsequent Events (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20241231_10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "dyai_AGlobalFoodIngredientCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "AGlobalFoodIngredientCompanyMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A Global Food Ingredient Company [Member]",
        "documentation": "Represents a global food ingredient company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Billing Status, Type [Axis]",
        "documentation": "Information by billing status of receivables."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r57"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "totalLabel": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r742"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccountsPayableCurrentAndNoncurrent",
        "terseLabel": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r950"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccountsPayableOtherCurrent",
        "terseLabel": "Other",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "dyai_AccountsPayablePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "AccountsPayablePolicyPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccountsReceivableNet",
        "terseLabel": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r671",
      "r764",
      "r953",
      "r954"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dyai_AccruedExpensesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "AccruedExpensesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Legal expenses",
        "label": "us-gaap_AccruedProfessionalFeesCurrent",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "dyai_AccruedResearchAndDevelopmentInProcessCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "AccruedResearchAndDevelopmentInProcessCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expenses",
        "label": "dyai_AccruedResearchAndDevelopmentInProcessCurrent",
        "documentation": "Represents current accrued research and development in process."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r742",
      "r988"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r840",
      "r841",
      "r842",
      "r844",
      "r917",
      "r992"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expenses",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r336"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-based compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r377"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r206",
      "r245",
      "r248",
      "r249",
      "r954"
     ]
    },
    "dyai_AlphazymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "AlphazymeMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alphazyme [Member]",
        "documentation": "Represents information related to Alphazyme."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt issuance costs",
        "terseLabel": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r292",
      "r832",
      "r932"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property (Square Foot)",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r95",
      "r121",
      "r138",
      "r170",
      "r176",
      "r192",
      "r196",
      "r242",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r420",
      "r422",
      "r451",
      "r553",
      "r623",
      "r704",
      "r705",
      "r742",
      "r770",
      "r874",
      "r875",
      "r939"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r124",
      "r138",
      "r242",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r420",
      "r422",
      "r451",
      "r742",
      "r874",
      "r875",
      "r939"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r787"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r787"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r787"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_BilledRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BilledRevenuesMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Billed Revenues [Member]",
        "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors [Member]",
        "documentation": "Represents a member of the board of directors."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_BradleyEmalfarbMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "BradleyEmalfarbMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bradley Emalfarb [Member]",
        "documentation": "Represents Bradley Emalfarb."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_BradleyScottEmalfarbMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "BradleyScottEmalfarbMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bradley Scott Emalfarb [Member]",
        "documentation": "Represents Bradley Scott Emalfarb."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_BusinessConsultingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "BusinessConsultingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business consulting expenses",
        "label": "dyai_BusinessConsultingExpense",
        "documentation": "The amount of expense in the period for business consulting."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, adjusted cost",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r556",
      "r594",
      "r617",
      "r742",
      "r770",
      "r823"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Subtotal, adjusted cost",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r119",
      "r690"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
       "parentTag": "dyai_CashCashEquivalentsAndInvestmentsFairValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalent, fair value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r920"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dyai_CashCashEquivalentsAndInvestmentsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "CashCashEquivalentsAndInvestmentsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_CashCashEquivalentsAndInvestmentsFairValue",
        "totalLabel": "Total, fair value",
        "documentation": "Represents fair value of cash, cash equivalents and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
        "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r67",
      "r136"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r67"
     ]
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r107",
      "r114"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 4)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r87",
      "r555",
      "r608"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r260",
      "r261",
      "r673",
      "r866",
      "r871"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r840",
      "r841",
      "r844",
      "r917",
      "r986",
      "r992"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r609"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r50",
      "r609",
      "r629",
      "r992",
      "r993"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 42,089,301 and 41,064,563, outstanding shares - 29,835,799 and 28,811,061 as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r558",
      "r742"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r36",
      "r37",
      "r204",
      "r672"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r36",
      "r37",
      "r204",
      "r584",
      "r672"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r36",
      "r37",
      "r204",
      "r672",
      "r813"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r109"
     ]
    },
    "dyai_ConcentrationRiskNumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConcentrationRiskNumberOfCustomers",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_ConcentrationRiskNumberOfCustomers",
        "terseLabel": "Concentration Risk, Number of Customers",
        "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ConcentrationRiskNumberOfSuppliers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConcentrationRiskNumberOfSuppliers",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_ConcentrationRiskNumberOfSuppliers",
        "terseLabel": "Concentration Risk, Number of Suppliers",
        "documentation": "Represents the number of suppliers accounting for 10% or more of the specified concentration risk benchmark."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ConcentrationRiskPercentage1",
        "terseLabel": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r36",
      "r37",
      "r204"
     ]
    },
    "dyai_ConcentrationRiskSignificantCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConcentrationRiskSignificantCustomers",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_ConcentrationRiskSignificantCustomers",
        "terseLabel": "Concentration Risk, Significant Customers",
        "documentation": "Represents the number of significant customer, which represent over 10%."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r36",
      "r37",
      "r204",
      "r672"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r145",
      "r170",
      "r178",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r704",
      "r705",
      "r874",
      "r875"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r145",
      "r170",
      "r178",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r704",
      "r705",
      "r874",
      "r875"
     ]
    },
    "dyai_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConsultantMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]",
        "documentation": "Represents information related to consultant."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ConsultantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConsultantOneMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant One [Member]",
        "documentation": "Represents information regarding a first consultant."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ConsultantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConsultantTwoMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant Two [Member]",
        "documentation": "Represents information regarding a second consultant, or a second transaction with a consultant."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ContractResearchOrganizationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ContractResearchOrganizationsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Research Organizations [Member]",
        "documentation": "Represents information related to contract research organizations, or to research services purchased from such organizations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred research and development obligations",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r323"
     ]
    },
    "dyai_ContractorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ContractorMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractor [Member]",
        "documentation": "Represents information related to contractor."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ConversionOfConvertibleNotesIntoCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConversionOfConvertibleNotesIntoCommonStockMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Convertible Notes Into Common Stock [Member]",
        "documentation": "Represents the monetary value of convertible notes converted into common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes, net of issuance costs",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ConvertibleDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConvertibleDebtTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Text Block]",
        "documentation": "Disclosure representing convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ConvertibleNotesConvertedIntoCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ConvertibleNotesConvertedIntoCommonStockMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Converted into Common Stock [Member]",
        "documentation": "Represents convertible notes converted into common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r725",
      "r730",
      "r743",
      "r759",
      "r983"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of revenues",
        "label": "Costs of research and development revenue",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r518"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CostsAndExpenses",
        "totalLabel": "Total costs and expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r280",
      "r298",
      "r480",
      "r500",
      "r551",
      "r693",
      "r695"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CurrentIncomeTaxExpenseBenefit",
        "terseLabel": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r836"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r204"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r803"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r793"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r793"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r793"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r798"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r798"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r797"
     ]
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion Description [Axis]",
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)",
        "negatedLabel": "Conversion to common stock (in shares)",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "us-gaap_DebtConversionNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionNameDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Name [Domain]",
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible notes",
        "terseLabel": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r40",
      "r41",
      "r84",
      "r86",
      "r145",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r740",
      "r834",
      "r867",
      "r868",
      "r869",
      "r931",
      "r933"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal outstanding",
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r279"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note principal",
        "terseLabel": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r464",
      "r465",
      "r715",
      "r716",
      "r740"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r278"
     ]
    },
    "us-gaap_DebtInstrumentIssuanceDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuanceDate1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance date",
        "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r876"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r714",
      "r922",
      "r923"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r145",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r740",
      "r834",
      "r867",
      "r868",
      "r869",
      "r931",
      "r933"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Year)",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount",
        "terseLabel": "Debt Securities, Held-to-maturity, Securities Purchased, Discount",
        "documentation": "Represents securities that were purchased at a discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsCurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredFinanceCostsCurrentGross",
        "negatedLabel": "Unamortized Debt Issuance Costs - Related Party",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r933"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredFinanceCostsGross",
        "terseLabel": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r933"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredFinanceCostsNet",
        "terseLabel": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r930",
      "r931",
      "r933"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredIncomeTaxExpenseBenefit",
        "terseLabel": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r112",
      "r836"
     ]
    },
    "dyai_DeferredLicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "DeferredLicenseRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_DeferredLicenseRevenue",
        "terseLabel": "Deferred License Revenue",
        "documentation": "Represents deferred license revenue."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 174 - R&amp;D expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
        "totalLabel": "Deferred tax asset, net of deferred tax liabilities",
        "documentation": "Represents net of liabilities before valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Represents portion of the deferred tax assets related to operating lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Business credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
       "parentTag": "dyai_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements",
        "negatedLabel": "Right-of-use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_DepositLiabilitiesAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositLiabilitiesAccruedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Amount of accrued but unpaid interest on deposit liabilities."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "dyai_DescendantTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "DescendantTrustMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Descendant Trust [Member]",
        "documentation": "Represents the descendant trust."
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r987"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r338",
      "r369",
      "r370",
      "r372",
      "r727"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r787"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r787",
      "r789"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per common share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r169",
      "r416",
      "r419",
      "r433",
      "r434",
      "r550",
      "r565",
      "r696"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r168"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r729"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
        "negatedLabel": "Tax at U.S. statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r385",
      "r407",
      "r729"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r729",
      "r837",
      "r908"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
        "negatedLabel": "Change in tax rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r729",
      "r837",
      "r908"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign operations",
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r389",
      "r729",
      "r837",
      "r908"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible items",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r837",
      "r908"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r729",
      "r837",
      "r908"
     ]
    },
    "dyai_EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "True-up adjustment",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying true-up adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ElevenSignificantCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ElevenSignificantCustomersMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eleven Significant Customers [Member]",
        "documentation": "Represents eleven significant customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee wages and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]",
        "documentation": "Represents information related to employees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-tables",
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r115",
      "r128",
      "r129",
      "r130",
      "r146",
      "r147",
      "r148",
      "r150",
      "r155",
      "r157",
      "r159",
      "r171",
      "r243",
      "r244",
      "r256",
      "r310",
      "r405",
      "r406",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r466",
      "r467",
      "r476",
      "r563",
      "r578",
      "r579",
      "r580",
      "r593",
      "r651"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r412",
      "r808",
      "r809",
      "r810",
      "r912",
      "r913",
      "r914",
      "r915"
     ]
    },
    "dyai_ExecutiveAndBoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ExecutiveAndBoardOfDirectorsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive And Board Of Directors [Member]",
        "documentation": "Represents executives and board of directors members."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dyai_ExecutivesAndKeyPersonnelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ExecutivesAndKeyPersonnelMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executives and Key Personnel [Member]",
        "documentation": "Represents executives and key personnel."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r731"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r731"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r446",
      "r447",
      "r449",
      "r487",
      "r488",
      "r489",
      "r715",
      "r716",
      "r723",
      "r724",
      "r725",
      "r730",
      "r733"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r325",
      "r330",
      "r436",
      "r447",
      "r487",
      "r723",
      "r724",
      "r725",
      "r730"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r325",
      "r330",
      "r436",
      "r437",
      "r447",
      "r488",
      "r715",
      "r716",
      "r723",
      "r724",
      "r725",
      "r730"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r446",
      "r447",
      "r449",
      "r487",
      "r488",
      "r489",
      "r715",
      "r716",
      "r723",
      "r724",
      "r725",
      "r730",
      "r733"
     ]
    },
    "dyai_FinalPaymentUponMeetingCertainProductivityThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "FinalPaymentUponMeetingCertainProductivityThreshold",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_FinalPaymentUponMeetingCertainProductivityThreshold",
        "terseLabel": "Final Payment Upon Meeting Certain Productivity Threshold",
        "documentation": "Represents the final payment upon meeting certain productivity thresholds in an agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r293",
      "r308",
      "r430",
      "r450",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r564",
      "r711",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r859",
      "r860",
      "r861",
      "r862",
      "r918",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax",
        "negatedLabel": "Foreign currency exchange loss",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r648"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ForeignCurrencyTransactionGainLossRealized",
        "negatedLabel": "Foreign currency exchange loss",
        "negatedTerseLabel": "Foreign currency exchange loss",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r769",
      "r927",
      "r928",
      "r991"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "dyai_FormerBoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "FormerBoardOfDirectorsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Board of Directors [Member]",
        "documentation": "Represents information related to former Board of Directors members."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_FormerChairmanOfTheBoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "FormerChairmanOfTheBoardOfDirectorsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Chairman of the Board of Directors [Member]",
        "documentation": "Represents information relating to the former Chairman of the Board of Directors."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_FormerEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "FormerEmployeeMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Employee [Member]",
        "documentation": "Represents a former employee."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_FourSignificantCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "FourSignificantCustomersMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Significant Customers [Member]",
        "documentation": "Relating to four significant customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GainLossOnInvestments",
        "negatedLabel": "Gain on investment in Alphazyme",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r806"
     ]
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of Alphazyme",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dyai_GatesFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "GatesFoundationMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gates Foundation [Member]",
        "documentation": "Represents the Gates Foundation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r634"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_HeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bonds, adjusted cost",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r222",
      "r250",
      "r864"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bonds, gross unrealized holding gains",
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r232"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
        "negatedLabel": "Corporate Bonds, gross unrealized holding losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r233"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term investment securities",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r858",
      "r864"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
       "parentTag": "dyai_CashCashEquivalentsAndInvestmentsFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bonds, fair value",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r231",
      "r436",
      "r446",
      "r549",
      "r552"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r787"
     ]
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeLossAttributableToParent",
        "totalLabel": "Total loss before provision for income taxes",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r130"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. operations",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r384"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
        "terseLabel": "Foreign operations",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r384"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r441",
      "r445",
      "r448",
      "r575",
      "r577",
      "r635",
      "r685",
      "r732",
      "r956"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r441",
      "r445",
      "r448",
      "r575",
      "r577",
      "r635",
      "r685",
      "r732",
      "r956"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r381",
      "r385",
      "r394",
      "r395",
      "r396",
      "r397",
      "r401",
      "r408",
      "r409",
      "r410",
      "r411",
      "r592",
      "r729"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r382",
      "r383",
      "r397",
      "r398",
      "r400",
      "r403",
      "r589"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dyai_IncreaseDecreaseInAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "IncreaseDecreaseInAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_IncreaseDecreaseInAccruedInterest",
        "terseLabel": "Accrued interest",
        "documentation": "The total increase (decrease) in accrued interest during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet",
        "negatedLabel": "Interest receivable",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
        "terseLabel": "Deferred research and development obligations",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r831"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInDeferredRevenue",
        "terseLabel": "Deferred license revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease assets and liabilities, net",
        "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r831"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dyai_InitialUpFrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "InitialUpFrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_InitialUpFrontPayment",
        "terseLabel": "Initial Up Front Payment",
        "documentation": "Represents the upfront payment for an agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestExpenseNonoperating",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r829"
     ]
    },
    "dyai_InterestIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "InterestIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The amount of interest income during the period, classified as nonoperating"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r134",
      "r135"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestPayableCurrentAndNoncurrent",
        "terseLabel": "Interest Payable",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r950"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dyai_InvestmentIncomeAmortizationAccretionOfPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "InvestmentIncomeAmortizationAccretionOfPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of held-to-maturity securities, net",
        "documentation": "Represents amortization (accretion) of premium on investment income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r585",
      "r586",
      "r587",
      "r588",
      "r659",
      "r660"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InvestmentsAndCash",
        "totalLabel": "Total, adjusted",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r952"
     ]
    },
    "dyai_InzymesAgreementApsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "InzymesAgreementApsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inzymes Agreement APS [Member]",
        "documentation": "Represents Inzymes Agreement ApS."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_IrrevocableTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "IrrevocableTrustMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Irrevocable Trust [Member]",
        "documentation": "Represents Irrevocable Trust"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_JanssenPharmaceuticalCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "JanssenPharmaceuticalCompaniesMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Janssen Pharmaceutical Companies [Member]",
        "documentation": "Represents Janssen Pharmaceutical Companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Compensation and related expenses",
        "label": "us-gaap_LaborAndRelatedExpense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r814"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r814"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-tables",
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_LegalExpensesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "LegalExpensesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal expenses",
        "documentation": "Represents the amount of legal expenses payable, current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "LesseeOperatingLeaseAdditionalNumberOfRenewalTerms",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_LesseeOperatingLeaseAdditionalNumberOfRenewalTerms",
        "terseLabel": "Lessee Operating Lease Additional Number of Renewal Terms",
        "documentation": "The additional number of renewal terms available for the lessee operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseRenewalTerm",
        "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dyai_LesseeOperatingLeaseYearlyPercentageIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "LesseeOperatingLeaseYearlyPercentageIncrease",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_LesseeOperatingLeaseYearlyPercentageIncrease",
        "terseLabel": "Lessee Operating Lease Yearly Percentage Increase",
        "documentation": "Percentage increase in operating lease payment based on lease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r40",
      "r41",
      "r42",
      "r45",
      "r46",
      "r47",
      "r48",
      "r138",
      "r242",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r421",
      "r422",
      "r423",
      "r451",
      "r607",
      "r697",
      "r770",
      "r874",
      "r939",
      "r940"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r88",
      "r560",
      "r742",
      "r835",
      "r863",
      "r926"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r118",
      "r138",
      "r242",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r421",
      "r422",
      "r423",
      "r451",
      "r742",
      "r874",
      "r939",
      "r940"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_LicenseAndDevelopmentExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "LicenseAndDevelopmentExtensionTerm",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_LicenseAndDevelopmentExtensionTerm",
        "terseLabel": "License and Development, Extension Term (Year)",
        "documentation": "The duration of the term extension for the research and development agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_LicenseAndDevelopmentInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "LicenseAndDevelopmentInitialTerm",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_LicenseAndDevelopmentInitialTerm",
        "terseLabel": "License and Development, Initial Term (Year)",
        "documentation": "The initial term length for the research and development agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Carrying Amount",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r86",
      "r284",
      "r294",
      "r715",
      "r716",
      "r740",
      "r951"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r722",
      "r753",
      "r757",
      "r878",
      "r955",
      "r957",
      "r958",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r332",
      "r378",
      "r439",
      "r516",
      "r574",
      "r576",
      "r583",
      "r599",
      "r600",
      "r657",
      "r661",
      "r663",
      "r664",
      "r666",
      "r683",
      "r684",
      "r710",
      "r719",
      "r726",
      "r733",
      "r734",
      "r738",
      "r739",
      "r754",
      "r876",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r332",
      "r378",
      "r439",
      "r516",
      "r574",
      "r576",
      "r583",
      "r599",
      "r600",
      "r657",
      "r661",
      "r663",
      "r664",
      "r666",
      "r683",
      "r684",
      "r710",
      "r719",
      "r726",
      "r733",
      "r734",
      "r738",
      "r754",
      "r876",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds, adjusted cost",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dyai_MrThomasEmalfarbMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "MrThomasEmalfarbMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Thomas Emalfarb [Member]",
        "documentation": "Represents Mr. Thomas Emalfarb"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r722",
      "r753",
      "r757",
      "r878",
      "r955",
      "r957",
      "r958",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r70"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      },
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r70",
      "r91",
      "r116",
      "r125",
      "r126",
      "r130",
      "r138",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r163",
      "r242",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r416",
      "r419",
      "r434",
      "r451",
      "r562",
      "r632",
      "r649",
      "r650",
      "r769",
      "r874"
     ]
    },
    "dyai_NetherlandsOfficeLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "NetherlandsOfficeLeaseMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands Office Lease [Member]",
        "documentation": "Represents information related to Netherlands Office lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "dyai_NonexecutiveEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "NonexecutiveEmployeesMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonexecutive Employees [Member]",
        "documentation": "Represents information related to nonexecutive employees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income (expenses), net",
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dyai_NonrefundableUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "NonrefundableUpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_NonrefundableUpfrontPaymentReceived",
        "terseLabel": "Non-refundable Upfront Payment, Received",
        "documentation": "Represents non-refundable upfront payment, received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839"
     ]
    },
    "dyai_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r846"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfReportableSegments",
        "terseLabel": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r709",
      "r846"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r698",
      "r845",
      "r847",
      "r848",
      "r849",
      "r850"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseLiability",
        "terseLabel": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset, net",
        "terseLabel": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r741"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r741"
     ]
    },
    "dyai_OperatingLeasesAnnualRentalRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "OperatingLeasesAnnualRentalRate",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_OperatingLeasesAnnualRentalRate",
        "terseLabel": "Operating Leases, Annual Rental Rate",
        "documentation": "Represents annual rental rate for operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_OperatingLeasesMonthlyRentalRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "OperatingLeasesMonthlyRentalRate",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_OperatingLeasesMonthlyRentalRate",
        "terseLabel": "Operating Leases, Monthly Rental Rate",
        "documentation": "Represents monthly rental rate for operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely",
        "terseLabel": "Operating Loss Carryforwards, Will Be Carried Forward Indefinitely",
        "documentation": "Amount of operating loss carryforward that will be carried forward Indefinitely, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage",
        "terseLabel": "Operating Loss Carryforwards, Will Be Carried Forward Indefinitely, Available to Offset Taxable Income, Percentage",
        "documentation": "Percentage available to Offset Taxable Income related to amount of operating loss carryforward that will be carried forward Indefinitely, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r704",
      "r705"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_OtherAccruedLiabilitiesCurrent",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other G&amp;A expenses",
        "label": "us-gaap_OtherGeneralAndAdministrativeExpense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r990"
     ]
    },
    "us-gaap_OtherIncomeDisclosureNonoperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeDisclosureNonoperatingAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses - various",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r865"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_OwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "OwnershipPercentage",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_OwnershipPercentage",
        "terseLabel": "Ownership Percentage",
        "documentation": "Percentage of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquireHeldToMaturitySecurities",
        "negatedLabel": "Purchases of held-to-maturity investment securities",
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r207"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r296"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r609"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r296"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r609",
      "r629",
      "r992",
      "r993"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r557",
      "r742"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r712",
      "r865"
     ]
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r713",
      "r865"
     ]
    },
    "dyai_ProceedsFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ProceedsFromGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_ProceedsFromGrant",
        "terseLabel": "Proceeds From Grant",
        "documentation": "Amount of proceeds from grant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromGrantors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromGrantors",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromGrantors",
        "terseLabel": "Proceeds from Grantors",
        "documentation": "Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible notes, net of issuance costs",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt",
        "terseLabel": "Proceeds from Issuance of Senior Long-Term Debt",
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from maturities of investment securities",
        "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r857"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments",
        "terseLabel": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromSaleOfInvestmentProjects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfInvestmentProjects",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of investment in Alphazyme",
        "documentation": "The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r518",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r688",
      "r720",
      "r752",
      "r754",
      "r755",
      "r758",
      "r760",
      "r872",
      "r873",
      "r878",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r518",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r688",
      "r720",
      "r752",
      "r754",
      "r755",
      "r758",
      "r760",
      "r872",
      "r873",
      "r878",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Legal and professional services",
        "label": "us-gaap_ProfessionalFees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r769",
      "r989",
      "r990"
     ]
    },
    "dyai_ProliantAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ProliantAgreementMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proliant Agreement [Member]",
        "documentation": "Represents Proliant Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Table Text Block]",
        "documentation": "Tabular disclosure of arrangements in which the entity has agreed to procure goods or services from one or more suppliers. May include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r87"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PurchaseObligation",
        "totalLabel": "Total",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "us-gaap_PurchaseObligationDueInNextTwelveMonths",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "us-gaap_PurchaseObligationDueInSecondYear",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "us-gaap_PurchaseObligationDueInThirdYear",
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r324",
      "r332",
      "r364",
      "r365",
      "r366",
      "r378",
      "r439",
      "r490",
      "r499",
      "r516",
      "r574",
      "r576",
      "r583",
      "r599",
      "r600",
      "r657",
      "r661",
      "r663",
      "r664",
      "r666",
      "r683",
      "r684",
      "r710",
      "r719",
      "r726",
      "r733",
      "r734",
      "r738",
      "r739",
      "r754",
      "r763",
      "r870",
      "r876",
      "r922",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r324",
      "r332",
      "r364",
      "r365",
      "r366",
      "r378",
      "r439",
      "r490",
      "r499",
      "r516",
      "r574",
      "r576",
      "r583",
      "r599",
      "r600",
      "r657",
      "r661",
      "r663",
      "r664",
      "r666",
      "r683",
      "r684",
      "r710",
      "r719",
      "r726",
      "r733",
      "r734",
      "r738",
      "r739",
      "r754",
      "r763",
      "r870",
      "r876",
      "r922",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ]
    },
    "us-gaap_ReceivablesBillingStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesBillingStatusDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables Billing Status [Domain]",
        "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r331",
      "r477",
      "r478",
      "r554",
      "r561",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r628",
      "r630",
      "r656"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r477",
      "r478",
      "r479",
      "r480",
      "r554",
      "r561",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r628",
      "r630",
      "r656"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r331",
      "r477",
      "r478",
      "r554",
      "r561",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r628",
      "r630",
      "r656",
      "r938"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r280",
      "r298",
      "r480",
      "r500",
      "r551",
      "r694",
      "r695"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r685",
      "r704",
      "r947"
     ]
    },
    "dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Facilities, overhead, and other",
        "label": "Facilities, overhead and other",
        "documentation": "Represents facilities, overhead and other for research and development expense."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseIncludingRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
        "totalLabel": "Research And Development Expense, Including Related Party",
        "documentation": "Represents research and development expense including related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ResearchAndDevelopmentExpenseOutsideContractedServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseOutsideContractedServices",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outside contracted services",
        "label": "Outside contracted services",
        "documentation": "Represents outside contracted services for research and development expense."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ResearchAndDevelopmentExpensePersonnelRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Personnel related costs",
        "label": "Personnel related costs",
        "documentation": "Represents personnel related costs for research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "dyai_ResearchAndDevelopmentInProcessCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ResearchAndDevelopmentInProcessCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_ResearchAndDevelopmentInProcessCurrent",
        "terseLabel": "Research and development expenses",
        "documentation": "Represents current research and development in process."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "documentation": "Represents research and development."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ResearchServicesPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ResearchServicesPurchased",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_ResearchServicesPurchased",
        "terseLabel": "Research Services Purchased",
        "documentation": "Represents the amount of research services purchased during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RestrictedCash",
        "terseLabel": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r833",
      "r948",
      "r952"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r77",
      "r559",
      "r581",
      "r582",
      "r591",
      "r610",
      "r742"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r146",
      "r147",
      "r148",
      "r150",
      "r155",
      "r157",
      "r159",
      "r243",
      "r244",
      "r256",
      "r405",
      "r406",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r424",
      "r426",
      "r427",
      "r429",
      "r432",
      "r466",
      "r467",
      "r578",
      "r580",
      "r593",
      "r992"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
        "terseLabel": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r916"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "label": "Research and development revenue",
        "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r170",
      "r177",
      "r178",
      "r190",
      "r196",
      "r200",
      "r202",
      "r204",
      "r321",
      "r322",
      "r518"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r687"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset obtained in exchange for lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r741"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r812"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r843"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r160",
      "r333",
      "r807",
      "r843"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r729",
      "r908"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r412",
      "r808",
      "r809",
      "r810",
      "r912",
      "r913",
      "r914",
      "r915"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Costs [Table Text Block]",
        "documentation": "Tabular disclosure of research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_SecondPaymentUponCompletionTransfer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "SecondPaymentUponCompletionTransfer",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dyai_SecondPaymentUponCompletionTransfer",
        "terseLabel": "Second Payment Upon Completion Transfer",
        "documentation": "Represents the second payment upon the completion of a transfer in an agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r596",
      "r597",
      "r598",
      "r658",
      "r662",
      "r665",
      "r667",
      "r670",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r689",
      "r721",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r756",
      "r763",
      "r878",
      "r955",
      "r957",
      "r958",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-9-segment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r180",
      "r181",
      "r182",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r204",
      "r699",
      "r702",
      "r703",
      "r704",
      "r706",
      "r708",
      "r709"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r199",
      "r202",
      "r700",
      "r701",
      "r707"
     ]
    },
    "dyai_SeniorSecured2024NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "SeniorSecured2024NotesMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured 2024 Notes [Member]",
        "documentation": "Represents the 2024 Senior Secured Convertible Promissory Notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested shares forfeited, Weighted-average Grant Date Fair Value (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, RSU (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, Weighted-average Grant Date Fair Value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodStartLabel": "Outstanding, Balance, RSU (in shares)",
        "periodEndLabel": "Outstanding, Balance, RSU (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodStartLabel": "Outstanding, Weighted-average Grant Date Fair Value (in dollars per share)",
        "periodEndLabel": "Outstanding, Weighted-average Grant Date Fair Value (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Vested, RSU (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, Weighted-average Grant Date Fair Value (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-Free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-Free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
        "negatedLabel": "Unvested shares forfeited, RSU (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, shares (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)",
        "negatedLabel": "Expired, shares (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)",
        "negatedLabel": "Canceled, shares (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, shares (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)",
        "periodStartLabel": "Outstanding, shares (in shares)",
        "periodEndLabel": "Outstanding, shares (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canceled, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r342",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r373",
      "r374",
      "r375",
      "r376"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options (Year)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted-average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, weighted-average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "SharebasedCompensationAwardTrancheTwoThroughFiveMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Award Tranche Two through Five [Member]",
        "documentation": "Represents shares-based compensation award tranche two through five."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ShortTermCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ShortTermCorporateBondsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Corporate Bonds [Member]",
        "documentation": "Represents short-term corporate bonds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShortTermInvestments",
        "terseLabel": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r826"
     ]
    },
    "dyai_SixSignificantCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "SixSignificantCustomersMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Six Significant Customers [Member]",
        "documentation": "Relating to six significant customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r50",
      "r54",
      "r55",
      "r115",
      "r128",
      "r129",
      "r130",
      "r146",
      "r147",
      "r148",
      "r150",
      "r155",
      "r157",
      "r159",
      "r171",
      "r243",
      "r244",
      "r256",
      "r310",
      "r405",
      "r406",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r466",
      "r467",
      "r476",
      "r563",
      "r578",
      "r579",
      "r580",
      "r593",
      "r651"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r596",
      "r597",
      "r598",
      "r658",
      "r662",
      "r665",
      "r667",
      "r670",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r689",
      "r721",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r756",
      "r763",
      "r878",
      "r955",
      "r957",
      "r958",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-tables",
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r171",
      "r467",
      "r518",
      "r585",
      "r595",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r630",
      "r633",
      "r634",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r651",
      "r764"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r160",
      "r333",
      "r807",
      "r811",
      "r843"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies",
      "http://www.dyadic.com/20241231/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privately-held-companies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-purchase-obligations-details",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-restricted-stock-units-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-component-of-deferred-tax-assets-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-components-of-loss-before-income-taxes-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-schedule-of-segment-reporting-information-details",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-tables",
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r171",
      "r205",
      "r467",
      "r518",
      "r585",
      "r595",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r630",
      "r633",
      "r634",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r651",
      "r764"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon settlement of convertible debt (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r30",
      "r50",
      "r54",
      "r77",
      "r287"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r49",
      "r50",
      "r77",
      "r590",
      "r651",
      "r668"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon vesting of restricted stock units (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r49",
      "r50",
      "r77"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of stock options (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)",
        "negatedLabel": "Exercised, shares (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r49",
      "r50",
      "r77",
      "r348"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon settlement of convertible debt",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r50",
      "r54",
      "r55",
      "r77"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon vesting of restricted stock units",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r77"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r50",
      "r54",
      "r55",
      "r77"
     ]
    },
    "dyai_StockOptions1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "StockOptions1Member",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options 1 [Member]",
        "documentation": "Related to stock options."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_StockOptions2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "StockOptions2Member",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options 2 [Member]",
        "documentation": "Related to stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r54",
      "r55",
      "r73",
      "r611",
      "r629",
      "r652",
      "r653",
      "r742",
      "r770",
      "r835",
      "r863",
      "r926",
      "r992"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r137",
      "r295",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r431",
      "r654",
      "r655",
      "r669"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r483"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-tables",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-tables",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-tables",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-tables",
      "http://www.dyadic.com/20241231/role/statement-note-8-income-taxes-tables",
      "http://www.dyadic.com/20241231/role/statement-note-9-segment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_The1044NLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "The1044NLeaseMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-",
      "http://www.dyadic.com/20241231/role/statement-note-4-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 1044 N Lease [Member]",
        "documentation": "Represent the 1044 N Lease."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_The2021PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "The2021PlanMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2021 Plan [Member]",
        "documentation": "Related to the 2021 plan."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_TheFranciscoTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "TheFranciscoTrustMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Francisco Trust [Member]",
        "documentation": "Represents the Francisco Trust"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ThirdPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ThirdPartyMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Party [Member]",
        "documentation": "Represents the third party group."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb [Member]",
        "documentation": "Represents Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_ThreeCROsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "ThreeCROsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three CROs [Member]",
        "documentation": "Represents information regarding three contract research organizations."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r937"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-",
      "http://www.dyadic.com/20241231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-convertible-debt-details",
      "http://www.dyadic.com/20241231/role/statement-note-5-convertible-notes-payable-details-textual",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r853",
      "r854",
      "r855"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-",
      "http://www.dyadic.com/20241231/role/statement-note-2-cash-cash-equivalents-and-investments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r293",
      "r308",
      "r430",
      "r450",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r564",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r859",
      "r860",
      "r861",
      "r862",
      "r918",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock (in shares)",
        "terseLabel": "Treasury Stock, Common, Shares (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.dyadic.com/20241231/role/statement-note-7-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TreasuryStockValue",
        "terseLabel": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, shares held at cost - 12,253,502",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r50",
      "r54"
     ]
    },
    "dyai_TwoCROsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "TwoCROsMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two CROs [Member]",
        "documentation": "Represents information regarding two contract research organizations."
       }
      }
     },
     "auth_ref": []
    },
    "dyai_TwoSignificantCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "TwoSignificantCustomersMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Significant Customers [Member]",
        "documentation": "Represents two significant customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnbilledRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnbilledRevenuesMember",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled Revenues [Member]",
        "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r106",
      "r108",
      "r110",
      "r111"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-",
      "http://www.dyadic.com/20241231/role/statement-note-6-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "dyai_VestingOfRestrictedStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "VestingOfRestrictedStock",
     "crdr": "credit",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting of restricted stock units",
        "documentation": "Represents the cash flow effect of the vesting of restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.dyadic.com/20241231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted weighted-average common shares outstanding (in shares)",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18"
     ]
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-2-cash-cash-equivalents-and-investments-major-security-type-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Cash, Cash Equivalents, and Investments - Major Security Type (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-2-cash-cash-equivalents-and-investments-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-2-cash-cash-equivalents-and-investments-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Cash, Cash Equivalents, and Investments"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-4-commitments-and-contingencies-future-minimum-lease-payments-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Commitments and Contingencies - Future Minimum Lease Payments (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-4-commitments-and-contingencies-purchase-obligations-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Commitments and Contingencies - Purchase Obligations (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-4-commitments-and-contingencies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-4-commitments-and-contingencies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Commitments and Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-5-convertible-notes-payable-convertible-debt-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-5-convertible-notes-payable-convertible-debt-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Convertible Notes Payable - Convertible Debt (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-5-convertible-notes-payable-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-5-convertible-notes-payable-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Convertible Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-6-sharebased-compensation-blackscholes-options-pricing-model-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-6-sharebased-compensation-noncash-stock-option-compensation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Share-based Compensation - Noncash Stock Option Compensation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-6-sharebased-compensation-restricted-stock-units-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-6-sharebased-compensation-restricted-stock-units-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Share-based Compensation - Restricted Stock Units (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-6-sharebased-compensation-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-6-sharebased-compensation-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Share-based Compensation - Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-6-sharebased-compensation-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-6-sharebased-compensation-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Share-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-8-income-taxes-component-of-deferred-tax-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Component of Deferred Tax Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-8-income-taxes-components-of-loss-before-income-taxes-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Components of Loss Before Income Taxes (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-8-income-taxes-reconciliation-between-statutory-tax-rate-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Reconciliation Between Statutory Tax Rate (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-8-income-taxes-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-8-income-taxes-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-9-segment-schedule-of-segment-reporting-information-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-9-segment-schedule-of-segment-reporting-information-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Segment - Schedule of Segment Reporting Information (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-note-9-segment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-note-9-segment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Segment"
       }
      }
     },
     "auth_ref": []
    },
    "dyai_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dyadic.com/20241231",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001437749-25-009350-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-009350-xbrl.zip
M4$L#!!0    ( +" >EJ$0 3D[04  (,&   '    83 Q+FIP9YW1>3C4>1P'
M\.\8<Y 68\S$)L:M5BHQV(V-4&R$RK%K9MWER.,>N;:(0GF01.$QW0>3<E6F
M6??5IB$2:S'C*.?,8&8,YK>C9X]_]H_=?7^>Y_O/Y_-\GN_K^4"#T!A0<+ [
M8@=@,!CX45( &@8V "$M"7SS12(02/16-!J%0BMLD9/9JJ2 5<(H8#!8O)H*
M%K<=A\&H:JENWZ%.(!"P*MIZVAJZ:AH$C<TE, 02B4:AY=%H>0UEC++&?P[T
M,U!$ T-@#H=I BE%&%P1!K4 =0!@"-CG@#\"DX)+(Y HM(SL%LE C0*0@L'A
M4I+_2P"2;I*D#Z05$1C"WH-()1<?E&8$=M^YW'*TEG55H[(KDZ-M[!MY7D86
MA]^FHJJCJZ=OL'._B2G1S-S"YI"MG?WA(PYNQT^<=/?P]/+S#P@,.G4Z."HZ
M)C:.$G\V->U">L;%2YEY^5<+KA5>+RJFWKI]Y^Z]^P\>/GU675-;5__\15-S
M2VM;>T=G5V_?N_Z!]X,?AL99[(G)J>F/GV:XO*7E%;Y N"K:=,$ '/9G_M&E
M*'%)2<XBC=ITP:3B-@<4I1&$O4C,01>43X22YKYS:*QU;GE5HXR6L2M'V3>2
M*8O3WC^NP]VD?9;].]CY_R7["_:W:PC(P6&2X\$5@1489E*%)4:--W(R!]2Q
M,?'A7\D)4(XOI1SC,08>^_+B)X_S^8+*0E=AR2,*OB6VU+3_#,VH@<":QY*\
MAEX6X=I6_>0G[E%?10C7W ]0::TZ0J)54X)\ND4!_1=NZ4A-2*?KUY1;U^P"
M?2TXC^V%RS1KX8.QI$/KVSAU%ZK53,.\PG0AX.Q:I1'(8Z]Z<P?]: ,OR48F
M=T8Y>]QKTTWX%>P<V>0W64F/9@N?"?M:W5UL0UXYA4[41SPU:^?,?5?FM_RP
M2LAN5>=T[]@=,N(U982GD#RC9V_4Y N&>P.:%P1NV8+&RAQ61EK#4?9B9C*.
M&>K/8%9[ZZK$Z U4L%'=+]X,]D>UC2&34E67>A363;COT_M8\NES[B>Y 669
M^R\NV%&9!G$-1S(Z!JTH=Q=IV%M=O71:_0B3;L"=;C;A!&6'6VH&DW28-5G=
M(0>LFUUL-75*(E70TQH0*#T:8,M.^9)L$S-&)[84[ID1+68O1G?$R#A?YYM&
M( )Y2WTJ[+ZRBM :1HY8AY;:H',_T8K.:<N@C@R3@O$OTKJ+TK9<./PNZII5
M@;_]F-'VH>]'A,V.G.6>BH_)^^C]AG.ZFL8II_6/#7^1P,XA)5]=7CO)6/$)
M>;M8799!5HB>#SGVEM80GU1)<1+U>WB3G8Y.UG35QE9:\A3,5=3L[QVH6R=$
MI;SMO)\R2MXX.[FN1$MTY(:WR*Q<)C<+2$J<$GI97G$8K[QT9NSF:E';<7!X
MV6S'RDQ_#U%[Q>3RX\0>O;D>%K[@UT3;B.>7VO/UHB#@;<#@O'ZE"0%J-@0$
M4\YB<_)1EQ^2F\K\^L2]+1 @CC$ZA DLO>:2H'%^3?FG?,K3I&]G7A^W4-'B
M/9FA$V]N+/:^G(7 !T8+SB*L?RG1)K>UP7DW$YL:^];):B#A!&/(66Q?)I7R
M:E1DNE.$;['B[0H>79DFBG\*0?=F72WT>W'7M/JT:][9+@$SSO* T(_SS$M8
M.+Y&)XVV*7VB#K'GIHA+VH:\74&$=D&5T#T. G+=+'61?@\$DOTAP"ZH6]L%
M@<YO!JSFM"!0[4H7/RS8YB!3;6>D1BJ)MY:WG<@I]MDH3K11?NVF?O%*D[ER
M!\]_&F4& 4^RHXMM=---'TZI=ZBM Y]_A2^K3WT\;1FT<1L"$_$<O;5Y"-SR
MI94GVD! L[8" J2HE(_(^I1+ZK)N+-SS\N PFFEQ]#7#R2P?HQN%)V?K_1;8
M#*]E0^N^>9'W2$[1Y 85GY5L7!>9>S-NUJ/-T,'Y^8CK8QVGJVX#1,9O%.<Y
M&@2T%ST@\"1'S'00B,8L<>M$<GKRCH9>O&>8^SQ1_=22E[Q>>,>C[#/A"]/<
M2G&)?GVC;E#6 ]6"2;/0IDS]"B<WZ,/O4$L#!!0    ( +" >EH/ /G1U1,
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M<&_"W]3OI7&15DXIZBJ6L=>^WK)]]373IYE!V]G9P9"$^YZK_/.8^6J6**<
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M30! ?*-IAZO5/JIVA57]0OTQ#@61G_P?4$L#!!0    ( +" >EK@'C7'Q58
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M#TM1&Z>%\H=5)5'YMZ%\855'+%S.4%;QJ2<6WC@HD_CT%6#H'\H@/HT%E#4
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ML?%RQ+ <2#1VB^MPQ'@Y&'9GK$W* WQ:%0LXRBLG'\A]L7-UGZZ^Y.D?)?E
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MRVIT5?[0.(#G#VBV$HS"B5HG]J-J:.!&5'?J<^"(4<>KU#+@B7+A:H\8ZJ8
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MIYT"+'X09[4P5 A;1JQ8744+TJ %F\AZQ_@Y^C=EVPE2(%03]8Y/3LAT]@Q
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MVEQ,C%QK\@"HBFI,*]@NP8FJ!HZ)94=&(NW'W,(X8\;P+-73#L^G@SY^ (F
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MMV%P&P:W87 ;!K>AGPZ KFV D;H/W1U=(W4@NM'C1E;;[\76 \X)E@:$;IU
M0.9_0L)\?]8=<")^'N%$0 Q^(/N_C)!]N&4'G(1?1S$)9@<ICG1"F367K&5V
M%3Z)*JGM.)$0^):!4PBM4(9@TBL,)AUH-V?1,BVB+/U3U4.[*8;4_BE]L'!%
MBNELKY%RG0A@# 2X>5@?#*T%;O[PB42<;, T=C2U'>O5G74 ;F]>Q3PK_%O
M4<-RLIMFRL7J9VPEEHFLEU%Y&%L\86 .&YH!PXB'Q2W^XTS\G!;/YG1=QWI:
M<J$)<?!'LGK8X'QO?K<VW9_5>^7)J4 ]2PO>7# B.QA:S(JK5PT[9^!@,=8
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M1M*B9.VFPN:Y>&:C^N-T627XGC\1%J=<>6=1^P=AX+=2\1QO KMGHID%]UO
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MI:<EO]\VXI%TEY8_7Q647N?\]<D%^([3X7WT)5UOUQ+S@V_P2)N%+S1=RR*
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M'7OP$Y'E9V(2= +2CN'0*FK!S8M'"9I06FTP:W/VID@W/",W6#IDA*] *_G
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M F0"Q&J.LP=3)YHA/Y\549+1E_N85=7E.LJ64?$H9^KIT1C.EL_JFKT;R$2
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M=^RV8,\I?_6>O7PL:7*=7XO<2BB(7CLHX%T[7M86/Q$^1%03H(\41%'?MB3
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MM 5& )K?*UU*,S9)"$-%])[F*2N$68<F\&M1 5NND*J,QRBF8_,ZOYL$;-(
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M$+>I$0[A+];A.8:FLU.][#1)^$:4S1_OTOS(A:0T%JVQ#<SI27UK0"[:OQ
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M-9S!:D3201@).YK,RR/S"*JVD%C &W%SM% )@"7!,,=)\&GW%-ZTRQ#!L$^
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M6Y0&N8V*ZN6!OVK+*!8W\=E+_S<CJ23Z$Z#SJ%4!N:_.6%>7@6/^ \O;8C,
M'X*Z B:8(#:#F5,X"+..IIG(!UI@/C^I)%-,%C*99(2\$G8*VMKJ)PX:^A/=
MY%"?]&9YG<.U)(KR2OA'X0LD(XW,[#[E),T)7,]1K<&?9IM5],O+VF_?7!T2
M,P3=#-^*#RO*?_CFEE-.[G.4#L*\\XXF<YY3NZ($(!( B?<,6L ;Z_RKC\**
MB=@YL90-'Q'@@25G!*9&)5/+QHH5%?2H/&?%!HIIT#.6)R-%J90^0%DKQB9V
M;I< X"<5ATXZ\$3 Q[.WY049^[G+W1KC;HV/@%((PX(2&S%]4OHS%H"Q7<3H
M]4/Y>I%\9R^[(4T4GWBW-99*X0$LK_/ZE?=3P:\FF?W '22L2<$^1LYU%P")
MB2"<,04"AZ#6:]C%G\)/^#K"N]P<R@OSR *OYBCK&:':Y3@ZRD8@!3K*!C#R
M%:WJ /401Z$5"@8^"OL1!_;B\8,2UB1@_QSL^=F<XO4=GCL6KX3)'3,-EH[*
M%?S_\A_;]#G*X%EPFB<]2\A5E!9#O:*17Z."I)6A>(GM5$='/S+:X4HK5D69
MGM ^P"<+LN1 R?/L%F2AXTB[+N%HY&@NQ'\)W6$K;.7I#M\0T=[Z0L8,R6]J
M0NJ%W[P=,1S)AZ',1<?3.3<2":=S Y.\-; ,V<#=V/2Y%QD6P@0TPA!,E5*A
M8T/JD,L/]+/X%2HR^NAC%^'/'1!OCQ,E;*R',1NLTU&L,L>H'C$#+5B/#54#
MCB4TMWBMO%&[5M[8O5;>A+A6WMBY5M"X?U77RB%##%TK@Y3R=JW\F6;) WL?
M55"_Z&57QTCV$-/^#GF93,[O/CMUSPVG_BYQ=':J$YRAJ>B-Z]ZET6/38Y"_
M$(0TK%B6\ L0W@[5BX3I5#]#\MS4]+Y4ERD\,$J+_;5A7_@DVZ$BWKME#YE_
M^:<_O'WS^S^)-_'40AT)FC*3,2QU/48;CM3ZE\B8TC?H&,21N=V'(P[G-@2*
M/U2A,D.1SB-[55&:T^0R*G*NDI>G,5?=MD(1NZ#+-$X/\^WU/T0SVA0 U]S6
M@\B938 ,Q&C*I&9X^GECN?<LIR_OH^)G6EUM97%B:H.1K#4\J6MV$E!)#98(
MN(K/-$=L-4%:ID<OPY?Z.UJ6E-YL*-3YSY_>T:BD_\E/R^SEEA90_S]ZHM=Y
M7,#/AY[PF.\Q;WL=.%Y\2SH(:5L#W*X682RK$2(=1D2@1&J<R XI,M,EXRPC
MO76E#6B($& =%3+QHTT36/ HP@Q8WOPX>BJH<!P',*2@Q)(9;X6_!C11N1J]
MOXX'8)O*=!,YMYJ 0S/HS31 -#9-"6^;WO+<!:W_O,X['CV/-BE_'Y\^EJ+Y
MFH0I]"= ,HTZ(.=,M8+PE7+_V(JX?#<.\YY!X8]!> ZQ)\R<T-YX]G3-BBK]
M1=P[-\NK-(_R&)"#O'D)EZI\@N3+L:F=O^IZL"&*0W2+2-O\<5$D 6.<L[LD
MA&ITN*X+6%>7%W\^O2Y'@J7$1@Q#2&_"<]$5V.BJ2TR<\ I?($5G9&9?MNT1
M%#"28W5%Z-JW%2,-KT49N><*NE"9PXB,"O<P! ']!;IL'TOZCRU8-Y_Y?T8U
MY-&QV#"6H3F=^^ [H$1 #:M#CY.5:='*&]]<L8*F3_GYMBAH'O?+/[29UW<T
MRM)?I$7=]"= <I@Z(%^GLCI&F$/:R7I-T@,:A$C<8$3HEUB\,0@_"E$:G(<E
M/NC?3B;K='2T((2,F9/9VR&T;W!JW<(O'SAA!,XRG4_Y.^21,SF_ZY/FYL#>
MV+[97Q8DKXNF-HB0#:CP+ _"G>K;P-"T=>#L.$V2%&@6974[,JATE]//408I
MZX=/=,-9;#D^QJ$%<W^,HV7%(V![Y?9<(3O,FL9[=9E,@1R9+P$,VIGM%IQW
M"RZ:!4.EBI)$SU&:B4J@T-L,RK5D-?$./"@S<9 H"O&8FT1G>T)?K'K7J9M+
MU)>2+@&/45>MK01Q]AP<.@NBN!*_5[[&13\/.\D#ASM2Y')BM!U;23NK=VL)
M  Y9M7**NG*3R3#)0A^KYYC'RKG+E\IY\&?*C-\GAY2?/K,&R1GRZ!HMACHY
MWM[QY:<TJN0 "UD1=9K&XX=8T/JH!_B44ZTB)\?;8:C27U^# X:"]@6JC0O\
M,-0 C>4,)2-<H'OQ+GU:53?+C_QM!%$G2M>BY!LKM^+!W+XOQ0+ G[#ER18B
M! $#8<0S?X@8K\O&<^2N7=U'L(@ 'C.XZF7<)+WI1TGI+\]OP+S0Z2!-_:'R
M0IIDJOLY-N]/$8RW_#]%?%!Y@,[6BLT'#)/DI\M9S)2$\Y"YCSDT_('&E32Y
M_!+SH74;2XP 3LWE0AIE,&<AFC+DK,NI/2J@?0>+0^=!SXZW('T$28TA4:%%
M"&F?9&-5T5?;%7^!AW1)^2,_N<YCMJ8/T9<F6?2,YG0I3<U4_ H;@#@^N[<@
MQ'$T4(&(ME>&D,P6!U(C03@6I$&#?-,@$J;PCRI7,21!YW&Y]NY^2#5ZX#!-
M-=NC>1RKN!V\65RH0XBY5'H-5H\05\Y<OY_?=3C*? @M6$)3?V&A;:F;]QS#
M;2$BLV]9EL8O]7^G3(7:WV.#0E7AN)9,0(0(3$@/E06IT2"?FC]#FQ?U]X49
M$WMVU\P'CN?#9YH]T_<LKU8RYZ_I=(XOG4.P<[M[#O%S>069TP)W$_TPZYM(
MRIB("VF<PK,3<7%_?F8V],C=+#ZTR,]L;G+<H.5<@\2L'">UOYNUU!XR'59[
M/*2G/[<R?0)$[JB(^<B?=/1&K6^Q[F85&,Y=SS42I,-B=JJBWE8P(_KZX\VC
M/AZ[+A^7ZTW&7B@=SYW4G@#+I<J G+/J4">='3(+TJ(3./U2?V<&>\#HD7L&
MB9I0/%/\,Q.A_*7B"]UT/NMIG!-PG;_@F[2_%C/21TU43.DC-[?3VGP[E1(&
MM?9H'J^"MH[S Z2C3$F%P4PN7@?#$%U+@HJOLF+DD?+K($T6I,62?!)X!I<%
MDTU4U;95=B: 5M-O8#:IP0P--M96^I-ZZUHR"-U>\SY_74E.ZDJ"<;^Q(:U=
M>#/JP#>N0,DIYR\0M5K10H3PE=-)Y&-CL8&G0W,Z#S@%H$V%MS#!EZ.49%KD
M\:P[B,-=47-6^,)(%QB<V=>=7P.?C5JK0NNC*UN!@![CB1ZK<Y8_\_N 'X?U
MWRJ(SRBK0J1?U\V8ZB9-;Z3A19A)T-%&.L#\!1_I8(6+17*[;E1HTF-%=C@M
M2(<5V:'5]BQK&YH9MB]V1@:CSL0=0O#PX-K1FO^M;ED5NCL;4C:9'8K/PG#*
M[W!J:CN5SN' ?'H$*[@%M8?1?(VH\BU2M*-.T-T;+[?].6YI(=!54_L4OT+R
MZ\3LKCFT!0\%_>O[9';^*%7Z,R11 ZF$-T7ZE.91!C^M(]_5M,"1[ZPH?@/S
M.Z]8OKOEH;)9?1&F8%',H6"LN39C94TV]+@6$5$R>A$RR4.=J:0:RR15 TG6
MV<O'//W'EE[0,BY2T39TI-2+UK=6)$P"P[64'3 CZ8$/60Q&C_Y29E0B:B"&
M_!"MQRMV3 VWPG:[:3US&E=S.>BP]3HF*2QE+!G9O/$2F-4+NJ)YF3[3.K]'
M)[)*]W,DKZF"<:]+]/!H4KMFI])J[PDS);0W;NT2T-2X<VHXDAMET[KFOETJ
MX>QX;I+23)=\0<,\H+KFS9(?TV.]0=0_M!C$L0\@9%3W/B:V KE-UV<SB1YP
M@3=CBPWY!D*@PQB$-9AM(MADC,)!A:Y7V59#X@:^LBANO=E#REH/#5N"9K0R
MFU+6KVD]-PD;8JX)\9+2U9MLC;8GK^]<B7QI?(F4,04(KN5LK_=\#XFV/,/L
M="N=75'M4C]$:K]>O\;S>%ND,6TMZ6,>OK'Q)MZ\H7F]1A@.(8 .,K2S&DR<
M83]:@(L0(+!S^PA_>L*R+"I*PH_+VK<>YIR?YJ9#Q^,T4;V)3AW>-EX2>G ,
M4D3VYO(E%GM 43T\S;#&5L_KRE('C)8<WGRF1!O/7+P+TIQHPCDUW(BWCZ=U
MS>8<XLD^IX3IE#Q)UB.NF:*5/ZMU5()> W]<_F.;/D<9Y"AWE41VC31E9FO=
M[[%V:U4XS@W7T L>%-X8_D([7!9D"25FG@&;8"WB]7:"&9,W< ;-3>T_S*&<
M&L<W?::W?*_*T9>9P4Q6<V]&(08.>)O-@\UDLR9S7S1VP!^?0\SLBF4)?S>
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M\!PW@1?S**AF<S_'RK%9WR1_-H$D20&%*+L550&:^NTR<\#X:*PE8'A6YT:
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MDL"T">A/2SJ(<+Q(RSAC4'YE,G16_4NLWC0-P;D"=10&NT."? H>\ZJQ!<R
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M5H.6S^S<D[8#76M7?>#DFP^,OY)_&Z;[M0J]&8*(3ILF7:0%5Y=8,6BME ]
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MYO_XVW6\+$ZW2<I9Z+2J.%R!U%46/1TPKMI@W83WT4F=)^:>7]V1!C3IP28
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MP3%*2:9*'H]Q9%&RZT_45$ZYHS%-GT%FZPH<TI@RC6_1\64*,)Q' [75<':
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MC=U"ZE-JM)]FN:#:U'V\HLD6*L"KOH6GHG\LS(@M8(J'[+[P>XU:+U0(:B,
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M:O.2'3C+4%7?DTYG>X46!*-JT5-/8WZ3O[TUP+Z@,\+DNV=4JZWK'&Y%KK<
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M-WF2OJ0)VY<$6$GIW'/)0S/N45;)>SSNY1%+9*0./;CU<"TP._;_7%]%NCY
M\N<+3(5UQV1->O)T\>M"=N+,^>I+GOY1HDM$8Y(N*Q5.[/;2:MOCJ-8B&DIV
MMPQ5U\72&TI+E+P'#4_5R2#>G[ *)Y2\1]ZG)'WF4:C\V_HB7]B+:6C7X[L
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M%=N*\ K)R@\(2$P\_!7%957@/4_@:P/>RB2+E#WMGVAUQTX\G.<H _ G;V*
MN6M,%HC D8/0&V/K8AZE9!$Q%>5QCG1YU&ALC.'-/%?QUDQW8B5,MM+%Q9YP
M<?:5O2@>;Q'/$=LK'^<$E\_S:[84),5-.O5D8BC<(S^M_/KTO81/,9EA)C[
MF/A@G FVU-B7[^^R*)>6?FDFLEY48K/^A?4XF@FL\[7=[^N"FV+^Y(0G6O#E
M<YK+N6KZ/92A"65H0AF:C3VX.BO9$R79E8TT3KG<2$T/B+RPS:\Z]L\/C_U;
M7-_,G%3\TD=<U#>];W[G9DHFZ_P7XE>)X><\_;-R1:8X8:+9^BM.)ZI7X9:)
MGE*=K0UR7_IP#?#^L_O&=<>*-#-;2>^4^^I28E2Y[TLJV2F$=/UQ*\W7EU Z
MY9@+Q(?WR1^PVD32"X]20)N)'!<3H 5)XV*][+^P_93>/WQ1U$$ M'&;@M^X
M^>W=97B^VI&L;\BL=L3JCWOT1YG2M-ALI?4)(SK8K#RKIWVVVUA^8_,@S9]M
MPO7V$6-#Z8J]ZV*U\]31*;\QXG$>Y>OCM=I1Z4U>C\\T@IJ/'QNZMR7?;Z:S
MLR2IA, HJSVA9V4QQX1+,J8!53]QK!BNQ_$2I1F/Y&#2=34W; $H>-S8T%LO
MHZM71.*4HNU*JL3LFYP=DCE-X]^B;!<_8 I)C4>/%M5E2FKEW]8&J7Y20 SZ
MI)'.,K;US%!:E 39QJSA22/%[*W8("MK:.%)7F#V+Y0^S[E5Y@61Z!E5/UY&
M!;J.4F+SN-#D8J183\N"%E'.KZZO!0Y+:!X]9ZAX4:F.5=FJ\P1DL;#YJ)%@
M)I*\#E;3YO<JN\ XFFV8&-WL% L;_6#=BHV M7TVQCJSI<>Q$Z#A'/2.\8;[
MW>"D463M.QC,^&YQCKH.4=B'^U$>1YX=25I/1R;,[4:@ULU,]-_7+ \ECRWQ
MB>/?Z\R8RY)L'0FU^7'?S[W9ZH033+NCGF;2VF$B<8TV4/3!H53-:*0)Q;(!
M"VOL)4M#L>R3+9;='#B'71H??(&R:8_'H.W5%P0: X#P\>\^8A"*8^O,%'$4
M'A80^8R&NKJ5.+1N[.4357L')"G'%PS4\T 2Y^X+"$J)!!AW//9*FO!)H0AI
M]F5B@,Z,#F:YL5?65$^8DZT(+\ZQ&_LN8;T2?B@_/?R)#ZNGJU6WP?_:N4K3
M[-AGAL(N8:PZ@0];*$ASE^7?CUUXT-A&9.5RQGZLP&&0%X\:^_;9XE0!5BNR
M5]!T0,A JV'8*U\Z(## !=_&?I H+1BP0CMC/TKT86@L]6.O:.W0UH:R"J"]
M*K7#A4)0B]"7/:*S,4L61@?77 ;J&(%/&'C)/S@H ]7G=$'1KC$(1VB@BTL7
M(2-K:*":#-B=HE%8 CY!!BJ::!U$DI*T8U=BU-8Q<S=+#51U@1L(P\U2$L'$
M>C$'>U98_]"%IDC:$Z+]PU2S>H8]Y7W8T-K( [$G@@T;RWYRR^R9K,>+=O=*
M"?8D1?]0U:G59D_\]!17>5$W>\;6X<+9.;O,GEEVN*#U6CS!HEUSO(AWKQIE
MT3(Z7E@M5TL8O:UUV'![9K?L?<MHB^<):6;=*]'!80TJF*'B:G#(@W[6I?PI
M'&=_]+5>[HJ  ^V/)M?OK2=PQ$](#;14'7V'==\7*S]E4?P[C>>L$9W@]5I<
M,M$SS9\G"YR@;',3\68$G>]<UG]D#5JOUS&W93K<U&SUIN;=^[/X)C<C<?;
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M3 J>=WE3E3:N(ME$9A%P!STIY9MK]K9'PT.]ED0#$M+WS/\]6C),H\IQ#!K
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M/@?N$7Y2GS]/:GO#6SG\O0Q0JP\<*WX'<^,><1LN.]?Y_=V\T'H998^(+!P
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M/<Z"S*8= FQ93M2FL9X4P+(7#,ZA%]@^BQ/^GFW%C6V3"-A<U>3/1\3/Y6
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MLZG1YZ!$ +26X4MCQ&#H.XE +!EX#@QUJ8=K. 7A@)BFEM?&1-YSU[@7_LB
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MPY$78#"T\8&,'</X;P:/@ORIA51,<A+@%!HIQ@3,>-(E8*DTNZ!D'-TJX<A
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M_59[T&TWRH-JU00E;8%VJ#98F=5J#;-?&]3-1A6<!X _^";S89(9TP(7\TW
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MU)PP7*/ U*XPU=AA8!=7J[I3(Q0^3;\[XL^ 8UM!5U!WM_"X#OW$Y2#1RYH
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MA-^=/C#3)SHSY,!P^9#ZO#F^P3S#FW 3-W M0SB&\#W#'#$7WGN?\N+6<MT
M2Y7_THC1OAN@ZD$C<GL$4$9EHJE 7W'%<.2'5!A[?-NFP(,EHMK0LMK0P&AT
M_FM[*W\^H?^(D,*.8BY8-!3SH\9B)S)P?'=Z(BT^;^5X^,3$E7<XSD86>@<M
M=)O=,Y<_8IBOCIF]04QL-24DU"8K?I6T>,L>SG4>BNIKM['V[!X<-YKE2J/3
M:C?:*_I_A6Q94QN1M## II1@5+K&OP-7>)8PR:X$]222DH4><X?,$?^AO]^_
M"3Y?W2]X%01Q?GA]>'-HZ/1@UT@SLW$A#]_O@T/QW&*O9UDN]SS]GZ_"X=7U
M15ZS@G'\1@.@[/HCXSLBXA]@1-VSJ7'I\))Q$PC@UEJE&@)@/9_BA8!R C\O
MW5MYOX&IT:P>'/]W,(%EN[.K+2V.6*8^3R+NTKT"@P?$V2[LH6;MX/C,EJZP
MV.PD5YSCE81)V/]/3)3%MO8$Z@?']7JCO5A-/H]OHU>#FF/B K#%A-E&5 0%
ME_'D=>^]\0Y6:N!2W[_<UM^\_?9<7/-N(4T@I_1<SC:D@L;!<;-5G:6!]XMI
M$'L/VU<CZ6P<XV@V#X[;C7JY4Z_77YCXKB-7^F]_Z=2J[8\>(-[F$UR>COB4
MT*"Q _2<#?!=&"P7:7!52MA?!78#+.@*7\"(*N+ 76X9D\#U @P]^-* )TC!
M5VOO^N^1@3'(V#/]H\6AAUH1>EC#&JRWMV@-ZIW\LBE![<"G;&;^C"[2?(X,
MZJ@670Q1 O!_)E.2$NR1DC@S1X9I,\_;Q(JNM78 -U]."!8*2#/P4Q.8O_]<
M<',9":B;Z;@O[7?>1F[6FZ.V"QU0)6+C#^8(3Z$W0*#=CP1<B:5>7J(&"XG-
M'?;?54H&_N_];O&II>0B/E!B]86X8*'-HE79M%KKDX39P&9IJ1TA( ZJ9BH9
M$^8:=\P.N/'7RF&E4L4M-<,;988WU^#%]5"\54'WTEC20DS)L U0U#[ C9OS
M9P3_F^.P6S#P'N6R4RU)4;S.>\XH9S=VFCL@M'LWGWO_,^<S$U<:WYC[D_O&
MUZ\G;R_@M):]/DS9ZP;V'3G,BQNSFZWE?P>>+P93F &6;YH8PNY/#7/$@6S@
MI9^&4/!([*X*SV#&/;@KY9^.O'?@F\P#0%EPPPO0,V2>8?&!<-3FZW4 MFNC
MT@PAFT ( /G06+1=O<J_C3]@%)TG]%A\Z%\PX]]QPC=ZON<TW0W8K0OL)N=8
M+4HU+<AEEEP<Z<.5/P.!K <<1YDC+F6.>=FL6,<=DN@O2I.*&?/Y:.:?T@X<
MG[F4O.)ZZ]-*J_+2M+( ?;DEH/L1I_VS&2IZ5WUOC$"P(.E8!K/MB'Z2A-7G
M^@$8,TU+*1I*B*!0*R-=X6U,M3,LN MN(SXZ<;G)R8FLU@Q*R_6,=S >Z&_#
M"\ =\D82\TK"U#%_Q/S9N=\S;Y[\Z66]AO<@,QU+H>1=32VT#Z8 /-3_-RP#
M7Z+GX4V<BAZ,^K?33&BFS/.-;L6PV-0[?(0%GL(_;^W?C\F(D\!U 1$J$18-
M=9_YP2:BHGIP#*)ID:P 8\2(,F(+L;&BV$!. B8:"]\'WN,V,),K'71Q[*G!
MP=V9&N=H*#*3ME4^,Y\99TH[I:1*/$92725-FVL^#%2IH'%3OC7>(:3:'XU:
MO788&3^"TM FF(:V:QFC)AQ)#>Z]?T0F%/]^7K&1(#ND.BU%-A ;M4)L;%UL
MD(MCPZC<8*8)8L-ER/O(2.C?.)E7P<QURIDWO#'(&_B*&^H(P/)XPIPI6B8P
M&FAR7,#0&+KRWA^%=P_!4.$T-7*G*$6==H1Q5ZY6^;AH@G2[^C%\[-$'%DXO
M>A"LD_#A!7,-GPP=OFJM7ZZ%]E;2R#I,[8)M6D9)^V'/744YMY_2?*:RDJ_9
MB$XQ=A3*,R6"S?GMH'JPXCH:E?]*\.AZFR//!8+>"HM?H2;FQ5"X0G&$>P*K
M&TIWFA$=I(=HW:9^:)- 8:N.WFB&D%KJH*Y#65BMEB:K7.<5/AOYWBS4 (\0
M!KWX*?"$PSUOZV5VK95*I#?FJXU$RCY(H]-L)?@8,L/7OM!;)^JE[2.UN4KM
M9&[#_SNW! =+3"Y,:UHQKHFN)3F4($0QP E.5^ I<PV^JPK!,TH+P>+#;]E3
M_/B]@$\CX3BP3HGBX4YX))0=YIB"V:CTL0 %'\;#+"WF6IZ!&9;"6K2-47_'
MWF=:7CMT!%:&_M/PG_%-NG#'7,$P*<I!5K)W%$C0L4<MQ#$C NUBYOL<\UX1
M]H &K#6#^;(AA>>B_#GF>2# \5*(&CX8<'+_')WGB6\*] H=P#LRO2MM0X+(
M2Y!#K#\"(+ X1-ZH-!+)9C?,[3,8MGSY8/,IA3;?59N4!7UR:+1K+<Q,>X\+
MCU>IM\7Z-LBM!-$-A#M6 8<)?)OA0T"GM--CT8Q98 E?STN'&## OE 2GIL#
MMX?O2+<70^[,9L/M"\+%1>216YSW(/QL7>:J#)#UP1E1#(+0BP/A@-IU$QH7
M"LLD#\6T2\GA*F8MYW>)*)M4[1BJUW2D>V!3 !PNF=)U>51/@S+<=3'V+9$T
M[X0,/'L:4F;65P\?[\MQ)IP;?^R?XL GT>=V0YSMY5KZJ=*QM9IP?'$B7$Y!
M%"-!8I&@6A6^8S((B39!6"2IHC@HBFI34I07)+(]]82G2['0H;KCY3Y#;8OZ
MF#N>$N$8BX5;M(44?3U)JI%(G\W&=[UD4-<%V^ .*3N:@K8 DIP5!HD;E<-J
MY7.Y"ORU2RW]/.&ZEU/2%+;S1MRV(XO\748R0BHV!7(,8+Y496E/#,?=F<W>
MR8NJ>K8,G1C)F#[%AD- )&)ZK)*55!*A1M*=)&,$S2T,LNH_395YB-SN3PU
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M[6/T*'"SR'^@-PW K@%[AB*L*L#KL@E1<#@PF=F^ *H1N-0[X$/T[)3Q/>9
MJQ),ZV2D*H,7@'OPNV;!% 53;#S9<R7V3>R<Y N*;X82/$7:2)B1<"8+^L]
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MG_4NCZ[ 06/?\77D?1!&WO$&=_XS'?.9B@6?"T?#!U-)A P\>QJVWK64XY9
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M.G*HPI#&H];&4^6;^X(Z1=E1PIDW8C_AR@#,1N5I(=)L7@[T+KF'I( %]65
M"[>3'CY8/F2Q>Z5$YE:X^P3>'6[S1=M/AE)XB$I:OF[Q+"(*#ZM)@1KB?15\
MJ1"/*V5+SD1C >A>=)0+P',L/%7^.6-BI6U-*@M7$M&>TJ-4WACO%"1LR;F
M"_G3VL8(8QG@!P3(?/U@+)0E:C&A#G/1]L?,Q 7&][&SDY)X*J*\=O""JP:E
MJ95&\8O87!J#H.M+3+9<'M989=LCN4V*X9FYK0^T+^@$597I%TDFM41O)<D,
MMJE2'/"PI."YKS18N'^Z0& OE]&Z\LF1R6T E3?UN)0E]0*RM2\9-D+(D*IZ
M#X6"_:M)5%+9)% ?EZ8E+7\QI#0G,X$D!%55>3/R%L97(RMI>6CTK)CPY_8V
M4GHC2A;">KY(&FL8:E&L J)JMWX[<CB.0&IB7RR8@7SQB'/J=F*<!:[R45T0
MRF#YA-2FR]42O#^TIP"<J>I2G0C[T9YA& @-L2;TKG*X+1:Q3+'!O!7#EC@@
M,SY>4MDBR>9WL5U*?BY(:Z295,"83GW6.>*QC$]20.I<@[C30Z!3VM>/HB=S
M4D+'.IE=%UJX"SSE4LIWC>D12'NH'& E95,QX&1:2U8Z3KSWH("(D!(.5M@[
M>(*9PP="9\NO%1-!"Y:\A1+F6FL9B8G5]/<5.(R"44JP!*=$7<=OG#L>)BJ>
MX)O&.W'(0<"F[%S*EO+,@'I$ &W(^Z,\D/'^U7MI5MNK%DD4'6I]W*=&2=_8
M&!Z%UQ3"CXR32(XH?<,QKL93$<X16&DD%L;X0Z5(/23LEL0NF$6;9<*Q=>$&
M'L>2R T.A4TD >*<&A6QBS5<F#">/*+01+6.81MMH*EM.3)(P7IVF#[\-N)U
M,%V%EW+^53 QF204Z$ZI48HM6> 8:$([+QT=T/X42R;+T-8GM_2QH;-Y&0DH
M8O" Z?1)QPJ_K[+T7!Y:\MD>.M@/DZ<<J9@BC.6;-ZM7G!;;7BMN>W6*;:_7
MMNU5J--"G>*4/ZDP-K./C/!G%%B)[4RJ^L/MDD1[-L< O3'%D 0VE:%$9IV)
M2D&4,?='4BFC9' G5+J)*+(<@!D<.0$)+];C=)"PE]PY251MIEW+,&Z-'D.F
MFWEH_$/>HW]20DFB.UC%QGJHV3$4H?+T)U-7@AL ?Q&_WS-;&>H@MJA@)=S@
MI'H6T,ACU134"X1BKG#K=6ZK=3;C/ZKKRDJ"/#2^@7:5-&_X4]H!CAV##V .
M[C_H?MJ$"GQ3^1N)-2:?!4LC3&$) ^>ZRZ/J+J0Z!@[!Z_'">'$JJ [6E;3U
MUIO*!%:E%E';-B?*%97D"MHJQN*%Q^6I:F$ )E@$.ASU&ONE%M+K6:;\!X@@
M> ,KPZCRW*/*C9#T2U@8Z_FEI$#+=)3#SJJA<1_ZY>0$K"8.DFQ*I:7@Z&-0
MP9=2U_307)+"@/H9JUU<2P>VB:QU?C+'"P  SL-M/ <@BA%"X22DCX[%D D>
MB1ZXZT1>!/D!"UT)</CCE(X96>51N9L.^'IQ4U<=!E$K(E8+6P,.@:$QZN@$
MXSY6P0TH6 N_+NCMRQG_"%834"R]D 'Y8*@]E $ZPJ6C <F_,N-=.AUIW@Q1
M[B[NY_A86FCK=B# 65:T3Z).H(-9I6(0);2$:#N(PN;E8*)3EJG?ZD!0C2[P
MH=Z$P%:> BTHBTWT:8V4J6NA$>6#V1-X9$]1-UR;=II0?B1WH>)I'R97EY41
MQ>@<6ZV^XSW4#)L,ED')0:KI*07>4X5A*XH0VG; '6ONI *8.G<L,KC";NV1
M;<'BHCX N]J^APGB'D\H+?BDD!.Y8+H]E!.W+JA^"40P9D?&I<.C>GV=2Y:1
MG1,3ZT!E:"5+I:@\0%H9JG.63U!-A[S"U.YEU,49INHRI,! ;Z+[*$NB'##L
MCVSQ(1V?F\&RBHL4_R5X7S=2I?1,ZMYBRR$N*WIKGB_#5)Y7V)?]^8J'3L)M
M'.D4-4)K;$VF>UY%)Q\(CTK80*-3HDBT1:;2KK29+*DE5%2M$^9@HK,;)I"9
M^FP0T&ZHBLE$]=(5H)&SGF!;[ H1-?^BK;WL8J)(2I2,41AAT/U%9O<&=>I$
M6(W#[Z2-41-?]=_V=(A4I:)@OVZR\EFT=MS!4$>+AIE,.KH?9N(F]U?5NV[\
MK.YV'&7LH$BCC-.P9?!AO)="36?Q93K?^YZI;!?UE?AXE$G@>E1'R>(B&S"7
M0+*%WZ#.[# //9J>;A1ZP,ZWR\JW$C$;W2U=P\'3Q>FIA/3L"K#[D529OO%N
M-K;K0DRHW0L-!!.PZF.%)A9=J7[G24>067+B1^L*TX9U9@4:>KK5/<:!"&D#
M1DF&8%CP*/MX;L.73F/0JH$RH<,N= LSF=%*0_$KO)'J+Y#@G,1#VI+##BL+
M!P+:QUP+70(]1.?5T:6]N/]MBG3*4I29#1H$IAXD\FB8&_60BT_#G?FP1Z?S
M)?WD\.0=3 )BKCTM>\AX,\?OZ.,',,\K=19?!+^23BE'!9K(%$VDCZ-GZKK8
M!SMQHCT10!J8B6SQ\T?[*)6B9(=9KE"N,":QN5PUM..)U'*1+'[,L#DHQT9U
MS?/&L5Q:W&:$.!-,@#)%[U9./)OM/*4S)I:GE>56B^1'R:E&G""LSN,#?*Q$
MS<@W)?L+^V!%S (T+X 3K]*<V$MP8@'*-4RMY87-6>4[:)?0EHX]319*ZTSP
M,#DO](Q0V%@N-8[H3^>*5%+J"N.RE&$8YE<(M,5(7FN)1?:1:F[@>,&8-#VF
M=U!7"Q+2JCF%RM;2&J9DS'<:2?A+6!#,*?]>-? BB6P)-G2DY\\D%Y9BG4=Q
MW+G^(HFT68HK*5LH6I:MSZSP1[J^"!O_X^%'=">=.I<,K"XH-S\T_A4W R'?
M,S25=1N@D1CXNLT5&D! .:J[IVK'$:=^9!2R>Y2<8H>ZFW;:%,P]JI!.+JID
MD-X&H)<'+@^KG*-%>F"J)1H6)1<ZEP2[H*V)MI#);JY]C).>T5$NZZ 8J*DH
M'S7JQJK.Y5V^V'!4"I=AVZ;YHWYUI(YY";6.*%>H&G/NAS;Z3/M([MP)5VHK
MBLX.@N&1<\+V!=H325!(N.2X)#Q5+Y=.UYS/9$?=7)Y@QC&\JSSZ=*>;.+DV
M=#M2E>OI#/;2S$0I,!DVU$KP5:H$5)L.65F3"_<UYYH:SC5ZZ?-AX*1:NT1M
M7!07/)8;&@884^V]:$=#662)=A0*4J&4"]N"AO!2M"4DFD0H,,*#F_0^-(V#
M["/IK#Q[F@LSJ<CX>)XX:+?5[NY5'!13@:.-!<KIBQR!(Z.G3'] ;]FEWE1:
M**4*9G2Q1=1"UQ^55!$$=]0!?]I\L,6 Q\>XJRT9$'NVU)''J!29=D?\Z81'
MS3LR)$9"&:M@[++N*L4N01Y(;0^YX_-%[\/U10_]:S$)[*@Z2O/'=6AKANE*
MR /)'4(@?K7I%_[I46J.&?7I4\>Y"A5>A _A-?P@-9^FSO5H'^'3W^!R4HMZ
M4P?^J[N&4KQG-A[AWB5/<BTES%JX_?^S]Z[-;1Q9FO#W]U=4S&R_(T44:5.^
MM-T].Q$T)=G:MBRM)+MC]LM& 4@ 916JT'4A!?_Z/=?,DW4A*5F20:LV8K8M
M$D1EY>7DN3SG>08G1L:SJ7.V!@/Q ?:GY\-T'#OS#AXF#-S/)1"S+9FFC=.<
MK>=C39Z^35?S>C&$?=SE)[T-&P#Y."TA5DH^-4Y$"#U;[4B;C_8/QWVK\C8&
M#+@D24QF%&1&UC@$E(@.PR7Y8QL5B:<YG[-CV+1W\)S%))YO?\CH,J-.Z"T)
M;<IQB0IH<:Y&V_';@4 GPS]1I#1G0>(2M0F;;;+<NEU@N(XB-0+58-#XV1HK
M=(P"H2P07$B[K&F81Z-F#.LZ1VA9[])EGK43'V_C1.6%?Q4X '-I^WWF$L^C
MJJN@#Z.DAB<PG:2N%3X^BB%8YE+Y;L80XR/;6<!<RP+\G1Y'"E:8EMA3Q1F.
ME-K=VX-20)7@@;6XL0VC'U$R$@:3TD'*-YFIKE%5%%%;61H-,ZJ]CAR"7DX/
M>[3D0&!VB%R[AK(+T<4@?>>>WSR<2 ZRPN'3&J/O,-6<4#1*F4"3WPUY)TQW
M(9$BPU!KOW:40&H4$FH661(^FN^9IF&.0K.YO72^2H_W*O4!'K-E?\<!$6G4
MG)W]7;1SO+S/R-GJ%4_T2MU5A:,2M0_>KJKZ];H@RQ?%:01)&&0W-*B[V[?8
MW& YWF#Y[=Q@.3=8SA?*G_%"^<DD%/A.(3&&)^4&G,2<KQI[N?RH8'I%LG%?
MOO0&P>NY9H\=! Q($Z_,7D,Q^54:N=X[E[4JSQ#R'E1*]M156-U4(9)A@=/4
M *.2ZXE2M:'CYU]M3AT>Q1Z\@\?F28@>+-8G/BN/1IC5QSPR0U&/(GXE@@\I
M9/44D\*CKW05#%59=Z[@',0F0ZX@3BD@X+ K]KS]LSVA?1$C1QVM,"D9PPS1
MJVOV129:LX8&5..^$P8W\[G$9NGYN!S'WKN#Q^7"9#3XEGE.^8[XO+R(TRIZ
MPRA?&W6F++)VN3UIJQ/ZCRA50KC97<[6GT:IR4#*=]#!V5&>17'1F#?)=BI7
M@Y#VN/?DG9(B=SL$.K9$WBC6J ?'Z<JB6KX6:E6+DQ+^HKB5XB;%*DW[$3Z0
MD$HJX6'4-6K'[ W"2I!:ND,VN()*HJR=D'6KVS(F6=C'.4TAFP;0N%OQ<EJ<
M$?9LA68"S/U932J&,$4SIJF[*"<N>3RF=E2)K:&0E!'=XC8P"Q07@2XJ0$F.
MUA" &F*J?=9N(7:,SN:D+EP$%)0= $\3I+.ZI<<)@CJVT_>?B_^:D<V_?QJ_
M4Q%[K!]A&@/=0$?GF,X/(_8*SRTC:A;PTZK<5!3B, =BD!K0MM 14LK)IALF
MH5BV?09VZN;X36V%%R]89BN\[*)^FD@FX.?3EZ?2:%H[F(6I'AU3.2&4:+L=
M$QJ7HUJ[7<8%P"1K:;AHG8-!(IX[4J9*+LYB+*HR4U 9W:&R%+K41APAN@>"
M&"1=!6%?LXB"5 DL$6B,R(1_(J>\06+^&4L'Y(+;M^@G"<.X:=BCOOGU[O<-
MKS'FX/:<?/3Q9;C7>^D?;05N\M!'7N /'[5UOX<"(<*!T!,T80F/CQP7SGOR
MD]F3^-5&MP:O-D.'.N^[>=]]F%%_9Q20/L,RJX@?4:CUO>'O^^S[$3(_=0CF
M_3GOSP\SZH=P)>.-O!,,N.D^L,V"!'ACQ,"<E7K/62E3=1H*6%DIE+RDK XQ
M@>0-<7%%[I6]T5)J T/$6=ECA)"4%3& 73S[Y<G#D[-OC8):4L!7-4OX'D-*
MP5*O OIMG-'7TBBK ".'ADO(-"G%RA4]>B\2#X8-QIKHD61;4->:;@?DIYJT
M6482'"51(J32'8O<'AAR888-'MC"1]WR=5 2FV06F%0/,Y/_9PS)YK+(GZ4L
M\NA-ZTA5TJ=)$Q:H8Z+-,9+\X1F8BW+'L)1W</<]*9O.%YB%%I'RCA$S\KR]
MCF&M[N#V^L'*H"E0*%5/PY.R2X]OZ"-D8@<J^<Y[[Q@6\@[NO1]1&=#NO0.I
M5)O+-7#D<C, T?(*(>_"$O(&BNIY-Q[#TM[!W?A#3FSN#!LA75T1$^\)=/<P
M7R5^F;"+&(USNZ\E!IMC^P^-.+FF;NGY0*^(E#$"1H!Y,=GK:W@@^0%YDS39
MV@5JT#;E)BU/>!/#1$Z3ER0=$+Z&B2$'DK&>*T=$-R,:_56.3X,H'&%50M-K
M +JANTLR 9I6\.V4VL46YP(L+:D?WU:81R.]1F0&( K%H6+CQ0_/4K7.AC0]
MXDP7'07C0MA>Z!'.\7'E$X^H4>Z$H,X89V@&[3 3DKG'"3&9>US&>US./I>'
MSDTN?YHFEV/@V7RA>?GG6=V6&F-?O'@VPZ=N>R,;VF<+9,RI[YXLN$@SPTWC
MRR#!,"..O58"#?AZ_D>[S>O5"2:BJ1ME4V<[@58I<:Z'2QEB)X.4P@N+(4!_
M2N#/''Z,G^K\O^Z=W4==IKL4@<"H7]B#\= $'N?8<T+_1;O_EU>ODE<('R3G
MUO_5!4)HB<OY<5YBK2E-?FQ7NG2#V9A#D-]C\%[FV)/]TNW!744RD0>?GWT=
MVSYFH'0EM6E[OOJW6KO3Y![)I'S^=_@S^J^SO]]'N3YK&:^W@2FZZ.NN)C-+
MC"<'Y9N'D,&A/2;:E@:Y_#**;=@(^QAWX)TGAK$S0G+W:R $)U=$O2H#QL7!
MVPFV>[8.:8QG)J93FDSD01M*L41WC(':QM<#O,"C#BF:!$G:TJ+)C47X=O,M
M42:@)++UW%QA(ZSKE"P@(;5V2[1-#O&Z8=P"AI49RF/D/>X:NW:JTW!Q=IQ!
MR[$=T%>]H^BTD(=>B%]8?WC\X20-A3V&YC1HZAYAS++5GH!C(R&J1ITCJ0.+
M,( _( UQ.4)R_+C-CQ3MC%)?ZE5\X)&%"X0HH3>0]WLP B(+8L;PJ\/X-CF/
M6(D17"VQM%3VQ_<W0;JE":NE:0FLUY(86QS&]4DBRV3P\L>Y:V<'[ ,Y8 _N
MH@/VC"PM!GZ<R?O^Z?/D:9#)J)O9C?J 5AIOO%Y\UY.-8<YQAXHMM#8[NS:>
MF.O:B)!ROFC:"7(%_ZLZ:21 LT,#25Q<0>QHS,HUY!H1\S"U\ZAT4;7XE=.^
MOB,//T9V5#5Z%EWK99$4V@5/^^J+[R0YV23W?LG <*ZJ(@<W\.4^RTMP^AZ[
M>K>HWB#0-;GW789*+Q5"M?YQGJ)02)[=YPEX5+CF-_C"[TD^]G4&'^Y6<$=A
M!^0/*!!3'^X?IRT^PKW9]'1_<.':PU[J1.2BD41>7@M#6Y(U)RA'B1=DUN2-
MM$U[52_5&.<+N'$^KP&^ LKS;C*AEF<U[ #[@^U,H@A)=IGEH8UUE3>9!H=-
M&G3 46.C(ID^+#:@5\Q:7P6*@Y'(F4IFT'=+GVE7QRZ!H:@W._L8%NR8-L\P
MC]B/W^]A'E$B.?CL"^JO?^A_>(8_O(_$FK05CC;I.#M+'\+M6$0)J\7=\IEH
M\$\T>QL2Z7XKC[[3[#/]WH[O4!;] :/*)R&<Q$SWD=J/8YO(L<9DNB?S$NZY
M-A'*6)&@ZE%:D'@4_-6OPH+%CNO0^Q*S_^C[D+_#>S:J>%#0G'#0/!F3&VTK
M\D-,JS,U 3!/I.?=JF"H+3JE:8*\QUEKB"\,!RQJ",14'>:Y^&4E+$E?KM2@
M6\#95HJ++"%/";_R!K:+@2H3,8ZE(XQ)\+^U6\.K(W.M\HO1HHSP@IPF_W '
MWX\_.9&:'%&7/)WPR=.XA7RN(+W3G?S5EW?O3KZ# +8+;[_Z67@Z/SYIV#O*
MAK)=,>6WM!Q_0J:Q>:M^E"%_'_"2PPTY<K>HR!/%W)HF=]S6%Q$>H0RC4E<*
M#]_OO5/,>.8-?Q2[YPYN^&?BD9BB#^[\#?F(R\14?E@DE+./4EAU<@X&=AU)
MLG:8MC$%6OC^-1),SGOU*!;^#N[5)RM);+.!INB$:HOD67 QDEIZ/0@R%"MQ
M0S>V9BTB%O2!JCA0OSM7%ADG5KO%P8"7J9M-:_PD#:,,??-V/H:]<0>W\U.C
M\3/B#5/@;'6_:*]62S3"%#965R43'I+ZB_^F2 U,)*TCL'I/944.@F)@-M6?
MDZIWWM0?1V$R[DDB1@CC!/0\ZM =YQ7P@N9=Y'L0+.U?0L[G):I5R]B0:> ^
MQAS.Y]_\W3>ZS![SO,/?VY ?O7'+3ET-DU<DZ5/AHF3"<TODFV1HDALNU094
MHV\,$P_:K7QH&>$)><LC97RYH3SA0)?.L]TV+?P@J]^A]?Z8<H?'G8]7[)CP
M02,*+1WDUVUWE\?MM!Y?2X*V[($R<,0FO 3#MX'+&SON;ILQS\?:/#GU;%/T
MBO<([BT\3T,^"O,,Z?F8-XV,U/BA<6--K8+&Z,.7!T.?QE!%_1QL?&F8\YR1
M2#6]RE<XR_RB?2RB?K$@6K4E^X0$%S>>6.UHZ9KG7KJ)7KJS6W:(S;UT<R_=
M.]KS%VY)R2JNG_*U#%YDA2&5BB=KV[&'UBVSO8$F*?<^"RD3P7.Q<JO4M_)2
M4CB+/-"YUVOV;8_:MS5BJ)'6!$$)B;.90*7H-3A\?K<#.[OH=H)'4(3?0.#6
MM\UK3T+*=_PH"25?]Y:)TDJLSI';,6R5.[B['\?M2K[L_-_G3TY@D9-[+\]?
MO#RYJ'XY>9"\^.[A?>^1>D?4=LU0,\YE5G#-H\W!?[:9#JR3X  X0'C\\)Q/
M!3QTI7!O8D0O(3Y,S(.5-F+>YD>Q9^[@-D?FM!.N5\04)6:7/>[ HWRYQT#I
M.1OH%)SA7;;9H%QV"=;\W@_G@MHO75>CS!6<  C][OV$/Z=-;?RE%75GMH<0
MD&8<C@KE/VG=1;2V<),\:XHJ^;G,,:)%G\HSO<(,=JL#'9"\7!>=*W_+YO-P
M%)OK#IZ'1\$HPR% 09O"O;$,17Y/$F1R0]M9+#J.9_GX,KGW](>+)T_D0,!F
MWL$@1:-J53$7LLG>Z &8]^Q1;( [N&=?=D22M>Z*!&QLM2PJQN.V.:YA<F]W
MOK@?=?.20;XXDYATE< '&A16H_((N.*TOU_GE.)KDLN\;CL*3W.JJ2^92>OB
MAV<GT3?,&_@H=L,=W,#?]W.UI(HEZ5J3/*%]2IN7HLN0N\T(9-=1 Z42W8?V
M;?"[\Y61VXJW[7^@SP)^29'_QJ[&RA\!Q7C,._LHMLD=W-G/(Y]ZD9\H!A29
M_NKHG[CQ'B]/UIT"X#@3DK5<%V>&;%LE'-IQ\_UJ_K%C-[C>N*E%:P9<D<:=
MP''9P^^<W^IBV1/_G;XG8:X0OM_6ITC,YY7AW]">L[G_Z5WJK5F^HSM#='"=
MD+7Q&T092J+904A@Q'Y"I<!86PESC?_J\II)0VHA>L/.*NEGXCY\:C1FL=O3
MY)QK!83EAM  I=GY\+*4,SZ),_^'I.E(*Y+&,[@$?3DA*E&J2BV^Z=^2>_E]
M?T6.$+F,7YD5SD.3W/O^\S3Y_@'\W^>/\3\>0]AR+X<O%*07S)/#3J(2ZQS/
M3J)1L,V"3\/'-9K)=[NNK."-\R5:DT!M.I*6G;?U]=MZX!9!J @;):*RH;9[
M;1&@=789EI=8ZZ9O^V,Z7/:RD L7?'QR6*+S$9T$BQ!X%1,C^AX$6.&ZRI9;
MQEUY6#=B!4RR,\4CRA!QSP4E1.E1[9\+:(43OEP!&/1WL1K0T7T?WYWSIKO-
MIGL4;9]E5:YSI8RVGO-/^655H'0"K.PV7Z"15<<BME3!+T<SFI>PLWQOYZ!F
M&O8F@S0LPQH!15!HUXU$N;FX_7;/#JI(@I)"W?&6FV..WR;-*GU_! F&)7ZZ
MELC@&/7Z>/P_#3N79S*##V@W>V#EJZPQ,$U*]_9X\@<DD^B*GC2P4,[R0>'U
M5U17)P2Y#WGHG8-UJ2 ,5+S;!#%\8C@N;VAFA_"7&/[Q;ZI5FI0=1*C!ST,E
M=@05GB;_M!KK0TXI$2E *PY# G=XXW&+#5$&[)6=FOP54D0/0)D=DGD2N95Q
M7;A$:EA\3*T*///EZ^(0H1O;XC!P4QA;@ZH8B(>D7,\(88"0^BO1IHBW@[TE
MI0(<:U?"W"?(C<240^IV]_6'5%1P4U2+(#F/RS&R#F,@B..\D/YHT\;#26[Q
M/Q?H2EZ &X.GZ"DI/TDZIM%W.M+X^NBSA]_>O>1A=9?2AB^,.7A)N*ESQDWQ
ME.<<LK5('(^;?"F;G.7-L&A9E22TAUZ[I!<:_B@VP;1;-/7U)0)2R.BME?K%
M7!;#+QY1(Z'8$8,WM:BD_TM?HV'_1.#H;PNN^9^LD5?86L$8+N:I3JX<TALR
M/)VE4S#^2QY\_N!!@N2%8-0/V0HOP-C FKC2O*21AK%@,^W:-%=T#V_V&7R'
M@9P%L)M &*ZY9HEOYW]U)0WZRYAJ.RO+"M8"2\H#_R#<?EI,UGMTF^_II::G
MCRY:,'Z(>&^3'TA8E[[T.X\^;3S#CW[.\G0K'35N)KCY:PK*J9'0I(AI$&%6
M!AY$O*58MOP4AI5CF%:Q(Q 3Q.M0XEGBJCPO?\ZKYYI64F;,BAPFPNP@=H@X
M:8[FCKH@T2=9)^?8C]/ N<J;AKE';-K$=.O@L[,ZXAQ<PY;$U)?OI:$51FO-
MK\X;TF]X.SB!1NH8(XR,/JEP$4:&)G&/\[(VY!.R[79=LQ0U5_9;^B^_5'D+
MKSQ$E.:\)BLXYZ@,)2)3IVQL^/__&:7$Z,.MP[RA0#[]GO+,_OJ^Q%4-[^K
MZ5JQ.!6O5;<'[P[=G.R@H+K_\=7GGZ>?P_\E&3^M<<A=+CG;X>=PH_$O92O
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M[_+J]^RN:R*9CY[Z)(01.6IV:^%VJGSE8)@2Y1VB>W1@GXWS^>6P,&.NRH#
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M98)B/^ BP1*\IL'SJZ?PHNB\R.Q%^75K'3&G+7,=VOX4;N-;\7@C!';%SK-
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M0=Z3GL'Q.@"!=P''DV$2"=/ +1;JUUVYZ=2ISAHE.] ?DP: /%^!TWB-'5
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M&S15EYZ6GG>(%DX%%?%R@2\3[U.^?G9N;I.[NV$M)N>ZC?]VH'>H.3SS&4S
M7+>N5Y(XPV3(;9]+M(T8U(Y_YVGR"U_7_K:.U<"%^Y3^=NP](K!$LP6/A5V#
MAGIC#:S7UTG@=_N\=5IAI%851G]KYFQJR^<(B<6 N_\*KP*[+P;6"H)EQ19T
M%,@+X<#/B9"UD$..K4IF50Q]O#DM/!-'[B;72SF%ID,_%B?#I% ;UZ*MYGKO
M"!^G*"NL<>X9N2ASM<L;1NOS DO=,J<EHIG2V1!7< C&-R*9(R%[?\=A5 M/
M4B&G121&3FE!JA1XCOC1EXFE.2^G-US0BJ?A]09#26;%8Z311C>G ><[IYXJ
MRAPQ1'],T5U&9;)]Y8$]>+LZT4#L2[U+VL@R&X15/$Y7[X_%7Y&/CR2VV*[)
M$]MOT8VK!<2AW$DNRE07YQONVAO.9*%#)M^ J25*,2N1&LY>#GFN7)3)ZZF_
MI(DK86!."M<(_=Z])98N9 EL4'VK-I>USPR+5-PU)83)^D!(WX6F.^FXNTGV
M^Q,]W+>$VH62(=E1XL0N\K:%D%@5FZ1I3FZ$?K&)[@0(PB.;3VT!\<?#C@X"
M0O3(,:$P-".1Y-%8NF.4K4MOI\$?3&\M7PK)Z3I2\G/:K=KE8Y^CN11P"Y 1
M._<HPO[X*7G=ANP9JWNC^%.Y04<0#IL<?)P=\-*DHE%N&LP*%9T*AD==7:3)
MLZT*HHAD;FX<KG:K\5SJO*N7M7*+-GR]I_5FN_*KE*O@B^">9S<6Z=%+[-,7
M_GT4&.B7PR3-&-O[Y+QHJE0Q*YB9*=LPKI$[Q%9RL<RLV&N9$U*:*ZEC?$$\
MW@OTW6#;<NFR5Z_FJH%6 KP=-'/)"",MAQ"V3VMQG%4R7XY3Q DJ)%Z'\:QD
MU]3>Q#CT+,NE\XV=/359EOT)*Z:E,6$;3_X9Q1&:BN+)XEWD]8/Y 9$V,'RT
MDXW;8KJ2:YK72?#Q=Y((KNBT95SJ%. [?2MK$<>E4%]M@]L$%J323B?!NAA4
M0+# 6/CE-DT4\O-( 7QA@?ARV9#%*X@XJH)W>.D$>>#>9'B:4W!*$O0CI*(N
M%73XZ06A,6@7;(IJ@415=FRA0JCE*?_HS#?&33B*I_Z!9W_O-8+RI!J+QY/*
M 5(0!QT(2GKG*)0E4^8#]P3V0ILIA)M1'Z('S46%U(&8%LW\%0X0"]$5$QQ&
MU6J,]4A<=*FXTUX;*J^'F+D<@Z@]-F%8JT$"5RLNNJ/,1\4*UH1("O=[%4%0
M@@C$=5AL_W(W6.$4KZX65P0M!*F!&J4*G B..^0J&4H1",HCN":1^( G?-"2
MEDH*>!T$@]7BPXQ9+RRI,FT$J7R$! !'L0<]!*RHAC95;H#>4E/:'<-4J=>.
MF0&T&3U3 /8D;[?(Q-;;G:*VX.7.[2G$_<%3F?)$LBA;WNRUZSJFE^_OX%A?
MY'?7\-G="%7:3UF"<R)"^]!F;X[7;HC7?#8!X>O!@<H2?(9C+?H@LL*8'ZES
MI?#'+9U=O?=:<)=6U0XQSDOEI^!Z)%,ORM)"@(6])C[(H28X<V[@\,?X,7DR
M5V(/E0?OT"UK*V\"CD9*1Y>]QJ/NR6_"Q@K/2<,>BCX:AK<L*%N%-MKLU* ^
M2=G(PG&0:1)I:"A_+FE27K9>BXQ]B5_!*6LHR8KV?03#R=DC?F 2VO6-8T*6
M<] /W_0,6N*+JSMZ^B!1IS:)W&1/;\&7Z:C_YW>+A2,]-OY-F.7 .L0YV\L*
MZ3(8 A86+(L5P##C>D*;!O80I5S5&5D7HKE#AY_UXAD%:M,%;V>T/TU+?!O+
M8,PR;B QS<9QGLY<1Y::R#[ -5CE>(?C(I/6BQ>$0HVU98:-_8,\)J:>&^>/
MG2Y[.KGNZ<U7PH0:V#0 CT,E4OA]4@K'C2:AP=)=E2V*<(Q=7@)L3*/CYE,_
M0;-8B>CQC5!MKF/\@Q^P>*E=J:X1N=[[#IS23)J)5XX=5F<T6OT'4@RF\"O9
MR/#9+ERV"A]>J8%8"W@Y2G\%!)THO*O(+3UYG?%B_5-TWB%B]K=!/D"=RN"$
M/JA"5$[C61="Y0H'0.TIU!] 8NDN3*V?]@VVQ7@G=9V_<2OYZGY?=<\L4K).
M=R2%WA0446B'(0M,94]QDG7>,=DHT-] 9)'!M=FT_#=(V$)Y)VV P6):.^')
M2*.,MY,6+#A9<!E>!>2 QV&/T*KH*%"9VSOG=0 >ZI2SJ%/51B<*13#%BDHK
M2/]"H'Z-([2?,ZQD'%;RX/,95C+#2MZ_KP 7HV;ED)*K"LXS]?E&W8_4[XO]
MR#X9$CX-]FE78>0.%GB%J;NRD0PEY5-WOC<!PP+^"'P3W"#*O]. F=14E*OK
M"A[C*3+$A"T%/P$_HFQ+')_ Z-1#Y5( W7PP5/9Q\[(A.@VN%L/]5!&<$?\B
M(\EX<%+!JT<2M2OLL'S1-4V>T8-_?DVW2LH5+J03:_SGO9?U-%^MX(Y_A/Z0
M]W*]1^-=_,@EXUN1WRXGJ4\&"ZHOK'GCOG]"K$XHZ4F7FR]6DW?3:._!'C\4
M+:#E4POI,'%3N"O;(A."SR\%,BQ^#]Q*N1 9/EI7F#W"]6C#.Q,PE:]Y@X@@
MWT#2LO"G=;?W]/R2T7+)/;/YJC'W#'82O >'H8@4I;@+5OI^2KE/W"U%OO8-
M<>!$M,@EM_/5)'9SK[TIQQ:L"A4E__YF<PP*_1.M("^YXSXSX6U35%?H(R45
M^MD^&#U]>4JY.!J&MB#=_ AU0.TKWA%'X(\#':R1)XQ9#H@ED@\D7%9PIFKT
MO<'-7\!_O&9KA"#Q38Z*K["-.?^K91FK_+M%]'*3*OS%.O2Q_R>'8<SM?=NL
MIA<C2@7F3:<M(K\>=N8813B5R+!&Q&^Z"2HCV8NCA75M26],9\#B8)YU\*H=
M-GF/(.W?9!ID1)]V>K#W_)';_M_^ZZ6QY#=L6 &[\<+KGMIW"[C?P!O,"J(]
MMO=%E,491S\IQV,YE7FZ)N<^DDYX#C]W8!_M%KWI&-*0%*N7-:T9;8P7&L1?
MF5A]/]H^WV\O;;;WHQL^<V!N!]5K%*XAV7*Y)&\X8=<DX'SA7%*3^DTGWH[1
M?9G:)("Y>B7DK\H3=H[\$=1CR\O3E=*FS:\@A:4@?*9,+E)IJF)YR9L..(7\
M5UMP+AE,1)7]8-)6'.!"T,O[J<8N5:Q0X>\ISQ/<V?W[VC1<?[=;!I8>EFN!
M;HYPI=)]@7KNX'@XV6'@TYV7)0H0O7#H&(V4E+4[^^0C5I'_N75\U+DH>T64
M(PR0T'+7V\^<H!0"M6L8KCG3Y*D+03'E17K5?6MG.->AN =*A7>JW2XW,;>S
MP@DS&U''F7H&4D83D,K\:I>71+BLJ2 /1H:_#JQ:]F'<@^ZP9+S?HH>VA'?A
MTV8/E0I%F#LPG$6%>,@L*P.K3);PJ<J<,PD!OP,MXR451:;2?.D0>Z0-OM:L
M"P1BM (3Y1@Q=I*>Y%!2X<;\,D:9W^PYWO4 ^AI9@"8K7!/O[$9ZVGP9CC*C
M9!>0J:N*O*<H=J4>KT_8G[EMN?,]3[K$;&Q"0P6-@D7-[!?5,N-+NVT@ M##
M&E4'3^&NHWOJNH=A=$^L5 S@B$JT_53+WXYR%\RR=W^XY-91#-FX*9J$@QNA
MU:KUFNJ"\#>:;PHU;VIF'JM,&W>8L$OQ!5>[?8:-'RWA<-9YV^A!CXOT5>UY
ME,@!X6&<Z!$.1#/'(LDW[_V[MO=?#9/9G,:>M]11K,^?8DM1"5[-:9FRE>4Z
M/OPZI1 98=P:PTC&+GO#\,P:HHBV98HGTX7"]?\&$V[&.E(_3[[*L08"S_D5
M'*8VP3H"(G/G37T4.^0.;NJ?(]4Z%EOB*H[NNR*[:M+(12#(CMLH+Q.UYS:V
M_IB]2>FDU.UGZ$S7+=/YGBRK6G)8'-*_$?"=!+CTJ'DK'\6^N(-;&>US/^%I
M,*1B/RWU.FQ91(I=:C/.PI5NG;<192"G$_.: LR0T8M ]8$-DT#U\Q8^BOUP
M![?P$X\"Y"2BEVA3L%_HHEP2V>9*O81>*1E+AP2Q$X;H0-6I%1+-L)K.%IOZ
M->V:)D?:CP&SEDH$5-]':-V.]5'Y3R@A2=24ZYQ%US-NEI%,:+Z$^<%99#75
MIHV\((@]J[)TUZ@ZSX=I/DS7#?F1UF0($ZSX)X(7R0Y&/*MX.<1D6<\IAWF_
MO?.0'UJL<Q\;31S*&@>2*11R ]I]P7J+7OF\!?_X];R#6_"54BU*"R]V:.'N
MBXH8PX8I&^JIUHMXLZ(CP6W[ZQZ2,U3[0_#'<9_$=_2?-KICX%XO%L1?S++G
MO[?NANC2R[PJ0GH_7BP__3:4#W00>!E:\AX&[U(]N2;E"&I,4@9F!_\6C,MN
M3\)'XM@A=9D .F7Y,2G&>P(^"-_I-MR:OLAJ^9OL#2G8-K"3!+>$-74$G*P#
M"H7V:9UUV"W4YAN!%]1NW[4>6(RB>L&%C,"WUR_5X(C^/2P5K52T4+).LDR?
M1Y9M[HZXOCOB;.Z.F+LCWI?RSA49&Y>\=H<0,-K+"'\1XDY2G*^R&H7XD"R0
M:1,PB1/Z_B2BM2&L(4.Q#U$Z.>&SZ"+%!$-3/\YHP2AA$0%5V0U19O(R4(.N
MQ'U7-YWARQ"FAC2P/A@@424L-8;"0KJ5E1>$$@=7I26^^H3!+;<!ZR*X!7FN
ML0W18*DC 3/8-IC/\"#94D&:R[K+*;L><S^17$J;DT1?@HWB"'$EG:"^,U91
MHX%V9HP RJ8T"K3-MS]D3%Z2TJ&.?80U:W2DBX-A&@\'S)P/)"V@/E4BOI+O
M4&7Q"'<N^9\U,A98>7M/M)(RGBA-O"1-&F63LB5%[QI=,9[1C263N,$4?F]2
M6$M^<W,L" \:WE5:H]2M 2^F1#V-0JV(%]$S0V(S@\"F"3C_^)C]F\;SPM&C
M0J)W^RSG(<$5=M5N P_9 /S\0W6%H,LTDN58,Q97TG)^;L;94M,)U9&80)4T
MJ+ S"EU.L$.*_J5YD]1E(&B%+0R[<-416^FV(KXS!&*1"LKK7.G<C8R0;$^?
M[91#<# *4?TW#']MWY&:X6 DKD9$K&>*Q?7(&-2)^:&\[?K,5,'D!A4D-,^C
M/&<CE\AX'G1R=\3+'\8_PKMUFCP6[MR;GAR^YDK ]=M\,1Q]$"WB%GB\<7IW
MB&D7&;:R+Y'V)^*_.T)#?H0!W'._/,K&@!MLO,L(CG;NH=&4?,=_H&DUBXP6
MWI5$>24-^P*1A^/G:M^=;O+\**=1\A'"@R+L3R?,]T+&2ER4'H ??!52C5JA
M?4 ()?,5FCU-F[-IL%>T\PT,8QR[]')"2F'^W.ONX1\S#)T9?3D\I",D7A/U
M]F-* P4:\(9CY#U,9T>=7)R-(!H"KNS9IBC"F<+?Z:\C\7<VK[Z!@LGS_!F6
MS1_&K'(1ZS6<+4.3X+^"[9F@/NH@I-:@WI[O&9"O%$8NW_R#&/9#S$'&7T\?
M<"JPZ_%\OG&V4DTT43KB2:@6A435C5"#'=7AN-5Y_4A^:0"7CXA*A19=E%1L
M<B9;XW8<W)0-]BP30ID;0,@AIW4.=+FN9KX,:CL@"D\F96?!&&GC*EI9N3&J
MZS30[.UK)E/A#X]J[O$E)M\66.H"D4I5VRR1U974;I9>LN4V8<1[3[I\N$TQ
M>JW<L)$16Q,V0+3BM#^\,S.RB7B-91LU//UAW;IV6PGA:"OZ,WA%F#6GW3$6
M?X;.NK">F:@<&C)7N.M=$7BMY%OAY7(F81_C9J?^4)<\?G@>S-3$J,FQ\)M+
MQPDV4IR099'E.Z4G0UM5$2=CD%P35W7HFJICJ"U)I#X %Q+*'+"*V$X"+=8.
M%Y$$.G\LFT"JS6M\(/?\<;.]63SZ9CE4+(R5UWT";=(BIWY_3ZY&;>+"_'J;
M9O9;T!Z.=Y)+''@K%L2/= 0_%@,]L1.+T-1@5WW:R8U;LGOW='4-L>:D,J3W
M<[88 ^)THRIP)-0@BKTMRHEYBGE,O=F/4%-;CM^V"HX)RI<)K+:J]Y5O\O7M
M^2,LKWADT4O\M6.H;-[(>0Y,MQUX5'FKTISP+[A?L8_0ZA![#?E(D=8D(8@9
M \)U[ZZ2U0HDN0MBD&W1,.("8< YTJ:OM0K5+*& 6&C%0ESE&6W?;F4PX8G>
M^ KGL?8=OT$_@Y.HTC$89$*0W<"M'?<?@E5"A%RV0<*.=M)<>XY8IC2VM23]
MJ(#O%B:@;X7(;)S;=_QZ%,F1S.J:T'!AQJ[D<N.DCG55XC97D[0R]&,OP)VI
M5X5K_%3ML&651DT&'UN$JZY%0>QT, -Q->VH>L.PH_CS+^86L1DPT,.LN!AP
MZ+N6ASI#PW,X0Z6.8@WOX+9[PI>SE#1"$7_>44>Q/'=P1UTHV:GX+4QVRKP/
M 3 R[Z^C6*P[N+\>8LJ\$;<T.(^BSM(0?0FGL6U2?=YO1[%X=W"_O0B9,Q8@
MTN2\ETU#0$%6H  F!LNK.KO*6*V<DG?#4!5S7U7H[O"<-_,>/8H%OX-[]$=!
M1$B9<(:NSYOI=W;7EY%87$@(N7Y,BMF_R;ATQI+_[DSP-H=#2?D\P8(,LWXH
MX5@S:"GG"C/I2U'RD/CYE:Z,DGB^VF-S@>HOF42:LCY2"7Q)='7N#?:8<Z:W
M0B9?%LKZ?3I2;ZE0 2/9)NNBNF+,J*_,P3X=RDF<)H^Y')2&2>(I(1%'QI:5
MC;9=2OH\$N\0+3+]M:K]Q7W&E%.OA")N(@?L>HJ'8P@BSL6+'N 3>P9E&$8;
M;.2%2*#:?BF"30BMB@*Q"$;2S/&-)3]9?RU94^*?,4HWR[^%ZN#B0"*'FLF:
MGIKC)%2>>P<F>@<>S+T#<^_ >ZD7/]:N7R[)@R]1@ WII()^C3)7D'^?:\DW
MR57T6@?C^S</-,HJ^, 5Q*R.JX,0Y3I2(55:I(HHDA@/:3!KN5]-JC(*-SI<
M3$3)O\)+H,;*(0'L&1.2$TH<XN4:;C'10]"13C*CP_6]0GU+>-ZC#K%:3/%_
M\>*9  #EK2P0$-\'E=;\.\@?-X1?5F)H__I,0,GXDT#AY_>JI\UAX38JE:.,
MA/!J1L#*%N[J)A-R6UBUBA57R<4"PW?R\\LP-8_M&;CF@;=D7C:Z>=$!$D%1
M]H&,$QA<+T^Q-2V7D)$3A<*T_"[1(G^2A_(:E*)QZ A. 3\JG16#H]8&HC=?
M5_555J^:Y)Y:.*&]YF_[Z=F/3?2+,_G%?:,S)NO?9F\8"E(N%<X:JX?K23$L
M:K-=O85=%?7-E "F=?)29#&_^.:!@A:><.,OLIG3:4LNJA4)]UD0#>'8Z"LV
M%1U#93BOKI!0=YOOQ?HH&WDL71ISWR4(DK#[#/5H?G/T8]PTZ4W[0\2C1\;^
MDDFR<3!%X<@:4L,"?.;0Y$T06O,-2?A S\TT,>18'0FL$N%S^J\^E.36%Z-G
M>*B/]KA Y'';Y< @D>$[AJ55M=_#0%*.A"/6;T-Q'-&##X"=Y>"%WG+/^$@6
M$:+7SP4U&BJ(B=9$X$#:8!7?#D-S$)N!3_#X7X]M)(U/FLM&576Y,+#S6E)!
M!QY.2LZ\DA[^WQ>-\C6JU.R8GKY3K A"&A34;:$$ _VN-TU5""T@WM+2+)D:
MY#&[-Y(],:!XDQF:[X%;8#5QMF'B7I/DUIN]^E'!]Q,)>^YB\1N'T)-AZR22
M9AK;/.1:FB:Y&&@9>)^MEH%B"DFG5%)5^8HZV5#]3%"79CS18*IZ9"!(W;OA
MC-](3W2$6@2GLVJ)@%I;>\)[8YX*NS>7#',M.?FE73LJ]&F38[=I@_FDMZ
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M@C/1H15R9)<$0L (^2NE14.Q+ID;D_ABH QR8P:B&5$LW.8;$A2(>FJ%5)B
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M?;MXV3@X'83Q%M@?[J3$03A[PX^)$ .$[B:!#O*0$.,B@]70 W^_KH)TUU$
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M4^2/&D>E$,J@Z.:8'29 3A;<QW$\7'3A:N3D=-:KO982)73.95)FK=M_[/F
M^D8F[67P[LI6;'EB6G*1">@68B40.4@S25!*8878-N@B934G]D@KVSSUT##?
MI*PUF"%2V"@GQ8660[1%RL$LKZC"NC_G^6%6Z#+0\PJ@[:/1J)H9(L1U9]%+
M[RQZ)24P#\CT=QD3+0U:YWD=1O0&51W!C4K'52''HU4V9- X>HP*$W DWL)-
M.@=S0FR),)<@=@C13L*]"T]!4D[-=H;$(=0<;)AAPJD16"AQR<)795$8SDA=
M.&1 RV41B*'5C#; [Q514ZK>;D]E*-&?JL'%#=OTQ0SM:-+!J>U*?X&,HG )
M9S'$-?' *HP"F"1_,(Q:6XOK&+G3$#4%9^4^JY')HSGC?.2_9@G6BE.?>K1-
MB;VL6_]'=-!X4XLC\"(I>&!.3$/XSD5<!0XJD3UDJ\68JI4,X&&2TZ%9GQF8
M"B;[*%8L4[/&]M@N>,!*)-1X0@\K02B$$M%864,RWAD?-LZJB<9"9O">=D[=
M^U@[?'&:"5F0XCZ@O*M!@'%2S3=!/R23J;0VTHE8:MC:&5*8ORV\NUC5A%'$
MR*4LD#&9OAVR@C\LC,<NO72H'DWDP[;R>UA _LUJ9E@-K]S8#_M%;KP@:?:;
M]OE1GW6K_[WW@VQUBYV4*<$97.]1E_$PL/O*N<&1I;8MI53Y*7$JZ])QDE7.
MNB?MQ/>)$H)$(RC"0JHDGJ5UM8RF<-#K%SD,>>-D=%;2UJ?;;&"$F()D96IR
M?F9X'7UAG=4Z.B\1X95S?8S$ZG#'JK+'=XW%EJ\_;XRQMD\+::+*QI[<J'.D
M(Y&SA ?%5Z!W0R/C5K&+3[%'G?F"L?K::+@;F3#AE)V6TIR+[I;D(\*FX>TO
M!+IE)&Q1E'Y+435/J56I5T2\.%"-;Z&+EM>EX'+.D.@;_1B3;B1(CGL*#AK3
M\:@)[)/BSHBMAPN5W*T5Q4G@7'OVRR7./9,A):#=+^277@-;>QW/%T^AMX#8
M;%8GIHVG;@,C\-3R?DJLHG3A(O%:B$=F2XC1I]X-'':.$*_X'^)#I\H;FB ,
M2]H9;0_G+(-WJLA)L3?%\"^/:WMK\#S6*5P<H(0R.6>R"/"SU2<+E&I*:D3K
M9WLI5S.D3S'=3FFO&3W-^/$LJ*EGKD2;N0H5C[=C;2\$6S2\6'W=N#)_S?AY
M^%I%N797)A<2+L2L0\;%8045#J1TMW.[\1P.TT56/(VT&1UA<).EB^!K# GR
M<:+8E9NL:Q3M6.H_!<1*G9LEHS'R.^6JZ^W!2ND>G27E@MZA<"QS)03,>+%U
MT&NODX;W2C( /:\R;'>8MHZM-L-W*2E.Q;WCJJ#.8[;,CM2GP@6=T1Y[-1&8
M9R"%IR^.KLZRR<EJ)P[KL0=[PJ(EA$6'/6%13UBT9IZ.1VU$?<N+$:K%C\D7
MC)]]O\Y.$!K67-F83D6:H 8GR#:'-I)?\ZE^YK;.;+'RV94V[^]NV=88_MQ+
M=?-FI(6!H.:U)M -P1X0/SX5\.HS+F2QF>PQ[F],=_" I\F<0#5$-X#X>?I+
M8V+""\Y1:9O@L*DQ?"">? 1U&8ES8;#S$C*<^Y0_K5PYG&6-J3IBBGZ11U*T
MBQ@[(TPX5!A'9< 4(>)O?W3+&)<H'D85?DK=:HJ$H?1X+[*$?'0] 7$HKIE\
MH1F2*1=+C3L+V"H;H=#IG E\= NWCZ]]SE3#U(FKR=%$(=M0JH:*<,Z7O!4Y
M/EY-CGV34 (RA69T-3,+ZX9"2!B7E<(TD=&24B+W*&)@%[EHR#E#,IW5&K$2
MP@.B0R9GO.,]+(45&(B!S\5NHPVLVF92X,EF3%F ]2/F5$JLR&,=(=:%D%P3
MY%W-L\\&5PYFA8*Y9.-1X_BR4$S)LG%1EE@R_95)R#9_*.J+]5!Z;PJ+\R>O
M/Q1^U1)MM_#*J#!''*J0[]XZ]8%"59X*D8$_9E56DT\BPFI3IBS#1IJW*'V$
MK2T,BG6EN'"!I\D%PSF$+]I/]"HSNE$0&>2CKBUJL7.?*WZ#C'B4J:)S+H)*
M2*_>S6-N(V]%\).6BKW=$,CU91!M0O&%#JD.@1 3#(9K,(LVPZJ[S.\#B'6T
MV&5%] BQR))RD=C6%\+(L'/HU43F95V[X (61!$"0\X;X67E4Q8\M+KA4F/R
M.$-)W(Q.O*!%AYL;%'-FH5!3=@F5%75!:I_H\4J:ERFBYYVZT'JSR2D(&[X%
M/+# 1,KBC;\O[>*;5,NJ;3F@6FK)+$@ FDI@)/D H18ZEOJ&..XT[O_DZ926
MF:%-PRXU,S;M<[%A%K6 K.6GE3D3@GJ.#1.[>WGA;JP=0NUS8[H)(:LI9:/0
M%3MHV7L4'G>L!5Y3%E!?='RQ)<$D":C2\%7Q3VL0<?27#1*Q"&O/[%"D6$(_
MT:>R6D""1MAY&WR$;N 1NH&G(?^ZADNXL0J%-,R79*)4RT@#DWPAD-0,FUQ)
MH[*77=K1>^K":SD$+'U.:^7>S/5.I?PL5VH%D,W4V7A4FYD4MA4-1>"GV!N&
M=RL3'=H2,9AB[5=7^(0$,H&;VDWSR#/N_3:P]A=$PV.+F7&D3D>B^I,^;]*1
M,@JNYE>U-CGM$*(6E\XX_LCP6AV="VC1A(BHU1V"[BI-1:V&Z%LYNOR%U#X(
M@;0P*<\B:%:'@7:I#V1WVM9MY^]7\U'T(V->)LD]V_P0X2/ Y/:AW*EVDPKW
M3J(+7!9BERQZA6$BPC9]0M$BV]@14A+C[M@@'#./60WRH5=2'3#=TF[X6G:\
MO]VM<<A'^=#@(8YYB'T)29X8$_T.\A<=2"\VQ8QXMJ/K?'UR%Q2PZRHH7GO6
M\7CCA: M3@AM<>1ADK^[F NRUI8DFLP<00C[\4:(1PGP]8\[W@?#SG4"Y-K$
MYM@J!56!%]![7Y5%B58&ATZ^.X&R2F<0K:IOQ"/P>EH/L2NK."H! [D_M[]D
MOW[SS:0_N C2.QM!^C9ERKWT_V H]!61C[P$&9@,P6_>&<3488J/5H]FP%W,
M(VW_8N<;GJVE;;@_>"&.XY+=>OGLN\TL6+[NB%K&@2DV07JU?X>1*X_/QDXA
MO\%(YG$I%%!^(20]@6UFE@@SW@)E] H*\0<^5'E^.-7YYR=;3R+,&4XQF5^<
MVK_K:3*R?W-V$9SZC_C3[N3SY0G<:\A;D'_;FGZ19.\OS;!,YYS1_*6IEJ;A
MHNIT^'1[;P^60/[KV<_1N:FH_$!/_&'9-.5$\Z._-.E=;Q(WZ4WZX$^!B< L
MXY^?/+\ZY7YW"L''';!P;? TPV73+Q'9"+0X6W&$_WF&Q*'WN"'D-2\[<JRB
MO-]EBF1S^?/1L7;PK^K7_]4+^#4$?+L7<!9P/&[62YI[<7A<<=A9+W&XEG+;
MV@6]MG/P:,I-(5C[:-C(^\%*>Z9OL)0!O.FN["!DI+O<$KUD<=4R^],=2OV2
M>;ALWS_@,'ZX? 3;?PI#/H2(O/]1#>+G6WOQ]O;6H\_/FBS3F@QC/:5E.][;
MW8L/GN\]^OQ\U:;IXVGLWX3DJE?07\N6&\0'AUOQX/GAH\_/FBS3F@QC/:5E
M9V\[/MP=//KL?-7&]5(OZ Z#TL<K!G,?5D,__.Y:\%0??6=UC&@0#PYWX^<8
MP'C$>7G@I>EE88DL'.Z#";S[@.?Q"K+@]"O\2],0\$_,AO3E@*T;/&8YX.Y6
M7P[X790#WG?*]/6U\KOQI2EFQ'6>FH***U*JWN(W'!S2#0;/6SU58J^E:#YG
MQ&%J1MA.B.#)5QDUP@6QF@5$HTNY5? 9B+3A(O7S+&4*)N6Z5(:>PM9\+'0K
M93YK!EA>E-5GCUQ)."]PKOA]\M!31HB0@!AETGG.NS$?N_PQCKR#RP?O\*;X
M]WPB507OJS)'[)=K5&D[>3!XW,_E+UGJG2N?^+>DJ&M3+#[DNH"ZZU'/K0\F
M966^YZLIYK[?$MFE(7_IPU=9_@)B6'6-_*BSDO835%JM.LFQILKKPU('*L$R
MPL519W_!3E8MKQLRW+>>45DG=R)\T-ZH:[Y@EN-L!>TB^DQU/&'??MB.MW9W
M8[ 9N.9 ('$_[,3;A_OT\2IJRV/NL2>(I_"U*"8WN++2Z&+LD9ZU2X3:1]Q[
MHAT<M/I;H9"]_)^C-QM@LT3'[_[[S<L-..NDWY5K;O450(T?0&_^A2P#)F4\
M2K&BKFXJKNZ['NGF-[:S_'E)PGFYP=X"E4C2O^HIA1+/O_SA>3S8V<,=IP?3
MBK=06*&W><&S'>S?^%8=;ROW603%KGAC3S_H#&F#7BJBX8]JG4/^7\M9%1 E
M8J5I@00]Q(.02UF+72I0"3]L'Y)"BZ]D)>++!UN'?#GV-31$#(P%A<+G&%QZ
ML,U7.N*@UMCI(GFZU[)P/$:*B>'<:D<\4_D77@TL$H 5H>258Y&.P;;<-3>G
M0F]L1_6<Q$:FIIY55'(17D$__J:I)5N SD#W@9<%;G01'5,=U6@.&H_)%[Y+
MC:>S,=+9L%UTJ,YQ=66')_P/X)4N&@\'^-E2;;)H/H2^I],,CMD$ACG.D:W.
M<J3A=Z]F5<F>$CX]JUTU))7%I>CO5NM5A]:.*5W+#6LQ@/O\U!)M^8V6$)E;
M_$*/5:3\+@?V&-3DUR C=Y/D^%16EM;=.'(6]*H'()_*AUL#MS&"'7,0;^]L
ML;DM2OKZVP;V0=[Q8F2(PS8X1785,<B3PIW#6>'URM X"9V+=.#0F/".-KZ!
MY\P/F,ZV7TD8)+8VD-!-U+,1<7M@XQ#]SD6TB M@6)Z;#2RKG]6UQF%6"D)Y
M]->6+MQ&29RS$:V-G_'0^^OV$9\.]1+^SSLR@9C[*H8G-;VF:6F:UROI$T<?
M:8U*FM'"--1L^H?#[25Z8Q#O[NQ>\[!=XJM?KB)LH7M@5^YNTTF_N*T*2O=C
M_0\6<5(TT^[[)$)Z%6&.XL%HZ[VN/8E<(T0-(@. GQ[ET[,$54X<_?;;L;.\
M06,->$#\O)V'.OIOVE?E4:(!P2,7VE4OYR@\G$K+/2&[6YDZ]_$("3N6H'.I
MI/2K']37.JA[VE#1_N9VQ[9:91+N_IF/J#0>T9&_=-6O0=[M6D:F7>P^3X5%
MZ/=WOPEET#-F_!'"G]JC6^.&*TMB8BY;N^KH8N55<X1"U('O"U'=P8G\P^XA
MN X[[I@G"QPAW'M;'!0*$[E'K5\_CP^?WSRR*,<R3$QK0HAT$5LKPJ<9\Y5R
M9P=8N3'8S_1TZ@$D%[H9!#M!8F('6W\2!J6 )>XCT5Y.$B9^\YB6A$6JBYLI
M'!C8*5E%G=O E"-"HU2Z$,/+GI[!"NT<K!806X<$P3V9L$&T;/'\5Q< +/L(
M?>;;G][W.=8UF,?+E!5.XLH!-K+(?UAUHX(FX!AV$(9+:*?0(RD&'.\?[EWJ
M*MQAE-]WX8-1'!X\=V/ EYQ6L.>S*7<"N"0Z85JQB;V=_5 A)JN!5\+0?[R]
MM[,\6M\:R.D*J2*\Z\[@X+*A^3Z>C&)G=V?U /V=0SEZE-\2E-^@1_GU*+_K
M$P^MJB]_R_XURU)J*80$.]*5YX.IRUDU\ESF!VDZ>4>'Z#V%3=XL$O&_/CIY
MX3.FG30PBV3_'9<I,0Q3_%<-^Z.38VO8;V_M;2!Y_WLFW+0II4Y6,0I$#7Z.
M_E+B4XY+9'YUM^56 'Q#O7_L$QLOH\N].#/2>09;BR/B:E06J5)$(J?T.4,'
ME?/9\<$GIZ<5DCP;Z9638 >Q>C;$1HW$$9J6LV$C]&=7<% C""LC,">R4I[2
M.X[D'8E %,YN@XS.@VWN>%EKEQY#_75H/;1OVQ**\92!9!3!RR9+2'N)#-PX
M6N:T-,QU*6RY/%;7=YSY22TMZ@1F[I0] J7B]]LH.2+5/"G\;@9,&F_@96=X
M]F>8-\ ?,,6_MJ]&@<ND9V>9MUY5_$';P([:+77U/T@J(SV)I*W\XIH1 ;=K
M3F$[1U"+]$"N5)!J7Y*ZIX%8O^F]Z]D8-D;&7*)@[)CSC&YQ]\(C#56OLRHQ
M<C&#U%<Q;IJRX$:B5O;'6#)V%CT=/).N >#D#MF;5.)E?DEU-_F)Y!,'ZRJ+
M:7LX)^-&9B^U>VJ%-604R-/M*X832X]I-X"81RAS(]W##:P%]7%S2@#9E4D'
MK+K-6STX5MSE=S0=#X&R>WQ'[[JMR3W6;P+1*I,^=PE$_:-L_>@EC9+Z+!KG
MY468Q,4(B$MA(AZWL2MJT5%*[S_)1B"(N$P@D(U!AO*J3&<,(P>);! J7P<@
M>KE 8.I\?QAX@CTE27=D4Y-GA0S;%*>)=!H<SRK2/"NTM15R3A"M@H=&3\2'
M7:!1F<@%).P^1%@+%K3/J#B#1KJ,:H:YI9%3,Z6.F"63K'L[04;'3S*CLP(U
MJS8&L,.2/-84-HI4-YQB*X024<X87#L7+Q!W([74<74.4H$A34LTVM306(<N
MT;[DM%PZI-CV6/ ;2)!*T':.\ 'O45(IM?%7 B%C8YCAAV-EOMN4V"-NYW=%
M]):$^\!/U]J%(U0#-QK$5J#6-+-Q#2]Z^</SS2WL&YB+O8G+>;"Y]:?HQ!09
M2,N)&1$'OI\_?0^* .Z/HL>I5 R2^ /:CY[B@%9R.G"RR6P5WV(A46M-9*+P
MAW<XIW?)$R;+]2(\V@R^\C;?8M:7"@1 ;B<3DZ*I$?%Z@E6#$286<?FHJ69U
M$R TX"T_1Z]@Z<9)->2&DVBQ8U<31J$<GV5F'+WZ M-&.O0=6C>FDBPS/T,[
MQ;PHB;9_'+W4OL6QUQ@%W^@U B>S>E1&'W$H,;6U0GL,+S@K\Y1O1LV*J$O1
MWI^6;6,XD?&43OF<G4RPG(';"S]%E:9F"8O2C5;NO9U^73)O;0KJ.ER.C$D]
M<SU,LK?6*I9S/S5T5I"&&ANJIM+8%O8"JB1ACQ!C1J2&3/6HX5'Q4I=X8\/U
MBX.Q=U\J/'@>8'D7S:&H.%Q8C<*!-XC-?!IC.R:O5!CR,(50CVY^M&<ST96K
M2=6@#F==XQI)T$9^.4]2<&CM80,[*B<?00X@B\(00)=VI?O7# YL4U%5$-LQ
MI>VQ'>I!."_YL#KX$U8&4??DB4I1>]AL*2?<\J*X,[WW%N^(A^A+>#7GML^*
M'(T)L&7R#$8VXN&@Q5X9U7?8^18MGA3+[CH[!!*:QZ"1M4RVE[WM"-YD:!3F
M(P]7X!S,&.'9O66R^N880W314:!KKC$]/R^>"W2?$[R/FQYQ!*3-M[P<*\9+
M#@$:QA/\MUQJSYBDH48!338A,4%SB>VN8'EN7>YUS_MMS8<G3=9:![DMILW"
M[HE89P=6HG2^2JH-ZN]N;=NJO&C8R@>A!Y>5U"\WD<9_GH+F**DSB72>1GG$
M#O?8D4]L8KK_K'!.P12$>@+#FA$]#+<P*XN-]L>N0?;M"P"_;XD @_8=&$!H
M&^UVF+01)4TX7D>YN 0$)B6AX:U\I'_;C;P,]K<9O6]U<[*_C;FS*6%U\5?4
M9 C$%)0H=:G2]IQ+#X6A_I*_:>G'[DBDIQQ![G\8;&*3,)@&^IW*J[/5;!M5
MO-L'T/C<"9VT4O0TH:9]U%=+XK+VY9[Q$,?8I0_[4,"DKJJ'9>S;SV%EN&Y_
M9WN# J]X4&8X4R %[B7+*CO-1&NC9TVN2"L@NV#J\>3B.[]-YG*<P@./9J?8
M34S^IH?_7IZS%2T?WL)[_+XWW9(#'YZ 6-@1_!2&4F'$ U1M8CD#< ')*V1]
MJ59_=*1E_U(#A^T(EF%OD[PN]4FUI55 RXX:I;3;1MH1@.RK?Q2398-QQCR;
M9)PP(=114VF'3]3MV)#312<XX(7S,(33!2OY8MQM\'NXB\'(*/7V)!((CM94
M=G3X&^QX;!L'8R08.RTT)G@#LDW!=4R*.N&!/ L=$DNE,)EB]8+::&C;NA>E
MCP1#=<D\LN75AFHLVQ)WT:/@;LOI[EG$5VY;WCV/<?3#X8"+2I;:DNB .K.<
ME?[>WO/X^?:.I_Q]ZU5L!<3AD^/N]P?"2$V5ND:M"WK2Q0?XH%)YL3$*S-TU
M)2Z7="O:NW:+M%M69'[?6A73PBGG2V+40/:X&CQ7H1*'=L&HL0K4^FPO\,S^
MSV0R_3EZB_'N-(G^0MFQURC&DDW&"\57:G]IS2%?)2=@-"=4V]N">/ZP$V\=
M;L>#G>>"$T+LHO#VT*4+S[:MWC%@CO'X(-1.D:FB'.54O8P9HF&9XIG18%V'
MMOJ=9A6'L>MY,9I3%ND\JV8<B)L@CT>61&!R@[V^K('Q\<"F$? %I7MX=)J7
M0X)/)121IVW45";A%N3L,[+!3\E-+*_&U$,YG6D-]V5S&_T%9]&&NOH0ST*&
M"4\T&ZVD  S1,^$_$'YPGN2<L-,/*7?@B5N'^NN40EJ(6&KP^7C6\[JVAHI4
MR-OTE4ML"?@0GQJ,F +!W-IT@=KH:?U,\()B^+LT-G4(Q]Z"Q#FC-8_8"5/9
M _QB_=P";@22X?K&69P#ARR_P#\N3 [FT-/!]K,%Y(/:UQ8!(2=69XY43"_U
M$\#S."J*&2%]T!?>C/ZJ:6_?"\/FP<Q<0#^Q/=?1GX"G3J9>T^$)6/&X#XUT
MX;VH2K39-(CGU@$STG2U%'Q3.I@[@$MF?@Y>"T7'O::CL^)S45X4W,V4>IQ3
MMOF<-C:8>/+6</^"@KR*FE"H-[8G9D E7AT(:=PMH9YT40?Z"VK8"Z?L9Y?V
M4L6/H6#-@$FVS44CW(*$@0>:MA'=59(4*#&-'3J9N102B54LIY2^0UM4HRE2
MF::A;,+J> 1K/@%8$-.C/5:000-W8]&D#81-QZN9HPS[T7X],6#A;H+@S"U%
MFFQ@7$V8X%EM',.8YF7;Q!D=X9BQ9AA=':M'5\8/;T?A;;P=+6T" ,#;1*>S
M!%6#$<@ MP"53*07'O+%)5P3B]N@? X#<.  @;'BO^'\2\YA9DFF,+H:(R0$
M'Y3G/. :\;0C;>V<9CDGA1!TI2)'-J*$(=?]#+FG;.O*5GJSM,)E]<*6Y><0
M6?(_/(_WMCP8]S7K4X)*6+C58._&MTJ6ONWJZ'?R.ZD2!44-X5E\1EA=AJ8@
MTJ5YQZ3S,!8[2M]^ ;B*8#O>/QC<#;'0_M[!HT[Q4G=I1?&_LQX,/6WNC0#U
MVSV@O@?4WT')W*H*XW<%U<T8@-R-J%N]%&IUS<L>/I*,WU3QLEFN+EJKF,M6
M?-WHUDF*<RL&XXHD:?%@^_D-'MA96"4G"_D@C@G-6YL:KE.\'T>4)>4!)]#>
M+2JEOIW*S55,O9M*O[ AK[K$W1S&4G*X[9EWETITJSSQ1B*ZO7L)]9["GTI*
M2EB;S*<34=HCKM^+70'?C41U<*NBOJ^5A?0>M+8B8'#-'D!UD]$\B _V;Z+O
M%HUF"^R62&F*PMCY,I;L<3_>Y<K^M>'OC(Y;T/3.%X"])$^ZSH2[;89#\D"&
MCFG: X6&4,()(X7(ER)>@+$%IM:=SE=GH'(Y5G*)HM@,/:"UW]GK< AYXB]R
M:N- 3H0""98W6PW@MX(&\%@KJ?<+GQ4,AL!//2E;!*WZH=Z%.%X@1GR]^8*1
MMIJ/G*F/6^*@&05 BG*AYJ-K5BR=U3IH\45?EQP7Z[5X'@DUKA$W[<]/MIY0
MZDIZC=F_8:U&^G>7GQP(U18U_247R#;(B?QF9.TV8TTY_;FCR9@\86]W>DFC
ML+LN"TZB+/WSDS>-F>P???JO_WH2-5F#S_0^.:O,^,]/_@/)?I)?\?-H_VAS
M28?E!QKV?R%^BS ?@A2!#W+]^V56C\"$FV'FG0O1$+0/F^=#5G_N&/?:=3AZ
ME"WT3R[X3:)Z@D68&.;&0+A4"VA-J:++P%SX,(-]--@>;FQ;YEOE[#T:<6Q?
M,Q=^L;'F9JE8-P ^R#5>G6D&PO9H3+F]$KF!$CGX]#HK B4BGRPJD8-'UB&=
MA?4HM2?8UX/^1O#;RZ1)>J6Q1&E\7 50Y)JEV$F%BQ.WXT&9V.U..F/*' CP
ME<EK<\$)/<E3LUJ*A@9&2D1<B-%-0.F\WAA8UC+:F."B8X9X:,"0^6G=,VOW
M;/%R6A\5]9N""U'1??@ DU@S!ND]9Y(][HK7636)GKX_/GKW(GKS,AKL[SQ[
M5!ZKC<.O8:*#W? BR<D\/SDSIED*U@Q]S35_OS4?7C#]G@J">7?<\T&$9FF'
M.XE&]")_BSDGN*M@&_YW](JQ*2O-?K@I^E6XS2I0G.PUN_/]W-]'/(EP4^#<
M7&D+]<[,5^3,''XZYAQ+X-!XGRXZ-8>/[-0<VZ00]YC,:@?X8U2Y6'B)=#3U
M##[\@9-9%T7YOKV?!?IIN^>+J[IK]#VP'QS,L].#>;XU,$]_=-WDZ#KZ!+8(
M$@.V#B__\X[CZ[$#^SHX[5X],BG&\?LCB*?GE>.B)-8@/:*CJ^;MFYJ/2P*2
M[V:5Q^48NT(Z0M\@YXM.'D)N+N-J<M\[FTB^CRW1)1=#6U+'0FC?\+>I6YR1
MOSA3NSA+BW<)M$TD%U)Y=O6]8BE#BT(& ,S1U-%@)]D8[#TUS^A'@[U4_M),
M2U#.'21Q8'B#PYW=F(IR)NPN/K59<!F=_PM;;QAS>4@X7B[=\&8 VTK8]!*7
M:%2(AZAAF86;MJ#7IN\ZTT5<RR,SQ,%D=TL)!W/,6"ILLB8:9SG7N=2SX23S
MN$U;.2P*-R.1#C+LT+!K(MNAJN^*:D"8LQ!O[U@\B6R'"&1 ILNTCK"(.QMG
MCI7AY-5Q5-':2%7+I-Z,7A"6K-1*)G^GWTZ@XBN%?8F@$Q\GLZ7AU,7R@'HV
M.J-RLWC5@1&PP&Z3]6I^><<J^NTBDZP&WXOHC9)-BKZ.WH$YX<W[!\VY?N>*
MFW=>/46J7;3P,&QE:CS;L_I,?57LQ-)H-Y84*;P:6ZMK63TM/3).M*N\L\GM
M513G.%"<XV=+U,5FU'H)Q&'6]66'Q,K#7+:UI1Q3E,8(=+C!:FF$ER*SYIDJ
MG+;@;> 'IQ7'J2I0[5A/%SW=WAKL/!/R7$[+4?$GZ$BLH<. +BY)221Y[ZK3
MI)":/4O]\K$R20K.$_^*^E:W%!M/"I_.93A?6%X::IQK3A("INP\7W:\MNM=
M';.W5%Y2.3Z\=-WH<:/YLU+X0S2'5KD<FE1C)BZD@G0F'J7#RF^R&76H$1D#
MOB2.%,ZN/X0;Q!^I5+1>;XC3%B42GTVRIGA8T6((4<JL]G$<Q(G=09\MH^TL
M+X83>Y0@%^.%@DYDVR[%GMA="OM0KD5"+L?XE=*A7FW*A=^>[NR,\;6W==T?
M*!XTP4<TNCF[GDHA8E=KN\'EA6'::NM9>)::CV@(3I T.$'@KR[$%"N\$=6X
MIQ$83LIV<6E3)BFV)[U/5!>D_X02$C<7]O@I"S@ZYU&>?4;B>>0G:/\@OMZ\
MW)KN;ETERFVS-P5*$.C$WRR]%)YAK]KGN&Z][VZ''5DIJ>=PO$QBW&@3/(LJ
M[)K ).K$Z)^=BZ?$-2HHG$@K&APA5DRQQS 1-=1E/D,? ZDE*J$05[I/)72T
MAU0X%!+\B0&3[#73#C"/!3N6ZG4&/Y@@RUQEQCD=J<A7D.B6;&PWE$K:X!#S
M5U.A_>EQH@U!),89IURM(T3W95Y [1K!5#S, @"_R]#-JK'=R LY%>65,A5
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M-S,U9(PE&7DP'+K0=C(.@[2W+$/?HQR;WXD29=GXD1)E;VPD9VDV,PTH:^<
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M!3F=B;SLC4?Z2,!8WY,$U)4$W*D$[&2J?+FG3W80<KN0W&,S]T!)0"4!Y9>
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MS" 3L4]NG4T,"V!\A>=TV2T9C@9_FB?)9IOR'?&?XY$=8G\^T"!\D)89=KN
M$?,X,+,_L;T$7NSKTGN9@7([LEWL92YZ2*_4'M:DGC+ :DGS_3\H&1C/E!CH
M$*.<& S@*4, !.O8;B95KI[P803<A[&21,@'?-;1&7_4T<<W/1[1$&&'+36S
M;C"CQGNQ10O\*L5LH\P8XCWP353Y^S,J_X2I_/0-E5^+>4.T(Y=IH1\ KQQL
MB_],G0E\UJ<^LF-LH\\ZZI.C?HQ9TVT??3P!H!!O[,/N&1[RTZ9]EXQ\&B"W
M[QNVCS,'<$( R.TA?,''K\+'(]A!,/^(D1?8K%V_:*DN0)\!\-.C!F.' QD'
M!$P!S7NRPUM;P)./%(!?#=&H9G,$C*GT&O$&.@Z ^(FZ?-P"?DY'"'O1#OZ'
M:\=6'=MEESE>C9.#(]>U6-NI$=C\/@23>X>,['$ 1)-.3R#O(^P> 2Z#->H@
M!LY2R=\#6,4UGMAO3L@M4.K<]VUF@M)7)$\DB(B2(XDR?5#J+GI&P.>=(Q-@
M[#8X(<!^<7<&&7%U+D$0."-#3$5@"E\\>$-H?A%U)_M-/;.QZ8-0Z#,?9NCE
M(_EPQ"(CR(MQVH@?SWVPQ+@,.Z%KLO4$JXG&1$1K(D>"97V+28-X9S].'DY(
MGUI(O:!)QB,D'.-EJFH9HQ%LGX6+_3&2.WX YQP[@M4LCIQ?,E\D?B0[U4H>
M4!06RD,/@%G ;:VQB0@P1;EE5P>(ZEJ ,S'X.4S)(Y^S$W\J$(9/;7FA!"Q'
M?@\@*I"U\RO&I1!GO%YHP((^-0)0#/#*P1(=^VQIH^>-X1$#RB;/+!6&B*5]
MGU+<5RP!$0&BKVCQ,ZPQ&_L" ADX(?R_[\-&\ @)Q U0C,^@/:H_&D(6C@-K
MP9FH^P1\@'TH3H424IQ*B$:;*SP."QWZGD,\H+W$"?A4%"#*$](%B6YP6RYQ
M#R]T@0 %M& I9@HRH"-9XY)9ER,] "H>,9+.H[$_PBN$APC6Q>?PS',OVN]S
MK<9%[K; &]<Y+T,O>(FZ"X)3<$S7(\$8Q_SPA16]SNSD-DFBIC-&;4I@'U>/
M/)-:8Y_[08&*$*),J-G!SV I<407F49:;Q".EB3K^2T@]7/Q:''9@"C&MG)"
M'O"2$U^.CT-? :0N/$I#I#, $$&(8M&&K=!GG%MLLCE !L,>SDF&*-NX!+#L
MP'2\0#QSZ;&X[!:@-)S 2VS@V7#&1A@_/%7['*.89E._X(;L/H@J "/LU!XR
MI7-H6&RBU%19T%#!?D'/&OQW;@F/#PZ+5'HCJ9ZG;Q[X=H\Z-GT6/#;!,@"F
M""6 7(*A]F+=+V%<'(8^G#K@;F,E^0R5"1,;=#(^_KL1 KV\1Y,_!@07:$,.
M"":-IJ]M)B;ZOL<E.JAB/K(38 >V9TU%X5*Q+?0#'[60X7#L\DE=R%SF5,Z9
MCX6:R1^/G]BP'RKT/ ..^:'Z4=CCC UR F83^9+<@2TNSL-YHGAPNH8!3_^@
M?P0V\>PYST);8GJOS8Q0T#O!XG>?&.,*QKU_<SG)AM*AH\2AKP!=ZVE*P!:%
M98'54;YM/CZ/;0ADH)D*_GTC7_D1/'UNT@J&\"GX]%9^V V\L4%V6 N)S /5
MY_KZ;CY'[(!]L1GA'KD< ^HCM0FWV535-#CL0?ZB/H"^HRSN]@,'VEN8>NV9
M3+G8 %O;1]^N[6?@;D&(;DD\US^!(]')!JB[ PC-5WL5NKB*J*^,J.LJHIZ,
MJ.<7(-\E)F<LU=E'X'A:%A,GHT:5,=,W9HICSO_LGE^=D:L;P*B;[N/5[4WW
M6H,_STY(]^:<//PX?;@ZO^K>7UT\;#>C>[O2O3T!\^SVYN'V^NJ\^WAQ3DZ[
MU]V;LPOR\.O%Q6,&:!28))#<PLP4W$Z,WDN9TQIWENV*]K6!:57=VL54@A^!
M>?.(/TV73+F=8F%.<;+>:JDNP\JI]48#Y+CXU\<O)+V:^"B9LI<7@<X4$Q?Q
M?#@VZDO_.&J^+7KS8T!)S2.EIHG%U&<KVXNK*OM*A\EU,.,,+&.;,:OE'R5C
MRE\_T>$W\:\EY5VYP5,07!)\<Y<<)>,JG%_ >5WA_)LXCP:9-+BLD$,ZY*A)
M@QP9&5VE#CRNUMX#HXMS^"LKBAUR5._A[KI!0!,E]X5144'/7[21RW.BN6QP
M=3&RG"CE8DJ@0^V>G9R)\)K!>,IGQ5!*<:*R/_]0;D1^[41H6*P964SY,XQE
M)JRY&T]-A[,:3.".,^,Q%O]L.+SX(87I1 ZD/'OZ+0%&.L84N(&_+EM;GRL+
M99&<W>]'A/PNL8H6TX;0+6Y6]4:[KC=:M=E GST3W1N[-G_[Q\/YD8@5CH/C
M)\,8?<;[[[H6_N=B>OG=\,SP?2SX^%_#&:,#$2B#,M\BIG\9(88+P\_N>'AL
M>:QLS1X:SA$1+X)_'%W=7!Y]:VJ-2E-K-2I1Z##:_((6]IX0:^\;*!5FUU,P
MNR8#9E<;6D5ORXK9TNO1,@G!AX'GA\>8I(597S0(6:[LM&+AW<O"U1N0D6TT
M-A6(OU+'>O1^-T*\^\FTZD389)LR#!W$(#"-5DM6AJ$V4 [$;FXJ#W>$V*UZ
M6],[TFIXRAA<0PZRLFVLPO"I24%CZCE4B;[2<8C6IJ(ONO[[^/:W%7IU3:]+
MJR*K#90#G]N;2KS<\;E:T2KMFJSXK$R^-41=-ZH54J*NQ*RALZFHBZY_RAIN
M:+BMM*NUM(JN#+P2;4!"G&Y7-A5WN\#I>K.I51L=67&Z--;=<>B->')T_$Y<
M )1X+\I->TUF!+Q^V8^(O//IR+"Q3G]$W4#T7?%8AP!S)D%A#X)S],K^J2Y"
MJG".L]W59LY!E(*1%736E?RQNJG,%_A\P=&YZUJWB,L\;V]+-EFKU+1*L[EG
M-BD14<BU&T6BQ9*HOJD*LTL2U5M:J]4H!8F6QI*77:TY^O;HA=BE2NDKBAGN
MB1ENG)J5"]OK:&U@?,WFOKWP$A& 7+M1Y%@L.6Z<3Y8+.;;!3&AIM=I!Z2'9
MW2MS:+B?/Z77KHHH,;GQW&-3E9F4\$1E?_ZAW$AI?,\RA%O%U$'W":[<8+UA
M0>P?>_WC<4 Y_]&(2T,5@I5!35LK7+5QHFV,$M>($?=XE-O^CX R/6MC<T?7
M]&I5UG"5VD Y<'KC'-N=X'2U7M7JM;+'8)6S<B.YR<*MRFVI_"1%^TDVSB).
MA&S R#2WSKBL=51<5=+=*)HLEB8WSH3.FR;K3;T4-%D:&UUVW83UZN&Q5&-U
MHZM"KKUV<,P/3D0L;\S&H,URA'U7ZQ=USI6<;_-$;X:MFT=/.[6*ILN2-B(#
MVLNU&T6$Q1%A9_/,]*V(L*WIU8ZFUR0Q ]Y ^]S=(66*F>Y/D2JHR^>U;;#Q
MK]$8TN7SIE4G4 E/I#J!2GHBU0DTA>7$_QRSL1-IW?M$!H<S94LJC:,<)RK[
M\P_E1J37;&1*XXBKYD?&1)7,EZR58F?CRKGHVN_XK6];4]S6M9HN;<>H][F!
M4B'RQO5E^2)RL]'4ZO5]^P;+GY@AB63SQW1:[/[N)9L40=>UN,+FA5;\[A.^
MG6V+KEHRA$C+A$][WX","+UYJ5+>"%W5*HV65FW6945I9<6M(>O.:9\".EC$
MIP%EX[31E6W19^IX(];ZVNL!0 R\8"4(R\<W-D[)/X-?X1/_L,/!V3@ 6J!^
MQ$0FVU8^UFI:NRIM\T2U@7+@]L:I^;O$[7JGHE7EQ>W2&(*R9\%EJ6R+0C$3
M+>XZ,O)\1(>B)>FVT"Q9,H\DW&S;0ZSD?ILGY<\4)N7%]QK8WWNOA4D*Q\N]
MX4,@RLVS\G="E/4V&.L'0Y3*L-_ B6V+QO?*=I>!^:QEWZQ(=/_7/76,D%IW
MAA].'GW##?@#@M-)\I/NJQT<WWBNGWCO=SKL47\U-SJG(R^PPX334*!3-$9A
M8\N_HE4J*MQ;H@W(1QC-RHKD<UD)HV^_4NOXO]3W%FB"Y0KK7V0E"N4Q*%!*
M'Q.!D;!='Q/'59F_*BDNIJ2X65F1$[8.6[V71=G06UJUM6]/K$3T)-=N%'47
M2]TK$N6DI&[I-2;5=F"O_=L3=2Y*35*,M#A&NG%N87XY6+I61]=N==\#YB2B
M KEVHVBR6)K<.#TR3YK4&U6MU=YWQ]$]C951K0EDCA#--GDOK$1X/9?S?E;=
M7?%J&4[_GE9]CS==&N^]##'S,\]E)\=F2*X7XI==&A*O3^P@&!NN24'+"/;2
M?5>%#+<+&:[(@]]QR#"!5.>T%V[?<[.F=:I5K=[:MZ)9)I3<^P9DI(D5^?.R
MT83TSF!5C5:D ";[CY,KYK,=\UF1OK[+<%3NTKBJ59H-K=W:=T?*,N'CWC<@
M(T&L2!V7BB .7A3OWQ:6/12[9NV;$.%[+H%3 :+W'"#:N&G\DL*<',SXNM;4
M]VW#2T01<NU&T6>A]%G=N)_\SNBSW0:M?M^E*BK';"\Y9BJW3+'!O;#!C=NR
M)O)8-F5X+:W>Z&B=]KZ;6$J$_G+M1A%CL<2X<6O9'(A1UVKUBM9LE,- 4-ED
M!SOHYLP;#NT0.P'R*3=($8 :U#5Q[LV'&R^DI/Y1#9K8;,5@9+C1<L<!-8_M
MU^.!;5G4_<S84*-9;[>F^\.O']RLFG=RC9V]7./.?-YKQ5W4EW?Y926G8(6'
MI=/7U!2D<IRH[,\_E!N1/DQ:W+ U'MJ\\Z,FV6S$HT;^^J; K]?:%=#;,GVO
M??3MI%*I5&.]@/T'$YO(L^&,J>)?Y3A1V9]_*#>BU*$Y_M4=AP//AZ_"20:&
M3S%],A-GZF3C8%701QO8UXWW=DMRL2^9%JI6,RY4R_@]/>/WZD??7,^ELWN>
MX\.8>0J00]^'-PZ#$%Z /EY46*A -_.^/;\<@6.7;OB6>W;C.OQ8GC.;X7]1
MQI8LV2T%5-*@R3O&R(VKT \>(Y5-,2>3T:WNN6L9%-5&1JG69 :%LB=*?J*R
M/_]0;D1Z>V*]"JX91K2CE/#*5G9'-:/GI-H^^E;E5D>:Y2$4]_66!I.GKFN5
M=D>KQ1R4Z?Y9?JT#T.M8$%37&LV:^+66-!O6VXT.=I'>T=JUAM;J=-;>#5A!
M>EL#ZPIV-#U+@+GXY]1DM2&D5@6$!;V9/175%0TGP8TH: [/U%&%=5(DPZQ3
M1U3=8N(;JB1O:Z!O#IT ^NGL.W&V3%BT]PW(B,9;#'?+"8U99:>L:"R]0253
M67D7=H*79SBP*]N"3XEIC.S0<)1\*QUCV'CNV10+[@ )KMPSC@(;%WY76EJ]
M#II>1UHFH390#I3>>&I8[BC=T"J TJV&M-T,#LP8WZW<>_2I$8S]2>1F%,;G
M@#H6,4+62B6K)9HQ\J;7 8NP$VI-:U3T^8":DK7R,:8/*SG3QF73$>IMKX=7
MVUI'[VB=JE1B]J.T>+3W#<B(R/K&]<7O!)%+8T_NIH1X-TYQ-M]K/!SS3F46
M[=NFO8]!G*J&\9!K&%<SOHTKBN]I:-@NM2X,WX5M!@E4/N>8O"$C) $ '33(
MHV_MIE:!?^KM?7N+EQ-(P7)>4>K[I=2-RXV+H-2*IK=:6DWBAD7K*3+[=Q"4
MI1=*L+2P2FDRBC\6UHU!WSC=-UD9>,$0=XNQ6RU@A'L/;DM$!7+M1M%DL32Y
M<<)S?C2)O9?;6J,D78O>N9LE3^WD:V^Q61O+8ENEL/3V$840J%$[. 8))R*6
M-\9N_7-<XZ\'Q1R7GW,E=]PX$R\Y+-FU\N.5':U30T-.$EXI T'(M1M%G@62
MY\89AKLBS[:F5SN:7MMW\D4V@N"JS*>PYUD3_,L ^'\C?R$@7"W[F;_:==.7
M:#^C%<O]?6ZAO\^M,5V"K2 6P)<)0C I3JO_DLRQJ#5YCL6 $L,TO>'(<">8
MX<_FUA##A[<!X>!G3S[+._19$_QP0 /X9&S9&!("_&-*-XL/]6W7<$V;N5S@
M#=9R[62O9YL#+UPK,1TC 'R]^W[ZV]$\-E8J?TLI!(S>B0D\/&*/FWO>Y>-]
M_, D!Q*[(XE%Q.]G'C#H'_O>2_3)_$<F=1QR]_WFQ^\KUUBMG,[!&N##UR*7
MQS6Q:HSY,Z^3+P>QZG_7_7YQ?'I_T?WMN'OY>''_F1C.BS$)(O;VF6!I^LS!
MOY !Y5#4D3:%Q?!+A?T/?K=@3(B/CCZE0?S7\W2(\UJM[>']>'MV;;L_XS4L
M.Q@Y!@#2=AW;I<<]!QCGK+AA2\=PY>B7$;2)5_CB+\G?O\F1WJ*CU7QHX0A2
M,":PC[X:3.*)%NG :XY(:(>XC^1; Q_EW"_PBT_&M_,_N^=79^3J!C#RIOMX
M=7O3O=;@S[,3TKTY)P\_3A^NSJ^Z]U<7#[$U]4XX/0#T[/;FX?;ZZKS[> &P
M>(3__'YQ\_A ;B_)[=W%/8/7 WD;,(7S;4$M3$@+_L+4$R14(?CCOX.18<9_
M<Y(&T?2(/TUG^;M)8>0:!R=XKF0(3I"7]T1PF5W7CQ:_#, "$R[_<=1\6]KM
MI/8_LW.Q /+@C) .D^N@"!K DQA5+__H3VKX ;D ?+1F"B:_?J+#;^)?28?2
M[FXZMH@2$$V[?JZ4*SI9DTYT12=OT@GZKJ3$>84Q\F),34J,68]+9LP4V>&Q
MA++5 EVKB$ZZ<*OW])FZ8QI\+NKJ]DS7Q78LV>7YX/*BE7K?U*65XWS++JUD
MZIQ,I6_W- #MW1RPB+ %[,SQ1NA1)3YG;:N8VGXJ:?:ZC[^^L04)JV;K<YGM
M%@^O5JKP_^0P\3O?L\9F>.L_4/_9-JF8DLS1H^M:YU/DR#(O68C&2]\;GL'J
MN+,_['!P-@Z NJA_\6HZ8SQ*-P@H_-]Z-%XW'RW>K#0T75^2;J805Z)]E)&
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M]B$C0:6-5M]UQ&<).3%-=K?4M->QU@> P;+L0T9*RC;/?5=%(SL347+[40X
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M ZUJ':W=4>K?8>Q#1LI*:U%82&!.R:F28K$L^Y"0FNK9<KHDE37UBE:KU<M
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M; 8)X+4#Q@"VM@=2H]%W;RC\VW?@2X %^%4[).,0S(;_PD\#^DQ12UQ!_.'
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M6 7,IQ=\D$6'2*!(F$).1$^!TR4>A%\:NT-LE XV#9(H<?E$$_@E92UX8#/
M?/KPAH7N$,Z(#--$;H>98/C &2*/-LH?,AC#3OAO7/0/ ?T:3LCKL_%SSN;@
M(7!W(%IG?BMXRB(?F64C'$.Z0=(A01;O0R-"?/M4Q!1,[YB^FL#D$>#,OF<
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M2A_SHMR9("T#GW >)(-+%!4\U^#1I<1I68/%1Z9=O'U]T\>-?#HR_/AAZ C
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M#4EYM7*8Z"&.#1V2(>[C@)K']NOQP+;@_C]'SNB6+KH[L%"UR(*8O_TH+4]
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M+[!5)"]Q<%LXRMAX%GMC4!41U^684VY!H\1\3@2:?,45J;)+XYG-A)VQ-@M
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M9TS#8LI^DMQ(.JT]%FUZ5UX.HJ=E+5&@"GUSH@!*H?Q2*$=<C\5TB"7Y9?T
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ME(9V3.,WK.WV ^,//WQJZ;ZI#J<XZX*WEZ6[PID6CNU8 ?7HHHS+']>WUZ
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MDUH!,E2NO7 3\/E'Y$#BCG#N\+4D=#FPI9."'%7.S/>)G !9'$!]Y=_';!B
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MKDFH\B14V/5[U'PR-+17P_%A%>30X1J.GXA^GF"JQJ@@5>/B"&H?U:T]:E:
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M;2'6 ./0M1N1WY#;R.<AIA1AB**O Q8N&*F5[G(3T1_2"LL:O6<9K_Q=(V/
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MXF/%%S@XSP52-6 5KF_87#-I!]9;2/\A^3(I\K$/[<7SF%-3PA_R^"YIL<5
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M72#G5,1A'%G_CS:^@;HHBRC23CZ#QIADPT23#>($IJ$,$.'4)9<"!TR8.*/
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M8]\]B,KKIK'I%])SE9[$?G\,<>[^')&7F:'-B,'*B>"W'/V/E$0$!4_FI*2
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M9'R2  +$-*B/L-%4=P:FP_)=N!+ 9ZU1IC(ZLWSJP39#S!JU2,@I@C=*Y:5
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M#\>@!!D3,=$#1<9WZ,,!?2)-0G,<#RYW-H7Q4DK8,1")TL2L1,?%78PAU.B
M@S5>$*X58P&]1G558>?0N!X9!()%-M\]JA:%*D'H?*CSM(B6$L-[")(%8E.X
M$6?-(2;S#=1,T1_.YVF<@3;J)=/'8+E+[*6M"S()L3"P^SK%EVOO"2;C%&Q1
M%GU;RSA&W(;1;A^W6N>8FT+-1$%8CY"C.TLQD]&?N,JUTYPI[42A9R-#B$0
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MXAC6:O")R<'BRYA-5IN),H""*Q.O?B06]:8#R.!\6[@@6"<YI/K.7[0Z)@_
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MO<[,T@2\/FV>  ;/?>#PAQ>],Y6\6SD!=AZ:S\-] 78K=C\.Y>,!7RO.W<<
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MPTTD'5N*J$;YR=S3^(76A]W8>-*RZW[P2N*PG]/YLJ@"HPH3"0YW6G&WMS
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M#)?D)#=V'CUDL+/+>D4*S^OK<0&_LA19M"39R]R@B$X@!14]0C.4 %:@7,A
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MXQ6 ?XS2: '#GA:S^/G_ U!+ P04    " "P@'I:SXR,7#<#   %#   #0
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M1XJX^CX1]W46M4; "D.8?UB*C>SOS)(_1UVO,<IY*IE,V6>E)[BC1U#.@5E
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MO0OP_1/L:TN664>\?Y)X?]IO(?'NM8YX+Y.J"YZ<<5.BQ5TRT5Z-%)6UJYQ
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M6279":ES0<>QG22S:*&@AS1GY!!C^N*DUHQRF"43KYL8K+C,PL=X'N=!7"=
MV1BDA6NF,$@5V.Z<,!V/IE7]L>T\>H0%<:[K=WAGT&R1^L$H#A<<"N:]V-K@
MR;[]N<%Z8-P'*BUJS-+9]3B=W%@7G'""QX]MFB&8]U0U#Q80*FOB3B?8>HO1
M1N24,SD</^F+6Y\I6E<) 4R0KR0G]X&; 3$16!MB6?7562Z2X'E92/P?^1#V
M8\ L/D[$<".'B0/Z1<GQY"7K&,U:,IJ?VLYHG"^"]1N@>E"OJ(K<IC37NTB#
MU"T+3(2]%V&;=!K49D1:%CV!(!F$%#-&3Q]"%7;'92T30MJ7ZMH,_75TNXYL
MOGVY(*A7I42R8"G!Q:08#4&I*M!3',H9=F/5;,I1-"<F$ ,*MAAT=M.WEI2L
M8IKXB:IY(U,UI+9:55KN7/.)*K'7@B2SC0WJI7T:P3%L-,[;QA;WXR#M+4 ;
M'9M]J!AETYU[0WP(K"./F<DXEP;1NXX:\7=080DSA=3(@E<(0>EI+!ADKC4O
M8D,%W.>C<M%C@T947'7N9H*6+S4+4TY*RL"HS[;%=J_JN\WMYN#08'R,O?2N
M][9I14=%(3*F!J]1U+-9"30BOS4V[Z9XX)-55M<S8]FN*+LI?8P<HB$@E[KW
MSS@I^MX(\LU\=D4SIZ*'#4?&E#@^'S"92FT<(*B=@.+!KA9*>O=ZCY/689Q.
M8:+RIVCTG4*REHR]?9E,BSL<HMO/<0U3R0 GU7G,'* (MMX!^YXY(/),Y%?P
ML^?U1S1].L3 'M'4I#UM;BS+B (^;4XV^T47U#[6 8!J9CU[0ZD6SZ;?=N=Q
M+<]CF[.G<I)5+H;2"(947JB9;2.VY#!1'1<%]*LTP^XXK*6]?-JZXU"5_(AK
MSW%TBRHA,7YW6%#/O>9^YDDV$^\H9:^SK]<2_*%]]O4UQ2\IRFQ,7-!=4H[Z
MZ@F5>F:NDZ%)4'W(3*JE@17:=/;K#L.:Z4"R=8?!.)MR#_3$U*(SB.?BV+R?
M?V#.$(/-<CZ'+#S_476X3%)DUUEZ+<_&X*6<#?3^F<.Q+'?%/Q^2/7=DL5N@
MO;DSP7;%IMX28\7A-F4;V&KG)S2 -5^9X84G<U/KK<6'TD;1_:"_?6G/<T<B
MTWH0]WY<6*0 T^?ZA(,#^[WG180K.@:PE@P@>"D,P E'/%*9"I3&S'U.X4<,
M1!NBJ#SAPSD4%*_BR2]U.L0Q6W4\7D*R_<%W2K8_Z)+MNV3[E\KNYQV?;6#W
M%<]&3N_*LORBKEZM_*JA^-451$ZFLH*A4@H[G_!:^LI:&+)DY^\$W5U^A;-?
MJ'R%W=8[@EY''M].?U>M& 5TOFW#YBGHAS7ZP.&S#.U9!DC+O)@X6,(E6\(]
MH8J@C_>GDL$&%Q\/'=\E$:6]IZXE>$[M=C8Q5[?,P'0&ZWZ+G .4XP0?)RE9
MV.J+R@*=F]0BNLL\=I.\SN1+0% !-XL%M;[>9+#\V-20>8?70@AT4FDM#W'[
M'',7F-I^I]74HOUXQ+R@6*]=P9CGF,DBU-J]728ZW>?'B=]Q6VQ&@^>DE/YR
MHA>2+%WB+472XY[#[)ST/9"31<"W\[5.FU3$HX=^"8_Q1EJ'9>/IZ)5D5&[K
M/?6>L/6<8*GWKII;MG-&$Z=E8Y].!F*$(X)P2L9)!D,2D$.#,JO$QB0(RHP#
MA;#:)O_53\IM@,,V81YBH"*;YQG-%D+FY.4@5W^4BN51<UE'"4LS^$H-L2'J
M-R,^MX[-9?2GA](8 7-[6.V%H.PHGU.@KD+UR)?6S/9MY)<NS7C]M8\D>:>^
MV>O>6:HY-:C$#H5>VHQK&<=)"6]BP5B;BU'!W:,67CD(__VS=Y-_>,>X<EE1
MOK=-(^&MF8Z3"7;IP*,\AKE'EL9KV=Z^\M0<FQY(Z,XC('FX2*DW*P>1_&T1
MR/?V[X$@W[/;=I7!,2D,>Z#(#?J<<W% VN3K.L-@Y&N+V&1W9@5?;]^\'O][
MVN $+O)DRMW-WZ\)A:?&1VHB#U4%T*Z?^W0]TRN_JK\R(@RXEB7QK'Z2'H.!
M2%U/0$;!$#:GJP,=?[%>I_8EYMXV^SR1GI5DBO46YU E48.A\4JU,N6P4SD3
M"8C7D8UE+W#55D@AQN-;.(!!]@2XPB76[JB7@>_SJJ+H7G)D51?_T.,PD2Q3
MGT YL:?807^ *C/_-&F1]O(D4@9NC\X(YBUGJBN%6=L3WCZ8O7H.IM.)8W%Y
M_I%:E\^C\#W0NIDB+RD=E K38G'G:;_<'4]>$WMT8#QKTHG'NJID06P\U^$"
MX%17HXF/X)$9C0CHF^%^F@^A<0GGU!A E&D0N,+$8"QU;454;!2!ZJF/7R_X
M ^L@88[<%(M\DYCID%#O[649"H)?BLW&&N/2KD&*UQ:MP]E8]T*(L]8Q)RZ<
M)6W:U#^8!O54X(:?MXJ25Z<YUNVXJA,D^V5AI\5Y0/>F >-JJI=9.-3DF,&4
MJ$9[BJA'3TZD=$HE%I,C'M'JN1U6D4NU,@C2ODBFBQQR=+Z,0]:@+!R!"2;:
MRSA.F*0J:_8^@#-W*([*8Z-TA$<[Y7$//Q@G4_3<\=_.[><=3T1D#PQ.(UHS
MW,$.[9-P*5H :7?+G1/MR@U^"<F/K[]3\N/K+OFQ2WY\J>*D?3'U*M6DRD,Q
M2K#M=UUFF2(I@U>,)18*>Q4PC$(G4CGS(UEV6 LZ1Z4Q:+7F0_98.R>V_$)V
MYAB$!^7(L_?.X.)R8"*0K,:YWJ<IXL<4GCSS87^\=_@WR+=-I<EG :*+^+AY
MM2"!B045C(?+MX&YC]'?40-N=JOCN?"%[<(JQ2!+/JMLZUY9N@R)(,DHY&$Q
M#)YR;]4<EHL;;,3.^5V;_0A:);,['K>V]3PX&;3M I. 5_&Q)6XSQ"G'CO/$
M2JIS:2X#'2*&@TMX7*;?L?7<D;N?CR\#=-^IS+(YQ6ACA+')X%WV\8B/;NJ#
M;#8##FV3 N<^0PAUER3A%>%6[T6L2N>@^)AXGY=VX]X2YD1G0L?POHH3J& U
M/ZNB@@IE"'-O-<Q8(0=8#.]\_*SI71DXSC#(W\W+G\&(KJF1S;2O3\=[M)D:
M[F?/ !C1YPZ7".'/$DQ%REV_(Z_+L__0=ID>'1M;VSH5TDD8XI>4LU#G%O(W
M]V%]:^>5_0.+F-S![M[FYRV3^,Q'"+/MYG+^L8'"7!8TZ41^@B!.:)*$7/_R
M=8K+G_;<M:^*\L6=Y@<7X-&N@H?.$9@N7WV"O^4L*W\=UO>3_C%WQ&JIM_VC
MP;$XVAD<=Y3\/>-FWY)&SEM!R5<8V38];&X*692$ H;)=A4FF(V:77M9N:VB
MX]6*FMDPF1<]RPW\P+*L9[_W#V7/HN>B1#@#%5;YZ:-,H2RM#^QI[9R="W\%
MF1[P;4.X/Y/<%: @7;L.L&SF1:1@"J7ZHW[/MA"8^AU !C,+LLP-1JOLA,84
MC,Z/?)/,&\])4PXHA\J571T<>,I.'7FD+T[B6974,4[0-L+D:\9SMGDHC.M\
M[Y)P2-"V5<D_W]O$:)7HNN//?X+SO6L%?[XD?)+ Y0B?V!PE4\U[0N;O^1<X
M&GA)QY:_BBTOX"25.]JEH"U(:J@I?)AGBBXC:]D0UW8%*YP21G@SRWK5]Y"'
MJHG$4B).>1_*(-<3M*#(JSS19#;U\#F3M "N5::&FRI+ JZTRL =#DK*I(T3
MZKE4B$BRPT3&7'LT*'.$;<^QH8#G35DR7E_<X.\FF8T],Z9@Q+28CM0=+DB(
M;:>CO#D;UQ:/)X869P0OR.O<Y62\6,],^W(R\!#$<N+<DIA26<RXYR0"2]-W
M#DN$^MI34=<C6'!'56L;FB6"03Q:5)$]%_]"'=A15T=472SL :+B< I65W+G
MAWKT>TI1)22E\+$.U8Z>UC8H0:(/GL-I90W^E$QC%=HN2M&,<R7L7SV;O&&U
MZ?G:]9IBZ3A<5U#P3(;W:E#0[Q>M(_HKA^ASJN]TU!.G&2+(2[+%Q)G. PWF
M6HS]P&_ :&N?%W2%B;9=#/VD=;1-%$UT[(CZ2L&_R-!;1<.KXS*ZI22:F(5;
MP&E'5=\LC*N3_+/.<<R[U&F*OP8R)O\]YBNJOOB-_-N_W:"_O6<@BG.#W6TB
M],M&RDJ./,YP/*PUINQ&D+.ASD=)-E(6'WRH"PY0FO3/*,ES(>\2'5;IEF;\
M'F9]5A=AZCCE YBK#(0R.LEL$#3TM0,"3$XR3E;R/C?"W[P,/R0@JDPM(8HR
MY<LRQ5 .^:+I^U/G8:0(+%'S6!3,XL'^:T\ B43D,R/8-95A1;CXA#XV[%A8
M78I-'&=*^E7?!FI]QR7-II@9EIN*2V\YJMVBS"FW+50 .I0!9F!\0JP;>PYQ
MR,:L8056+\+P$HHB?OQ.11$_=D4175'$2]6!VM="W#)TI\FW*]5]=32?WUG8
M>3$NDYF \:IF/L$]V@OE%YC4!9LLT',I!$G5C+EGU!:-\3!\;P,HP:7!9H0@
MR=(D,T4F"/<2PP5CG<)%18:1M\3F AA'/ODQ! '0Q4661%&52#&'4F.U,E/O
M>%)5IMS:L;W/#*51C]?*G8M9SN8MC8J&T3R+?*-"PO6R.=(+5L'<5%FAIL2D
M7OUIE!D<QX7:!+=FYCTCR#U9YFKUE(V..:]MO\IK!8?7UDLX!M/9IL^3SF :
M0>5-;DUH-DV.36QYA$4N\?WF)W'?SW$RK8+\=TXT6$Y*'-?B:?4X!R*CS>8J
M&7>#GDR !\($")UA60J6^ WS'2(PTV+;?,=B9[NA>DNS*Q8VYR9V2]/TX+P8
ML,CO#>%GV=M"O$B-8.4"4+=S%?4X,R]4S&V5RT"K8QA3DIG%A.6FX/?FOQOX
MBWN&6K"89@%OSD][XE+FH?RC5\D_#SG1[#,6>:*?DQ%OBUDG&EKH<&^?Q_TB
M1H]5YX)\2I""^08KDH*3K\PB8IJNS%C?\]C\<EZZ"N_SXIQ-/WTG9]-/G;/I
M7F<3W9\0,!ZH&<16@.)EE"NS0\@9M],1[./;#16'C5&_\S$Y&AR?G/[C\N._
M_GE^]O[\P_GEK?CX3ER?GYY?7-VZLJ)5.LO?=287"(.H4 4-4#\%RWYD"IOA
M&WFGO$:/0!2I,_@WKBS>.5OB[TO0\M!3E(OW3B&VBK6MBL$+;UDCWN"LKE'&
MUCHAV\]8R\0R:50,\S[,@4H:J 239W7G>U0>\IA0]8(KR*CY&";T6 XL/11K
M$(N?3I$@G&?3N3/_'.>,4*CMG\U@N@&L#MS-K@8)*O%%'/3[[(TH*+4-WDW+
MK(KVM-)1\5UG<@-_J_"-^-^O^V\57F%U%O,2DW@W4]:JP":*BZTGKNPJO,7J
MK"=B+WPU::[@8O[;5%+2')<:J4LGM;):W5/?837TJM4Y.*#A77Z\O7AW<7IR
M>_'Q$M6[J^N/5Q]OSL_$[?7)V7FGY<UEX"1O_%8:C__WULM/M5J<9Q]7;D""
MM-E8]-4&M?A;KO.(S0WSY<;6*JS5ZNS:NRR9?.6^/462B,U+4[MC=KK;AGE!
M_>_?AE5XU=59]$WCOAMBH("[Z;F"#9U[@(<=L2ZVYQ=7SWI=7]C&IP8(E CI
M0!E]SL"^.N+@!A9S9TI-8L%$W0PR3#"TK0[!&*WB^E/0J'R^W\10J_,?A"[;
MZN'G S66T1!O?#3SPHJ*@/,GFN6&!@W.PD!D:H3-=3(5/FO_Q+6FFD$YV\G1
MQ?@P-2RAJPJ*\!&T\F?II2.79VI$VP1\9?^7;0QE*M@=62'2B&VZVE6N/V<R
MS<+(ZK=$W=AK!3;(A9 3VRBMCJF'^0$;#R06;""Y!\:I;;A4#Z$U0S74,;<?
M-Q__/7\&US@;4U?D3=[H^I.OSV':;\5ANN4X^0"A;!&5<B9<Z*AGZU \.5 U
ME#')57X-30/N:NA 8/9^M#$6#\OJ_$LPEO%((:@5?KWWRZL#4;4[/5AP2W7E
M*SJR(.R!KN8+C5?Z4'UGY; 9A--#$.T&RX,P2RU+A?ULMBHW /&UR)E#N6D2
M *H,ID;+PW9X7)2.JY86W&TK4+W0FYP#C5."V>TWU?3<__M[]Z0H/@M[_>J$
MB28[\/ETQ967L*K7=-&#?/>U&6MIIM6WBA>6 ]=7@=?[NT_)W_SO/IE'VN3\
MWXK,>1.#P+( ;6QK16;4RE5$%W&W@']B 6]U@;T&0/C!-Y2LXGLOY-*BG"H9
MF:0F5^1LK8KV\A42[+MNP[6ZTVJ*V4R8?60 (G="G;N&MK5M6>8'>SD^C$XO
M>&:&LR+\YH/,/HMSN'HHL\&*S&D^L7I%)M8I67\VUYXPS^4T-["ZWW]&2VAM
ME43FWL_5_*VOZ[Y2M=61H@^DKMTWQ;F:F<-J6C2KVJ3,G,R4=FM>O&;2V3]/
M;FZWJQROA94-3ZY8>$S"//PR2,+9\='.N)A$Q_\/4$L! A0#%     @ L(!Z
M6H1 !.3M!0  @P8   <              ( !     &$P,2YJ<&=02P$"% ,4
M    " "P@'I:#P#YT=43  !]\0  $0              @ $2!@  9'EA:2TR
M,#(T,3(S,2YX<V102P$"% ,4    " "P@'I:4QSA72P0   3[P  %0
M        @ $6&@  9'EA:2TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @
ML(!Z6N >-<?%5@  DU$' !4              ( !=2H  &1Y86DM,C R-#$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( +" >EJ3N;.O<W    9>!@ 5
M      "  6V!  !D>6%I+3(P,C0Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "P
M@'I: +3_-?%9   AQP< %0              @ $3\@  9'EA:2TR,#(T,3(S
M,5]P<F4N>&UL4$L! A0#%     @ L(!Z6FW+8<3S: ( !/\8 !0
M     ( !-TP! &1Y86DR,#(T,3(S,5\Q,&LN:'1M4$L! A0#%     @ L(!Z
M6CP.%[;>)0  A.D   T              ( !7+4# &5X7S<R-S(R-BYH=&U0
M2P$"% ,4    " "P@'I:>ZH@ E\C   $VP  #0              @ %EVP,
M97A?-S(W,C(W+FAT;5!+ 0(4 Q0    ( +" >EK/C(Q<-P,   4,   -
M          "  >_^ P!E>%\W,C<R,CDN:'1M4$L! A0#%     @ L(!Z6MN6
M /9E"   \#0   T              ( !40($ &5X7S<R-S(S,2YH=&U02P$"
M% ,4    " "P@'I:B(V0AVX(  !E-0  #0              @ 'A"@0 97A?
M-S(W,C,R+FAT;5!+ 0(4 Q0    ( +" >EHOZGT$Q 0  +,2   -
M      "  7H3! !E>%\W,C<R,S,N:'1M4$L! A0#%     @ L(!Z6KTS 1&Y
M!   0A(   T              ( !:1@$ &5X7S<R-S(S-"YH=&U02P$"% ,4
M    " "P@'I:.XMR%TXG  !=: $ #0              @ %-'00 97A?-SDT
=.#0Q+FAT;5!+!08     #P / )H#  #&1 0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>dyai20241231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:dyai="http://www.dyadic.com/20241231"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dyai-20241231.xsd" xlink:type="simple"/>
    <context id="d_2024-01-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2025-03-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ProductOrServiceAxis-ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="d_2024-03-08_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="i_2024-10-03_DebtInstrumentAxis-SeniorSecured2024NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-03</instant>
        </period>
    </context>
    <context id="i_2024-10-04_DebtInstrumentAxis-SeniorSecured2024NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConversionOfConvertibleNotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-11-16_2024-11-16_CounterpartyNameAxis-GatesFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-16</startDate>
            <endDate>2024-11-16</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoSignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoSignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ElevenSignificantCustomersMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:ElevenSignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:SixSignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-FourSignificantCustomersMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:FourSignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-FourSignificantCustomersMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:FourSignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:SixSignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:SixSignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoCROsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:ThreeCROsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoCROsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:TwoCROsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dyai:ThreeCROsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">dyai:ThreeCROsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-08-01_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dyai:The1044NLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dyai:The1044NLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByAssetClassAxis-CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByAssetClassAxis-CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dyai:ShortTermCorporateBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-11-30_CounterpartyNameAxis-GatesFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="d_2024-12-01_2024-12-31_CounterpartyNameAxis-GatesFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_CounterpartyNameAxis-GatesFoundationMember_StatementScenarioAxis-ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2026-01-01_2026-12-31_CounterpartyNameAxis-GatesFoundationMember_StatementScenarioAxis-ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-GatesFoundationMember_ProductOrServiceAxis-ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:GatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ProliantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-ProliantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ProliantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-10-05_2023-10-05_CounterpartyNameAxis-InzymesAgreementApsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:InzymesAgreementApsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-05</startDate>
            <endDate>2023-10-05</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-InzymesAgreementApsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:InzymesAgreementApsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-InzymesAgreementApsMember_ProductOrServiceAxis-ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:InzymesAgreementApsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-AGlobalFoodIngredientCompanyMember_ProductOrServiceAxis-ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:AGlobalFoodIngredientCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_CounterpartyNameAxis-AGlobalFoodIngredientCompanyMember_ProductOrServiceAxis-ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:AGlobalFoodIngredientCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember_ProductOrServiceAxis-ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dyai:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:JanssenPharmaceuticalCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-01_OwnershipAxis-AlphazymeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:AlphazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-NetherlandsOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dyai:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:TheFranciscoTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:TheFranciscoTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConversionOfConvertibleNotesIntoCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-DescendantTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:DescendantTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-DescendantTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:DescendantTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dyai:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember_TitleOfIndividualAxis-MrThomasEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:MrThomasEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:TheFranciscoTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConversionOfConvertibleNotesIntoCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConversionOfConvertibleNotesIntoCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BradleyScottEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:SeniorSecured2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyai:IrrevocableTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2021-04-16_2021-04-16_PlanNameAxis-The2021PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_PlanNameAxis-The2021PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PlanNameAxis-The2021PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2021PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_PlanNameAxis-The2021PlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_PlanNameAxis-The2021PlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="d_2023-01-03_2023-01-03_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="d_2023-01-03_2023-01-03_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember_VestingAxis-SharebasedCompensationAwardTrancheTwoThroughFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyai:SharebasedCompensationAwardTrancheTwoThroughFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="d_2023-01-03_2023-01-03_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="d_2024-01-02_2024-01-02_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveAndBoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutiveAndBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-11</startDate>
            <endDate>2024-04-11</endDate>
        </period>
    </context>
    <context id="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-11</startDate>
            <endDate>2024-04-11</endDate>
        </period>
    </context>
    <context id="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-11</startDate>
            <endDate>2024-04-11</endDate>
        </period>
    </context>
    <context id="d_2024-09-23_2024-09-23_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dyai:StockOptions1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dyai:StockOptions2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerBoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:FormerBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerChairmanOfTheBoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:FormerChairmanOfTheBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:FormerEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-02_2024-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="d_2024-03-13_2024-03-13_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ContractorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConvertibleNotesConvertedIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConvertibleNotesConvertedIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConvertibleNotesConvertedIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">dyai:ConvertibleNotesConvertedIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:NonexecutiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:NonexecutiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">dyai:ExecutivesAndKeyPersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2024-01-01_2024-12-31"
      id="thunderdome-EntityCentralIndexKey">0001213809</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2024-01-01_2024-12-31"
      id="thunderdome-EntityRegistrantName">DYADIC INTERNATIONAL INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-11436">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2024-01-01_2024-12-31" id="ixv-11437">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2024-01-01_2024-12-31" id="ixv-11438">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2024-01-01_2024-12-31" id="ixv-11439">2024</dei:DocumentFiscalYearFocus>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="d_2024-01-01_2024-12-31" id="c125843295">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="d_2024-01-01_2024-12-31" id="c125843826">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="d_2024-01-01_2024-12-31" id="c125843297">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="d_2024-01-01_2024-12-31" id="c125843299">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="d_2024-01-01_2024-12-31" id="c125843831">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="d_2024-01-01_2024-12-31" id="c125843834">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2024-01-01_2024-12-31" id="c125843306">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2024-01-01_2024-12-31" id="c125843837">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2024-01-01_2024-12-31" id="c125843856">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2024-01-01_2024-12-31" id="c125843857">false</ecd:NonRule10b51ArrAdoptedFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2024-12-31"
      id="c125856487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-12-31"
      id="c125856489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843807"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843808"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843809"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843810"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125843811"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125843813"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125843812"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125843814"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843815"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843816"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843817"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843818"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843819"
      unitRef="Share">42089301</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843820"
      unitRef="Share">41064563</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843821"
      unitRef="Share">29835799</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843822"
      unitRef="Share">28811061</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843823"
      unitRef="Share">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843824"
      unitRef="Share">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843372"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c125843379"
      unitRef="Pure">19</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c125843380"
      unitRef="Pure">16</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c125843382"
      unitRef="Pure">9</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c125843383"
      unitRef="Pure">13</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskSignificantCustomers
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember"
      decimals="INF"
      id="c125843386"
      unitRef="Pure">2</dyai:ConcentrationRiskSignificantCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember"
      decimals="INF"
      id="c125843897"
      unitRef="Pure">2</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c125843393"
      unitRef="Pure">11</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c125843394"
      unitRef="Pure">6</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c125843400"
      unitRef="Pure">4</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfCustomers
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c125843401"
      unitRef="Pure">6</dyai:ConcentrationRiskNumberOfCustomers>
    <dyai:ConcentrationRiskNumberOfSuppliers
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"
      decimals="INF"
      id="c125843407"
      unitRef="Pure">2</dyai:ConcentrationRiskNumberOfSuppliers>
    <dyai:ConcentrationRiskNumberOfSuppliers
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember"
      decimals="INF"
      id="c125843408"
      unitRef="Pure">3</dyai:ConcentrationRiskNumberOfSuppliers>
    <dyai:ConcentrationRiskNumberOfSuppliers
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"
      decimals="INF"
      id="c125843413"
      unitRef="Pure">2</dyai:ConcentrationRiskNumberOfSuppliers>
    <dyai:ConcentrationRiskNumberOfSuppliers
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember"
      decimals="INF"
      id="c125843416"
      unitRef="Pure">3</dyai:ConcentrationRiskNumberOfSuppliers>
    <us-gaap:RestrictedCash
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125843898"
      unitRef="USD">0</us-gaap:RestrictedCash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125843899"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-GatesFoundationMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"
      decimals="-3"
      id="c125843554"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="-6"
      id="c125843609"
      unitRef="USD">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2024-03-08_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      id="c125843622">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentIssuanceDate1
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember"
      id="c125843007">2024-03-08</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember"
      id="c125843008">2027-03-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember"
      decimals="2"
      id="c125843009"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentIssuanceDate1
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"
      id="c125843014">2024-03-08</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"
      id="c125843015">2027-03-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"
      decimals="2"
      id="c125843016"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentIssuanceDate1
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      id="c125843021">2024-03-08</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      id="c125843022">2027-03-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="2"
      id="c125843023"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentIssuanceDate1
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-DescendantTrustMember"
      id="c125843028">2024-03-08</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-DescendantTrustMember"
      id="c125843029">2027-03-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-12-31_DebtInstrumentAxis-DescendantTrustMember"
      decimals="2"
      id="c125843030"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125843038"
      unitRef="USD">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125843040"
      unitRef="Share">910000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125843041"
      unitRef="USD">1090000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DeferredFinanceCostsCurrentGross
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125843048"
      unitRef="USD">24124</us-gaap:DeferredFinanceCostsCurrentGross>
    <us-gaap:LongTermDebt
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125843055"
      unitRef="USD">1065876</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentIssuanceDate1
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"
      id="c125843056">2024-03-08</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"
      id="c125843057">2027-03-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="2"
      id="c125843058"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"
      decimals="INF"
      id="c125843059"
      unitRef="USD">4000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"
      decimals="INF"
      id="c125843062"
      unitRef="USD">4000000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DeferredFinanceCostsCurrentGross
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"
      decimals="INF"
      id="c125843069"
      unitRef="USD">88529</us-gaap:DeferredFinanceCostsCurrentGross>
    <us-gaap:LongTermDebt
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"
      decimals="INF"
      id="c125843076"
      unitRef="USD">3911471</us-gaap:LongTermDebt>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2021PlanMember"
      id="c125843677">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_PlanNameAxis-The2021PlanMember_RangeAxis-MinimumMember"
      id="c125843678">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_PlanNameAxis-The2021PlanMember_RangeAxis-MaximumMember"
      id="c125843679">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember"
      decimals="4"
      id="c125843097"
      unitRef="Pure">0.6222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember"
      decimals="4"
      id="c125843098"
      unitRef="Pure">0.6427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="d_2023-01-03_2023-01-03_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      id="c125843687">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-03_2023-01-03_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember_VestingAxis-SharebasedCompensationAwardTrancheTwoThroughFiveMember"
      id="c125843688">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-03_2023-01-03_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-DirectorMember"
      id="c125843690">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-01-02_2024-01-02_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-EmployeesMember"
      id="c125843692">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ConsultantMember"
      id="c125843694">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveOfficerMember"
      id="c125843697">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-BoardOfDirectorsMember"
      id="c125843699">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-09-23_2024-09-23_TitleOfIndividualAxis-ConsultantMember"
      id="c125843703">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-01-02_2024-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      id="c125843738">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843986"
      unitRef="Share">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c125843987"
      unitRef="USD">18900000</us-gaap:TreasuryStockValue>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125843992"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125843993"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125843994"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      id="c125843795">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember"
      id="c125843797">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember"
      id="c125843799">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-EmployeeStockOptionMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ConsultantMember"
      id="c125843801">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="d_2024-01-01_2024-12-31" id="ixv-13143">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2024-01-01_2024-12-31" id="ixv-13144">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2024-01-01_2024-12-31" id="ixv-13145">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2024-01-01_2024-12-31" id="ixv-13146">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-13147">000-55264</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2024-01-01_2024-12-31" id="ixv-13148">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-13149">45-0486747</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2024-01-01_2024-12-31" id="ixv-13150">1044 North U.S. Highway One, Suite 201&#160;</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2024-01-01_2024-12-31" id="ixv-13151">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2024-01-01_2024-12-31" id="ixv-13152">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2024-01-01_2024-12-31" id="ixv-13153">33477</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2024-01-01_2024-12-31" id="ixv-13154">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-13155">743-8333</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2024-01-01_2024-12-31" id="ixv-13156">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2024-01-01_2024-12-31" id="ixv-13157">DYAI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2024-01-01_2024-12-31" id="ixv-13158">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2024-01-01_2024-12-31" id="ixv-13159">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2024-01-01_2024-12-31" id="ixv-13160">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2024-01-01_2024-12-31" id="ixv-13161">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2024-01-01_2024-12-31" id="ixv-13162">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2024-01-01_2024-12-31" id="ixv-13163">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2024-01-01_2024-12-31" id="ixv-13164">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2024-01-01_2024-12-31" id="ixv-13165">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-13166">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-13167">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2024-01-01_2024-12-31" id="ixv-13168">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2024-06-30"
      decimals="INF"
      id="ixv-13169"
      unitRef="USD">30477226</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2025-03-26"
      decimals="INF"
      id="ixv-13170"
      unitRef="Share">30090661</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877256">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;Cybersecurity Risk Management and Strategy&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item &lt;em style="font: inherit;"&gt;106&lt;/em&gt;(a) of Regulation S-K. These risks include, among other things, operational risks, the risk of intellectual property theft, fraud, harm to employees or &lt;span style="-sec-ix-hidden:c125843295"&gt;third&lt;/span&gt; parties with which we conduct business and violation of data privacy or security laws.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. We have established policies and controls for assessing, identifying and managing material cybersecurity risks and responding to material cybersecurity incidents.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;We routinely assess material cybersecurity risks, including potential unauthorized occurrences on, or conducted through, our information systems that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;compromise the confidentiality, integrity or availability of those systems or information maintained in them. We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments when there is a material change in our business practices that we believe could affect information systems that are vulnerable to cybersecurity threats. These risk assessments include identifying reasonably foreseeable internal and external risks and the potential harm if the risks were to materialize. We conduct these risk assessments directly and also periodically engage &lt;span style="-sec-ix-hidden:c125843297"&gt;third&lt;/span&gt;-party providers to support these processes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Following these risk assessments, we evaluate how to appropriately implement and maintain reasonable safeguards to mitigate identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We have implemented cybersecurity tools, conducted employee training, and monitored emerging laws and regulations related to data protection and information security. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;a&lt;span style="background-color:#ffffff;"&gt;lso obligate&#160;certa&lt;/span&gt;in &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party business partners to certify that they can implement and maintain appropriate security measures, consistent with all applicable laws, in connection with their work for us, and to promptly report any suspected breach of their security measures that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;affect the&#160;Company.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Cybersecurity events and data incidents are evaluated, assessed based on severity and prioritized for response and remediation. Under our incident response policies, incidents are evaluated to determine materiality as well as operational and business impact and reviewed for privacy impact.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   We have not, to date, experienced a cybersecurity incident that was determined to be material, although, as a technology provider, we have experienced incidents in the past. Despite our cybersecurity efforts, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on our business. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to &#x201c;Item 1A, Risk Factors&#x201d; in this Annual Report on Form 10-K.
  </cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125843825">Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. We have established policies and controls for assessing, identifying and managing material cybersecurity risks and responding to material cybersecurity incidents.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125843827">We have not, to date, experienced a cybersecurity incident that was determined to be material, although, as a technology provider, we have experienced incidents in the past. Despite our cybersecurity efforts, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on our business. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to &#x201c;Item 1A, Risk Factors&#x201d; in this Annual Report on Form 10-K.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877257">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;Cybersecurity Governance&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management team. Our board of directors has delegated responsibility to the Audit Committee for the oversight of risks from cybersecurity threats. Members of the Audit Committee receive regular updates from senior management, including leaders from our information technology, legal and compliance teams regarding matters of cybersecurity. This includes existing and new cybersecurity risks, information on how management is addressing and/or mitigating those risks, cybersecurity incidents (if any) and the status on key information security initiatives.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   Our Chief Executive Officer and Chief Financial Officer are principally responsible for overseeing the cybersecurity risk management program, in partnership with outside consultants, as well as managing and responding to material cyber incidents if any occur. Our CFO also serves as a board member at a cybersecurity and mobile IT solutions company. Although our CEO and CFO do not otherwise have cybersecurity expertise, their many years in Company management and risk oversight more generally position them well to oversee the cybersecurity risk management program, which they do in partnership with outside consultants. They provide periodic briefings to the Audit Committee and to the Board of Directors about our cybersecurity risks and activities, including cybersecurity incidents and responses, cybersecurity systems testing, third-party activities and related topics. In addition, our policies for managing and responding to cybersecurity incidents include procedures for appropriate escalations to our Audit Committee Chair.
  </cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125843828">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management team. Our board of directors has delegated responsibility to the Audit Committee for the oversight of risks from cybersecurity threats. Members of the Audit Committee receive regular updates from senior management, including leaders from our information technology, legal and compliance teams regarding matters of cybersecurity. This includes existing and new cybersecurity risks, information on how management is addressing and/or mitigating those risks, cybersecurity incidents (if any) and the status on key information security initiatives.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125843832">Our Chief Executive Officer and Chief Financial Officer are principally responsible for overseeing the cybersecurity risk management program, in partnership with outside consultants, as well as managing and responding to material cyber incidents if any occur. Our CFO also serves as a board member at a cybersecurity and mobile IT solutions company. Although our CEO and CFO do not otherwise have cybersecurity expertise, their many years in Company management and risk oversight more generally position them well to oversee the cybersecurity risk management program, which they do in partnership with outside consultants. They provide periodic briefings to the Audit Committee and to the Board of Directors about our cybersecurity risks and activities, including cybersecurity incidents and responses, cybersecurity systems testing, third-party activities and related topics. In addition, our policies for managing and responding to cybersecurity incidents include procedures for appropriate escalations to our Audit Committee Chair.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877258">
   &lt;table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;tbody&gt;&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="vertical-align: top; width: 79px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;&lt;a href="#" id="Item9B_Other" title="Item9B_Other"&gt;&lt;/a&gt;Item &lt;em style="font: inherit;"&gt;9B.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 941px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 23pt;"&gt;&lt;b&gt;&lt;i&gt;Insider Trading Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;During the quarter ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c125843306"&gt;&lt;span style="-sec-ix-hidden:c125843837"&gt;&lt;span style="-sec-ix-hidden:c125843856"&gt;&lt;span style="-sec-ix-hidden:c125843857"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our directors or officers (as defined in Rule &lt;em style="font: inherit;"&gt;16a&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;(f) under the Exchange Act) adopted or terminated a &#x201c;Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement&#x201d; or a &#x201c;non-Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement&#x201d; (each as defined in Item &lt;em style="font: inherit;"&gt;408&lt;/em&gt;(a) and (c), respectively, of Regulation S-K).&lt;/p&gt;
  </ecd:MtrlTermsOfTrdArrTextBlock>
    <dei:AuditorFirmId contextRef="d_2024-01-01_2024-12-31" id="ixv-13176">173</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2024-01-01_2024-12-31" id="ixv-13177">Crowe LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2024-01-01_2024-12-31" id="ixv-13178">Livingston, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842573"
      unitRef="USD">6506750</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842574"
      unitRef="USD">6515028</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842575"
      unitRef="USD">2756577</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842576"
      unitRef="USD">748290</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842577"
      unitRef="USD">24248</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842578"
      unitRef="USD">10083</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842579"
      unitRef="USD">237027</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842580"
      unitRef="USD">466159</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842581"
      unitRef="USD">303066</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842582"
      unitRef="USD">327775</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842583"
      unitRef="USD">9827668</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842584"
      unitRef="USD">8067335</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842585"
      unitRef="USD">92211</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842586"
      unitRef="USD">141439</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842587"
      unitRef="USD">10396</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842588"
      unitRef="USD">10462</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842589"
      unitRef="USD">9930275</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842590"
      unitRef="USD">8219236</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842591"
      unitRef="USD">482320</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842592"
      unitRef="USD">656445</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842593"
      unitRef="USD">970462</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842594"
      unitRef="USD">1057164</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842595"
      unitRef="USD">833813</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842596"
      unitRef="USD">490113</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842597"
      unitRef="USD">54249</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842598"
      unitRef="USD">48059</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842599"
      unitRef="USD">80000</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842600"
      unitRef="USD">0</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842601"
      unitRef="USD">27173</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842602"
      unitRef="USD">0</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842603"
      unitRef="USD">2448017</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842604"
      unitRef="USD">2251781</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842605"
      unitRef="USD">3911471</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842606"
      unitRef="USD">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842607"
      unitRef="USD">1065876</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842608"
      unitRef="USD">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842609"
      unitRef="USD">34621</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842610"
      unitRef="USD">88870</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842611"
      unitRef="USD">7459985</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842612"
      unitRef="USD">2340651</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842613"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842614"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842615"
      unitRef="USD">42090</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842616"
      unitRef="USD">41065</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842617"
      unitRef="USD">107444595</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842618"
      unitRef="USD">105044756</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842619"
      unitRef="USD">18929915</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842620"
      unitRef="USD">18929915</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842621"
      unitRef="USD">-86086480</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842622"
      unitRef="USD">-80277321</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842623"
      unitRef="USD">2470290</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842624"
      unitRef="USD">5878585</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842625"
      unitRef="USD">9930275</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842626"
      unitRef="USD">8219236</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-ResearchAndDevelopmentMember"
      decimals="INF"
      id="c125842641"
      unitRef="USD">1605220</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31_ProductOrServiceAxis-ResearchAndDevelopmentMember"
      decimals="INF"
      id="c125842642"
      unitRef="USD">2545865</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-LicenseMember"
      decimals="INF"
      id="c125842643"
      unitRef="USD">1890169</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31_ProductOrServiceAxis-LicenseMember"
      decimals="INF"
      id="c125842644"
      unitRef="USD">352941</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842645"
      unitRef="USD">3495389</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842646"
      unitRef="USD">2898806</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842647"
      unitRef="USD">1194624</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842648"
      unitRef="USD">1975849</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842649"
      unitRef="USD">2044253</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842650"
      unitRef="USD">3297266</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842651"
      unitRef="USD">6134773</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842652"
      unitRef="USD">5817013</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842653"
      unitRef="USD">-22561</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842654"
      unitRef="USD">-38417</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:CostsAndExpenses
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842655"
      unitRef="USD">9396211</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842656"
      unitRef="USD">11128545</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842657"
      unitRef="USD">-5900822</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842658"
      unitRef="USD">-8229739</us-gaap:OperatingIncomeLoss>
    <dyai:InterestIncomeNonoperating
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842659"
      unitRef="USD">456992</dyai:InterestIncomeNonoperating>
    <dyai:InterestIncomeNonoperating
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842660"
      unitRef="USD">416686</dyai:InterestIncomeNonoperating>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842661"
      unitRef="USD">62642</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842662"
      unitRef="USD">1017592</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842663"
      unitRef="USD">288142</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842664"
      unitRef="USD">-0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842665"
      unitRef="USD">139829</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842666"
      unitRef="USD">-0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842667"
      unitRef="USD">91663</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842668"
      unitRef="USD">1434278</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842669"
      unitRef="USD">-5809159</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842670"
      unitRef="USD">-6795461</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842671"
      unitRef="USDPerShare">-0.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842672"
      unitRef="USDPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842673"
      unitRef="Share">29318123</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842674"
      unitRef="Share">28798833</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842692"
      unitRef="Share">40816602</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842693"
      unitRef="USD">40817</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842694"
      unitRef="Share">-12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842695"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842696"
      unitRef="USD">103458697</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842697"
      unitRef="USD">-73481860</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c125842698"
      unitRef="USD">11087739</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842700"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842702"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842703"
      unitRef="USD">1244121</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842704"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842705"
      unitRef="USD">1244121</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842706"
      unitRef="Share">247961</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842707"
      unitRef="USD">248</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842708"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842709"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842710"
      unitRef="USD">341938</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842711"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842712"
      unitRef="USD">342186</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842714"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842716"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842717"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842718"
      unitRef="USD">-6795461</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842719"
      unitRef="USD">-6795461</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842720"
      unitRef="Share">41064563</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842721"
      unitRef="USD">41065</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842722"
      unitRef="Share">-12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842723"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842724"
      unitRef="USD">105044756</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842725"
      unitRef="USD">-80277321</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842726"
      unitRef="USD">5878585</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842728"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842730"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842731"
      unitRef="USD">1126279</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842732"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842733"
      unitRef="USD">1126279</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842734"
      unitRef="Share">437546</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842735"
      unitRef="USD">437</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842736"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842737"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842738"
      unitRef="USD">339897</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842739"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842740"
      unitRef="USD">340334</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842741"
      unitRef="Share">30569</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842742"
      unitRef="USD">31</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842743"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842744"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842745"
      unitRef="USD">24220</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842746"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842747"
      unitRef="USD">24251</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842748"
      unitRef="Share">556623</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842749"
      unitRef="USD">557</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842750"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842751"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842752"
      unitRef="USD">909443</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842753"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842754"
      unitRef="USD">910000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842756"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842758"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842759"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842760"
      unitRef="USD">-5809159</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842761"
      unitRef="USD">-5809159</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842762"
      unitRef="Share">42089301</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125842763"
      unitRef="USD">42090</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842764"
      unitRef="Share">-12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c125842765"
      unitRef="USD">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c125842766"
      unitRef="USD">107444595</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c125842767"
      unitRef="USD">-86086480</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842768"
      unitRef="USD">2470290</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842773"
      unitRef="USD">-5809159</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842774"
      unitRef="USD">-6795461</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842775"
      unitRef="USD">1126279</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842776"
      unitRef="USD">1244121</us-gaap:ShareBasedCompensation>
    <dyai:InvestmentIncomeAmortizationAccretionOfPremium
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842777"
      unitRef="USD">-71057</dyai:InvestmentIncomeAmortizationAccretionOfPremium>
    <dyai:InvestmentIncomeAmortizationAccretionOfPremium
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842778"
      unitRef="USD">-53032</dyai:InvestmentIncomeAmortizationAccretionOfPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842779"
      unitRef="USD">63021</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842780"
      unitRef="USD">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GainLossOnInvestments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842781"
      unitRef="USD">60977</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842782"
      unitRef="USD">1017592</us-gaap:GainLossOnInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842783"
      unitRef="USD">-22561</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842784"
      unitRef="USD">-38418</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842785"
      unitRef="USD">14165</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842786"
      unitRef="USD">-48202</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842787"
      unitRef="USD">-219425</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842788"
      unitRef="USD">141332</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842789"
      unitRef="USD">-24742</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842790"
      unitRef="USD">-64902</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842791"
      unitRef="USD">1169</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842792"
      unitRef="USD">-4510</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842793"
      unitRef="USD">-180182</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842794"
      unitRef="USD">-651168</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842795"
      unitRef="USD">252664</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842796"
      unitRef="USD">444269</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <dyai:IncreaseDecreaseInAccruedInterest
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842797"
      unitRef="USD">80000</dyai:IncreaseDecreaseInAccruedInterest>
    <dyai:IncreaseDecreaseInAccruedInterest
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842798"
      unitRef="USD">0</dyai:IncreaseDecreaseInAccruedInterest>
    <dyai:IncreaseDecreaseInAccruedInterest
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842799"
      unitRef="USD">27173</dyai:IncreaseDecreaseInAccruedInterest>
    <dyai:IncreaseDecreaseInAccruedInterest
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842800"
      unitRef="USD">0</dyai:IncreaseDecreaseInAccruedInterest>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842801"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842802"
      unitRef="USD">-352942</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842803"
      unitRef="USD">343700</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842804"
      unitRef="USD">449370</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842805"
      unitRef="USD">-3974806</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842806"
      unitRef="USD">-6726755</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842807"
      unitRef="USD">7343230</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842808"
      unitRef="USD">2995988</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842809"
      unitRef="USD">5406000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842810"
      unitRef="USD">9148000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfInvestmentProjects
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842811"
      unitRef="USD">60977</us-gaap:ProceedsFromSaleOfInvestmentProjects>
    <us-gaap:ProceedsFromSaleOfInvestmentProjects
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842812"
      unitRef="USD">1297884</us-gaap:ProceedsFromSaleOfInvestmentProjects>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842813"
      unitRef="USD">-1876253</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842814"
      unitRef="USD">7449896</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842815"
      unitRef="USD">3882884</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember"
      decimals="INF"
      id="c125842816"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842817"
      unitRef="USD">1941442</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125842818"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842819"
      unitRef="USD">24251</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842820"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842821"
      unitRef="USD">5848577</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842822"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842823"
      unitRef="USD">-5796</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842824"
      unitRef="USD">-2385</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842825"
      unitRef="USD">-8278</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842826"
      unitRef="USD">720756</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842827"
      unitRef="USD">6515028</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c125842828"
      unitRef="USD">5794272</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842829"
      unitRef="USD">6506750</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842830"
      unitRef="USD">6515028</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <dyai:VestingOfRestrictedStock
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842831"
      unitRef="USD">340334</dyai:VestingOfRestrictedStock>
    <dyai:VestingOfRestrictedStock
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842832"
      unitRef="USD">342186</dyai:VestingOfRestrictedStock>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842833"
      unitRef="USD">910000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842834"
      unitRef="USD">0</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:InterestPaidNet
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842835"
      unitRef="USD">257778</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842836"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125842837"
      unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125842838"
      unitRef="USD">156983</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877259">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1:&lt;/em&gt;&#160;&#160;&#160;&#160;&#160;Organization and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;"&gt;&lt;b&gt;Description of Business&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Dyadic International, Inc. (&#x201c;Dyadic&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, or the &#x201c;Company&#x201d;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands, and it utilizes several &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party consultants and contract research organizations to carry out the Company&#x2019;s activities. Over the past &lt;em style="font: inherit;"&gt;two&lt;/em&gt; plus decades, the Company developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and previously licensed this technology to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, such as Abengoa Bioenergy SA, BASF SE, Codexis, Inc. and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the &lt;i&gt;Thermothelomyces heterothallica &lt;/i&gt;(formerly known as &lt;i&gt;Myceliophthora thermophila&lt;/i&gt;) fungus, which the Company named &lt;em style="font: inherit;"&gt;C1.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;For the past &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; years since&#160;the Company sold its industrial technology business to Danisco USA (&#x201c;Danisco&#x201d;), the industrial biosciences business of DuPont (NYSE: DD) (the &#x201c;DuPont Transaction&#x201d;), the Company has been focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health and for other biologic products for use in non-pharmaceutical applications.&#160;As part of the DuPont Transaction, Dyadic retained co-exclusive rights to its proprietary and patented &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; protein production platform (the &lt;em style="font: inherit;"&gt;&#x201c;C1&lt;/em&gt; platform&#x201d;) for use in all human and animal pharmaceutical applications, and currently, the Company has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions) for use in all human and animal pharmaceutical applications. Danisco retained certain rights to utilize the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; platform in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic &lt;em style="font: inherit;"&gt; may &lt;/em&gt;owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or in licensed by Danisco.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;After the DuPont Transaction, the Company has directed its efforts toward&#160;advancing the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; platform to address the increasing global demand for the development and manufacturing of prophylactic and therapeutic biopharmaceuticals for human and animal health. The Company&#x2019;s biopharmaceutical development efforts have been centered on enhancing the capability of the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; platform to produce stable, properly folded, and functional proteins for pharmaceutical applications, including vaccines and monoclonal antibodies. In addition to improving the quality and productivity of the &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; platform, the Company has sought to validate its platform for human use through a series of fully funded biopharmaceutical projects, extensive animal studies utilizing &lt;em style="font: inherit;"&gt;C1&lt;/em&gt;-produced proteins, and&#160;in &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the successful completion of a Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in-human study for a vaccine antigen produced using &lt;em style="font: inherit;"&gt;C1,&lt;/em&gt; which demonstrated&#160;its safety for human applications.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Recognizing the longer development timelines, clinical testing, and regulatory requirements associated with human and animal pharmaceutical products, the Company has refined its core business strategy to expand into recombinant (non-animal derived) alternative proteins for non-pharmaceutical applications in research, nutrition, and industrial markets. To address these opportunities, the Company has developed and launched the Dapibus&#x2122; Protein Production Platform (&#x201c;Dapibus&#x2122;&#x201d;), which supports various applications within the alternative proteins field, namely&#160;in Life Sciences, Food &amp;amp; Nutrition, and Bioindustrial applications. Given the reduced developmental costs, shorter timelines, and fewer regulatory requirements associated with alternative proteins, Dapibus&#x2122; has enabled the Company to generate near-term recurring revenue while continuing to build long-term value through &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; for pharmaceutical applications. The Company anticipates achieving commercialization of certain alternative protein products in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; through a combination of existing collaborations and internal manufacturing efforts.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;b&gt;&lt;span style="background-color:#ffffff;"&gt;Liquidity,&#160;Capital Resources, and Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In accordance with FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;em style="font: inherit;"&gt;205&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40,&lt;/em&gt; Presentation of Financial Statements &#x2013; Going Concern (&#x201c;Topic &lt;em style="font: inherit;"&gt;205&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&#x201d;&lt;/em&gt;), management is required to evaluate whether there are conditions and events, considered in the aggregate that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months from the issuance date of the Company&#x2019;s condensed interim financial statements. This evaluation does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; take into consideration the potential mitigating effect of management&#x2019;s plans that have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been fully implemented or are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) it is probable that the plans will be effectively implemented within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued, and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company expects to incur losses and have negative net cash flows from operating activities as it continues developing its microbial protein production platforms and related products, and as it expands its pipelines and engages in further research and development activities for internal products as well as for its&#160;&lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party collaborators and licensees. The success of the Company depends on its ability to develop its technologies and products to the point of regulatory approval and subsequent revenue generation or through the sublicensing of the Company&#x2019;s technologies and products, and its ability to raise capital to finance these developmental efforts.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; March 8, 2024,&#160;&lt;/em&gt;the Company&#160;issued an aggregate principal amount of $6.0&#160;million of its&#160;8.0% Senior Secured Convertible Promissory Notes due&#160;&lt;em style="font: inherit;"&gt; March 8, 2027 (&lt;/em&gt;the &#x201c;Convertible Notes&#x201d;) in a private placement. The purchasers of the Convertible Notes included immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than&#160;&lt;em style="font: inherit;"&gt;5%&lt;/em&gt;&#160;of the Company&#x2019;s outstanding common stock, (collectively, the &#x201c;Purchasers&#x201d;).&#160;The net proceeds from the sale of the Convertible Notes, after deducting offering expenses, we&lt;span style="background-color:#ffffff;"&gt;re&#160;$5,824,326. The&lt;/span&gt; Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Convertible Notes are&#160;senior, secured obligations of Dyadic and its affiliates, and interest is&#160;payable quarterly in cash on the principal amount equal to&#160;8% per annum. The Convertible Notes will mature on&#160;&lt;em style="font: inherit;"&gt; March 8, 2027 (&lt;/em&gt;the &#x201c;Maturity Date&#x201d;), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Convertible Notes can be&#160;converted&#160;into shares of Dyadic&#x2019;s Class A common stock (the &#x201c;Common Stock&#x201d;), at the option of the holders of the Convertible Notes (the &#x201c;Noteholders&#x201d;) at any time prior to the Maturity Date.&#160;This private placement funding is expected to support our near-term revenue growth and accelerate our strategic objective of commercialization opportunities for pharmaceutical and non-pharmaceutical applications.&#160;On&#160;&lt;em style="font: inherit;"&gt; October 4, 2024,&#160;&lt;/em&gt;the Company entered into an amendment (the &#x201c;Amendment&#x201d;) to the Convertible Notes. Pursuant to the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company&#x2019;s common stock is changed from $1.79 to $1.40&#160;per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fall on any of the&#160;&lt;em style="font: inherit;"&gt;26,&lt;/em&gt;&#160;&lt;em style="font: inherit;"&gt;29&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;32&lt;/em&gt;-month anniversaries of the original issue date of the Convertible Notes, which are &lt;em style="font: inherit;"&gt; May 8, 2026, &lt;/em&gt;&lt;em style="font: inherit;"&gt; August 8, 2026 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; November 8, 2026.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restrictions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;$910,000&#160;of the Convertible Notes have been converted into 556,623&#160;shares of Common Stock.&#160;For more information regarding the Convertible Notes, including the covenants related thereto&lt;span style="background-color:#ffffff;"&gt;, see Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt;&#160;to the Co&lt;/span&gt;nsolidated Financial Statements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In addition, on &lt;em style="font: inherit;"&gt; November 16, 2024, &lt;/em&gt;Dyadic entered into an agreement with the Bill &amp;amp; Melinda Gates Foundation (the &#x201c;Gates Foundation&#x201d;) relating to a grant in the amount of $3,092,136&#160;awarded from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company&#x2019;s &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; platform to provide globally accessible treatment options for underserved populations (the &#x201c;Gates Foundation Grant&#x201d;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company had $6,506,750 cash and $2,780,825 short-term investment securities (including accrued interest) on its balance sheet, totaling $9,287,575.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company expects its existing cash and cash equivalents, and cash raised from the Convertible Notes, or other debt instruments, and or other means, the Gates Foundation Grant, investments in debt securities, and operating cash flows will be sufficient to meet its operational, business, and other liquidity requirements for at least the next&#160;&lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;&#160;(&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months from the date of issuance of the financial statements contained in this Annual Report. However, the Company has based this estimate on assumptions that&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;prove to be wrong, and its operating plan&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;change as a result of many factors currently unknown to it. In the event our financing needs are&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;able to be met by our existing cash, cash equivalents and investments, we would seek to raise additional capital through strategic financial opportunities that could include, but are&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;limited to, future public or private equity offerings, collaboration agreements,&#160;convertible notes and other debt instruments, and/or other means. Any amounts raised&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;be used for the further development and commercialization of product candidates, and for other working capital purposes. There is&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing shareholders.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -36pt; text-align: justify; text-indent: 36pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -36pt; text-align: justify; text-indent: 36pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Dyadic consolidates entities in which we have a controlling financial interest. We consolidate our subsidiaries in which we hold and/or control, directly or indirectly, more than &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; of the voting rights.&#160;All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The CODM is the Company's senior management team that includes the Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer. The Company views its operations as and manages its business in &lt;span style="-sec-ix-hidden:c125843372"&gt;one&lt;/span&gt;&#160;operating segment, which is the business of developing and commercializing synthetic protein products using the Company&#x2019;s proprietary microbial platforms, including &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; and Dapibus&#x2122;. Segment information is further described in Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; to the consolidated financial statements included in this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Estimates inherent in the preparation of these consolidated financial statements include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense,&#160;and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Concentrations and Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company&#x2019;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#x201c;FDIC&#x201d;) and the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any losses in such accounts.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;span style="background-color:#ffffff;"&gt;For the years&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s revenue was generated from&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:c125843379"&gt;19&lt;/span&gt;&#160;&lt;span style="background-color:#ffffff;"&gt;and&#160;&lt;span style="-sec-ix-hidden:c125843380"&gt;16&lt;/span&gt; customers, respectively. As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s accounts receivable was from &lt;span style="-sec-ix-hidden:c125843382"&gt;nine&lt;/span&gt;&#160;and &lt;span style="-sec-ix-hidden:c125843383"&gt;thirteen&lt;/span&gt; customers, respectively. Significant customers are those that account for greater than &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; of the Company&#x2019;s revenues. For the years&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;span style="-sec-ix-hidden:c125843386"&gt;&lt;span style="-sec-ix-hidden:c125843897"&gt;two&lt;/span&gt;&lt;/span&gt; significant customers accounted for approximately $1,915,000 or 54.8% and $1,503,000 or 51.9%&#160;of revenue, respectively. The loss of business from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or a combination of the Company&#x2019;s customers could adversely affect its operations.&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the years ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company had &lt;span style="-sec-ix-hidden:c125843393"&gt;eleven&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;and &lt;span style="-sec-ix-hidden:c125843394"&gt;six&lt;/span&gt; customers outside of the United States (i.e., European and Asian customers) that accounted for&#160;approximately&#160;$1,526,000&#160;or 43.7% and&#160;&lt;/span&gt;&lt;/span&gt;$537,000&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;or&#160;&lt;/span&gt;&lt;/span&gt;18.5%&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;of total revenue, respectively.&#160;As of&#160;&lt;/span&gt;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#160;had &lt;span style="-sec-ix-hidden:c125843400"&gt;four&lt;/span&gt; and&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-hidden:c125843401"&gt;six&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;customers outside of the United States (i.e., European and Asian customers) that accounted for approximately $146,000 or 61.5% and&#160;&lt;/span&gt;&lt;/span&gt;$213,000&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;or &lt;/span&gt;&lt;/span&gt;45.6%&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;of&#160;accounts receivable, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company uses CROs&#160;to conduct its research projects and manage its clinical trial. For&#160;the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;span style="-sec-ix-hidden:c125843407"&gt;two&lt;/span&gt; and &lt;span style="-sec-ix-hidden:c125843408"&gt;three&lt;/span&gt; CROs&#160;accounted for approximately $2,389,000&#160;or 93.0% and $4,644,000&#160;or 96.0%&#160;of total research serv&lt;/span&gt;ices we purchased, respectively. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;span style="-sec-ix-hidden:c125843413"&gt;two&lt;/span&gt;&#160;CROs accounted for approximately&#160;$284,000 or 58.9%&#160;of ac&lt;/span&gt;counts payable. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;span style="-sec-ix-hidden:c125843416"&gt;three&lt;/span&gt;&#160;CROs accounted for approximately&#160;$620,000 or 94.4%&#160;of accounts payable. The loss of business from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of these CROs or a combination of them could adversely affect the Company's operations.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;We treat highly liquid investments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.&#160;The Company has no restricted cash balances as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Investment Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company&#x2019;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months or less, and long-term investment securities mature over &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months from the applicable reporting date. Management determines the appropriate classification of each investment&#160;at the time of purchase and reevaluates the classifications at each balance sheet date.&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company classifies its&#160;investments in debt securities as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow.&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the Company will be required to sell the investment before recovery of the investment&#x2019;s cost basis. The Company measures expected credit losses on held to maturity debt securities on an individual security basis. The estimate of expected credit losses considers historical credit information from external sources. The impairment of the investment that is related to the credit loss, if any,&#160;is expensed in the period in which the event or change occurred.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, all of our money market funds were invested in U.S. Government money market funds. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any investment securities classified as trading as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.&lt;/p&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company&#x2019;s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances&#160;and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company&#x2019;s evaluation of current and expected future economic conditions and changes in our customer collection trends. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months. Management determined that&#160;no allowance for credit losses was required as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;.&lt;/p&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accounts receivable consist of the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Billed receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;173,993&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;410,617&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unbilled receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,034&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55,542&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;237,027&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;466,159&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Prepaid Expenses and Other Current Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;182,270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;209,888&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid expenses - various&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;117,560&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;117,887&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,236&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;div&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;303,066&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;327,775&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;/div&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accounts payable consist of the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;340,698&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;575,436&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;68,420&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,957&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;73,202&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;79,052&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;div&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;482,320&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;656,445&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;/div&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee wages and benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;496,905&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;561,720&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;437,196&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;274,080&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;210,004&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,360&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,360&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;970,462&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,057,164&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; products approved for sale. All our revenue to date has been research revenue from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party collaborations and government grants, as well as revenue from sublicensing&#160;agreements and collaborative arrangements, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include upfront payments,&#160;options to obtain a license, payment for research and development services,&#160;milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest).&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&lt;i&gt;Revenue related to research collaborations and agreements:&lt;/i&gt;&#160;The Company typically&#160;performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the &lt;em style="font: inherit;"&gt;5&lt;/em&gt;-step process outlined in ASC Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; (&#x201c;Topic &lt;em style="font: inherit;"&gt;606&#x201d;&lt;/em&gt;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; to measure the progress toward complete satisfaction of a performance obligation.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Under the input method, revenue will be recognized based on the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="background-color:#ffffff;"&gt;Revenue related to grants: &lt;/span&gt;&lt;/i&gt;&lt;span style="background-color:#ffffff;"&gt;T&lt;/span&gt;he Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive&#160;grants&#160;from governments, agencies, and other private and &lt;em style="font: inherit;"&gt;not&lt;/em&gt;-for-profit organizations. These grants are intended to be used to partially or fully fund the Company&#x2019;s research collaborations&lt;span style="background-color:#ffffff;"&gt;.&lt;/span&gt; However, most, if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; all, of such potential grant revenues, when&#160;received, is expected to be earmarked for &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties to advance the research required, including preclinical and clinical trials.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;Revenue related to sublicensing agreements: &lt;/i&gt;If the sublicense to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;Customer options: &lt;/i&gt;If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate&#160;if such&#160;options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="background-color:#ffffff;"&gt;Milestone payments: &lt;/span&gt;&lt;/i&gt;&lt;span style="background-color:#ffffff;"&gt;At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#x2019;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;Royalties: &lt;/i&gt;With respect to licenses deemed to be the predominant item to which the&lt;i&gt; &lt;/i&gt;sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all&#160;the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognized any royalty revenue resulting from any of its sublicensing arrangements.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;We invoice customers based on our contractual arrangements with each customer, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. The Company does&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;recognize leases with terms of&#160;&lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;&#160;months or less on the balance sheet. Options to extend or terminate a lease are&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;included in the Company&#x2019;s initial lease term assessment, unless there is&#160;reasonable&#160;certainty that the Company will exercise any such option. Leases are classified as either finance leases or operating leases based on criteria in Accounting Standards Codification (&#x201c;ASC&#x201d;)&#160;&lt;em style="font: inherit;"&gt;842.&lt;/em&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For operating leases, right-of-use assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses an estimated rate of interest that they would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating lease right-of-use asset also includes any lease payments made and excludes any lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s&#160;prior lease for its corporate headquarters located at&#160;&lt;em style="font: inherit;"&gt;140&lt;/em&gt;&#160;Intracoastal Pointe Dr. expired on&#160;&lt;em style="font: inherit;"&gt; August 31, 2023,&#160;&lt;/em&gt;and there was&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;right-of-use asset or lease liability recognized for this lease due to its short-term nature. In&#160;&lt;em style="font: inherit;"&gt; August&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2023,&lt;/em&gt;&#160;the Company entered into a new lease (&lt;em style="font: inherit;"&gt;&#x201c;1044&lt;/em&gt;&#160;N Lease&#x201d;) for&#160;office space for its new corporate headquarters located at&#160;&lt;em style="font: inherit;"&gt;1044&lt;/em&gt;&#160;N US&#160;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt;&#160;Jupiter, Florida, commencing&#160;&lt;em style="font: inherit;"&gt; September 1, 2023 (&lt;/em&gt;&#x201c;Commencement Date&#x201d;) and expiring&#160;on &lt;em style="font: inherit;"&gt; August 31, 2026. &lt;/em&gt;Rent is subject to &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;percent (3%) annual increases, and the Company is responsible for certain common area maintenance charges and taxes throughout the life of the&#160;&lt;em style="font: inherit;"&gt;1044&lt;/em&gt;&#160;N Lease. The&#160;&lt;em style="font: inherit;"&gt;1044&lt;/em&gt;&#160;N Lease has an initial term of&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;(3) years, following the Commencement Date with an option to extend for&#160;&lt;em style="font: inherit;"&gt;two&lt;/em&gt;&#160;(2) successive&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;(1) year terms. The options were&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;included in the lease term used in determining the right-of-use asset or lease liability as the Company did&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;consider it reasonably certain they would exercise the options.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For&lt;span style="background-color:#ffffff;"&gt; the years ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s total operating lease expense was&#160;&lt;/span&gt;$106,785&#160;and $71,656, &lt;span style="background-color:#ffffff;"&gt;respectively. As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s total operating lease liabilities was $&lt;/span&gt;88,870, &lt;span style="background-color:#ffffff;"&gt;which is presented net of imputed interest o&lt;/span&gt;f $6,669, and the&#160;oper&lt;span style="background-color:#ffffff;"&gt;ating lease right-of-use&#160;asset was&#160;&lt;/span&gt;$92,211.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company&#x2019;s total operating lease liabilities was $136,929, which is presented net of imputed interest of $16,770, and the operating lease right-of-use asset was $141,439.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff"&gt;, the &lt;/span&gt;weighted average remaining lease term was&#160;1.7&#160;years, and the weighted average discount rate was 8.8%.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. R&amp;amp;D costs are related to the Company&#x2019;s internally funded pharmaceutical programs and other governmental and commercial projects.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; were as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outside contracted services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,503,397&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,677,941&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Personnel related costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;473,444&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;553,741&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Facilities, overhead and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;67,412&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;65,584&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;div&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,044,253&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,297,266&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;/div&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Transaction Gain or Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure&#160;the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into &lt;em style="font: inherit;"&gt;three&lt;/em&gt; levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:18pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:18pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:18pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company&#x2019;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#x2019;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party broker service for disclosure purposes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#x2019;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; some portion or all the deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;In determining taxable income for the Company&#x2019;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#x2019;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company is required to evaluate the provisions of ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt; related to the accounting for uncertainty in income taxes recognized in a company&#x2019;s financial statements. ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt; prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-&lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#x201c;unrecognized benefits.&#x201d; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#x2019;s potential future obligation to the taxing authority for a tax position that was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognized as a result of applying the provision of ASC &lt;em style="font: inherit;"&gt;740.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="background-color:#ffffff;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#x2019; equity but are excluded from net income (loss) under U.S. GAAP. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separately present a statement of comprehensive income (loss) in its consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;We recognize all share-based payments to employees, consultants, and our Board of Directors (the &#x201c;Board&#x201d;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock, restricted stock units and convertible debt, were exercised and&#160;converted into common stock, calculated by applying the treasury stock method.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;For the years ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the effect of the potential exercise of options to purchase&#160;&lt;/span&gt;5,788,597&lt;span style="background-color:#ffffff;"&gt;&#160;and &lt;/span&gt;5,469,247&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;New and Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (the &#x201c;ASU&#x201d;) &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; &#x2013; Segment Reporting (Topic ASC &lt;em style="font: inherit;"&gt;280&lt;/em&gt;), or ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosure about significant segment expenses. The enhancements under this update require disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and included within each reported measure of segment profit or loss, require disclosure of &lt;i&gt;other segment items &lt;/i&gt;by reportable segment and a description of the composition of &lt;i&gt;other segment items&lt;/i&gt;, require annual disclosures under ASC &lt;em style="font: inherit;"&gt;280&lt;/em&gt; to be provided in interim periods, clarify use of more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; measure of segment profit or loss by the CODM, require that the title of the CODM be disclosed with an explanation of how the CODM uses the reported measures of segment profit or loss to make decisions, and require that entities with a single reportable segment provide all disclosures required by this update and required under ASC &lt;em style="font: inherit;"&gt;280.&lt;/em&gt; ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; is effective for public business entities for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;and interim periods within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;The Company adopted ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; and applied the guidance retrospectively to all periods presented in the consolidated financial statements.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; &#x2013; Income Taxes (Topic ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;) Income Taxes. The ASU improves the transparency of income tax disclosures by requiring (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) consistent categories and greater disaggregation of information in the rate reconciliation and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; will become effective beginning with our &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; fiscal year. We do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect that this guidance will have a material impact on our financial position and our results of operations.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="-6"
      id="c125843347"
      unitRef="USD">6000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="2"
      id="c125843348"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="d_2024-03-08_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="INF"
      id="c125843350"
      unitRef="USD">5824326</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="2"
      id="c125843351"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2024-10-03_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="INF"
      id="c125843352"
      unitRef="USDPerShare">1.79</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2024-10-04_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="INF"
      id="c125843353"
      unitRef="USDPerShare">1.4</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember"
      decimals="INF"
      id="c125843357"
      unitRef="USD">910000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember"
      decimals="INF"
      id="c125843358"
      unitRef="Share">556623</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ProceedsFromGrantors
      contextRef="d_2024-11-16_2024-11-16_CounterpartyNameAxis-GatesFoundationMember"
      decimals="INF"
      id="c125843360"
      unitRef="USD">3092136</us-gaap:ProceedsFromGrantors>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843362"
      unitRef="USD">6506750</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843363"
      unitRef="USD">2780825</us-gaap:ShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843364"
      unitRef="USD">9287575</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860054">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -36pt; text-align: justify; text-indent: 36pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Dyadic consolidates entities in which we have a controlling financial interest. We consolidate our subsidiaries in which we hold and/or control, directly or indirectly, more than &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; of the voting rights.&#160;All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860055">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The CODM is the Company's senior management team that includes the Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer. The Company views its operations as and manages its business in &lt;span style="-sec-ix-hidden:c125843372"&gt;one&lt;/span&gt;&#160;operating segment, which is the business of developing and commercializing synthetic protein products using the Company&#x2019;s proprietary microbial platforms, including &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; and Dapibus&#x2122;. Segment information is further described in Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; to the consolidated financial statements included in this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2024-01-01_2024-12-31" id="c125860056">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Estimates inherent in the preparation of these consolidated financial statements include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense,&#160;and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2024-01-01_2024-12-31" id="c125860109">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Concentrations and Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company&#x2019;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#x201c;FDIC&#x201d;) and the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any losses in such accounts.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;span style="background-color:#ffffff;"&gt;For the years&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s revenue was generated from&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:c125843379"&gt;19&lt;/span&gt;&#160;&lt;span style="background-color:#ffffff;"&gt;and&#160;&lt;span style="-sec-ix-hidden:c125843380"&gt;16&lt;/span&gt; customers, respectively. As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s accounts receivable was from &lt;span style="-sec-ix-hidden:c125843382"&gt;nine&lt;/span&gt;&#160;and &lt;span style="-sec-ix-hidden:c125843383"&gt;thirteen&lt;/span&gt; customers, respectively. Significant customers are those that account for greater than &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; of the Company&#x2019;s revenues. For the years&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;span style="-sec-ix-hidden:c125843386"&gt;&lt;span style="-sec-ix-hidden:c125843897"&gt;two&lt;/span&gt;&lt;/span&gt; significant customers accounted for approximately $1,915,000 or 54.8% and $1,503,000 or 51.9%&#160;of revenue, respectively. The loss of business from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or a combination of the Company&#x2019;s customers could adversely affect its operations.&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the years ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company had &lt;span style="-sec-ix-hidden:c125843393"&gt;eleven&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;and &lt;span style="-sec-ix-hidden:c125843394"&gt;six&lt;/span&gt; customers outside of the United States (i.e., European and Asian customers) that accounted for&#160;approximately&#160;$1,526,000&#160;or 43.7% and&#160;&lt;/span&gt;&lt;/span&gt;$537,000&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;or&#160;&lt;/span&gt;&lt;/span&gt;18.5%&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;of total revenue, respectively.&#160;As of&#160;&lt;/span&gt;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#160;had &lt;span style="-sec-ix-hidden:c125843400"&gt;four&lt;/span&gt; and&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-hidden:c125843401"&gt;six&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;customers outside of the United States (i.e., European and Asian customers) that accounted for approximately $146,000 or 61.5% and&#160;&lt;/span&gt;&lt;/span&gt;$213,000&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;or &lt;/span&gt;&lt;/span&gt;45.6%&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;of&#160;accounts receivable, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company uses CROs&#160;to conduct its research projects and manage its clinical trial. For&#160;the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;span style="-sec-ix-hidden:c125843407"&gt;two&lt;/span&gt; and &lt;span style="-sec-ix-hidden:c125843408"&gt;three&lt;/span&gt; CROs&#160;accounted for approximately $2,389,000&#160;or 93.0% and $4,644,000&#160;or 96.0%&#160;of total research serv&lt;/span&gt;ices we purchased, respectively. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;span style="-sec-ix-hidden:c125843413"&gt;two&lt;/span&gt;&#160;CROs accounted for approximately&#160;$284,000 or 58.9%&#160;of ac&lt;/span&gt;counts payable. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;span style="-sec-ix-hidden:c125843416"&gt;three&lt;/span&gt;&#160;CROs accounted for approximately&#160;$620,000 or 94.4%&#160;of accounts payable. The loss of business from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of these CROs or a combination of them could adversely affect the Company's operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember"
      decimals="INF"
      id="c125843387"
      unitRef="USD">1915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember"
      decimals="3"
      id="c125843388"
      unitRef="Pure">0.548</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember"
      decimals="INF"
      id="c125843389"
      unitRef="USD">1503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoSignificantCustomersMember"
      decimals="3"
      id="c125843390"
      unitRef="Pure">0.519</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ElevenSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c125843395"
      unitRef="USD">1526000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ElevenSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"
      decimals="3"
      id="c125843396"
      unitRef="Pure">0.437</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c125843397"
      unitRef="USD">537000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"
      decimals="3"
      id="c125843398"
      unitRef="Pure">0.185</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-FourSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c125843402"
      unitRef="USD">146000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-FourSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"
      decimals="3"
      id="c125843403"
      unitRef="Pure">0.615</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"
      decimals="INF"
      id="c125843404"
      unitRef="USD">213000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-SixSignificantCustomersMember_StatementGeographicalAxis-NonUsMember"
      decimals="3"
      id="c125843405"
      unitRef="Pure">0.456</us-gaap:ConcentrationRiskPercentage1>
    <dyai:ResearchServicesPurchased
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"
      decimals="INF"
      id="c125843409"
      unitRef="USD">2389000</dyai:ResearchServicesPurchased>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"
      decimals="2"
      id="c125843410"
      unitRef="Pure">0.93</us-gaap:ConcentrationRiskPercentage1>
    <dyai:ResearchServicesPurchased
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember"
      decimals="INF"
      id="c125843411"
      unitRef="USD">4644000</dyai:ResearchServicesPurchased>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-ContractResearchOrganizationsMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-ThreeCROsMember"
      decimals="2"
      id="c125843412"
      unitRef="Pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"
      decimals="INF"
      id="c125843414"
      unitRef="USD">284000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_MajorCustomersAxis-TwoCROsMember"
      decimals="3"
      id="c125843415"
      unitRef="Pure">0.589</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"
      decimals="INF"
      id="c125843417"
      unitRef="USD">620000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-ThreeCROsMember"
      decimals="3"
      id="c125843418"
      unitRef="Pure">0.944</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860110">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;We treat highly liquid investments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.&#160;The Company has no restricted cash balances as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125843422"
      unitRef="USD">0</us-gaap:RestrictedCash>
    <us-gaap:InvestmentPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860111">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Investment Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company&#x2019;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months or less, and long-term investment securities mature over &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months from the applicable reporting date. Management determines the appropriate classification of each investment&#160;at the time of purchase and reevaluates the classifications at each balance sheet date.&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company classifies its&#160;investments in debt securities as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow.&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the Company will be required to sell the investment before recovery of the investment&#x2019;s cost basis. The Company measures expected credit losses on held to maturity debt securities on an individual security basis. The estimate of expected credit losses considers historical credit information from external sources. The impairment of the investment that is related to the credit loss, if any,&#160;is expensed in the period in which the event or change occurred.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, all of our money market funds were invested in U.S. Government money market funds. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any investment securities classified as trading as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="d_2024-01-01_2024-12-31" id="c125860112">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.&lt;/p&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company&#x2019;s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances&#160;and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company&#x2019;s evaluation of current and expected future economic conditions and changes in our customer collection trends. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;em style="font: inherit;"&gt;12&lt;/em&gt;) months. Management determined that&#160;no allowance for credit losses was required as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;.&lt;/p&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accounts receivable consist of the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Billed receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;173,993&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;410,617&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unbilled receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,034&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55,542&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;237,027&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;466,159&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125843434"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877260">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Billed receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;173,993&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;410,617&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unbilled receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,034&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55,542&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;237,027&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;466,159&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="INF"
      id="c125842849"
      unitRef="USD">173993</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2023-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="INF"
      id="c125842850"
      unitRef="USD">410617</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="INF"
      id="c125842851"
      unitRef="USD">63034</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2023-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="INF"
      id="c125842852"
      unitRef="USD">55542</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842853"
      unitRef="USD">237027</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842854"
      unitRef="USD">466159</us-gaap:AccountsReceivableNetCurrent>
    <dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860113">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Prepaid Expenses and Other Current Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;182,270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;209,888&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid expenses - various&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;117,560&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;117,887&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,236&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877261">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;182,270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;209,888&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid expenses - various&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;117,560&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;117,887&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,236&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842859"
      unitRef="USD">182270</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842860"
      unitRef="USD">209888</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842861"
      unitRef="USD">117560</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842862"
      unitRef="USD">117887</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidTaxes
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842863"
      unitRef="USD">3236</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842864"
      unitRef="USD">0</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842865"
      unitRef="USD">303066</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842866"
      unitRef="USD">327775</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <dyai:AccountsPayablePolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860114">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accounts payable consist of the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;340,698&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;575,436&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;68,420&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,957&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;73,202&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;79,052&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </dyai:AccountsPayablePolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877262">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;340,698&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;575,436&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;68,420&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,957&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;73,202&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;79,052&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <dyai:ResearchAndDevelopmentInProcessCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842871"
      unitRef="USD">340698</dyai:ResearchAndDevelopmentInProcessCurrent>
    <dyai:ResearchAndDevelopmentInProcessCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842872"
      unitRef="USD">575436</dyai:ResearchAndDevelopmentInProcessCurrent>
    <dyai:LegalExpensesPayableCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842873"
      unitRef="USD">68420</dyai:LegalExpensesPayableCurrent>
    <dyai:LegalExpensesPayableCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842874"
      unitRef="USD">1957</dyai:LegalExpensesPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842875"
      unitRef="USD">73202</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842876"
      unitRef="USD">79052</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842877"
      unitRef="USD">482320</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842878"
      unitRef="USD">656445</us-gaap:AccountsPayableCurrent>
    <dyai:AccruedExpensesPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860115">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee wages and benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;496,905&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;561,720&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;437,196&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;274,080&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;210,004&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,360&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,360&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;970,462&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,057,164&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;</dyai:AccruedExpensesPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877263">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee wages and benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;496,905&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;561,720&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;437,196&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;274,080&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Legal expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;210,004&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,360&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,360&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;970,462&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,057,164&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842883"
      unitRef="USD">496905</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842884"
      unitRef="USD">561720</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <dyai:AccruedResearchAndDevelopmentInProcessCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842885"
      unitRef="USD">437196</dyai:AccruedResearchAndDevelopmentInProcessCurrent>
    <dyai:AccruedResearchAndDevelopmentInProcessCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842886"
      unitRef="USD">274080</dyai:AccruedResearchAndDevelopmentInProcessCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842887"
      unitRef="USD">25000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842888"
      unitRef="USD">210004</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842889"
      unitRef="USD">11360</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842890"
      unitRef="USD">11360</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842891"
      unitRef="USD">970462</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842892"
      unitRef="USD">1057164</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860116">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; products approved for sale. All our revenue to date has been research revenue from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party collaborations and government grants, as well as revenue from sublicensing&#160;agreements and collaborative arrangements, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include upfront payments,&#160;options to obtain a license, payment for research and development services,&#160;milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest).&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&lt;i&gt;Revenue related to research collaborations and agreements:&lt;/i&gt;&#160;The Company typically&#160;performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the &lt;em style="font: inherit;"&gt;5&lt;/em&gt;-step process outlined in ASC Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; (&#x201c;Topic &lt;em style="font: inherit;"&gt;606&#x201d;&lt;/em&gt;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; to measure the progress toward complete satisfaction of a performance obligation.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Under the input method, revenue will be recognized based on the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="background-color:#ffffff;"&gt;Revenue related to grants: &lt;/span&gt;&lt;/i&gt;&lt;span style="background-color:#ffffff;"&gt;T&lt;/span&gt;he Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive&#160;grants&#160;from governments, agencies, and other private and &lt;em style="font: inherit;"&gt;not&lt;/em&gt;-for-profit organizations. These grants are intended to be used to partially or fully fund the Company&#x2019;s research collaborations&lt;span style="background-color:#ffffff;"&gt;.&lt;/span&gt; However, most, if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; all, of such potential grant revenues, when&#160;received, is expected to be earmarked for &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties to advance the research required, including preclinical and clinical trials.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;Revenue related to sublicensing agreements: &lt;/i&gt;If the sublicense to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;Customer options: &lt;/i&gt;If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate&#160;if such&#160;options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="background-color:#ffffff;"&gt;Milestone payments: &lt;/span&gt;&lt;/i&gt;&lt;span style="background-color:#ffffff;"&gt;At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#x2019;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;i&gt;Royalties: &lt;/i&gt;With respect to licenses deemed to be the predominant item to which the&lt;i&gt; &lt;/i&gt;sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all&#160;the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognized any royalty revenue resulting from any of its sublicensing arrangements.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;We invoice customers based on our contractual arrangements with each customer, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860117">&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. The Company does&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;recognize leases with terms of&#160;&lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;&#160;months or less on the balance sheet. Options to extend or terminate a lease are&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;included in the Company&#x2019;s initial lease term assessment, unless there is&#160;reasonable&#160;certainty that the Company will exercise any such option. Leases are classified as either finance leases or operating leases based on criteria in Accounting Standards Codification (&#x201c;ASC&#x201d;)&#160;&lt;em style="font: inherit;"&gt;842.&lt;/em&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For operating leases, right-of-use assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses an estimated rate of interest that they would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating lease right-of-use asset also includes any lease payments made and excludes any lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s&#160;prior lease for its corporate headquarters located at&#160;&lt;em style="font: inherit;"&gt;140&lt;/em&gt;&#160;Intracoastal Pointe Dr. expired on&#160;&lt;em style="font: inherit;"&gt; August 31, 2023,&#160;&lt;/em&gt;and there was&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;right-of-use asset or lease liability recognized for this lease due to its short-term nature. In&#160;&lt;em style="font: inherit;"&gt; August&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2023,&lt;/em&gt;&#160;the Company entered into a new lease (&lt;em style="font: inherit;"&gt;&#x201c;1044&lt;/em&gt;&#160;N Lease&#x201d;) for&#160;office space for its new corporate headquarters located at&#160;&lt;em style="font: inherit;"&gt;1044&lt;/em&gt;&#160;N US&#160;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt;&#160;Jupiter, Florida, commencing&#160;&lt;em style="font: inherit;"&gt; September 1, 2023 (&lt;/em&gt;&#x201c;Commencement Date&#x201d;) and expiring&#160;on &lt;em style="font: inherit;"&gt; August 31, 2026. &lt;/em&gt;Rent is subject to &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;percent (3%) annual increases, and the Company is responsible for certain common area maintenance charges and taxes throughout the life of the&#160;&lt;em style="font: inherit;"&gt;1044&lt;/em&gt;&#160;N Lease. The&#160;&lt;em style="font: inherit;"&gt;1044&lt;/em&gt;&#160;N Lease has an initial term of&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;(3) years, following the Commencement Date with an option to extend for&#160;&lt;em style="font: inherit;"&gt;two&lt;/em&gt;&#160;(2) successive&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;(1) year terms. The options were&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;included in the lease term used in determining the right-of-use asset or lease liability as the Company did&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;consider it reasonably certain they would exercise the options.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For&lt;span style="background-color:#ffffff;"&gt; the years ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s total operating lease expense was&#160;&lt;/span&gt;$106,785&#160;and $71,656, &lt;span style="background-color:#ffffff;"&gt;respectively. As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s total operating lease liabilities was $&lt;/span&gt;88,870, &lt;span style="background-color:#ffffff;"&gt;which is presented net of imputed interest o&lt;/span&gt;f $6,669, and the&#160;oper&lt;span style="background-color:#ffffff;"&gt;ating lease right-of-use&#160;asset was&#160;&lt;/span&gt;$92,211.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company&#x2019;s total operating lease liabilities was $136,929, which is presented net of imputed interest of $16,770, and the operating lease right-of-use asset was $141,439.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff"&gt;, the &lt;/span&gt;weighted average remaining lease term was&#160;1.7&#160;years, and the weighted average discount rate was 8.8%.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <dyai:LesseeOperatingLeaseYearlyPercentageIncrease
      contextRef="d_2023-08-01_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember"
      decimals="2"
      id="c125843465"
      unitRef="Pure">0.03</dyai:LesseeOperatingLeaseYearlyPercentageIncrease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember"
      id="c125843469">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dyai:LesseeOperatingLeaseAdditionalNumberOfRenewalTerms
      contextRef="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember"
      decimals="INF"
      id="c125843471"
      unitRef="Pure">2</dyai:LesseeOperatingLeaseAdditionalNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember"
      id="c125843473">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843477"
      unitRef="USD">106785</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843478"
      unitRef="USD">71656</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843479"
      unitRef="USD">88870</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843480"
      unitRef="USD">6669</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843481"
      unitRef="USD">92211</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843482"
      unitRef="USD">136929</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843483"
      unitRef="USD">16770</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843484"
      unitRef="USD">141439</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2024-12-31" id="c125843485">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2024-12-31"
      decimals="3"
      id="c125860141"
      unitRef="Pure">0.088</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2024-01-01_2024-12-31" id="c125860118">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. R&amp;amp;D costs are related to the Company&#x2019;s internally funded pharmaceutical programs and other governmental and commercial projects.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; were as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outside contracted services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,503,397&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,677,941&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Personnel related costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;473,444&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;553,741&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Facilities, overhead and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;67,412&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;65,584&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877264">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outside contracted services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,503,397&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,677,941&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Personnel related costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;473,444&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;553,741&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Facilities, overhead and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;67,412&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;65,584&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock>
    <dyai:ResearchAndDevelopmentExpenseOutsideContractedServices
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125842897"
      unitRef="USD">1503397000</dyai:ResearchAndDevelopmentExpenseOutsideContractedServices>
    <dyai:ResearchAndDevelopmentExpenseOutsideContractedServices
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125842898"
      unitRef="USD">2677941000</dyai:ResearchAndDevelopmentExpenseOutsideContractedServices>
    <dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125842899"
      unitRef="USD">473444000</dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts>
    <dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125842900"
      unitRef="USD">553741000</dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts>
    <dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125842901"
      unitRef="USD">67412000</dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther>
    <dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125842902"
      unitRef="USD">65584000</dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther>
    <dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125842903"
      unitRef="USD">2044253000</dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty>
    <dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125842904"
      unitRef="USD">3297266000</dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860119">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Transaction Gain or Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure&#160;the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860120">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into &lt;em style="font: inherit;"&gt;three&lt;/em&gt; levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:18pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:18pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:18pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; font-size: 10pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company&#x2019;s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities,&#160;approximates fair value due to the short-term maturities of these instruments. The Company&#x2019;s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party broker service for disclosure purposes.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860121">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#x2019;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; some portion or all the deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;In determining taxable income for the Company&#x2019;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#x2019;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company is required to evaluate the provisions of ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt; related to the accounting for uncertainty in income taxes recognized in a company&#x2019;s financial statements. ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt; prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-&lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#x201c;unrecognized benefits.&#x201d; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#x2019;s potential future obligation to the taxing authority for a tax position that was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognized as a result of applying the provision of ASC &lt;em style="font: inherit;"&gt;740.&lt;/em&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860122">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="background-color:#ffffff;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#x2019; equity but are excluded from net income (loss) under U.S. GAAP. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separately present a statement of comprehensive income (loss) in its consolidated financial statements.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2024-01-01_2024-12-31" id="c125860123">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;We recognize all share-based payments to employees, consultants, and our Board of Directors (the &#x201c;Board&#x201d;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860124">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock, restricted stock units and convertible debt, were exercised and&#160;converted into common stock, calculated by applying the treasury stock method.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;For the years ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the effect of the potential exercise of options to purchase&#160;&lt;/span&gt;5,788,597&lt;span style="background-color:#ffffff;"&gt;&#160;and &lt;/span&gt;5,469,247&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c125843506"
      unitRef="Share">5788597</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c125843507"
      unitRef="Share">5469247</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125860125">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;New and Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (the &#x201c;ASU&#x201d;) &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; &#x2013; Segment Reporting (Topic ASC &lt;em style="font: inherit;"&gt;280&lt;/em&gt;), or ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosure about significant segment expenses. The enhancements under this update require disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and included within each reported measure of segment profit or loss, require disclosure of &lt;i&gt;other segment items &lt;/i&gt;by reportable segment and a description of the composition of &lt;i&gt;other segment items&lt;/i&gt;, require annual disclosures under ASC &lt;em style="font: inherit;"&gt;280&lt;/em&gt; to be provided in interim periods, clarify use of more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; measure of segment profit or loss by the CODM, require that the title of the CODM be disclosed with an explanation of how the CODM uses the reported measures of segment profit or loss to make decisions, and require that entities with a single reportable segment provide all disclosures required by this update and required under ASC &lt;em style="font: inherit;"&gt;280.&lt;/em&gt; ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; is effective for public business entities for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;and interim periods within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;The Company adopted ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; and applied the guidance retrospectively to all periods presented in the consolidated financial statements.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; &#x2013; Income Taxes (Topic ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;) Income Taxes. The ASU improves the transparency of income tax disclosures by requiring (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) consistent categories and greater disaggregation of information in the rate reconciliation and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; will become effective beginning with our &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; fiscal year. We do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect that this guidance will have a material impact on our financial position and our results of operations.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877265">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2:&lt;/em&gt;&#160;&#160;&#160;&#160;&#160;Cash, Cash Equivalent, and Investments &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company&#x2019;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost,&#160;net of allowance for credit losses, and its investments in money market funds are classified as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. The following table shows the Company&#x2019;s cash, available-for-sale securities, and investment securities by major security type as&#160;of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Adjusted Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;926,287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;926,287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money Market Funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,580,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,580,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,506,750&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,506,750&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Short-Term Investment Securities &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate Bonds &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,756,428&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(149&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,756,577&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,263,178&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(149&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,263,327&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2023&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" rowspan="1" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Adjusted Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;25,775&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;25,775&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money Market Funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,489,253&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,489,253&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,515,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,515,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Short-Term Investment Securities &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate Bonds &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;748,105&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(185&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;748,290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,263,133&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(185&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,263,318&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Notes:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Definition of the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-level fair value hierarchy:&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:14pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Quoted prices (unadjusted) in active markets for identical assets or liabilities&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:14pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Other inputs that are directly or indirectly observable in the markets&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:14pt;vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; - Inputs that are generally unobservable&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) Short-term investment securities will mature within &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months or less, from the applicable reporting date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) For the&#160;years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;,&#160;the Company received discounts of&lt;span style="background-color:#ffffff;"&gt;$78,770&#160;and $39,012 to purchase held-to-maturity investment securities,&#160;&lt;/span&gt;respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The Company considers declines in market value of its investment portfolio to be temporary in nature. The Company&#x2019;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the Company will be required to sell the investment before recovery of the investment&#x2019;s cost basis. As of &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consider any of its investments to be other-than-temporarily impaired.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;


  </us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="d_2024-01-01_2024-12-31"
      id="BC338F45-26BE-4997-AEB0-8547E4EAA83C">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Adjusted Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;926,287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;926,287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money Market Funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,580,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,580,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,506,750&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,506,750&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Short-Term Investment Securities &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate Bonds &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,756,428&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(149&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,756,577&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,263,178&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(149&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,263,327&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2023&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" rowspan="1" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Holding Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Adjusted Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;25,775&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;25,775&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money Market Funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,489,253&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,489,253&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,515,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,515,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Short-Term Investment Securities &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate Bonds &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;748,105&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(185&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;748,290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,263,133&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(185&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,263,318&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByAssetClassAxis-CashMember"
      decimals="INF"
      id="c125842926"
      unitRef="USD">926287</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842929"
      unitRef="USD">926287</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="INF"
      id="c125842931"
      unitRef="USD">5580463</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842934"
      unitRef="USD">5580463</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842936"
      unitRef="USD">6506750</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842939"
      unitRef="USD">6506750</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c125842941"
      unitRef="USD">2756428</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c125842942"
      unitRef="USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c125842943"
      unitRef="USD">149</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i_2024-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c125842944"
      unitRef="USD">2756577</us-gaap:HeldToMaturitySecurities>
    <dyai:CashCashEquivalentsAndInvestmentsFairValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842946"
      unitRef="USD">9263178</dyai:CashCashEquivalentsAndInvestmentsFairValue>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842947"
      unitRef="USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842948"
      unitRef="USD">149</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:InvestmentsAndCash
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842949"
      unitRef="USD">9263327</us-gaap:InvestmentsAndCash>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-12-31_FairValueByAssetClassAxis-CashMember"
      decimals="INF"
      id="c125842973"
      unitRef="USD">25775</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842976"
      unitRef="USD">25775</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="INF"
      id="c125842978"
      unitRef="USD">6489253</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842981"
      unitRef="USD">6489253</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842983"
      unitRef="USD">6515028</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842986"
      unitRef="USD">6515028</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c125842988"
      unitRef="USD">748105</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c125842989"
      unitRef="USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c125842990"
      unitRef="USD">185</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i_2023-12-31_FairValueByAssetClassAxis-ShortTermCorporateBondsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="INF"
      id="c125842991"
      unitRef="USD">748290</us-gaap:HeldToMaturitySecurities>
    <dyai:CashCashEquivalentsAndInvestmentsFairValue
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842993"
      unitRef="USD">7263133</dyai:CashCashEquivalentsAndInvestmentsFairValue>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842994"
      unitRef="USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842995"
      unitRef="USD">185</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:InvestmentsAndCash
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125842996"
      unitRef="USD">7263318</us-gaap:InvestmentsAndCash>
    <dyai:DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount
      contextRef="d_2024-01-01_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="INF"
      id="c125843541"
      unitRef="USD">78770</dyai:DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount>
    <dyai:DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount
      contextRef="d_2023-01-01_2023-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="INF"
      id="c125843542"
      unitRef="USD">39012</dyai:DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877268">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&#160;&#160;&#160;&#160;&#160;Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 17pt;"&gt;&lt;b&gt;&lt;i&gt;Gates Foundation Grant&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2024, &lt;/em&gt;Bill &amp;amp; Melinda Gates Foundation (the &#x201c;Gates Foundation&#x201d;) awarded the Company a grant in the amount of $3,092,136 for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company&#x2019;s &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; platform to provide globally accessible treatment options for underserved populations (the &#x201c;Gates Foundation Grant&#x201d;).&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2024,&#160;&lt;/em&gt;the Company received approximately $0.8 million of the Gates Foundation Grant, and the remaining award will be received in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2026&lt;/em&gt; in the amount of approximately $1.5 million and $0.7 million, respectively. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company has &lt;span style="-sec-ix-hidden:c125843554"&gt;not&lt;/span&gt; recognized any research and development revenue, in connection with the Gates Foundation Grant.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"&gt;&lt;b&gt;&lt;i&gt;Proliant&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; June 27, 2024&lt;/em&gt;&lt;i&gt;,&lt;/i&gt;&#160;the Company entered into a License and Development Agreement (the &#x201c;Proliant Agreement&#x201d;) with Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals (&#x201c;Proliant&#x201d;), pursuant to which, Proliant will license Dyadic&#x2019;s proprietary fungal microbial expression and production platforms and microbial strains for the production of recombinant serum albumin, for an initial period of 10 years with an option to extend for an additional 3 years under certain circumstances. &#160;Under the terms of the Proliant Agreement, Dyadic has received an initial upfront payment of $500,000, a&#160;&lt;em style="font: inherit;"&gt;second&lt;/em&gt;&#160;payment of $500,000 for&#160;completing&#160;the transfer of a Production Strain (as defined in the Proliant Agreement) and will receive a final payment of $500,000&#160;upon the meeting of a certain productivity threshold. Upon commencing commercial sales of&#160;animal-free recombinant serum albumin products produced pursuant to the Proliant Agreement, the Company will receive royalties based on a certain percentage of the gross margin received by Proliant, as defined in the Proliant Agreement.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;For the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, the Company recognized a total of $1.0&#160;million in license revenue&#160;related to the Proliant Agreement, as the performance obligations&#160;for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; and &lt;em style="font: inherit;"&gt;second&lt;/em&gt; payments have been satisfied.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"&gt;&lt;b&gt;&lt;i&gt;Inzymes ApS&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; September 18, 2023, &lt;/em&gt;Dyadic International (USA) Inc., a subsidiary of the Company, signed a Development and Exclusive License Agreement (the &#x201c;Inzymes Agreement&#x201d;) with Inzymes ApS (&#x201c;Inzymes&#x201d;), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic&#x2019;s proprietary Dapibus&#x2122; platform. In &lt;em style="font: inherit;"&gt; October 2023, &lt;/em&gt;the Company received an upfront payment of $0.6 million in accordance with the terms of the Inzymes Agreement.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; October 11, 2024, &lt;/em&gt;the Inzymes Agreement was amended (&#x201c;the Amended Inzymes Agreement&#x201d;) to&#160;change the scope of research and development services required under the agreement as well as adjust the success fees&#160;upon the achievement of certain target yields, milestone payments upon &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of each product and royalties.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;For the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, the Company has completed all product research and development services and satisfied all related performance obligations under the Amended Inzymes Agreement, and recognized $890,169 in license revenues, including success fees upon the achievement of target yield of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; related product. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company also recognized research and development revenues of $25,000 related to the Amended Inzymes Agreement.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company will continue evaluating the achievement of milestones related to target yields and product commercialization of each product when they are considered probable and estimable under the Inzymes Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;"&gt;&lt;b&gt;&lt;i&gt;A Global Food Ingredient&lt;/i&gt;&lt;/b&gt;&#160;&lt;b&gt;&lt;i&gt;Company&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; May 10, 2022, &lt;/em&gt;the Company entered into a Joint Development Agreement (the &#x201c;JDA&#x201d;) with a Global Food Ingredient Company (&#x201c;GFIC&#x201d;) to develop and manufacture several&#160;animal free ingredient products using the Company&#x2019;s biotechnologies.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Under&#160;the initial terms of the JDA, Dyadic was to develop its proprietary production cell lines for the manufacture of animal free ingredient product candid&lt;span style="background-color:#ffffff;"&gt;ates. As of &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;th&lt;/span&gt;e GFIC has completed its &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-year funding commitment for the initial phase of research collaboration in an amount approximatin&lt;span style="background-color:#ffffff;"&gt;g&#160;&lt;em style="font: inherit;"&gt;$1.35&lt;/em&gt; million, and, pu&lt;/span&gt;rsuant to the GFIC&#x2019;s rights under the JDA, the Company and&#160;the GFIC are conferring to decide whether or &lt;em style="font: inherit;"&gt;not,&lt;/em&gt; and if it is possible, to&#160;move forward to the next phase of the proj&lt;span style="background-color:#ffffff;"&gt;ect. The Company is also considering other funding sources to continue the project.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;For the years ended&lt;span style="background-color:#ffffff"&gt;&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, the Company recorded research and development revenues, including milestone payments, of&#160;&lt;span style="background-color:#ffffff;"&gt;$0 and &lt;/span&gt;approximately &lt;span style="background-color:#ffffff;"&gt;$631,000, respectively, in c&lt;/span&gt;onnection with the&#160;JDA.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;"&gt;&lt;i&gt;&lt;b&gt;Janssen&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; text-indent: 18pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; text-indent: 36pt; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; December 16, 2021, &lt;/em&gt;the Company entered&#160;a Research, License, and Collaboration Agreement (the &#x201c;Janssen Agreement&#x201d;) for the manufacture of therapeutic protein candidates using its &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; platform with Janssen Biotech, Inc., &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson (&#x201c;Janssen&#x201d;).&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;On &lt;em style="font: inherit;"&gt; October 2, 2023, &lt;/em&gt;Janssen provided written notice to Dyadic that it has decided to wind down the collaboration with an effective end date of &lt;em style="font: inherit;"&gt; December 31, 2023.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;,&#160;&lt;/span&gt;there were no revenues related to the Janssen Agreement. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company recognized approximately $353,000 in license revenue and approximately $520,000 in research and development revenues in connection with the Janssen Agreement.&lt;span style="background-color:#ffffff;"&gt;&#160;As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, $0&lt;/span&gt;&lt;span style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;an&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;d approximately $145,000&#160;of&#160;accounts receivable&#160;were related to Janssen, respectively.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Alphazyme&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="text-align: left; margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; the Company entered into a sub-licensing agreement with Alphazyme, LLC (&#x201c;Alphazyme&#x201d;) that was subsequently amended (the &#x201c;Amended Alphazyme LLC Agreement&#x201d;). Under the Amended Alphazyme LLC Agreement,&#160;Alphazyme obtained additional capital contribution&#160;and Dyadic&#x2019;s ownership was diluted to 1.99%.&#160;&lt;/p&gt;
   &lt;p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the primary beneficiary of Alphazyme as Dyadic does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consolidate its investment&#160;in Alphazyme. The Company reports&#160;its investment in Alphazyme under the cost method of accounting, given that it does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the ability to exercise significant influence or control over Alphazyme.&#160;&lt;/p&gt;
   &lt;p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 18, 2023, &lt;/em&gt;the Company entered into a Securities Purchase Agreement, under which the Company agreed to sell its equity interest in Alphazyme, LLC (the &#x201c;Alphazyme Sale Agreement&#x201d;). The Company continues to have&#160;the potential to receive additional payments based on the future sales of Alphazyme&#x2019;s existing products, pursuant to the Alphazyme Sale Agreement.&lt;/p&gt;
   &lt;p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;The Amended Sublicense Agreement between Dyadic and Alphazyme, which was previously entered on &lt;em style="font: inherit;"&gt; June 24, 2020, &lt;/em&gt;remains in effect. Under the Amended Alphazyme Sub-License Agreement, Dyadic is entitled to potential milestone and royalty payments upon the commercialization of Alphazyme products using Dyadic&#x2019;s proprietary &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; platform.&#160;&lt;/p&gt;
   &lt;p style="text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;For the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;there were no revenues related to Alphazyme. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company recognized a total revenue of approximately $1.3 million from the sale of its equity interest in Alphazyme, LLC.&lt;/p&gt;
  </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2024-11-30_CounterpartyNameAxis-GatesFoundationMember"
      decimals="INF"
      id="c125843547"
      unitRef="USD">3092136</us-gaap:AccountsReceivableNet>
    <dyai:ProceedsFromGrant
      contextRef="d_2024-12-01_2024-12-31_CounterpartyNameAxis-GatesFoundationMember"
      decimals="-5"
      id="c125843549"
      unitRef="USD">800000</dyai:ProceedsFromGrant>
    <dyai:ProceedsFromGrant
      contextRef="d_2025-01-01_2025-12-31_CounterpartyNameAxis-GatesFoundationMember_StatementScenarioAxis-ScenarioForecastMember"
      decimals="-5"
      id="c125843552"
      unitRef="USD">1500000</dyai:ProceedsFromGrant>
    <dyai:ProceedsFromGrant
      contextRef="d_2026-01-01_2026-12-31_CounterpartyNameAxis-GatesFoundationMember_StatementScenarioAxis-ScenarioForecastMember"
      decimals="-5"
      id="c125843553"
      unitRef="USD">700000</dyai:ProceedsFromGrant>
    <dyai:LicenseAndDevelopmentInitialTerm
      contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember"
      id="c125843555">P10Y</dyai:LicenseAndDevelopmentInitialTerm>
    <dyai:LicenseAndDevelopmentExtensionTerm
      contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember"
      id="c125843556">P3Y</dyai:LicenseAndDevelopmentExtensionTerm>
    <dyai:InitialUpFrontPayment
      contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember"
      decimals="INF"
      id="c125843557"
      unitRef="USD">500000</dyai:InitialUpFrontPayment>
    <dyai:SecondPaymentUponCompletionTransfer
      contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember"
      decimals="INF"
      id="c125843559"
      unitRef="USD">500000</dyai:SecondPaymentUponCompletionTransfer>
    <dyai:FinalPaymentUponMeetingCertainProductivityThreshold
      contextRef="i_2024-06-27_CounterpartyNameAxis-ProliantAgreementMember"
      decimals="INF"
      id="c125843560"
      unitRef="USD">500000</dyai:FinalPaymentUponMeetingCertainProductivityThreshold>
    <dyai:DeferredLicenseRevenue
      contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-ProliantAgreementMember"
      decimals="-6"
      id="c125843561"
      unitRef="USD">1000000</dyai:DeferredLicenseRevenue>
    <dyai:NonrefundableUpfrontPaymentReceived
      contextRef="d_2023-10-05_2023-10-05_CounterpartyNameAxis-InzymesAgreementApsMember"
      decimals="-5"
      id="c125843564"
      unitRef="USD">600000</dyai:NonrefundableUpfrontPaymentReceived>
    <dyai:DeferredLicenseRevenue
      contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-InzymesAgreementApsMember"
      decimals="INF"
      id="c125843566"
      unitRef="USD">890169</dyai:DeferredLicenseRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-InzymesAgreementApsMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"
      decimals="INF"
      id="c125843568"
      unitRef="USD">25000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-AGlobalFoodIngredientCompanyMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"
      decimals="-3"
      id="c125843574"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31_CounterpartyNameAxis-AGlobalFoodIngredientCompanyMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"
      decimals="INF"
      id="c125843575"
      unitRef="USD">631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember"
      decimals="-3"
      id="c125843578"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dyai:DeferredLicenseRevenue
      contextRef="d_2023-01-01_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember"
      decimals="INF"
      id="c125843579"
      unitRef="USD">353000</dyai:DeferredLicenseRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember_ProductOrServiceAxis-ResearchAndDevelopmentMember"
      decimals="INF"
      id="c125843580"
      unitRef="USD">520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2024-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember"
      decimals="-3"
      id="c125843582"
      unitRef="USD">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2023-12-31_CounterpartyNameAxis-JanssenPharmaceuticalCompaniesMember"
      decimals="INF"
      id="c125843583"
      unitRef="USD">145000</us-gaap:AccountsReceivableNet>
    <dyai:OwnershipPercentage
      contextRef="i_2020-12-01_OwnershipAxis-AlphazymeMember"
      decimals="4"
      id="c125843585"
      unitRef="Pure">0.0199</dyai:OwnershipPercentage>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="d_2024-01-01_2024-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember"
      decimals="-3"
      id="c125843592"
      unitRef="USD">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="d_2023-01-01_2023-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AlphazymeMember"
      decimals="-5"
      id="c125843593"
      unitRef="USD">1300000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877269">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4:&lt;/em&gt;&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Jupiter&#160;Florida Headquarters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In&#160;&lt;em style="font: inherit;"&gt; August&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2023,&lt;/em&gt;&#160;the Company entered into a new lease comprising approximately&#160;1,719&#160;square feet of office space located at&#160;&lt;em style="font: inherit;"&gt;1044&lt;/em&gt;&#160;N US&#160;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt;&#160;Jupiter, Florida, commencing&#160;&lt;em style="font: inherit;"&gt; September 1, 2023,&#160;&lt;/em&gt;and will expire on &lt;em style="font: inherit;"&gt; August 31, 2026. &lt;/em&gt;The Company occupies this space for an annual rental rate of approximately $59,000, excluding common area maintenance expenses.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;The Netherlands Office&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies a flexible office space for an annual rental rate of approximatel&lt;span style="background-color:#ffffff;"&gt;y $4,600. The lease expires on &lt;em style="font: inherit;"&gt; January 31, 2026, &lt;/em&gt;and thereafter, the Company will reconsider the leased space to align with the future operations of the Company.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the future minimum annual lease payments under the operating leases are below. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; future minimum annual lease payments after &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;59,901&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;35,638&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;95,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="text-align: left; text-indent: 18pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:'Times New Roman', Times, serif"&gt;
     &lt;b&gt;&lt;i&gt;&#160; &#160; &#160; &#160;Purchase Obligations&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
   &lt;/div&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Purchase obligations are primarily related to our contracts with the Company&#x2019;s contract research organizations to provide certain research services. The contracts set forth the Company&#x2019;s minimum purchase requirements that are subject to adjustments based on certain performance conditions.&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;span style="background-color:#ffffff"&gt;As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the commitments related to agreements to purchase certain services in the ordinary course of business are below. All current contracts expire in or before &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,134,460&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,429,044&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,563,504&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate.&#160;The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently involved in any litigation that it believes could have a materially adverse effect in our financial condition or results of operations. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#x2019;s consolidated financial position, cash flows or results of operations.&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember"
      decimals="INF"
      id="c125843596"
      unitRef="SquareFoot">1719</us-gaap:AreaOfRealEstateProperty>
    <dyai:OperatingLeasesMonthlyRentalRate
      contextRef="d_2023-08-01_2023-08-31_LeaseContractualTermAxis-The1044NLeaseMember"
      decimals="INF"
      id="c125843599"
      unitRef="USD">59000</dyai:OperatingLeasesMonthlyRentalRate>
    <dyai:OperatingLeasesAnnualRentalRate
      contextRef="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-NetherlandsOfficeLeaseMember"
      decimals="INF"
      id="c125843600"
      unitRef="USD">4600</dyai:OperatingLeasesAnnualRentalRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877270">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;59,901&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;35,638&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;95,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125842999"
      unitRef="USD">59901</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843000"
      unitRef="USD">35638</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843001"
      unitRef="USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843002"
      unitRef="USD">95539</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877271">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,134,460&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,429,044&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,563,504&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843003"
      unitRef="USD">2134460</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843004"
      unitRef="USD">1429044</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843005"
      unitRef="USD">0</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligation
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843006"
      unitRef="USD">3563504</us-gaap:PurchaseObligation>
    <dyai:ConvertibleDebtTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877272">
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note&lt;/b&gt; &lt;b&gt;&lt;em style="font: inherit;"&gt;5:&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160; &lt;b&gt;Convertible Notes&#160;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; March 8, 2024,&#160;&lt;/em&gt;the Company issued senior secured convertible promissory notes (the &#x201c;Convertible Notes&#x201d;) with an aggregate principal amount of $6.0&#160;million, of which,&#160;&lt;span style="-sec-ix-hidden:c125843609"&gt;$2.0&lt;/span&gt;&#160;million were sold to related parties, including immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Convertible Notes are senior, secured obligations of the Company and its affiliates, and interest is payable quarterly in cash on the principal amount equal to&#160;8% per annum, and guaranteed by its subsidiary, Dyadic International (USA), Inc. under a subsidiary guarantee for the benefit of the holders of the Convertible Notes (each such holder, a &#x201c;Holder&#x201d;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Convertible Notes mature on&#160;&lt;em style="font: inherit;"&gt; March 8, 2027,&#160;&lt;/em&gt;unless earlier converted or redeemed in accordance with the terms of the Convertible Notes. The Convertible Notes are secured by a&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;priority lien on substantially all assets of the Company and Dyadic International (USA), Inc.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Convertible Notes are accounted for in accordance with ASC&#160;&lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20,&lt;/em&gt; &lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt;&#160;and ASC&#160;&lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15,&lt;/em&gt; &lt;i&gt;Derivatives and Hedging&lt;/i&gt;. Under ASC&#160;&lt;em style="font: inherit;"&gt;815,&lt;/em&gt;&#160;contracts that are both indexed to its own stock and classified in stockholders&#x2019; equity in its statement of financial position are&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;considered to be derivative instruments. Based on the Company&#x2019;s analysis, it is determined that the Convertible Notes contain embedded features that are indexed to the Company&#x2019;s own stock and are classified in stockholders&#x2019; equity in the Company&#x2019;s statement of financial position, but do&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;meet the requirements for bifurcation and recognition as derivatives, and therefore, do&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;need to be accounted for separately. Accordingly, the proceeds received from the issuance of the Convertible Notes were recorded as a single liability in accordance with ASC&#160;&lt;em style="font: inherit;"&gt;470&lt;/em&gt;&#160;on the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company incurred $175,674&#160;of debt issuance costs associated with the Convertible Notes, which were recorded as a reduction of&#160;the Convertible Notes on the consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Convertible Notes using the effective interest method. We determined the expected life of the debt is equal to the&#160;&lt;span style="-sec-ix-hidden:c125843622"&gt;three&lt;/span&gt;-year term of the Convertible Notes.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; October 4, 2024,&#160;&lt;/em&gt;the Company entered into an amendment (the &#x201c;Amendment&#x201d;) to the Convertible Notes. Under the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company&#x2019;s common stock is $1.40&#160;per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fal&lt;span style="background-color:#ffffff;"&gt;l on any of the&#160;&lt;em style="font: inherit;"&gt;26,&lt;/em&gt;&#160;&lt;em style="font: inherit;"&gt;29&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;32&lt;/em&gt;-month anniversaries of the original issue date of the Convertible Notes&#160;which are &lt;em style="font: inherit;"&gt; May 8, 2026, &lt;/em&gt;&lt;em style="font: inherit;"&gt; August 8, 2026 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; November 8, 2026.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company assessed the Amendment for a debt extinguishment or modification in accordance with ASC &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;50.&lt;/em&gt;&#160;As both the change in the present value of future cash flows of the modified Convertible Notes to that of the original Convertible Notes (including callable features) and the change in fair value of the embedded conversion option to that of the carrying value of the Convertible Notes immediately before modification resulted in a less than&#160;&lt;em style="font: inherit;"&gt;10%&lt;/em&gt; change, the Amendment was deemed &lt;em style="font: inherit;"&gt;not&lt;/em&gt; substantial and is regarded as a note modification. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; incur any gain or loss relating to the modification and any incremental costs related to the Amendment were expensed.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For the year&#160;ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;,&#160;$&lt;span style="background-color:#ffffff;"&gt;257,778&#160;o&lt;/span&gt;f interest was paid and debt issuance costs o&lt;span style="background-color:#ffffff;"&gt;f $63,020&#160;wer&lt;/span&gt;e amortized and recorded in interest expense in the consolidated statements of operations.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, accrued interest&#160;on the Convertible Notes to related parties and other&#160;&lt;em style="font: inherit;"&gt;third&lt;/em&gt;&#160;parties was&#160;&lt;span style="background-color:#ffffff;"&gt;$27,173&#160;and $80,000, respe&lt;/span&gt;ctively. As of &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, accumulated amortized debt issuance costs were $36,376.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; $910,000&#160;of the Convertible Notes were converted into&#160;556,623&#160;shares o&lt;/span&gt;f the Company&#x2019;s common stock. As of &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, convertible notes payable consisted of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Holder&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Issuance Date&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Interest Rate&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Convertible Note &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Principal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Principal Repayments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Conversion to &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Principal Outstanding&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Francisco Trust dated 2/28/1996 (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843007"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843008"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843009"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Bradley Emalfarb (2)&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843014"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843015"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843016"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;(500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Bradley Scott Emalfarb Irrevocable Trust (2)&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843021"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843022"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843023"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;410,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;(410,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Emalfarb Descendent Trust (3)&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843028"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843029"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843030"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;90,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;90,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Convertible Notes - Related Party&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843038"&gt;2,000,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843040"&gt;(910,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843041"&gt;1,090,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Unamortized Debt Issuance Costs - Related Party&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843048"&gt;(24,124&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843055"&gt;1,065,876&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Convertible Notes - Third Party&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843056"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843057"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843058"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843059"&gt;4,000,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843062"&gt;4,000,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Unamortized Debt Issuance Costs - Third Party&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843069"&gt;(88,529&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843076"&gt;3,911,471&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;Notes:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Francisco Trust. Mr. Thomas Emalfarb&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;have therein, directly or indirectly. The amount of accrued interest as of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, is $20,000.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore,&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;have therein, directly or indirectly.&#160;For the year&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, $500,000&#160;of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into&#160;294,891&#160;shares of the Company&#x2019;s common stock. For the year&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, $410,000&#160;of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into 261,732&#160;shares of the Company&#x2019;s common stock. As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the amount of accrued interest for Bradley Emalfarb and&#160;Bradley Scott Emalfarb Irrevocable Trust was $1,733&#160;and $3,640,&#160;respectively.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, are co-trustees of the Descendant Trust and&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Descendant Trust. The amount of accrued interest as of &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, is $1,800.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restri&lt;span style="background-color:#ffffff;"&gt;ctions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;


  </dyai:ConvertibleDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="-6"
      id="c125843608"
      unitRef="USD">6000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c125843610"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i_2024-03-08_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="INF"
      id="c125843621"
      unitRef="USD">175674</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2024-10-04_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="INF"
      id="c125843623"
      unitRef="USDPerShare">1.4</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:InterestPaidNet
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="INF"
      id="c125843633"
      unitRef="USD">257778</us-gaap:InterestPaidNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="INF"
      id="c125843634"
      unitRef="USD">63020</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="INF"
      id="c125843636"
      unitRef="USD">27173</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_RelatedPartyTransactionsByRelatedPartyAxis-ThirdPartyMember"
      decimals="INF"
      id="c125843637"
      unitRef="USD">80000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember"
      decimals="INF"
      id="c125843638"
      unitRef="USD">36376</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember"
      decimals="INF"
      id="c125843641"
      unitRef="USD">910000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember"
      decimals="INF"
      id="c125843642"
      unitRef="Share">556623</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877273">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Holder&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Issuance Date&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Interest Rate&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Convertible Note &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Principal&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Principal Repayments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Conversion to &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Principal Outstanding&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); vertical-align: middle;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Francisco Trust dated 2/28/1996 (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843007"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843008"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843009"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Bradley Emalfarb (2)&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843014"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843015"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843016"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;(500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Bradley Scott Emalfarb Irrevocable Trust (2)&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843021"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843022"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843023"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;410,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;(410,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Emalfarb Descendent Trust (3)&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843028"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843029"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843030"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;90,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;90,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Convertible Notes - Related Party&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843038"&gt;2,000,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843040"&gt;(910,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843041"&gt;1,090,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Unamortized Debt Issuance Costs - Related Party&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843048"&gt;(24,124&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843055"&gt;1,065,876&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Convertible Notes - Third Party&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843056"&gt;03/08/24&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 6%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843057"&gt;03/08/27&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c125843058"&gt;8%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843059"&gt;4,000,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843062"&gt;4,000,000&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Unamortized Debt Issuance Costs - Third Party&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843069"&gt;(88,529&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 27%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 7%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 6%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; text-align: center; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 9%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c125843076"&gt;3,911,471&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember"
      decimals="INF"
      id="c125843010"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember"
      decimals="INF"
      id="c125843013"
      unitRef="USD">1000000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"
      decimals="INF"
      id="c125843017"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"
      decimals="INF"
      id="c125843019"
      unitRef="Share">500000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyEmalfarbMember"
      decimals="INF"
      id="c125843020"
      unitRef="USD">0</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843024"
      unitRef="USD">410000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843026"
      unitRef="Share">410000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843027"
      unitRef="USD">0</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-DescendantTrustMember"
      decimals="INF"
      id="c125843031"
      unitRef="USD">90000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i_2024-12-31_DebtInstrumentAxis-DescendantTrustMember"
      decimals="INF"
      id="c125843034"
      unitRef="USD">90000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFranciscoTrustMember_TitleOfIndividualAxis-MrThomasEmalfarbMember"
      decimals="INF"
      id="c125843644"
      unitRef="USD">20000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843646"
      unitRef="USD">500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843647"
      unitRef="Share">294891</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843648"
      unitRef="USD">410000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843649"
      unitRef="Share">261732</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-SeniorSecured2024NotesMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843650"
      unitRef="USD">1733</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-BradleyScottEmalfarbMember"
      decimals="INF"
      id="c125843651"
      unitRef="USD">3640</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-IrrevocableTrustMember_TitleOfIndividualAxis-ThomasEmalfarbScottEmalfarbAndMichaelEmalfarbMember"
      decimals="INF"
      id="c125843653"
      unitRef="USD">1800</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877274">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6:&lt;/em&gt;&#160;&#160;&#160;&#160;&#160;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Description of Equity Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Equity Incentive Award Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2021&lt;/em&gt; Plan&#x201d;) was adopted by the Company's Board of Directors on &lt;em style="font: inherit;"&gt; April 9, 2021,&#160;&lt;/em&gt;and approved&#160;by the Company&#x2019;s&#160;Annual Meeting of Shareholders (the &#x201c;Annual Meeting&#x201d;) on &lt;em style="font: inherit;"&gt; June 11, 2021. &lt;/em&gt;The &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan serves as a successor to the Company&#x2019;s &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Equity Incentive Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2011&lt;/em&gt; Plan&#x201d;).&#160;Since the adoption of the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan, all equity awards were made from the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional awards will be granted under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan. The &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan provides&#160;for the issuance of a variety of share-based compensation awards, including&#160;stock options,&#160;restricted stock awards, restricted stock unit awards, performance awards, dividend equivalents awards, deferred stock awards, stock payment awards and stock appreciation rights. As of &lt;em style="font: inherit;"&gt; April 16, 2021, &lt;/em&gt;the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan increased the number of shares available for grant by&#160;3,000,000&#160;in addition to&#160;the number of shares remaining available for the grant of new awards under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, the Company had 5,788,597&#160;stock options outstanding and an additio&lt;span style="background-color:#ffffff;"&gt;nal&#160;&lt;/span&gt;2,056,629&lt;span style="background-color:#ffffff;"&gt; share&lt;/span&gt;s of common stock available for grant under the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan. As of &lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt;, there were 5,469,247 stock options outstanding and an additional 3,672,561 shares of common stock available for grant under the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Stock Options &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Plan and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan is &lt;span style="-sec-ix-hidden:c125843677"&gt;ten&lt;/span&gt; years, except for certain options granted to the contractors which are between &lt;span style="-sec-ix-hidden:c125843678"&gt;two&lt;/span&gt; to&#160;&lt;span style="-sec-ix-hidden:c125843679"&gt;three&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;i&gt;Risk-free interest rate&lt;/i&gt;. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;i&gt;Expected dividend yield&lt;/i&gt;. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently anticipate paying any in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;i&gt;Expected stock price volatility.&lt;/i&gt; The expected stock price volatility was calculated based on the Company&#x2019;s own volatility. The Company reviews its volatility assumption on an annual basis and has used the Company&#x2019;s historical volatilities.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&lt;i style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Expected life of option. &lt;/i&gt;The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option&lt;span style="background-color:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The assumptions used in the Black-Scholes option pricing model for stock options granted for the years ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;3.56% - 4.61&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3.90% -5.12&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expected dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expected stock price volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;63.02-63.64&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843097"&gt;62.22%&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c125843098"&gt;64.27&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expected life of options (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2.63-6.25&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;1.13 -6.25&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The following table summarizes the combined stock option activity under the Company&#x2019;s Equity Compensation Plans:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Intrinsic&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term (Years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,031,097&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;805,350&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.45&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(351,520&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(15,680&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,469,247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.08&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;322,738&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Granted&lt;sup style="vertical-align:top;line-height:120%;"&gt; (1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;830,725&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.61&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Exercised&lt;sup style="vertical-align:top;line-height:120%;"&gt; (2)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(55,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Expired &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(383,063&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.16&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Canceled&lt;sup style="vertical-align:top;line-height:120%;"&gt; (4)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(73,312&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,788,597&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.97&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;655,578&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Exercisable at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;4,438,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;3.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;4.44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;436,263&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Notes:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Represents the following options granted:&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 36pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Annual share-based compensation awards on&#160;&lt;em style="font: inherit;"&gt; January 2,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; with an exercise price of $1.59, including: (a)&#160;387,500&#160;stock options granted to executives and key personnel, vesting upon&#160;&lt;span style="-sec-ix-hidden:c125843687"&gt;one&lt;/span&gt;&#160;year anniversary, or annually in equal installments over&#160;&lt;span style="-sec-ix-hidden:c125843688"&gt;four&lt;/span&gt;&#160;years, (b)&#160;352,500&#160;stock options granted to members of the Board of Directors, vesting upon&#160;&lt;span style="-sec-ix-hidden:c125843690"&gt;one&lt;/span&gt;&#160;year anniversary, (c)&#160;17,600&#160;stock options&#160;granted to employees, vesting annually in equal installments over&#160;&lt;span style="-sec-ix-hidden:c125843692"&gt;four&lt;/span&gt;&#160;years, and (d)15,000&#160;stock options&#160;granted to a consultant, vesting upon&#160;&lt;span style="-sec-ix-hidden:c125843694"&gt;one&lt;/span&gt;&#160;year anniversary.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 36pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;One-time awards on&#160;&lt;em style="font: inherit;"&gt; April 11, 2024,&#160;&lt;/em&gt;with an exercise price of $1.84, including&#160;20,000&#160;stock options&#160;granted to an executive, vesting annually in equal installments over&#160;&lt;span style="-sec-ix-hidden:c125843697"&gt;four&lt;/span&gt;&#160;years, and 13,125&#160;stock options&#160;granted to a member of the Board of Directors, vesting upon&#160;&lt;span style="-sec-ix-hidden:c125843699"&gt;one&lt;/span&gt;&#160;year anniversary.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 36pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;A&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time award on&#160;&lt;em style="font: inherit;"&gt; September 23, 2024,&#160;&lt;/em&gt;of&#160;25,000&#160;stock options granted to a consultant with an exercise price of $1.79, vesting in&#160;&lt;span style="-sec-ix-hidden:c125843703"&gt;three&lt;/span&gt;&#160;months.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) Represents the following options exercised:&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(a) &lt;span style="background-color:#ffffff;"&gt;25,000&#160;stock options exercised at $0.97, and (b) 30,000&#160;stock options exercised at $1.36.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) Represents the following options expired:&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(a)&#160;300,000&#160;stock options with an exercise price of $1.87&#160;per share&#160;granted to an executive, (b)&#160;25,000&#160;stock options with an exercise price of $1.76&#160;per share granted to a member&#160;of the Board of Directors, (c)&#160;7,500&#160;stock options with an exercise price of $5.56&#160;per share granted to&#160;a consultant, (d)&#160;25,000&#160;stock options with an exercise price of $4.14&#160;per share granted to&#160;a consultant, and (e) 25,563&#160;stock options with a weighted average&#160;exercise price of $2.93 per share&#160;granted to employees.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) Represents the following options canceled:&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(a)&#160;50,000&#160;stock options granted to a former member of the Board of Directors, (b)&#160;13,125&#160;stock options&#160;granted to the Company's former Chairman of the Board of Directors, and (c)&#160;10,187&#160;stock options granted to the Company's former employee.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;The weighted average grant-date fair market value of stock options granted for the years ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; was&#160;$0.95 and &lt;/span&gt;$0.81&lt;span style="background-color:#ffffff;"&gt;, respectively, based on the Black-Scholes option pricing model. The intrinsic value of options exercised for the years ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; was &lt;/span&gt;$33,300&lt;span style="background-color:#ffffff;"&gt;&#160;and &lt;/span&gt;$0&lt;span style="background-color:#ffffff;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, total unrecognized compensation cost related to non-vested stock options granted under the Company&#x2019;s equity compensation plans was &lt;/span&gt;$319,978&lt;span style="background-color:#ffffff;"&gt;&#160;and &lt;/span&gt;$559,121&lt;span style="background-color:#ffffff;"&gt;, respectively, which is expected to be recognized over a weighted average period of &lt;/span&gt;2.40&lt;span style="background-color:#ffffff;"&gt;&#160;years and &lt;/span&gt;2.68&lt;span style="background-color:#ffffff;"&gt;&#160;years, respectively. The Company adjusts the unrecognized compensation cost for actual forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt; text-align: left;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Restricted stock units (the &#x201c;RSUs&#x201d;) are granted subject to certain restrictions. Vesting conditions are determined at the discretion of the Board of Directors.&#160;The fair market value of RSUs is generally determined based on the closing market price of the stock on the grant date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The following table summarizes the&#160;restricted stock units activity during the&#160;year&#160;ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grant Date&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;213,044&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;354,219&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(437,546&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Unvested shares forfeited&lt;sup style="vertical-align:top;line-height:120%;"&gt; (3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(11,792&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;117,925&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Notes:&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; January 2, 2024,&#160;&lt;/em&gt;the Company granted&#160;141,510&#160;RSUs, vesting upon&#160;&lt;span style="-sec-ix-hidden:c125843738"&gt;one&lt;/span&gt;&#160;year anniversary of the grant, to members of the Board of Directors.&#160;On&#160;&lt;em style="font: inherit;"&gt; March 13, 2024,&#160;&lt;/em&gt;the Company granted&#160;212,709&#160;RSUs with immediate vesting, to&#160;executives and key personnel in lieu of cash bonuses earned for the year of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&#160;The fair value of the restricted stock unit is the Company&#x2019;s closing stock price on the grant date as reported on the Nasdaq Stock Exchange.&#160;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Represents the vesting of&#160;212,709&#160;RSUs granted to executives and key personnel,&#160;174,837&#160;RSUs granted to the Board of Directors, and&#160;50,000&#160;RSUs granted to a consultant.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Represents the cancellation of RSUs granted to a former member of the Board of Directors.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Compensation Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;We recognize all share-based payments to employees, consultants, and our Board, as non-cash compensation expenses, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact on the Company&#x2019;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. There was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; performance-based award recognized during the years ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;Total non-cash stock option compensation expense was allocated among the following expense categories:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,067,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,201,027&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;58,529&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;43,094&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,126,279&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,244,121&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The following table summarizes the Company&#x2019;s non-cash share-based compensation expense&#160;allocation between options and restricted stock units:&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation expenses- stock option&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;861,999&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,004,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation expenses- restricted stock units&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;264,280&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;240,067&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,126,279&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,244,121&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2021-04-16_2021-04-16_PlanNameAxis-The2021PlanMember"
      decimals="INF"
      id="c125843667"
      unitRef="Share">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31_PlanNameAxis-The2021PlanMember"
      decimals="INF"
      id="c125843669"
      unitRef="Share">5788597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2024-12-31_PlanNameAxis-The2021PlanMember"
      decimals="INF"
      id="c125843670"
      unitRef="Share">2056629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31_PlanNameAxis-The2021PlanMember"
      decimals="INF"
      id="c125843672"
      unitRef="Share">5469247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2023-12-31_PlanNameAxis-The2021PlanMember"
      decimals="INF"
      id="c125843673"
      unitRef="Share">3672561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877275">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;3.56% - 4.61&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3.90% -5.12&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expected dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expected stock price volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;63.02-63.64&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125843097"&gt;62.22%&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c125843098"&gt;64.27&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expected life of options (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2.63-6.25&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;1.13 -6.25&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember"
      decimals="4"
      id="c125843085"
      unitRef="Pure">0.0356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember"
      decimals="4"
      id="c125843086"
      unitRef="Pure">0.0461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember"
      decimals="4"
      id="c125843089"
      unitRef="Pure">0.6302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember"
      decimals="4"
      id="c125843090"
      unitRef="Pure">0.6364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember"
      id="c125843091">P2Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember"
      id="c125843092">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877276">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Intrinsic&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term (Years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,031,097&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;805,350&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.45&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(351,520&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(15,680&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,469,247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.08&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;322,738&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Granted&lt;sup style="vertical-align:top;line-height:120%;"&gt; (1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;830,725&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.61&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Exercised&lt;sup style="vertical-align:top;line-height:120%;"&gt; (2)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(55,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Expired &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(383,063&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.16&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Canceled&lt;sup style="vertical-align:top;line-height:120%;"&gt; (4)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(73,312&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,788,597&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.97&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;655,578&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Exercisable at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;4,438,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;3.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;4.44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"&gt;436,263&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c125843121"
      unitRef="Share">5031097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c125843122"
      unitRef="USDPerShare">3.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2022-01-01_2022-12-31" id="c125843123">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c125843124"
      unitRef="USD">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843125"
      unitRef="Share">805350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843126"
      unitRef="USDPerShare">1.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843129"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843130"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843133"
      unitRef="Share">351520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843134"
      unitRef="USDPerShare">1.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843137"
      unitRef="Share">15680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843138"
      unitRef="USDPerShare">3.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843141"
      unitRef="Share">5469247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843142"
      unitRef="USDPerShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-01-01_2023-12-31" id="c125843143">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843144"
      unitRef="USD">322738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843145"
      unitRef="Share">830725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843146"
      unitRef="USDPerShare">1.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843149"
      unitRef="Share">55000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843150"
      unitRef="USDPerShare">1.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843153"
      unitRef="Share">383063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843154"
      unitRef="USDPerShare">2.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843157"
      unitRef="Share">73312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843158"
      unitRef="USDPerShare">1.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843161"
      unitRef="Share">5788597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843162"
      unitRef="USDPerShare">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2024-01-01_2024-12-31" id="c125843163">P5Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843164"
      unitRef="USD">655578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843165"
      unitRef="Share">4438810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843166"
      unitRef="USDPerShare">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2024-01-01_2024-12-31" id="c125843167">P4Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843168"
      unitRef="USD">436263</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      decimals="INF"
      id="c125843685"
      unitRef="USDPerShare">1.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      decimals="INF"
      id="c125843686"
      unitRef="Share">387500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c125843689"
      unitRef="Share">352500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-EmployeesMember"
      decimals="INF"
      id="c125843691"
      unitRef="Share">17600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-02_2024-01-02_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c125843693"
      unitRef="Share">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveAndBoardOfDirectorsMember"
      decimals="INF"
      id="c125843695"
      unitRef="USDPerShare">1.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="INF"
      id="c125843696"
      unitRef="Share">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-04-11_2024-04-11_TitleOfIndividualAxis-BoardOfDirectorsMember"
      decimals="INF"
      id="c125843698"
      unitRef="Share">13125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-09-23_2024-09-23_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c125843701"
      unitRef="Share">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-09-23_2024-09-23_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c125843702"
      unitRef="USDPerShare">1.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions1Member"
      decimals="INF"
      id="c125843705"
      unitRef="Share">25000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions1Member"
      decimals="INF"
      id="c125843706"
      unitRef="USDPerShare">0.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions2Member"
      decimals="INF"
      id="c125843707"
      unitRef="Share">30000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptions2Member"
      decimals="INF"
      id="c125843708"
      unitRef="USDPerShare">1.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="INF"
      id="c125843710"
      unitRef="Share">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="INF"
      id="c125843711"
      unitRef="USDPerShare">1.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c125843712"
      unitRef="Share">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c125843713"
      unitRef="USDPerShare">1.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantOneMember"
      decimals="INF"
      id="c125843714"
      unitRef="Share">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantOneMember"
      decimals="INF"
      id="c125843715"
      unitRef="USDPerShare">5.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantTwoMember"
      decimals="INF"
      id="c125843716"
      unitRef="Share">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ConsultantTwoMember"
      decimals="INF"
      id="c125843717"
      unitRef="USDPerShare">4.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c125843718"
      unitRef="Share">25563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c125843719"
      unitRef="USDPerShare">2.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerBoardOfDirectorsMember"
      decimals="INF"
      id="c125843721"
      unitRef="Share">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerChairmanOfTheBoardOfDirectorsMember"
      decimals="INF"
      id="c125843722"
      unitRef="Share">13125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerEmployeeMember"
      decimals="INF"
      id="c125843723"
      unitRef="Share">10187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843725"
      unitRef="USDPerShare">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843726"
      unitRef="USDPerShare">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843728"
      unitRef="USD">33300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125843729"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843731"
      unitRef="USD">319978</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843732"
      unitRef="USD">559121</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2024-01-01_2024-12-31" id="c125843733">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2023-01-01_2023-12-31" id="c125843734">P2Y8M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877277">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grant Date&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;213,044&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;354,219&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(437,546&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Unvested shares forfeited&lt;sup style="vertical-align:top;line-height:120%;"&gt; (3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(11,792&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;117,925&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843175"
      unitRef="Share">213044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843176"
      unitRef="USDPerShare">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843177"
      unitRef="Share">354219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843178"
      unitRef="USDPerShare">1.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843179"
      unitRef="Share">437546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843180"
      unitRef="USDPerShare">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843181"
      unitRef="Share">11792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843182"
      unitRef="USDPerShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843183"
      unitRef="Share">117925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843184"
      unitRef="USDPerShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-02_2024-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c125843737"
      unitRef="Share">141510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-03-13_2024-03-13_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      decimals="INF"
      id="c125843739"
      unitRef="Share">212709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      decimals="INF"
      id="c125843742"
      unitRef="Share">212709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c125843743"
      unitRef="Share">174837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-ContractorMember"
      decimals="INF"
      id="c125843744"
      unitRef="Share">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="d_2024-01-01_2024-12-31"
      id="EFBBBEFB-AC01-49C7-BA37-9C8A063D774B">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,067,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,201,027&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;58,529&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;43,094&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,126,279&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,244,121&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation expenses- stock option&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;861,999&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,004,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation expenses- restricted stock units&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;264,280&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;240,067&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,126,279&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,244,121&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c125843189"
      unitRef="USD">-1067750</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c125843190"
      unitRef="USD">-1201027</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="c125843191"
      unitRef="USD">58529</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="c125843192"
      unitRef="USD">43094</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843193"
      unitRef="USD">1126279</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843194"
      unitRef="USD">1244121</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c125843199"
      unitRef="USD">861999</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c125843200"
      unitRef="USD">1004054</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843201"
      unitRef="USD">264280</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843202"
      unitRef="USD">240067</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843203"
      unitRef="USD">1126279</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843204"
      unitRef="USD">1244121</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877280">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7:&lt;/em&gt;&#160;&#160;&#160;&#160;&#160;Shareholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Issuances of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;For the year&#160;ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, there wer&lt;span style="background-color:#ffffff;"&gt;e 556,623&#160;shares of the Company&#x2019;s common stock issued resulting from the conversion of convertible notes with a weighted average issue price of&#160;$1.63&#160;pe&lt;/span&gt;r share,&#160;&lt;span style="background-color:#ffffff;"&gt;437,546&#160;shares of the Company&#x2019;s common stock issued resulting from the vesting of restricted stock units with a weighted average issue price of&#160;$1.52&#160;pe&lt;/span&gt;r share, and 30,569 shares of the Company's common stock issued resulting from the exercise of stock options, with a weighted average issue price of $1.04 per share.&#160;For the year&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2023,&#160;&lt;/em&gt;there were&#160;247,961&#160;shares of the Company&#x2019;s common stock issued resulting from the vesting of restricted stock units with a weighted average issue price of&#160;$1.38&#160;per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"&gt;&lt;b&gt;&lt;i&gt;Treasury Stock &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, there were 12,253,502&#160;shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConvertibleNotesConvertedIntoCommonStockMember"
      decimals="INF"
      id="c125843751"
      unitRef="Share">556623</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConvertibleNotesConvertedIntoCommonStockMember"
      decimals="INF"
      id="c125843752"
      unitRef="USDPerShare">1.63</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843753"
      unitRef="Share">437546</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843754"
      unitRef="USDPerShare">1.52</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843755"
      unitRef="Share">30569</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c125843756"
      unitRef="USDPerShare">1.04</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843757"
      unitRef="Share">247961</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c125843758"
      unitRef="USDPerShare">1.38</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843760"
      unitRef="Share">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c125843761"
      unitRef="USD">18900000</us-gaap:TreasuryStockValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877281">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8:&lt;/em&gt;&#160;&#160;&#160;&#160;&#160;Income Taxes &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;"&gt;For the year ended &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, there was&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt; provision for income taxes or unrecognized tax benefits recorded.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 27pt; text-align: justify;"&gt;The significant components of gain (loss) before income taxes are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;U.S. operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(5,757,824&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(6,766,409&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Foreign operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(51,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(29,052&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Total loss before provision for income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(5,809,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(6,795,461&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"&gt;The Company has no current or deferred income tax&#160;for the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to&#160;permanent differences, state income taxes and a change in the deferred tax valuation allowance.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;The reconciliation between the statutory tax rate and the Company&#x2019;s actual effective tax rate is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Tax at U.S. statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;State taxes, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(4.29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(4.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Non-deductible items&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;0.26&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;0.76&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;20.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;14.54&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;True-up adjustment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;4.44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;10.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Foreign operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(0.11&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Change in tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"&gt;The significant components of the Company&#x2019;s net deferred income tax assets are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Section 174 - R&amp;amp;D expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,123,800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,769,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Stock option expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,584,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,419,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;NOL carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;12,655,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;11,620,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;General Business credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,278,400&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,503,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Operating lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;22,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;34,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Right-of-use asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(23,400&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(35,800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;134,800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Deferred tax asset, net of deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17,642,100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,446,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(17,642,100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(16,446,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Net deferred tax asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets, Management evaluates whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on Management&#x2019;s evaluation, the net deferred tax asset, was offset by a full valuation allowance as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company had federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards available as of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; in the amount of &lt;span style="background-color:#ffffff;"&gt;approximately $49,903,000&#160;and $45,850,000, respectively. Approximately $46,965,000&lt;/span&gt;&#160;of the federal net operating loss carryforwards will be carried forward indefinitely and will be available to offset 80% of taxable income. The remaining amount of the net operating loss carryforwards will expire at varying dates through &lt;em style="font: inherit;"&gt;2038.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Tax Cuts and Jobs Act eliminated the current year deduction election for research and experimental expenditures. Instead, a taxpayer must charge such expenditures to a capital account and is allowed to amortize such expenditures ratably over a &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-year period (or &lt;em style="font: inherit;"&gt;fifteen&lt;/em&gt;-year period for expenditures attributable to foreign research), beginning with the midpoint of the tax year in which such expenditures are paid or incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877282">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;U.S. operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(5,757,824&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(6,766,409&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Foreign operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(51,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(29,052&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Total loss before provision for income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(5,809,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(6,795,461&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843209"
      unitRef="USD">-5757824</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843210"
      unitRef="USD">-6766409</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843211"
      unitRef="USD">-51335</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843212"
      unitRef="USD">-29052</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843213"
      unitRef="USD">-5809159</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125843214"
      unitRef="USD">-6795461</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125843764"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877283">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Tax at U.S. statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;State taxes, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(4.29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(4.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Non-deductible items&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;0.26&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;0.76&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;20.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;14.54&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;True-up adjustment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;4.44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;10.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Foreign operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(0.11&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Change in tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c125843219"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c125843220"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125843221"
      unitRef="Pure">-0.0429</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125843222"
      unitRef="Pure">-0.0419</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125843223"
      unitRef="Pure">0.0026</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125843224"
      unitRef="Pure">0.0076</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125843225"
      unitRef="Pure">0.2059</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125843226"
      unitRef="Pure">0.1454</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <dyai:EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125843227"
      unitRef="Pure">0.0444</dyai:EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent>
    <dyai:EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="1"
      id="c125843228"
      unitRef="Pure">0.10</dyai:EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c125843229"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125843230"
      unitRef="Pure">-0.0011</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c125843231"
      unitRef="Pure">-0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c125843232"
      unitRef="Pure">-0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c125843233"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c125843234"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c125843235"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c125843236"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877284">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Section 174 - R&amp;amp;D expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,123,800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,769,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Stock option expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,584,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,419,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;NOL carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;12,655,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;11,620,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;General Business credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,278,400&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,503,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Operating lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;22,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;34,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Right-of-use asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(23,400&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(35,800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;134,800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Deferred tax asset, net of deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17,642,100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,446,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(17,642,100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(16,446,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Net deferred tax asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <dyai:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843241"
      unitRef="USD">2123800</dyai:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <dyai:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843242"
      unitRef="USD">1769000</dyai:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843243"
      unitRef="USD">1584700</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843244"
      unitRef="USD">1419300</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843245"
      unitRef="USD">12655300</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843246"
      unitRef="USD">11620700</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843247"
      unitRef="USD">1278400</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843248"
      unitRef="USD">1503600</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <dyai:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843249"
      unitRef="USD">22500</dyai:DeferredTaxAssetsOperatingLeaseLiability>
    <dyai:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843250"
      unitRef="USD">34700</dyai:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843251"
      unitRef="USD">23400</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843252"
      unitRef="USD">35800</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843253"
      unitRef="USD">800</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843254"
      unitRef="USD">134800</us-gaap:DeferredTaxAssetsOther>
    <dyai:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843255"
      unitRef="USD">17642100</dyai:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance>
    <dyai:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843256"
      unitRef="USD">16446300</dyai:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843257"
      unitRef="USD">17642100</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843258"
      unitRef="USD">16446300</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843259"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843260"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843771"
      unitRef="USD">49903000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125843772"
      unitRef="USD">45850000</us-gaap:OperatingLossCarryforwards>
    <dyai:OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125843773"
      unitRef="USD">46965000</dyai:OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely>
    <dyai:OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage
      contextRef="i_2024-12-31"
      decimals="1"
      id="c125843774"
      unitRef="Pure">0.80</dyai:OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877285">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;9:&lt;/em&gt;&#160;&#160;&#160;&#160; Segment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company operates and manages its business as one&#160;reportable segment and one&#160;operating segment, which is the business of developing and commercializing synthetic protein products using the Company&#x2019;s proprietary microbial platforms, including &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; and Dapibus&#x2122;. The Company's chief operating decision maker, or CODM, is the Company's senior management team that includes the Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The Company operates in the U.S. and Europe.&#160;All material long-lived assets of the Company reside in the U.S. For geographic information about the Company&#x2019;s product revenues, see Note &lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;i&gt;Concentration&lt;/i&gt;. Long-lived assets primarily consist of operating lease right-of-use assets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The CODM uses consolidated net loss to evaluate the Company's spend and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing performance of the segment and in establishing resource allocation across the organization. Factors used in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; of the notes to the consolidated financial statements included in this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The C&lt;span style="background-color:#ffffff;"&gt;ODM reviews cash, cash equivalents and investment securities as a measure of segment assets.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company&#x2019;s cash, cash equivalents and investment securities were $9.3&#160;million and $7.3&#160;million, respectively.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The following table presents information about segment revenue, significant segment expenses and segment operating loss for the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2023:&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;3,495,389&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,898,806&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cost of revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,194,624&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,975,849&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Outside contracted services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,503,397&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,677,941&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Personnel related costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;414,916&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;510,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Facilities, overhead, and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;67,411&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;65,584&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;General and administrative expenses:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Compensation and related expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,308,566&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,200,914&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Business consulting expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;764,326&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;305,348&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Legal and professional services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;998,630&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;931,038&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other G&amp;amp;A expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;995,501&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,244,121&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,126,279&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,178,686&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign currency exchange loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22,561&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;38,417&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other Income (expenses), net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,663&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,434,278&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Net loss&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(5,809,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(6,795,461&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843779"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125843780"
      unitRef="Pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c125843787"
      unitRef="USD">9300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c125843788"
      unitRef="USD">7300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877286">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;3,495,389&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,898,806&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cost of revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,194,624&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,975,849&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Outside contracted services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,503,397&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,677,941&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Personnel related costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;414,916&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;510,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Facilities, overhead, and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;67,411&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;65,584&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;General and administrative expenses:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Compensation and related expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,308,566&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,200,914&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Business consulting expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;764,326&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;305,348&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Legal and professional services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;998,630&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;931,038&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other G&amp;amp;A expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;995,501&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,244,121&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,126,279&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,178,686&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign currency exchange loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22,561&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;38,417&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other Income (expenses), net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,663&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,434,278&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Net loss&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(5,809,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(6,795,461&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843265"
      unitRef="USD">3495389</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843266"
      unitRef="USD">2898806</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843267"
      unitRef="USD">1194624</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843268"
      unitRef="USD">1975849</us-gaap:CostOfGoodsAndServicesSold>
    <dyai:ResearchAndDevelopmentExpenseOutsideContractedServices
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843269"
      unitRef="USD">1503397</dyai:ResearchAndDevelopmentExpenseOutsideContractedServices>
    <dyai:ResearchAndDevelopmentExpenseOutsideContractedServices
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843270"
      unitRef="USD">2677941</dyai:ResearchAndDevelopmentExpenseOutsideContractedServices>
    <dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843271"
      unitRef="USD">414916</dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts>
    <dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843272"
      unitRef="USD">510647</dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts>
    <dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843273"
      unitRef="USD">67411</dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther>
    <dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843274"
      unitRef="USD">65584</dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther>
    <us-gaap:LaborAndRelatedExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843277"
      unitRef="USD">2308566</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843278"
      unitRef="USD">2200914</us-gaap:LaborAndRelatedExpense>
    <dyai:BusinessConsultingExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843279"
      unitRef="USD">764326</dyai:BusinessConsultingExpense>
    <dyai:BusinessConsultingExpense
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843280"
      unitRef="USD">305348</dyai:BusinessConsultingExpense>
    <us-gaap:ProfessionalFees
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843281"
      unitRef="USD">998630</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843282"
      unitRef="USD">931038</us-gaap:ProfessionalFees>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843283"
      unitRef="USD">995501</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843284"
      unitRef="USD">1244121</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843285"
      unitRef="USD">1126279</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843286"
      unitRef="USD">1178686</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843287"
      unitRef="USD">-22561</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843288"
      unitRef="USD">-38417</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843289"
      unitRef="USD">91663</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843290"
      unitRef="USD">1434278</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843291"
      unitRef="USD">-5809159</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c125843292"
      unitRef="USD">-6795461</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2877287">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;10:&lt;/em&gt;&#160;&#160;&#160;&#160;&#160;Subsequent Events &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through &lt;em style="font: inherit;"&gt; March 26, 2025&lt;/em&gt;, the date the consolidated financial statements were available to be issued. Except for items mentioned in the notes, and as discussed below, management is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; January 2, 2025, &lt;/em&gt;the Company granted an annual stock option award with an exercise price of $1.74, including: (a) 356,500 stock options granted to executives and key personnel, vesting upon &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year anniversary, or annually in equal installments over &lt;span style="-sec-ix-hidden:c125843795"&gt;four&lt;/span&gt; years, (b) 277,500 stock options granted to members of the Board of Directors, vesting upon &lt;span style="-sec-ix-hidden:c125843797"&gt;one&lt;/span&gt; year anniversary, (c) 19,500 stock options granted to employees, vesting annually in equal installments over &lt;span style="-sec-ix-hidden:c125843799"&gt;four&lt;/span&gt; years, and (d) 20,000 stock options granted to a consultant, vesting upon &lt;span style="-sec-ix-hidden:c125843801"&gt;one&lt;/span&gt; year anniversary.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; January 2, 2025, &lt;/em&gt;the Company granted 96,984 restricted stock units, vesting upon &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year anniversary, to the Board of Directors as a result of reduction in director cash compensation of &lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; and &#160;an aggregate of 133,039 restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; March 20, 2025, &lt;/em&gt;the Company announced that it has received a funding award from CEPI to use &lt;em style="font: inherit;"&gt;C1&lt;/em&gt; to accelerate the development of protein-based vaccines through the partnership with Fondazione Biotecnopolo di Siena (FBS), a non-profit foundation backed by the Italian government.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c125843792"
      unitRef="USDPerShare">1.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      decimals="INF"
      id="c125843793"
      unitRef="Share">356500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c125843796"
      unitRef="Share">277500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember"
      decimals="INF"
      id="c125843798"
      unitRef="Share">19500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-02_2025-01-02_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c125843800"
      unitRef="Share">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c125843802"
      unitRef="Share">96984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2025-01-02_2025-01-02_AwardTypeAxis-RestrictedStockUnitsRSUMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember"
      decimals="INF"
      id="c125843805"
      unitRef="Share">133039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c125843013"
          xlink:label="c125843013"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843009"
          xlink:label="c125843009"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843008"
          xlink:label="c125843008"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843007"
          xlink:label="c125843007"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843010"
          xlink:label="c125843010"
          xlink:type="locator"/>
        <link:footnote id="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e" xlink:label="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Francisco Trust. Mr. Thomas Emalfarb  may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he  may have therein, directly or indirectly. The amount of accrued interest as of  December 31, 2024, is $20,000.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843013"
          xlink:to="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843009"
          xlink:to="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843008"
          xlink:to="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843007"
          xlink:to="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843010"
          xlink:to="f5ad8edb2-9e8f-4f0c-9e2b-756a61de357e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843150"
          xlink:label="c125843150"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843149"
          xlink:label="c125843149"
          xlink:type="locator"/>
        <link:footnote id="f9eb6a786-1eb8-4731-a986-e6549f25e955" xlink:label="f9eb6a786-1eb8-4731-a986-e6549f25e955" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Represents the following options exercised:


(a) 25,000 stock options exercised at $0.97, and (b) 30,000 stock options exercised at $1.36.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843150"
          xlink:to="f9eb6a786-1eb8-4731-a986-e6549f25e955"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843149"
          xlink:to="f9eb6a786-1eb8-4731-a986-e6549f25e955"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843180"
          xlink:label="c125843180"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843179"
          xlink:label="c125843179"
          xlink:type="locator"/>
        <link:footnote id="f804fad0d-2a65-4335-8b95-e20af567b94f" xlink:label="f804fad0d-2a65-4335-8b95-e20af567b94f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Represents the vesting of 212,709 RSUs granted to executives and key personnel, 174,837 RSUs granted to the Board of Directors, and 50,000 RSUs granted to a consultant.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843180"
          xlink:to="f804fad0d-2a65-4335-8b95-e20af567b94f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843179"
          xlink:to="f804fad0d-2a65-4335-8b95-e20af567b94f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843182"
          xlink:label="c125843182"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843181"
          xlink:label="c125843181"
          xlink:type="locator"/>
        <link:footnote id="fbaed1767-1ff0-47d3-a4fd-478ede0efb78" xlink:label="fbaed1767-1ff0-47d3-a4fd-478ede0efb78" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Represents the cancellation of RSUs granted to a former member of the Board of Directors.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843182"
          xlink:to="fbaed1767-1ff0-47d3-a4fd-478ede0efb78"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843181"
          xlink:to="fbaed1767-1ff0-47d3-a4fd-478ede0efb78"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843027"
          xlink:label="c125843027"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843014"
          xlink:label="c125843014"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843021"
          xlink:label="c125843021"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843026"
          xlink:label="c125843026"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843015"
          xlink:label="c125843015"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843024"
          xlink:label="c125843024"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843017"
          xlink:label="c125843017"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843019"
          xlink:label="c125843019"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843016"
          xlink:label="c125843016"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843020"
          xlink:label="c125843020"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843023"
          xlink:label="c125843023"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843022"
          xlink:label="c125843022"
          xlink:type="locator"/>
        <link:footnote id="fe6a258d7-2b50-4b5b-b18d-0f21596c8347" xlink:label="fe6a258d7-2b50-4b5b-b18d-0f21596c8347" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Mark A. Emalfarb, our President and Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore,  may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he  may have therein, directly or indirectly. For the year ended  December 31, 2024, $500,000 of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into 294,891 shares of the Company&#x2019;s common stock. For the year ended  December 31, 2024, $410,000 of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into 261,732 shares of the Company&#x2019;s common stock. As of December 31, 2024, the amount of accrued interest for Bradley Emalfarb and Bradley Scott Emalfarb Irrevocable Trust was $1,733 and $3,640, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843027"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843014"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843021"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843026"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843015"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843024"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843017"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843019"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843016"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843020"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843023"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843022"
          xlink:to="fe6a258d7-2b50-4b5b-b18d-0f21596c8347"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843158"
          xlink:label="c125843158"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843157"
          xlink:label="c125843157"
          xlink:type="locator"/>
        <link:footnote id="f7f686efb-cac5-4e80-ab47-429a51e099ad" xlink:label="f7f686efb-cac5-4e80-ab47-429a51e099ad" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">(4) Represents the following options canceled:


(a) 50,000 stock options granted to a former member of the Board of Directors, (b) 13,125 stock options granted to the Company's former Chairman of the Board of Directors, and (c) 10,187 stock options granted to the Company's former employee.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843158"
          xlink:to="f7f686efb-cac5-4e80-ab47-429a51e099ad"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843157"
          xlink:to="f7f686efb-cac5-4e80-ab47-429a51e099ad"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843145"
          xlink:label="c125843145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843146"
          xlink:label="c125843146"
          xlink:type="locator"/>
        <link:footnote id="fd4668ce7-78e0-474e-8a35-8a9ea1b23e6a" xlink:label="fd4668ce7-78e0-474e-8a35-8a9ea1b23e6a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Represents the following options granted:

Annual share-based compensation awards on  January 2, 2024, with an exercise price of $1.59, including: (a) 387,500 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 352,500 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 17,600 stock options granted to employees, vesting annually in equal installments over four years, and (d)15,000 stock options granted to a consultant, vesting upon one year anniversary.

One-time awards on  April 11, 2024, with an exercise price of $1.84, including 20,000 stock options granted to an executive, vesting annually in equal installments over four years, and 13,125 stock options granted to a member of the Board of Directors, vesting upon one year anniversary.

A one-time award on  September 23, 2024, of 25,000 stock options granted to a consultant with an exercise price of $1.79, vesting in three months.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843145"
          xlink:to="fd4668ce7-78e0-474e-8a35-8a9ea1b23e6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843146"
          xlink:to="fd4668ce7-78e0-474e-8a35-8a9ea1b23e6a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125842988"
          xlink:label="c125842988"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125842943"
          xlink:label="c125842943"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125842989"
          xlink:label="c125842989"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125842991"
          xlink:label="c125842991"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125842944"
          xlink:label="c125842944"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125842990"
          xlink:label="c125842990"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125842941"
          xlink:label="c125842941"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125842942"
          xlink:label="c125842942"
          xlink:type="locator"/>
        <link:footnote id="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0" xlink:label="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842988"
          xlink:to="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842943"
          xlink:to="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842989"
          xlink:to="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842991"
          xlink:to="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842944"
          xlink:to="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842990"
          xlink:to="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842941"
          xlink:to="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842942"
          xlink:to="f150e9c18-ecd4-4b5b-bd33-00dd20512bf0"
          xlink:type="arc"/>
        <link:footnote id="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0" xlink:label="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">For the years ended December 31, 2024 and 2023, the Company received discounts of $78,770 and $39,012 to purchase held-to-maturity investment securities, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842988"
          xlink:to="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842943"
          xlink:to="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842989"
          xlink:to="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842991"
          xlink:to="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842944"
          xlink:to="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842990"
          xlink:to="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842941"
          xlink:to="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125842942"
          xlink:to="f8f4dd1d4-e90a-40d2-a0c3-e2c15c125fd0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843030"
          xlink:label="c125843030"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843031"
          xlink:label="c125843031"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843028"
          xlink:label="c125843028"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843029"
          xlink:label="c125843029"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843034"
          xlink:label="c125843034"
          xlink:type="locator"/>
        <link:footnote id="fab67f974-f11c-4ed5-814a-a224cb2f3c41" xlink:label="fab67f974-f11c-4ed5-814a-a224cb2f3c41" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our President and Chief Executive Officer, are co-trustees of the Descendant Trust and  may therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Descendant Trust. The amount of accrued interest as of December 31, 2024, is $1,800.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843030"
          xlink:to="fab67f974-f11c-4ed5-814a-a224cb2f3c41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843031"
          xlink:to="fab67f974-f11c-4ed5-814a-a224cb2f3c41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843028"
          xlink:to="fab67f974-f11c-4ed5-814a-a224cb2f3c41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843029"
          xlink:to="fab67f974-f11c-4ed5-814a-a224cb2f3c41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843034"
          xlink:to="fab67f974-f11c-4ed5-814a-a224cb2f3c41"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843154"
          xlink:label="c125843154"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843153"
          xlink:label="c125843153"
          xlink:type="locator"/>
        <link:footnote id="fb14433de-4b52-4cc5-afe7-792fca231589" xlink:label="fb14433de-4b52-4cc5-afe7-792fca231589" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">(3) Represents the following options expired:


(a) 300,000 stock options with an exercise price of $1.87 per share granted to an executive, (b) 25,000 stock options with an exercise price of $1.76 per share granted to a member of the Board of Directors, (c) 7,500 stock options with an exercise price of $5.56 per share granted to a consultant, (d) 25,000 stock options with an exercise price of $4.14 per share granted to a consultant, and (e) 25,563 stock options with a weighted average exercise price of $2.93 per share granted to employees.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843154"
          xlink:to="fb14433de-4b52-4cc5-afe7-792fca231589"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843153"
          xlink:to="fb14433de-4b52-4cc5-afe7-792fca231589"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c125843177"
          xlink:label="c125843177"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c125843178"
          xlink:label="c125843178"
          xlink:type="locator"/>
        <link:footnote id="f7c86250f-e2ac-4546-9dd0-9565d8e6fc5d" xlink:label="f7c86250f-e2ac-4546-9dd0-9565d8e6fc5d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">On  January 2, 2024, the Company granted 141,510 RSUs, vesting upon one year anniversary of the grant, to members of the Board of Directors. On  March 13, 2024, the Company granted 212,709 RSUs with immediate vesting, to executives and key personnel in lieu of cash bonuses earned for the year of 2023. The fair value of the restricted stock unit is the Company&#x2019;s closing stock price on the grant date as reported on the Nasdaq Stock Exchange.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843177"
          xlink:to="f7c86250f-e2ac-4546-9dd0-9565d8e6fc5d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c125843178"
          xlink:to="f7c86250f-e2ac-4546-9dd0-9565d8e6fc5d"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
